"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,ZA,B,ZA 813330 B,050-756-021-402-855,1982-06-30,1982,ZA 813330 A,1981-05-19,GB 8016669 A,1980-05-20,WORKING GEMSTONES,,GERSAN ETS,MARTIN COOPER;;COOPER MARTIN,,https://lens.org/050-756-021-402-855,Granted Patent,no,0,0,2,7,0,B28D5/0011,B28D5/00,,0,0,,,,EXPIRED
2,US,A,US 3080547 A,085-097-113-019-662,1963-03-05,1963,US 77164158 A,1958-11-03,US 77164158 A,1958-11-03,Selective calling apparatus,,MOTOROLA INC,MARTIN COOPER,,https://lens.org/085-097-113-019-662,Granted Patent,no,11,17,1,1,0,H04W88/028;;H04W88/028,H04W88/02,,0,0,,,,EXPIRED
3,US,S,US D0670058 S,129-381-136-568-667,2012-10-30,2012,US 201229420367 F,2012-05-08,US 201229420367 F,2012-05-08,Combined boot and glove dryer,,COOPER MARTIN,COOPER MARTIN,,https://lens.org/129-381-136-568-667,Design Right,no,0,6,1,1,0,,,0705;;D32/58,0,0,,,,ACTIVE
4,US,A,US 4401876 A,184-642-813-051-700,1983-08-30,1983,US 26471081 A,1981-05-18,GB 8016669 A;;GB 8025737 A,1980-05-20,Working gemstones,"In order to provide a better way of kerfing a gemstone such as a diamond, a high energy, high pulse rate, low order mode, laser beam is employed to cut the kerf. Apparatus for kerfing a gemstone can in general comprise a laser, reflecting means which bends the incident beam through a substantial angle and which is moveable substantially parallel to the axis of the incident beam, and a focusing arrangement which focuses the beam on the gemstone.",COOPER MARTIN,COOPER MARTIN,,https://lens.org/184-642-813-051-700,Granted Patent,yes,4,34,3,7,0,B23K26/032;;B28D1/221;;B28D5/0011;;B23K26/40;;B23K2103/30;;B23K2103/50;;B28D5/0011;;B28D1/221;;B23K26/032;;B23K26/40;;B23K2103/30;;B23K2103/50,B23K26/03;;B28D1/22;;B28D5/00,219121LJ;;X125 30R;;125/39;;X219121LH;;X219121LZ,5,0,,,"Laser Institute of America, ""Guide for Material Processing by Lasers"" 1978.;;""Industrial Diamond Review"", Mar. 1980, pp. 90 and 91.;;""Laser Application Notes"", vol. 1, No. 1 of Feb. 1979.;;""New Hyperyag"", on Model DLPY 4-System 2000 Yag Laser.;;""Diamonds"": N.A.G. Press LTD, Chapter Eleven, pp. 235, 239-242.",EXPIRED
5,US,S,US D0407498 S,154-746-478-520-730,1999-03-30,1999,US 7732297 F,1997-09-30,US 7732297 F,1997-09-30,Massager,,COOPER MARTIN,COOPER MARTIN,,https://lens.org/154-746-478-520-730,Design Right,yes,7,27,1,1,0,,,D24/215;;2404,0,0,,,,EXPIRED
6,US,S,US D0530020 S,161-862-195-295-483,2006-10-10,2006,US 22450305 F,2005-03-03,US 22450305 F,2005-03-03,Massage apparatus,,COOPER MARTIN,COOPER MARTIN,,https://lens.org/161-862-195-295-483,Design Right,no,0,26,1,1,0,,,2803;;D24/215,0,0,,,,EXPIRED
7,US,A,US 1858322 A,170-184-603-012-160,1932-05-17,1932,US 24365827 A,1927-12-30,US 24365827 A,1927-12-30,Rotary combustion engine,,MARTIN COOPER,MARTIN COOPER,,https://lens.org/170-184-603-012-160,Granted Patent,no,0,2,1,1,0,F02B53/00;;F02B53/00;;F02B2730/05;;F02B2730/05;;Y02T10/12;;Y02T10/12,F02B53/00,,0,0,,,,EXPIRED
8,US,A,US 1714549 A,109-419-600-869-347,1929-05-28,1929,US 20178427 A,1927-06-27,US 20178427 A,1927-06-27,Combustion turbine,,JAMES K CRATTS,MARTIN COOPER,,https://lens.org/109-419-600-869-347,Granted Patent,no,0,3,1,1,0,F02C5/12;;F02C5/12,F02C5/12,,0,0,,,,EXPIRED
9,US,A,US 3234484 A,114-865-780-830-116,1966-02-08,1966,US 34526064 A,1964-02-17,US 34526064 A,1964-02-17,Frequency calibrator for crystal oscillators,,MOTOROLA INC,MARTIN COOPER,,https://lens.org/114-865-780-830-116,Granted Patent,no,0,2,1,1,0,G01R23/00;;G01R23/00,G01R23/00,,0,0,,,,EXPIRED
10,US,S,US D0529620 S,135-838-097-873-478,2006-10-03,2006,US 22452305 F,2005-03-03,US 22452305 F,2005-03-03,Massage apparatus,,COOPER MARTIN,COOPER MARTIN,,https://lens.org/135-838-097-873-478,Design Right,no,0,20,1,1,0,,,2803;;D24/215,0,0,,,,EXPIRED
11,US,A,US 913471 A,121-482-915-169-747,1909-02-23,1909,US 1908/0456957 A,1908-10-09,US 1908/0456957 A,1908-10-09,MAIL-HOLDER.,,COOPER MARTIN,COOPER MARTIN,,https://lens.org/121-482-915-169-747,Granted Patent,no,0,0,1,1,0,B65D63/10;;B65D63/10;;Y10T24/1402;;Y10T24/1402;;Y10T24/1408;;Y10T24/1408,,,0,0,,,,EXPIRED
12,CA,A1,CA 2051958 A1,191-233-574-724-248,1993-03-21,1993,CA 2051958 A,1991-09-20,CA 2051958 A,1991-09-20,POLITICAL BOARD GAME,"The invention is a board game which simulates politics. Players move about spaces on a game board in which different coloured squares provide the players with votes. Players who land on Issue squares must deal with an issue from a card in a pack and other players vote on the player's position or handling of an issue. Players may also be required to deal with scandals, go to meetings, obtain a decision on an issue, and accumulate or lose votes according to the rules. Players who achieve a number of votes and other criteria may advance to a Second Stage as members of an Inner Cabinet. By achieving certain accomplishments, they may become candidates for Prime Minister and the player who becomes Prime Minister wins.",MURPHY SEAN;;COOPER MARTIN,MARTIN SEAN;;COOPER MARTIN,,https://lens.org/191-233-574-724-248,Patent Application,no,0,0,1,1,0,,A63F3/00;;A63F9/00,,0,0,,,,DISCONTINUED
13,CN,B,CN 102132195 B,063-120-754-557-617,2014-05-28,2014,CN 200980134116 A,2009-06-19,US 2009/0047994 W;;US 16322808 A,2008-06-27,Carabiner glasses,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/063-120-754-557-617,Granted Patent,no,0,0,5,5,0,G02C5/143;;G02C11/00;;G02C3/00;;G02C5/143;;G02C11/00;;G02C3/00,G02C5/14,,0,0,,,,INACTIVE
14,GB,A,GB 2385490 A,097-774-679-239-753,2003-08-20,2003,GB 0203436 A,2002-02-13,GB 0203436 A,2002-02-13,Terminal and network monitoring and testing in mobile communications systems,"A method of monitoring the performance of a mobile communications network and/or a terminal using the network in which signals are routed via the network between the terminal and a server, the method comprising analysing signals received by the server relating to the performance of the terminal or network whereby to monitor the operation of the network and/or terminal. System performance may be analysed using any number of the following parameters over time, possibly the duration of a data stream: received signal strength indicator, signal to noise ratio, ratio of energy per bit to noise, ratio of energy per chip to noise, block error rate, frame error rate for voice, measured data rate, location of terminal. System performance may be measured with respect to location. Sampling of the above parameters may be carried out and stored, possibly removably, in the terminal, and transmitted to the server upon a request from the server. Preferably, there is more than one sampling rate that is varied according to the mode of operation, either governed by the terminal or the server. The monitoring of performance may be carried out during a test sequence sent from the server upon request by the terminal, user, user contact centre, or upon abnormal operating conditions. An abrupt deterioration of a measured parameter may be interpreted as a fraud attempt.",HUTCHISON WHAMPOA THREE G IP,COOPER DAVID MARTIN,,https://lens.org/097-774-679-239-753,Patent Application,no,5,4,2,2,0,H04W24/00;;H04B17/18;;H04B17/318;;H04B17/336,H04B17/00;;H04W24/00,H4L LFMB          NONE;;H4L LRNMR         LRNMR;;H4L L201          LRNMR;;H4L L205          LRNMR;;H4L L213          LRNMR,0,0,,,,DISCONTINUED
15,US,A,US 4152207 A,035-364-431-707-049,1979-05-01,1979,US 87105578 A,1978-01-20,US 80857477 A,1977-06-21,Magnetic nuclear core restraint and control,"A lateral restraint and control system for a nuclear reactor core adaptable to provide an inherent decrease of core reactivity in response to abnormally high reactor coolant fluid temperatures. An electromagnet is associated with structure for radially compressing the core during normal reactor conditions. A portion of the structures forming a magnetic circuit are composed of ferromagnetic material having a curie temperature corresponding to a selected coolant fluid temperature. Upon a selected signal, or inherently upon a preselected rise in coolant temperature, the magnetic force is decreased a given amount sufficient to relieve the compression force so as to allow core radial expansion. The expanded core configuration provides a decreased reactivity, tending to shut down the nuclear reaction.",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H,,https://lens.org/035-364-431-707-049,Granted Patent,yes,3,7,2,2,0,G21C7/30;;G21D5/06;;Y02E30/30;;Y02E30/00;;G21D5/06;;G21C7/30;;Y02E30/30,G21C7/30;;G21D5/06,176/87,0,0,,,,EXPIRED
16,US,A1,US 2013/0221044 A1,055-765-873-813-992,2013-08-29,2013,US 201213404155 A,2012-02-24,US 201213404155 A,2012-02-24,ACCESSORY FOR WRIST WATCH,"An accessory for a wrist watch is provided and includes a substantially planar lower surface, an end surface, and an upper surface. The substantially planar lower surface is configured for selective attachment to a wrist watch. The end surface extends upwardly from the substantially planar lower surface. The upper surface extends between the substantially planar lower surface and the end surface. The upper surface is configured to conform to a user's wrist.",COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/055-765-873-813-992,Patent Application,yes,2,1,2,2,0,G04B47/00;;G04B47/00,A44C5/00,224/171,0,0,,,,DISCONTINUED
17,US,B1,US 6755152 B1,190-528-225-684-112,2004-06-29,2004,US 44335703 A,2003-05-22,US 44335703 A,2003-05-22,Method and apparatus for clearing moisture in milking system pulsation monitor,"
    There is provided an apparatus and method for monitoring pulsation of a milking system in a dairy facility. The milking system includes vacuum hoses that extend from a vacuum source to a milking claw. The pressure in each vacuum hose is changed by a pulsator, with the vacuum hoses being out of phase with one another. The pressure sensors are coupled to the respective vacuum hoses, which sensors monitor the pressure pulsations to ensure that the pulsator is operating satisfactorily. The pressure sensors are coupled to the vacuum hoses by way of passageways or hoses. A bypass is provided between the passageways so as to provide air circulation in the otherwise dead air space in these passageways. The bypass is small so as to not interfere with the pressure measurements by the sensors and is located in close proximity to the pressure sensors so as to minimize the amount of dead air space. The bypass is operated continuously as long as the milking system is operated in order to prevent the accumulation of moisture and debris in the space between the bypass and the pressure sensors. The bypass enhances the reliability of a continuously operating pulsation monitoring apparatus. 
",SENSEABILITY INC,COOPER MARTIN CHANDLER,SENSEABILITY INC (2003-05-19),https://lens.org/190-528-225-684-112,Granted Patent,yes,10,6,1,1,0,A01J5/007;;A01J5/007,A01J5/007,119/14.02;;119/14.14;;119/14.37;;119/14.44,4,0,,,"InnovAg, 4 sheets of information of products available.;;DairyTest Professional, Document No. DR54-0053-01, 5 pages, InnovAg Pty. Ltd.;;DairyTest Monitor, 3 sheets of information.;;DairyTest Monitor, Document No. DR54-0047-07, 8 pages, InnovAg PTY. Ltd.",EXPIRED
18,CN,A,CN 102132195 A,037-377-383-208-549,2011-07-20,2011,CN 200980134116 A,2009-06-19,US 2009/0047994 W;;US 16322808 A,2008-06-27,Carabiner glasses,"A frame for glasses includes two temple bars and a lens receiving portion. The temple bar comprises a first end and a second end. The second end of at least one of the temple bars includes a fastening device having a body portion and a closure member, which is configured to move between an open position and a closed position. A temple bar is also provided for herein.",COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/037-377-383-208-549,Patent Application,no,2,0,5,5,0,G02C5/143;;G02C11/00;;G02C3/00;;G02C5/143;;G02C11/00;;G02C3/00,G02C5/14,,0,0,,,,INACTIVE
19,US,S,US D0576404 S,099-008-762-102-280,2008-09-09,2008,US 29339307 F,2007-11-20,US 29339307 F,2007-11-20,Pill organizer,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/099-008-762-102-280,Design Right,no,0,14,1,1,0,,,0301;;D 32033,0,0,,,,EXPIRED
20,US,A,US 4768290 A,105-382-641-599-433,1988-09-06,1988,US 3011787 A,1987-03-26,US 3011787 A,1987-03-26,Portable distance measuring device with pull out measuring filament,"The present invention provides a portable distance measuring device having a housing, a thread measuring member mounted to the housing and a spool of filament in the form of a thread or a thin metal wire which is pulled out of the housing and operates the thread measuring member to provide accurately measured distances. The filament is wound for low resistance unwinding from the spool which is itself fixed against rotation to prevent spool inertia breakage of the filament.",COOPER MARTIN F,COOPER MARTIN F,,https://lens.org/105-382-641-599-433,Granted Patent,yes,5,20,1,1,0,G01B3/11;;G01B5/043;;Y10S224/904;;G01B3/11;;G01B5/043;;Y10S224/904,G01B3/11;;G01B5/04,33/139;;224/252;;224/269;;224/904,0,0,,,,EXPIRED
21,WO,A1,WO 2013/126791 A1,113-044-322-412-166,2013-08-29,2013,US 2013/0027454 W,2013-02-22,US 201213404155 A,2012-02-24,ACCESSORY FOR WRIST WATCH,"An accessory for a wrist watch is provided and includes a substantially planar lower surface, an end surface, and an upper surface. The substantially planar lower surface is configured for selective attachment to a wrist watch. The end surface extends upwardly from the substantially planar lower surface. The upper surface extends between the substantially planar lower surface and the end surface. The upper surface is configured to conform to a user's wrist.",COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/113-044-322-412-166,Patent Application,yes,6,1,2,2,0,G04B47/00;;G04B47/00,B32B3/26;;G04B47/00;;B32B7/12,,0,0,,,,PENDING
22,US,A,US 3989945 A,174-260-000-115-766,1976-11-02,1976,US 47938774 A,1974-06-14,US 47938774 A,1974-06-14,Method for determining the concentration of fission products in a reactor coolant,"A method is disclosed for determining the concentration of fission products in the reactor coolant of a liquid metal cooled nuclear reactor. Reactor coolant is bypassed at constant temperatures and constant velocity through a flow sampling system containing a sampling tube. After a period of time, the sampling tube is isolated and removed from the bypass system; the liquid metal coolant is removed from the tube; and, the radionuclides deposited on the sampling tube are measured by gamma spectroscopy. The concentration of fission products in the reactor coolant is then determined from the measured radioactivity of the deposited nuclides.",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H,,https://lens.org/174-260-000-115-766,Granted Patent,yes,3,5,1,1,0,G01T7/02;;G21C17/025;;Y02E30/30;;G01T7/02;;G21C17/025,G01T7/02;;G21C17/025,250/304,0,0,,,,EXPIRED
23,EP,A1,EP 0195542 A1,009-797-354-864-446,1986-09-24,1986,EP 86301411 A,1986-02-27,GB 8505545 A,1985-03-05,Self watering means for plant pots.,"Self watering means for a plant pot comprise a reservoir (5, 22) to be placed in the bottom of a plant pot (1, 21), and a generally horizontal cover or bridge (3,25) supporting a wick ribbon (6, 26) in contact with plant nutrient medium in the pot to transfer water to the medium through the wick. A partition (28) or sleeve (8) defines a compartment in which a container (9, 29) is located with its outlet (10, 30) directed downwardly and defining water level in the reservoir. A normally closed valve (11, 31) is opened by pressing the container into position. A side compartment (32) with a marker float may be provided (Figure 3) with an outlet close to the outlet of the container (29), sudden emptying of the side compartment and dissapearance of the marker float (33) signaling that the container is nearly empty. The reservoir may extend substantially over the base of the pot, and have a boss (24) with a drainage aperture, or be a relatively small cup (5).",COOPER JAMES MARTIN,COOPER JAMES MARTIN,,https://lens.org/009-797-354-864-446,Patent Application,yes,8,15,2,2,0,A01G27/06,A01G27/06,,0,0,,,,DISCONTINUED
24,US,S,US D0785939 S,093-149-160-099-572,2017-05-09,2017,US 201429511855 F,2014-12-15,US 201429511855 F,2014-12-15,Container for electronic device,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/093-149-160-099-572,Design Right,no,0,8,1,1,0,,,0301;;D 3295;;D14/250,0,0,,,,ACTIVE
25,DE,A1,DE 2329899 A1,135-326-158-911-978,1974-01-03,1974,DE 2329899 A,1973-06-12,US 26305472 A,1972-06-15,VERFAHREN ZUR ABSCHEIDUNG VON VERUNREINIGUNGS-SPALTPRODUKTEN AUS DEM KUEHLMITTEL EINES KERNREAKTORS,,WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H,,https://lens.org/135-326-158-911-978,Patent Application,no,0,1,7,8,0,G21C19/31;;G21C19/31;;Y02E30/30,G21C19/313;;G21C19/31,,0,0,,,,PENDING
26,US,S,US D0642789 S,145-013-021-113-233,2011-08-09,2011,US 37550110 F,2010-09-23,US 37550110 F,2010-09-23,Pill container base,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/145-013-021-113-233,Design Right,no,0,10,1,1,0,,,0301;;D 32033,0,0,,,,ACTIVE
27,US,B1,US 7556374 B1,154-947-180-902-438,2009-07-07,2009,US 16322808 A,2008-06-27,US 16322808 A,2008-06-27,Carabiner glasses,"A frame for glasses includes two temple bars and a lens receiving portion. The temple bar comprises a first end and a second end. The second end of at least one of the temple bars includes a fastening device having a body portion and a closure member, which is configured to move between an open position and a closed position. A temple-bar is also provided for herein.",COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/154-947-180-902-438,Granted Patent,yes,11,16,5,5,0,G02C5/143;;G02C11/00;;G02C3/00;;G02C5/143;;G02C11/00;;G02C3/00,G02C1/00,351/158;;351/112;;351/121,0,0,,,,INACTIVE
28,WO,A1,WO 2015/085345 A1,003-575-607-986-731,2015-06-18,2015,AU 2014/001094 W,2014-12-04,AU 2013/904840 A,2013-12-12,HANGING APPARATUS IMPROVEMENTS,"This application discloses a hanging system comprising a pair of hanging elements, each hanging element comprising at least one bevelled edge, and wherein at least one of the hanging elements comprises a means for resisting sliding of its bevelled edge relative to the bevelled edge of the other hanging element when the two hanging elements are arranged so that the respective bevel led edges are facing and adjacent. A hanging element for the hanging system, and a method of using the hanging system are also disclosed.",GB USE PTY LTD,COOPER MARTIN ALBERT,,https://lens.org/003-575-607-986-731,Patent Application,yes,4,0,1,1,0,A47G1/1606,A47G1/16;;A47G1/20;;A47G29/02;;A47G29/087,,0,0,,,,PENDING
29,CA,A,CA 1258968 A,091-997-268-708-615,1989-09-05,1989,CA 532752 A,1987-03-23,CA 532752 A,1987-03-23,THREAD MEASURING DEVICE,"The present invention provides a portable distance measuring device having a housing, a thread measuring member mounted to the housing and a spool of filament in the form of a thread or a thin metal wire which is pulled out of the housing and operates the thread measuring member to provide accurately measured distances. The filament is wound for low resistance unwinding from the spool which is itself fixed against rotation to prevent spool inertia breakage of the filament.",COOPER MARTIN F,COOPER MARTIN F,,https://lens.org/091-997-268-708-615,Granted Patent,no,0,0,1,1,0,,G01B3/00,33-112,0,0,,,,EXPIRED
30,US,S,US D0505867 S,140-474-796-332-677,2005-06-07,2005,US 18202303 F,2003-05-19,US 18202303 F;;US 16314202 F,2002-06-27,Time display device,,COOPER AND COMPANY INC,COOPER MARTIN R,,https://lens.org/140-474-796-332-677,Design Right,no,0,9,2,2,0,,,1001;;D10/2;;D10/15;;D10/68,0,0,,,,EXPIRED
31,US,A,US 4069100 A,067-107-326-586-517,1978-01-17,1978,US 54957075 A,1975-02-13,US 54957075 A,1975-02-13,Adsorption seal for nuclear reactors,"A system for reducing the possibility of leakage of fission gases from a nuclear reactor of the gas-cooled type or of a type utilizing a liquid coolant, for example a liquid metal with a cover gas above free surfaces of the coolant. The disclosed system reduces the leakage of fission gases from the cover gas through joints between a pressure vessel and a pressure vessel head in the nuclear reactor by installing an adsorbent material between two seals placed in the joints. This adsorbent material provides sufficient delay time to allow all radioactive isotopes, except long-lived nuclides, to decay to innocuous concentrations before escaping from the pressure vessel.",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H,,https://lens.org/067-107-326-586-517,Granted Patent,yes,10,11,6,6,0,G21C13/10;;G21C13/10;;Y02E30/30;;Y02E30/30,F16J15/10;;G21C13/073;;G21C13/10,176/37,0,0,,,,EXPIRED
32,US,A,US 4204911 A,082-756-617-931-599,1980-05-27,1980,US 66816276 A,1976-03-16,US 66816276 A;;US 26305472 A,1972-06-15,Method and apparatus for removing iodine from a nuclear reactor coolant,A method and apparatus for removing iodine-131 and iodine-125 from a liquid sodium reactor coolant. Non-radioactive iodine is dissolved in hot liquid sodium to increase the total iodine concentration. Subsequent precipitation of the iodine in a cold trap removes both the radioactive iodine isotopes as well as the non-radioactive iodine.,WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H,,https://lens.org/082-756-617-931-599,Granted Patent,yes,7,12,1,8,0,G21C19/31;;Y02E30/30;;G21C19/31,G21C19/31,176/37,1,0,,,"1974 Annual Book of ASTM Standards, ""Standard Methods of Testing for Radioactive Iodine in Water"", 1974, pp. 526-534.",EXPIRED
33,WO,A1,WO 2007/120445 A1,118-697-097-375-249,2007-10-25,2007,US 2007/0007633 W,2007-03-27,US 78856506 P;;US 80890506 P,2006-03-31,"SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES","The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.",DYNOGEN PHARMACEUTICALS INC;;COOPER MARTIN IAN,COOPER MARTIN IAN,,https://lens.org/118-697-097-375-249,Patent Application,yes,3,0,2,2,0,C07D495/04;;A61P1/00;;A61P1/08;;A61P1/12;;A61P13/02;;A61P13/10;;C07D495/04,C07D495/04;;A61K31/519;;A61P1/08;;A61P13/02,,1,1,040-089-442-352-13X,10.1021/op000018u,"BASTIN R J ET AL: ""Salt Selection and Optimisation for Pharmaceutical New Chemical Entities"", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, CAMBRIDGE, GB, vol. 4, no. 5, 2000, pages 427 - 435, XP002228592",PENDING
34,US,A1,US 2008/0210701 A1,139-474-070-124-769,2008-09-04,2008,US 4152808 A,2008-03-03,US 4152808 A;;US 90447507 P;;US 1016608 P,2007-03-02,Medicinal Organizer,A medicinal organizer having a base and a plurality of containers. The base includes an alert system and a hanging arrangement. The plurality of containers is configured to be placed on the hanging arrangement. Each container is configured with at least one access opening disposed on a bottom section of each container allowing for the retrieval of medicinal item held within each respective container. Methods of using a medicinal organizer are also provided.,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/139-474-070-124-769,Patent Application,yes,41,15,1,1,0,A61J7/0481;;A61J7/0481;;A61J1/035;;A61J1/035;;A61J7/0454;;A61J7/0454;;A61J7/0463;;A61J7/0463,G07F11/00;;B65D83/04;;G06F17/00,221/3;;206/538;;221/1;;700/231,0,0,,,,DISCONTINUED
35,US,S,US D0571673 S,147-914-469-899-263,2008-06-24,2008,US 26438906 F,2006-08-09,US 26438906 F,2006-08-09,Clip watch,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/147-914-469-899-263,Design Right,no,0,1,1,1,0,,,1002;;D10/37,0,0,,,,EXPIRED
36,US,A,US 4010068 A,159-557-029-882-890,1977-03-01,1977,US 55478675 A,1975-03-03,US 55478675 A;;US 29323872 A,1972-09-28,Removal of radioactive contamination from a nuclear reactor coolant,"A system for removing radioactive fission products from a liquid metal reactor coolant. Isotopic diluents and reacting compounds are added to hot liquid sodium. The reactants isotopically exchange or chemically react with the fission products and are precipitated out of solution in a first cold trap. When the supply of reactants is exhausted, the flow is reversed; the first trap then functions to supply the reactants and the precipitation occurs in a second cold trap. The process operates continuously and reversibly.",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H,,https://lens.org/159-557-029-882-890,Granted Patent,yes,1,36,1,8,0,G21C19/31;;G21C19/313;;Y02E30/30;;G21C19/313;;G21C19/31,G21C19/31;;G21C19/313,176/37,0,0,,,,EXPIRED
37,MX,A,MX PA05007494 A,096-065-814-661-474,2005-09-21,2005,MX PA05007494 A,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,NOVEL COMPOUNDS.,"The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO-G or SO2-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C1-4 alkyl; Q is CR5R6 where R5 and R6 are as defined in the specification; and R4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,MARTIN EDWARD COOPER,,https://lens.org/096-065-814-661-474,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,EXPIRED
38,US,A,US 4131510 A,103-882-096-031-057,1978-12-26,1978,US 80857477 A,1977-06-21,US 80857477 A,1977-06-21,Magnetic nuclear core restraint and control,"A lateral restraint and control system for a nuclear reactor core adaptable to provide an inherent decrease of core reactivity in response to abnormally high reactor coolant fluid temperatures. An electromagnet is associated with structure for radially compressing the core during normal reactor conditions. A portion of the structures forming a magnetic circuit are composed of ferromagnetic material having a curie temperature corresponding to a selected coolant fluid temperature. Upon a selected signal, or inherently upon a preselected rise in coolant temperature, the magnetic force is decreased a given amount sufficient to relieve the compression force so as to allow core radial expansion. The expanded core configuration provides a decreased reactivity, tending to shut down the nuclear reaction.",US ENERGY,COOPER MARTIN H,,https://lens.org/103-882-096-031-057,Granted Patent,yes,4,6,2,2,0,G21C7/30;;G21D5/06;;Y02E30/30;;Y02E30/00;;G21D5/06;;G21C7/30;;Y02E30/30,G21C7/30;;G21D5/06,176/50,0,0,,,,EXPIRED
39,US,A,US 631952 A,174-846-897-782-00X,1899-08-29,1899,US 1898/0683391 A,1898-06-14,US 1898/0683391 A,1898-06-14,VAPORIZER.,,COOPER MARTIN L,COOPER MARTIN L,,https://lens.org/174-846-897-782-00X,Granted Patent,no,0,1,1,1,0,A61M16/1075;;A61M16/1075,,,0,0,,,,EXPIRED
40,US,S,US D0644950 S,067-987-538-386-398,2011-09-13,2011,US 201129391342 F,2011-05-06,US 201129391342 F,2011-05-06,Timepiece fob,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/067-987-538-386-398,Design Right,no,0,4,1,1,0,,,1007;;D10/128,0,0,,,,ACTIVE
41,US,A,US 5030411 A,102-515-496-768-161,1991-07-09,1991,US 27055888 A,1988-11-14,US 27055888 A,1988-11-14,Removal of impurities from coolant of a nuclear reactor,"The coolant is circulated thorugh the core of the reactor by a pump between a higher-pressure plenum and a lower-pressure plenum. The impurities are removed by a cold trap between the higher-pressure plenum and the lower-pressure plenum. The trap is an integrated unit including an inner tube and an outer tube defining between them an annulus which contains packing. The outer surface of the outer tube is cooled to a temperature such that the impurities are precipitated from the coolant. Since the packing is coldest on the outside, the precipitation progresses axially upstream to downstream and radially inwardly. The precipitation in the outer part of the annulus insulates the inner part of the annulus thermally so that the reduction of the temperature of the coolant to saturation level in the inner part is delayed precluding premature blocking of the cold trap. The cooled coolant in the annulus also precools the coolant flowing in through the inner tube.",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H,WESTINGHOUSE ELECTRIC CORPORATION A CORP. OF PA (1988-11-03),https://lens.org/102-515-496-768-161,Granted Patent,yes,6,16,3,3,0,G21C19/313;;Y02E30/30;;G21C19/313,G21C19/313,376/312;;376/315,0,0,,,,EXPIRED
42,WO,A1,WO 2013/166554 A1,114-635-266-308-639,2013-11-14,2013,AU 2013/000477 W,2013-05-10,AU 2012/901936 A,2012-05-11,"A MEANS AND METHOD FOR HANGING MIRRORS, PICTURES AND THE LIKE","This invention relates to a hanging element for hanging objects on vertical surfaces such as walls. The hanging element comprises a plate like body, at least one straight, lengthwise extending bevelled edge, and which is adapted for length adjustment thereof. An associated hanging system, and method of use for the hanging system are also disclosed.",GB USE PTY LTD,COOPER MARTIN ALBERT,,https://lens.org/114-635-266-308-639,Patent Application,yes,3,1,2,2,0,A47G1/16;;A47G1/1606,A47G1/16;;A47G1/20;;A47G29/02;;A47G29/087,,0,0,,,,PENDING
43,CA,C,CA 2214953 C,137-608-742-921-532,2001-09-04,2001,CA 2214953 A,1997-09-10,CA 2214953 A,1997-09-10,PORTABLE STAND,"In a combination stand and rack releasably secured atop the stand, the stand is convertible between an extended use position and a collapsed storage position. The rack includes a hollow spine for storage of the stand in the collapsed storage position. The stand comprises a main telescopic post and a plurality of support legs all of which are secured to a common housing. The main post extends upwardly from the housing and the legs are attached to the housing by connectors which are bendable through an angle of more than 90.degree. such that the legs fold upwardly beside the main post in the storage position and unfold downwardly from the housing to the use position.",COOPER MARTIN FREEMAN,COOPER MARTIN FREEMAN,,https://lens.org/137-608-742-921-532,Granted Patent,no,0,0,2,2,0,A47B19/08;;A47B19/002,A47B19/00;;A47B19/08,,0,0,,,,EXPIRED
44,US,B1,US 6234668 B1,199-727-839-770-33X,2001-05-22,2001,US 15094098 A,1998-09-10,US 15094098 A,1998-09-10,Holder for securing a timepiece to an article,"A holder for securing a timepiece to an article, such as a backpack, tent, bicycle, or ski coat for example. In a preferred embodiment, the holder comprises a base which is securable to a watch case, and a cover to shield the watch case when it is attached to the base. In one embodiment, the watch case is secured to the base by an elastic strap which is of a width and thickness to fit between the pins of the watch case and the body of the watch case. The cover can comprise a flexible band which is movable from an open position to a closed position, and which can be locked in the closed position. Rings may be provided at opposing ends of the base to connect the base to an article. A belt may be fed through the rings to assist in connecting the holder to the article.",COOPER & COMPANY INC,COOPER MARTIN R,COOPER AND COMPANY INC (1998-08-28),https://lens.org/199-727-839-770-33X,Granted Patent,yes,9,29,1,1,0,G04B37/1406;;G04B37/1406,G04B37/14,368/281;;368/283;;368/286;;224/164;;224/171,0,0,,,,EXPIRED
45,US,S,US D0569274 S,025-090-680-326-345,2008-05-20,2008,US 26440006 F,2006-08-09,US 26440006 F,2006-08-09,Watch casing,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/025-090-680-326-345,Design Right,no,0,0,1,1,0,,,1002;;D10/37,0,0,,,,EXPIRED
46,US,S,US D0493722 S,093-759-298-709-861,2004-08-03,2004,US 17991103 F,2003-04-16,US 17991103 F,2003-04-16,Watch holding device,,COOPER AND COMPANY INC,COOPER MARTIN R,COOPER AND COMPANY INC (2003-04-16),https://lens.org/093-759-298-709-861,Design Right,no,0,24,1,1,0,,,D 9504,0,0,,,,EXPIRED
47,US,A,US 1565260 A,152-324-240-403-718,1925-12-15,1925,US 68949224 A,1924-01-30,US 68949224 A,1924-01-30,Trunk,,MARTIN COOPER ROBERT,MARTIN COOPER ROBERT,,https://lens.org/152-324-240-403-718,Granted Patent,no,0,2,1,1,0,A45C5/065;;A45C5/065,A45C5/06,,0,0,,,,EXPIRED
48,US,A,US 875158 A,173-470-857-754-507,1907-12-31,1907,US 1907/0369636 A,1907-04-22,US 1907/0369636 A,1907-04-22,REINFORCING-FRAME FOR CONCRETE BUILDING CONSTRUCTION.,,COOPER MARTIN L,COOPER MARTIN L,,https://lens.org/173-470-857-754-507,Granted Patent,no,0,1,1,1,0,E04B2/8629;;E04B2/8629,,,0,0,,,,EXPIRED
49,US,S,US D0427104 S,184-176-666-724-462,2000-06-27,2000,US 9250398 F,1998-08-20,US 9250398 F,1998-08-20,Back cover for a watch,,COOPER AND COMPANY INC,COOPER MARTIN R,COOPER AND COMPANY INC (1998-08-18),https://lens.org/184-176-666-724-462,Design Right,yes,14,1,1,1,0,,,D10/128;;1002,0,0,,,,EXPIRED
50,US,S,US D0574692 S,198-793-860-256-203,2008-08-12,2008,US 26440906 F,2006-08-09,US 26440906 F,2006-08-09,Multifunctional clip device,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/198-793-860-256-203,Design Right,no,0,4,1,1,0,,,0805;;D 8105,0,0,,,,EXPIRED
51,WO,A1,WO 2009/158281 A1,119-735-867-110-476,2009-12-30,2009,US 2009/0047994 W,2009-06-19,US 16322808 A,2008-06-27,CARABINER GLASSES,"A frame for glasses includes two temple bars and a lens receiving portion. The temple bar comprises a first end and a second end. The second end of at least one of the temple bars includes a fastening device having a body portion and a closure member, which is configured to move between an open position and a closed position. A temple bar is also provided for herein.",COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/119-735-867-110-476,Patent Application,yes,3,0,5,5,0,G02C5/143;;G02C11/00;;G02C3/00;;G02C5/143;;G02C11/00;;G02C3/00,G02C5/14,,0,0,,,,PENDING
52,US,S,US D0789194 S,119-770-583-276-902,2017-06-13,2017,US 201529515392 F,2015-01-22,US 201529515392 F,2015-01-22,Display case,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/119-770-583-276-902,Design Right,no,0,3,1,1,0,,,0903;;D 9418;;D3/302;;D3/903,0,0,,,,ACTIVE
53,US,S,US D0493726 S,092-574-966-835-365,2004-08-03,2004,US 15778502 F,2002-03-26,US 15778502 F,2002-03-26,Timepiece device,,COOPER AND COMPANY INC,COOPER MARTIN R,COOPER AND COMPANY INC (2002-03-06),https://lens.org/092-574-966-835-365,Design Right,no,0,0,1,1,0,,,D10/4;;D10/31;;D10/2,0,0,,,,EXPIRED
54,AU,A1,AU 2013/258876 A1,111-658-526-531-793,2014-11-20,2014,AU 2013/258876 A,2013-05-10,AU 2012/901936 A;;AU 2013/000477 W;;AU 2013/258876 A,2012-05-11,"A means and method for hanging mirrors, pictures and the like","This invention relates to a hanging element for hanging objects on vertical surfaces such as walls. The hanging element comprises a plate like body, at least one straight, lengthwise extending bevelled edge, and which is adapted for length adjustment thereof. An associated hanging system, and method of use for the hanging system are also disclosed.",GB USE PTY LTD,COOPER MARTIN ALBERT,,https://lens.org/111-658-526-531-793,Patent Application,no,0,0,2,2,0,A47G1/16;;A47G1/1606,A47G1/16;;A47G1/20;;A47G29/02;;A47G29/087,,0,0,,,,DISCONTINUED
55,FR,A1,FR 2639140 A1,163-037-078-501-578,1990-05-18,1990,FR 8914859 A,1989-11-13,US 27055888 A,1988-11-14,"REACTEUR NUCLEAIRE, PIEGE A FROID, ET PROCEDE POUR RETIRER LES IMPURETES DU CALOPORTEUR D'UN REACTEUR NUCLEAIRE","<P>Le caloporteur circule à travers le coeur 25 du réacteur 11 grâce à une pompe entre une chambre à haute pression 31 et une chambre à basse pression 33. Les impuretés sont retirées par un piège à froid 51, 53 entre la chambre à haute pression 31 et la chambre à basse pression 33. Le piège 51, 53 est une unité intégrée comprenant un tube intérieur 59 et un tube extérieur 61 définissant entre ceux-ci un anneau qui contient le rembourrage. La surface extérieure du tube extérieur 61 est refroidi à une température telle que les impuretés sont précipitées à partir du caloporteur. Comme le rembourrage est le plus froid sur l'extérieur, la précipitation progresse axialement d'amont en aval et radialement vers l'intérieur. La précipitation dans la partie extérieure de l'anneau isole la partie intérieure de l'anneau thermiquement, ce qui fait que la réduction de la température du caloporteur au niveau de saturation dans la partie intérieure est retardée, ce qui empêche le blocage prématuré du piège à froid 51, 53. Le caloporteur refroidi dans l'anneau pré-refroidit également le caloporteur s'écoulant à travers le tube intérieur 59.</P>",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN HOWARD,,https://lens.org/163-037-078-501-578,Patent Application,no,4,0,3,3,0,G21C19/313;;Y02E30/30;;G21C19/313,G21C19/313,,3,0,,,"ENERGIE NUCLEAIRE, vol. 13, no. 6, novembre-décembre 1971, pages 430-433; J. CORON et al.: ""Les méthodes de purification du sodium"";;PATENT ABSTRACTS OF JAPAN, vol. 6, no. 106 (C-108)[984], 16 juin 1982; & JP-A-57 35 649 (TOKYO SHIBAURA DENKI K.K.) 26-02-1982;;PATENT ABSTRACTS OF JAPAN, vol. 6, no. 250 (C-139)[1128], 9 décembre 1982; & JP-A-57 147 402 (TOKYO SHIBAURA DENKI K.K.) 11-09-1982",DISCONTINUED
56,US,S,US D0505337 S,004-455-835-260-457,2005-05-24,2005,US 18373903 F,2003-06-17,US 18373903 F,2003-06-17,Time display device,,COOPER & CO INC,COOPER MARTIN R,COOPER & CO. INC (2003-06-17),https://lens.org/004-455-835-260-457,Design Right,no,0,11,1,1,0,,,1002;;D10/2,0,0,,,,EXPIRED
57,US,S,US D0547052 S,032-858-272-826-50X,2007-07-24,2007,US 25496806 F,2006-03-02,US 25496806 F,2006-03-02,Pill organizer,,COOPER MARTIN R,COOPER MARTIN R,,https://lens.org/032-858-272-826-50X,Design Right,no,0,16,1,1,0,,,0301;;D 32033,0,0,,,,EXPIRED
58,US,S,US D0478011 S,051-033-326-680-87X,2003-08-05,2003,US 16314202 F,2002-06-27,US 16314202 F,2002-06-27,Time display device,,COOPER AND COMPANY INC,COOPER MARTIN R,COOPER AND COMPANY INC (2002-06-20),https://lens.org/051-033-326-680-87X,Design Right,no,0,8,2,2,0,,,D10/31;;D10/2;;D10/5,0,0,,,,EXPIRED
59,DE,A1,DE 2348804 A1,130-871-952-643-175,1974-04-04,1974,DE 2348804 A,1973-09-28,US 29323872 A,1972-09-28,VERFAHREN ZUR ENTFERNUNG VON SPALTPRODUKTEN AUS KUEHLMITTELN VON KERNREAKTORANLAGEN,,WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H,,https://lens.org/130-871-952-643-175,Patent Application,no,0,5,7,8,0,G21C19/31;;G21C19/313;;Y02E30/30;;G21C19/313;;G21C19/31,G21F9/06;;C22B26/10;;G21C19/31;;G21C19/313;;G21F9/00,,0,0,,,,PENDING
60,US,A,US 5713553 A,191-456-039-598-997,1998-02-03,1998,US 70784996 A,1996-09-06,US 70784996 A,1996-09-06,Portable stand,"In a combination stand and rack releasably secured atop the stand, the stand is convertible between an extended use position and a collapsed storage position. The rack includes a hollow spine for storage of the stand in the collapsed storage position. The stand comprises a main telescopic post and a plurality of support legs all of which are secured to a common housing. The main post extends upwardly from the housing and the legs are attached to the housing by connectors which are bendable through an angle of more than 90.degree. such that the legs fold upwardly beside the main post in the storage position and unfold downwardly from the housing to the use position.",COOPER; MARTIN F.,COOPER MARTIN F,,https://lens.org/191-456-039-598-997,Granted Patent,yes,11,36,1,1,0,A47B3/10;;A47B19/002;;A47B19/08;;A47B2019/004;;A47B19/002;;A47B3/10;;A47B2019/004;;A47B19/08,A47B19/00;;A47B19/08,248/461;;248/170;;248/188.6;;248/188.7;;248/464,0,0,,,,EXPIRED
61,US,A,US 3233243 A,094-470-532-045-16X,1966-02-01,1966,US 6416960 A,1960-10-21,US 6416960 A,1960-10-21,Decoder and printer,,MOTOROLA INC,MARTIN COOPER;;JOSEPH GARDBERG,,https://lens.org/094-470-532-045-16X,Granted Patent,no,16,1,1,1,0,G08B25/10;;G08B25/10,G08B25/10,,0,0,,,,EXPIRED
62,CA,A,CA 741016 A,162-976-155-420-683,1966-08-16,1966,CA 741016D A,,CA 741016T A,,DECODER AND PRINTER APPARATUS IN RADIO ALARM SYSTEM,,MOTOROLA INC,COOPER MARTIN;;GARDBERG JOSEPH,,https://lens.org/162-976-155-420-683,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
63,DE,T2,DE 69618201 T2,172-097-512-424-853,2002-07-18,2002,DE 69618201 T,1996-07-17,GB 9514558 A;;GB 9601712 W,1995-07-17,MARKIEREN VON DIAMANTEN,,GERSAN ESTABLISHMENT VADUZ,SMITH GORDON;;COOPER MARTIN,,https://lens.org/172-097-512-424-853,Granted Patent,no,0,1,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B44B7/00;;B28D5/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
64,DE,T2,DE 60108478 T2,043-983-318-402-30X,2006-03-23,2006,DE 60108478 T,2001-03-05,GB 0005038 A;;GB 0100900 W,2000-03-03,MEHRWEGGEGENSTAND ZUR BENUTZUNG IN LAGERUNG UND TRANSPORT KOMMERZIELLER ARTIKEL,,LINPAC MOULDINGS LTD,LOFTUS CLIVE;;COOPER MARTIN,,https://lens.org/043-983-318-402-30X,Granted Patent,no,0,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,G06K19/04;;B65D23/14;;G06K19/077,,0,0,,,,EXPIRED
65,DE,D1,DE 69618201 D1,099-989-315-784-794,2002-01-31,2002,DE 69618201 T,1996-07-17,GB 9514558 A;;GB 9601712 W,1995-07-17,MARKIEREN VON DIAMANTEN,,GERSAN ESTABLISHMENT VADUZ,SMITH GORDON;;COOPER MARTIN,,https://lens.org/099-989-315-784-794,Granted Patent,no,0,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B44B7/00;;B28D5/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
66,DE,D1,DE 69911451 D1,016-249-697-978-994,2003-10-23,2003,DE 69911451 T,1999-10-22,GB 9823029 A;;GB 9903516 W,1998-10-22,VERPACKUNGSSYSTEM ZUR MISCHUNG UND ABGABE VON MEHRKOMPONENTENPRODUKTEN,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MARTIN;;HEALY MICHAEL,,https://lens.org/016-249-697-978-994,Granted Patent,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,EXPIRED
67,DE,D1,DE 68906265 D1,076-609-175-187-178,1993-06-03,1993,DE 68906265 T,1989-08-15,GB 8900942 W;;GB 8819351 A,1988-08-15,HERSTELLUNG EINES LAENGLICHEN SCHNITTES MITTELS HOHER ENERGIESTRAHLUNG.,,GERSAN ANSTALT,COOPER MARTIN;;STEWART ANDREW,,https://lens.org/076-609-175-187-178,Granted Patent,no,0,0,2,30,0,,B23K26/06,,0,0,,,,EXPIRED
68,DE,D1,DE 60108478 D1,032-599-515-148-43X,2005-02-24,2005,DE 60108478 T,2001-03-05,GB 0005038 A;;GB 0100900 W,2000-03-03,MEHRWEGGEGENSTAND ZUR BENUTZUNG IN LAGERUNG UND TRANSPORT KOMMERZIELLER ARTIKEL,,LINPAC MOULDINGS LTD,LOFTUS CLIVE;;COOPER MARTIN,,https://lens.org/032-599-515-148-43X,Granted Patent,no,0,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,,0,0,,,,EXPIRED
69,DE,T2,DE 68906265 T2,090-115-242-814-336,1993-08-19,1993,DE 68906265 T,1989-08-15,GB 8900942 W;;GB 8819351 A,1988-08-15,HERSTELLUNG EINES LAENGLICHEN SCHNITTES MITTELS HOHER ENERGIESTRAHLUNG.,,GERSAN ANSTALT,COOPER MARTIN;;STEWART ANDREW,,https://lens.org/090-115-242-814-336,Granted Patent,no,0,0,2,30,0,,B23K26/06,,0,0,,,,EXPIRED
70,GB,A,GB 2563901 A,107-981-465-022-922,2019-01-02,2019,GB 201710424 A,2017-06-29,GB 201710424 A,2017-06-29,Coaxial cable connector,"A coaxial cable connector 10 comprises a gripping portion and a threaded portion 20. The gripping portion comprises two spaced apart resiliently expandable metal collars 14, 16, and the threaded portion is located in a region 18 between the collars. The collars may be interconnected by at least two struts (26, Fig 2) and the threaded portion 20 formed with channels (30, Fig 2) to receive the struts.",TECHNETIX BV,BRYNN COOPER;;DAVID MARTIN,,https://lens.org/107-981-465-022-922,Patent Application,no,3,0,3,3,0,H01R13/187;;H01R24/40;;H01R24/40,H01R24/40,,0,0,,,,ACTIVE
71,GB,B,GB 2563901 B,017-513-921-294-893,2022-08-10,2022,GB 201710424 A,2017-06-29,GB 201710424 A,2017-06-29,Coaxial cable connector,,TECHNETIX BV,BRYNN COOPER;;DAVID MARTIN,,https://lens.org/017-513-921-294-893,Granted Patent,no,10,0,3,3,0,H01R13/187;;H01R24/40;;H01R24/40,H01R24/40;;H01R13/187;;H01R13/6581,,0,0,,,,ACTIVE
72,HK,A1,HK 1160231 A1,034-603-549-640-782,2012-08-10,2012,HK 12100674 A,2012-01-20,US 2009/0047994 W;;US 16322808 A,2008-06-27,CARABINER GLASSES,,COOPE MARTIN,COOPER MARTIN R R,,https://lens.org/034-603-549-640-782,Patent Application,no,0,0,5,5,0,G02C5/143;;G02C11/00;;G02C3/00;;G02C5/143;;G02C11/00;;G02C3/00,G02C/,,0,0,,,,DISCONTINUED
73,DE,T2,DE 69911451 T2,194-053-234-509-075,2004-07-08,2004,DE 69911451 T,1999-10-22,GB 9823029 A;;GB 9903516 W,1998-10-22,VERPACKUNGSSYSTEM ZUR MISCHUNG UND ABGABE VON MEHRKOMPONENTENPRODUKTEN,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MARTIN;;HEALY MICHAEL,,https://lens.org/194-053-234-509-075,Granted Patent,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,EXPIRED
74,ZA,B,ZA 896206 B,032-476-820-345-683,1990-05-30,1990,ZA 896206 A,1989-08-15,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH DENSITY RADIATION,,GERSAN ANSTALT,COOPER MARTIN;;MARTIN COOPER;;STEWART ANDREW DAVID GARRY;;ANDREW DAVID GARRY STEWART,,https://lens.org/032-476-820-345-683,Granted Patent,no,0,0,13,30,0,B23K26/364;;B23K26/364,B23K26/06;;B23K26/073;;B23K26/36;;B23K26/00,,0,0,,,,EXPIRED
75,CN,A,CN 1761670 A,039-662-158-450-473,2006-04-19,2006,CN 200480007101 A,2004-01-15,SE 0300120 A,2003-01-17,Novel compounds,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,TASNEEM COOPER MARTIN EDWARD G,,https://lens.org/039-662-158-450-473,Patent Application,no,0,1,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,EXPIRED
76,WO,A3,WO 1996/039779 A3,123-133-294-275-615,1996-12-12,1996,US US9608521,1996-06-03,GB 9510870.0,1995-06-02,CONTROL MESSAGE TRANSMISSION IN TELECOMMUNICATIONS SYSTEMS,"A communications interface is used in a telecommunications network station including a number of network elements, a controller for controlling the network elements and an internal bus interconnecting the controller and the network elements. The controller operates as a busmaster on the bus and each of the network elements operates as a slave on the bus. The communications interface has a pool of buffers for temporary message storage and a polling function for temporarily storing a message received from the bus in a buffer and/or for taking a message from a buffer for transmission over the bus. A binary sequence number is inverted for a reply if a received message is valid, otherwise it is not changed for the reply. A message is re-sent when the sequence number in a reply has not changed.",DSC COMMUNICATIONS CORPORATION,"LYSEJKO, Martin;;COOPER, Guy, Alexander",,https://lens.org/123-133-294-275-615,Search Report,yes,0,0,1,2,0,,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J11/00;;H04J13/00;;H04J3/06;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04L9/32;;H04Q11/04;;H04W12/06;;H04W52/52;;H04W52/08,,0,0,,,,UNKNOWN
77,EP,A1,EP 2964339 A1,161-022-775-820-297,2016-01-13,2016,EP 14713564 A,2014-03-05,GB 201304316 A;;US 201361843476 P;;GB 2014050639 W,2013-03-07,FIRE AND/OR SMOKE BARRIER,,COOPERS FIRE LTD,COOPER ANDREW;;REED JAMES MARTIN,,https://lens.org/161-022-775-820-297,Patent Application,yes,0,1,6,6,0,A62C2/10;;A62C2/10;;E06B5/00;;E06B9/42;;E06B9/42;;E06B9/56,A62C2/10;;E06B9/42,,1,0,,,See references of WO 2014135863A1,ACTIVE
78,US,A1,US 2004/0053215 A1,005-611-175-244-045,2004-03-18,2004,US 38056503 A,2003-06-17,GB 0022505 A;;GB 0104053 W,2000-09-14,Method and primers for detecting viral genes,"
   A method for detecting luteoviruses comprises extracting nucleic acid from plant tissue and making a first strand DNA using a PCR primer and amplifying the DNA using a second PCR primer to obtain as PCR product and comparing amino acid sequences in the PCR product obtained with known amino acid sequences characteristic of the luteovirus to detect the presence of the luteovirus. 
",COOPER JOSEPH IAN;;NAYLOR MARTIN,COOPER JOSEPH IAN;;NAYLOR MARTIN,NATURAL ENVIRONMENT RESEARCH COUNCIL THE (2003-05-21),https://lens.org/005-611-175-244-045,Patent Application,yes,0,0,6,6,41,C12Q1/701;;C12Q1/701,C12Q1/68;;C12Q1/70,435/5,0,0,,,,DISCONTINUED
79,GB,B,GB 2301751 B,012-874-386-434-736,2000-02-09,2000,GB 9510870 A,1995-06-02,GB 9510870 A,1995-06-02,Control message transmission in telecommunications systems,,DSC COMMUNICATIONS;;DSC TELECOM LP;;AIRSPAN COMM CORP,LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/012-874-386-434-736,Granted Patent,no,9,0,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,H4P PPD           PPD;;H4P PPEC          PPEC,0,0,,,,EXPIRED
80,NL,A1,NL 1033167 A1,054-877-692-729-409,2007-07-09,2007,NL 1033167 A,2007-01-04,GB 0600122 A,2006-01-05,Mutatie in de groeihormoonreceptor.,,UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/054-877-692-729-409,Granted Patent,no,0,0,9,9,0,C07K14/71;;C12Q1/6883;;C12Q1/6883;;C12Q2600/156,C12Q1/68;;C07K14/61,,0,0,,,,INACTIVE
81,EP,B1,EP 1261937 B1,097-394-720-361-992,2005-01-19,2005,EP 01907967 A,2001-03-05,GB 0100900 W;;GB 0005038 A,2000-03-03,RETURNABLE ITEM FOR USE IN STORAGE AND TRANSPORTATION OF COMMERCIALS GOODS,,LINPAC MOULDINGS LTD,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,LINPAC MOULDINGS LIMITED (2004-12-08);;LINPAC MATERIALS HANDLING LIMITED (2005-11-16),https://lens.org/097-394-720-361-992,Granted Patent,yes,6,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,,0,0,,,,EXPIRED
82,AU,A,AU 2001/035832 A,062-751-869-283-059,2001-09-17,2001,AU 2001/035832 A,2001-03-05,GB 0005038 A;;GB 0100900 W,2000-03-03,Returnable item for use in storage and transportation of commercials goods,,MCKECHNIE INVEST HOLDINGS,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,,https://lens.org/062-751-869-283-059,Patent Application,no,0,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,,0,0,,,,PENDING
83,EP,A2,EP 1322783 A2,106-140-704-401-258,2003-07-02,2003,EP 01967475 A,2001-09-10,GB 0104053 W;;GB 0022505 A,2000-09-14,METHOD AND PRIMERS FOR DETECTING VIRAL GENES,,NATURAL ENVIRONMENT RES,COOPER JOSEPH IAN;;NAYLOR MARTIN,,https://lens.org/106-140-704-401-258,Patent Application,yes,0,0,6,6,0,C12Q1/701;;C12Q1/701,C12Q1/68;;C12Q1/70,,1,0,,,See references of WO 0222868A3,DISCONTINUED
84,WO,A3,WO 2007/077425 A3,008-230-494-117-676,2008-01-24,2008,GB 2006004923 W,2006-12-27,GB 0600122 A,2006-01-05,MUTATION IN THE GROWTH HORMONE RECEPTOR,The invention relates to a novel method for assaying for the exon (3) deletion in the growth hormone receptor gene and the use of the exon (3) deletion for screening individuals for susceptibility to hypertension or stroke.,UNIV CARDIFF;;COOPER DAVID NEIL;;HORAN MARTIN,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/008-230-494-117-676,Search Report,yes,2,0,9,9,0,C07K14/71;;C12Q1/6883;;C12Q1/6883;;C12Q2600/156,C12Q1/68,,10,8,060-694-166-596-306;;023-603-319-873-821;;003-101-140-171-904;;030-253-099-402-484;;074-100-191-687-282;;020-312-701-947-992;;036-810-690-409-955;;005-613-652-908-094,10.1210/jcem.81.2.8636303;;10.1210/jc.81.2.775;;8636303;;10.1210/jc.80.7.2154;;7608270;;10.1210/jcem.80.7.7608270;;10.1073/pnas.93.22.12394;;pmc38002;;8901592;;10.1007/s00439-006-0166-5;;16572267;;10.1210/jc.2002-021667;;12679461;;8360189;;10.1016/s0021-9258(17)46730-5;;10.1210/me.6.2.279;;1569971;;10.1210/mend.6.2.1569971;;02813379;;2813379;;pmc298219;;10.1073/pnas.86.20.8083,"ZOGOPOULOS G ET AL: ""Expression of exon 3-retaining and -deleted human growth hormone receptor messenger ribonucleic acid isoforms during development"", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 81, no. 2, 1996, pages 775 - 782, XP002458639, ISSN: 0021-972X;;WICKELGREN RUTH B ET AL: ""Expression of exon 3-retaining and exon 3-excluding isoforms of the human growth hormone-receptor is regulated in an interindividual, rather than a tissue-specific, manner"", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 80, no. 7, 1995, pages 2154 - 2157, XP002458640, ISSN: 0021-972X;;STALLINGS-MANN M L ET AL: ""Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 93, no. 22, 1996, pages 12394 - 12399, XP002269536, ISSN: 0027-8424;;SALMON M: ""TECHNOSCOPE: LA PCR EN TEMPS REEL"", BIOFUTUR, LAVOISIER, CACHAN, FR, vol. 219, February 2002 (2002-02-01), pages 2 - 8, XP001106456, ISSN: 0294-3506;;HORAN MARTIN ET AL: ""Genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke"", HUMAN GENETICS, BERLIN, DE, vol. 119, no. 5, June 2006 (2006-06-01), pages 527 - 540, XP002438470, ISSN: 0340-6717;;PANTEL J ET AL: ""HETEROZYGOUS NONSENSE MUTATION IN EXON 3 OF THE GROWTH HORMONE RECEPTOR (GHR) IN SEVERE GH INSENSITIVITY (LARON SYNDROME) AND THE ISSUE OF THE ORIGIN AND FUNCTION OF THE GHRD3 ISOFORM"", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, ENDOCRINE SOCIETY, CHEVY CHASE, MD, US, vol. 88, no. 4, April 2003 (2003-04-01), pages 1705 - 1710, XP009025421, ISSN: 0021-972X;;URBANEK MARGRIT ET AL: ""Functional characterization of the alternatively spliced, placental human growth hormone receptor"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 25, 1993, pages 19025 - 19032, XP002458641, ISSN: 0021-9258;;URBANEK M ET AL: ""EXPRESSION OF A HUMAN GROWTH HORMONE HGH RECEPTOR ISOFORM IS PREDICTED BY TISSUE-SPECIFIC ALTERNATIVE SPLICING OF EXON 3 OF THE HGH RECEPTOR GENE TRANSCRIPT"", MOLECULAR ENDOCRINOLOGY, vol. 6, no. 2, 1992, pages 279 - 287, XP002458642, ISSN: 0888-8809;;GODOWSKI P J ET AL: ""CHARACTERIZATION OF THE HUMAN GROWTH HORMONE RECEPTOR GENE AND DEMONSTRATION OF A PARTIAL GENE DELETION IN TWO PATIENTS WITH LARON-TYPE DWARFISM"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 86, no. 20, 1989, pages 8083 - 8087, XP002458643, ISSN: 0027-8424;;DATABASE NCBI [online] 8 November 1994 (1994-11-08), GODOWSKI P.J. ET AL: ""Human Growth Hormone Receptor Gene"", XP002458644, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/ENTREZ/VIEWER.FCGI?DB=NUCCORE&ID=183170 Database accession no. AH002706",PENDING
85,GB,A8,GB 2379836 A8,008-109-612-001-240,2003-03-24,2003,GB 0220851 A,2001-03-05,GB 0100900 W;;GB 0005038 A,2000-03-03,Returnable item for use in storage and transportation of commercials goods,,PAXTON C G LTD,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,,https://lens.org/008-109-612-001-240,Patent Application,no,0,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,H4L LASS,0,0,,,,EXPIRED
86,WO,A3,WO 2007/077422 A3,030-174-426-564-750,2007-09-27,2007,GB 2006004904 W,2006-12-23,GB 0600116 A,2006-01-05,ALLELE-SPECIFIC SEQUENCING,"The invention relates to a novel method of allele-specific sequencing in any gene which involves the knowledge of the existing SNPs within said gene and, in particular, those SNPs that are phenotypically significant for a given condition.",UNIV CARDIFF;;COOPER DAVID NEIL;;HORAN MARTIN,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/030-174-426-564-750,Search Report,yes,4,0,9,9,0,C12Q1/6827;;C12Q1/6858;;C12Q1/6869;;C12Q1/6827;;C12Q1/6883,C12Q1/68,,6,5,090-469-323-879-623;;085-845-399-135-271;;069-127-368-437-406;;018-029-634-423-113;;030-253-099-402-484,9254859;;10.1007/s004390050500;;10.1186/1471-2393-5-2;;15691369;;pmc548522;;9405026;;10.1530/eje.0.1370474;;12655556;;10.1002/humu.10167;;10.1007/s00439-006-0166-5;;16572267,"GIORDANO M ET AL: ""EVIDENCE FOR GENE CONVERSION IN THE GENERATION OF EXTENSIVE POLYMORPHISM IN THE PROMOTER OF THE GROWTH HORMONE GENE"", HUMAN GENETICS, BERLIN, DE, vol. 100, 1997, pages 249 - 255, XP000990217, ISSN: 0340-6717;;ADKINS R.M. ET AL.,: ""association between fetal growth restriction and polymorphisms at sites -1 and +3 of pituitary growth hormone: a case -control study"", BMC PREGNANCY AND CHILDBIRTH, vol. 5, no. 2, 3 February 2005 (2005-02-03), pages 1 - 7, XP002440410;;DATABASE WPI Week 200623, Derwent World Patents Index; AN 2006-213610, XP002440429;;WAGNER J K ET AL: ""ALLELIC VARIATIONS IN THE HUMAN GROWTH HORMONE-1 GENE PROMOTER OF GROWTH HORMONE-DEFICIENT PATIENTS AND NORMAL CONTROLS"", EUROPEAN JOURNAL OF ENDOCRINOLOGY, SCANDINAVIAN UNIVERSITY PRESS, NO, vol. 137, 1997, pages 474 - 481, XP000990216, ISSN: 0804-4643;;HORAN M. ET AL.,: ""human growth hormone 1 (GH1) geneexpression: complex haplotype-dependent influence of polymorphic variation in the proximal promoter and locus control region"", HUM. MUTAT., vol. 21, 2003, pages 408 - 423, XP002440411;;HORAN M. ET AL.,: ""genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke"", HUM. GENETR., vol. 119, 30 March 2006 (2006-03-30), pages 527 - 540, XP002438470",PENDING
87,AU,A,AU 1996/059738 A,113-393-190-572-920,1996-12-24,1996,AU 1996/059738 A,1996-06-03,GB 9510870 A;;US 9608521 W,1995-06-02,Control message transmission in telecommunications systems,,DSC COMMUNICATIONS,LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/113-393-190-572-920,Patent Application,no,0,0,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,PENDING
88,WO,A2,WO 1996/039779 A2,188-606-041-896-187,1996-12-12,1996,US 9608521 W,1996-06-03,GB 9510870 A,1995-06-02,CONTROL MESSAGE TRANSMISSION IN TELECOMMUNICATIONS SYSTEMS,"A communications interface is used in a telecommunications network station including a number of network elements, a controller for controlling the network elements and an internal bus interconnecting the controller and the network elements. The controller operates as a busmaster on the bus and each of the network elements operates as a slave on the bus. The communications interface has a pool of buffers for temporary message storage and a polling function for temporarily storing a message received from the bus in a buffer and/or for taking a message from a buffer for transmission over the bus. A binary sequence number is inverted for a reply if a received message is valid, otherwise it is not changed for the reply. A message is re-sent when the sequence number in a reply has not changed.",DSC COMMUNICATIONS,LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/188-606-041-896-187,Patent Application,no,0,0,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,PENDING
89,WO,A2,WO 2007/077425 A2,046-074-028-357-96X,2007-07-12,2007,GB 2006004923 W,2006-12-27,GB 0600122 A,2006-01-05,MUTATION IN THE GROWTH HORMONE RECEPTOR,The invention relates to a novel method for assaying for the exon 3 deletion in the growth hormone receptor gene and the use of the exon 3 deletion for screening individuals for susceptibility to hypertension or stroke.,UNIV CARDIFF;;COOPER DAVID NEIL;;HORAN MARTIN,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/046-074-028-357-96X,Patent Application,yes,0,0,9,9,9,C07K14/71;;C12Q1/6883;;C12Q1/6883;;C12Q2600/156,C12Q1/68,,0,0,,,,PENDING
90,EP,B1,EP 0839098 B1,116-721-131-536-320,2001-12-19,2001,EP 96924981 A,1996-07-17,GB 9601712 W;;GB 9514558 A,1995-07-17,MARKING DIAMOND,,GERSAN ETS,SMITH JAMES GORDON;;COOPER MARTIN,,https://lens.org/116-721-131-536-320,Granted Patent,yes,3,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B44B7/00;;B28D5/00;;C30B29/04;;H01S3/00,,1,0,,,"Diamond International, January/February 1992, page 25, ""New Distributors for Laser Diamonds"".",EXPIRED
91,IN,B,IN 152600 B,028-734-316-099-561,1984-02-18,1984,IN 673CA1980 A,1980-06-06,GB 7919970 A,1979-06-08,WORKING GEM STONES,,GERSAN ETS,BEAL DAVID WILLIAM;;COOPER MARTIN,,https://lens.org/028-734-316-099-561,Granted Patent,no,0,0,7,9,0,B28D5/00,B28D5/00,,0,0,,,,EXPIRED
92,GB,A,GB 2301751 A,125-230-026-037-490,1996-12-11,1996,GB 9510870 A,1995-06-02,GB 9510870 A,1995-06-02,Control message transmission in telecommunications systems,,DSC COMMUNICATIONS,LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/125-230-026-037-490,Patent Application,no,9,13,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,H4P PPD           PPD;;H4P PPEC          PPEC,0,0,,,,EXPIRED
93,WO,A1,WO 2001/067384 A1,116-504-266-964-41X,2001-09-13,2001,GB 0100900 W,2001-03-05,GB 0005038 A,2000-03-03,RETURNABLE ITEM FOR USE IN STORAGE AND TRANSPORTATION OF COMMERCIALS GOODS,"A container (10) (or other returnable item) for the storage and delivery of goods, comprises antenna means (16) for radio frequency use, and connection means (18) for receiving a removable drive circuit means (20). The drive circuit (20) is operable to communicate by means of the antenna (16) when connected therewith. The connections (18) serve, in use, to connect an installed drive circuit (20) with the antenna (16) to allow the drive circuit (20) to communicate. This allows the identity of the container or its contents to be communicated to a remote location.",MCKECHNIE INVEST HOLDINGS;;LOFTUS STEPHEN CLIVE;;COOPER MARTIN,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,,https://lens.org/116-504-266-964-41X,Patent Application,yes,6,6,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,,0,0,,,,PATENTED
94,GB,A,GB 2433992 A,129-702-708-112-679,2007-07-11,2007,GB 0625889 A,2006-12-23,GB 0600116 A,2006-01-05,ALLELE-SPECIFIC SEQUENCING,"A method of allele-specific sequencing any gene which involves the knowledge of the existing SNPs within said gene wherein a sample comprising a nucleic acid to be sequenced is hybridized with an allele specific primer whose terminal 3' base is homologous with at least one single nucleotide polymorphism (SNP) within said nucleic acid, transcribing the nucleic acid to produce a complementary nucleic acid strand, sequencing said complementary nucleic acid strand to determine the existence of other known SNPs and using this information to haplotype an individual. The method is claimed in use on the growth hormone gene GH1, as are specific primers. Alternatively claimed are methods of detecting hypertension or stroke in an individual by determining the haplotype of the GH1 gene, including specific haplotypes.",UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/129-702-708-112-679,Patent Application,no,4,0,9,9,0,C12Q1/6827;;C12Q1/6858;;C12Q1/6869;;C12Q1/6827;;C12Q1/6883,C12Q1/68,G1B BAC           BAC;;G1B B224          BAC;;U1S S4001,2,2,016-352-960-597-845;;018-029-634-423-113,10.1016/s0165-022x(02)00114-8;;12559584;;12655556;;10.1002/humu.10167,"J Biochemical Biophysical Methods, Vol 55 , 2003, M Nagano et al, ""Allele-specific long-range PCR/sequencing method for ..."", 1-9;;Human Mutation, Vol 21, 2003, M Horan et al, ""Human growth hormone 1(GH1) gene expression:..."", 408-423",DISCONTINUED
95,WO,A2,WO 2002/022868 A2,077-110-645-237-461,2002-03-21,2002,GB 0104053 W,2001-09-10,GB 0022505 A,2000-09-14,METHOD AND PRIMERS FOR DETECTING VIRAL GENES,A method for detecting luteoviruses comprises extracting nucleic acid from plant tissue and making a first strand DNA using a PCR primer and amplifying the DNA using a second PCR primer to obtain as PCR product and comparing amino acid sequences in the PCR product obtained with known amino acid sequences characteristic of the luteovirus to detect the presence of the luteovirus.,NATURAL ENVIRONMENT RES;;COOPER JOSEPH IAN;;NAYLOR MARTIN,COOPER JOSEPH IAN;;NAYLOR MARTIN,,https://lens.org/077-110-645-237-461,Patent Application,yes,0,0,6,6,41,C12Q1/701;;C12Q1/701,C12Q1/68;;C12Q1/70,,0,0,,,,PENDING
96,NL,A1,NL 1033168 A1,132-314-922-637-015,2007-07-09,2007,NL 1033168 A,2007-01-04,GB 0600116 A,2006-01-05,Allelspecifieke sequentiebepaling.,,UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/132-314-922-637-015,Granted Patent,no,0,0,9,9,0,C12Q1/6827;;C12Q1/6858;;C12Q1/6869;;C12Q1/6827;;C12Q1/6883,C12Q1/68,,0,0,,,,INACTIVE
97,EP,B1,EP 2964339 B1,137-078-083-947-249,2017-09-20,2017,EP 14713564 A,2014-03-05,GB 201304316 A;;US 201361843476 P;;GB 2014050639 W,2013-03-07,FIRE AND/OR SMOKE BARRIER,,COOPERS FIRE LTD,COOPER ANDREW;;REED JAMES MARTIN,,https://lens.org/137-078-083-947-249,Granted Patent,yes,1,0,6,6,0,E06B9/42;;A62C2/10;;E06B9/42;;A62C2/10;;E06B5/00;;E06B9/56,A62C2/10;;E06B9/42,,0,0,,,,ACTIVE
98,NL,C2,NL 1033168 C2,189-089-960-870-088,2008-01-08,2008,NL 1033168 A,2007-01-04,GB 0600116 A,2006-01-05,Allelspecifieke sequentiebepaling.,,UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/189-089-960-870-088,Granted Patent,no,4,0,9,9,0,C12Q1/6827;;C12Q1/6858;;C12Q1/6869;;C12Q1/6827;;C12Q1/6883,C12Q1/68,,6,5,090-469-323-879-623;;085-845-399-135-271;;069-127-368-437-406;;018-029-634-423-113;;030-253-099-402-484,9254859;;10.1007/s004390050500;;10.1186/1471-2393-5-2;;15691369;;pmc548522;;9405026;;10.1530/eje.0.1370474;;12655556;;10.1002/humu.10167;;10.1007/s00439-006-0166-5;;16572267,"GIORDANO M ET AL: ""EVIDENCE FOR GENE CONVERSION IN THE GENERATION OF EXTENSIVE POLYMORPHISM IN THE PROMOTER OF THE GROWTH HORMONE GENE"", HUMAN GENETICS, BERLIN, DE, vol. 100, 1997, pages 249 - 255, XP000990217, ISSN: 0340-6717;;ADKINS R.M. ET AL.,: ""association between fetal growth restriction and polymorphisms at sites -1 and +3 of pituitary growth hormone: a case -control study"", BMC PREGNANCY AND CHILDBIRTH, vol. 5, no. 2, 3 February 2005 (2005-02-03), pages 1 - 7, XP002440410;;DATABASE WPI Week 200623, Derwent World Patents Index; AN 2006-213610, XP002440429;;WAGNER J K ET AL: ""ALLELIC VARIATIONS IN THE HUMAN GROWTH HORMONE-1 GENE PROMOTER OF GROWTH HORMONE-DEFICIENT PATIENTS AND NORMAL CONTROLS"", EUROPEAN JOURNAL OF ENDOCRINOLOGY, SCANDINAVIAN UNIVERSITY PRESS, NO, vol. 137, 1997, pages 474 - 481, XP000990216, ISSN: 0804-4643;;HORAN M. ET AL.,: ""human growth hormone 1 (GH1) geneexpression: complex haplotype-dependent influence of polymorphic variation in the proximal promoter and locus control region"", HUM. MUTAT., vol. 21, 2003, pages 408 - 423, XP002440411;;HORAN M. ET AL.,: ""genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke"", HUM. GENETR., vol. 119, 30 March 2006 (2006-03-30), pages 527 - 540, XP002438470",INACTIVE
99,EP,A1,EP 0839098 A1,189-663-643-785-553,1998-05-06,1998,EP 96924981 A,1996-07-17,GB 9601712 W;;GB 9514558 A,1995-07-17,MARKING DIAMOND,,GERSAN ETS,SMITH JAMES GORDON;;COOPER MARTIN,,https://lens.org/189-663-643-785-553,Patent Application,yes,0,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B44B7/00;;B28D5/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
100,GB,A,GB 2182893 A,004-489-721-644-116,1987-05-28,1987,GB 8503903 A,1985-02-15,GB 8503903 A,1985-02-15,Mobile wrapping materials dispenser,"A trolley comprises a base 1 supported on castors 9, an openwork shell or body 2, and support rails 3 across of the top of the openwork body. Each support rail has an upward projection 15 and a smooth rounded knob 16 at the top. A stack of bags can be draped over each rail, with the upward projection passing through the bag handle orifice, thus protecting them against accidental displacement without hindering individual removal of bags. <IMAGE>",MARKS SPENCER PLC,COOPER ALLISON BARBARA;;FOLEY MARTIN,,https://lens.org/004-489-721-644-116,Patent Application,no,0,3,2,2,0,B62B3/002;;B62B3/02;;B62B3/106,B62B3/00,B7B BTL1          BTL1,0,0,,,,DISCONTINUED
101,GB,A,GB 2379836 A,012-065-212-105-537,2003-03-19,2003,GB 0220851 A,2001-03-05,GB 0100900 W;;GB 0005038 A,2000-03-03,Returnable item for use in storage and transportation of commercials goods,"A container (10) (or other returnable item) for the storage and delivery of goods, comprises antenna means (16) for radio frequency use, and connection means (18) for receiving a removable drive circuit means (20). The drive circuit (20) is operable to communicate by means of the antenna (16) when connected therewith. The connections (18) serve, in use, to connect an installed drive circuit (20) with the antenna (16) to allow the drive circuit (20) to communicate. This allows the identity of the container or its contents to be communicated to a remote location.",PAXTON C G LTD,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,,https://lens.org/012-065-212-105-537,Patent Application,no,3,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,H4L LASS          LASS,0,0,,,,EXPIRED
102,WO,A3,WO 2002/022868 A3,013-908-219-232-618,2003-03-13,2003,GB 0104053 W,2001-09-10,GB 0022505 A,2000-09-14,METHOD AND PRIMERS FOR DETECTING VIRAL GENES,A method for detecting luteoviruses comprises extracting nucleic acid from plant tissue and making a first strand DNA using a PCR primer and amplifying the DNA using a second PCR primer to obtain as PCR product and comparing amino acid sequences in the PCR product obtained with known amino acid sequences characteristic of the luteovirus to detect the presence of the luteovirus.,NATURAL ENVIRONMENT RES;;COOPER JOSEPH IAN;;NAYLOR MARTIN,COOPER JOSEPH IAN;;NAYLOR MARTIN,,https://lens.org/013-908-219-232-618,Search Report,yes,0,0,6,6,0,C12Q1/701;;C12Q1/701,C12Q1/68;;C12Q1/70,,5,5,021-514-051-551-081;;124-688-980-419-557;;168-612-888-623-251;;004-784-009-679-640;;181-838-730-506-031,10.1016/s0166-0934(00)00196-8;;10960703;;10.1099/0022-1317-72-6-1473;;1675249;;10.1111/j.1744-7348.1997.tb05781.x;;1816257;;10.1016/0166-0934(91)90070-g;;10.1094/phyto-84-1201,"VERCRUYSSE P ET AL.: ""RT-PCR using redundant primers to detect the three viruses associated with carrot motley dwarf disease"", JOURNAL OF VIROLOGICAL METHODS, vol. 88, August 2000 (2000-08-01), pages 153 - 161, XP002215279;;ROBERTSON N L ET AL.: ""Use of group-specific primers and the polymerase chain reaction for the detection and identification of luteoviruses"", JOURNAL OF GENERAL VIROLOGY, vol. 72, 1991, pages 1473 - 1477, XP008008301;;NAIDU R A ET AL.: ""Diversity among coat proteins of luteoviruses associated with chickpea stunt disease in India"", ANNALS OF APPLIED BIOLOGY, vol. 130, 1997, pages 37 - 47, XP008008303;;JONES T D ET AL.: ""The detection of beet western yellow virus andbeet mild yellowing virus in crop plants using the polymerase chain reaction"", JOURNA OF VIROLOGICAL METHODS, vol. 35, 1991, pages 287 - 296, XP002215280;;BARIANA H S ET AL.: ""Detection of five seedborne legume viruses in one sensitive multiplex polymerase chain reaction"", PHYTOPATHOLOGY, vol. 84, no. 10, 1994, pages 1201 - 1205, XP001113127",PENDING
103,TW,A,TW 200734639 A,050-744-984-300-44X,2007-09-16,2007,TW 95148932 A,2006-12-26,GB 0600116 A,2006-01-05,Allele-specific sequencing,"The invention relates to a novel method of allele-specific sequencing in any gene which involves the knowledge of the existing SNPs within said gene and, in particular, those SNPs that are phenotypically significant for a given condition.",UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/050-744-984-300-44X,Patent of Addition,no,0,0,9,9,0,C12Q1/6827;;C12Q1/6858;;C12Q1/6869;;C12Q1/6827;;C12Q1/6883,G01N33/53;;C12N15/12,,0,0,,,,PENDING
104,GB,A8,GB 2379836 A8,065-155-620-072-131,2003-03-19,2003,GB 0220851 A,2001-03-05,GB 0100900 W;;GB 0005038 A,2000-03-03,Returnable item for use in storage and transportation of commercials goods,,PAXTON C G LTD,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,,https://lens.org/065-155-620-072-131,Patent Application,no,0,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10,B65D23/14;;G06K19/04;;G06K19/077,H4L LASS          LASS,0,0,,,,EXPIRED
105,GB,B,GB 2379836 B,107-603-683-847-035,2004-08-11,2004,GB 0220851 A,2001-03-05,GB 0100900 W;;GB 0005038 A,2000-03-03,Reusable item for use in storage and transportation of commercial goods,,PAXTON C G LTD,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,,https://lens.org/107-603-683-847-035,Granted Patent,no,8,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,H4L LASS          LASS,0,0,,,,EXPIRED
106,WO,A2,WO 2007/077422 A2,161-279-055-803-089,2007-07-12,2007,GB 2006004904 W,2006-12-23,GB 0600116 A,2006-01-05,ALLELE-SPECIFIC SEQUENCING,"The invention relates to a novel method of allele-specific sequencing in any gene which involves the knowledge of the existing SNPs within said gene and, in particular, those SNPs that are phenotypically significant for a given condition.",UNIV CARDIFF;;COOPER DAVID NEIL;;HORAN MARTIN,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/161-279-055-803-089,Patent Application,yes,0,0,9,9,25,C12Q1/6827;;C12Q1/6858;;C12Q1/6869;;C12Q1/6827;;C12Q1/6883,C12Q1/68,,0,0,,,,PENDING
107,US,A,US 5838913 A,021-846-143-872-617,1998-11-17,1998,US 55840995 A,1995-11-16,GB 9510870 A,1995-06-02,Control message transmission in telecommunications systems,"A communications interface is used in a telecommunications network station which including a number of network elements, a controller for controlling the network elements and an internal bus interconnecting the controller and the network elements. The controller operates as a busmaster on the bus and each of the network elements operates as a slave on the bus. The communications interface has a pool of buffers for temporary message storage and a polling function for temporarily storing a message received from the bus in a buffer and/or for taking a message from a buffer for transmission over the bus. A binary sequence number is inverted for a reply if a received message is valid, otherwise it is not changed for the reply. A message is re-sent when the sequence number in a reply has not changed.",DSC COMMUNICATIONS,LYSEJKO MARTIN;;COOPER GUY A,AIRSPAN MERGER CORPORATION (1999-08-06);;AIRSPAN NETWORKS INC (1999-12-15);;DSC COMMUNICATIONS CORPORATION A CORP. OF DELAWARE (1995-08-09);;DSC TELECOM L.P (1998-01-01);;AIRSPAN COMMUNICATIONS CORPORATION (1999-08-06),https://lens.org/021-846-143-872-617,Granted Patent,yes,47,37,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,395/200.38;;370/419;;370/421;;370/423;;370/428;;370/429,5,1,151-564-574-673-845,10.1145/65000.65003,"A. Udaya Shankar, Verified Data Transfer Protocols with Variable Flow Control , ACM Transactions on Computer Systems, vol. 7, No. 3, Aug. 1989, pp. 281 316.;;Patent Abstracts of Japan, vol. 95, No. 003, Mar. 19, 1995.;;Patent Abstracts of Japan, vol. 017, No. 359, Jul. 7, 1993.;;IBM Technical Disclosure Bulletin, vol. 21, No. 4, Sep. 1978, pp. 1388 1390.;;O. Kremien, et al., Memory Management for Token Bus LAN , Motorola Technical Developments, vol. 6, No. 1, Oct. 1986, pp. 20 23.",EXPIRED
108,WO,A3,WO 1996/039779 A3,016-935-686-859-279,1997-03-06,1997,US 9608521 W,1996-06-03,GB 9510870 A,1995-06-02,CONTROL MESSAGE TRANSMISSION IN TELECOMMUNICATIONS SYSTEMS,"A communications interface is used in a telecommunications network station including a number of network elements, a controller for controlling the network elements and an internal bus interconnecting the controller and the network elements. The controller operates as a busmaster on the bus and each of the network elements operates as a slave on the bus. The communications interface has a pool of buffers for temporary message storage and a polling function for temporarily storing a message received from the bus in a buffer and/or for taking a message from a buffer for transmission over the bus. A binary sequence number is inverted for a reply if a received message is valid, otherwise it is not changed for the reply. A message is re-sent when the sequence number in a reply has not changed.",DSC COMMUNICATIONS,LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/016-935-686-859-279,Search Report,yes,2,0,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,5,1,151-564-574-673-845,10.1145/65000.65003,"PATENT ABSTRACTS OF JAPAN vol. 95, no. 003;;PATENT ABSTRACTS OF JAPAN vol. 017, no. 359 (E - 1395) 7 July 1993 (1993-07-07);;""Peer communications network"", IBM TECHNICAL DISCLOSURE BULLETIN, vol. 21, no. 4, September 1978 (1978-09-01), NEW YORK US, pages 1388 - 1390, XP002012716;;O. KREMIEN ET AL.: ""Memory management for token-bus LAN"", MOTOROLA TECHNICAL DEVELOPMENTS, vol. 6, no. 1, October 1986 (1986-10-01), SCHAUMBURG, ILLINOIS US, pages 20 - 23, XP002012717;;SHANKAR A U: ""VERIFIED DATA TRANSFER PROTOCOLS WITH VARIABLE FLOW CONTROL"", ACM TRANSACTIONS ON COMPUTER SYSTEMS, vol. 7, no. 3, August 1989 (1989-08-01), pages 281 - 316, XP000054517",PENDING
109,US,A1,US 2003/0179092 A1,050-930-787-264-469,2003-09-25,2003,US 22079903 A,2003-04-07,GB 0005038 A;;GB 0100900 W,2000-03-03,Returnable item for use in storage and transportation of commercial goods,"
    A container ( 10 ) (or other returnable item) for the storage and delivery of goods, comprises antenna means ( 16 ) for radio frequency use, and connection means ( 18 ) for receiving a removable drive circuit means ( 20 ). The drive circuit ( 20 ) is operable to communicate by means of the antenna ( 16 ) when connected therewith. The connections ( 18 ) serve, in use, to connect an installed drive circuit ( 20 ) with the antenna ( 16 ) to allow the drive circuit ( 20 ) to communicate. This allows the identity of the container or its contents to be communicated to a remote location. 
",LOFTUS STEPHEN CLIVE;;COOPER MARTIN,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,C. G. PAXTON LIMITED (2003-03-22);;LINPAC MOULDINGS LIMITED (2004-10-12);;LINPAC ALLIBERT LIMITED (2005-10-07),https://lens.org/050-930-787-264-469,Patent Application,yes,6,13,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,340/572.7,0,0,,,,EXPIRED
110,TW,A,TW 200734636 A,181-266-377-270-038,2007-09-16,2007,TW 95148940 A,2006-12-26,GB 0600122 A,2006-01-05,Mutation in the growth hormone receptor,The invention relates to a novel method for assaying for the exon 3 deletion in the growth hormone receptor gene and the use of the exon 3 deletion for screening individuals for susceptibility to hypertension or stroke.,UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/181-266-377-270-038,Patent of Addition,no,0,0,9,9,0,C07K14/71;;C12Q1/6883;;C12Q1/6883;;C12Q2600/156,G01N33/50,,0,0,,,,PENDING
111,GB,A,GB 2433990 A,174-980-346-745-621,2007-07-11,2007,GB 0625887 A,2006-12-23,GB 0600122 A,2006-01-05,EXON 3 MUTATION OF THE GROWTH HORMONE RECEPTOR,A method for assaying for the exon 3 deletion in the growth hormone receptor (GHR) gene comprising amplification of the exon 3 region of GHR using proximal and distal primers and the detection of the transcribed product with a labeled hybridisation probe. Said probe is preferably a labeled oligonucleotide labeled with a light emitting molecule. The method may further include the steps of transcribing either another gene such a b -actin or exon 10 of GHR. Primers for the amplification reactions are disclosed and the method is exemplified by using quantitative PCR. Also disclosed is the use of the exon 3 deletion assay method to screen individuals for susceptibility to hypertension or stroke.,UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/174-980-346-745-621,Patent Application,no,3,0,9,9,0,C07K14/71;;C12Q1/6883;;C12Q1/6883;;C12Q2600/156,C12Q1/68;;C12N15/12,C3H HB4A          HB4A;;G1B BAC           BAC;;G1B B200          BAC;;G1B B223          BAC;;U1S S4001,6,6,030-253-099-402-484;;026-453-911-467-29X;;003-101-140-171-904;;047-452-042-032-936;;008-799-425-161-012;;038-267-723-757-587,10.1007/s00439-006-0166-5;;16572267;;12611612;;10.1530/eje.0.1480317;;10.1073/pnas.93.22.12394;;pmc38002;;8901592;;7794815;;10.1159/000071873;;12876416;;10764769;;10.1074/jbc.m001615200,"Human Genetics, Vol 119, 2006, M Horan et al, ""Genetic variation at the growth hormone (GH) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke"", 527-540;;Eur J Endocrinology, Vol 148, 2003, B Seidel et al, ""Association between the GH receptor/exon 3 genotype and the level of exon 3-positive GH-binding protein in human serum"", 317-324;;Proc Natl Acad Sci USA, Vol 93, 1996, ML Stallings-Mann et al, Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism"", 12394-99;;Cell Growth & Differentiation, Vol 6, 1995, C Decouvelaere et al, ""Presence of the two growth hormone receptor messenger RNA isoforms in human breast cancer"", 477-83;;Endocrine Research, Vol 60, 2003, R Ochoa et al, ""Expression of growth hormone receptor isoform exon-3-retaining messenger RNAs in peripheral lymphocytes from normal and acromegalic subjects"", 68-72;;J Biological Chemistry, Vol 275, 2000, J Pantel et al, ""Species-specific alternative splice mimicry at the growth hormone receptor locus..."", 18664-18669",DISCONTINUED
112,NL,C2,NL 1033167 C2,178-377-863-194-839,2008-02-20,2008,NL 1033167 A,2007-01-04,GB 0600122 A,2006-01-05,Mutatie in de groeihormoonreceptor.,,UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN,,https://lens.org/178-377-863-194-839,Granted Patent,no,2,0,9,9,0,C07K14/71;;C12Q1/6883;;C12Q1/6883;;C12Q2600/156,C12Q1/68;;C07K14/72,,2,2,008-799-425-161-012;;030-253-099-402-484,10.1159/000071873;;12876416;;10.1007/s00439-006-0166-5;;16572267,"Ochoa, R., et al. ""Expression of Growth Hormone Receptor Isoform Exon-3-excluding and exon-3-retaining messenger RNAs in peripheral lymphocytes from normal and acromegalic subjects"", Hormone Research, 2003, Vol. 60, Nr. 2, blz. 68-72 …*blz 69, rechter kolom en figuur 1b* …;;Horan, M. et al. ""Genetic Variation at the Growth Hormone (GH1) and Growth Hormone Receptor (GHR) loci as a risk factor for Hypertension and Stroke"", Human Genetics, 2006 (e-publication 30 maart 2006), Vol. 199, blz. 527-540 …*gehele document, met name bladzijde 530, kolom links regel 30 --- kolom rechts regel 42 en tabel 2* …",INACTIVE
113,US,B2,US 6844857 B2,090-621-580-663-595,2005-01-18,2005,US 22079903 A,2003-04-07,GB 0005038 A;;GB 0100900 W,2000-03-03,Returnable item for use in storage and transportation of commercial goods,"A container ( 10 ) (or other returnable item) for the storage and delivery of goods, comprises antenna means ( 16 ) for radio frequency use, and connection means ( 18 ) for receiving a removable drive circuit means ( 20 ). The drive circuit ( 20 ) is operable to communicate by means of the antenna ( 16 ) when connected therewith. The connections ( 18 ) serve, in use, to connect an installed drive circuit ( 20 ) with the antenna ( 16 ) to allow the drive circuit ( 20 ) to communicate. This allows the identity of the container or its contents to be communicated to a remote location.",LINPAC MOULDINGS LTD,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,C. G. PAXTON LIMITED (2003-03-22);;LINPAC MOULDINGS LIMITED (2004-10-12);;LINPAC ALLIBERT LIMITED (2005-10-07),https://lens.org/090-621-580-663-595,Granted Patent,yes,13,9,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,343/725;;340/572.7;;342/359,0,0,,,,EXPIRED
114,GB,A,GB 189411918 A,110-092-165-631-118,1895-04-20,1895,GB 189411918D A,1894-06-20,GB 189411918T A,1894-06-20,Improvements in or relating to Combined Feeders and Openers employed in the Preparation of Cotton and other Fibrous Materials.,,MUSGRAVE MARTIN;;COOPER CHARLES EDWIN,MUSGRAVE MARTIN;;COOPER CHARLES EDWIN,,https://lens.org/110-092-165-631-118,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
115,EP,A1,EP 1261937 A1,010-224-133-449-799,2002-12-04,2002,EP 01907967 A,2001-03-05,GB 0100900 W;;GB 0005038 A,2000-03-03,RETURNABLE ITEM FOR USE IN STORAGE AND TRANSPORTATION OF COMMERCIALS GOODS,,PAXTON C G LTD,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,LINPAC MOULDINGS LIMITED (2004-12-08);;LINPAC MATERIALS HANDLING LIMITED (2005-11-16),https://lens.org/010-224-133-449-799,Patent Application,yes,0,2,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,,1,0,,,See references of WO 0167384A1,EXPIRED
116,AU,A,AU 2001/087851 A,172-093-960-716-173,2002-03-26,2002,AU 2001/087851 A,2001-09-10,GB 0022505 A;;GB 0104053 W,2000-09-14,Method and primers for detecting viral genes,,NATURAL ENVIRONMENT RES,COOPER JOSEPH IAN;;NAYLOR MARTIN,,https://lens.org/172-093-960-716-173,Patent Application,no,0,0,6,6,0,C12Q1/701;;C12Q1/701,C12Q1/68;;C12Q1/70,,0,0,,,,PENDING
117,ES,T3,ES 2234813 T3,184-827-327-853-442,2005-07-01,2005,ES 01907967 T,2001-03-05,GB 0005038 A,2000-03-03,ARTICULO RETORNABLE PARA USO EN EL ALMACENAMIENTO Y TRANSPORTE DE BIENES COMERCIALES.,"Un artículo (10, 10A) retornable para su uso en el almacenamiento y transporte de bienes comerciales, comprendiendo el artículo un medio de antena (16, 16A) de RF y medios de conexión (18, 18A) para suministrar conexión entre el medio de la antena y un medio (20) de circuito excitador operable para comunicar por medio del medio de antena cuando está conectado con el mismo, caracterizado porque los medios de conexión están dispuestos para recibir selectivamente de forma reemplazable el medio de circuito excitador para conectar el medio de circuito excitador con la antena para permitir que el medio de circuito excitador comunique en la forma anteriormente mencionada, por medio de lo cual el circuito excitador es desmontable y fácilmente reconectable por medio de los medios de conexión.",LINPAC MOULDINGS LTD,LOFTUS STEPHEN CLIVE;;COOPER MARTIN,,https://lens.org/184-827-327-853-442,Granted Patent,no,0,0,15,15,0,B65D23/14;;B65D23/14;;B65D2203/10;;B65D2203/10;;G06K19/04;;G06K19/04;;G06K19/07749;;G06K19/07749;;Y02W30/80;;Y02W30/80,B65D23/14;;G06K19/04;;G06K19/077,,0,0,,,,EXPIRED
118,DE,D1,DE 69506268 D1,141-212-167-849-864,1999-01-07,1999,DE 69506268 T,1995-09-05,GB 9418050 A;;GB 9502092 W,1994-09-07,DIAMANTENUNTERSUCHUNG,,GERSAN ETS,SMITH MARTIN;;SMITH JAMES;;COOPER MARTIN;;SUSSMANN RICARDO,,https://lens.org/141-212-167-849-864,Granted Patent,no,0,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
119,DE,T2,DE 69506268 T2,102-146-796-913-040,1999-06-24,1999,DE 69506268 T,1995-09-05,GB 9418050 A;;GB 9502092 W,1994-09-07,DIAMANTENUNTERSUCHUNG,,GERSAN ETS,SMITH MARTIN;;SMITH JAMES;;COOPER MARTIN;;SUSSMANN RICARDO,,https://lens.org/102-146-796-913-040,Granted Patent,no,0,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
120,ZA,B,ZA 893363 B,101-777-148-013-890,1991-01-30,1991,ZA 893363 A,1989-05-08,GB 8810723 A,1988-05-06,A METHOD OF IDENTIFYING SPECIFIC OBJECTS OR ZONES,,GERSAN ETS,COOPER MARTIN;;MARTIN COOPER;;WELBOURN CHRISTOPHER MARK;;CHRISTOPHER MARK WELBOURN;;SMITH MARTIN PHILLIP;;MARTIN PHILLIP SMITH;;SPEAR MARTIN PAUL;;MARTIN PAUL SPEAR,,https://lens.org/101-777-148-013-890,Granted Patent,no,0,0,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
121,AU,B2,AU 2002/232698 B2,011-733-744-842-217,2006-03-09,2006,AU 2002/232698 A,2001-12-27,US 75382501 A;;US 0149625 W,2001-01-03,Method and apparatus for monitoring milking facility pulsation,,SENSEABILITY INC,COOPER MARTIN CHANDLER;;GENTNER JEFFREY W,,https://lens.org/011-733-744-842-217,Granted Patent,no,1,0,11,11,0,A01J5/007;;A01J5/007,A01J5/007;;A01J5/00;;A01K1/12,,0,0,,,,EXPIRED
122,EP,A1,EP 0888475 A1,045-202-887-185-50X,1999-01-07,1999,EP 97903449 A,1997-02-13,GB 9700397 W;;GB 9602991 A,1996-02-14,METHOD OF REDUCING THE TENDENCY OF A LYOCELL FABRIC TO PRIMARY FIBRILLATION,,COURTAULDS FIBRES HOLDINGS LTD,COOPER KAREN JANE;;TAYLOR JAMES MARTIN,ACORDIS FIBRES (HOLDINGS) LIMITED (1999-10-06),https://lens.org/045-202-887-185-50X,Patent Application,yes,0,0,6,6,0,D01F2/00;;D06M11/30;;D06M11/30;;D06M11/50;;D06M11/50;;D10B2401/00,D01F2/00;;D06M11/30;;D06M11/50,,1,0,,,See references of WO 9730204A1,DISCONTINUED
123,GB,A,GB 2585841 A,044-383-518-086-505,2021-01-27,2021,GB 201910187 A,2019-07-16,GB 201910187 A,2019-07-16,Firebreak device,"A firebreak device 300 for arresting a flow of medical or therapeutic gas capable of combustion or of supporting combustion comprises a housing having an inlet and an outlet within which is located a valve assembly 330 movable by a biasing assembly 340 between an open position, in which gas can flow between the inlet and outlet, and a closed position in which gas flow is arrested. A heat activatable or fusible stop 350 located between the biasing assembly 340 and the outlet holds the valve assembly 330 open until the fusible stop softens or fuses when an activation temperature is reached. The fusible stop may comprise three radial spokes 350 to minimise obstruction of the flow of gas adjacent an inner surface of the device to prevent a turbulent eddy forming downstream of the fusible stop, enabling fresh oxygen to flow into a space adjacent the stop and combustion to progress to the fusible stop 350. Burn ribs 390 may also be provided to help very low energy flames to track to the stop.",BPR MEDICAL LTD,BENJAMIN JOHNSON;;MARTIN COOPER;;MICHAEL BRUDENELL,,https://lens.org/044-383-518-086-505,Patent Application,no,3,0,6,6,0,A61M16/20;;A61M16/201;;F16K17/383;;F16L55/1022;;F16L55/1026;;A61M16/0816;;A61M2202/0208;;A61M2205/02;;F16L57/04;;A62C4/02;;A62C2/20;;A61M16/208;;F16K17/383;;A61M16/208;;A61M2205/3368;;A62C2/04,A61M16/20;;F16K17/38,,0,0,,,,ACTIVE
124,DE,A1,DE 4033346 A1,078-049-893-311-524,1991-05-23,1991,DE 4033346 A,1990-10-19,US 43787889 A,1989-11-17,THERMOELEKTRISCHE HOCHLEISTUNGS-UMWANDLUNGSVORRICHTUNG AUF DUENNSCHICHT-ALKALIMETALL BASIS,,WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN HOWARD;;SIEVERS ROBERT KEVIN,,https://lens.org/078-049-893-311-524,Patent Application,no,0,1,4,4,0,H01G9/21;;H01G9/21,B22F5/00;;B22F5/12;;H01G9/00;;H01G9/21;;H01M4/64;;H01M6/36;;H02N3/00,,0,0,,,,DISCONTINUED
125,GB,A,GB 2112832 A,118-868-074-856-449,1983-07-27,1983,GB 8138827 A,1981-12-23,GB 8138827 A,1981-12-23,Cladding,A cladding member 3 comprises aboard of plastics material with a lip 4 along one edge so that when it is secured to an existing board of a cladding 1 the lip extends along the lower edge of the existing board. Where the existing boards overlap each other widthwise and cladding members also overlap each other widthwise. <IMAGE>,REED INTERNATIONAL LTD,MARTIN JOHN LEWIS;;COOPER PETER ROBIN,,https://lens.org/118-868-074-856-449,Patent Application,no,0,2,2,2,0,E04F13/0864,E04F13/08,E1D DLEQG         LEQG;;E1D DLES          LES855;;E1D D106          LEQG;;E1D D106          LES855;;E1D D2022         LEQG;;E1D D2022         LES855;;E1D D2141         LEQG;;E1D D2141         LES855;;E1D D358          LES855;;E1D D401          LEQG;;E1D D401          LES855,0,0,,,,EXPIRED
126,US,B2,US 10679505 B2,132-284-089-346-992,2020-06-09,2020,US 201815902672 A,2018-02-22,US 201815902672 A,2018-02-22,"Automatic vehicle control apparatus able to determine track occupancy of a vehicle, and corresponding method for automatically controlling the vehicle","This automatic vehicle control apparatus comprises a first image sensor positioned on a vehicle, able to capture a first global image of a first scene, including an area in front of the vehicle, in a first field of view of said first image sensor; a track occupancy detector for receiving the first global image and deducing therefrom a track occupancy of the vehicle among at least two set of parallel tracks positioned in front of the vehicle; a distinguishable object disposed in the first field of view; and a proper functioning checking apparatus configured for searching, in the first global image, a first specific image of the distinguishable object, and for generating an alert signal in case the first specific image is not found in the first global image.",ALSTOM TRANSP TECH,MARTIN PHILLIP;;SNYDER SENECA;;COOPER JARED,ALSTOM TRANSPORT TECHNOLOGIES (2018-03-07),https://lens.org/132-284-089-346-992,Granted Patent,yes,5,0,7,7,0,G05D1/0246;;G06T7/73;;G06T2207/10028;;G06T2207/30256;;G08G1/166;;B61L23/041;;B61L25/025;;B61L2205/04;;G06V20/56;;G06V10/751;;G08G1/166;;G06T2207/30236;;G08G1/056;;G06T7/70;;G06T7/73;;G06V10/751;;G06V20/56,G08G1/00;;G06T7/70;;G08G1/056;;G08G1/16,,0,0,,,,ACTIVE
127,GB,B,GB 2585841 B,156-835-377-405-669,2023-06-21,2023,GB 201910187 A,2019-07-16,GB 201910187 A,2019-07-16,Firebreak device,,BPR MEDICAL LTD,BENJAMIN JOHNSON;;MARTIN COOPER;;MICHAEL BRUDENELL,,https://lens.org/156-835-377-405-669,Granted Patent,no,3,0,6,6,0,A61M16/20;;A61M16/201;;F16K17/383;;F16L55/1022;;F16L55/1026;;A61M16/0816;;A61M2202/0208;;A61M2205/02;;F16L57/04;;A62C4/02;;A62C2/20;;A61M16/208;;F16K17/383;;A61M16/208;;A61M2205/3368;;A62C2/04,A61M16/20;;F16K17/38,,0,0,,,,ACTIVE
128,EP,A2,EP 1353546 A2,164-674-140-920-852,2003-10-22,2003,EP 01992233 A,2001-12-27,US 0149625 W;;US 75382501 A,2001-01-03,SPECIFICATION,,SENSEABILITY INC,JEFFREY W GENTNER;;MARTIN CHANDLER COOPER,,https://lens.org/164-674-140-920-852,Patent Application,yes,0,0,11,11,0,A01J5/007;;A01J5/007,A01J5/007,,0,0,,,,DISCONTINUED
129,WO,A2,WO 2002/052927 A2,023-404-229-192-748,2002-07-11,2002,US 0149625 W,2001-12-27,US 75382501 A,2001-01-03,SPECIFICATION,"A pulsator (23) provides alternating vacuum pressure and atmospheric pressure to an elastomeric liner (35) in a sleeve (13) of a milking claw (11) in a diary barn. The purpose of pulsation is to alternate to cow teat between a milking phase and a rest phase. The invention (41) monitors the operation of the pulsator to determine if the pulsator is operating satisfactorily. The invention records data during a calibration mode from the pulsator in normal operation. The data that is recorded is the duration of the miling phase and the rest phase and the assocated pressures. During pulsator operation, the invention measures the pulsation between atmospheric and vacuum pressures provided to the milking claw and compares this measured data to the recorded calibraton data. If the pulsator is not found to be operating within predetermined tolerances, then an indication of a pulsator malfunction is provided, typically in the form of a light located in the milking pen. This indicates to the milking crew that the pulsator requires attention and should not be used until properly fixed",SENSEABILITY INC,JEFFREY W. Gentner;;MARTIN Chandler Cooper,,https://lens.org/023-404-229-192-748,Patent Application,yes,0,0,11,11,0,A01J5/007;;A01J5/007,A01J5/007,,0,0,,,,PATENTED
130,GB,A,GB 2111617 A,022-080-733-598-62X,1983-07-06,1983,GB 8234834 A,1982-12-07,US 32785181 A,1981-12-07,Improved snubber,"A snubber for disposition between two components for dampening relative motion therebetween and utilising a motion converter for transforming translational into rotary motion includes at least one rotary motion sensor adapted to sense such motion of component(s) of the snubber which are critical to proper snubber action, thereby providing indication of snubber operability. Such component may be the ball screw 1 or inertia wheel 2 of the snubber of Figure 1 or the verge wheels 8 or verge 9 of the snubber of Figure 5. The sensor may utilise a revolution counter 12, a magnetic position indicator 14, 15 or an acoustical monitor. Electrical signals may be provided for remote readout. <IMAGE>",WESTINGHOUSE ELECTRIC CORP,JONES ROBERT GLYN;;COOPER MARTIN HOWARD,,https://lens.org/022-080-733-598-62X,Patent Application,no,0,0,6,6,0,F16F7/1022;;F16L3/202,F16F7/10;;F16L3/20;;F16L3/202;;F16L3/215,F2E EF            EF(DAMPERS);;F2E EKM           EKM(DAMPERS);;U1S S1905;;U1S S2011,0,0,,,,DISCONTINUED
131,DE,D1,DE 69515845 D1,030-864-726-391-730,2000-04-27,2000,DE 69515845 T,1995-01-25,GB 9401354 A;;GB 9500139 W,1994-01-25,UNTERSUCHUNG EINES DIAMANTEN,,GERSAN ESTABLISHMENT VADUZ,SMITH PHILLIP;;SMITH GORDON;;COOPER MARTIN,,https://lens.org/030-864-726-391-730,Granted Patent,no,0,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
132,NZ,A,NZ 526645 A,024-048-844-394-980,2004-12-24,2004,NZ 52664501 A,2001-12-27,US 75382501 A;;US 0149625 W,2001-01-03,Method and apparatus for monitoring milking facility pulsation,"Milking is achieved by applying a vacuum and then a rest period to simulate the suckling action of a calf. Pulsation equipment within a milking facility is used to mimic this action and operates by providing a milking phase (vacuum pressure) and a rest phase (atmospheric pressure) to a teat that is retained within a sleeve (13) of a milking claw (11). Data is recorded from a fully functioning pulsator (23) by measuring both the duration and pressure of these milking and rest phases during a calibration mode. This data is then used as a comparison during normal pulsator operation by means of measuring the vacuum hose (27) pressure provided to the milking claw (11). If the pulsator is found to be operating outside its normal range of predetermined tolerances an indication of a pulsator malfunction occurs, typically in the form of a light located in the milking pen. This indicates to the milking crew that the pulsator requires attention and should not be used until properly fixed.",SENSEABILITY INC,GENTNER JEFFREY W;;COOPER MARTIN CHANDLER,,https://lens.org/024-048-844-394-980,Patent Application,no,0,0,11,11,0,A01J5/007;;A01J5/007,A01J5/007,,0,0,,,,PENDING
133,GB,B,GB 2286705 B,040-729-433-186-910,1997-05-14,1997,GB 9403044 A,1994-02-17,GB 9403044 A,1994-02-17,Multi-processor module,,GEC ALSTHOM LTD,COOPER MARK EDWIN;;PLATT CHRISTOPHER MARTIN,,https://lens.org/040-729-433-186-910,Granted Patent,no,0,0,4,4,0,B61L19/06,B61L19/06;;B61L27/00,G4A AFD           FD;;G4Q QBT           QBT,0,0,,,,EXPIRED
134,GB,A,GB 2246638 A,054-292-503-994-42X,1992-02-05,1992,GB 9016333 A,1990-07-25,GB 9016333 A,1990-07-25,Mounting for flow meter,"A mounting for a liquid flow meter, such as a domestic water meter (35), incorporates a stop valve in a fluid passage between a fluid inlet (12) and a fluid outlet (13). The valve comprises a movable member (16) which on rotation moves axially to seal against O-ring (24). The member is rotated using a handle (33) which engages a flange (17) on the member (16). A non-return valve (31) is mounted in pipe (26) extending from the meter outlet. <IMAGE>",PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/054-292-503-994-42X,Patent Application,no,4,6,3,3,0,G01F15/185;;G01F15/18,G01F15/18,E1X XK7F          XK7;;E1X XK7K          XK7;;F2V VX3           VX3;;G1R RAB           RAB;;U1S S2150,0,0,,,,EXPIRED
135,DE,A1,DE 3212215 A1,050-410-019-737-834,1983-03-17,1983,DE 3212215 A,1982-04-01,US 29597581 A,1981-08-25,KUEHLEINRICHTUNG FUER KERNREAKTOREN,,WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H;;RACKI DANIEL J,,https://lens.org/050-410-019-737-834,Patent Application,no,0,2,4,4,0,G21C15/18;;G21C1/03;;Y02E30/30,G21C1/02;;G21C1/03;;G21C15/02;;G21C15/18,,0,0,,,,DISCONTINUED
136,EP,A1,EP 0566304 A1,086-825-694-903-470,1993-10-20,1993,EP 93302683 A,1993-04-06,GB 9208048 A,1992-04-11,Gas treatment process.,The solvent laden waste gases from the drying chamber (2) of an industrial process plant (1) are supplied directly to an inlet (11) of an internal combustion engine (8). The exhaust gases of the engine may be used to heat air which is supplied to the drying chamber (2) or exhaust gas may be supplied directly to the drying chamber. The engine drives a generator (9) which can supply electrical energy to an external load and the engine has an inlet (12) for gaseous fuel which is supplied to the engine when there is insufficient solvent in the waste gases to drive the engine.,AIRAQUA ENG CONSULTANT,COOPER ALAN;;LITTLE CHRISTOPHER MARTIN DONA,,https://lens.org/086-825-694-903-470,Patent Application,yes,2,7,2,2,0,B01D53/72;;F26B23/022,B01D53/72;;F26B23/02,,0,0,,,,DISCONTINUED
137,US,A1,US 2007/0254891 A1,085-426-491-816-575,2007-11-01,2007,US 72894707 A,2007-03-27,US 72894707 A;;US 78833806 P;;US 80860306 P,2006-03-31,"Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine","The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.",DYNOGEN PHARMACEUTICALS INC,COOPER MARTIN I;;FRAMPTON CHRISTOPHER S,EDUSA PHARMACEUTICALS INC (2010-08-17);;DYNOGEN PHARMACEUTICALS INC (2007-06-15),https://lens.org/085-426-491-816-575,Patent Application,yes,0,3,7,7,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P1/12;;A61P13/00;;A61P13/10;;A61P15/00;;C07D495/04,A61P1/00;;A61K31/496;;C07D239/00,514/252.14;;544/333,0,0,,,,DISCONTINUED
138,IE,A1,IE 20070126 A1,084-122-805-323-599,2007-04-18,2007,IE 20070126 A,2004-07-13,GB 0316991 A;;GB 0403608 A,2003-07-21,Sealing strip for a ridge tile roof ventilation system,"A sealing strip (100) for bridging the gap between adjacent ridge tiles comprises a planar member (104) and a limb (102). The planar member (104) covers the gap between adjacent tiles and the limb (102) is inserted in the gap in use. The limb (102) comprises a plurality of spaced fingers and the planar member is bendable to allow it to conform to the profile of the ridge tiles in use. The strip (100) may be arranged with the planar member (104) adapted to conform to the interior surface of ridge tiles or to the exterior surface of ridge tiles. The free end of the limb (102) may carry mutually opposing projections (108), (110) which, with the planar member, sandwich the edges of ridge tiles in use. <Figure 13>",PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/084-122-805-323-599,Patent Application,no,0,0,8,10,0,E04D1/30;;E04D1/3402;;E04D1/365;;E04D13/174;;E04D2001/305;;E04D2001/306;;E04D1/3402;;E04D1/36;;E04D13/152;;E04D2001/306;;E04D1/30;;E04D2001/305;;E04D1/30;;E04D1/3402;;E04D2001/305;;E04D2001/306,E04D1/34;;E04D1/30;;E04D13/15;;E04D13/17,,0,0,,,,PENDING
139,AU,A,AU 1997/018006 A,091-006-790-712-385,1997-09-02,1997,AU 1997/018006 A,1997-02-13,GB 9602991 A;;GB 9700397 W,1996-02-14,Method of reducing the tendency of a lyocell fabric to primary fibrillation,,COURTAULDS FIBRES HOLDINGS LTD,COOPER KAREN JANE;;TAYLOR JAMES MARTIN,,https://lens.org/091-006-790-712-385,Patent Application,no,0,0,6,6,0,D01F2/00;;D06M11/30;;D06M11/30;;D06M11/50;;D06M11/50;;D10B2401/00,D01F2/00;;D06M11/30;;D06M11/50,,0,0,,,,PENDING
140,WO,A1,WO 1997/030204 A1,118-048-723-700-96X,1997-08-21,1997,GB 9700397 W,1997-02-13,GB 9602991 A,1996-02-14,METHOD OF REDUCING THE TENDENCY OF A LYOCELL FABRIC TO PRIMARY FIBRILLATION,"The tendency of a lyocell fabric to primary fibrillation after dyeing and washing is reduced by contacting the fabric, before dyeing, at elevated temperature with an aqueous solution of an oxidising agent such as a hypochlorite or hydrogen peroxide. Depending on the nature and concentration of the oxidising agent, the fabric produced may have substantially no fibrillation after subsequent dyeing and washing or may develop a peach-skin hand after subsequent dyeing and washing.",COURTAULDS FIBRES HOLDINGS LTD;;COOPER KAREN JANE;;TAYLOR JAMES MARTIN,COOPER KAREN JANE;;TAYLOR JAMES MARTIN,,https://lens.org/118-048-723-700-96X,Patent Application,yes,4,5,6,6,0,D01F2/00;;D06M11/30;;D06M11/30;;D06M11/50;;D06M11/50;;D10B2401/00,D01F2/00;;D06M11/30;;D06M11/50,,4,0,,,"BREIER, RUDI: ""Die Veredelung von Lyocellfasern - Ein Erfahrungsbericht"", LENZINGER BERICHTE, vol. 94, no. 9, September 1994 (1994-09-01), pages 99 - 101, XP002032693;;DATABASE WPI Section Ch Week 9003, Derwent World Patents Index; Class A11, AN 90-018791, XP002032695;;MING G ET AL: ""TREATING FABRIC THROUGH ALKALINE OXIDATION FOR A SILK-LIKE EFFECT"", AMERICAN DYESTUFF REPORTER, vol. 85, no. 7, July 1996 (1996-07-01), pages 20, 22 - 24, 26, XP000598049;;CHEMICAL ABSTRACTS, vol. 105, no. 18, 3 November 1986, Columbus, Ohio, US; abstract no. 154531x, page 72; column 1; XP002032694",PENDING
141,GB,B,GB 2246638 B,116-719-721-948-568,1994-08-10,1994,GB 9016333 A,1990-07-25,GB 9016333 A,1990-07-25,Liquid flow meter mounting,,PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/116-719-721-948-568,Granted Patent,no,5,0,3,3,0,G01F15/185;;G01F15/18,G01F15/18,E1X XK7F          XK7;;E1X XK7K          XK7;;F2V VX3           VX3;;G1R RAB           RAB;;U1S S2150,0,0,,,,EXPIRED
142,US,A,US 4813564 A,045-638-700-891-883,1989-03-21,1989,US 16043888 A,1988-02-25,US 16043888 A,1988-02-25,Package,"The package includes a body and a closure. A readily breakable electrical oscillatory network sans power supply is physically connected between the body and the closure. The network is tuned to resonate at a predetermined frequency. The package is monitored by a transmitter-receiver when it is distributed to a customer. The transmitter produces pulse signals in a carrier frequency band which overlaps the resonant frequency of the network. During monitoring the package is placed in the field of the transmitter and the oscillatory network is excited to produce a decaying pulse for each transmitter pulse. The receiver is gated during the interval when each transmitter pulse is generated but is receptive of the corresponding decaying pulse from the network. If the package is sealed, the oscillatory network is intact and the receiver receives decaying pulses which produce visual or audible signals. If the package has been opened, the network is broken and no signals are produced.",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H;;PETROSKY LYMAN J,WESTINGHOUSE ELECTRIC CORPORATION A CORP. OF PA (1988-02-02),https://lens.org/045-638-700-891-883,Granted Patent,yes,17,101,4,4,0,B65D5/4291;;B65D55/028;;Y10S206/807;;B65D55/028;;B65D5/4291;;Y10S206/807,B65D5/42;;B65D5/74;;B65D55/02,215/366;;215/250;;215/252;;206/807;;229/102;;336/200;;340/572,0,0,,,,EXPIRED
143,AU,A,AU 1999/057677 A,067-618-384-290-620,2000-03-21,2000,AU 1999/057677 A,1999-08-18,SE 9802895 A;;SE 9901400 W,1998-08-28,Novel compounds,"Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/067-618-384-290-620,Patent Application,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,EXPIRED
144,EP,A1,EP 3999158 A1,087-111-768-564-902,2022-05-25,2022,EP 20747085 A,2020-07-16,GB 201910187 A;;GB 2020051706 W,2019-07-16,FIREBREAK DEVICE,,BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL,,https://lens.org/087-111-768-564-902,Patent Application,yes,0,0,6,6,0,A61M16/20;;A61M16/201;;F16K17/383;;F16L55/1022;;F16L55/1026;;A61M16/0816;;A61M2202/0208;;A61M2205/02;;F16L57/04;;A62C4/02;;A62C2/20;;A61M16/208;;F16K17/383;;A61M16/208;;A61M2205/3368;;A62C2/04,A61M16/20;;F16K17/38;;F16L55/10,,0,0,,,,PENDING
145,US,B2,US 7855682 B2,077-262-051-085-23X,2010-12-21,2010,US 58713906 A,2006-07-05,EP 05270033 A;;GB 0515300 A;;GB 2006050188 W,2005-07-27,Time synchronization,"A transmitter of a platform is arranged to generate a transmission pulse, which is transmitted to a receiver of another platform and is also arranged to couple its transmission pulse to a digital receiver associated with its platform via an attenuator and a coupler. Another platform performs a similar task. Each digital receiver determines the time separation between its transmission pulse and a received pulse from the other platform. The determined time separation information is shared with the other platform, and each digital receiver then determines a time offset between the time at its platform and the other platform.",SELEX GALILEO LTD,GOULD DALE MARTIN;;COOPER ROBERT DAVID,LEONARDO UK LTD (2021-03-31);;SELEX SENSORS AND AIRBORNE SYSTEMS LTD (2006-09-20),https://lens.org/077-262-051-085-23X,Granted Patent,yes,5,5,7,8,0,G04G7/02;;G04G7/02;;G01S5/021;;G01S5/021;;G01S5/06;;G01S5/06,G01S1/24,342/387,3,2,150-750-983-600-498;;051-450-531-362-835,10.1109/igarss.2004.1370671;;10.1109/5.84975,"Weiss, M: ""Synchronisation of bistatic radar systems"" Geoscience and Remote Sensing Symposium, 2004, IGARSS '04. Proceedings. 2004 IEEE International Anchorage, AK, USA Sep. 20-24, 2004, Piscataway, NJ, USA, IEEE, Sep. 20, 2004, pp. 1750-1753, XP 010751951, ISBN: 0-7803-8742-2 *Section II. ""Time Synchornisation""; p. 1750-1752; Figures 2, 5*.;;Kirchner, D: ""Two-Way Time Transfer Via Communication Satellites"" Proceedings of the IEEE, IEEE, New York, US, vol. 79, No. 7, Jul. 1, 1991, pp. 983-990, XP000264855; ISSN: 0018-9219 *Section II. ""Theory""; Figure 1, pp. 984-985.;;European Search Report British Search Report, Sep. 20, 2006.",ACTIVE
146,AU,A,AU 1998/070909 A,090-565-011-285-770,1998-11-11,1998,AU 1998/070909 A,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,Novel compounds,,ASTRA PHARMA PROD,COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,ASTRAZENECA AB (2001-01-04),https://lens.org/090-565-011-285-770,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
147,AU,A1,AU 2019/201157 A1,111-822-891-038-78X,2019-09-05,2019,AU 2019/201157 A,2019-02-19,US 201815902672 A,2018-02-22,"Automatic vehicle control apparatus able to determine track occupancy of a vehicle, and corresponding method for automatically controlling the vehicle","AUTOMATIC VEHICLE CONTROL APPARATUS ABLE TO DETERMINE TRACK OCCUPANCY OF A VEHICLE, AND CORRESPONDING METHOD FOR AUTOMATICALLY CONTROLLING A VEHICLE This automatic vehicle control apparatus comprises a first image sensor positioned on a vehicle, able to capture a first global image of a first scene, including an area in front of the vehicle, in a first field of view of said first image sensor; a track occupancy detector for receiving the first global image and deducing therefrom a track occupancy of the vehicle among at least two set of parallel tracks positioned in front of the vehicle; a distinguishable object disposed in the first field of view; and a proper functioning checking apparatus configured for searching, in the first global image, a first specific image of the distinguishable object, and for generating an alert signal in case the first specific image is not found in the first global image. oo-Co 4:0",ALSTOM TRANSP TECH,MARTIN PHILLIP;;SNYDER SENECA;;COOPER JARED,,https://lens.org/111-822-891-038-78X,Patent Application,no,0,0,7,7,0,G05D1/0246;;G06T7/73;;G06T2207/10028;;G06T2207/30256;;G08G1/166;;B61L23/041;;B61L25/025;;B61L2205/04;;G06V20/56;;G06V10/751;;G08G1/166;;G06T2207/30236;;G08G1/056;;G06T7/70;;G06T7/73;;G06V10/751;;G06V20/56,B61L25/02,,0,0,,,,ACTIVE
148,CA,A1,CA 2647329 A1,128-982-528-093-573,2008-05-02,2008,CA 2647329 A,2007-03-27,US 80860306 P;;US 78833806 P;;US 2007/0007816 W,2006-03-31,"CRYSTALLINE FORMS OF 4-(2-FLUOROPHENYL)-6-METHYL-2-(PIPERAZIN-1-YL)THIENO(2,3-D)PYRIMIDINE","The present invention is directed to novel crystalline forms of 4-(2-fIuorophenyl)-6-methyl-2-(piperazin-l-yl)thieno[2,3-d]py.tau.imidine salts, including 4-(2- fluorophenyl)-6-methyl-2-(piperazin- 1 -yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.",DYNOGEN PHARMACEUTICALS INC,COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,,https://lens.org/128-982-528-093-573,Patent Application,no,0,0,7,7,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P1/12;;A61P13/00;;A61P13/10;;A61P15/00;;C07D495/04,C07D495/04;;A61K31/519;;A61P1/00;;A61P13/00,,0,0,,,,DISCONTINUED
149,GB,A,GB 2104710 A,169-762-111-415-971,1983-03-09,1983,GB 8208291 A,1982-03-22,US 29597581 A,1981-08-25,Standby heat removal system for a nuclear reactor using flow diodes,"A nuclear reactor using flow diodes (19) to limit reactor core coolant flow through an emergency flow path (12) during normal reactor coplant flow, and to allow unhindered natural circulation around the path with opposite direction when normal reactor coolant flow stops. The emergency flow path may be a separate circuit with a heat exchanger (Figure 3), or may include the core blanket as a heat sink with reverse flow (Figure 4).",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN HOWARD;;RACKI DANIEL JOSEPH,,https://lens.org/169-762-111-415-971,Patent Application,no,0,11,4,4,0,G21C15/18;;G21C1/03;;Y02E30/30,G21C1/02;;G21C1/03;;G21C15/02;;G21C15/18,G6C CBK           CBK;;G6C C39Y          CBK;;G6C C405          CBK;;G6C C680          CBK;;G6C C684          CBK,0,0,,,,DISCONTINUED
150,FR,A1,FR 2517778 A1,183-567-063-464-43X,1983-06-10,1983,FR 8220421 A,1982-12-06,US 32785181 A,1981-12-07,AMORTISSEUR PERFECTIONNE,<P>Cet amortisseur est prévu pour être placé entre deux éléments auxquels il est relié afin d'amortir leurs mouvements relatifs. L'amortisseur est équipé d'un détecteur 12 directement sensible au mouvement de l'organe 1 de l'amortisseur qui est critique pour le fonctionnement correct de ce dernier. Ce détecteur indique donc l'état de fonctionnement de l'amortisseur. <BR/> Applications : notamment pour protéger les réseaux de tuyauteries et systèmes connexes contre les chocs sismiques.</P>,WESTINGHOUSE ELECTRIC CORP,JONES ROBERT GLYN;;COOPER MARTIN HOWARD,,https://lens.org/183-567-063-464-43X,Patent Application,no,5,2,6,6,0,F16F7/1022;;F16L3/202,F16F7/10;;F16L3/20;;F16L3/202;;F16L3/215,,0,0,,,,EXPIRED
151,US,A1,US 2009/0266498 A1,009-565-354-103-337,2009-10-29,2009,US 38441809 A,2009-04-03,GB 0806117 A,2008-04-04,Smoke curtain,"A heat resistant curtain has a vent typically extending up from a bottom edge. At the vent, flaps of the curtain on either side of the vent have marginal overlaps. To these are stitched elevated temperature resistant hook and loop fastening tapes. These normally keep the vent closed. The curtain is provided with a bottom bar drawn up to close the head box when the curtain is not deployed. When the curtain is deployed, the bottom bar rests on the floor.",COOPER ANDREW PAUL;;REED JAMES MARTIN,COOPER ANDREW PAUL;;REED JAMES MARTIN,COOPERS BLINDS LIMITED (2009-06-25),https://lens.org/009-565-354-103-337,Patent Application,yes,4,12,6,6,0,A62C2/10;;E06B9/13;;E06B2009/17053;;Y10T24/44;;Y10T24/27;;Y10T24/44;;Y10T24/27;;E06B9/13;;A62C2/10;;E06B2009/17053,A44B18/00;;A47H23/01;;A44B99/00;;E06B9/56,160/309;;160/349.1;;24/455;;24/442,0,0,,,,DISCONTINUED
152,AU,B2,AU 628073 B2,017-308-704-567-899,1992-09-10,1992,AU 1989/040774 A,1989-08-15,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION,,GERSAN ANSTALT,COOPER MARTIN;;STEWART ANDREW DAVID GARRY,,https://lens.org/017-308-704-567-899,Granted Patent,no,3,0,13,30,0,B23K26/364;;B23K26/364,B23K26/00;;B23K26/06;;B23K26/073;;B23K26/36,,0,0,,,,EXPIRED
153,GB,A,GB 2160513 A,036-017-351-200-950,1985-12-24,1985,GB 8416016 A,1984-06-22,GB 8416016 A,1984-06-22,Feeding sheets from a stack,A top sheet feeder for feeding sheets one at a time from the top of a stack of sheets comprises a stack support surface and an upwardly inclined ramp 91 arranged downstream of the stack support surface which has retard pads 90 provided therein. A paddle feeder 54 is arranged to engage the top sheet in the stack and advance the sheet to the ramp 91 whereby it initially engages the ramp below the retard pads 90 before engaging the retard pads. <IMAGE>,XEROX CORP,KERSHAW IAN GEOFFREY;;COOPER JOHN MARTIN,,https://lens.org/036-017-351-200-950,Patent Application,no,1,0,3,3,0,B65H3/5223,B65H3/52,B8R RAE3          RAE3;;B8R R404          RAE3;;B8R R461          RAE3;;B8R R471          RAE3;;U1S S2243;;U1S S2249,0,0,,,,EXPIRED
154,GB,B,GB 2290568 B,104-530-815-123-124,1997-09-03,1997,GB 9512949 A,1995-06-26,GB 9512949 A;;GB 9412824 A,1994-06-25,A ventilated tile,,PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/104-530-815-123-124,Granted Patent,no,3,0,3,4,0,E04D1/30;;E04D1/30;;E04D2001/309;;E04D2001/309,E04D1/30,E1D DCE2          F124CE;;E1D DF124         F124CE;;E1D D120          F124CE;;E1D D2022         F124CE;;E1D D2055         F124CE;;E1D D2139         F124CE;;E1D D401          F124CE,0,0,,,,EXPIRED
155,WO,A1,WO 2007/112762 A1,113-523-783-686-539,2007-10-11,2007,EP 2006002973 W,2006-03-31,EP 2006002973 W,2006-03-31,SCHEDULING RADIO RESOURCES IN A MULTI-CARRIER TDMA MOBILE COMMUNICATION SYSTEM,"A method for scheduling radio resources on at least two carriers in a multi-carrier frequency hopping TDMA mobile communication system for simultaneous downlink reception in a TDMA frame by a mobile station comprising the steps of assigning downlink time slots on a first carrier for use by the mobile terminal, assigning downlink time slots on a second carrier for simultaneous use by said mobile terminal, wherein the assignment of downlink time slots on the first carrier is independent from the assignment of downlink time slots on the second carrier. The invention also relates to a base station for scheduling radio resources and a mobile terminal for receiving data in the mobile communication system.",MATSUSHITA ELECTRIC IND CO LTD;;COOPER DAVID;;GREAVES MARTIN;;BRISTOW ROBERT,COOPER DAVID;;GREAVES MARTIN;;BRISTOW ROBERT,,https://lens.org/113-523-783-686-539,Patent Application,yes,6,33,1,1,0,H04B7/2656;;H04B7/2615;;H04L5/06;;H04W28/06;;H04W72/0446;;H04W72/12;;H04W74/00,H04B7/26;;H04W72/12,,2,0,,,"""GERAN evolution: proposed text on dual-carrier and multi-carrier for technical report"", 3GPP TSG GERAN #25, XX, XX, 24 June 2005 (2005-06-24), pages complete, XP002362276;;""Digital cellular telecommunications system (Phase 2+)"", ETSI STANDARDS, EUROPEAN TELECOMMUNICATIONS STANDARDS INSTITUTE, SOPHIA-ANTIPO, FR, vol. 3-G1, no. V6110, September 2005 (2005-09-01), XP014032087, ISSN: 0000-0001",PENDING
156,US,A,US 1148245 A,125-405-948-353-301,1915-07-27,1915,US 1913/0801146 A,1913-11-15,US 1913/0801146 A,1913-11-15,"NAIL, SPIKE, AND THE LIKE WITH SOFT-METAL HEAD.",,MARTIN FRED GARDINER;;CROWTHER JOHN COOPER,MARTIN FRED GARDINER;;CROWTHER JOHN COOPER,,https://lens.org/125-405-948-353-301,Granted Patent,no,0,3,1,1,0,B21G5/00;;B21G5/00,,,0,0,,,,EXPIRED
157,US,A,US 5130432 A,128-644-002-051-246,1992-07-14,1992,US 63363690 A,1990-12-21,US 63363690 A,1990-12-21,Process for preparing cyclic amines and intermediate products thereof,"A process for preparing a cyclic amine of Formula I ##STR1## in which R.sup.1 is phenyl, optionally substituted by 1 to 3 lower alkoxy groups; R.sup.2, R.sup.3 and R.sup.4 are independently hydrogen or lower alkyl; and n is 1 or 2, comprises (1) converting an aminoalcohol of Formula III ##STR2## to a dioxooxathiazolidine of Formula II ##STR3## in which R.sup.2, R.sup.3, R.sup.4 and n are as defined above; and (2) reacting the dioxooxathiazolidine of Formula II with an organometallic nucleophile, R.sup.1 M*, wherein R.sup.1 is as defined above, and hydrolyzing the resulting sulfamate salt.",SYNTEX INC,COOPER GARY F;;MARTIN MICHAEL G,SYNTEX (U.S.A.) INC. A CORP. OF DE (1991-02-12),https://lens.org/128-644-002-051-246,Granted Patent,yes,2,14,1,1,0,C07D207/08;;C07D515/04;;C07D207/08;;C07D515/04,C07D207/08;;C07D515/04,546/114;;546/192;;546/236;;548/122;;548/570,4,3,162-466-069-966-540;;007-415-522-865-706;;023-998-221-611-929,10.1016/s0957-4166(00)82278-8;;10.1246/bcsj.40.1554;;6063125;;10.1021/ja00259a052,"Alker, D. et al. The Direct Synthesis of the Cyclic Sulphamidate of (s) Prolinol: Simultaneous N Protection and Activation Towards Nucleophilic Displacement of Oxygen Tetrahedron: Asymmetry 1990; 1(12): 877 880.;;Zubovic, Z. et al. Synthesis and antiarrhythmic Activity on N aryl Alkylenediamines Eur. J. Med. Chem. Chim. Ther. 1986; 21(5): 370 378.;;Noda, Y. A New Imino Acid Derived from L serine O sulfate Bull. Chem. Soc. Japan 1967; 40(6): 1554.;;Lyle, T. A. et al. Fluoride Induced Formation and Ring Opening of Cyclid Sulfamates from Hydroxy Triflamides. Synthetic and Mechanistic Studies J. Am. Chem. Soc. 1987: 109: 7890 7891.",EXPIRED
158,GB,B,GB 2374132 B,009-245-637-123-175,2004-06-23,2004,GB 0108624 A,2001-04-05,GB 0108624 A,2001-04-05,Saddle for underground valve,,PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/009-245-637-123-175,Granted Patent,no,5,0,3,3,0,E03B7/08;;E03B7/095;;E03B9/10;;F16K27/12,E03B7/07;;E03B9/10;;F16K27/12,E1G G96B          G96;;F2V VG5           VG5;;F2V VW59          VW59,0,0,,,,EXPIRED
159,AU,A1,AU 2012/216243 A1,023-480-305-216-006,2012-09-06,2012,AU 2012/216243 A,2012-08-16,AU 2006/273784 A;;AU 2012/216243 A,2006-07-05,System and method for determining the time difference between two platforms,"A transmitter (106, 120, 118, 122 and 110) of a platform (100) is arranged to generate a transmission pulse which is transmitted to a receiver 5 (212, 224 and 208) of another platform (200) and is also arranged to couple its transmission pulse to a digital receiver (104) associated with its platform (100) via attenuater (126) and coupler (124). The other platform (200) performs a similar task. Each digital receiver (108, 208) determines the time separation between its transmission pulse and received pulse from the other platform (100 10 or 200). The determined time separation information is shared with the other platform (100, 200) and each digital receiver (108, 208) then determines a time offset (At) between the time at its platform (100) and the other platform (200). 3810722_1 (GHMatters) P78436 AU.1 N( C>C",SELEX GALILEO LTD,GOULD DALE MARTIN;;COOPER ROBERT DAVID,LEONARDO UK LTD (2021-05-20);;LEONARDO MW LTD (2016-11-03),https://lens.org/023-480-305-216-006,Patent Application,no,0,0,2,2,0,,G04G7/02,,0,0,,,,ACTIVE
160,SE,D0,SE 9704542 D0,037-884-414-762-857,1997-12-05,1997,SE 9704542 A,1997-12-05,SE 9704542 A,1997-12-05,Novel pyridazinone compounds,,ASTRA PHARMA PROD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP,,https://lens.org/037-884-414-762-857,Patent Application,no,0,0,1,29,0,,C07D/,,0,0,,,,PENDING
161,WO,A1,WO 1990/001392 A1,053-976-461-200-695,1990-02-22,1990,GB 8900942 W,1989-08-15,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION,"To make an elongate cut (1) in a diamond (2) using a laser radiation, a cylindrical optical system (5, 6) is used which converges the radiation at a greater angle of convergence in the plane of the cut (1) than in the transverse plane. In this way, the focal spot energy density is increased and cutting at depth is made more effective.",GERSAN ANSTALT;;COOPER MARTIN;;STEWART ANDREW DAVID GARRY,COOPER MARTIN;;STEWART ANDREW DAVID GARRY,,https://lens.org/053-976-461-200-695,Patent Application,yes,1,1,13,30,0,B23K26/364;;B23K26/364,B23K26/06;;B23K26/00;;B23K26/073;;B23K26/36,,1,0,,,"IBM TECHNICAL DISCLOSURE BULLETIN. vol. 14, no. 9, February 1972, NEW YORK US pages 2641 - 2642; M.A. GRIMM: ""Optical system for laser machining of narrow slots"" see the whole document",PATENTED
162,WO,A1,WO 2007/112761 A1,075-746-488-937-085,2007-10-11,2007,EP 2006002972 W,2006-03-31,EP 2006002972 W,2006-03-31,SCHEDULING RADIO BLOCKS IN A MULTI-CARRIER TDMA MOBILE COMMUNICATION SYSTEM,"A method of scheduling radio blocks on at least two carriers in a multi-carrier frequency hopping TDMA mobile communication system for uplink transmission by a mobile terminal capable of simultaneous downlink reception on two carriers, comprising the step of assigning N, N being an integer, downlink timeslots on at least a first carrier for use by the mobile terminal, said N downlink timeslots having the same timeslot number on consecutive TDMA frames, the step of assigning M, M being an integer, uplink timeslots on the first carrier for use by the mobile terminal on consecutive TDMA frames, and the step of assigning M uplink timeslots on the second carrier for use by the mobile terminal on consecutive TDMA frames, said uplink timeslots having a different timeslot number than the uplink timeslots on the first carrier, wherein each radio block scheduled for uplink for the mobile terminal consists of 4 timeslots transmitted on the first carrier and 4 timeslots transmitted on the second carrier over a period of 4 consecutive TDMA frames.",MATSUSHITA ELECTRIC IND CO LTD;;COOPER DAVID;;DHANDA MUNGAL;;GREAVES MARTIN,COOPER DAVID;;DHANDA MUNGAL;;GREAVES MARTIN,,https://lens.org/075-746-488-937-085,Patent Application,yes,2,12,1,1,0,H04W72/1263;;H04B7/2615;;H04B7/2656;;H04W28/22;;H04W72/0453,H04B7/26;;H04W28/22;;H04W72/12,,1,0,,,"""GERAN evolution: proposed text on dual-carrier and multi-carrier for technical report"", 3GPP TSG GERAN #25, XX, XX, 24 June 2005 (2005-06-24), pages complete, XP002362276",PENDING
163,EP,A1,EP 0668204 A1,135-316-054-454-742,1995-08-23,1995,EP 95300671 A,1995-02-02,GB 9403044 A,1994-02-17,Multi-processor module.,"A multi-processor module (33) for use in a solid-state interlocking system for a railway network includes a first processor for receiving instructions concerning the operation of parts of the trackside equipment (40) within the network and carrying out those instructions in dependence upon the current overall status of that trackside equipment, and a second processor for receiving the instructions from the first processor and effecting the operation of the appropriate trackside equipment via a data link. The first processor runs at a higher clock speed than the second. A program run in the first processor is arranged to be slowed down in those areas which interface with the second processor. The slowing down may be effected by the inclusion of delay loops, no-operation instructions, or by the increasing of time constants in timing hardware.",GEC ALSTHOM SIGNALLING LTD,COOPER MARK EDWIN;;PLATT CHRISTOPHER MARTIN,,https://lens.org/135-316-054-454-742,Patent Application,yes,6,3,4,4,0,B61L19/06,B61L19/06;;B61L27/00,,0,0,,,,DISCONTINUED
164,US,A1,US 2022/0280819 A1,126-539-328-554-436,2022-09-08,2022,US 202017627173 A,2020-07-16,GB 201910187 A;;GB 2020051706 W,2019-07-16,FIREBREAK DEVICE,"A firebreak device configured to arrest a flow of medical gas capable of combustion or of supporting combustion, said device comprising: a housing having a body portion, an inlet and an outlet, said inlet and outlet being linked by a conduit; a valve assembly located within said body portion, said valve assembly being movable between an open position, in which gas can flow between said inlet and outlet along said conduit, and a closed position in which gas flow between said inlet and said outlet is arrested; a biasing assembly ( 340 ) arranged within said body portion to move said valve assembly into said closed position; and a heat activatable stop ( 350 ) located between said biasing assembly and said outlet to hold said valve assembly in said open position against said biasing assembly, and adapted to release said valve assembly to allow said biasing assembly to move said valve assembly to said closed position at an activation temperature, to close flow of gas through the device if said heat activatable stop is activated, wherein: said heat activatable stop is arranged to prevent obstruction of said flow of gas adjacent an inner surface of said device.",BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL,BPR MEDICAL LIMITED (2022-01-19),https://lens.org/126-539-328-554-436,Patent Application,yes,0,0,6,6,0,A61M16/20;;A61M16/201;;F16K17/383;;F16L55/1022;;F16L55/1026;;A61M16/0816;;A61M2202/0208;;A61M2205/02;;F16L57/04;;A62C4/02;;A62C2/20;;A61M16/208;;F16K17/383;;A61M16/208;;A61M2205/3368;;A62C2/04,A62C2/04;;A61M16/20,,0,0,,,,PENDING
165,GB,A,GB 2319225 A,131-568-662-301-008,1998-05-20,1998,GB 9801072 A,1996-07-17,GB 9601712 W;;GB 9514558 A,1995-07-17,Marking diamond,"In order to produce on the table of a diamond gemstone (7), an information mark which is invisible to the naked eye using a x10 loupe, an ultraviolet laser (1) having a wavelength of 193 nm is used in association with a mask (2) to irradiate the surface of the stone (7) at a fluence of less than 2 J/cm 2 per pulse and with not fewer than 100 pulses, in the presence of air which reacts with the diamond (7) and causes the mark to be formed without any darkening which is visible when viewing using a microscope.",GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/131-568-662-301-008,Patent Application,no,3,3,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B28D5/00;;B44B7/00;;C30B29/04;;H01S3/00,B6J JMY           JMY;;B6J J70X          JMY;;U1S S1431,0,0,,,,EXPIRED
166,GB,B,GB 2420571 B,151-045-094-569-446,2006-11-01,2006,GB 0602427 A,2004-07-12,GB 0316991 A;;GB 0403608 A;;GB 0415569 A,2003-07-21,Sealing strip for a ridge tile roof ventilation system,,PHI DESIGN LTD,NUNN ROBERT CHARLES;;COOPER ROGER MARTIN,,https://lens.org/151-045-094-569-446,Granted Patent,no,5,0,8,10,0,E04D1/30;;E04D1/3402;;E04D1/365;;E04D13/174;;E04D2001/305;;E04D2001/306;;E04D1/3402;;E04D1/36;;E04D13/152;;E04D2001/306;;E04D1/30;;E04D2001/305;;E04D1/30;;E04D1/3402;;E04D2001/305;;E04D2001/306,E04D1/36;;E04D1/30;;E04D1/34;;E04D13/17,E1D DDJ2          F112DJ;;E1D DF112         F112DJ;;E1D D124          F112DJ;;E1D D2055         F112DJ;;E1D D401          F112DJ,0,0,,,,ACTIVE
167,GB,A,GB 2315784 A,168-801-427-477-485,1998-02-11,1998,GB 9615888 A,1996-07-29,GB 9615888 A,1996-07-29,A vent for a roof,"A fascia vent (10) for a roof which permits air to circulate within the roof space while preventing the entry of birds and insects is disclosed. In a preferred embodiment the vent (10) comprises an elongate plastic moulding (11) having an exterior opening and an interior opening (13) in fluid communication with one another. The vent (10) may be secured to a fascia board (108) under the edge of a roof such that the exterior opening is at least partially occluded. The exterior opening (14) is provided with two or more steps (22,23) to ensure that the degree of occlusion is uniform along the length of the vent (10). Preferably tubular fixing holes are moulded in the vent at regular intervals.",PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/168-801-427-477-485,Patent Application,no,1,0,3,3,0,E04D13/004;;E04D13/178,E04D13/00;;E04D13/17,E1D DDV2          FZDV;;E1D DF124         FZDV;;E1D DF172         FZDV;;E1D D401          FZDV;;E1D D547          FZDV,0,0,,,,EXPIRED
168,US,A1,US 2003/0210614 A1,170-766-584-066-744,2003-11-13,2003,US 14437602 A,2002-05-13,US 14437602 A,2002-05-13,Customizable timepiece device,"
   The present invention relates to a timepiece device, and more particularly to a timepiece device having a customized dial. The timepiece device has a housing and a face plate attached to the housing. The face plate has a peripheral rim which has a plurality of intermittently spaced lands. Each land is configured to provide a surface for receiving customized indicia. An outer cover which can be removed or opened to provide access to customize the face plate is provided. 
",COOPER MARTIN R.;;TAYLOR KIMBERLY R.,COOPER MARTIN R;;TAYLOR KIMBERLY R,8 POINT 5 CONCEPTS LTD (2002-05-08),https://lens.org/170-766-584-066-744,Patent Application,yes,25,11,2,2,0,G04B19/10;;G04B19/10;;G04B47/046;;G04B47/046,G04B19/10;;G04B47/04,368/223,0,0,,,,EXPIRED
169,AU,B2,AU 2012/216243 B2,024-971-214-431-774,2014-11-27,2014,AU 2012/216243 A,2012-08-16,AU 2006/273784 A;;AU 2012/216243 A,2006-07-05,System and method for determining the time difference between two platforms,"A transmitter (106, 120, 118, 122 and 110) of a platform (100) is arranged to generate a transmission pulse which is transmitted to a receiver 5 (212, 224 and 208) of another platform (200) and is also arranged to couple its transmission pulse to a digital receiver (104) associated with its platform (100) via attenuater (126) and coupler (124). The other platform (200) performs a similar task. Each digital receiver (108, 208) determines the time separation between its transmission pulse and received pulse from the other platform (100 10 or 200). The determined time separation information is shared with the other platform (100, 200) and each digital receiver (108, 208) then determines a time offset (At) between the time at its platform (100) and the other platform (200). 3810722_1 (GHMatters) P78436 AU.1 N( C>C",LEONARDO UK LTD,GOULD DALE MARTIN;;COOPER ROBERT DAVID,LEONARDO UK LTD (2021-05-20);;LEONARDO MW LTD (2016-11-03),https://lens.org/024-971-214-431-774,Granted Patent,no,1,0,2,2,0,,G04R20/00,,0,0,,,,ACTIVE
170,GB,A,GB 2374132 A,052-394-004-829-352,2002-10-09,2002,GB 0108624 A,2001-04-05,GB 0108624 A,2001-04-05,Saddle for an underground valve,"A saddle 15 comprises an annular seat 16 having a continuous ring 19 with one surface 20 adapted to engage a body of a valve and another surface 24 adapted to engage a surface access tube (13, fig 1) which maybe latched thereto by a snap fitting. Legs 17 with feet 18 extend from the annular seat 16 and arch over a conduit (pipe) to stabilise the saddle 15. A tab 23 is connected to the saddle 15 by a frangible strap 25. The tab 23 is broken off and inserted through apertures 26 in the legs 17 beneath the conduit and prevent the legs 17 from spreading by saw tooth shaped teeth 27 having an abutment surface 29 and abutment surface 28. More than one tab 23 maybe provided and maybe connected to the saddle 15 by a long flexible strap so that separation is not necessary.",PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/052-394-004-829-352,Patent Application,no,5,1,3,3,0,E03B7/08;;E03B7/095;;E03B9/10;;F16K27/12,E03B7/07;;E03B9/10;;F16K27/12,E1G G96B          G96;;F2V VG5           VG5;;F2V VW59          VW59,0,0,,,,EXPIRED
171,AU,B2,AU 708323 B2,073-340-880-034-646,1999-07-29,1999,AU 1996/065247 A,1996-07-17,GB 9514558 A;;GB 9601712 W,1995-07-17,Marking diamond,,GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/073-340-880-034-646,Granted Patent,no,0,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B28D5/00;;B23K26/00;;B23K26/06;;B41M5/24;;B44B7/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
172,DE,T2,DE 3853477 T2,088-272-011-363-037,1995-11-09,1995,DE 3853477 T,1988-12-02,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,MAKROZYKLISCHE VERBINDUNGEN.,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN;;DONALD DAVID;;HARDERN DAVID,"FUJISAWA PHARMACEUTICAL CO., LTD., OSAKA, JP (2005-06-30);;ASTELLAS PHARMA INC., TOKIO/TOKYO, JP (2006-04-27)",https://lens.org/088-272-011-363-037,Granted Patent,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
173,WO,A1,WO 2021/009511 A1,091-698-386-459-074,2021-01-21,2021,GB 2020051706 W,2020-07-16,GB 201910187 A,2019-07-16,FIREBREAK DEVICE,"A firebreak device configured to arrest a flow of medical gas capable of combustion or of supporting combustion, said device comprising: a housing having a body portion, an inlet and an outlet, said inlet and outlet being linked by a conduit; a valve assembly located within said body portion, said valve assembly being movable between an open position, in which gas can flow between said inlet and outlet along said conduit, and a closed position in which gas flow between said inlet and said outlet is arrested; a biasing assembly (340) arranged within said body portion to move said valve assembly into said closed position; and a heat activatable stop (350) located between said biasing assembly and said outlet to hold said valve assembly in said open position against said biasing assembly, and adapted to release said valve assembly to allow said biasing assembly to move said valve assembly to said closed position at an activation temperature, to close flow of gas through the device if said heat activatable stop is activated, wherein: said heat activatable stop is arranged to prevent obstruction of said flow of gas adjacent an inner surface of said device.",BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL,,https://lens.org/091-698-386-459-074,Patent Application,yes,5,0,6,6,0,A61M16/20;;A61M16/201;;F16K17/383;;F16L55/1022;;F16L55/1026;;A61M16/0816;;A61M2202/0208;;A61M2205/02;;F16L57/04;;A62C4/02;;A62C2/20;;A61M16/208;;F16K17/383;;A61M16/208;;A61M2205/3368;;A62C2/04,A61M16/20;;F16K17/38;;F16L55/10,,0,0,,,,PENDING
174,US,A,US 5892659 A,097-877-999-979-218,1999-04-06,1999,US 75585696 A,1996-12-02,US 75585696 A;;US 844395 P,1995-12-12,Retention system for solenoid coils,"The invention comprises a retention system for retaining a component within a housing, the system having a body to receive the component therein. The body has a bottom wall against which the component will be mounted. A resiliently deflectable latching arm extends upwardly from the bottom wall. The latching arm has a lower section, an angled section, and a latching section. The angled section has an opening therein. The latching section offset section has a latching surface. The opening receiving a latching tooth therein and the latching surface engaging the latching tooth to secure the component.",WHITAKER CORP,COOPER RALPH MELVIN;;MARTIN GALEN MONROE,WHITAKER CORPORATION THE (1996-10-30),https://lens.org/097-877-999-979-218,Granted Patent,yes,6,18,3,3,0,H01F7/06;;H05K7/12;;H05K7/12;;H01F7/06,H01F5/00;;F16B1/02;;H01F7/06;;H05K7/12,361/727;;361/658;;361/747;;174/48;;174/49;;174/50;;220/4.02;;439/575,0,0,,,,EXPIRED
175,US,B2,US 11867296 B2,128-925-848-260-085,2024-01-09,2024,US 202217839146 A,2022-06-13,EP 21179207 A,2021-06-14,Valve assembly,"A valve assembly ( 1 ) comprising: a common housing having a first side ( 8 a ), a second side ( 8 b ), an inlet port ( 2 ) and an outlet port ( 3 ); the valve assembly ( 1 ) comprising a first pair of valve members or poppets ( 4 a, 4 c ) and a second pair of valve members or poppets ( 4 b, 4 d ), a first pair of valve seats ( 5 a, 5 c ) for cooperation with the first pair of valve members or poppets ( 4 a, 4 c ), and a second pair of valve seats ( 5 b, 5 d ) for cooperation with the second pair of valve members or poppets ( 4 b, 4 d ); a central flow diverter ( 13 c ) disposed in between the first pair of valve members or poppets ( 4 a, 4 c ) and the second pair of valve seats ( 5 b, 5 d ), the central flow diverter ( 13 c ) defining a first side ( 11 a ) of the valve assembly ( 1 ) and a second side ( 11 b ) of the valve assembly ( 1 ).",SIEMENS AG,WETZEL MARTIN;;COOPER NILS;;WIEGAND ARMIN,SIEMENS AKTIENGESELLSCHAFT (2022-07-07),https://lens.org/128-925-848-260-085,Granted Patent,yes,20,0,4,4,0,F16K1/34;;F16K1/32;;F16K27/02;;F23K2900/05002;;F23N2235/24;;F23N2235/18;;F23N2235/16;;F23N1/005;;F16K1/446;;F16K1/443;;F16K27/02,F16K1/44;;F16K27/02,,0,0,,,,ACTIVE
176,US,B2,US 9956442 B2,166-507-294-399-873,2018-05-01,2018,US 201414773357 A,2014-03-05,US 201414773357 A;;GB 201304316 A;;US 201361843476 P;;GB 2014050639 W,2013-03-07,Fire and/or smoke barrier,"A curtain is wound on a roller ( 2 ), provided in a head box ( 4 ), mounted in a ceiling ( 6 ). The curtain is also provided with a bottom bar ( 10 ). When the curtain is drawn up onto the roller, the bottom bar ( 10 ) can be used to close the head box ( 4 ). When deployed the bottom bar provides stability to the descending curtain, and in full deployment rests on the floor. The curtain is provided with additional strips ( 30 ) of fabric, to allow ease of roll up onto the roller. The strip(s) arc attached at their top end only, to the curtain. Typically this will be by sewing ( 32 ), but also may be rivets or other form of heat resistant connection. The strip(s) are also connected to the bottom bar. A cable ( 34 ) is attached to the strip(s), usually through a rivet, but any other form of secure attachment may be used. The cable is then connected to the bottom bar, via a spring ( 36 ). This connects to keep the strip(s) in tension, to enable ease of rolling of the curtain.",COOPERS FIRE LTD,COOPER ANDREW PAUL;;REED JAMES MARTIN,COOPERS FIRE LIMITED (2016-01-15),https://lens.org/166-507-294-399-873,Granted Patent,yes,8,8,6,6,0,A62C2/10;;A62C2/10;;E06B5/00;;E06B9/42;;E06B9/42;;E06B9/56,A62C2/10;;E06B5/00;;E06B9/42;;E06B9/56,,0,0,,,,ACTIVE
177,US,B2,US 7126881 B2,174-338-912-112-389,2006-10-24,2006,US 14437602 A,2002-05-13,US 14437602 A,2002-05-13,Customizable timepiece device,"The present invention relates to a timepiece device, and more particularly to a timepiece device having a customized dial. The timepiece device has a housing and a face plate attached to the housing. The face plate has a peripheral rim which has a plurality of intermittently spaced lands. Each land is configured to provide a surface for receiving customized indicia. An outer cover which can be removed or opened to provide access to customize the face plate is provided.",POINT 5 CONCEPTS LTD 8,COOPER MARTIN R;;TAYLOR KIMBERLY R,8 POINT 5 CONCEPTS LTD (2002-05-08),https://lens.org/174-338-912-112-389,Granted Patent,yes,26,9,2,2,0,G04B19/10;;G04B19/10;;G04B47/046;;G04B47/046,G04B19/00;;G04B19/10;;G04B25/00;;G04B47/04,368/223;;368/285,0,0,,,,EXPIRED
178,EP,B1,EP 2107205 B1,006-951-521-312-133,2018-05-09,2018,EP 09004969 A,2009-04-03,GB 0806117 A,2008-04-04,Smoke curtain apparatus,,COOPERS BLINDS LTD,COOPER PAUL ANDREW;;REED JAMES MARTIN,"COOPERS FIRE LIMITED (2018-11-14);;COOPERS FIRE LIMITED, GB (2018-11-05)",https://lens.org/006-951-521-312-133,Granted Patent,yes,2,0,6,6,0,A62C2/10;;E06B9/13;;E06B2009/17053;;Y10T24/44;;Y10T24/27;;Y10T24/44;;Y10T24/27;;E06B9/13;;A62C2/10;;E06B2009/17053,E06B9/13;;A44B99/00;;A62C2/10;;E06B9/17,,0,0,,,,ACTIVE
179,GB,B,GB 2404206 B,015-088-026-072-568,2006-10-04,2006,GB 0415569 A,2004-07-12,GB 0316991 A;;GB 0403608 A,2003-07-21,Ridge tile roof ventilation system and fixing,,PHI DESIGN LTD,NUNN ROBERT CHARLES;;COOPER ROGER MARTIN,,https://lens.org/015-088-026-072-568,Granted Patent,no,6,0,8,10,0,E04D1/30;;E04D1/3402;;E04D1/365;;E04D13/174;;E04D2001/305;;E04D2001/306;;E04D1/3402;;E04D1/36;;E04D13/152;;E04D2001/306;;E04D1/30;;E04D2001/305;;E04D1/30;;E04D1/3402;;E04D2001/305;;E04D2001/306,E04D1/34;;E04D1/30;;E04D13/152;;E04D13/17,E1D DDJ2          FZDJ;;E1D DF112         FZDJ;;E1D DF124         FZDJ;;E1D D2055         FZDJ,0,0,,,,EXPIRED
180,DE,A1,DE 3140272 A1,026-447-187-189-426,1982-07-22,1982,DE 3140272 A,1981-10-10,US 19738080 A,1980-10-15,"""ABSCHALTSYSTEM FUER KERNREAKTOREN""",,WESTINGHOUSE ELECTRIC CORP,MANGUS JAMES DONALD;;COOPER MARTIN HOWARD,,https://lens.org/026-447-187-189-426,Patent Application,no,0,0,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,,0,0,,,,DISCONTINUED
181,CN,A,CN 110187702 A,062-255-236-545-570,2019-08-30,2019,CN 201910133572 A,2019-02-22,US 201815902672 A,2018-02-22,"Automatic vehicle control apparatus capable of determining track occupancy of vehicle, and corresponding method for automatically controlling vehicle","The invention discloses an automatic vehicle control apparatus capable of determining the track occupancy of a vehicle and a corresponding method for automatically controlling the vehicle. The automatic vehicle control apparatus comprises a first image sensor positioned on a vehicle, able to capture a first global image of a first scene, including an area in front of the vehicle, in a first fieldof view of said first image sensor; a track occupancy detector for receiving the first global image and deducing therefrom a track occupancy of the vehicle among at least two set of parallel tracks positioned in front of the vehicle; a distinguishable object disposed in the first field of view; and a proper functioning checking apparatus configured for searching, in the first global image, a firstspecific image of the distinguishable object, and for generating an alert signal in case the first specific image is not found in the first global image.",ALSTOM TRANSP TECH,MARTIN PHILLIP;;SNYDER SENECA;;COOPER JARED,,https://lens.org/062-255-236-545-570,Patent Application,no,7,0,7,7,0,G05D1/0246;;G06T7/73;;G06T2207/10028;;G06T2207/30256;;G08G1/166;;B61L23/041;;B61L25/025;;B61L2205/04;;G06V20/56;;G06V10/751;;G08G1/166;;G06T2207/30236;;G08G1/056;;G06T7/70;;G06T7/73;;G06V10/751;;G06V20/56,G05D1/02,,0,0,,,,PENDING
182,GB,A,GB 2327414 A,106-345-606-241-886,1999-01-27,1999,GB 9815609 A,1998-07-20,GB 9715358 A,1997-07-21,Coiling metal strip,"Apparatus for coiling successive lengths of metal strip onto mandrels 7,8, comprising means for changing the strip path from a path leading to the mandrel 8 currently being wound to a path to a new mandrel when the current strip ends and a new strip appears. The new mandrel has mandrel strip guide means 12 comprising a chain of driven mandrel guide rollers located around the new mandrel in its initial position to receive the leading edge of a new length of strip and guide it around the mandrel. Adjacent rollers in the chain have interlocking grooves and flanges. Similar chains of rollers 3, 5, and 13 are used to guide the strip between the shears 2 and the mandrels. The new mandrel 7 is positioned in an initial position such that the strip path to it is a straight path, and the mandrels are mounted on a carousel 6 which moves that mandrel to a second position such that the strip path to it is an angled path 14 the first segment of which is common with the first part of the straight strip path. A tail restraining unit 11 holds the tail of the old strip onto its mandrel.",KVAERNER TECH & RES LTD,BERRY JOHN;;COOPER BRIAN;;PHILIPSON MARTIN,,https://lens.org/106-345-606-241-886,Patent Application,no,6,3,8,8,0,B21C47/245;;B21C47/34;;B21C47/3475;;B21C47/3475;;B21C47/245;;B21C47/34,B21C47/06;;B21C47/24;;B21C47/34,B8R RRR2          RRR2;;B8R R8A4          RRR2;;B8R R8D1D         RRR2,0,0,,,,DISCONTINUED
183,EP,A3,EP 0329960 A3,105-137-425-307-169,1991-02-06,1991,EP 89101212 A,1989-01-24,US 16043888 A,1988-02-25,SECURED PACKAGE INTEGRITY,"The package (21) includes a body (23) and a closure (25) and a readily breakable electrical oscillatory network (29) sans power supply is physically connected between the body (23) and the closure (25). The network (29), is tuned to resonate at a predetermined frequency. The package (21) is monitored by a transmitter-receiver when it is distributed to a customer. The transmit­ter produces pulse signals in a carrier frequency band which overlaps the resonant frequency of the network (29). During monitoring the package (21) is placed in the field of the transmitter and the oscillatory network (29) is excited to produce a decaying pulse for each transmitter pulse. If the package (21) is sealed, the oscillatory network (29), is intact decaying pulses are received to produce visual or audible signals. If the package (21) has been opened, the network (29) is broken and no signals are produced.  ",WESTINGHOUSE ELECTRIC CORPORATION,"COOPER, MARTIN HOWARD;;PETROSKY, LYMAN JAY",,https://lens.org/105-137-425-307-169,Search Report,yes,5,0,4,4,0,B65D5/4291;;B65D55/028;;Y10S206/807;;B65D55/028;;B65D5/4291;;Y10S206/807,B65D5/74;;B65D5/42;;B65D55/02,,0,0,,,,DISCONTINUED
184,US,A,US 3175191 A,117-964-919-806-878,1965-03-23,1965,US 250360 A,1960-01-14,US 250360 A,1960-01-14,Binary code signalling system having a binary counter at the receiver responsive to a selected code,,MOTOROLA INC,JONA COHN;;MARTIN COOPER;;THEODORE SALTZBERG,,https://lens.org/117-964-919-806-878,Granted Patent,no,5,26,1,1,0,H04W88/188;;H04W88/188,H04W88/18,,0,0,,,,EXPIRED
185,CA,A1,CA 2029493 A1,125-230-867-696-837,1991-05-18,1991,CA 2029493 A,1990-11-16,US 43787889 A,1989-11-17,HIGH PERFORMANCE THIN FILM ALKALI METAL THERMOELECTRIC DEVICE,"55,178 ABSTRACT OF THE DISCLOSURE An alkali metal thermoelectric conversion device formed from a porous tube or plate coated with a thin film of beta-alumina, the porous tube or plate is sintered metal or metal alloy having a coefficient of thermal expansion which approaches that of the beta-alumina to form a mechanically stable device with high electrical output.",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H;;SIEVERS ROBERT K,,https://lens.org/125-230-867-696-837,Patent Application,no,0,0,4,4,0,H01G9/21;;H01G9/21,B22F5/00;;B22F5/12;;H01G9/00;;H01G9/21;;H01M4/64;;H01M6/36;;H02N3/00,D132200015   M,0,0,,,,DISCONTINUED
186,FR,A1,FR 2512258 A1,184-542-401-853-186,1983-03-04,1983,FR 8206527 A,1982-04-15,US 29597581 A,1981-08-25,DISPOSITIF D'ENLEVEMENT DE CHALEUR EN RESERVE POUR UN REACTEUR NUCLEAIRE UTILISANT DES VALVES A CIRCULATION,"<P>L'INVENTION CONCERNE UN REACTEUR NUCLEAIRE UTILISANT DES VALVES A CIRCULATION 19 POUR LIMITER LE COURANT EN DERIVATION SUR LE NOYAU DU REACTEUR, PAR LA REGION DE MANTEAU 12 PENDANT LA CIRCULATION NORMALE DE L'AGENT DE REFROIDISSEMENT DU REACTEUR ET POUR PERMETTRE UNE CIRCULATION NATURELLE NON PERTURBEE LORSQUE LA CIRCULATION NORMALE D'AGENT DE REFROIDISSEMENT EST INTERROMPUE.</P>",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN HOWARD;;RACKI DANIEL JOSEPH,,https://lens.org/184-542-401-853-186,Patent Application,no,6,0,4,4,0,G21C15/18;;G21C1/03;;Y02E30/30,G21C1/02;;G21C1/03;;G21C15/02;;G21C15/18,,0,0,,,,DISCONTINUED
187,CN,A,CN 114981668 A,012-615-615-465-936,2022-08-30,2022,CN 202080093949 A,2020-11-17,US 201916706028 A;;US 2020/0060823 W,2019-12-06,"Matching dynamic and static parameters in dies, discrete devices and/or modules","A device boxing and/or matching process includes measuring a current and/or voltage of a device with a test device relative to time; determining, using the test device, a boxing and/or matching criterion of the device based on transmission data generated from the current and/or the voltage of the device measured with respect to time; and outputting the boxing and/or matching criteria of the device with the test device. A system and a power module are also disclosed.",WOFU SEMICONDUCTOR CO LTD,MARTIN DANIEL JOHN;;WILLIAM AUSTIN COOPER,,https://lens.org/012-615-615-465-936,Patent Application,no,0,0,7,7,0,H01L25/50;;H01L25/072;;H01L25/18;;H01L23/49811;;H01L23/3735;;H01L2224/49111;;H01L2224/0603;;H01L25/072;;H01L25/50;;H01L23/50;;H01L22/14;;B07C5/344;;G01R31/3004,G01R19/00,,0,0,,,,PENDING
188,US,A1,US 2012/0202825 A1,011-153-134-332-008,2012-08-09,2012,US 201113021652 A,2011-02-04,US 201113021652 A,2011-02-04,"Soluble Salts of Thieno [2,3-d] Pyrimidine Derivatives","The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.",COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,,https://lens.org/011-153-134-332-008,Patent Application,yes,0,0,1,1,0,A61K31/519;;A61K31/519;;A61P1/00;;A61P1/08;;A61P13/00;;A61P15/00;;C07D495/04;;C07D495/04,A61K31/519;;A61P1/00;;A61P1/08;;A61P13/00;;A61P15/00;;C07D495/04,514/252.16;;544/278,0,0,,,,DISCONTINUED
189,GB,B,GB 2344836 B,047-793-380-679-914,2002-08-21,2002,GB 9929018 A,1999-12-09,GB 9827993 A,1998-12-17,Ventilated roof tile,,PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/047-793-380-679-914,Granted Patent,no,3,1,4,4,0,E04D1/30;;E04D1/30;;E04D13/17;;E04D2001/309;;E04D2001/309,E04D1/30;;E04D13/17,E1D DF124         F124LE;;E1D DLEKG2        F124LE;;E1D D2139         F124LE;;E1D D401          F124LE,0,0,,,,EXPIRED
190,DE,A1,DE 3245081 A1,048-784-589-368-713,1983-06-09,1983,DE 3245081 A,1982-12-06,US 32785181 A,1981-12-07,STOSSDAEMPFER,,WESTINGHOUSE ELECTRIC CORP,JONES ROBERT G;;COOPER MARTIN H,,https://lens.org/048-784-589-368-713,Patent Application,no,0,0,6,6,0,F16F7/1022;;F16L3/202,F16F7/10;;F16L3/20;;F16L3/202;;F16L3/215,,0,0,,,,DISCONTINUED
191,ES,T3,ES 2602736 T3,070-618-063-390-936,2017-02-22,2017,ES 06744368 T,2006-07-05,GB 0515300 A;;EP 05270033 A;;GB 2006050188 W,2005-07-27,Sistema y método para determinar la diferencia de tiempo entre dos plataformas,"Método para determinar diferencias de tiempo entre dos o más plataformas (100, 200), incluyendo el método las etapas de: a) transmitir una señal de inicialización desde cada plataforma (100) hasta al menos otra plataforma (200); b) acoplar la señal de inicialización de cada plataforma (100, 200) a un receptor (108, 208) en esa plataforma; c) recibir una señal de inicialización recibida en el receptor (108, 208) en cada plataforma (100) de al menos una plataforma (200) a la que se transmitió una señal de inicialización; d) medir la separación (316, 318) de tiempo entre la señal de inicialización transmitida acoplada y cada señal de inicialización recibida en cada receptor (108, 208); y e) calcular un desfase de tiempo (Δt) entre al menos dos plataformas; caracterizado por las etapas de: sincronizar las dos o más plataformas usando el desfase de tiempo determinado (Δt); recibir una señal de emisor en cada uno de dichos receptores (108, 208); calcular la diferencia de tiempo de llegada de la señal de emisor recibida a las dos o más plataformas (100, 200) sincronizadas; y ubicar el emisor usando la diferencia de tiempo de llegada calculada.",SELEX ES LTD,GOULD DALE MARTIN;;COOPER R D,,https://lens.org/070-618-063-390-936,Granted Patent,no,0,0,7,8,0,G04G7/02;;G04G7/02;;G01S5/021;;G01S5/021;;G01S5/06;;G01S5/06,G01S5/02;;G01S5/06;;G04G7/00,,0,0,,,,ACTIVE
192,CA,C,CA 1325042 C,132-455-733-761-171,1993-12-07,1993,CA 608274 A,1989-08-14,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION,"To make an elongate cut in a diamond using a laser radiation, a cylindrical optical system is used which converges the radiation at a greater angle of convergence in the plane of the cut than in the transverse plane. In this way, the focal spot energy density is increased and cutting at depth is made more effective.",COOPER MARTIN,COOPER MARTIN;;STEWART ANDREW D G,,https://lens.org/132-455-733-761-171,Granted Patent,no,0,0,13,30,0,B23K26/364;;B23K26/364,B23K26/06;;B23K26/00;;B23K26/073;;B23K26/36,D232700015   M,0,0,,,,EXPIRED
193,US,A,US 5039351 A,127-034-173-556-535,1991-08-13,1991,US 64440491 A,1991-01-22,US 43787889 A,1989-11-17,High performance thin film alkali metal thermoelectric device,"An alkali metal thermoelectric conversion device formed from a porous tube or plate coated with a thin film of beta-alumina, the porous tube or plate is sintered metal or metal alloy having a coefficient of thermal expansion which approaches that of the beta-alumina to form a mechanically stable device with high electrical output.",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN H;;SIEVERS ROBERT K,,https://lens.org/127-034-173-556-535,Granted Patent,yes,12,53,4,4,0,H01G9/21;;H01G9/21,B22F5/00;;B22F5/12;;H01G9/00;;H01G9/21;;H01M4/64;;H01M6/36;;H02N3/00,136/202;;429/11;;429/104;;429/112;;429/120;;136/200;;136/205;;136/240,0,0,,,,EXPIRED
194,WO,A1,WO 2007/012888 A1,150-213-353-533-522,2007-02-01,2007,GB 2006050188 W,2006-07-05,GB 0515300 A;;EP 05270033 A,2005-07-27,SYSTEM AND METHOD FOR DETERMINING THE TIME DIFFERENCE BETWEEN TWO PLATFORMS,"A transmitter (106, 120, 118, 122 and 110) of a platform (100) is arranged to generate a transmission pulse which is transmitted to a receiver (212, 224 and 208) of another platform (200) and is also arranged to couple its transmission pulse to a digital receiver (104) associated with its platform (100) via attenuater (126) and coupler (124). The other platform (200) performs a similar task. Each digital receiver (108, 208) determines the time separation between its transmission pulse and received pulse from the other platform (100 or 200). The determined time separation information is shared with the other platform (100, 200) and each digital receiver (108, 208) then determines a time offset (Δt) between the time at its platform (100) and the other platform (200).",SELEX SENSORS & AIRBORNE SYS;;GOULD DALE MARTIN;;COOPER ROBERT DAVID,GOULD DALE MARTIN;;COOPER ROBERT DAVID,,https://lens.org/150-213-353-533-522,Patent Application,yes,2,1,7,8,0,G04G7/02;;G04G7/02;;G01S5/021;;G01S5/021;;G01S5/06;;G01S5/06,G04G7/02,,2,2,051-450-531-362-835;;150-750-983-600-498,10.1109/5.84975;;10.1109/igarss.2004.1370671,"KIRCHNER D: ""TWO-WAY TIME TRANSFER VIA COMMUNICATION SATELLITES"", PROCEEDINGS OF THE IEEE, IEEE. NEW YORK, US, vol. 79, no. 7, 1 July 1991 (1991-07-01), pages 983 - 990, XP000264855, ISSN: 0018-9219;;WEISS M: ""Synchronisation of bistatic radar systems"", GEOSCIENCE AND REMOTE SENSING SYMPOSIUM, 2004. IGARSS '04. PROCEEDINGS. 2004 IEEE INTERNATIONAL ANCHORAGE, AK, USA 20-24 SEPT. 2004, PISCATAWAY, NJ, USA,IEEE, 20 September 2004 (2004-09-20), pages 1750 - 1753, XP010751951, ISBN: 0-7803-8742-2",PENDING
195,CA,A1,CA 2227185 A1,152-261-346-932-567,1997-02-06,1997,CA 2227185 A,1996-07-17,GB 9514558 A;;GB 9601712 W,1995-07-17,MARKING DIAMOND,"In order to produce on the table of a diamond gemstone (7), an information mark which is invisible to the naked eye using a x10 loupe, an ultraviolet laser (1) having a wavelength of 193 nm is used in association with a mask (2) to irradiate the surface of the stone (7) at a fluence of less than 2 J/cm2 per pulse and with not fewer than 100 pulses, in the presence of air which reacts with the diamond (7) and causes the mark to be formed without any darkening which is visible when viewing using a microscope.",GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/152-261-346-932-567,Patent Application,no,0,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B28D5/00;;B41M5/24;;B44B7/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
196,CA,A1,CA 2427075 A1,166-787-985-201-490,2002-07-11,2002,CA 2427075 A,2001-12-27,US 75382501 A;;US 0149625 W,2001-01-03,SPECIFICATION,"A pulsator (23) provides alternating vacuum pressure and atmospheric pressure to an elastomeric liner (35) in a sleeve (13) of a milking claw (11) in a diary barn. The purpose of pulsation is to alternate to cow teat between a milking phase and a rest phase. The invention (41) monitors the operation of the pulsator to determine if the pulsator is operating satisfactorily. The invention records data during a calibration mode from the pulsator in normal operation. The data that is recorded is the duration of the miling phase and the rest phase and the assocated pressures. During pulsator operation, the invention measures the pulsation between atmospheric and vacuum pressures provided to the milking claw and compares this measured data to the recorded calibraton data.If the pulsator is not found to be operating within predetermined tolerances, then an indication of a pulsator malfunction is provided, typically in the form of a light located in the milking pen. This indicates to the milking crew that the pulsator requires attention and should not be used until properly fixed",SENSEABILITY INC,JEFFREY W GENTNER;;MARTIN CHANDLER COOPER,,https://lens.org/166-787-985-201-490,Patent Application,no,0,0,11,11,0,A01J5/007;;A01J5/007,A01J5/007,,0,0,,,,DISCONTINUED
197,EP,A3,EP 2107205 A3,190-956-199-155-102,2013-12-04,2013,EP 09004969 A,2009-04-03,GB 0806117 A,2008-04-04,Smoke curtain,"A heat resistant curtain 1 has a vent 2 typically extending up from a bottom edge 3. At the vent, flaps 4 of the curtain on either side of the vent have marginal overlaps 5. To these are stitched elevated temperature resistant hook and loop fastening tapes 6. These normally keep the vent closed. The curtain is provided with a bottom bar 16 drawn up to close the head box when the curtain is not deployed. When the curtain is deployed, the bottom bar rests on the floor 17. Ceiling-to-floor guides 21 are provided on walls 22 at the edges of the aperture 23 to be closed by the curtain when deployed. These have in-turned lips 24 between which the edges 25 of the curtain extend. Retention elements, in the form of small rolling element bearings 26 are attached intermittently along the edges. They hold the edges of the deployed curtain into the guides. The combined effect of the these edge arrangements and the stiffening battens 7 is to keep the curtain flat when deployed. The bottom bar 16 has a head box closure plate 31, extending rigidly across the width of the aperture between the guides 21. The curtain is connected to bottom bar members 33 associated with the closure plate, but free to move with respect to it, at least centrally of the closure plate. At the edges of the curtain, the edges 25 are connected to both the closure plate and the bar members. The result is that the bottom bar members are pivotally attached to the bottom of the guides 21 (when the curtain is deployed). The pivotable members 33 extend in along the bottom of the curtain as far as the vent, where they have chamfered overlaps 34, complementary to the curtain overlaps 5. One of the pivotable members has a slot 35 and the other has a tongue 36, engageable in the slot. The tongue and the slot have complementary magnets (not shown) where by the tongue is normally held in the slot. Thus the bottom bar members form a separable continuous member, which holds the bottom of the curtain steady as if it were connected to the closure plate 31.
",COOPERS BLINDS LTD,COOPER PAUL ANDREW;;REED JAMES MARTIN,"COOPERS FIRE LIMITED (2018-11-14);;COOPERS FIRE LIMITED, GB (2018-11-05)",https://lens.org/190-956-199-155-102,Search Report,yes,2,0,6,6,0,A62C2/10;;E06B9/13;;E06B2009/17053;;Y10T24/44;;Y10T24/27;;Y10T24/44;;Y10T24/27;;E06B9/13;;A62C2/10;;E06B2009/17053,E06B9/13;;A44B99/00;;A62C2/10;;E06B9/17,,0,0,,,,ACTIVE
198,WO,A3,WO 2008/051282 A3,193-485-014-703-370,2008-07-31,2008,US 2007/0007816 W,2007-03-27,US 78833806 P;;US 80860306 P,2006-03-31,"CRYSTALLINE FORMS OF 4-(2-FLUOROPHENYL)-6-METHYL-2-(PIPERAZIN-1-YL)THIENO(2,3-D)PYRIMIDINE","The present invention is directed to novel crystalline forms of 4-(2-fIuorophenyl)-6-methyl-2-(piperazin-l-yl)thieno[2,3-d]pyτimidine salts, including 4-(2- fluorophenyl)-6-methyl-2-(piperazin- 1 -yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.",DYNOGEN PHARMACEUTICALS INC;;COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,,https://lens.org/193-485-014-703-370,Search Report,yes,3,0,7,7,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P1/12;;A61P13/00;;A61P13/10;;A61P15/00;;C07D495/04,C07D495/04;;A61K31/519;;A61P1/00;;A61P13/00,,2,2,036-306-180-744-291;;104-949-654-022-72X,9450161;;10.1007/3-540-69178-2_5,"EGUCHI J ET AL: ""PHARMACOLOGICAL PROFILE OF THE NOVEL ANTIDEPRESSANT 4-(2-FLUOROPHENYL)-6-METHYL-2-(1-PIPERAZINYL)THIENO-[2,3-D]PYRIDIMINE MONOHYDRATE HYDROCHLORIDE"", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 47, no. 12, 1 December 1997 (1997-12-01), pages 1337 - 1347, XP008059239, ISSN: 0004-4172;;CAIRA M R: ""CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS"", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022",PENDING
199,EP,A2,EP 2107205 A2,022-828-989-889-604,2009-10-07,2009,EP 09004969 A,2009-04-03,GB 0806117 A,2008-04-04,Smoke curtain apparatus,"A heat resistant curtain 1 has a vent 2 typically extending up from a bottom edge 3. At the vent, flaps 4 of the curtain on either side of the vent have marginal overlaps 5. To these are stitched elevated temperature resistant hook and loop fastening tapes 6. These normally keep the vent closed. The curtain is provided with a bottom bar 16 drawn up to close the head box when the curtain is not deployed. When the curtain is deployed, the bottom bar rests on the floor 17. Ceiling-to-floor guides 21 are provided on walls 22 at the edges of the aperture 23 to be closed by the curtain when deployed. These have in-turned lips 24 between which the edges 25 of the curtain extend. Retention elements, in the form of small rolling element bearings 26 are attached intermittently along the edges. They hold the edges of the deployed curtain into the guides. The combined effect of the these edge arrangements and the stiffening battens 7 is to keep the curtain flat when deployed. The bottom bar 16 has a head box closure plate 31, extending rigidly across the width of the aperture between the guides 21. The curtain is connected to bottom bar members 33 associated with the closure plate, but free to move with respect to it, at least centrally of the closure plate. At the edges of the curtain, the edges 25 are connected to both the closure plate and the bar members. The result is that the bottom bar members are pivotally attached to the bottom of the guides 21 (when the curtain is deployed). The pivotable members 33 extend in along the bottom of the curtain as far as the vent, where they have chamfered overlaps 34, complementary to the curtain overlaps 5. One of the pivotable members has a slot 35 and the other has a tongue 36, engageable in the slot. The tongue and the slot have complementary magnets (not shown) where by the tongue is normally held in the slot. Thus the bottom bar members form a separable continuous member, which holds the bottom of the curtain steady as if it were connected to the closure plate 31.
",COOPERS BLINDS LTD,COOPER PAUL ANDREW;;REED JAMES MARTIN,"COOPERS FIRE LIMITED (2018-11-14);;COOPERS FIRE LIMITED, GB (2018-11-05)",https://lens.org/022-828-989-889-604,Patent Application,yes,1,3,6,6,0,A62C2/10;;E06B9/13;;E06B2009/17053;;Y10T24/44;;Y10T24/27;;Y10T24/44;;Y10T24/27;;E06B9/13;;A62C2/10;;E06B2009/17053,E06B9/13;;A44B99/00;;A62C2/10;;E06B9/17,,0,0,,,,ACTIVE
200,GB,A,GB 2500331 A,022-525-012-533-956,2013-09-18,2013,GB 201310288 A,2013-06-10,GB 201310288 A,2013-06-10,Interlocking building block with partition wall and drainage aperture,"A building block has a top and bottom provided with a first kind of form locking male 23 and female 24 connector, and sides provided with a second kind of form of locking male 15 and female 16-20 connector. Both kinds of connector are engageable by relative motion in a direction perpendicular to the top face of the block, with only one male connector of the second kind provided. The block further comprises a partition wall 100 parallel to the top and bottom of the block, the wall having an aperture 105 to permit drainage. The second kind of male connector may include a projecting nib 110 for jamming engagement in the second kind of female connector, which may permit interconnection by movement in one direction only. The block may be used to form a wall which may include reinforcement passing through the apertures of a plurality of blocks.",PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/022-525-012-533-956,Patent Application,no,4,6,3,3,0,E02D29/0266;;E04B2/18;;E04C1/39;;E04C1/397;;E04B2/18;;E04B2002/0223;;E04B2002/0234;;E04B2002/025;;E04B2002/0252,E04B2/18;;E02D29/02;;E04C1/39,,0,0,,,,ACTIVE
201,US,A1,US 2022/0397200 A1,025-972-908-715-940,2022-12-15,2022,US 202217839146 A,2022-06-13,EP 21179207 A,2021-06-14,Valve Assembly,"A valve assembly ( 1 ) comprising: a common housing having a first side ( 8 a ), a second side ( 8 b ), an inlet port ( 2 ) and an outlet port ( 3 ); the valve assembly ( 1 ) comprising a first pair of valve members or poppets ( 4 a , 4 c ) and a second pair of valve members or poppets ( 4 b , 4 d ), a first pair of valve seats ( 5 a, 5 c ) for cooperation with the first pair of valve members or poppets ( 4 a, 4 c ), and a second pair of valve seats ( 5 b , 5 d ) for cooperation with the second pair of valve members or poppets ( 4 b , 4 d ); a central flow diverter ( 13 c ) disposed in between the first pair of valve members or poppets ( 4 a, 4 c ) and the second pair of valve seats ( 5 b, 5 d ), the central flow diverter ( 13 c ) defining a first side ( 11 a ) of the valve assembly ( 1 ) and a second side ( 11 b ) of the valve assembly ( 1 ).",SIEMENS AG,WETZEL MARTIN;;COOPER NILS;;WIEGAND ARMIN,SIEMENS AKTIENGESELLSCHAFT (2022-07-07),https://lens.org/025-972-908-715-940,Patent Application,yes,14,0,4,4,0,F16K1/34;;F16K1/32;;F16K27/02;;F23K2900/05002;;F23N2235/24;;F23N2235/18;;F23N2235/16;;F23N1/005;;F16K1/446;;F16K1/443;;F16K27/02,F16K1/44;;F16K27/02,,0,0,,,,ACTIVE
202,US,A1,US 2002/0104484 A1,058-746-984-978-509,2002-08-08,2002,US 75382501 A,2001-01-03,US 75382501 A,2001-01-03,Method and apparatus for monitoring milking facility pulsation,"
   A pulsator provides alternating vacuum pressure and atmospheric pressure to an elastomeric liner in a sleeve of a milking claw in a dairy barn. The purpose of pulsation is to alternate the cow teat between a milking phase and a rest phase. The invention monitors the operation of the pulsator to determine if the pulsator is operating satisfactorily. The invention records data during a calibration mode from the pulsator in normal operation. The data that is recorded is the duration of the milking phase and the rest phase and the associated pressures. During pulsator operation, the invention measures the pulsation between atmospheric and vacuum pressures provided to the milking claw and compares this measured data to the recorded calibration data. If the pulsator is not found to be operating within predetermined tolerances, then an indication of a pulsator malfunction is provided, typically in the form of a light located in the milking pen. This indicates to the milking crew that the pulsator requires attention and should not be used until properly fixed. 
",GENTNER JEFFREY W.;;COOPER MARTIN CHANDLER,GENTNER JEFFREY W;;COOPER MARTIN CHANDLER,SENSEABILITY INC (2001-12-27),https://lens.org/058-746-984-978-509,Patent Application,yes,0,9,11,11,0,A01J5/007;;A01J5/007,A01J5/007,119/14.02,0,0,,,,EXPIRED
203,GB,B,GB 2276181 B,089-426-739-622-076,1996-04-17,1996,GB 9305586 A,1993-03-18,GB 9305586 A,1993-03-18,Building block,,PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/089-426-739-622-076,Granted Patent,no,0,0,3,3,0,E04B2/18;;E04B1/0015;;E04B2002/0234;;E04B2002/0245;;E04B2002/0252,E04B2/02;;E04B2/18,E1D DLEQWNT       LEQWNT;;E1D D2131         LEQWNT;;E1D D2162         LEQWNT;;E1D D401          LEQWNT;;E1D D509          LEQWNT;;E1D D532          LEQWNT,0,0,,,,EXPIRED
204,US,A,US 5422807 A,178-484-551-194-032,1995-06-06,1995,US 93890792 A,1992-08-31,US 93890792 A,1992-08-31,Microcontroller with improved A/D conversion,"A semiconductor microcontroller includes the capability to perform analog to digital conversions of an analog signal representative of a variable parameter indicative of the need to exercise a control function. While the analog to digital conversions are being performed, the microcontroller processor can be powered down to eliminate noise arising from switching activities of the processor as a source of inaccuracy in the conversion process. At the end of the conversion, the analog to digital converter can either shut itself down or wake up the processor. The powering down is achieved by simply disabling the clock input to the microcontroller so that the processor is still activated but incapable of undergoing switching functions.",MICROCHIP TECH INC,MITRA SUMIT;;COOPER RUSS;;BURGHARDT MARTIN,MICROCHIP TECHNOLOGY INCORPORATED (1992-12-02);;MICROCHIP TECHNOLOGY INCORPORATED A DE CORP (1992-08-31),https://lens.org/178-484-551-194-032,Granted Patent,yes,12,120,1,1,0,G06F3/05;;H03M1/06;;H03M1/462;;H03M1/06;;G06F3/05;;H03M1/462,G06F3/05;;H03M1/06;;H03M1/46,364/184;;341/142;;327/544,0,0,,,,EXPIRED
205,AU,A,AU 1999/017916 A,005-168-420-632-882,1999-06-28,1999,AU 1999/017916 A,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,Novel compounds,,ASTRAZENECA UK LTD,COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/005-168-420-632-882,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
206,WO,A1,WO 1995/030470 A1,002-610-470-703-60X,1995-11-16,1995,GB 9501007 W,1995-05-02,GB 9408770 A,1994-05-04,PROCESS FOR TREATING VOLATILE ORGANIC COMPOUNDS IN A GAS STREAM,"A process for treating volatile organic compounds known as VOCs, carried in a gaseous process medium from an industrial process plant (11) includes the steps of concentrating the VOCs in gaseous medium by an adsorption/desorption process and supply the thus concentrated VOC to a combustion engine (14) as a fuel for the engine. Two or more adsorption desorption units (22, 23) are provided whereby adsorption of VOCs in one of said units is decoupled from desorption of VOCs for combustion from another of said units. In this way the rates of adsorption and desorption can be controlled independently. Similarly desorption need not necessarily take place at the same time as adsorption and thus need not necessarily take place at the same time as process plant operation.",AIRAQUA ENG CONSULTANT;;COOPER ALAN;;LITTLE CHRISTOPHER MARTIN DONA,COOPER ALAN;;LITTLE CHRISTOPHER MARTIN DONA,,https://lens.org/002-610-470-703-60X,Patent Application,yes,4,18,2,2,0,B01D53/04;;B01D2257/708;;B01D2258/01;;B01D2259/402;;Y02A50/20,B01D53/04,,0,0,,,,PENDING
207,PT,T,PT 3008272 T,004-253-252-446-262,2018-02-13,2018,PT 14744618 T,2014-06-02,GB 201310791 A;;US 201361843473 P,2013-06-14,FIRE AND SMOKE CURTAIN,,COOPERS FIRE LTD,ANDREW PAUL COOPER;;JAMES MARTIN REED,,https://lens.org/004-253-252-446-262,Patent Application,no,0,0,13,13,0,A62C2/16;;A62C2/10;;A62C2/10;;A62C2/24;;A62C2/242;;E06B9/0692;;E06B9/80;;E06B5/16;;E06B9/0692;;E06B2009/807;;E06B2009/807,E06B5/16;;A62C2/10;;A62C2/24;;E06B9/06;;E06B9/80,,0,0,,,,PENDING
208,TW,B,TW 380093 B,033-350-883-174-175,2000-01-21,2000,TW 85108670 A,1996-07-17,GB 9514558 A,1995-07-17,"Method and apparatus of producing an information mark on a polished facet of a diamond gemstone, and the diamond gemstone thus obtained","In order to produce on the table of a diamond gemstone 7, an information mark which is invisible to the naked eye using a x10 loupe, an ultraviolet laser 1 having a wavelength of 193 nm is used in association with a mask 2 to irradiate the surface of the stone 7 at a fluence of less than 2 J/cm spuare per pulse and with not fewer than 100 pulses, in the presence of air which reacts with the diamond 7 and causes the mark to be formed without any darkening which is visible when viewing using a microscope.",GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/033-350-883-174-175,Granted Patent,no,0,3,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B28D5/00;;B41M5/24;;B44B7/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
209,GB,B,GB 2112832 B,047-392-016-476-435,1985-10-16,1985,GB 8138827 A,1981-12-23,GB 8138827 A,1981-12-23,CLADDING,,REED INTERNATIONAL LTD,MARTIN JOHN LEWIS;;COOPER PETER ROBIN,,https://lens.org/047-392-016-476-435,Granted Patent,no,0,0,2,2,0,E04F13/0864,E04F13/08,E1D106;;E1D2022;;E1D2141;;E1D358;;E1D401;;E1DLES,0,0,,,,EXPIRED
210,US,B1,US 6187213 B1,052-275-605-868-793,2001-02-13,2001,US 11098 A,1998-05-15,GB 9514558 A;;GB 9601712 W,1995-07-17,Marking diamond,"In order to produce on the table of a diamond gemstone (7), an information mark which is invisible to the naked eye using a .times.10 loupe, an ultraviolet laser (1) having a wavelength of 193 nm is used in association with a mask (2) to irradiate the surface of the stone (7) at a fluence of less than 2 J/cm.sup.2 per pulse and with not fewer than 100 pulses, in the presence of air which reacts with the diamond (7) and causes the mark to be formed without any darkening which is visible when viewing using a microscope.",GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,GERSAN ESTABLISHMENT (1998-02-13),https://lens.org/052-275-605-868-793,Granted Patent,yes,37,55,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B28D5/00;;B41M5/24;;B44B7/00;;C30B29/04;;H01S3/00,216/28;;216/65;;216/81,34,13,057-200-055-185-845;;039-041-449-429-832;;057-886-762-922-495;;015-554-783-064-181;;072-829-069-163-518;;048-061-027-879-301;;016-184-435-991-588;;057-138-761-128-712;;067-774-177-410-700;;025-227-226-800-961;;087-510-985-148-807;;066-670-677-575-701;;169-519-128-441-797,10.1117/12.944383;;10.1080/10426919308934810;;10.1116/1.570864;;10.1063/1.102042;;10.1117/12.950146;;10.1070/qe1991v021n10abeh004298;;10.1070/qe1991v021n04abeh003834;;10.1063/1.115437;;10.1116/1.583320;;10.1117/12.963702;;10.1117/12.960213;;10.2493/jjspe.56.2255;;10.1117/12.937297,"Author unknown. ""New Distributors For Lazare Diamonds"", Diamond International, p. 25 Jan./Feb. 1992.;;Znotins, Norris, ""Industrial Excimer Lasers; issues and answers"", Proceedings of SPIE, 1988, vol. 894, pp. 9-15.;;Ageev , ""Laser Processing of a Diamond and Diamond-Like Films"", Materials & Manuf. Processes, 8(1), 1-8 (1993), pp. 1-8.;;Armeyev, ""Direct Laser Writing of Microstructures in Diamond-Like Carbon Films"", Materials & Manuf. Proceses, 9(1), 9-17 (1993) pp. 7-17.;;Bar-Isaac Thesis, pp. 92-97 Sep. 1975.;;Bruton, ""Diamonds"", 1981, p. 409.;;Crater, ""Multiple Roles For Laser Marking"", Laser & Optronics, Oct. 1987, vol. 6 No. 10, pp. 63-65.;;Dance Article ""Novel Excimer Laser System Marks Wires On-The-Fly"", Laser Ffocus Word, May 1990.;;Deckman, ""Micromachining Applications for ICF Target Fabrication"", J. Vac. Sci. Technol., 18(3), Apr. 1981 pp. 1171-1174.;;Geis, Rothschild et al., ""Electrical, Crystallographic, and Optical peoperties of ArF Laser Modified Diamond Surfaces"", Appl. Phys, Lett, 355(22), Nov. 27, 1989, pp 2295-2297.;;Harano, Ota, Fujimori ""Diamond Processing By Excimer Laser Ablation"", Conference Proceedings of Advances in New Diamond Science and Technology, MFU, Tokyo 1994, pp 497-500.;;Kahlert, Sowada, Basting ""Excimer Lasers for Material processing; Results and Industrial Application"", Proceedings of the SPIE, 1988 vol. 1023, pp. 171-178.;;Klimt, ""Review of Laser Marking and Engraving"", Lasers and Optronics, Sep. 1988, vol. 7, No. 9, pp 61-67.;;Kononenko, ""KrF of Excimer Laser Etching of Diamond-Like Carbon Films"", Proceedings of SPIE-Inter. Soc. of Optical Eng. vol. 1759, 1992.;;Konov, ""Pulse-Periodic Laser Etching of Diamond-Like Carbon Coatings"" Jou. J. Quantum Electron 21(16) Oct. 1991 pp. 1112-1115.;;Konov, ""Light-Induced Polishing of an Evaporating Surface"" Sov. J. Quantum Electron 21(4) Apr. 1991, pp 442-444.;;Marsh, ""Beaming in on a Sales Explosion"", Financial Times, Sep. 2, 1986, p. 13.;;Nilson, ""Laser Marking Via Mask Projection"", Proc Materials Processing Symposium ICALEO '82, Boston, MA Sep. 20-23, 1982, 1982 Laser Institute of America, vol. 31, pp 17-24.;;Dr. R L Penny's Technique-not published.;;Pruess and Stuke, ""Subpicosecond Ultraviolet Laser Ablation of Diamond, Nonlinear Properties at 248 nm and Time-Resolved Characterisation of Ablation Dynamics"", Appl. Phys. Lett. 67(3), Jul. 17, 1995, pp. 338-340.;;Rothschild, Arnone, Ehrlich, ""Excimer-Laser Etching of Diamond and Hard Carbon Films by Direct Writing and Optical Projection"", Journal of Vacuum Science and Technology, Jan./Feb. 1986, vol. 84, No. 1, pp. 310-314.;;Rothchild, Arnone, Ehrlich, ""Excimer Laser Projection Patterning with and without Resists; Submicrometer Etching of Diamond and Diamond-Like Carbon Resis"", SPIE vol. 633, Optical Microlithography V (1986), pp. 51-57.;;Sercel, Sowada, ""Why Excimer Lasers Excel in Marking"", Lasers and Optronics, Sep. 1988, vol. 7, No. 9, pp 69-72.;;Sercel, Sowada, Kahlert, Basting, Austin, ""Industrial Microprocessing Applications of Excimer Lasers"", Proceedings of SPIE, 1988 vol. 998, pp 76-83.;;Sowada, Kahlert, Basting, Lambda Industrial Report No. 4, Oct. 1988, pp. 1-6.;;Sowada, Kahlert, Gerhardt, basting, Laser and Optoelektronik: 29(2), 1988, pp 96-101.;;Tezuka, ""Processing of CVD Diamond Films by YAG Laser"", J. of JAP Soc. of Precision Eng. vol. 56, No. 12 Dec. 1990.;;Willis, ""Techniques and Applications of Laser Marking"", Proc. 1st Int. Conf. Lasers in Manufacturing, Brighton, Nov. 1-3, 1983, IFS/North Hiland, pp 53-62, 1983.;;Wright, ""Lasers for Materials Processing: Past, Present and Future"", Welding and Metal Fabrication, Aug.-Sep. 1987, vol. 55 No. 6, pp 275-288.;;Znotins, ""Industrial Applications of Excimer Lasers"", Proceedings of SPIE 1986, vo.. 668, pp 339-346.;;Znotins, Poulin, Reid, Excimer Lasers: an emerging technology in materials processing:, Laser Focus, May 1987, vol. 23, pp 54-70.;;""Guide for Material Processing By Lasers"", Laser Institute of America, Second Edition, 1978, pp 8-27 to 8-35.;;Spectrum Technologies Data Sheet, Sep. 1990, entitled ""Cable Printing and Identification Systems CAPRIS 500; Excimer Laser Cable Marker"".;;Marketers Place Diamonds Among Other Brand Name Products, New York Diamonds, Spring 1990, 38-44.",EXPIRED
211,US,A1,US 2019/0259281 A1,065-084-962-695-640,2019-08-22,2019,US 201815902672 A,2018-02-22,US 201815902672 A,2018-02-22,"AUTOMATIC VEHICLE CONTROL APPARATUS ABLE TO DETERMINE TRACK OCCUPANCY OF A VEHICLE, AND CORRESPONDING METHOD FOR AUTOMATICALLY CONTROLLING THE VEHICLE","This automatic vehicle control apparatus comprises a first image sensor positioned on a vehicle, able to capture a first global image of a first scene, including an area in front of the vehicle, in a first field of view of said first image sensor; a track occupancy detector for receiving the first global image and deducing therefrom a track occupancy of the vehicle among at least two set of parallel tracks positioned in front of the vehicle; a distinguishable object disposed in the first field of view; and a proper functioning checking apparatus configured for searching, in the first global image, a first specific image of the distinguishable object, and for generating an alert signal in case the first specific image is not found in the first global image.",ALSTOM TRANSP TECH,MARTIN PHILLIP;;SNYDER SENECA;;COOPER JARED,ALSTOM TRANSPORT TECHNOLOGIES (2018-03-07),https://lens.org/065-084-962-695-640,Patent Application,yes,3,7,7,7,0,G05D1/0246;;G06T7/73;;G06T2207/10028;;G06T2207/30256;;G08G1/166;;B61L23/041;;B61L25/025;;B61L2205/04;;G06V20/56;;G06V10/751;;G08G1/166;;G06T2207/30236;;G08G1/056;;G06T7/70;;G06T7/73;;G06V10/751;;G06V20/56,G08G1/16;;G06T7/70;;G08G1/056,,0,0,,,,ACTIVE
212,CZ,A3,CZ 226298 A3,078-732-405-286-945,1999-08-11,1999,CZ 226298 A,1998-07-17,GB 9715358 A,1997-07-21,DEVICE FOR COILING AND CUTTING OFF METAL STRIP,,KVAERNER TECH & RES LTD,BERRY JOHN;;COOPER BRIAN;;PHILIPSON MARTIN,,https://lens.org/078-732-405-286-945,Patent Application,no,0,0,8,8,0,B21C47/245;;B21C47/34;;B21C47/3475;;B21C47/3475;;B21C47/245;;B21C47/34,B21C47/06;;B21C47/24;;B21C47/34,,0,0,,,,PENDING
213,WO,A3,WO 2002/052927 A3,085-193-418-157-695,2003-01-23,2003,US 0149625 W,2001-12-27,US 75382501 A,2001-01-03,SPECIFICATION,"A pulsator (23) provides alternating vacuum pressure and atmospheric pressure to an elastomeric liner (35) in a sleeve (13) of a milking claw (11) in a diary barn. The purpose of pulsation is to alternate to cow teat between a milking phase and a rest phase. The invention (41) monitors the operation of the pulsator to determine if the pulsator is operating satisfactorily. The invention records data during a calibration mode from the pulsator in normal operation. The data that is recorded is the duration of the miling phase and the rest phase and the assocated pressures. During pulsator operation, the invention measures the pulsation between atmospheric and vacuum pressures provided to the milking claw and compares this measured data to the recorded calibraton data. If the pulsator is not found to be operating within predetermined tolerances, then an indication of a pulsator malfunction is provided, typically in the form of a light located in the milking pen. This indicates to the milking crew that the pulsator requires attention and should not be used until properly fixed",SENSEABILITY INC,JEFFREY W GENTNER;;MARTIN CHANDLER COOPER,,https://lens.org/085-193-418-157-695,Search Report,yes,1,0,11,11,0,A01J5/007;;A01J5/007,A01J5/007,,1,0,,,See also references of EP 1353546A4,PATENTED
214,US,A1,US 2007/0254899 A1,098-772-826-824-969,2007-11-01,2007,US 72896607 A,2007-03-27,US 72896607 A;;US 78856506 P;;US 80890506 P,2006-03-31,"Soluble salts of thieno[2,3-d]pyrimidine derivatives","The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.",DYNOGEN PHARMACEUTICALS INC,COOPER MARTIN I;;FRAMPTON CHRISTOPHER S,EDUSA PHARMACEUTICALS INC (2010-08-17);;DYNOGEN PHARMACEUTICALS INC (2007-07-02),https://lens.org/098-772-826-824-969,Patent Application,yes,1,0,2,2,0,C07D495/04;;A61P1/00;;A61P1/08;;A61P1/12;;A61P13/02;;A61P13/10;;C07D495/04,A61K31/519;;A61P1/00;;A61P1/08;;A61P1/12;;A61P13/10;;C07D495/02,514/260.1;;544/278,0,0,,,,DISCONTINUED
215,DE,A1,DE 2834892 A1,134-657-803-716-746,1979-02-22,1979,DE 2834892 A,1978-08-09,GB 3334477 A,1977-08-09,GASBRENNER,,TENNANT & SONS WARRINGTON LTD,MARTIN JOHN DOUGLAS;;COOPER CHARLES FRANK,"TENNANT RADIANT HEAT LTD., WARRINGTON, CHESHIRE, G (1983-04-14)",https://lens.org/134-657-803-716-746,Patent Application,no,2,3,6,6,0,F23D14/151;;F23D14/145;;F23D14/151;;F23D14/145,F23D14/14,,0,0,,,,DISCONTINUED
216,GB,B,GB 2500331 B,137-483-226-387-47X,2014-03-12,2014,GB 201310288 A,2013-06-10,GB 201310288 A,2013-06-10,Building block,,PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/137-483-226-387-47X,Granted Patent,no,4,0,3,3,0,E02D29/0266;;E04B2/18;;E04C1/39;;E04C1/397;;E04B2/18;;E04B2002/0223;;E04B2002/0234;;E04B2002/025;;E04B2002/0252,E04B2/18;;E02D29/02;;E04C1/39,,0,0,,,,ACTIVE
217,EP,A4,EP 1353546 A4,149-264-449-725-275,2009-07-22,2009,EP 01992233 A,2001-12-27,US 0149625 W;;US 75382501 A,2001-01-03,SPECIFICATION,,SENSEABILITY INC,JEFFREY W GENTNER;;MARTIN CHANDLER COOPER,,https://lens.org/149-264-449-725-275,Search Report,no,4,0,11,11,0,A01J5/007;;A01J5/007,A01J5/007,,1,0,,,See also references of WO 02052927A3,DISCONTINUED
218,US,A1,US 2012/0153608 A1,165-527-374-751-015,2012-06-21,2012,US 97480210 A,2010-12-21,US 97480210 A,2010-12-21,WET DISCONNECT SYSTEM WITH POST DISCONNECTION PRESSURE INTEGRITY,A wet disconnect system with post disconnection pressure integrity includes a bridge tube. One or more seals on the bridge tube that seal the bridge tube to one or more conductors passing through the bridge tube. A defeatable seal/anchor at the bridge tube sealing an outside surface of the bridge tube to an inside surface of a separate structure. The defeatable seal/anchor being defeatable upon application of an axial load above a threshold.,GILL COOPER C;;MARTIN CARL S;;BAKER HUGHES INC,GILL COOPER C;;MARTIN CARL S,BAKER HUGHES INCORPORATED (2011-01-26),https://lens.org/165-527-374-751-015,Patent Application,yes,35,5,3,3,0,F16L19/0656;;G02B6/4428;;F16L19/0656;;G02B6/4428,F16L37/00,285/1,0,0,,,,ACTIVE
219,DK,T3,DK 2107205 T3,177-325-326-909-607,2018-08-13,2018,DK 09004969 T,2009-04-03,GB 0806117 A,2008-04-04,Røggardinindretning,,COOPERS BLINDS LTD,COOPER PAUL ANDREW;;REED JAMES MARTIN,,https://lens.org/177-325-326-909-607,Granted Patent,no,0,0,6,6,0,A62C2/10;;E06B9/13;;E06B2009/17053;;Y10T24/44;;Y10T24/27;;Y10T24/44;;Y10T24/27;;E06B9/13;;A62C2/10;;E06B2009/17053,E06B9/13;;A44B99/00;;A62C2/10;;E06B9/17,,0,0,,,,ACTIVE
220,HK,A1,HK 1009786 A1,194-770-250-898-519,1999-06-11,1999,HK 98110824 A,1998-09-22,GB 9514558 A;;GB 9601712 W,1995-07-17,Marking diamond,,GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/194-770-250-898-519,Patent Application,no,0,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B28D5/00;;B44B7/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
221,GB,B,GB 2319225 B,032-023-705-270-207,1999-06-09,1999,GB 9801072 A,1996-07-17,GB 9601712 W;;GB 9514558 A,1995-07-17,Marking diamond,,GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/032-023-705-270-207,Granted Patent,no,3,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B28D5/00;;B44B7/00;;C30B29/04;;H01S3/00,B6J JMY           JMY;;B6J J70X          JMY;;U1S S1431,0,0,,,,EXPIRED
222,GB,B,GB 2160513 B,024-163-154-346-651,1987-11-11,1987,GB 8416016 A,1984-06-22,GB 8416016 A,1984-06-22,FEEDING SHEETS FROM A STACK,,XEROX CORP,KERSHAW IAN GEOFFREY;;COOPER JOHN MARTIN,,https://lens.org/024-163-154-346-651,Granted Patent,no,0,0,3,3,0,B65H3/5223,B65H3/52,B8R404;;B8R461;;B8R471;;B8RAE3;;U1S2243;;U1S2249;;U1SB8R,0,0,,,,EXPIRED
223,CN,A,CN 115479136 A,054-515-979-146-798,2022-12-16,2022,CN 202210667758 A,2022-06-14,EP 21179207 A,2021-06-14,Valve assembly,"A valve assembly (1) comprising: a common housing having a first side (8a), a second side (8b), an inlet port (2) and an outlet port (3); the valve assembly (1) comprises a first pair of valve members or poppet valves (4a, 4c) and a second pair of valve members or poppet valves (4b, 4d), a first pair of valve seats (5a, 5c) for cooperating with the first pair of valve members or poppet valves (4a, 4c) and a second pair of valve seats (5b, 5d) for cooperating with the second pair of valve members or poppet valves (4b, 4d); a central flow diverter (13c) disposed between the first pair of valve members or poppet valves (4a, 4c) and the second pair of valve seats (5b, 5d), the central flow diverter (13c) defining a first side (11a) of the valve assembly (1) and a second side (11b) of the valve assembly (1).",SIEMENS AG,WETZEL MARTIN;;COOPER NICOLA;;WIEGAND ARMIN,,https://lens.org/054-515-979-146-798,Patent Application,no,0,0,4,4,0,F16K1/34;;F16K1/32;;F16K27/02;;F23K2900/05002;;F23N2235/24;;F23N2235/18;;F23N2235/16;;F23N1/005;;F16K1/446;;F16K1/443;;F16K27/02,F16K1/34;;F16K1/32;;F16K27/02,,0,0,,,,PENDING
224,ES,T3,ES 2166459 T3,072-382-867-995-468,2002-04-16,2002,ES 96924981 T,1996-07-17,GB 9514558 A,1995-07-17,MARCADO DE DIAMANTE.,"A FIN DE PRODUCIR EN LA MESETA DE UNA GEMA DE DIAMANTE (7) UNA MARCA INFORMATIVA INVISIBLE AL OJO DESNUDO UTILIZANDO UNA LUPA 10, SE UTILIZA UN LASER ULTRAVIOLETA (1) CON UNA LONGITUD DE ONDA DE 193 NM EN ASOCIACION CON UNA MASCARA (2) PARA IRRADIAR LA SUPERFICIE DE LA PIEDRA (7) CON UNA FLUENCIA INFERIOR A 2 J/CM SUP,2} POR PULSO Y CON NO MENOS DE 100 PULSOS, EN PRESENCIA DE AIRE QUE REACCIONA CON EL DIAMANTE (7) Y HACE QUE SE FORME LA MARCA SIN OSCURECIMIENTO VISIBLE CUANDO SE UTILIZA UN MICROSCOPIO.",GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/072-382-867-995-468,Granted Patent,no,0,1,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B44B7/00;;B28D5/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
225,AU,B9,AU 2019/201157 B9,104-943-379-610-377,2023-03-02,2023,AU 2019/201157 A,2019-02-19,US 201815902672 A,2018-02-22,"Automatic vehicle control apparatus able to determine track occupancy of a vehicle, and corresponding method for automatically controlling the vehicle","AUTOMATIC VEHICLE CONTROL APPARATUS ABLE TO DETERMINE TRACK OCCUPANCY OF A VEHICLE, AND CORRESPONDING METHOD FOR AUTOMATICALLY CONTROLLING A VEHICLE This automatic vehicle control apparatus comprises a first image sensor positioned on a vehicle, able to capture a first global image of a first scene, including an area in front of the vehicle, in a first field of view of said first image sensor; a track occupancy detector for receiving the first global image and deducing therefrom a track occupancy of the vehicle among at least two set of parallel tracks positioned in front of the vehicle; a distinguishable object disposed in the first field of view; and a proper functioning checking apparatus configured for searching, in the first global image, a first specific image of the distinguishable object, and for generating an alert signal in case the first specific image is not found in the first global image. oo-Co 4:0",ALSTOM TRANSP TECH,MARTIN PHILLIP;;SNYDER SENECA;;COOPER JARED,,https://lens.org/104-943-379-610-377,Amended Patent,no,3,0,7,7,0,G05D1/0246;;G06T7/73;;G06T2207/10028;;G06T2207/30256;;G08G1/166;;B61L23/041;;B61L25/025;;B61L2205/04;;G06V20/56;;G06V10/751;;G08G1/166;;G06T2207/30236;;G08G1/056;;G06T7/70;;G06T7/73;;G06V10/751;;G06V20/56,B61L25/02,,0,0,,,,ACTIVE
226,GB,A,GB 2286705 A,131-937-895-166-16X,1995-08-23,1995,GB 9403044 A,1994-02-17,GB 9403044 A,1994-02-17,Multi-processor module,,GEC ALSTHOM LIMITED,COOPER MARK EDWIN;;PLATT CHRISTOPHER MARTIN,,https://lens.org/131-937-895-166-16X,Patent Application,no,0,3,4,4,0,B61L19/06,B61L19/06;;B61L27/00,G4A AFD           FD;;G4Q QBT           QBT,0,0,,,,EXPIRED
227,CA,A,CA 23586 A,140-441-477-462-211,1886-03-11,1886,CA 23586D A,,CA 23586T A,,COMBINED POLE AND SHAFT FOR VEHICULES,,COOPER HOLSTEN T;;MARTIN AARON J,COOPER HOLSTEN T;;MARTIN AARON J,,https://lens.org/140-441-477-462-211,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
228,DE,T2,DE 69515845 T2,185-991-717-445-568,2000-11-02,2000,DE 69515845 T,1995-01-25,GB 9401354 A;;GB 9500139 W,1994-01-25,UNTERSUCHUNG EINES DIAMANTEN,,GERSAN ESTABLISHMENT VADUZ,SMITH PHILLIP;;SMITH GORDON;;COOPER MARTIN,,https://lens.org/185-991-717-445-568,Granted Patent,no,0,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
229,GB,A,GB 2322642 A,021-193-420-778-157,1998-09-02,1998,GB 9704073 A,1997-02-27,GB 9704073 A,1997-02-27,Lyocell fabric treatment,"A method of producing a lyocell fabric, having substantially only secondary fibrillation, comprises flame treating the surface of a lyocell fabric, processing the lyocell fabric in an aqueous medium, such as a dye solution, to generate fibrillation and thereafter softening and tumbling the fabric. A lyocell fabric having a peach-skin finish produced by this method is also disclosed.",COURTAULDS FIBRES,TAYLOR JAMES MARTIN;;COOPER KAREN JANE,,https://lens.org/021-193-420-778-157,Patent Application,no,0,3,2,2,0,D06C9/02;;D06C27/00,D06B3/28;;D06C9/02;;D06C27/00,D1S S16           S16,0,0,,,,DISCONTINUED
230,AU,A1,AU 2006/273784 A1,036-431-912-537-208,2007-02-01,2007,AU 2006/273784 A,2006-07-05,GB 0515300 A;;EP 05270033 A;;GB 2006050188 W,2005-07-27,System and method for determining the time difference between two platforms,,SELEX GALILEO LTD,GOULD DALE MARTIN;;COOPER ROBERT DAVID,,https://lens.org/036-431-912-537-208,Patent Application,no,0,0,7,8,0,G01S5/021;;G01S5/06;;G04G7/02;;G04G7/02;;G01S5/06;;G01S5/021,G04G7/02,,0,0,,,,DISCONTINUED
231,EP,B1,EP 3008272 B1,046-131-258-957-002,2017-11-08,2017,EP 14744618 A,2014-06-02,GB 201310791 A;;US 201361843473 P;;GB 2014051678 W,2013-06-14,FIRE AND SMOKE CURTAIN,,COOPERS FIRE LTD,COOPER ANDREW PAUL;;REED JAMES MARTIN,,https://lens.org/046-131-258-957-002,Granted Patent,yes,5,0,13,13,0,A62C2/10;;A62C2/24;;E06B9/0692;;E06B9/80;;E06B2009/807;;E06B5/16;;A62C2/10;;A62C2/16;;A62C2/242;;E06B9/0692;;E06B2009/807,E06B5/16;;A62C2/10;;A62C2/24;;E06B9/06;;E06B9/80,,0,0,,,,ACTIVE
232,DE,A1,DE 19651529 A1,068-851-403-569-684,1997-06-19,1997,DE 19651529 A,1996-12-11,US 844395 P,1995-12-12,Retainer device for holding solenoid coils in housings,"The holding device includes a main body for receiving the solenoid coil (12). The main body has a base wall against which the solenoid coil lies in its supported state. An elastic spring deflectable locking arm (16) which extends upwards and outwards from the base wall. The locking arm has a lower section (16a), a middle section and a locking section (16b). The middle section has a bent back part in which an opening (16c) is formed. The locking section has a locking face. The opening admits a latching tooth (13) and the locking face engages with the latching tooth to fix the component.",WHITAKER CORP,COOPER RALPH MELVIN;;MARTIN GALEN MONROE,,https://lens.org/068-851-403-569-684,Patent Application,no,0,2,3,3,0,H01F7/06;;H05K7/12;;H05K7/12;;H01F7/06,F16B1/02;;H01F5/00;;H01F7/06;;H05K7/12,,0,0,,,,DISCONTINUED
233,GB,A,GB 2276181 A,071-527-061-365-174,1994-09-21,1994,GB 9305586 A,1993-03-18,GB 9305586 A,1993-03-18,Interlocking building blocks,"A building block has the top and bottom provided with a first kind of form looking male (23) and female (24) connector, and each side provided with a second kind of form locking male (15) and female (16 - 20) connector; both kinds of connector are engageable by relative motion in a direction perpendicular to the top face of a block, and only one male connector of the second kind is provided. The block may be rectangular, of plastics material, (e.g. polyproplylene), and may be used to construct chambers below ground level. <IMAGE>",PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/071-527-061-365-174,Patent Application,no,0,12,3,3,0,E04B2/18;;E04B1/0015;;E04B2002/0234;;E04B2002/0245;;E04B2002/0252,E04B2/02;;E04B2/18,E1D DLEQWNT       LEQWNT;;E1D D2131         LEQWNT;;E1D D2162         LEQWNT;;E1D D401          LEQWNT;;E1D D509          LEQWNT;;E1D D532          LEQWNT,0,0,,,,EXPIRED
234,WO,A8,WO 2002/052927 A8,142-466-974-311-75X,2003-10-02,2003,US 0149625 W,2001-12-27,US 75382501 A,2001-01-03,METHOD AND APPARATUS FOR MONITORING MILKING FACILITY PULSATION,"A pulsator (23) provides alternating vacuum pressure and atmospheric pressure to an elastomeric liner (35) in a sleeve (13) of a milking claw (11) in a diary barn. The purpose of pulsation is to alternate to cow teat between a milking phase and a rest phase. The invention (41) monitors the operation of the pulsator to determine if the pulsator is operating satisfactorily. The invention records data during a calibration mode from the pulsator in normal operation. The data that is recorded is the duration of the miling phase and the rest phase and the assocated pressures. During pulsator operation, the invention measures the pulsation between atmospheric and vacuum pressures provided to the milking claw and compares this measured data to the recorded calibraton data. If the pulsator is not found to be operating within predetermined tolerances, then an indication of a pulsator malfunction is provided, typically in the form of a light located in the milking pen. This indicates to the milking crew that the pulsator requires attention and should not be used until properly fixed",SENSEABILITY INC,JEFFREY W GENTNER;;MARTIN CHANDLER COOPER,,https://lens.org/142-466-974-311-75X,Patent Application,no,0,0,11,11,0,A01J5/007;;A01J5/007,A01J5/007,,0,0,,,,PATENTED
235,US,A,US 3450508 A,133-729-495-947-772,1969-06-17,1969,US 3450508D A,1966-09-01,US 57673666 A,1966-09-01,EXTRACTION OF SALTS FROM SALINE WATER USING DIMETHYLSULFOXIDE,,UNITED NUCLEAR CORP,COOPER MARTIN H;;HAWKINS THOMAS D,GA TECHNOLOGIES INC (1982-10-29),https://lens.org/133-729-495-947-772,Granted Patent,no,6,6,1,1,0,B01D61/243;;B01D71/06;;C02F1/265;;C02F1/265;;B01D71/06;;B01D61/243,B01J14/00;;C02F1/26,23/312,0,0,,,,EXPIRED
236,GB,A,GB 2184591 A,139-304-320-436-289,1987-06-24,1987,GB 8618897 A,1986-08-01,US 81204585 A,1985-12-23,SELF-ACTUATED NUCLEAR REACTOR SHUTDOWN SYSTEM,,WESTINGHOUSE ELECTRIC CORP,SIEVERS ROBERT KEVIN;;COOPER MARTIN HOWARD,,https://lens.org/139-304-320-436-289,Patent Application,no,0,2,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,G6C CQR           CQR;;G6C C39Y          CQR;;G6C C405          CQR;;G6C C63Y          CQR;;G6C C630          CQR,0,0,,,,EXPIRED
237,EP,A1,EP 4105555 A1,154-556-450-578-87X,2022-12-21,2022,EP 21179207 A,2021-06-14,EP 21179207 A,2021-06-14,GAS VALVE ASSEMBLY,"A valve assembly (1) comprising: a common housing having a first side (8a), a second side (8b), an inlet port (2) and an outlet port (3); the valve assembly (1) comprising a first pair of valve members or poppets (4a, 4c) and a second pair of valve members or poppets (4b, 4d), a first pair of valve seats (5a, 5c) for cooperation with the first pair of valve members or poppets (4a, 4c), and a second pair of valve seats (5b, 5d) for cooperation with the second pair of valve members or poppets (4b, 4d); a central flow diverter (13c) disposed in between the first pair of valve members or poppets (4a, 4c) and the second pair of valve seats (5b, 5d), the central flow diverter (13c) defining a first side (11a) of the valve assembly (1) and a second side (11b) of the valve assembly (1).
",SIEMENS AG,COOPER NILS;;WETZEL MARTIN;;WIEGAND ARMIN,,https://lens.org/154-556-450-578-87X,Patent Application,yes,8,0,4,4,0,F16K1/34;;F16K1/32;;F16K27/02;;F23K2900/05002;;F23N2235/24;;F23N2235/18;;F23N2235/16;;F23N1/005;;F16K1/446;;F16K1/443;;F16K27/02,F23N1/00,,0,0,,,,PENDING
238,FR,B1,FR 2492150 B1,144-943-227-558-937,1988-04-01,1988,FR 8119362 A,1981-10-14,US 19738080 A,1980-10-15,SYSTEME POUR ARRETER LE FONCTIONNEMENT D'UN REACTEUR NUCLEAIRE,,WESTINGHOUSE ELECTRIC CORP,MANGUS JAMES DONALD;;COOPER MARTIN HOWARD,,https://lens.org/144-943-227-558-937,Granted Patent,no,0,0,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,,0,0,,,,EXPIRED
239,AU,A,AU 1996/065247 A,159-637-631-672-255,1997-02-18,1997,AU 1996/065247 A,1996-07-17,GB 9514558 A;;GB 9601712 W,1995-07-17,Marking diamond,,GERSAN ETS,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/159-637-631-672-255,Patent Application,no,0,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B28D5/00;;B23K26/00;;B23K26/06;;B41M5/24;;B44B7/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
240,FR,A1,FR 2492150 A1,180-867-165-430-228,1982-04-16,1982,FR 8119362 A,1981-10-14,US 19738080 A,1980-10-15,SYSTEME POUR ARRETER LE FONCTIONNEMENT D'UN REACTEUR NUCLEAIRE,"<P>SYSTEME POUR ARRETER LE FONCTIONNEMENT D'UN REACTEUR NUCLEAIRE.</P><P>LE SYSTEME SELON LA PRESENTE INVENTION COMPREND UN DISPOSITIF 70 SENSIBLE A LA TEMPERATURE ET BRANCHE DE MANIERE A COMMANDER L'ALIMENTATION EN ENERGIE ELECTRIQUE D'UN MECANISME DE VERROUILLAGE MAGNETIQUE 44 SUPPORTANT UN CORPS OU MASSE D'UNE MATIERE ABSORBANT LES NEUTRONS. LE DISPOSITIF 70 SENSIBLE A LA TEMPERATURE EST EXPOSE AU REFRIGERANT DU REACTEUR DE MANIERE QUE LORSQUE LA TEMPERATURE DE CE REFRIGERANT AUGMENTE AU-DESSUS D'UN NIVEAU SPECIFIQUE, LE DISPOSITIF 70 SENSIBLE A LA TEMPERATURE FAIT CESSER L'EXCITATION DU MECANISME DE VERROUILLAGE MAGNETIQUE 44 POUR PERMETTRE AU CORPS DE MATIERE ABSORBANT LES NEUTRONS DE PENETRER DANS LE COEUR DU REACTEUR.</P>",WESTINGHOUSE ELECTRIC CORP,MANGUS JAMES DONALD;;COOPER MARTIN HOWARD,,https://lens.org/180-867-165-430-228,Patent Application,no,5,0,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,,0,0,,,,EXPIRED
241,EP,B1,EP 1910900 B1,184-569-576-438-523,2016-08-31,2016,EP 06744368 A,2006-07-05,GB 2006050188 W;;GB 0515300 A;;EP 05270033 A;;EP 06744368 A,2005-07-27,SYSTEM AND METHOD FOR DETERMINING THE TIME DIFFERENCE BETWEEN TWO PLATFORMS,,SELEX ES LTD,GOULD DALE MARTIN;;COOPER R D,"LEONARDO UK LTD, GB (2021-07-19);;LEONARDO MW LTD., BASILDON, GB (2016-11-18);;SELEX GALILEO LIMITED (2010-03-03);;LEONARDO MW LTD. (2017-09-12);;SELEX ES LTD (2013-06-12);;LEONARDO MW LTD, GB (2017-02-07)",https://lens.org/184-569-576-438-523,Granted Patent,yes,2,0,7,8,0,G04G7/02;;G04G7/02;;G01S5/021;;G01S5/021;;G01S5/06;;G01S5/06,G01S5/02;;G01S5/06;;G04G7/00,,0,0,,,,ACTIVE
242,GB,A,GB 2344836 A,013-821-353-504-248,2000-06-21,2000,GB 9929018 A,1999-12-09,GB 9827993 A,1998-12-17,Ventilated roof tile,"A ventilated roof tile (2) which can be fitted into an array of overlapping tiles on a roof (fig 6, not shown). The tile (2) has a base (8) and a number of upstanding walls (12) thereon, which extend down the tile, where the walls (12) define a number of ventilation channels (14) and can support overlying tiles when in use. The base (8) of the tile (2) can be shaped so that it can engage with a transverse roof member (fig 6). The tile (2) may also have a channelled lower portion, an upper portion and a collection tray (28). The width of the channels (14) may be 3-6 mm to prevent wind blown debris entering the roof structure via the duct (48). The collection tray (28) may be provided with transverse ridges (30, 32) to also impede moisture and debris from reaching the tray. The collection tray (28) is preferably funnel shaped to drain moisture to the ventilation channels and the whole tile (2) can be a one piece plastic moulding.",PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/013-821-353-504-248,Patent Application,no,3,17,4,4,0,E04D1/30;;E04D1/30;;E04D13/17;;E04D2001/309;;E04D2001/309,E04D1/30;;E04D13/17,E1D DF124         F124LE;;E1D DLEKG2        F124LE;;E1D D2139         F124LE;;E1D D401          F124LE,0,0,,,,EXPIRED
243,EP,A1,EP 3008272 A1,025-190-799-749-271,2016-04-20,2016,EP 14744618 A,2014-06-02,GB 201310791 A;;US 201361843473 P;;GB 2014051678 W,2013-06-14,FIRE AND SMOKE CURTAIN,,COOPERS FIRE LTD,COOPER ANDREW PAUL;;REED JAMES MARTIN,,https://lens.org/025-190-799-749-271,Patent Application,yes,0,0,13,13,0,A62C2/16;;A62C2/10;;A62C2/10;;A62C2/24;;A62C2/242;;E06B9/0692;;E06B9/80;;E06B5/16;;E06B9/0692;;E06B2009/807;;E06B2009/807,E06B5/16;;A62C2/10;;A62C2/24;;E06B9/06;;E06B9/80,,1,0,,,See references of WO 2014199126A1,ACTIVE
244,GB,A,GB 2420571 A,079-899-314-505-621,2006-05-31,2006,GB 0602427 A,2004-07-12,GB 0316991 A;;GB 0403608 A;;GB 0415569 A,2003-07-21,Ridge tile sealing strip,"A sealing strip <B>100</B> for bridging the gap between adjacent ridge tiles comprises a planar member <B>104</B> and a limb <B>102</B>. The planar member <B>104</B> covers the gap between adjacent tiles and the limb <B>102</B> is inserted in the gap in use. The limb <B>102</B> comprises a plurality of spaced fingers and the planar member is bendable to allow it to conform to the profile of the ridge tiles in use. The strip <B>100</B> may be arranged with the planar member <B>104</B> adapted to conform to the interior surface of ridge tiles or to the exterior surface of ridge tiles. The free end of the limb <B>102</B> may carry mutually opposing projections <B>108</B>, <B>110</B> which, with the planar member, sandwich the edges of ridge tiles in use.",PHI DESIGN LTD,NUNN ROBERT CHARLES;;COOPER ROGER MARTIN,,https://lens.org/079-899-314-505-621,Patent Application,no,5,2,8,10,0,E04D1/30;;E04D1/3402;;E04D1/365;;E04D13/174;;E04D2001/305;;E04D2001/306;;E04D1/3402;;E04D1/36;;E04D13/152;;E04D2001/306;;E04D1/30;;E04D2001/305;;E04D1/30;;E04D1/3402;;E04D2001/305;;E04D2001/306,E04D1/36;;E04D1/30;;E04D1/34;;E04D13/17,E1D DDJ2          F112DJ;;E1D DF112         F112DJ;;E1D D124          F112DJ;;E1D D2055         F112DJ;;E1D D401          F112DJ,0,0,,,,ACTIVE
245,EP,A1,EP 1910900 A1,110-248-270-921-027,2008-04-16,2008,EP 06744368 A,2006-07-05,GB 2006050188 W;;GB 0515300 A;;EP 05270033 A;;EP 06744368 A,2005-07-27,SYSTEM AND METHOD FOR DETERMINING THE TIME DIFFERENCE BETWEEN TWO PLATFORMS,,SELEX SENSORS & AIRBORNE SYS,GOULD DALE MARTIN;;COOPER R D,"LEONARDO UK LTD, GB (2021-07-19);;LEONARDO MW LTD., BASILDON, GB (2016-11-18);;SELEX GALILEO LIMITED (2010-03-03);;LEONARDO MW LTD. (2017-09-12);;SELEX ES LTD (2013-06-12);;LEONARDO MW LTD, GB (2017-02-07)",https://lens.org/110-248-270-921-027,Patent Application,yes,0,1,7,8,0,G04G7/02;;G04G7/02;;G01S5/021;;G01S5/021;;G01S5/06;;G01S5/06,G01S5/02;;G01S5/06;;G04G7/00,,1,0,,,See references of WO 2007012888A1,ACTIVE
246,WO,A1,WO 1997/003846 A1,154-386-657-026-002,1997-02-06,1997,GB 9601712 W,1996-07-17,GB 9514558 A,1995-07-17,MARKING DIAMOND,"In order to produce on the table of a diamond gemstone (7), an information mark which is invisible to the naked eye using a x10 loupe, an ultraviolet laser (1) having a wavelength of 193 nm is used in association with a mask (2) to irradiate the surface of the stone (7) at a fluence of less than 2 J/cm2 per pulse and with not fewer than 100 pulses, in the presence of air which reacts with the diamond (7) and causes the mark to be formed without any darkening which is visible when viewing using a microscope.",GERSAN ETS;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/154-386-657-026-002,Patent Application,yes,3,31,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B41M5/24;;B44B7/00;;B28D5/00;;C30B29/04;;H01S3/00,,0,0,,,,PATENTED
247,US,S,US D0423772 S,160-558-260-773-38X,2000-05-02,2000,US 10326699 F,1999-04-12,US 10326699 F,1999-04-12,Hinged container,,COOPER DESIGNS LTD,COOPER MARTIN R;;AKATA WILLIAM K,COOPER DESIGNS LTD (1999-03-05),https://lens.org/160-558-260-773-38X,Design Right,yes,7,93,1,1,0,,,D 3218;;0301,0,0,,,,EXPIRED
248,IL,A,IL 91320 A,168-318-502-971-302,1993-03-15,1993,IL 9132089 A,1989-08-15,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION,,GERSAN ANSTALT,MARTIN COOPER;;ANDREW DAVID GARRY STEWART,,https://lens.org/168-318-502-971-302,Patent Application,no,0,0,13,30,0,B23K26/364;;B23K26/364,B23K26/06;;B23K26/00;;B23K26/073;;B23K26/36,,0,0,,,,DISCONTINUED
249,DE,D1,DE 3853477 D1,010-981-497-296-218,1995-05-04,1995,DE 3853477 T,1988-12-02,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,MAKROZYKLISCHE VERBINDUNGEN.,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN;;DONALD DAVID;;HARDERN DAVID,"FUJISAWA PHARMACEUTICAL CO., LTD., OSAKA, JP (2005-06-30);;ASTELLAS PHARMA INC., TOKIO/TOKYO, JP (2006-04-27)",https://lens.org/010-981-497-296-218,Granted Patent,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
250,US,B1,US 7896266 B1,027-983-572-053-264,2011-03-01,2011,US 37837409 A,2009-02-17,US 37837409 A;;US 13807608 P,2008-12-16,Wheeled attachment for pressure washer,"Method and apparatus for a wheeled attachment for use with a conventional pressure washer wherein the attachment comprises a wheeled platform having an inlet to receive fluid, i.e., water or cleaning fluid, from the pressure washer along with a plurality of outlets for spraying water directly onto a relatively wide area of the surface to be cleaned. The attachment is expected to be most effective for cleaning horizontal surfaces such as sidewalks, driveways, decks, docks and other horizontal surfaces. The attachment further comprises first and second height-adjustable wheels for attachment to the sides of the platform along with a splash guard disposed on the rear of the platform for protecting the user from overspray. A manifold connects the single inlet to the plurality of outlets in order to transfer fluid from the inlet to the outlets so that fluid is uniformly applied to the surface to be cleaned.",COOPER MARTIN L;;HOUSER CHARLES S,COOPER MARTIN L;;HOUSER CHARLES S,,https://lens.org/027-983-572-053-264,Granted Patent,yes,16,17,1,1,0,B05B9/007;;B08B3/028;;B05B15/62;;B05B15/63;;B05B12/34;;B05B9/007;;B08B3/028;;B05B15/62;;B05B12/22;;B05B15/63;;B05B12/34,A62C31/24;;B05B3/00;;B05B3/18;;B05B7/02;;B05B15/06,239/754;;239/280;;239/280.5;;239/525;;239/532;;239/600;;134/172,0,0,,,,INACTIVE
251,GB,B,GB 2184591 B,047-611-084-115-225,1989-10-18,1989,GB 8618897 A,1986-08-01,US 81204585 A,1985-12-23,SELF-ACTUATED NUCLEAR REACTOR SHUTDOWN SYSTEM,,WESTINGHOUSE ELECTRIC CORP,SIEVERS ROBERT KEVIN;;COOPER MARTIN HOWARD,,https://lens.org/047-611-084-115-225,Granted Patent,no,0,0,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,G6C CQR           CQR;;G6C C39Y          CQR;;G6C C405          CQR;;G6C C63Y          CQR;;G6C C630          CQR,0,0,,,,EXPIRED
252,EP,A1,EP 0897765 A1,067-957-371-932-678,1999-02-24,1999,EP 98305759 A,1998-07-20,GB 9715358 A,1997-07-21,Metal strip shearing and coiling,"Apparatus for coiling successive lengths of metal strip onto mandrels 7,8, comprising means for changing the strip path from a path leading to the mandrel 8 currently being wound to a path to a new mandrel when the current strip ends and a new strip appears. The new mandrel has mandrel strip guide means 12 comprising a chain of driven mandrel guide rollers located around the new mandrel in its initial position to receive the leading edge of a new length of strip and guide it around the mandrel. Adjacent rollers in the chain have interlocking grooves and flanges. Similar chains of rollers 3, 5, and 13 are used to guide the strip between the shears 2 and the mandrels. The new mandrel 7 is positioned in an initial position such that the strip path to it is a straight path, and the mandrels are mounted on a carousel 6 which moves that mandrel to a second position such that the strip path to it is an angled path 14 the first segment of which is common with the first part of the straight strip path. A tail restraining unit 11 holds the tail of the old strip onto its mandrel.",KVAERNER TECH & RES LTD,BERRY JOHN;;COOPER BRIAN;;PHILIPSON MARTIN,,https://lens.org/067-957-371-932-678,Patent Application,yes,5,6,8,8,0,B21C47/245;;B21C47/34;;B21C47/3475;;B21C47/3475;;B21C47/245;;B21C47/34,B21C47/06;;B21C47/24;;B21C47/34,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 013, no. 420 (M - 872) 19 September 1989 (1989-09-19)",DISCONTINUED
253,US,A,US 5967448 A,066-057-668-205-367,1999-10-19,1999,US 11883198 A,1998-07-20,GB 9715358 A,1997-07-21,Metal strip shearing and coiling,"An apparatus for coiling successive lengths of metal strip onto mandrels changes the strip path from a path leading to the mandrel currently being wound to a path to a new mandrel when the current strip ends and a new strip appears. The new mandrel has a mandrel strip guide that includes a chain of driven mandrel guide rollers located around the new mandrel in its initial position to receive the leading edge of a new length of strip and guide it around the mandrel. Adjacent rollers in the chain have interlocking grooves and flanges. Similar chains of rollers are used to guide the strip between the shears and the mandrels. The new mandrel is positioned in an initial position such that the strip path to it is a straight path, and the mandrels are mounted on a carousel which moves that mandrel to a second position such that the strip path to it is an angled path, the first segment of which is common with the first part of the straight strip path. A tail restraining unit holds the tail of the old strip onto its mandrel.",KVAERNER TECH & RES LTD,BERRY JOHN;;COOPER BRIAN;;PHILIPSON MARTIN,KVAERNER TECHNOLOGY & RESEARCH LIMITED (1998-07-14),https://lens.org/066-057-668-205-367,Granted Patent,yes,29,5,8,8,0,B21C47/245;;B21C47/34;;B21C47/3475;;B21C47/3475;;B21C47/245;;B21C47/34,B21C47/06;;B21C47/24;;B21C47/34,242/531.1;;242/532.7;;242/535.1;;242/535.5;;242/548.3;;226/181,0,0,,,,EXPIRED
254,US,A1,US 2002/0108398 A1,089-565-676-362-384,2002-08-15,2002,US 11487802 A,2002-04-02,US 11487802 A;;GB 9514558 A;;US 58816100 A;;US 11098 A,1995-07-17,Diamond etching,"
    In order to produce on the table of a diamond gemstone, an information mark which is invisible to the naked eye using a x10 loupe, an ultraviolet laser having a wavelength of 193 nm is used in association with a mask irradiate the surface of the stone at a fluence of less that 2 J/cm ² per pulse and with not fewer than 100 pulses, in the presence of air which reacts with the diamond and causes the mark to be formed without any darkening which is visible when viewing a microscope. 
",SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/089-565-676-362-384,Patent Application,yes,0,14,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B23K26/00;;B23K26/06;;B28D5/00;;B41M5/24;;B44B7/00;;C30B29/04;;H01S3/00,63/32;;63/33,0,0,,,,DISCONTINUED
255,CA,A1,CA 3033871 A1,110-272-058-837-16X,2019-08-22,2019,CA 3033871 A,2019-02-12,US 201815902672 A,2018-02-22,"AUTOMATIC VEHICLE CONTROL APPARATUS ABLE TO DETERMINE TRACK OCCUPANCY OF A VEHICLE, AND CORRESPONDING METHOD FOR AUTOMATICALLY CONTROLLING THE VEHICLE","This automatic vehicle control apparatus comprises a first image sensor positioned on a vehicle, able to capture a first global image of a first scene, including an area in front of the vehicle, in a first field of view of said first image sensor; a track occupancy detector for receiving the first global image and deducing therefrom a track occupancy of the vehicle among at least two set of parallel tracks positioned in front of the vehicle; a distinguishable object disposed in the first field of view; and a proper functioning checking apparatus configured for searching, in the first global image, a first specific image of the distinguishable object, and for generating an alert signal in case the first specific image is not found in the first global image.",ALSTOM TRANSP TECH,MARTIN PHILLIP;;SNYDER SENECA;;COOPER JARED,,https://lens.org/110-272-058-837-16X,Patent Application,no,0,0,7,7,0,G05D1/0246;;G06T7/73;;G06T2207/10028;;G06T2207/30256;;G08G1/166;;B61L23/041;;B61L25/025;;B61L2205/04;;G06V20/56;;G06V10/751;;G08G1/166;;G06T2207/30236;;G08G1/056;;G06T7/70;;G06T7/73;;G06V10/751;;G06V20/56,B61C17/00;;B60R11/04;;B60W30/00,,0,0,,,,PENDING
256,US,A,US 4405558 A,151-105-034-528-505,1983-09-20,1983,US 19738080 A,1980-10-15,US 19738080 A,1980-10-15,Nuclear reactor shutdown system,"The nuclear reactor shutdown system comprises a temperature sensitive device connected to a magnetic latch of a neutron absorbing mechanism. The temperature sensitive device is disposed in the neutron absorbing mechanism in such a manner that it is exposed to the reactor coolant so that when the reactor coolant temperature rises above a specific level, the temperature sensitive device will cause the magnetic latch to open and allow neutron absorbing material to enter the reactor core. The temperature sensitive device comprises temperature sensitive material which may be a temperature sensitive resistor sometimes referred to as a thermistor. The thermistor is a device wherein its resistivity significantly increases with increase in its temperature such that when its temperature has significantly increased, the current passing through this system substantially decreases. Therefore, when the nuclear reactor coolant temperature rises significantly, the resistivity in the temperature sensitive material significantly increases to the point where little electricity flows through the circuit thereby causing the magnetic field in the magnetic latch to fall to a level at which the magnetic latch opens thereby inserting neutron absorbing material in the reactor core.",WESTINGHOUSE ELECTRIC CORP,MANGUS JAMES D;;COOPER MARTIN H,WESTINGHOUSE ELECTRIC CORPORATION (1980-09-30),https://lens.org/151-105-034-528-505,Granted Patent,yes,14,6,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,376/233;;376/243;;376/336,1,0,,,"Apex-492, 5/59, pp. 7, 16, 21, 71-74.",EXPIRED
257,ES,T3,ES 2659067 T3,133-507-726-089-071,2018-03-13,2018,ES 14744618 T,2014-06-02,GB 201310791 A;;US 201361843473 P;;GB 2014051678 W,2013-06-14,Cortina de fuego y humo,"Una barrera de fuego y/o humo (1) que comprende: - Una caja de entrada (6), - Un rodillo (4, 104), - Una cortina (2), para rodar y desplegarse desde el rodillo, - Una barra inferior (10), unida a la parte inferior de la cortina, para cargar la cortina para el despliegue y - Un freno de fricción dispuesto para frenar el rodillo y para un despliegue lento de la cortina caracterizado porque el freno de fricción comprende un elemento de fricción en la forma de uno de: - Una correa (34) dispuesta para actuar sobre un eje o una extensión (22) del rodillo (4) y unida por un muelle (40) al extremo de la caja de entrada, o a una pared, para mantener la correa en tensión o - Una almohadilla de fricción (134) dispuesta para actuar sobre un eje o una extensión del rodillo (104) y provista en una barra (136) por lo que la barra está unida a la pared o al extremo de la caja de entrada mediante un puntal (144).",COOPERS FIRE LTD,COOPER ANDREW PAUL;;REED JAMES MARTIN,,https://lens.org/133-507-726-089-071,Granted Patent,no,0,0,13,13,0,A62C2/16;;A62C2/10;;A62C2/10;;A62C2/24;;A62C2/242;;E06B9/0692;;E06B9/80;;E06B5/16;;E06B9/0692;;E06B2009/807;;E06B2009/807,E06B5/16;;A62C2/10;;A62C2/24;;E06B9/06;;E06B9/80,,0,0,,,,ACTIVE
258,CA,C,CA 2227185 C,128-102-637-697-300,2007-05-01,2007,CA 2227185 A,1996-07-17,GB 9514558 A;;GB 9601712 W,1995-07-17,MARKING DIAMOND,"In order to produce on the table of a diamond gemstone, an information mark which is invisible to the naked eye using a x10 loupe, an ultraviolet laser having a wavelength of 193 nm is used in association with a mask to irradiate the surface of the stone at a fluence of less than 2 J/cm2 per pulse and with not fewer than 100 pulses, in the presence of air which reacts with the diamond and causes the mark to be formed without any darkening which is visible when viewing using a microscope.",GERSAN ETS,COOPER MARTIN;;SMITH JAMES GORDON CHARTERS,,https://lens.org/128-102-637-697-300,Granted Patent,no,0,0,27,27,0,B41M5/24;;B44B7/00;;B23K26/066;;G01N21/87;;B23K26/066;;B23K26/361;;B41M5/24;;B44B7/00;;B23K2103/50;;B44B7/00;;B41M5/24;;B23K26/066;;G01N21/87,B28D5/00;;B23K26/00;;B28D5/04;;B23K26/06;;B41M5/24;;B44B7/00;;C30B29/04;;H01S3/00,,0,0,,,,EXPIRED
259,US,A1,US 2009/0160699 A1,133-593-941-564-721,2009-06-25,2009,US 58713906 A,2006-07-05,EP 05270033 A;;GB 0515300 A;;GB 2006050188 W,2005-07-27,Time synchronization,"A transmitter ( 106, 120, 118, 122 and 110 ) of a platform ( 100 ) is arranged to generate a transmission pulse which is transmitted to a receiver ( 212, 224 and 208 ) of another platform ( 200 ) and is also arranged to couple its transmission pulse to a digital receiver ( 104 ) associated with its platform ( 100 ) via attenuater ( 126 ) and coupler ( 124 ). The other platform ( 200 ) performs a similar task. Each digital receiver ( 108, 208 ) determines the time separation between its transmission pulse and received pulse from the other platform ( 100 or 200 ). The determined time separation information is shared with the other platform ( 100, 200 ) and each digital receiver ( 108, 208 ) then determines a time offset (Δt) between the time at its platform ( 100 ) and the other platform ( 200 ).",SELEX SENSORS & AIRBORNE SYS,GOULD DALE MARTIN;;COOPER ROBERT DAVID,LEONARDO UK LTD (2021-03-31);;SELEX SENSORS AND AIRBORNE SYSTEMS LTD (2006-09-20),https://lens.org/133-593-941-564-721,Patent Application,yes,3,6,7,8,0,G04G7/02;;G04G7/02;;G01S5/021;;G01S5/021;;G01S5/06;;G01S5/06,G01S1/24,342/189,0,0,,,,ACTIVE
260,WO,A1,WO 2012/087479 A1,139-296-775-463-50X,2012-06-28,2012,US 2011/0061677 W,2011-11-21,US 97480210 A,2010-12-21,WET DISCONNECT SYSTEM WITH POST DISCONNECTION PRESSURE INTEGRITY,A wet disconnect system with post disconnection pressure integrity includes a bridge tube. One or more seals on the bridge tube that seal the bridge tube to one or more conductors passing through the bridge tube. A defeatable seal/anchor at the bridge tube sealing an outside surface of the bridge tube to an inside surface of a separate structure. The defeatable seal/anchor being defeatable upon application of an axial load above a threshold.,BAKER HUGHES INC;;GILL COOPER C;;MARTIN CARL S,GILL COOPER C;;MARTIN CARL S,,https://lens.org/139-296-775-463-50X,Patent Application,yes,4,0,3,3,0,F16L19/0656;;G02B6/4428;;F16L19/0656;;G02B6/4428,E21B17/02;;E21B23/14,,0,0,,,,PENDING
261,US,A,US 6138919 A,141-587-492-552-619,2000-10-31,2000,US 93408397 A,1997-09-19,US 93408397 A,1997-09-19,Multi-section evaporator for use in heat pump,"A multi-section evaporator is employed in a heat pump system which includes a compressor, a condenser and an evaporator. A control valve is connected between each adjacent set of evaporator sections and the control valve is operable in response to temperature and/or pressure conditions sensed by a sensor. In response to a sensed condition, one or more sections of the evaporator are brought into operation concurrently with the previously operating section(s). Thus, the effective size of the evaporator is variable depending on the sensed condition.",POOL FACT INC,COOPER KENNETH W;;RAWHOUSER MARTIN A,RAYPAK INC (2008-03-27);;COOPER KENNETH W (1997-09-17);;POOL FACT INC (1997-09-17),https://lens.org/141-587-492-552-619,Granted Patent,yes,15,25,1,1,0,F25B5/02;;F25B2339/047;;F25B5/02;;F25B2339/047,F25B5/02,237  2B;;62/199;;62/238.6,1,0,,,"Advertisement: Heat Perfector XXI C, Mar. 1994.",EXPIRED
262,GB,B,GB 2315784 B,145-595-149-596-951,2000-02-23,2000,GB 9615888 A,1996-07-29,GB 9615888 A,1996-07-29,A vent for a roof,,PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/145-595-149-596-951,Granted Patent,no,1,0,3,3,0,E04D13/004;;E04D13/178,E04D13/00;;E04D13/17,E1D DDV2          FZDV;;E1D DF124         FZDV;;E1D DF172         FZDV;;E1D D401          FZDV;;E1D D547          FZDV,0,0,,,,EXPIRED
263,EP,A2,EP 0329960 A2,181-101-156-703-113,1989-08-30,1989,EP 89101212 A,1989-01-24,US 16043888 A,1988-02-25,Secured package integrity.,"The package (21) includes a body (23) and a closure (25) and a readily breakable electrical oscillatory network (29) sans power supply is physically connected between the body (23) and the closure (25). The network (29), is tuned to resonate at a predetermined frequency. The package (21) is monitored by a transmitter-receiver when it is distributed to a customer. The transmit­ter produces pulse signals in a carrier frequency band which overlaps the resonant frequency of the network (29). During monitoring the package (21) is placed in the field of the transmitter and the oscillatory network (29) is excited to produce a decaying pulse for each transmitter pulse. If the package (21) is sealed, the oscillatory network (29), is intact decaying pulses are received to produce visual or audible signals. If the package (21) has been opened, the network (29) is broken and no signals are produced.  ",WESTINGHOUSE ELECTRIC CORP,COOPER MARTIN HOWARD;;PETROSKY LYMAN JAY,,https://lens.org/181-101-156-703-113,Patent Application,yes,0,5,4,4,0,B65D5/4291;;B65D55/028;;Y10S206/807;;B65D55/028;;B65D5/4291;;Y10S206/807,B65D5/74;;B65D5/42;;B65D55/02,,0,0,,,,DISCONTINUED
264,AU,A1,AU 2007/309718 A1,000-273-139-925-90X,2008-05-02,2008,AU 2007/309718 A,2007-03-27,US 80860306 P;;US 78833806 P;;US 2007/0007816 W,2006-03-31,"Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno(2,3-d)pyrimidine",,DYNOGEN PHARMACEUTICALS INC,COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,,https://lens.org/000-273-139-925-90X,Patent Application,no,0,0,7,7,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P1/12;;A61P13/00;;A61P13/10;;A61P15/00;;C07D495/04,C07D495/04;;A61K31/519;;A61P1/00;;A61P13/00,,0,0,,,,DISCONTINUED
265,US,B2,US 6553934 B2,011-268-826-271-867,2003-04-29,2003,US 75382501 A,2001-01-03,US 75382501 A,2001-01-03,Method and apparatus for monitoring milking facility pulsation,"
    A pulsator provides alternating vacuum pressure and atmospheric pressure to an elastomeric liner in a sleeve of a milking claw in a dairy barn. The purpose of pulsation is to alternate the cow teat between a milking phase and a rest phase. The invention monitors the operation of the pulsator to determine if the pulsator is operating satisfactorily. The invention records data during a calibration mode from the pulsator in normal operation. The data that is recorded is the duration of the milking phase and the rest phase and the associated pressures. During pulsator operation, the invention measures the pulsation between atmospheric and vacuum pressures provided to the milking claw and compares this measured data to the recorded calibration data. If the pulsator is not found to be operating within predetermined tolerances, then an indication of a pulsator malfunction is provided, typically in the form of a light located in the milking pen. This indicates to the milking crew that the pulsator requires attention and should not be used until properly fixed. 
",SENSEABILITY INC,GENTNER JEFFREY W;;COOPER MARTIN CHANDLER,SENSEABILITY INC (2001-12-27),https://lens.org/011-268-826-271-867,Granted Patent,yes,8,21,11,11,0,A01J5/007;;A01J5/007,A01J5/007,119/14.02,4,0,,,"InnovAg, 4 sheets of information of products available.;;DairyTest Professional, Document No. DR54-0053-01 5 pages, InnovAg Pty. Ltd.;;DairyTest Monitor, 3 sheets of information.;;DairyTest Monitor, Document No. DR54-0047-07, 8 pages, InnovAg Pty. Ltd.",EXPIRED
266,JP,A,JP 2000042628 A,014-098-512-446-134,2000-02-15,2000,JP 20924598 A,1998-07-24,JP 20924598 A,1998-07-24,SHEARING AND COILING OF METALLIC STRIP STOCK,"PROBLEM TO BE SOLVED: To obtain a hot rolled strip shearing and coiling device having a means for changing a path from a mandrel under coiling at present to a new mandrel. SOLUTION: This device is provided with a mandrel strip guide means 12 consisting of a chained driven mandrel guide rollers which are arranged around a mandrel in an initial position of a new mandrel 7 to receive the tip end of a new strip and guides it around the mandrel, and mutually adjacent rollers chained are provided with a mutually engaging groove and flange. The strip is guided between a shearing machine 2 and the mandrel using rovers 3, 5, 13 which are likewise chained.",KVAERNER TECHNOL & RES LTD,JOHN BERRY;;COOPER BRYAN;;MARTIN PHILIPSON,,https://lens.org/014-098-512-446-134,Patent Application,no,0,0,1,1,0,,B21C47/02;;B21C47/34,,0,0,,,,PENDING
267,US,A,US 5248877 A,021-938-825-209-933,1993-09-28,1993,US 65540191 A,1991-04-04,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION,"To make an elongate cut (1) in a diamond (2) using a laser radiation, a cylindrical optical system (5, 6) is used which converges the radiation at a greater angle of convergence in the plane of the cut (1) than in the transverse plane. In this way, the focal spot energy density is increased and cutting at depth is made more effective.",GERSAN ANSTALT,COOPER MARTIN;;STEWART ANDREW D G,ANSTALT GERSAN (1992-10-15),https://lens.org/021-938-825-209-933,Granted Patent,yes,13,9,13,30,0,B23K26/364;;B23K26/364,B23K26/06;;B23K26/00;;B23K26/073;;B23K26/36,219/121.67;;219/121.72;;219/121.75,2,0,,,"Electro Optics/Laser 80 Conference and Exposition, Boston, Mass., Nov. 19 21, 1980, pp. 223, 226.;;IBM Technical Disclosure Bulletin, vol. 14, No. 9, Feb. 1972, pp. 2641 and 2642.",EXPIRED
268,TW,B,TW 336965 B,066-347-874-210-189,1998-07-21,1998,TW 86101817 A,1997-02-13,GB 9602991 A,1996-02-14,Method of reducing the tendency of a lyocell fabric to primary fibrillation,"A method of reducing the tendency of a lyocell fabric to primary fibrillation, being the tendency of lyocell fabric primary fabrillation generated by dyeing and washing; featuring: before dyeing, keeping it in contact with a sort of oxidant aqueous solution selected from sub chlorate, peroxide of hydrogen and other oxides as oxidants and under a temperature range of 40 to 100 deg. C, being the content of the oxidant sufficient to lower the tendency of the primary fabrillation of the fabric.",COURTAULDS FIBRES HOLDINGS LTD,KAREN JANE COOPER;;JAMES MARTIN TAYLOR,,https://lens.org/066-347-874-210-189,Granted Patent,no,0,0,6,6,0,D01F2/00;;D06M11/30;;D06M11/30;;D06M11/50;;D06M11/50;;D10B2401/00,D01F2/00;;D06M11/30;;D06M11/50,,0,0,,,,EXPIRED
269,GB,A,GB 2290568 A,105-133-057-680-446,1996-01-03,1996,GB 9512949 A,1995-06-26,GB 9512949 A;;GB 9412824 A,1994-06-25,Ventilation tile,A ventilation tile has a tortuous ventilation passage defined by walls (108) extending inwardly from the outer face and walls (111) extending outwardly from the inner face. The passage opens to the inner face of the tile over substantially the entire length of the tile which is exposed in use in the downward direction. The passage includes apertures (123 - 125) formed in the lower surface of the tile. <IMAGE>,PHI DESIGN LTD,COOPER ROGER MARTIN;;NUNN ROBERT CHARLES,,https://lens.org/105-133-057-680-446,Patent Application,no,3,6,3,4,0,E04D1/30;;E04D1/30;;E04D2001/309;;E04D2001/309,E04D1/30,E1D DCE2          F124CE;;E1D DF124         F124CE;;E1D D120          F124CE;;E1D D2022         F124CE;;E1D D2055         F124CE;;E1D D2139         F124CE;;E1D D401          F124CE,0,0,,,,EXPIRED
270,EP,A2,EP 2016082 A2,108-078-662-835-442,2009-01-21,2009,EP 07861278 A,2007-03-27,US 2007/0007816 W;;US 80860306 P;;US 78833806 P,2006-03-31,"CRYSTALLINE FORMS OF 4-(2-FLUOROPHENYL)-6-METHYL-2-(PIPERAZIN-1-YL)THIENO(2,3-D)PYRIMIDINE",,DYNOGEN PHARMACEUTICALS INC,COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,,https://lens.org/108-078-662-835-442,Patent Application,yes,0,0,7,7,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P1/12;;A61P13/00;;A61P13/10;;A61P15/00;;C07D495/04,C07D495/04;;A61K31/519;;A61P1/00;;A61P13/00,,0,0,,,,DISCONTINUED
271,ID,A,ID 21495 A,129-672-481-752-748,1999-06-17,1999,ID 981028 A,1998-07-21,GB 9715358 A,1997-07-21,PEREGANGAN DAN PENGGULUNGAN POTONGAN LOGAM,,KVAERNER TECHNOLOGY & RES LTD,BERRY JOHN;;COOPER BRIAN;;PHILIPSON MARTIN,,https://lens.org/129-672-481-752-748,Patent Application,no,0,0,8,8,0,B21C47/245;;B21C47/34;;B21C47/3475;;B21C47/3475;;B21C47/245;;B21C47/34,B21C47/06;;B21C47/24;;B21C47/34,,0,0,,,,PENDING
272,IN,B,IN 174289 B,175-135-963-992-626,1994-10-29,1994,IN 612MA1989 A,1989-08-16,GB 8819351 A,1988-08-15,A method and an apparatus for manufacturing a cut workpiece such as a gemstone with desired cutting using high energy radiation,,GERSAN ANSTALT,COOPER MARTIN;;STEWART ANDREW DAVID GARRY,,https://lens.org/175-135-963-992-626,Granted Patent,no,0,0,13,30,0,B23K26/364;;B23K26/364,B23K26/06;;B23K26/00;;B23K26/073;;B23K26/36,,0,0,,,,EXPIRED
273,HR,T1,HR P20180247 T1,183-599-962-658-613,2018-03-23,2018,HR P20180247 T,2018-02-08,GB 201310791 A;;US 201361843473 P;;EP 14744618 A;;GB 2014051678 W,2013-06-14,FIRE AND SMOKE CURTAIN,,COOPERS FIRE LTD,COOPER ANDREW PAUL;;REED JAMES MARTIN,,https://lens.org/183-599-962-658-613,Granted Patent,no,0,0,13,13,0,A62C2/16;;A62C2/10;;A62C2/10;;A62C2/24;;A62C2/242;;E06B9/0692;;E06B9/80;;E06B5/16;;E06B9/0692;;E06B2009/807;;E06B2009/807,E06B5/16;;A62C2/10;;A62C2/24;;E06B9/06;;E06B9/80,,0,0,,,,ACTIVE
274,WO,A2,WO 2008/051282 A2,015-320-671-131-499,2008-05-02,2008,US 2007/0007816 W,2007-03-27,US 78833806 P;;US 80860306 P,2006-03-31,"CRYSTALLINE FORMS OF 4-(2-FLUOROPHENYL)-6-METHYL-2-(PIPERAZIN-1-YL)THIENO(2,3-D)PYRIMIDINE","The present invention is directed to novel crystalline forms of 4-(2- fluorophenyl)-6-methyl-2-(piperazin-l-yl)thieno[2,3-d]pyrimidine salts, including 4-(2- fluorophenyl)-6-methyl-2-(piperazin-l-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.",DYNOGEN PHARMACEUTICALS INC;;COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,COOPER MARTIN IAN;;FRAMPTON CHRISTOPHER STEPHEN,,https://lens.org/015-320-671-131-499,Patent Application,yes,0,0,7,7,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P1/12;;A61P13/00;;A61P13/10;;A61P15/00;;C07D495/04,A61K31/519;;C07D495/04;;A61P13/00,,0,0,,,,PENDING
275,US,A1,US 2005/0007877 A1,023-300-163-743-239,2005-01-13,2005,US 85524304 A,2004-05-26,US 85524304 A;;US 48546603 P,2003-07-08,Acoustic system for communication in pipelines,"A system for communication in a pipe, or pipeline, or network of pipes containing a fluid. The system includes an encoding and transmitting sub-system connected to the pipe, or pipeline, or network of pipes that transmits a signal in the frequency range of 3-100 kHz into the pipe, or pipeline, or network of pipes containing a fluid, and a receiver and processor sub-system connected to the pipe, or pipeline, or network of pipes containing a fluid that receives said signal and uses said signal for a desired application.",UNIV CALIFORNIA,MARTIN LOUIS PETER;;COOPER JOHN F,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2004-05-12);;LAWRENCE LIVERMORE NATIONAL SECURITY LLC (2007-09-24),https://lens.org/023-300-163-743-239,Patent Application,yes,12,19,2,7,0,G01F1/667;;G01F1/667;;H04B13/00;;H04B13/00,G01F1/66;;H04B13/00,367/82,0,0,,,,INACTIVE
276,AU,B2,AU 2019/201157 B2,054-112-727-381-568,2023-02-16,2023,AU 2019/201157 A,2019-02-19,US 201815902672 A,2018-02-22,"Automatic vehicle control apparatus able to determine track occupancy of a vehicle, and corresponding method for automatically controlling the vehicle","AUTOMATIC VEHICLE CONTROL APPARATUS ABLE TO DETERMINE TRACK OCCUPANCY OF A VEHICLE, AND CORRESPONDING METHOD FOR AUTOMATICALLY CONTROLLING A VEHICLE This automatic vehicle control apparatus comprises a first image sensor positioned on a vehicle, able to capture a first global image of a first scene, including an area in front of the vehicle, in a first field of view of said first image sensor; a track occupancy detector for receiving the first global image and deducing therefrom a track occupancy of the vehicle among at least two set of parallel tracks positioned in front of the vehicle; a distinguishable object disposed in the first field of view; and a proper functioning checking apparatus configured for searching, in the first global image, a first specific image of the distinguishable object, and for generating an alert signal in case the first specific image is not found in the first global image. oo-Co 4:0",ALSTOM TRANSP TECH,MARTIN PHILLIP;;SNYDER SENECA;;COOPER JARED,,https://lens.org/054-112-727-381-568,Granted Patent,no,3,0,7,7,0,G05D1/0246;;G06T7/73;;G06T2207/10028;;G06T2207/30256;;G08G1/166;;B61L23/041;;B61L25/025;;B61L2205/04;;G06V20/56;;G06V10/751;;G08G1/166;;G06T2207/30236;;G08G1/056;;G06T7/70;;G06T7/73;;G06V10/751;;G06V20/56,B61L25/02,,0,0,,,,ACTIVE
277,AU,A,AU 1989/040774 A,065-527-914-301-571,1990-03-05,1990,AU 1989/040774 A,1989-08-15,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION,,GERSAN ANSTALT,COOPER MARTIN;;STEWART ANDREW DAVID GARRY,,https://lens.org/065-527-914-301-571,Patent Application,no,0,0,13,30,0,B23K26/364;;B23K26/364,B23K26/00;;B23K26/06;;B23K26/073;;B23K26/36,,0,0,,,,EXPIRED
278,US,B2,US 8459700 B2,060-574-979-504-329,2013-06-11,2013,US 97480210 A,2010-12-21,US 97480210 A,2010-12-21,Wet disconnect system with post disconnection pressure integrity,A wet disconnect system with post disconnection pressure integrity includes a bridge tube. One or more seals on the bridge tube that seal the bridge tube to one or more conductors passing through the bridge tube. A defeatable seal/anchor at the bridge tube sealing an outside surface of the bridge tube to an inside surface of a separate structure. The defeatable seal/anchor being defeatable upon application of an axial load above a threshold.,GILL COOPER C;;MARTIN CARL S;;BAKER HUGHES INC,GILL COOPER C;;MARTIN CARL S,BAKER HUGHES INCORPORATED (2011-01-26),https://lens.org/060-574-979-504-329,Granted Patent,yes,42,4,3,3,0,F16L19/0656;;G02B6/4428;;F16L19/0656;;G02B6/4428,F16L19/06,285/342;;285/353;;166/242.6,5,3,072-486-506-857-541;;071-227-506-938-859;;020-916-610-538-509,10.2118/23147-ms;;10.2118/136948-ms;;10.2118/71676-ms,"Swagelok ""Gaugeable Tube Fittings and Adapter Fittings"", www.swagelok.com; Replacement Parts, Ferrules; Swagelok Company; Mar. 2010; pp. 1-66.;;Bjornstad et al. ""Fibre Optic Well Monitoring System,"" Offshore Europe, Sep. 3-6, 1991, Aberdeen, United Kingdom. [Abstract and Introduction Only].;;Jenkins, Dave. ""Underwater Mateable Connectors: Enabling Technology and the Next Step in Performance for Navy and Telecom Applications,"" Underwater Intervention Conference, 2002.;;Shawly et al. ""Successful Isolation of a Water Contribution Zone Using Fiber Optic Telemetry Enabled Coiled Tubing Conveyed Inflatable Packer Capped with Cement (Case Study),"" SPE/DGS Saudi Arabia Section Technical Symposium and Exhibition, Apr. 4-7, 2010, Al-Khobar, Saudi Arabia. [Abstract and Introduction Only].;;Tolan et al. ""The Use of Fiber-Optic Distributed Temperature Sensing and Remote Hydraulically Operated Interval Control Valves for the Management of Water Production in the Douglas Field,"" SPE Annual Technical Conference and Exhibition, Sep. 30-Oct. 3, 2001, New Orleans, Louisiana. [Abstract and Introduction Only].",ACTIVE
279,GB,A,GB 2404206 A,060-361-986-657-623,2005-01-26,2005,GB 0415569 A,2004-07-12,GB 0316991 A;;GB 0403608 A,2003-07-21,Ridge tile fixing kit,"A kit comprises a ridge tile clip (160) and a weather strip (100 where the clip includes a body (162, figure 16), two legs (164, 166, figure 16) each having a waist region (165, 167, figure 17) and being connected to the body such that each leg is bendable with respect to the body and a fixing receiving portion (172, figure 16) located on one side of the body and where the weather strip includes a planar member (119) with an upstanding web and projections extending from the opposing sides of the top of the web, the web having a fixing receiving portion. Preferably the weather strip web comprises a plurality of spaced fingers and the planar member includes at least one low wall defining a run off channel (68, Figure 10). Preferably the legs of the clip are hinged to the body. In use, the waist portions of a ridge clip allow the legs to be trapped between adjacent roof battens (180, 182), the weather strip locates around the edges of adjacent ridge tiles (figure 5), sealing the gap there between and the fixing receiving portions of both the clip and strip line up to receive a screw (184) to secure the ridge tiles to the roof.",PHI DESIGN LTD,NUNN ROBERT CHARLES;;COOPER ROGER MARTIN,,https://lens.org/060-361-986-657-623,Patent Application,no,6,2,8,10,0,E04D1/30;;E04D1/3402;;E04D1/365;;E04D13/174;;E04D2001/305;;E04D2001/306;;E04D1/3402;;E04D1/36;;E04D13/152;;E04D2001/306;;E04D1/30;;E04D2001/305;;E04D1/30;;E04D1/3402;;E04D2001/305;;E04D2001/306,E04D1/30;;E04D1/34;;E04D13/17,E1D DDJ2          FZDJ;;E1D DF112         FZDJ;;E1D DF124         FZDJ;;E1D D2055         FZDJ,0,0,,,,EXPIRED
280,US,S,US D0500958 S,108-222-904-453-863,2005-01-18,2005,US 17478903 F,2003-01-24,US 17478903 F;;US 14437602 F,2002-05-13,Timepiece face,,POINT 5 CONCEPTS LTD 8,COOPER MARTIN R;;TAYLOR KIMBERLY R,8 POINT 5 CONCEPTS LTD (2003-06-11),https://lens.org/108-222-904-453-863,Design Right,yes,25,5,1,1,0,,,D10/126,0,0,,,,EXPIRED
281,GB,A,GB 2191394 A,145-236-476-201-094,1987-12-16,1987,GB 8614482 A,1986-06-13,GB 8614482 A,1986-06-13,Body member with adjustably hinged support leg,"A generally flat body member (10), preferably the base of a computer keyboard, has a support leg (30) hinged along one edge (32) to the body member, to support the body member at one of a number of different heights. The pivotal position of the support leg (30) is controlled by a manually-operable locking mechanism (46, 47) which slides transversely of the support leg (30). The locking mechanism (46, 47), is indexed at specific transverse positions by sliding lengthwise of the support leg (30) into a locked position at which lands (475) on the locking mechanism (47) interlock with corresponding lands (110) on the body member (10). <IMAGE>",FUTURE INTERNATIONAL LIMITED,COOPER GEOFFREY MARTIN;;POKE MICHAEL JOHN,,https://lens.org/145-236-476-201-094,Patent Application,no,5,11,2,2,0,B41J5/105;;G06F3/0208,B41J5/10;;F16M11/10;;G06F3/02,A4L LCC           LCC4;;A4L LC4           LCC4;;A4L LC56          LCC4;;A4L L1004         LCC4;;A4L L118          LCC4;;B6F FMK7          MK7;;U1S S1224;;U1S S2123,0,0,,,,DISCONTINUED
282,US,A,US 5811824 A,108-692-384-174-436,1998-09-22,1998,US 68254396 A,1996-09-23,GB 9401354 A;;GB 9500139 W,1994-01-25,Method and an apparatus for testing whether a diamond has a layer of synthetic diamond deposited thereon,"In order to test whether a diamond 2 comprises synthetic diamond material, a plurality of different zones of the diamond 2 are irradiated with radiation substantially of wavelength substantially 230 nm to 320 nm, an image or reading of the radiation transmitted by each zone of the diamond 2 being produced.",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,GERSAN ESTABLISHMENT A CORP. OF LIECHTENSTEIN (1996-08-01),https://lens.org/108-692-384-174-436,Granted Patent,yes,14,30,17,17,0,G01N21/87;;G01N21/87,G01N21/87,250/559.4;;356/30,0,0,,,,EXPIRED
283,AU,A,AU 1995/014617 A,107-266-594-538-05X,1995-08-08,1995,AU 1995/014617 A,1995-01-25,GB 9401354 A;;GB 9500139 W,1994-01-25,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/107-266-594-538-05X,Patent Application,no,0,1,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
284,GB,A,GB 2286251 A,044-250-765-324-815,1995-08-09,1995,GB 9401354 A,1994-01-25,GB 9401354 A,1994-01-25,Examining a diamond for synthetic diamond,"In order to test whether a diamond 2 comprises synthetic diamond material, a plurality of different zones of the diamond 2 are irradiated with radiation of wavelength substantially 230 nm to 320 nm, an image or reading of the radiation transmitted by each zone of the diamond 2 being produced. UV light source 3, UV filter 9 and TV camera 7 are shown. The diamond 2 may be in an integrating sphere (21, Fig. 7). An image of the diamond may be viewed by eye on a UV conversion phosphor screen (31, Fig. 8). <IMAGE>",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/044-250-765-324-815,Patent Application,no,4,6,17,17,0,G01N21/87;;G01N21/87,G01N21/87,G1A AA9           MHL;;G1A AG17          MHL;;G1A AG6           MHL;;G1A AMHL          MHL;;G1A AR7           MHL;;G1A AT20          MHL;;G1A AT21          MHL;;G1A AT24          MHL;;G1A AT3           MHL;;G2J JX3           JX3,0,0,,,,EXPIRED
285,EP,B1,EP 0741862 B1,195-262-082-682-385,2000-03-22,2000,EP 95906420 A,1995-01-25,GB 9500139 W;;GB 9401354 A,1994-01-25,EXAMINING A DIAMOND,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/195-262-082-682-385,Granted Patent,yes,6,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
286,GB,A,GB 2219082 A,045-057-828-099-582,1989-11-29,1989,GB 8910420 A,1989-05-05,GB 8816165 A;;GB 8906853 A;;GB 8810723 A;;GB 8826225 A,1988-05-06,Identifying specific objects or zones,"In order to identify specific objects such as diamonds (or zones of an article), the objects 2 are subjected to an exciting radiation chosen such that the objects to be identified emit a weaker luminescence which is characteristic of the object and a stronger luminescence which is less characteristic of the object. The weaker luminescence is detected using a large aperture optical system 6-13 and a photo-multiplier tube 14. The stronger luminescence is detected more directly using a CCD array 20 or 20', which locates the track on the conveyor belt 1 from which the signal was emitted. In accordance with the track, the appropriate sort jet 23 is actuated when the PMT 14 and the CCD array 20, 20' give simultaneous signals. <IMAGE>",GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/045-057-828-099-582,Patent Application,no,0,1,10,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,G1A AA4           BG;;G1A AA4           CJ;;G1A AA6           BG;;G1A AA6           CJ;;G1A ABG           BG;;G1A ABGG          BGG;;G1A ACJ           CJ;;G1A ACJN          CJN;;G1A AD1           BG;;G1A AD1           CJ;;G1A AD10          BG;;G1A AD10          CJ;;G1A AD3           BG;;G1A AD3           CJ;;G1A AD6           BG;;G1A AD6           CJ;;G1A AG1           BG;;G1A AG1           CJ;;G1A AG2           BG;;G1A AG2           CJ;;G1A AG6           BG;;G1A AG6           CJ;;G1A AG9           BG;;G1A AG9           CJ;;G1A AP16          BG;;G1A AP16          CJ;;G1A AP17          BG;;G1A AP17          CJ;;G1A AP6           BG;;G1A AP6           CJ;;G1A AP9           BG;;G1A AP9           CJ;;G1A AR2           BG;;G1A AR2           CJ;;G1A AR7           BG;;G1A AR7           CJ;;G1A AS3           BG;;G1A AS3           CJ;;G1A AS4           BG;;G1A AS4           CJ;;G1A AT14          BG;;G1A AT14          CJ;;G1A AT23          BG;;G1A AT23          CJ;;G1A AT5           BG;;G1A AT5           CJ;;G1A AT7           BG;;G1A AT7           CJ;;G1A AT8           BG;;G1A AT8           CJ;;U1S S1488,0,0,,,,EXPIRED
287,EP,A1,EP 0741862 A1,146-994-954-946-306,1996-11-13,1996,EP 95906420 A,1995-01-25,GB 9500139 W;;GB 9401354 A,1994-01-25,EXAMINING A DIAMOND,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/146-994-954-946-306,Patent Application,yes,0,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
288,AU,B2,AU 688448 B2,176-969-580-916-420,1998-03-12,1998,AU 1995/014617 A,1995-01-25,GB 9401354 A;;GB 9500139 W,1994-01-25,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/176-969-580-916-420,Granted Patent,no,3,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
289,GB,B,GB 2286251 B,121-213-852-334-024,1997-07-09,1997,GB 9401354 A,1994-01-25,GB 9401354 A,1994-01-25,Examining a diamond for synthetic diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/121-213-852-334-024,Granted Patent,no,4,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,G1A AA9           MHL;;G1A AG17          MHL;;G1A AG6           MHL;;G1A AMHL          MHL;;G1A AR7           MHL;;G1A AT20          MHL;;G1A AT21          MHL;;G1A AT24          MHL;;G1A AT3           MHL;;G2J JX3           JX3,0,0,,,,EXPIRED
290,CA,A1,CA 2181988 A1,009-199-039-072-203,1995-07-27,1995,CA 2181988 A,1995-01-25,GB 9401354 A,1994-01-25,EXAMINING A DIAMOND,"In order to test whether a diamond (2) comprises synthetic diamond material, a plurality of different zones of the diamond (2) are irradiated with radiation substantially of wavelength substantially 230 nm to 320 nm, an image or reading of the radiation transmitted by each zone of the diamond (2) being produced.",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/009-199-039-072-203,Patent Application,no,0,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,DISCONTINUED
291,WO,A1,WO 1995/020152 A1,027-447-323-975-744,1995-07-27,1995,GB 9500139 W,1995-01-25,GB 9401354 A,1994-01-25,EXAMINING A DIAMOND,"In order to test whether a diamond (2) comprises synthetic diamond material, a plurality of different zones of the diamond (2) are irradiated with radiation substantially of wavelength substantially 230 nm to 320 nm, an image or reading of the radiation transmitted by each zone of the diamond (2) being produced.",GERSAN ETS;;SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/027-447-323-975-744,Patent Application,yes,6,1,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,PATENTED
292,ZA,B,ZA 95606 B,149-386-273-178-786,1995-12-12,1995,ZA 95606 A,1995-01-25,GB 9401354 A,1994-01-25,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;SMITH JAMES GORDON CHARTERS,,https://lens.org/149-386-273-178-786,Granted Patent,no,0,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
293,AU,A,AU 1989/034543 A,004-447-924-708-25X,1989-11-09,1989,AU 1989/034543 A,1989-05-08,GB 8810723 A;;GB 8816165 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,A METHOD OF IDENTIFYING SPECIFIC OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/004-447-924-708-25X,Patent Application,no,0,0,10,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,EXPIRED
294,BR,A,BR 8902138 A,137-434-496-376-016,1990-01-02,1990,BR 8902138 A,1989-05-08,GB 8810723 A;;GB 8816165 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,PROCESSO E APARELHO PARA IDENTIFICAR OBJETOS OU ZONAS ESPECIFICOS,,GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/137-434-496-376-016,Patent Application,no,0,0,10,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,DISCONTINUED
295,ES,T3,ES 2144121 T3,102-547-196-784-000,2000-06-01,2000,ES 95906420 T,1995-01-25,GB 9401354 A,1994-01-25,EXAMINANDO UN DIAMANTE.,"PARA PROBAR SI UN DIAMANTE (2) INCORPORA MATERIAL DE DIAMANTE SINTETICO, SE IRRADIAN UNA PLURALIDAD DE DISTINTAS ZONAS DEL DIAMANTE CON UNA RADIACION SUSTANCIALMENTE DE UNA LONGITUD DE ONDA SUSTANCIALMENTE ENTRE 230 NM A 320 NM, PRODUCIENDOSE UNA IMAGEN O LECTURA DE LA RADIACION TRASMITIDA POR CADA ZONA DEL DIAMANTE.",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN,,https://lens.org/102-547-196-784-000,Granted Patent,no,0,0,17,17,0,G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
296,IN,B,IN 174052 B,157-635-336-008-456,1994-09-03,1994,IN 359MA1989 A,1989-05-08,GB 8810723 A,1988-05-06,Apparatus for identifying specific objects of zones,,GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/157-635-336-008-456,Granted Patent,no,0,0,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
297,GB,B,GB 2219082 B,156-686-718-587-717,1992-08-26,1992,GB 8910420 A,1989-05-05,GB 8816165 A;;GB 8906853 A;;GB 8810723 A;;GB 8826225 A,1988-05-06,A METHOD OF IDENTIFYING SPECIFIC OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/156-686-718-587-717,Granted Patent,no,0,0,10,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,G1A AA4           BG;;G1A AA4           CJ;;G1A AA6           BG;;G1A AA6           CJ;;G1A ABG           BG;;G1A ACJ           CJ;;G1A AD1           BG;;G1A AD1           CJ;;G1A AD10          BG;;G1A AD10          CJ;;G1A AD3           BG;;G1A AD3           CJ;;G1A AD6           BG;;G1A AD6           CJ;;G1A AG1           BG;;G1A AG1           CJ;;G1A AG2           BG;;G1A AG2           CJ;;G1A AG6           BG;;G1A AG6           CJ;;G1A AG9           BG;;G1A AG9           CJ;;G1A AP16          BG;;G1A AP16          CJ;;G1A AP17          BG;;G1A AP17          CJ;;G1A AP6           BG;;G1A AP6           CJ;;G1A AP9           BG;;G1A AP9           CJ;;G1A AR2           BG;;G1A AR2           CJ;;G1A AR7           BG;;G1A AR7           CJ;;G1A AS3           BG;;G1A AS3           CJ;;G1A AS4           BG;;G1A AS4           CJ;;G1A AT14          BG;;G1A AT14          CJ,0,0,,,,EXPIRED
298,EP,A2,EP 0341092 A2,024-418-481-673-221,1989-11-08,1989,EP 89304635 A,1989-05-08,GB 8810723 A;;GB 8816165 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,A method of identifying specific objects or zones.,"In order to identify specific objects such as diamonds (or zones of an article), the objects 2 are subjected to an exciting radiation chosen such that the objects to be identified emit a weaker luminescence which is characteristic of the object and a stronger luminescence which is less characteristic of the object. The weaker luminescence is detected using a large aperture optical system 6-13 and a photo-multiplier tube 14. The stronger luminescence is detected more directly using a CCD array 20 or 20′, which locates the track on the conveyer belt 1 from which the signal was emitted. In accordance with the track, the appropriate sort jet 23 is actuated when the PMT 14 and the CCD array 20, 20′ give simultaneous signals.  ",GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/024-418-481-673-221,Patent Application,yes,0,3,10,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,DISCONTINUED
299,EP,A3,EP 0341092 A3,051-565-625-045-574,1991-02-27,1991,EP 89304635 A,1989-05-08,GB 8810723 A;;GB 8816165 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,A METHOD OF IDENTIFYING SPECIFIC OBJECTS OR ZONES,"In order to identify specific objects such as diamonds (or zones of an article), the objects 2 are subjected to an exciting radiation chosen such that the objects to be identified emit a weaker luminescence which is characteristic of the object and a stronger luminescence which is less characteristic of the object. The weaker luminescence is detected using a large aperture optical system 6-13 and a photo-multiplier tube 14. The stronger luminescence is detected more directly using a CCD array 20 or 20′, which locates the track on the conveyer belt 1 from which the signal was emitted. In accordance with the track, the appropriate sort jet 23 is actuated when the PMT 14 and the CCD array 20, 20′ give simultaneous signals.  ",GERSAN ESTABLISHMENT,"SMITH, MARTIN PHILLIP;;COOPER, MARTIN;;WELBOURN, CHRISTOPHER MARK;;SPEAR, PAUL MARTIN",,https://lens.org/051-565-625-045-574,Search Report,yes,6,0,10,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,DISCONTINUED
300,AU,A,AU 1999/063556 A,190-974-613-629-342,2000-05-15,2000,AU 1999/063556 A,1999-10-22,GB 9823029 A;;GB 9903516 W,1998-10-22,Packaging system for mixing and dispensing multicomponent products,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,,https://lens.org/190-974-613-629-342,Patent Application,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,DISCONTINUED
301,US,A1,US 2024/0026662 A1,019-037-418-709-340,2024-01-25,2024,US 202318354291 A,2023-07-18,US 202318354291 A;;US 202263390742 P,2022-07-20,HEATER AND CONTROL SYSTEM FOR A HEATING SYSTEM,A heating and pumping system is disclosed. The system may be usable in a portable sink that includes a clean water source having incorporated therein the system with a submersible heater. The heater may include an enclosed heating element that transfers thermal energy (heat) to the water in the clean tank. A powered and/or automatic pump may be provided to move water relative to the heater. A controller with the system may control the operation of the heater and/or the pump to achieve the selected temperature of the clean water.,POLYJOHN ENTPR LLC,ZELTNER MARTIN;;COOPER MICHAEL SCOT;;SHEIKHTAHERI ARASH,POLYJOHN ENTERPRISES LLC (2023-08-02),https://lens.org/019-037-418-709-340,Patent Application,yes,0,0,1,2,0,E03C1/044;;E03C1/182;;E03C1/182;;E03C1/044,E03C1/044;;E03C1/182,,0,0,,,,PENDING
302,CA,C,CA 2338366 C,156-214-466-713-231,2008-01-08,2008,CA 2338366 A,1999-10-22,GB 9823029 A;;GB 9903516 W,1998-10-22,PACKAGING SYSTEM FOR MIXING AND DISPENSING MULTICOMPONENT PRODUCTS,"A packaging system which comprises a first container having a valve controlling the opening of an outlet and which contains a first ingredient, and a second container having an openable entry portion and containing a second ingredient. The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,,https://lens.org/156-214-466-713-231,Granted Patent,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B65D81/32;;B05B9/04;;B65D83/14,,0,0,,,,EXPIRED
303,DK,T3,DK 1127016 T3,075-681-429-150-86X,2004-01-26,2004,DK 99950970 T,1999-10-22,GB 9823029 A;;GB 9903516 W,1998-10-22,Emballagesystem til blanding og afgivelse af flerkomponentprodukter,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,,https://lens.org/075-681-429-150-86X,Granted Patent,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,EXPIRED
304,EP,B1,EP 1127016 B1,081-016-944-143-629,2003-09-17,2003,EP 99950970 A,1999-10-22,GB 9903516 W;;GB 9823029 A,1998-10-22,PACKAGING SYSTEM FOR MIXING AND DISPENSING MULTICOMPONENT PRODUCTS,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,,https://lens.org/081-016-944-143-629,Granted Patent,yes,4,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,EXPIRED
305,AT,T1,AT E249985 T1,014-778-337-209-295,2003-10-15,2003,AT 99950970 T,1999-10-22,GB 9823029 A;;GB 9903516 W,1998-10-22,VERPACKUNGSSYSTEM ZUR MISCHUNG UND ABGABE VON MEHRKOMPONENTENPRODUKTEN,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,,https://lens.org/014-778-337-209-295,Granted Patent,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,PENDING
306,WO,A1,WO 1994/015448 A1,021-769-033-892-506,1994-07-21,1994,EP 9303610 W,1993-12-17,GB 9300142 A,1993-01-06,TREATMENT OF PLANT MATERIAL,"Pathogenic fungal infection, especially Fusarium oxysporum, is eradicated from oil palm seeds by applying fungicide solution using vacuum infiltration such that an effective amount of the fungicide is found between the shell and kernel of the seed.",UNILEVER PLC;;UNILEVER NV,COOPER RICHARD MARTIN;;FLOOD JULIE;;MEPSTED ROGER,,https://lens.org/021-769-033-892-506,Patent Application,yes,0,4,3,3,0,A01C1/06,A01C1/06,,6,0,,,"CHEMICAL ABSTRACTS, vol. 88, no. 21, 22 May 1978, Columbus, Ohio, US; abstract no. 150906f, F.HIRSCHBERG ET. AL.: ""Preservation of oil seeds by infiltration under vacuum"" page 467;;G.E.HARMAN ET. AL.: ""Soaking Brassica seeds in fungicide solutions to eradicate seedborne fungi: A comparison of aqueous and organic solvent techniques"", PLANT DISEASE REPORTER, vol. 62, no. 5, May 1978 (1978-05-01), pages 408 - 412;;S.T. DE BARROS ET. AL.: ""Influence of fungicides on the control of Colletotrichum lindemuthanium Scrib, artificially inoculated on seeds of cowpea, Vigna unguiculata (L.) Walp, cultivar alagoano"", FITOPATOLOGIA BRASILEIRA, vol. 6, no. 3, 1981, BR, pages 465 - 468;;H.P.NANDA ET. AL.: ""Modern approach to control seedling infection of rice due to fungal diseases"", INTERNATIONAL JOURNAL OF TROPICAL PLANT DISEASES, vol. 1, no. 2, 1983, pages 157 - 161;;CENTRAL PATENTS INDEX, BASIC ABSTRACTS JOURNAL Section Ch Week 8113, Derwent World Patents Index; Class C, AN 3828;;G.MARINESCU: ""Méthodes et pesticides utilisés dans la destruction des bactéries phytopathogènes du matériel semencier de légumes"", BULLETIN DE L ACADEMIE DES SCIENCES AGRICOLES ET FORESTIÈRES, no. 11, 1982, pages 107 - 112",PENDING
307,EP,A1,EP 0428609 A1,157-400-597-041-864,1991-05-29,1991,EP 89909587 A,1989-08-15,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION.,"Pour procéder à un taillage allongé (1) dans un diamant à l'aide d'un rayonnement laser, on utilise un système optique cylindrique (5, 6) faisant converger le rayonnement à un angle de convergence supérieur dans le plan de la taille (1) par rapport au plan transversal. Ainsi, on augmente la densité de l'énergie du point focal et la taille en profondeur est plus efficace.",GERSAN ANSTALT,COOPER MARTIN;;STEWART ANDREW DAVID GARRY THE,ANSTALT GERSAN (1993-03-31),https://lens.org/157-400-597-041-864,Patent Application,yes,0,0,13,30,0,B23K26/364;;B23K26/364,B23K26/06;;B23K26/00;;B23K26/073;;B23K26/36,,0,0,,,,EXPIRED
308,EP,A1,EP 1127016 A1,061-546-956-459-658,2001-08-29,2001,EP 99950970 A,1999-10-22,GB 9903516 W;;GB 9823029 A,1998-10-22,PACKAGING SYSTEM FOR MIXING AND DISPENSING MULTICOMPONENT PRODUCTS,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,,https://lens.org/061-546-956-459-658,Patent Application,yes,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,EXPIRED
309,DE,D1,DE 69819723 D1,009-941-845-661-225,2003-12-18,2003,DE 69819723 T,1998-06-10,GB 9712172 A;;US 9811616 W,1997-06-11,VERARBEITUNG VON ZWISCHEN ELEMENTEN EINES TELEKOMMUNIKATIONSNETZWERKS ÜBERTRAGENEN TELEKOMMUNIKATIONSSIGNALEN,,AIRSPAN NETWORKS INC,COOPER L;;THOMPSON A;;LYSEJKO MARTIN;;YEUNG CHI;;WALDING M;;COOPER A,"AIRSPAN NETWORKS INC., BOCA RATON, FLORIDA, US (2004-09-02)",https://lens.org/009-941-845-661-225,Granted Patent,no,0,0,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,,0,0,,,,EXPIRED
310,US,B1,US 6435231 B1,171-386-138-445-05X,2002-08-20,2002,US 78696901 A,2001-03-12,GB 9823029 A;;GB 9903516 W,1998-10-22,Packaging system for mixing and dispensing multicomponent products,"
    A packaging system which comprises a first container (  24  ) having a valve (  27  ) controlling the opening of an outlet and which contains a first ingredient (  25  ), and a second container (  28  ) having an openable entry portion (  14  ) and containing a second ingredient (  29  ). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product. 
",GILTECH LTD,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,GILTECH LIMITED (2000-12-13),https://lens.org/171-386-138-445-05X,Granted Patent,yes,11,56,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,141/346;;141/18;;141/20;;141/107;;141/349;;141/369;;141/386,0,0,,,,EXPIRED
311,TW,A,TW 201823235 A,018-945-591-374-65X,2018-07-01,2018,TW 106129555 A,2017-08-30,US 201662382153 P,2016-08-31,Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate,"The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.",TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN;;SHARP EMMA KAY,,https://lens.org/018-945-591-374-65X,Patent of Addition,no,0,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,C07D403/12;;A61K31/4178;;A61P1/16,,0,0,,,,PENDING
312,AU,A,AU 1994/058136 A,167-234-934-111-547,1994-08-15,1994,AU 1994/058136 A,1993-12-17,EP 9303610 W;;GB 9300142 A,1993-01-06,Treatment of plant material,,UNILEVER PLC,COOPER RICHARD MARTIN;;FLOOD JULIE;;MEPSTED ROGER,,https://lens.org/167-234-934-111-547,Patent Application,no,0,0,3,3,0,A01C1/06,A01C1/06,,0,0,,,,PENDING
313,ES,T3,ES 2207294 T3,077-208-099-408-272,2004-05-16,2004,ES 99950970 T,1999-10-22,GB 9823029 A,1998-10-22,SISTEMA DE ENVASADO PARA MEZCLAR Y DISPENSAR PRODUCTOS MULTICOMPONENTE.,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,,https://lens.org/077-208-099-408-272,Granted Patent,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,EXPIRED
314,DE,D1,DE 69609867 D1,162-695-321-838-030,2000-09-21,2000,DE 69609867 T,1996-06-03,GB 9510870 A;;GB 9511167 A;;GB 9511189 A;;GB 9511192 A;;GB 9511546 A;;GB 9513168 A;;GB 9513172 A;;GB 9513166 A;;GB 9513170 A;;US 9608565 W,1995-06-02,GERÄT UND VERFAHREN ZUM AUFBAUEN UND ERHALTEN VON ÜBERTRAGUNGSWEGEN IN EINEM DRAHTLOSEN NACHRICHTENÜBERTRAGUNGSSYSTEM,,AIRSPAN COMM CORP,YEUNG CHI;;THOMPSON ANDREW;;BHAGALIA SHASHIKANT;;COOPER LESLIE;;LYSEJKO MARTIN;;COOPER ALEXANDER,"AIRSPAN NETWORKS INC. PTSGE CORP., SEATTLE, WASH., (2000-11-16)",https://lens.org/162-695-321-838-030,Granted Patent,no,0,0,8,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/0631;;H04L41/069;;H04L41/0816;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14;;H04L69/32;;H04L69/325;;H04L69/324,G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J3/06;;H04J11/00;;H04J13/00;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04L29/08;;H04Q11/04;;H04W52/00;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
315,WO,A2,WO 2024/020066 A2,047-761-307-626-043,2024-01-25,2024,US 2023/0028096 W,2023-07-19,US 202263390742 P;;US 202318354291 A,2022-07-20,HEATER AND CONTROL SYSTEM FOR A HEATING SYSTEM,A heating and pumping system is disclosed. The system may be usable in a portable sink that includes a clean water source having incorporated therein the system with a submersible heater. The heater may include an enclosed heating element that transfers thermal energy (heat) to the water in the clean tank. A powered and/or automatic pump may be provided to move water relative to the heater. A controller with the system may control the operation of the heater and/or the pump to achieve the selected temperature of the clean water.,POLYJOHN ENTPR LLC,ZELTNER MARTIN;;COOPER MICHAEL SCOT;;SHEIKHTAHERI ARASH,,https://lens.org/047-761-307-626-043,Patent Application,yes,0,0,1,2,0,A47K1/02;;E03B11/02,A47K1/02,,0,0,,,,PENDING
316,US,B2,US 7423931 B2,019-665-777-564-275,2008-09-09,2008,US 85524304 A,2004-05-26,US 85524304 A;;US 48546603 P,2003-07-08,Acoustic system for communication in pipelines,"A system for communication in a pipe, or pipeline, or network of pipes containing a fluid. The system includes an encoding and transmitting sub-system connected to the pipe, or pipeline, or network of pipes that transmits a signal in the frequency range of 3-100 kHz into the pipe, or pipeline, or network of pipes containing a fluid, and a receiver and processor sub-system connected to the pipe, or pipeline, or network of pipes containing a fluid that receives said signal and uses said signal for a desired application.",L LIVERMORE NAT SECURITY LLC,MARTIN II LOUIS PETER;;COOPER JOHN F,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (2004-05-12);;LAWRENCE LIVERMORE NATIONAL SECURITY LLC (2007-09-24),https://lens.org/019-665-777-564-275,Granted Patent,yes,14,40,2,7,0,G01F1/667;;G01F1/667;;H04B13/00;;H04B13/00,E21B47/18;;G01F1/66;;H04B13/00,367/83;;340/870.01,0,0,,,,INACTIVE
317,CA,A1,CA 2338366 A1,026-168-733-895-175,2000-05-04,2000,CA 2338366 A,1999-10-22,GB 9823029 A;;GB 9903516 W,1998-10-22,PACKAGING SYSTEM FOR MIXING AND DISPENSING MULTICOMPONENT PRODUCTS,"A packaging system which comprises a first container (24) having a valve (27 ) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into th e second container via the entry portion thereof, so that said first and secon d ingredients are admixed in said second container to form a final product.</S DOAB>",GILTECH LTD,HEALY DAVID MICHAEL;;COOPER MATTHEW MARTIN DEROME,,https://lens.org/026-168-733-895-175,Patent Application,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,EXPIRED
318,PT,E,PT 1127016 E,071-982-990-791-690,2004-02-27,2004,PT 99950970 T,1999-10-22,GB 9823029 A,1998-10-22,SISTEMA DE EMBALAGEM PARA MISTURA E DISTRIBUICAO DE PRODUTOS DE COMPONENTES MULTIPLOS,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD,HEALY DAVID MICHAEL;;COOPER MATTHEW MARTIN DEROME,,https://lens.org/071-982-990-791-690,Granted Patent,no,0,0,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,EXPIRED
319,DE,T2,DE 69819723 T2,105-173-247-853-471,2004-10-14,2004,DE 69819723 T,1998-06-10,GB 9712172 A;;US 9811616 W,1997-06-11,VERARBEITUNG VON ZWISCHEN ELEMENTEN EINES TELEKOMMUNIKATIONSNETZWERKS ÜBERTRAGENEN TELEKOMMUNIKATIONSSIGNALEN,,AIRSPAN NETWORKS INC,COOPER L;;THOMPSON A;;LYSEJKO MARTIN;;YEUNG CHI;;WALDING M;;COOPER A,"AIRSPAN NETWORKS INC., BOCA RATON, FLORIDA, US (2004-09-02)",https://lens.org/105-173-247-853-471,Granted Patent,no,0,0,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,,0,0,,,,EXPIRED
320,WO,A1,WO 2000/024649 A1,037-282-299-694-319,2000-05-04,2000,GB 9903516 W,1999-10-22,GB 9823029 A;;US 83624697 A,1997-05-07,PACKAGING SYSTEM FOR MIXING AND DISPENSING MULTICOMPONENT PRODUCTS,"A packaging system which comprises a first container (24) having a valve (27) controlling the opening of an outlet and which contains a first ingredient (25), and a second container (28) having an openable entry portion (14) and containing a second ingredient (29). The packaging system further comprises means for connecting the first and second containers together in order to allow said first ingredient to be displaced from the first container into the second container via the entry portion thereof, so that said first and second ingredients are admixed in said second container to form a final product.",GILTECH LTD;;COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,COOPER MATTHEW MARTIN DEROME;;HEALY DAVID MICHAEL,,https://lens.org/037-282-299-694-319,Patent Application,yes,4,31,16,16,0,B65D81/3211;;B65D83/42;;B65D83/60;;B65D83/682;;B65D83/60;;B65D81/3211;;B65D83/42;;B65D83/682,B05B9/04;;B65D81/32;;B65D83/14,,0,0,,,,PATENTED
321,IN,B,IN 182224 B,131-370-062-988-738,1999-02-06,1999,IN 374MA1993 A,1993-06-01,GB 9211734 A,1992-06-03,Apparatus for detecting diamonds in a rock sample,,GERSAN ETS,ROONEY;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,,https://lens.org/131-370-062-988-738,Granted Patent,no,0,1,11,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083,G01N23/14;;G01N33/38,,0,0,,,,EXPIRED
322,JP,A,JP 2003102485 A,090-343-097-799-436,2003-04-08,2003,JP 2002176686 A,2002-06-18,GB 0114869 A;;US 30534601 P,2001-06-18,WOUND HEALING BIOMARKER,"PROBLEM TO BE SOLVED: To provide a biomarker participating in a wound healing process and provide a use of the biomarker. SOLUTION: The invention provides a gene confirmed to have participation in a wound healing process and a biomarker such as a corresponding mRNA transcript or a protein product. It further provides a method for the identification of a compound useful for the treatment of wound, wound healing disturbance or inflammation, the compound identified by the method, a method for monitoring the progress of the healing of wound and a method for confirming the individual accompanying the wound healing disturbance.",PFIZER,BURSLEM MARTIN F;;JOHNSON CLAIRE MICHELLE;;COOPER LISA;;MARTIN PAUL,,https://lens.org/090-343-097-799-436,Patent Application,no,0,2,5,6,39,A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;A61P29/00;;C12Q1/6883;;C12Q1/6883;;C07K14/47;;C07K14/47;;C12Q2600/158;;C12Q2600/158;;G01N33/5091;;G01N33/5091;;G01N33/6893;;G01N33/6893;;G01N33/86;;G01N33/86;;G01N33/92;;G01N33/92,A61K45/00;;A61K48/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;C07K14/47;;C12N15/09;;C12Q1/02;;C12Q1/68;;G01N33/15;;G01N33/50;;G01N33/68;;G01N33/86;;G01N33/92,,0,0,,,,PENDING
323,ZA,B,ZA 893367 B,092-095-026-798-666,1991-01-30,1991,ZA 893367 A,1989-05-08,GB 8810723 A,1988-05-06,IDENTIFYING THE POSITION OF OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;MARTIN PHILLIP SMITH;;SMITH ROBIN WYNCLIFFE;;ROBIN WYNCLIFFE SMITH;;COOPER MARTIN;;MARTIN COOPER;;WELBOURN CHRISTOPHER MARK;;CHRISTOPHER MARK WELBOURN;;SPEAR PAUL MARTIN;;PAUL MARTIN SPEAR,,https://lens.org/092-095-026-798-666,Granted Patent,no,0,0,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
324,AU,B2,AU 623140 B2,097-604-247-043-325,1992-05-07,1992,AU 1989/034543 A,1989-05-08,GB 8810723 A;;GB 8816165 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,IDENTIFYING OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTYN,,https://lens.org/097-604-247-043-325,Granted Patent,no,1,1,10,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,EXPIRED
325,ES,T3,ES 2126312 T3,067-395-426-077-268,1999-03-16,1999,ES 95930636 T,1995-09-05,GB 9418050 A,1994-09-07,EXAMEN DE UN DIAMANTE.,"PARA EXAMINAR SI UN DIAMANTE (3) HA TENIDO UNA CAPA DE UN MATERIAL DE DIAMANTE SINTETICO SOBRE EL MISMO, SE OBSERVA UNA RADIACION DE INFRARROJOS QUE INCLUYE UNA RADIACION DE LONGITUD DE ONDA ESENCIALMENTE ENTRE 7 {MI}M Y 25{MI}NM, PREFERIBLEMENTE ENTRE 7 {MI}M Y 10{MI} M, EMITIDA O TRANSMITIDA POR EL DIAMANTE PARA DETECTAR LAS DIFERENCIAS ENTRE LAS COMPOSICIONES DE ZONAS DIFERENTES DEL DIAMANTE (3).",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,,https://lens.org/067-395-426-077-268,Granted Patent,no,0,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
326,ZA,B,ZA 875592 B,094-033-559-588-900,1988-08-31,1988,ZA 875592 A,1987-07-29,GB 8618398 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;GORDON HANLEY PHILLIPPS;;JONES PAUL SPENCER;;PAUL SPENCER JONES;;COOPER MARTIN EDWARD;;MARTIN EDWARD COOPER,,https://lens.org/094-033-559-588-900,Granted Patent,no,0,0,4,51,0,,C07D471/04;;A61K/;;A61K31/47;;A61P35/00;;C07F/;;C07F9/09,,0,0,,,,EXPIRED
327,EE,A,EE 200000318 A,002-919-844-146-63X,2001-08-15,2001,EE P200000318 A,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,Uudsed ühendid,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/002-919-844-146-63X,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,PENDING
328,BR,A,BR 8203874 A,021-053-717-372-137,1983-06-28,1983,BR 8203874 A,1982-07-01,DE 3126021 A,1981-07-02,PROCESSO PARA OBTENCAO DE ACIDO LATICO D OU L OTICAMENTE PURO,,BASF AG,COOPER BRYAN;;KUESTERS WERNER;;MARTIN CHRISTOPH;;SIEGEL HARDO,,https://lens.org/021-053-717-372-137,Patent Application,no,0,0,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,,0,0,,,,DISCONTINUED
329,EP,B1,EP 0975636 B1,024-550-206-150-168,2003-07-23,2003,EP 98917859 A,1998-04-07,SE 9800640 W;;SE 9701398 A,1997-04-15,"1H-PYRAZOLO[3,4-D]PYRIMIDINE-4,6-DIONES AS T-CELL PROLIFERATION INHIBITORS",,ASTRAZENECA AB,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,ASTRAZENECA AB (2000-08-30);;ASTRAZENECA UK LIMITED (2000-05-10),https://lens.org/024-550-206-150-168,Granted Patent,yes,5,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,1,0,,,"J. MED. CHEM., Volume 38, 1995, WILLIAM F. MICHNE et al., ""Novel Inhibitors of the Nuclear Factor of Activated T Cells (NFAT)-Mediated Transcription of beta-Galactosidase: Potential Immunosuppressive and Antiinflammatory Agents"", pages 2557-2569.",EXPIRED
330,DK,T3,DK 1107973 T3,042-233-409-834-264,2004-02-23,2004,DK 99944964 T,1999-08-18,SE 9802895 A;;SE 9901400 W,1998-08-28,"Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi","Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/042-233-409-834-264,Granted Patent,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,EXPIRED
331,EP,A1,EP 1033041 A1,049-455-532-709-643,2000-09-06,2000,EP 98954584 A,1998-11-13,GB 9803420 W;;GB 9724612 A,1997-11-20,SUBSCRIBER TERMINAL FOR WIRELESS TELECOMMUNICATIONS SYSTEM,,AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/049-455-532-709-643,Patent Application,yes,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,1,0,,,See references of WO 9927720A1,EXPIRED
332,US,A,US 3175193 A,048-061-263-956-639,1965-03-23,1965,US 3967560 A,1960-06-29,US 3967560 A,1960-06-29,Traffic signal synchronizing system,,MOTOROLA INC,WILLYARD CHARLES H;;MARTIN COOPER;;TUREK CLARENCE W,,https://lens.org/048-061-263-956-639,Granted Patent,no,12,7,1,1,0,G08G1/081;;G08G1/081,G08G1/081,,0,0,,,,EXPIRED
333,DE,T2,DE 69623013 T2,106-928-740-024-027,2002-12-12,2002,DE 69623013 T,1996-06-03,GB 9511167 A;;GB 9510870 A;;GB 9511192 A;;GB 9511189 A;;US 9608659 W,1995-06-02,STEUERNACHRICHTENUEBERTRAGUNG IN TELEKOMMUNIKATIONSSYSTEMEN,,AIRSPAN NETWORKS INC,YEUNG CHI;;THOMPSON ANDREW;;LYSEJKO MARTIN;;COOPER ALEXANDER,"AIRSPAN NETWORKS INC., BOCA RATON, FLORIDA, US (2004-06-17)",https://lens.org/106-928-740-024-027,Granted Patent,no,0,0,8,251,0,H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04L12/403;;H04L41/0226;;H04L41/0233;;H04L41/0654;;H04L41/0677;;H04L41/069;;H04L41/22;;H04L63/08;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/13199;;H04Q2213/13216;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/52;;H04W84/14;;H04L69/08;;H04L69/32;;H04B1/7073;;H04L69/08;;H04L69/32,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04L12/24;;H04L12/28;;H04L12/403;;H04L29/06;;H04L29/08;;H04W52/04;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
334,EP,A1,EP 1107973 A1,136-706-710-774-841,2001-06-20,2001,EP 99944964 A,1999-08-18,SE 9901400 W;;SE 9802895 A,1998-08-28,NOVEL COMPOUNDS,"Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/136-706-710-774-841,Patent Application,yes,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,EXPIRED
335,ES,T3,ES 2605205 T3,171-716-176-289-181,2017-03-13,2017,ES 09723661 T,2009-03-26,US 3975208 P;;US 2009/0001956 W,2008-03-26,Formas sólidas de clorhidrato de bendamustina,"Una forma sólida de clorhidrato de bendamustina que es la Forma 1 y que produce un patrón de difracción de rayos X de polvo que comprende las siguientes reflexiones: 25,1, 22,9, 22,0, 18,5, 16,8 y 14,1 ± 0,2 grados 2θ.",CEPHALON INC,COOPER MARTIN;;COURVOISIER LAURENT;;EDDLESTON MARK;;MCKEAN ROBERT,,https://lens.org/171-716-176-289-181,Granted Patent,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/14;;A61K9/19;;A61K31/4184,,0,0,,,,ACTIVE
336,NO,L,NO 995006 L,191-077-222-796-641,1999-10-14,1999,NO 995006 A,1999-10-14,SE 9701398 A;;SE 9800640 W,1997-04-15,Nye forbindelser,"Farmasøytisk nyttige pyra2o]o[3,4-d]pyrimidindionforbindelser av formel (I) w / N-R (D fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende slike forbindelser, og deres anvendelse for behandling av forskjellige sykdommer.",ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/191-077-222-796-641,Abstract,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
337,AT,T1,AT E253580 T1,190-839-266-933-152,2003-11-15,2003,AT 99944964 T,1999-08-18,SE 9802895 A;;SE 9901400 W,1998-08-28,"NEUE THIENO(2,3-D)PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE","Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/190-839-266-933-152,Granted Patent,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,DISCONTINUED
338,EP,A1,EP 0594600 A1,031-892-521-679-225,1994-05-04,1994,EP 91905827 A,1991-03-13,GB 9005672 A;;GB 9008507 A;;GB 9008556 A;;GB 9009480 A;;GB 9017447 A;;GB 9023242 A;;GB 9100393 W,1990-03-13,IMMUNOSUPPRESSIVE MACROCYCLIC COMPOUNDS.,"On décrit des composés de formule (I), dans laquelle R1 représente H, OH ou alkoxy; R2 représente H; de plus, R1 et R2 peuvent ensemble représenter une deuxième liaison entre les atomes de carbone auxquels ils sont liés; R3 représente méthyle, éthyle, propyle ou allyle; R4 représente H, OH, alkyle, alkoxy, halogène, amino, S-alkyle, NHCHO ou NHCO-alkyle; n représente 1 ou 2; X représente O, (H, OH), (H, H) ou = NH; et Y représente un groupe cyclohexyle facultativement substitué ou un groupe cyclopentyle substitué; sous réserve de respecter certaines conditions. Les composés sont utiles, entre autres, comme agents immunosuppresseurs.",FISONS PLC,DONALD DAVID KEITH;;FURBER MARK;;COOPER MARTIN EDWARD,,https://lens.org/031-892-521-679-225,Patent Application,yes,0,0,4,12,0,A61P37/06;;C07D498/18;;C07H19/01,A61K31/40;;A61K31/435;;A61P37/06;;C07D498/18;;C07H19/01,,1,0,,,See references of WO 9113889A1,DISCONTINUED
339,SE,D0,SE 9902903 D0,056-945-073-284-281,1999-08-13,1999,SE 9902903 A,1999-08-13,SE 9902903 A,1999-08-13,Novel compounds,,ASTRA PHARMA PROD,PERRY MATTHEW;;BANTICK JOHN;;COOPER MARTIN;;KINCHIN ELIZABETH,,https://lens.org/056-945-073-284-281,Patent Application,no,0,0,1,1,0,,C07D/,,0,0,,,,PENDING
340,EP,B1,EP 1107973 B1,091-280-320-175-310,2003-11-05,2003,EP 99944964 A,1999-08-18,SE 9901400 W;;SE 9802895 A,1998-08-28,"NOVEL THIENO[2,3-d]PYRIMIDINEDIONES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THERAPY","Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/091-280-320-175-310,Granted Patent,yes,2,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,2,0,,,"CHEMICAL ABSTRACTS, vol. 112, no. 15, 1990, Columbus, Ohio, US; abstract no. 112:139045T, HIROSHI F. ET AL: 'Preparation of Thienopyrimidine-2,4-Diones as Allergy Inhibitors' page 722; XP002921999 & JP 1 213 284 A 28 August 1989;;GÜTSCHOW M.: '3-Mercaptoalkylthieno(2,3-d)Pyrimidin-2,4( 1H,3H)-Dione: Synthese und Prufung auf Immunstimulatorische Wirksamkeit' ARCH. PHARM. (WEINHEIM) vol. 328, 02 August 1994, pages 231 - 234, XP002922000",EXPIRED
341,NO,L,NO 20002087 L,182-643-646-681-407,2000-07-20,2000,NO 20002087 A,2000-04-19,GB 9724612 A;;GB 9803420 W,1997-11-20,Abonnentterminal for trÕdløst telekommunikasjonssystem,En abonnentterminal for kommunikasjon over en trådløs forbindelse med en sentral terminal i et trådløst telekommunikasjonssystem omfatter en første signalbehandlende enhet (110) knyttet til en antenne (100) for å sende og motta signaler over den trådløse forbindelse ved første frekvenser innenfor et arbeidsfrekvensbånd. Den første signal- behandlende enhet omfatter en frekvensomformer for å omforme signaler mellom nevnte første frekvenser og en andre frekvens. Videre er det anordnet en andre signalbehand- lende enhet (130) fjernt fra den første signalbehandlende enhet og knyttet til en tele- kommunikasjonsutstyrsenhet (150) for å overføre signaler mellom telekommunikasjons- utstyrsenheten og den første signalbehandlende enhet. Den andre signalbehandlende enhet er dannet av signalbehandlende kretsutstyr som er uavhengig av arbeidsfrekvens- båndet på et forbindelsesmedium (120).,AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/182-643-646-681-407,Abstract,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,DISCONTINUED
342,DE,D1,DE 69806633 D1,183-246-032-263-291,2002-08-22,2002,DE 69806633 T,1998-11-13,GB 9724612 A;;GB 9803420 W,1997-11-20,TEILNEHMERENDGERÄT FÜR EIN DRAHTLOSES TELEKOMMUNIKATIONSSYSTEM,,AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,"AIRSPAN NETWORKS INC., BOCA RATON, FLORIDA, US (2004-05-27)",https://lens.org/183-246-032-263-291,Granted Patent,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,EXPIRED
343,US,A,US 6028074 A,034-200-788-807-360,2000-02-22,2000,US 6830498 A,1998-05-07,SE 9701398 A;;SE 9800640 W,1997-04-15,"Pyrazolo[3,4-d]pyrimidineone compounds","The invention relates to pharmaceutically useful pyrazolo[3,4-d]pyrimidinedione compounds, processes for their production, pharmaceutical compositions containing them and their use for the treatment of various diseases.",ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,ASTRAZENECA UK LIMITED (2001-01-25);;ASTRA PHARMACEUTICALS LTD (1998-04-17),https://lens.org/034-200-788-807-360,Granted Patent,yes,4,5,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,514/258;;544/262,1,1,036-724-332-810-326,10.1021/jm00014a009;;7629796,"Michne et al. Novel inhibitors of the Nuclear Factor of . . . J. Med. Chem. 38, 2557 2569, 1995.",EXPIRED
344,PT,E,PT 1107973 E,032-833-616-594-095,2004-03-31,2004,PT 99944964 T,1999-08-18,SE 9802895 A,1998-08-28,"NOVAS TIENO¬2,3-D| PIRIMIDINODIONAS PROCESSO PARA A SUA PREPARACAO E SUA UTILIZACAO EM TERAPIA","Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,PERRY MATTHEW;;BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP,,https://lens.org/032-833-616-594-095,Granted Patent,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,EXPIRED
345,DE,D1,DE 69623013 D1,084-552-786-795-434,2002-09-19,2002,DE 69623013 T,1996-06-03,GB 9511167 A;;GB 9510870 A;;GB 9511192 A;;GB 9511189 A;;US 9608659 W,1995-06-02,STEUERNACHRICHTENUEBERTRAGUNG IN TELEKOMMUNIKATIONSSYSTEMEN,,AIRSPAN NETWORKS INC,YEUNG CHI;;THOMPSON ANDREW;;LYSEJKO MARTIN;;COOPER ALEXANDER,"AIRSPAN NETWORKS INC., BOCA RATON, FLORIDA, US (2004-06-17)",https://lens.org/084-552-786-795-434,Granted Patent,no,0,0,8,251,0,H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04L12/403;;H04L41/0226;;H04L41/0233;;H04L41/0654;;H04L41/0677;;H04L41/069;;H04L41/22;;H04L63/08;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/13199;;H04Q2213/13216;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/52;;H04W84/14;;H04L69/08;;H04L69/32;;H04B1/7073;;H04L69/08;;H04L69/32,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04L12/24;;H04L12/28;;H04L12/403;;H04L29/06;;H04L29/08;;H04W52/04;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
346,DE,D1,DE 69725994 D1,122-284-678-815-475,2003-12-11,2003,DE 69725994 T,1997-09-19,US 2644296 P;;US 9716690 W,1996-09-19,KONZENTRIERTE QUATERNÄRE AMMONIUMGEWEBEWEICHMACHERZUSAMMENSETZUNGEN MIT KATIONISCHEN POLYMEREN,,PROCTER & GAMBLE,COOPER A;;TRINH TOAN;;WAHL HOFFMAN;;WARD MARTIN,,https://lens.org/122-284-678-815-475,Granted Patent,no,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,D06M13/322;;C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,EXPIRED
347,WO,A1,WO 2000/012514 A1,123-949-782-951-258,2000-03-09,2000,SE 9901400 W,1999-08-18,SE 9802895 A,1998-08-28,NOVEL COMPOUNDS,"The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.",ASTRA PHARMA PROD;;ASTRA AB;;BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/123-949-782-951-258,Patent Application,yes,2,33,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,2,1,024-960-871-387-554,10.1002/ardp.19953280305;;7763139,"CHEMICAL ABSTRACTS, vol. 112, no. 15, 1990, Columbus, Ohio, US; abstract no. 112:139045T, HIROSHI F. ET AL: ""Preparation of Thienopyrimidine-2,4-Diones as Allergy Inhibitors"" page 722; XP002921999;;GÜTSCHOW M.: ""3-Mercaptoalkylthieno(2,3-d)Pyrimidin-2,4(1H,3H)-Dione: Synthese und Prufung auf Immunstimulatorische Wirksamkeit"", ARCH. PHARM. (WEINHEIM), vol. 328, 2 August 1994 (1994-08-02), pages 231 - 234, XP002922000",PATENTED
348,DE,T2,DE 69807741 T2,130-645-660-596-842,2004-07-15,2004,DE 69807741 T,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,NEUARTIGE VERBINDUNGEN,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/130-645-660-596-842,Granted Patent,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,EXPIRED
349,US,B2,US 10301287 B2,139-383-852-060-217,2019-05-28,2019,US 201715691191 A,2017-08-30,US 201715691191 A;;US 201662382153 P,2016-08-31,Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate,"The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.",TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/139-383-852-060-217,Granted Patent,yes,26,1,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,C07D403/12;;C07C309/04,,24,16,121-690-112-853-226;;069-260-006-235-500;;034-105-894-546-47X;;000-365-257-637-448;;046-560-943-632-068;;001-555-640-337-185;;071-731-900-665-193;;008-277-158-769-841;;058-390-168-630-091;;018-952-685-207-364;;007-210-693-011-394;;026-200-294-447-350;;029-696-393-344-382;;087-990-722-849-156;;012-981-243-714-072;;074-494-620-106-402,10318947;;pmc21923;;10.1073/pnas.96.10.5698;;16251299;;pmc1280155;;10.1128/aac.49.11.4584-4591.2005;;10.1016/s0021-9150(98)00318-9;;10208497;;11403814;;10.1016/s0140-6736(00)04898-4;;8004700;;10.1248/cpb.42.551;;10.1016/s1359-6101(01)00014-4;;11544102;;10.1016/s0968-0896(03)00161-5;;12788340;;8756719;;10.1016/s0092-8674(00)80110-5;;10.1016/j.coph.2004.07.004;;15351348;;10.1136/ard.2004.023333;;15331395;;pmc1755415;;16005254;;10.1016/j.cytogfr.2005.05.009;;26299310;;pmc4547396;;10.1038/srep13180;;8751444;;10.1038/382722a0;;08751444;;15133211;;10.1248/cpb.52.577;;10.1021/jm0509703;;16539392;;10.1021/jm0509703.s001;;19441905;;10.1517/13543770902755129,"PCT/JP2002/008043, International Search Report dated Nov. 11, 2002, 4 pages.;;PCT/JP2002/008043, International Preliminary Examination Report dated Nov. 7, 2003, 38 pages.;;PCT/US2015/000289, International Search Report and Written Opinion dated Apr. 12, 2016, 16 pages.;;PCT/US2015/000289, International Preliminary Report on Patentability dated Jun. 27, 2017, 12 pages.;;PCT/US2017/049400, International Search Report and Written Opinion dated Jan. 8, 2018, 11 pages.;;Baba, M., et al., “A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity,” Proc. Natl. Acad Sci. USA (1999); 96: 5698-5703.;;Baba, M., et al., “TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans,” Antimicrobial Agents and Chemotherapy (2005); 49(11): 4584-4591.;;Dawson, T. C., et al. “Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice,” Atherosclerosis (1999); 143: 205-211.;;Carr, R.L., “Evaluating Flow Properties of Solids.” Chem Eng (1965); 72: 163-168.;;Fischereder, M., et al., “CC chemokine receptor 5 and renal-transplant survival,” The Lancet (2001); 357: 1758-1761.;;Fukushi et al., “Synthesis and Platelet-Activating Factor (PAF)—Antagonistic Activities of 1,4-Disubstituted Piperazine Derivatives,” Chem. Pharm. Bull. (1994); 42(3): 541-550.;;Horuk, R., “Chemokine receptors,” Cytokine and Growth Factor Reviews (2001); 12(4): 313-335.;;Kazmierski, W., et al., “Recent Progress in Discovery of Small-Molecule CCR5 Chemokine Receptor Ligands as HIV-1 Inhibitors,” Bioorganic & Medicinal Chemistry (2003), 11: 2663-2676.;;Liu, R., et al., “Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection,” Cell (1996); 86: 367-377.;;Maeda, K., et al. “The current status of and challenges in the development of CCR5 inhibitors as therapeutics for HIV-1 infection,” Current Opinion in Pharmacology (2004); 4(5): 447-452.;;Pokorny, V., et al., “Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis,” Ann. Rheum. Dis. (2005); 64: 487-490.;;Princen, K. et al. “HIV chemokine receptor inhibitors as novel anti-HIV drugs”, Cytokine & Growth Factor Reviews (2005); 16: 659-677.;;Salmas et al., “Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations.” Scientific Reports (2015); 5: 13180.;;Samson, M., et al., “Resistance to HIV-I infection in caucasian individuals bearing mutant alleles ot he CCR-5 chemokine receptor gene,” Nature (1996); 382: 722-725.;;Sellebjerg, F. et al. “CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis”, Journal of Neuroimmunology (2000); 102(1): 98-106.;;Seto, M., et al., “Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety.” Chem Pharm Bull (Tokyo) (2004); 52(5): 577-590.;;Seto, M., et al., “Highly Potent and Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activities of 1-Benzazocine Derivatives Containing a Sulfoxide Moiety.” J. Med. Chem. (2006); 49 (6): 2037-2048.;;University of North Carolina School of Medicine, “Case of the Missing Monocyte: Gene Appears to Protect Against Rheumatoid Arthritis,” ScienceDaily LLC, United States, Oct. 11, 2011, 3 pages.;;Xia et al., “Recent Developments in CCR2 Antagonists.” Expert Opinion on Therapeutic Patents (2009); 19(3): 295-303.",ACTIVE
350,HU,A2,HU P0100280 A2,170-874-932-696-178,2001-10-28,2001,HU P0100280 A,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,"PYRROLO-, THIENO-, FURANO- AND PYRAZOLO- [3,4D]-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","A találmány (I) általános képletű vegyületekre, azok gyógyászatilagalkalmazható sóira és szolvátjaira vonatkozik - a képletben B -CH=csoportot vagy nitrogén-, oxigén- vagy kénatomot jelent, D szénatomotvagy nitrogénatomot jelent, E nitrogénatomot vagy =CR3- csoportotjelent, amelyben R3 jelentése a később közlendő, azzal a feltétellel,hogy ha D szénatomot jelent, akkor B csak kén- vagy oxigénatom és Ecsak 0CR3- csoport lehet, míg ha D nitrogénatomot jelent, akkor B =CH-csoport és ugyanakkor E nitrogénatom vagy =CR3- csoport lehet, vagy Bnitrogénatom és ugyanakkor E =CR3- csoport lehet; R1 -NR'R< csoportotjelent, amelyben R' hidrogénatomot vagy 1-6 szénatomos alkilcsoportot,R< pedig 1-6 szénatomos alkilcsoportot jelent, vagy R' és R< aközbezárt nitrogénatommal együtt 3-7 tagú telített heterociklusosgyűrűt alkothat, vagy R1 1-6 szénatomos alkil-, 1-6 szénatomosalkoxi-, (1-3 szénatomos alkil)-oxi-(1-3 szénatomos alkil)-, (3-6szénatomos cikloalkil)-oxi-(1-3 széntomos alkil)-, 3-6 szénatomosalkenil-, fenil-, 3-7 szénatomos cikloalkil-, (3-5 szénatomoscikloalkil)-metil- vagy 3-7 szénatomos cikloalkenil-csoportot jelent,és a felsorolt csoportok bármelyikéhez adott esetben egy vagy többhalogén szubsztituens kapcsolódhat; R2 metilcsoportot vagy az 1-estőleltérő helyzetben adott esetben 1-6 szénatomos alkoxicsoporttalszubsztituált 2-6 szénatomos alkilcsoportot jelent; R3 jelentésehidrogénatom vagy -X-R5 vagy -X-Ar1 csoport, és R4 -CHR7Ar2 vagy -Ar3csoportot jelent, vagy ha D szénatomot jelent, akkor -C(O)Ar2 vagy -CR7(OH)Ar2 csoportot is jelenthet. Az (I) általános képletűvegyületeket hatóanyagként tartalmazó gyógyászati készítmények jólalkalmazhatók autoimmun, gyulladásos betegségek megelőzésében éskezelésében. Ó",ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/170-874-932-696-178,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,PENDING
351,DE,D1,DE 69807741 D1,172-388-265-143-789,2002-10-10,2002,DE 69807741 T,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,NEUARTIGE VERBINDUNGEN,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/172-388-265-143-789,Granted Patent,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,EXPIRED
352,PL,A1,PL 340556 A1,181-050-074-520-818,2001-02-12,2001,PL 34055698 A,1998-11-13,GB 9803420 W;;GB 9724612 A,1997-11-20,SUBSCRIBER'S TERMINAL FOR A WIRELESS TELECOMMUNICATION SYSTEM,,AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/181-050-074-520-818,Patent Application,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,PENDING
353,AT,T1,AT E245648 T1,183-685-815-993-228,2003-08-15,2003,AT 98917859 T,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,"1H-PYRAZOLO(3,4-D)PYRIMIDINE-4,6-DIONE ALS INHIBITOREN FÜR DIE VERMEHRUNG VON T-ZELLEN",,ASTRAZENECA AB,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/183-685-815-993-228,Granted Patent,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
354,ZA,B,ZA 889136 B,036-698-096-037-354,1989-08-30,1989,ZA 889136 A,1988-12-06,GB 8728820 A,1987-12-09,IMMUNOSUPPRESSIVE MACROLIDES,,FISONS PLC,COOPER MARTIN EDWARD;;MARTIN EDWARD COOPER;;DONALD DAVID KEITH;;DAVID KEITH DONALD;;HARDERN DAVID NORMAN;;DAVID NORMAN HARDERN,,https://lens.org/036-698-096-037-354,Granted Patent,no,0,0,3,44,0,C07D498/18;;C07D498/22;;C07H19/01;;C07D498/18;;C07D498/22;;C07H19/01,C07D498/18;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
355,DE,T2,DE 69816608 T2,007-923-190-914-188,2004-04-15,2004,DE 69816608 T,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,"1H-PYRAZOLO[3,4-D]PYRIMIDINE-4,6-DIONE ALS INHIBITOREN FÜR DIE VERMEHRUNG VON T-ZELLEN",,ASTRAZENECA AB,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/007-923-190-914-188,Granted Patent,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
356,PT,A,PT 95039 A,044-543-116-867-288,1991-04-18,1991,PT 9503990 A,1990-08-17,GB 8918927 A;;GB 8922653 A;;GB 9012426 A,1989-08-18,PROCESSO PARA A PREPARACAO DE COMPOSTOS MACROCICLICOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM,,FISONS PLC,DONALD DAVID KEIT;;COOPER MARTIN EDWARD;;FURBER MARK,,https://lens.org/044-543-116-867-288,Patent Application,no,0,0,9,13,0,C07D498/18;;C07H19/01;;A61P37/06,A61K31/395;;A61K31/40;;A61P37/06;;C07D498/18;;A61K31/435;;C07H19/01,,0,0,,,,DISCONTINUED
357,NO,D0,NO 995006 D0,106-119-910-345-465,1999-10-14,1999,NO 995006 A,1999-10-14,SE 9701398 A;;SE 9800640 W,1997-04-15,Nye forbindelser,,ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/106-119-910-345-465,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
358,GB,A,GB 2581999 A,115-277-722-812-775,2020-09-09,2020,GB 201903074 A,2019-03-07,GB 201903074 A,2019-03-07,Gas flow alarm,"A gas flow alarm system comprising a device 6 configurable to introduce back pressure into a flow of gas, a supply sensor (22, Fig 4) configured to determine whether gas flow to the device is enabled, and a pressure sensor configured to determine whether a flow of gas through the device has developed back pressure. Logic circuitry in provided in communication with the supply sensor and the pressure sensor, the logic circuitry determining from signals received from the supply and pressure sensors whether gas flow to the device is enabled and whether a flow of gas through the device has developed back pressure. If back pressure has not developed, an alarm condition is activated, and an alarm preferably sounded. The system operates to warn a user against conditions in which a flow of therapeutic gas to a patient is required, yet not being provided. The back pressure is preferably generated by a check valve biased to a closed position by a spring.",BPR MEDICAL LTD,MICHAEL BRUDENELL;;BENJAMIN JOHNSON;;MARTIN COOPER;;RICHARD RADFORD,,https://lens.org/115-277-722-812-775,Patent Application,no,1,0,12,12,0,F17C2221/011;;F17C2223/0123;;F17C2223/0161;;F17C2223/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025;;F17C2250/036;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C7/00;;A61M16/0051;;A62B9/006;;A61M2016/0027;;A61M2016/003;;A61M16/0003;;A61M16/1005;;A61M16/0051;;A61M16/208;;A61M2016/0027;;A61M2016/0033;;A61M2205/581;;F17C13/02;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C2221/011;;F17C2223/0123;;F17C2250/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025,A61M16/00;;A62B9/00,,0,0,,,,ACTIVE
359,ZA,B,ZA 9810601 B,121-589-095-409-732,1999-05-19,1999,ZA 9810601 A,1998-11-19,GB 9724612 A,1997-11-20,A subscriber terminal for a wireless telecommuncations system,,AIRSPAN COMM CORP,COOPER IAN LESLIE;;LYSEJKO MARTIN;;GOHLAR TARLOCHAN SINGH,,https://lens.org/121-589-095-409-732,Granted Patent,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,EXPIRED
360,SK,A3,SK 8402000 A3,118-816-031-105-026,2001-03-12,2001,SK 8402000 A,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,NOVEL COMPOUNDS,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/118-816-031-105-026,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,PENDING
361,CA,A1,CA 2311536 A1,198-965-780-769-365,1999-06-03,1999,CA 2311536 A,1998-11-13,GB 9724612 A;;GB 9803420 W,1997-11-20,SUBSCRIBER TERMINAL FOR WIRELESS TELECOMMUNICATIONS SYSTEM,"The present invention provides a subscriber terminal for communicating over a wireless link with a central terminal of a wireless telecommunications system, the subscriber terminal comprising a first signal processing unit (110) associated with an antenna (100) to transmit and receive signals over the wireless link at first frequencies within an operating frequency band. The first signal processing unit comprises a frequency converter for converting signals between said first frequencies and a second frequency. Further, a second signal processing unit (130) is provided remote from the first signal processing unit and associated with an item of telecommunications equipment (150) to pass signals between said item of telecommunications equipment and the first signal processing unit. The second signal processing unit is formed from signal processing circuitry which is independent of the operating frequency band via a connection medium (120).",AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;GOHLAR TARLOCHAN SINGH;;COOPER IAN LESLIE,,https://lens.org/198-965-780-769-365,Patent Application,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,DISCONTINUED
362,WO,A1,WO 2018/045043 A1,016-942-006-835-966,2018-03-08,2018,US 2017/0049400 W,2017-08-30,US 201662382153 P,2016-08-31,SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE,"The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.",TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/016-942-006-835-966,Patent Application,yes,9,11,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/395;;A61K31/4164;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,2,0,,,"ME AULTON, THE SCIENCE OF DOSAGE FORM DESIGN, 1988;;CARR, R.L.: ""Evaluating Flow Properties of Solids"", CHEM ENG, vol. 72, 1965, pages 163 - 168, XP001131974",PENDING
363,ES,T3,ES 2211161 T3,029-446-649-315-947,2004-07-01,2004,ES 99944964 T,1999-08-18,SE 9802895 A,1998-08-28,"TIENO(2,3-D)PIRIMIDINDIONAS NOVEDOSAS, PROCEDIMIENTO PARA SU PREPARACION Y USO DE LAS MISMAS EN TERAPIA.","Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/029-446-649-315-947,Granted Patent,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,EXPIRED
364,EP,B1,EP 1036076 B1,028-626-367-544-444,2002-09-04,2002,EP 98962754 A,1998-12-01,SE 9802191 W;;SE 9704542 A;;SE 9801989 A,1997-12-05,NOVEL COMPOUNDS,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/028-626-367-544-444,Granted Patent,yes,5,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,1,0,,,"CHEM. PHARM. BULL., Volume 43, No. 2, 1995, MASAHISA YAMAGUCHI et al., ""Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. V.1. Thienopyridazione Derivatives"", pages 236-240.",EXPIRED
365,GB,B,GB 2581999 B,039-128-544-433-444,2023-01-04,2023,GB 201903074 A,2019-03-07,GB 201903074 A,2019-03-07,Gas flow alarm,,BPR MEDICAL LTD,MICHAEL BRUDENELL;;BENJAMIN JOHNSON;;MARTIN COOPER;;RICHARD RADFORD,,https://lens.org/039-128-544-433-444,Granted Patent,no,3,0,12,12,0,F17C2221/011;;F17C2223/0123;;F17C2223/0161;;F17C2223/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025;;F17C2250/036;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C7/00;;A61M16/0051;;A62B9/006;;A61M2016/0027;;A61M2016/003;;A61M16/0003;;A61M16/1005;;A61M16/0051;;A61M16/208;;A61M2016/0027;;A61M2016/0033;;A61M2205/581;;F17C13/02;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C2221/011;;F17C2223/0123;;F17C2250/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025,A61M16/00;;A62B9/00,,0,0,,,,ACTIVE
366,ID,A,ID 24676 A,078-867-069-554-370,2000-07-27,2000,ID 20000957 A,1998-11-13,GB 9724612 A,1997-11-20,TERMINAL PENDUKUNG UNTUK SISTEM TELEKOMUNIKASI TANPA KABEL,,AIRSPAN NETWORKS INC,MARTIN LYSEJKO;;LESLIE COOPER IAN;;SINGH GOHLAR TARLOCHAN,,https://lens.org/078-867-069-554-370,Patent Application,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,PENDING
367,DK,A,DK 296382 A,117-118-489-921-055,1983-01-03,1983,DK 296382 A,1982-07-01,DE 3126021 A,1981-07-02,FREMGANGSMAADE TIL FREMSTILLING AF OPTISK REN D- ELLER L-MAELKESYRE,,BASF AG,COOPER B;;KUESTERS W;;MARTIN C;;SIEGEL H,,https://lens.org/117-118-489-921-055,Patent Application,no,0,0,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,,0,0,,,,DISCONTINUED
368,EP,A1,EP 3506896 A1,141-753-185-422-92X,2019-07-10,2019,EP 17847477 A,2017-08-30,US 201662382153 P;;US 2017/0049400 W,2016-08-31,SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE,,TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/141-753-185-422-92X,Patent Application,yes,0,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/395;;A61K31/4164;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,0,0,,,,PENDING
369,CN,A,CN 115916276 A,156-768-490-646-512,2023-04-04,2023,CN 202180043391 A,2021-06-16,EP 20180620 A;;EP 2021066301 W,2020-06-17,Cured three-dimensional printing compositions and uses thereof,"The present invention generally relates to the field of tissue engineering, in particular tissue engineering in the context of cartilage tissue. More specifically, the present invention relates to a three-dimensional structure comprising a sufficient number of cartilage cells and a cross-linked biopolymer formulation wherein the three-dimensional composition has mechanical stability suitable for implantation in a subject in need thereof. In a further aspect, the invention relates to a method for preparing such a three-dimensional composition, for example by bioprinting, to the composition obtainable by such a method, and to the medical use of the three-dimensional composition.",ORIGEN BIOTHERAPEUTICS INC,KESTY MARTIN J J;;COOPER KATHRYN SHANNON U,,https://lens.org/156-768-490-646-512,Patent Application,no,0,0,10,10,0,A61L27/3817;;A61L27/3852;;A61L27/3895;;A61L27/20;;A61L27/26;;A61L27/52;;B33Y70/00;;B33Y80/00;;A61L27/3817;;A61L27/3895;;B33Y70/00;;A61L27/3852;;C08L5/00;;A61L27/26;;A61L27/52;;C08L5/04;;B33Y80/00;;A61L27/20;;A61L27/26;;A61L27/20;;A61L27/3817;;A61L27/3852;;A61L27/3895;;A61L27/52;;B33Y70/00;;B33Y80/00;;A61L2430/06,A61L27/20;;A61L27/26;;A61L27/38;;A61L27/52;;B33Y70/00;;B33Y80/00,,0,0,,,,PENDING
370,CA,A1,CA 3178179 A1,161-759-397-558-549,2021-10-07,2021,CA 3178179 A,2021-03-31,US 202063002414 P;;US 202017077090 A;;CA 2021050429 W,2020-03-31,LONGITUDINAL AND CIRCUMFERENTIAL ULTRASOUND SCANNER,"A scanning device is provided. The scanning device includes a frame having a first portion and a second portion pivotably coupled to the first frame portion. The scanning device also has a first set of wheels coupled with the first frame portion and a second set of wheels coupled with the second frame portion. In addition, the scanning device has a rail movably disposed on the first frame portion that includes a channel and a rail along with a rail arm coupled with the channel. The scanning device has a sensor assembly that includes sensor forks, a sensor coupled with the sensor forks and a sensor arm. The sensor arm is coupled with the sensor forks and with the rail arm. In addition, the sensor is adjustable between a first position and a second position via the rail.",EVIDENT CANADA INC,COOPER LUIS;;DUPUIS MARTIN;;SIMARD VERONIQUE;;SPAY BENJAMIN,,https://lens.org/161-759-397-558-549,Patent Application,no,0,0,9,9,0,G01N29/262;;G01N2291/2634;;G01N29/225;;G01N29/265;;G01N29/069;;G01N29/043;;G01N2291/0289;;G01N2291/267;;G01N29/28;;G01N2291/0289;;G01N2291/267;;G01N29/069;;G01N29/041;;G01N29/225;;G01N2291/2636;;G01N29/265;;G01N29/262;;G01N29/043;;G01N2291/2634,G01N29/26;;G01N29/28;;G01S7/521,,0,0,,,,PENDING
371,CA,A,CA 699475 A,050-749-468-342-371,1964-12-08,1964,CA 699475D A,,CA 699475T A,,TRAFFIC SIGNAL SYNCHRONIZING SYSTEM,,MOTOROLA INC,TUREK CLARENCE W;;COOPER MARTIN;;WILLYARD CHARLES H,,https://lens.org/050-749-468-342-371,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
372,EP,B1,EP 1033041 B1,080-454-809-834-017,2002-07-17,2002,EP 98954584 A,1998-11-13,GB 9803420 W;;GB 9724612 A,1997-11-20,SUBSCRIBER TERMINAL FOR WIRELESS TELECOMMUNICATIONS SYSTEM,,AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/080-454-809-834-017,Granted Patent,yes,4,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,EXPIRED
373,US,A1,US 2021/0302382 A1,082-538-004-419-669,2021-09-30,2021,US 202017077090 A,2020-10-22,US 202017077090 A;;US 202063002414 P,2020-03-31,LONGITUDINAL AND CIRCUMFERENTIAL ULTRASOUND SCANNER,"A scanning device is provided. The scanning device includes a frame having a first portion and a second portion pivotably coupled to the first frame portion. The scanning device also has a first set of wheels coupled with the first frame portion and a second set of wheels coupled with the second frame portion. In addition, the scanning device has a rail movably disposed on the first frame portion that includes a channel and a rail along with a rail arm coupled with the channel. The scanning device has a sensor assembly that includes sensor forks, a sensor coupled with the sensor forks and a sensor arm. The sensor arm is coupled with the sensor forks and with the rail arm. In addition, the sensor is adjustable between a first position and a second position via the rail.",OLYMPUS NDT CANADA INC,SPAY BENJAMIN;;DUPUIS MARTIN;;COOPER LUIS;;SIMARD VERONIQUE,EVIDENT CANADA INC (2020-03-26),https://lens.org/082-538-004-419-669,Patent Application,yes,1,1,9,9,0,G01N29/262;;G01N2291/2634;;G01N29/225;;G01N29/265;;G01N29/069;;G01N29/043;;G01N2291/0289;;G01N2291/267;;G01N29/28;;G01N2291/0289;;G01N2291/267;;G01N29/069;;G01N29/041;;G01N29/225;;G01N2291/2636;;G01N29/265;;G01N29/262;;G01N29/043;;G01N2291/2634,G01N29/22;;G01N29/04,,0,0,,,,ACTIVE
374,PL,A1,PL 336230 A1,120-850-963-311-39X,2000-06-19,2000,PL 33623098 A,1998-04-07,SE 9800640 W;;SE 9701398 A,1997-04-15,NOVEL CHEMICAL COMPOUNDS,,ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/120-850-963-311-39X,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
375,CA,A1,CA 2286078 A1,018-488-842-850-278,1998-10-22,1998,CA 2286078 A,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,NOVEL COMPOUNDS,"The present invention relates to pharmaceutically useful pyrazolo¢3,4d!pyrimidinedione compounds of formula (I), processes for their production, pharmaceutical compositions containing them and their use for the treatment of various diseases.",ASTRA PHARMA PROD,THORNE PHILIP;;DONALD DAVID;;CHESHIRE DAVID;;COOPER MARTIN,,https://lens.org/018-488-842-850-278,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
376,EP,A4,EP 3506896 A4,065-755-351-457-146,2020-08-26,2020,EP 17847477 A,2017-08-30,US 201662382153 P;;US 2017/0049400 W,2016-08-31,SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE,,TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/065-755-351-457-146,Search Report,no,2,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/395;;A61K31/4164;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,1,1,104-949-654-022-72X,10.1007/3-540-69178-2_5,"MINO R CAIRA ED - MONTCHAMP JEAN-LUC: ""CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS"", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5",PENDING
377,US,A,US 5296489 A,081-007-007-595-933,1994-03-22,1994,US 92406792 A,1992-09-11,US 92406792 A;;GB 9005672 A;;GB 9008507 A;;GB 9008556 A;;GB 9009480 A;;GB 9017447 A;;GB 9023242 A;;GB 9100393 W,1990-03-13,Immunosuppressive macrocyclic compounds,"There are provided compounds of formula (I), wherein R.sup.1 represents H, OH or alkoxy; R.sup.2 represents H; in addition R.sup.1 and R.sup.2 may together represent a second bond between the carbon atoms to which they are attached; R.sup.3 represents methyl, ethyl, propyl or allyl; R.sup.4 represents H, OH, alkyl, alkoxy, halogen, amino, S-alkyl, NHCHO or NHCO-alkyl; n represents 1 or 2; X represents O, (H, OH), (H, H) or .dbd.NH; and Y represents an optionally substituted cyclohexyl or substituted cyclopentyl group; with various provisos. The compounds are useful, inter alia, as immunosuppressive agents.",FISONS,DONALD DAVID K;;FURBER MARK;;COOPER MARTIN E,FISONS PLC (1992-08-17),https://lens.org/081-007-007-595-933,Granted Patent,yes,3,4,1,12,0,C07D498/18;;C07H19/01;;C07D498/18;;C07H19/01,C07D498/18;;C07H19/01,514/291;;514/411;;540/456,0,0,,,,EXPIRED
378,EP,A1,EP 4127699 A1,192-848-927-252-571,2023-02-08,2023,EP 21780036 A,2021-03-31,US 202063002414 P;;US 202017077090 A;;CA 2021050429 W,2020-03-31,LONGITUDINAL AND CIRCUMFERENTIAL ULTRASOUND SCANNER,,EVIDENT CANADA INC,SIMARD VERONIQUE;;DUPUIS MARTIN;;SPAY BENJAMIN;;COOPER LUIS,,https://lens.org/192-848-927-252-571,Patent Application,yes,0,0,9,9,0,G01N29/262;;G01N2291/2634;;G01N29/225;;G01N29/265;;G01N29/069;;G01N29/043;;G01N2291/0289;;G01N2291/267;;G01N29/28;;G01N2291/0289;;G01N2291/267;;G01N29/069;;G01N29/041;;G01N29/225;;G01N2291/2636;;G01N29/265;;G01N29/262;;G01N29/043;;G01N2291/2634,G01N29/26;;G01N29/28;;G01S7/521,,0,0,,,,PENDING
379,US,A1,US 2022/0178500 A1,014-524-311-937-999,2022-06-09,2022,US 202017436994 A,2020-03-06,GB 201903074 A;;GB 2020050542 W,2019-03-07,GAS FLOW ALARM,"Aspects and embodiments relate to a gas flow alarm apparatus and gas flow alarm method. The apparatus comprises: a device configurable to introduce back pressure into a flow of gas, a supply sensor configured to determine whether gas flow to the device is enabled; a pressure sensor configured to determine whether a flow of gas through the device has developed back pressure; and logic circuitry in communication with the supply sensor and the pressure sensor configured to determine whether gas flow to the device is enabled and whether a flow of gas through the device has developed back pressure and, if not, to activate an alarm condition. Aspects and embodiments can provide a system which operates to warn a user against various adverse conditions in which a flow of therapeutic gas to a patient is required, yet not being provided.",BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL;;RADFORD RICHARD,BPR MEDICAL LIMITED (2021-09-06),https://lens.org/014-524-311-937-999,Patent Application,yes,28,0,12,12,0,F17C2221/011;;F17C2223/0123;;F17C2223/0161;;F17C2223/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025;;F17C2250/036;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C7/00;;A61M16/0051;;A62B9/006;;A61M2016/0027;;A61M2016/003;;A61M16/0003;;A61M16/1005;;A61M16/0051;;A61M16/208;;A61M2016/0027;;A61M2016/0033;;A61M2205/581;;F17C13/02;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C2221/011;;F17C2223/0123;;F17C2250/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025,F17C13/02;;A61M16/00;;A61M16/10;;A61M16/20,,0,0,,,,PENDING
380,WO,A1,WO 2021/195769 A1,018-601-227-699-475,2021-10-07,2021,CA 2021050429 W,2021-03-31,US 202063002414 P;;US 202017077090 A,2020-03-31,LONGITUDINAL AND CIRCUMFERENTIAL ULTRASOUND SCANNER,"A scanning device is provided. The scanning device includes a frame having a first portion and a second portion pivotably coupled to the first frame portion. The scanning device also has a first set of wheels coupled with the first frame portion and a second set of wheels coupled with the second frame portion. In addition, the scanning device has a rail movably disposed on the first frame portion that includes a channel and a rail along with a rail arm coupled with the channel. The scanning device has a sensor assembly that includes sensor forks, a sensor coupled with the sensor forks and a sensor arm. The sensor arm is coupled with the sensor forks and with the rail arm. In addition, the sensor is adjustable between a first position and a second position via the rail.",OLYMPUS NDT CANADA INC,SIMARD VERONIQUE;;DUPUIS MARTIN;;SPAY BENJAMIN;;COOPER LUIS,,https://lens.org/018-601-227-699-475,Patent Application,yes,3,2,9,9,0,G01N29/262;;G01N2291/2634;;G01N29/225;;G01N29/265;;G01N29/069;;G01N29/043;;G01N2291/0289;;G01N2291/267;;G01N29/28;;G01N2291/0289;;G01N2291/267;;G01N29/069;;G01N29/041;;G01N29/225;;G01N2291/2636;;G01N29/265;;G01N29/262;;G01N29/043;;G01N2291/2634,G01N29/26;;G01N29/28;;G01S7/521,,0,0,,,,PENDING
381,US,B1,US 6236956 B1,025-668-445-971-932,2001-05-22,2001,US 30523899 A,1999-05-04,US 30523899 A;;US 60222396 A,1996-02-16,Component-based analog and mixed-signal simulation model development including newton step manager,"The Model Editor (106) makes simulation modeling easier and more intuitive by extracting essential information and presenting it to the user, and by providing tools to investigate simulation and model robustness, in an interactive, graphical environment. The Model Editor (106) includes a Newton step manager as an interactive, graphical tool. During simulation of a model, the Newton step manager captures matrix norms. Any indications of Newton limiting are also captured. The matrix norms are plotted as a function of iteration count, and the iterations at which Newton limiting were encountered are identified. Newton step manager can also be run automatically using a functional dependency analysis.",AVANT CORP,MANTOOTH H ALAN;;COOPER DOUGLAS K;;VLACH MARTIN,ANALOGY INC (1999-05-13);;AVANTI CORPORATION (2001-04-26);;SYNOPSYS INC (2002-06-11),https://lens.org/025-668-445-971-932,Granted Patent,yes,8,91,1,3,0,G06F8/34;;G06F8/34;;G06F30/367;;G06F30/367,G06F9/44;;G06F17/50,703/14;;703/4;;703/2,7,4,052-976-706-177-301;;012-446-414-948-064;;099-769-347-804-644;;051-217-495-180-936,10.1109/edtc.1994.326823;;10.1109/43.127622;;10.1109/43.24882;;10.1109/81.563628,"V. Moser, P. Nussbaum, H.P. Amann, L.Astier, F. Pellandini, ""A graphical approach to analogue behavioural modelling,"" IEEE Proc. of European Design and Test Conf., pp. 535-539, Mar. 1994.;;V. M. Ma, J. Singh, R. Saleh, ""Modeling, simulation and optimization of analog macromodels,"" IEEE Proc. of CICC '92, p. 12.1.1, May 1992.;;""Saber(TM) DesignStar(TM) Design and Modeling Environment"", Analogy, Inc., 1991.;;Beetem, ""Hierarchical Topological Sorting of Apparent Loops via Partitioning"", IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems, pp. 607-619, May 1992.*;;Yeager, ""Improvement in Norm-Reducing Newton Methods for Circuit Simulation"", IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems, pp. 607-619, May 1989.*;;Brambilla et al, ""A Control-Based Approach to the Solution of Nonlinear Algebraic Equations"", IEEE Transactions on Circuits and Systems I: Fundamental Theory and Applications, pp. 366-369, Apr. 1997.*;;Analogy, Inc., Simulation Product Page, Jun. 14, 1999, pp. 1-6.",EXPIRED
382,ID,A,ID 25628 A,085-032-657-263-498,2000-10-19,2000,ID 20001021 D,1998-12-01,SE 9704542 A;;SE 9801989 A,1997-12-05,SENYAWA-SENYAWA BARU,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/085-032-657-263-498,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,PENDING
383,MX,A,MX 2019002057 A,103-094-521-283-339,2019-11-18,2019,MX 2019002057 A,2017-08-30,US 201662382153 P;;US 2017/0049400 W,2016-08-31,SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE.,"The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.",TOBIRA THERAPEUTICS INC,MARTIN IAN COOPER;;PASIT PHIASIVONGSA;;EMMA KAY SHARP,,https://lens.org/103-094-521-283-339,Patent Application,no,0,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/395;;A61K31/4164;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,0,0,,,,PENDING
384,CZ,A3,CZ 20001871 A3,140-334-804-611-453,2000-12-13,2000,CZ 20001871 A,1998-11-13,CZ 20001871 A,1998-11-13,"Subscriber terminal for wireless telecommunication system, first and second unit for signal processing and communication method through wireless communication",,AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/140-334-804-611-453,Patent Application,no,0,0,1,1,0,,H04W88/04;;H04B17/20,,0,0,,,,PENDING
385,US,B2,US 11686710 B2,167-981-966-369-234,2023-06-27,2023,US 202017077090 A,2020-10-22,US 202017077090 A;;US 202063002414 P,2020-03-31,Longitudinal and circumferential ultrasound scanner,"A scanning device is provided. The scanning device includes a frame having a first portion and a second portion pivotably coupled to the first frame portion. The scanning device also has a first set of wheels coupled with the first frame portion and a second set of wheels coupled with the second frame portion. In addition, the scanning device has a rail movably disposed on the first frame portion that includes a channel and a rail along with a rail arm coupled with the channel. The scanning device has a sensor assembly that includes sensor forks, a sensor coupled with the sensor forks and a sensor arm. The sensor arm is coupled with the sensor forks and with the rail arm. In addition, the sensor is adjustable between a first position and a second position via the rail.",EVIDENT CANADA INC,SPAY BENJAMIN;;DUPUIS MARTIN;;COOPER LUIS;;SIMARD VERONIQUE,EVIDENT CANADA INC (2020-03-26),https://lens.org/167-981-966-369-234,Granted Patent,yes,33,0,9,9,0,G01N29/262;;G01N2291/2634;;G01N29/225;;G01N29/265;;G01N29/069;;G01N29/043;;G01N2291/0289;;G01N2291/267;;G01N29/28;;G01N2291/0289;;G01N2291/267;;G01N29/069;;G01N29/041;;G01N29/225;;G01N2291/2636;;G01N29/265;;G01N29/262;;G01N29/043;;G01N2291/2634,G01N29/28;;G01N29/04;;G01N29/06;;G01N29/22;;G01N29/26;;G01N29/265,,6,0,,,"“International Application Serial No. PCT/CA2021/050419, International Search Report dated Jun. 17, 2021”, 3 pgs.;;“International Application Serial No. PCT/CA2021/050419, Written Opinion dated Jun. 17, 2021”, 3 pgs.;;“International Application Serial No. PCT/CA2021/050429, International Search Report dated Jun. 17, 2021”, 3 pgs.;;“International Application Serial No. PCT/CA2021/050429, Written Opinion dated Jun. 17, 2021”, 5 pgs.;;“U.S. Appl. No. 17/077,116, Non Final Office Action dated Jun. 29, 22”, 10 pgs.;;“U.S. Appl. No. 17/077,116, Response filed Sep. 29, 2022 to Non Final Office Action dated Jun. 29, 2022”, 12 pgs.",ACTIVE
386,CZ,A3,CZ 360599 A3,021-768-743-438-143,2000-04-12,2000,CZ 360599 A,1998-04-07,CZ 360599 A,1998-04-07,Novel compounds,,ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/021-768-743-438-143,Patent Application,no,0,0,1,1,0,,A61K31/415;;A61K31/505;;A61P19/02;;C07D231/00;;C07D239/00;;C07D487/04,,0,0,,,,PENDING
387,TR,T2,TR 199902538 T2,052-912-241-027-609,2000-02-21,2000,TR 9902538 T,1998-04-07,SE 9701398 A,1997-04-15,Yeni bilesimler.,"Mevcut bulus; formülü formül (I) olan farmasötik olarak yararli pirazolo [3,4-d]pIrimidindion bilesimleriyle, bunlarin üretilme süreçleriyle, bunlari içeren farmasötik bilesiklerle ve bunlarin çesitli hastaliklarin tedavisinde kullanilmalariyla ilgilidir.",ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/052-912-241-027-609,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
388,AT,T1,AT E223413 T1,109-043-932-797-463,2002-09-15,2002,AT 98962754 T,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,NEUARTIGE VERBINDUNGEN,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/109-043-932-797-463,Granted Patent,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
389,WO,A1,WO 1991/013889 A1,109-997-895-065-075,1991-09-19,1991,GB 9100393 W,1991-03-13,GB 9005672 A;;GB 9008507 A;;GB 9008556 A;;GB 9009480 A;;GB 9017447 A;;GB 9023242 A,1990-03-13,IMMUNOSUPPRESSIVE MACROCYCLIC COMPOUNDS,"There are provided compounds of formula (I), wherein R1 represents H, OH or alkoxy; R2 represents H; in addition, R?1 and R2¿ may together represent a second bond between the carbon atoms to which they are attached; R3 represents methyl, ethyl, propyl or allyl; R4 represents H, OH, alkyl, alkoxy, halogen, amino, S-alkyl, NHCHO or NHCO-alkyl; n represents 1 or 2; X represents O, (H, OH), (H, H) or =NH; and Y represents an optionally substituted cyclohexyl or substituted cyclopentyl group; with various provisos. The compounds are useful, inter alia, as immunosuppressive agents.",FISONS PLC,DONALD DAVID KEITH;;FURBER MARK;;COOPER MARTIN EDWARD,,https://lens.org/109-997-895-065-075,Patent Application,yes,3,49,4,12,0,A61P37/06;;C07D498/18;;C07H19/01,A61K31/40;;A61K31/435;;A61P37/06;;C07D498/18;;C07H19/01,,0,0,,,,PENDING
390,SG,A,SG 11201901438V A,135-015-634-048-83X,2019-03-28,2019,SG 11201901438V A,2017-08-30,US 201662382153 P;;US 2017/0049400 W,2016-08-31,SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE,,TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/135-015-634-048-83X,Unknown,no,0,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/4164;;A61K31/395;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,0,0,,,,PENDING
391,SE,D0,SE 9903080 D0,164-387-776-668-996,1999-09-01,1999,SE 9903080 A,1999-09-01,SE 9903080 A,1999-09-01,Novel compounds,,ASTRA PHARMA PROD,BANTICK JOHN;;COOPER MARTIN;;KINCHIN ELIZABETH;;PERRY MATTHEW,,https://lens.org/164-387-776-668-996,Patent Application,no,0,0,1,1,0,,C07D/,,0,0,,,,PENDING
392,BR,A2,BR 112019003987 A2,157-502-281-158-000,2019-05-28,2019,BR 112019003987 A,2017-08-30,US 2017/0049400 W;;US 201662382153 P,2016-08-31,formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc,"a invenção refere-se a formas sólidas do mesilato de cenicriviroc, métodos de sua preparação, suas composições farmacêuticas e seus métodos de uso.",TOBIRA THERAPEUTICS INC,EMMA KAY SHARP;;MARTIN IAN COOPER;;PASIT PHIASIVONGSA,,https://lens.org/157-502-281-158-000,Patent Application,no,0,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/395;;A61K31/4164;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,0,0,,,,DISCONTINUED
393,CA,A,CA 1165249 A,196-967-594-587-652,1984-04-10,1984,CA 376625 A,1981-04-30,US 14582980 A,1980-05-01,REVERSE-OSMOSIS TUBULAR MEMBRANE,"A membrane module which includes a unitary, curved, backing support which retains all the U bends, serially connecting the membrane tubes, in a sealing relationship, and which includes an annular permeate-collector ring system at the end of each membrane tube and channels with a permeate manifold passageway, to provide efficient removal and easy cleaning of the permeate flow path.",ABCOR INC,ROOS MARTIN;;EYKAMP WILLIAM;;COOPER WILLIAM W IV,,https://lens.org/196-967-594-587-652,Granted Patent,no,0,0,7,7,0,B01D61/10;;B01D63/063;;B01D65/02;;B01D2321/02;;B01D61/10;;B01D2321/02;;B01D63/063;;B01D65/02,B01D61/08;;B01D61/10;;B01D61/18;;B01D61/20;;B01D63/06;;B01D65/02;;B01D65/06;;B01D69/04,182-14,0,0,,,,EXPIRED
394,SE,D0,SE 9701398 D0,193-997-797-856-224,1997-04-15,1997,SE 9701398 A,1997-04-15,SE 9701398 A,1997-04-15,Novel compounds,,ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/193-997-797-856-224,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
395,EP,A1,EP 3935307 A1,010-995-944-697-150,2022-01-12,2022,EP 20711274 A,2020-03-06,GB 201903074 A;;GB 2020050542 W,2019-03-07,GAS FLOW ALARM,,BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL;;RADFORD RICHARD,,https://lens.org/010-995-944-697-150,Patent Application,yes,0,0,12,12,0,F17C2221/011;;F17C2223/0123;;F17C2223/0161;;F17C2223/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025;;F17C2250/036;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C7/00;;A61M16/0051;;A62B9/006;;A61M2016/0027;;A61M2016/003;;A61M16/0003;;A61M16/1005;;A61M16/0051;;A61M16/208;;A61M2016/0027;;A61M2016/0033;;A61M2205/581;;F17C13/02;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C2221/011;;F17C2223/0123;;F17C2250/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025,F17C7/00;;A61M16/00,,0,0,,,,ACTIVE
396,NZ,A,NZ 509809 A,014-594-241-132-16X,2002-11-26,2002,NZ 50980999 A,1999-08-18,SE 9802895 A;;SE 9901400 W,1998-08-28,"Thienol[2,3-d]pyrimidinediones which exhibit immunosuppressive activity","Use of a thienol[2,3-d]pyrimidinedione of given formula for use in effecting immunosuppression.",ASTRAZENECA AB,THORNE PHILIP;;BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW,,https://lens.org/014-594-241-132-16X,Patent Application,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,PENDING
397,CA,A1,CA 2339664 A1,064-542-098-401-521,2000-03-09,2000,CA 2339664 A,1999-08-18,SE 9802895 A;;SE 9901400 W,1998-08-28,NOVEL COMPOUNDS,"The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones , processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.",ASTRAZENECA AB,PERRY MATTHEW;;THORNE PHILIP;;COOPER MARTIN;;BANTICK JOHN,,https://lens.org/064-542-098-401-521,Patent Application,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,DISCONTINUED
398,WO,A1,WO 1998/046606 A1,085-534-639-677-603,1998-10-22,1998,SE 9800640 W,1998-04-07,SE 9701398 A,1997-04-15,NOVEL COMPOUNDS,"The present invention relates to pharmaceutically useful pyrazolo[3,4-d]pyrimidinedione compounds of formula (I), processes for their production, pharmaceutical compositions containing them and their use for the treatment of various diseases.",ASTRA PHARMA PROD;;ASTRA AB;;CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/085-534-639-677-603,Patent Application,yes,5,84,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,1,1,036-724-332-810-326,10.1021/jm00014a009;;7629796,"J. MED. CHEM., Volume 38, 1995, WILLIAM F. MICHNE et al., ""Novel Inhibitors of the Nuclear Factor of Activated T Cells (NFAT)-Mediated Transcription of beta-Galactosidase: Potential Immunosuppressive and Antiinflammatory Agents"", pages 2557-2569.",PATENTED
399,BR,A,BR 9814218 A,083-308-179-514-53X,2000-10-03,2000,BR 9814218 A,1998-11-13,GB 9724612 A;;GB 9803420 W,1997-11-20,Terminal de assinante para sistema de telecomunicações sem fio,"""TERMINAL DE ASSINANTE PARA SISTEMA DE TELECOMUNICAçõES SEM FIO"" A presente invenção proporciona um terminal de assinante para comunicação por um ligação sem fio com um terminal central de um sistema de telecomunicações sem fio, o terminal de assinante compreendendo uma primeira unidade de processamento de sinal (110) associada com uma antena (100) para transmitir e receber sinais pela ligação sem fio em freq³ências primárias dentro de uma banda de freq³ências operacionais. A primeira unidade de processamento de sinal compreende um conversor de freq³ência, para converter os sinais entre as freq³ências primárias e uma freq³ência secundária. Além disso, uma segunda unidade de processamento de sinal (130) é proporcionada distante da primeira unidade de processamento de sinal e associada com um item de equipamento de telecomunicações (150), para passar os sinais entre o ítem de equipamento de telecomunicações e a primeira unidade de processamento de sinal. A segunda unidade de processamento de sinal é formada do conjunto de circuitos de processamento de sinal, que é independente da banda de freq³ências operacionais, via um meio de conexão.",AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/083-308-179-514-53X,Patent Application,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,DISCONTINUED
400,EP,A2,EP 0039583 A2,102-606-690-717-628,1981-11-11,1981,EP 81301910 A,1981-04-30,US 14582980 A,1980-05-01,Reverse-osmosis tubular membrane module.,A reverse-osmosis tubular membrane module has a plurality of tubular membrane tubes (50) arranged in a set of parallel supporting tubes (12) with an axial annular permeate flow channel (64) defined between each membrane tube and the supporting tubes (12) within which it is contained and containing an open neck resilient material (54). Supports (18) are provided at each end of the supporting tubes to receive the opposite ends of the membrane tubes and have permeate collection passageways (24) therein connected (at 46) to receive permeate from the annular channels (64). U-shaped connecting tubes (26) connect the adjacent ends of pairs of membrane tubes to provide a continuous flow path with the interior of the membrane tubes of the module. Means are provided for forcing the U-shaped connecting tubes (26) at each end of the module into a resilient grommet (56) to provide a sealing relationship with the interior of the membrane tubes (50).,ABCOR INC,ROOS MARTIN;;EYKAMP WILLIAM;;COOPER IV WILLIAM W,,https://lens.org/102-606-690-717-628,Patent Application,yes,0,6,7,7,0,B01D61/10;;B01D63/063;;B01D65/02;;B01D2321/02;;B01D61/10;;B01D2321/02;;B01D63/063;;B01D65/02,B01D61/08;;B01D61/10;;B01D61/18;;B01D61/20;;B01D63/06;;B01D65/02;;B01D65/06;;B01D69/04,,0,0,,,,DISCONTINUED
401,AU,A1,AU 2017/321594 A1,155-121-968-157-547,2019-04-18,2019,AU 2017/321594 A,2017-08-30,US 201662382153 P;;US 2017/0049400 W,2016-08-31,Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate,"The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.",TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/155-121-968-157-547,Patent Application,no,0,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/395;;A61K31/4164;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,0,0,,,,DISCONTINUED
402,CN,A,CN 110167550 A,180-118-329-073-119,2019-08-23,2019,CN 201780061529 A,2017-08-30,US 201662382153 P;;US 2017/0049400 W,2016-08-31,SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE,"The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.",TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/180-118-329-073-119,Patent Application,no,0,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/395;;A61K31/4164;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,0,0,,,,DISCONTINUED
403,WO,A1,WO 1999/027720 A1,183-153-714-018-434,1999-06-03,1999,GB 9803420 W,1998-11-13,GB 9724612 A,1997-11-20,SUBSCRIBER TERMINAL FOR WIRELESS TELECOMMUNICATIONS SYSTEM,"The present invention provides a subscriber terminal for communicating over a wireless link with a central terminal of a wireless telecommunications system, the subscriber terminal comprising a first signal processing unit (110) associated with an antenna (100) to transmit and receive signals over the wireless link at first frequencies within an operating frequency band. The first signal processing unit comprises a frequency converter for converting signals between said first frequencies and a second frequency. Further, a second signal processing unit (130) is provided remote from the first signal processing unit and associated with an item of telecommunications equipment (150) to pass signals between said item of telecommunications equipment and the first signal processing unit. The second signal processing unit is formed from signal processing circuitry which is independent of the operating frequency band via a connection medium (120).",AIRSPAN COMM CORP;;AIRSPAN COMM LTD,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/183-153-714-018-434,Patent Application,yes,4,10,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,PATENTED
404,NO,D0,NO 20002087 D0,186-678-771-688-857,2000-04-19,2000,NO 20002087 A,2000-04-19,GB 9724612 A;;GB 9803420 W,1997-11-20,Abonnentterminal for trõdløst telekommunikasjonssystem,,AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/186-678-771-688-857,Patent Application,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,DISCONTINUED
405,GB,A9,GB 2331666 A9,016-422-023-014-079,,,GB 9724612 A,1997-11-20,GB 9724612 A,1997-11-20,Subscriber terminal for a wireless telecommunications system,,DSC TELECOM LP,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLER TARLOCHAN SINGH,,https://lens.org/016-422-023-014-079,Patent Application,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,H4L LECX          NONE;;H4L LEQF          LEQF;;H4L L1H9          LEQF;;H4L L217          LEQF;;H4L L30           LEQF,0,0,,,,DISCONTINUED
406,US,A,US 4769329 A,022-482-903-510-136,1988-09-06,1988,US 39363082 A,1982-06-30,DE 3126021 A,1981-07-02,Preparation of optically pure D- and L- lactic acid,"A process for the preparation of optically pure D- or L-lactic acid by fermentation of an aqueous nutrient medium, which contains nitrogen, vitamins, aminoacids, sugars and trace elements, by means of a microorganism, at pH 4-6, wherein the nutrient medium contains brewers' yeast as the source of nitrogen, vitamins, aminoacids and trace elements.",BASF AG,COOPER BRYAN;;KUESTERS WERNER;;MARTIN CHRISTOPH;;SIEGEL HARDO,BASF AKTIENGESELLSCHAFT (1982-06-22),https://lens.org/022-482-903-510-136,Granted Patent,yes,10,21,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,435/139;;435/42;;435/253;;435/256;;435/835;;435/940,7,2,046-174-104-918-422;;013-208-549-295-040,10.1111/j.1365-2672.1960.tb00188.x;;pmc375057;;10.1128/jb.17.5.329-337.1929;;16559366,"J. Appl. Bacteriol. 23 (1960), pp. 130 135.;;De Man, J. C. et al., Jour. Appl. Bact., vol. 23, (1), pp. 130 135 (1960), A Medium for the Cultivation of Lactobacilli .;;Chemical Abstracts, vol. 23, Abstract No. 3948 5, Neill, J. M. et al., The Use of Culture Media Made from Commercial Dried Yeast as a Routine Substitute for Meat Infusion Peptone Media .;;Chemical Abstracts, vol. 65, No. 3, 1966, Abstract No. 4616c, Krumphanzl, V. et al., Lactic Acid .;;Chemical Abstracts, vol. 82, 1975, p. 445, Abstract No. 56031w, Fujino, S. et al., Preparation of Yeast Extract by Cell Wall Lytic Enzymes .;;The Yeasts, vol. 3, Rose, A. H. et al., editors, Mixed Culture of Sak Yeast and Sak Lactic Acid Bacteria , Chapter 5, pp. 235 237, Academic Press, New York (1970).;;Chemical Abstracts 29, 1128 5 (1935).",EXPIRED
407,DE,T2,DE 69912618 T2,025-627-474-152-839,2004-10-28,2004,DE 69912618 T,1999-08-18,SE 9802895 A;;SE 9901400 W,1998-08-28,"NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE","Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/025-627-474-152-839,Granted Patent,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,EXPIRED
408,TR,T2,TR 200001603 T2,025-258-661-189-943,2000-10-23,2000,TR 200001603 T,1998-12-01,SE 9704542 A;;SE 9801989 A,1997-12-05,Yeni bileşikler,"Bulus, belirli pirolo-, tiyeno-, furano- ve pirazolo- [3,4-d] piridazinonlarla, bunlari hazirlama yöntemleriyle, bunlari içeren farmasötik bilesimlerle, farmasötik bilesimlerin hazirlanmasi için bir yöntemle ve bunlarin kullanimi kapsayan tedavi yöntemleriyle ilgilidir.",ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/025-258-661-189-943,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,PENDING
409,EP,B1,EP 3935307 B1,059-040-674-658-712,2024-01-10,2024,EP 20711274 A,2020-03-06,GB 201903074 A;;GB 2020050542 W,2019-03-07,GAS FLOW ALARM,,BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL;;RADFORD RICHARD,,https://lens.org/059-040-674-658-712,Granted Patent,yes,5,0,12,12,0,F17C2221/011;;F17C2223/0123;;F17C2223/0161;;F17C2223/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025;;F17C2250/036;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C7/00;;A61M16/0051;;A62B9/006;;A61M2016/0027;;A61M2016/003;;A61M16/0003;;A61M16/1005;;A61M16/0051;;A61M16/208;;A61M2016/0027;;A61M2016/0033;;A61M2205/581;;F17C13/02;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C2221/011;;F17C2223/0123;;F17C2250/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025,F17C7/00;;A61M16/00,,0,0,,,,ACTIVE
410,IS,A,IS 5198 A,069-956-131-556-173,1999-09-27,1999,IS 5198 A,1999-09-27,SE 9800640 W;;SE 9701398 A,1997-04-15,Ný efnasambönd,,ASTRAZENECA AB,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/069-956-131-556-173,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
411,NZ,A,NZ 338008 A,082-453-562-034-461,2001-04-27,2001,NZ 33800898 A,1998-04-07,SE 9800640 W;;US 70139897 A,1997-04-15,"Pyrazolo[3,4-d]pyrimidinedione compounds","A compound of formula (I) wherein: R1 is alkyl, alkenyl or cycloalkyl; R2 is alkyl or alkenyl; R3 is 1- or 2-indanyl, 1- or 2-(1,2,3,4-tetrahydronaphthalenyl), 9-fluorenyl, acenaphthyl or CHR4(CH2)nAr wherein n is 0 or 1, R4 is hydrogen or alkyl and Ar is quinolinyl, naphthalenyl, benzodioxolinyl optionally substituted by one or more halogen atoms, or phenyl optionally substituted by one or more substituent groups selected from halogen, alkyl, alkoxy and phenylsulfonylmethyl; W is H, CH2 OH, CO2 H, CO2alkyl, CH2NR5R6, CONR5R6, wherein R5 and R6 are independently hydrogen or alkyl, or W is pyridyl or phenyl, each of which may be optionally substituted by one or more substituent groups selected from halogen, hydroxyl, alkyl and alkoxy; X is a bond or alkylene; Y is S(O)p, C=C, CH=CH, CH2CH2 or CH2CH=CH; and p is 0, 1 or 2; or a pharmaceutically acceptable salt thereof, provided that X is not a bond when W is H, CH2 OH, CO2 H, CO2 C1-6 alkyl, CH2 NR5 R6 or CONR5 R6 and Y is sulfur.",ASTRAZENECA AB,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/082-453-562-034-461,Patent Application,no,0,0,1,1,0,,A61K31/415;;A61K31/505;;C07D487/04,,0,0,,,,PENDING
412,US,A1,US 2002/0099055 A1,080-650-062-614-03X,2002-07-25,2002,US 624401 A,2001-12-10,US 624401 A;;SE 9704542 A;;SE 9801989 A;;SE 9802191 W;;US 21475599 A,1997-12-05,Novel compounds,"
   The invention provides certain pyrrolo-, thieno-, furano-and pyrazolo-3,4-d-pyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use. 
",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/080-650-062-614-03X,Patent Application,yes,1,2,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,514/248;;544/236,0,0,,,,EXPIRED
413,CA,A1,CA 2312419 A1,141-597-348-231-115,1999-06-17,1999,CA 2312419 A,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,NOVEL COMPOUNDS,"The invention provides certain pyrrolo-, thieno-, furano- and pyrazolo-¢3,4-d!-pyridazinones of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.",ASTRAZENECA UK LTD,COOPER MARTIN;;BANTICK JOHN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/141-597-348-231-115,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
414,EP,A1,EP 1036076 A1,173-384-539-096-747,2000-09-20,2000,EP 98962754 A,1998-12-01,SE 9802191 W;;SE 9704542 A;;SE 9801989 A,1997-12-05,NOVEL COMPOUNDS,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/173-384-539-096-747,Patent Application,yes,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,EXPIRED
415,DE,D1,DE 69816608 D1,010-047-448-436-875,2003-08-28,2003,DE 69816608 T,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,"1H-PYRAZOLO[3,4-D]PYRIMIDINE-4,6-DIONE ALS INHIBITOREN FÜR DIE VERMEHRUNG VON T-ZELLEN",,ASTRAZENECA AB,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/010-047-448-436-875,Granted Patent,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
416,WO,A1,WO 1999/029695 A1,019-310-473-555-932,1999-06-17,1999,SE 9802191 W,1998-12-01,SE 9704542 A;;SE 9801989 A,1997-12-05,NOVEL COMPOUNDS,"The invention provides certain pyrrolo-, thieno-, furano- and pyrazolo-[3,4-d]-pyridazinones of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.",ASTRA PHARMA PROD;;ASTRA AB;;BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/019-310-473-555-932,Patent Application,yes,5,46,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,1,1,017-674-977-915-385,7728930;;10.1248/cpb.43.236,"CHEM. PHARM. BULL., Volume 43, No. 2, 1995, MASAHISA YAMAGUCHI et al., ""Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. V.1. Thienopyridazione Derivatives"", pages 236-240.",PATENTED
417,EP,A2,EP 0444829 A2,027-940-901-111-024,1991-09-04,1991,EP 91301431 A,1991-02-22,GB 9004396 A;;GB 9009485 A,1990-02-27,Immunosuppressive compounds.,"Compounds of formula I,
  
 wherein R¹ represents H, OH, protected OH or alkoxy; R² represents H; R³ represents O or (H,OH); R⁴ represents methyl, ethyl, propyl or allyl; R⁵ represents OH, protected OH or alkoxy; R⁶ represents OH; R⁷ represents OH, alkoxy or NR⁸R⁹ where R⁸ and R⁹ independently represent H, alkyl or aryl; in addition, R¹ and R² may together represent a second bond between the carbon atoms to which they are attached; and R⁶ and R⁷ may together represent O; and pharmaceutically acceptable salts thereof; are useful inter alia as immunosuppressive agents. The invention also provides the novel compounds of formula I.",FISONS PLC;;FUJISAWA PHARMACEUTICAL CO,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;TANAKA HIROKAZU,,https://lens.org/027-940-901-111-024,Patent Application,yes,0,6,4,6,0,A61P37/06;;C07D309/30;;C07D309/30;;C07C69/734;;C07C69/734;;C07C69/738;;C07C69/738;;C07C235/30;;C07C235/30;;C07C403/20;;C07C403/20;;C07C2601/14;;C07C2601/14,A61K31/16;;A61K31/165;;A61K31/19;;A61K31/215;;A61K31/23;;A61P37/06;;C07C59/62;;C07C59/90;;C07C69/734;;C07C69/738;;C07C233/10;;C07C235/30;;C07C235/78;;C07D309/30;;C07D498/18,,0,0,,,,DISCONTINUED
418,EP,A1,EP 0975636 A1,042-880-316-487-591,2000-02-02,2000,EP 98917859 A,1998-04-07,SE 9800640 W;;SE 9701398 A,1997-04-15,NOVEL COMPOUNDS,,ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,ASTRAZENECA AB (2000-08-30);;ASTRAZENECA UK LIMITED (2000-05-10),https://lens.org/042-880-316-487-591,Patent Application,yes,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
419,DE,T2,DE 69806633 T2,069-631-553-610-875,2002-11-28,2002,DE 69806633 T,1998-11-13,GB 9724612 A;;GB 9803420 W,1997-11-20,TEILNEHMERENDGERÄT FÜR EIN DRAHTLOSES TELEKOMMUNIKATIONSSYSTEM,,AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,"AIRSPAN NETWORKS INC., BOCA RATON, FLORIDA, US (2004-05-27)",https://lens.org/069-631-553-610-875,Granted Patent,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,EXPIRED
420,PT,A,PT 97377 A,061-064-459-076-451,1992-01-31,1992,PT 9737791 A,1991-04-16,GB 9008507 A;;GB 9008556 A;;GB 9009480 A;;GB 9017447 A;;GB 9023242 A,1990-04-17,Process for the preparation of macrocyclic immunosuppressive compounds,"The invention relates to a process for the preparation of a compound of formula I <IMAGE> and of the pharmaceutically acceptable derivatives thereof, which notably comprises a) obtaining a compound of formula I in which R1 and R2 together represent a second carbon-carbon bond between the carbon atoms to which they are bound, by dehydration of a corresponding compound in which R1 represents OH and R2 represents H; b) obtaining a compound of formula I in which R1 and R2 individually represent the hydrogen atom, by reduction of a corresponding compound in which R1 and R2 together represent a second carbon-carbon bond between the carbon atoms to which they are bound; c) obtaining a compound of formula I in which X represents (H, OH), by reduction of a corresponding compound in which X represents O; [remainder of abstract missing?]",FISONS PLC,COOPER MARTIN EDWARD;;FURBER MARK;;DONALD DAVID KEITH,,https://lens.org/061-064-459-076-451,Patent Application,no,0,0,1,12,0,,A61K/;;C07D/,,0,0,,,,DISCONTINUED
421,BR,A,BR 9813373 A,091-069-014-843-997,2000-10-03,2000,BR 9813373 A,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,"Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente","""COMPOSTO, PROCESSO PARA A PREPARAçãO DO MESMO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA PREPARAçãO DA MESMA, USO DE UM COMPOSTO, E, PROCESSOS PARA EFETUAR IMUNOSSUPRESSãO E PARA TRATAR OU REDUZIR O RISCO DE UMA DOENçA DAS VIAS AéREAS OBSTRUTIVA REVERSìVEL EM UM PACIENTE"" A invenção provê certas pirrol-, tieno-, furano-, e pirazol - [3,4-d]-piridazinonas de fórmula geral (I): processos para a sua preparação, composições farmacêuticas contendo as mesmas, um processo para preparar as composições farmacêuticas, e processos de tratamento envolvendo o seu uso.",ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/091-069-014-843-997,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
422,AU,A1,AU 2020/231606 A1,110-835-664-400-095,2021-09-23,2021,AU 2020/231606 A,2020-03-06,GB 201903074 A;;GB 2020050542 W,2019-03-07,Gas flow alarm,"Aspects and embodiments relate to a gas flow alarm apparatus and gas flow alarm method. The apparatus comprises: a device configurable to introduce back pressure into a flow of gas, a supply sensor configured to determine whether gas flow to the device is enabled; a pressure sensor configured to determine whether a flow of gas through the device has developed back pressure; and logic circuitry in communication with the supply sensor and the pressure sensor configured to determine whether gas flow to the device is enabled and whether a flow of gas through the device has developed back pressure and, if not, to activate an alarm condition. Aspects and embodiments can provide a system which operates to warn a user against various adverse conditions in which a flow of therapeutic gas to a patient is required, yet not being provided.",BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL;;RADFORD RICHARD,,https://lens.org/110-835-664-400-095,Patent Application,no,0,0,12,12,0,F17C2221/011;;F17C2223/0123;;F17C2223/0161;;F17C2223/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025;;F17C2250/036;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C7/00;;A61M16/0051;;A62B9/006;;A61M2016/0027;;A61M2016/003;;A61M16/0003;;A61M16/1005;;A61M16/0051;;A61M16/208;;A61M2016/0027;;A61M2016/0033;;A61M2205/581;;F17C13/02;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C2221/011;;F17C2223/0123;;F17C2250/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025,F17C7/00;;A61M16/00,,0,0,,,,PENDING
423,ID,A,ID 22746 A,127-484-822-649-220,1999-12-09,1999,ID 991207 A,1998-04-07,SE 9701398 A,1997-04-15,SENYAWA-SENYAWA BARU,,ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/127-484-822-649-220,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
424,AU,B2,AU 763758 B2,133-102-301-310-222,2003-07-31,2003,AU 1999/057677 A,1999-08-18,SE 9802895 A;;SE 9901400 W,1998-08-28,Novel compounds,"Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/133-102-301-310-222,Granted Patent,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,EXPIRED
425,EE,A,EE 9900465 A,029-867-670-013-148,2000-04-17,2000,EE P9900465 A,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,Uued ühendid,,ASTRA PHARMA PROD,DAVID CHESHIRE;;MARTIN COOPER;;DAVID DONALD;;PHILIP THORNE,,https://lens.org/029-867-670-013-148,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
426,WO,A1,WO 2020/178600 A1,095-193-170-408-94X,2020-09-10,2020,GB 2020050542 W,2020-03-06,GB 201903074 A,2019-03-07,GAS FLOW ALARM,"Aspects and embodiments relate to a gas flow alarm apparatus and gas flow alarm method. The apparatus comprises: a device configurable to introduce back pressure into a flow of gas, a supply sensor configured to determine whether gas flow to the device is enabled; a pressure sensor configured to determine whether a flow of gas through the device has developed back pressure; and logic circuitry in communication with the supply sensor and the pressure sensor configured to determine whether gas flow to the device is enabled and whether a flow of gas through the device has developed back pressure and, if not, to activate an alarm condition. Aspects and embodiments can provide a system which operates to warn a user against various adverse conditions in which a flow of therapeutic gas to a patient is required, yet not being provided.",BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL;;RADFORD RICHARD,,https://lens.org/095-193-170-408-94X,Patent Application,yes,7,0,12,12,0,F17C2221/011;;F17C2223/0123;;F17C2223/0161;;F17C2223/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025;;F17C2250/036;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C7/00;;A61M16/0051;;A62B9/006;;A61M2016/0027;;A61M2016/003;;A61M16/0003;;A61M16/1005;;A61M16/0051;;A61M16/208;;A61M2016/0027;;A61M2016/0033;;A61M2205/581;;F17C13/02;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C2221/011;;F17C2223/0123;;F17C2250/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025,F17C7/00;;A61M16/00,,0,0,,,,PENDING
427,SK,A3,SK 135699 A3,096-083-692-197-739,2000-05-16,2000,SK 135699 A,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,"PYRAZOLO[3,4-D]PYRIMIDINEDIONE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE",,ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/096-083-692-197-739,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
428,US,B1,US 6342601 B1,103-189-951-292-122,2002-01-29,2002,US 21475599 A,1999-01-12,SE 9704542 A;;SE 9801989 A,1997-12-05,Compounds,"
    The invention provides certain pyrrolo-, thieno-, furano- and pyrazolo-3,4-dpyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use. 
",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,ASTRAZENECA UK LIMITED (2001-01-25);;ASTRA PHARMACEUTICALS LTD (1998-12-18),https://lens.org/103-189-951-292-122,Granted Patent,yes,6,118,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,544/235;;514/248,3,1,017-674-977-915-385,7728930;;10.1248/cpb.43.236,"Chemical Abstracts, 28-Heterocycles, vol. 115, pp. 869 (1991).;;Chemical Abstracts, Accession No. 115:256193, Ohi et al.;;Yamaguchi et al, ""Novel Antiasthmatic Agents with Dual . . . ,"" Chem. Pharm. Bull., vol. 43, No. 2, pp. 236-240 (1995).",EXPIRED
429,US,B1,US 6300334 B1,109-547-810-147-023,2001-10-09,2001,US 40283799 A,1999-10-13,SE 9802895 A;;SE 9901400 W,1998-08-28,"Thieno[2,3-d]pyrimidine-2,4-diones","Compounds of formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,ASTRAZENECA UK LIMITED (2001-01-25);;ASTRA PHARMACEUTICALS LTD (1999-10-04),https://lens.org/109-547-810-147-023,Granted Patent,yes,2,17,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,514/258;;544/278,2,1,024-960-871-387-554,10.1002/ardp.19953280305;;7763139,"Fukumi et al, Chemical Abstracts, vol. 112, No. 139045t, pp. 722-723 (1990).;;Gutschowe et al, ""3-Mercaptoalkylthieno[2,3-d]pyrimidin-2,4(1H,3H)-dione: Synthese . . . ,"" Arch. Pharm. (Weinheim), vol. 328, pp. 231-234 (1995).",EXPIRED
430,PT,A,PT 95038 A,158-997-654-000-374,1991-04-18,1991,PT 9503890 A,1990-08-17,GB 8918886 A;;GB 8918929 A,1989-08-18,PROCESSO PARA A PREPARACAO DE COMPOSTOS MACROCICLICOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM,,FISONS PLC,DONALD DAVID KEIT;;COOPER MARTIN EDWARD;;FURBER MARK,,https://lens.org/158-997-654-000-374,Patent Application,no,0,0,11,13,0,A61P37/06;;C07H15/26;;C07H19/01;;C07H19/01,C07D498/18;;A61K31/445;;A61P37/06;;C07H19/01,,0,0,,,,DISCONTINUED
431,AU,B2,AU 733066 B2,168-214-535-089-598,2001-05-03,2001,AU 1998/070909 A,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,Novel compounds,,ASTRAZENECA AB,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,ASTRAZENECA AB (2001-01-04),https://lens.org/168-214-535-089-598,Granted Patent,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,EXPIRED
432,NZ,A,NZ 504452 A,174-418-577-928-099,2002-05-31,2002,NZ 50445298 A,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,"[3,4-d]Pyridazinones, process for their preparation and pharmaceutical compositions containing them","Pyrrolo-, thieno-, furano- and pyrazolo-[3,4-d]pyridazinones of general formula I, processes for their preparation, pharmaceutical compositions containing them, and processes for preparing the pharmaceutical compositions.",ASTRAZENECA UK LTD,THORNE PHILIP;;PERRY MATTHEW;;BANTICK JOHN;;COOPER MARTIN,,https://lens.org/174-418-577-928-099,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,PENDING
433,CA,A,CA 1193992 A,025-058-921-138-290,1985-09-24,1985,CA 406410 A,1982-06-30,DE 3126021 A,1981-07-02,PREPARATION OF OPTICALLY PURE D- AND L- LACTIC ACID,"of the Disclosure: A process for the preparation of optically pure D- or L-lactic acid by fermentation of an aqueous nutrient medium, which contains nitrogen, vitamins, aminoacids, sugars and trace elements, by means of a microorganism, at pH 4 - 6, wherein the nutrient medium contains brewers' yeast as the source of nitrogen, vitamins, aminoacids and trace elements.",BASF AG,COOPER BRYAN;;KUESTERS WERNER;;MARTIN CHRISTOPH;;SIEGEL HARDO,,https://lens.org/025-058-921-138-290,Granted Patent,no,0,1,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,195-133,0,0,,,,EXPIRED
434,US,B1,US 6298246 B1,067-361-718-966-15X,2001-10-02,2001,US 19299498 A,1998-11-16,GB 9724612 A,1997-11-20,Subscriber terminal and method for passing control signals between a first and second signal processing units,"The present invention provides a subscriber terminal for communicating over a wireless link with a central terminal of a wireless telecommunications system, the subscriber terminal comprising a first signal processing unit associated with an antenna to transmit and receive signals over the wireless link at first frequencies within an operating frequency band. The first signal processing unit comprises a frequency converter for converting signals between said first frequencies and a second frequency. Further, a second signal processing unit is provided remote from the first signal processing unit and associated with an item of telecommunications equipment to pass signals between said item of telecommunications equipment and the first signal processing unit. The second signal processing unit is formed from signal processing circuitry which is independent of the operating frequency band, the signals being passed between the first signal processing unit and the second signal processing unit at the second frequency via a connection medium connecting the first and second signal processing units. Given this approach, the second signal processing unit can then be formed from signal processing circuitry which is independent of the operating frequency band.",AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN L;;GOHLAR TARLOCHAN S,AIRSPAN MERGER CORPORATION (1999-08-06);;AIRSPAN NETWORKS INC (1999-12-15);;DSC TELECOM L.P (1997-11-17);;AIRSPAN COMMUNICATIONS CORPORATION (1999-08-06);;AIRSPAN COMMUNICATIONS CORPORATION A CORP. OF DE (1998-01-30),https://lens.org/067-361-718-966-15X,Granted Patent,yes,22,43,17,17,0,H04B7/26;;H04B7/26,H04B7/26,455/557,0,0,,,,EXPIRED
435,US,A,US 5210227 A,072-934-563-821-082,1993-05-11,1993,US 66180291 A,1991-02-27,GB 9004396 A;;GB 9009485 A,1990-02-27,IMMUNOSUPPRESSIVE COMPOUNDS,"Compounds of formula I, ##STR1## wherein R.sup.1 represents H, OH, protected OH or alkoxy; R.sup.2 represents H; R.sup.3 represents O or (H,OH); R.sup.4 represents methyl, ethyl, propyl or allyl; R.sup.5 represents OH, protected OH or alkoxy; R.sup.6 represents OH; R.sup.7 represents OH, alkoxy or NR.sup.8 R.sup.9 where R.sup.8 and R.sup.9 independently represent H, alkyl or aryl; in addition, R.sup.1 and R.sup.2 may together represent a second bond between the carbon atoms to which they are attached; and R.sup.6 and R.sup.7 may together represent O; and pharmaceutically acceptable salts thereof; are useful inter alia as immunosuppressive agents. The invention also provides the novel compounds of formula I.",FISONS PLC;;FUJISAWA PHARMACEUTICAL CO,TANAKA HIROKAZU;;COOPER MARTIN E;;DONALD DAVID K,FISONS PLC (1991-02-15);;FISON PLC (1991-02-16);;FUJISAWA PHARMACEUTICAL COMPANY LIMITED (1991-02-15);;FUJISAWA PHARMACEUTICAL COMPANY (1991-02-16),https://lens.org/072-934-563-821-082,Granted Patent,yes,1,0,4,6,0,A61P37/06;;C07D309/30;;C07D309/30;;C07C69/734;;C07C69/734;;C07C69/738;;C07C69/738;;C07C235/30;;C07C235/30;;C07C403/20;;C07C403/20;;C07C2601/14;;C07C2601/14,A61K31/16;;A61K31/165;;A61K31/19;;A61K31/215;;A61K31/23;;A61P37/06;;C07C59/62;;C07C59/90;;C07C69/734;;C07C69/738;;C07C233/10;;C07C235/30;;C07C235/78;;C07D309/30;;C07D498/18,549/273;;554/35;;554/69;;554/127;;554/167;;554/141;;554/158;;554/156,1,0,,,"Coleman, R. et al, Heterocycles, vol. 28, 1, 1989, pp. 107 161.",EXPIRED
436,BR,A,BR 9808540 A,098-335-277-655-350,2000-05-23,2000,BR 9808540 A,1998-04-07,SE 9701398 A;;SE 9800640 W,1997-04-15,"Composto, processo para a preparação do mesmo, composição farmacêutica e processo para preparação dos mesmos, uso de um composto, e, processo para produzir a imunossupressão","""COMPOSTO, PROCESSO PARA A PREPARAçãO DO MESMO, COMPOSIçãO FARMACêUTICA E PROCESSO PARA PREPARAçãO DOS MESMOS, USO DE UM COMPOSTO, E, PROCESSO PARA PRODUZIR A IMUNOSSUPRESSãO"". A presente invenção diz respeito a compostos de pirazol[3,4-d]pirimidinodiona farmaceuticamente utilizáveis da fórmula (I): processos para a sua produção, composições farmacêuticas que os contenham e seu uso para o tratamento de várias doenças.",ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/098-335-277-655-350,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,DISCONTINUED
437,CA,A1,CA 3132284 A1,111-585-185-194-594,2020-09-10,2020,CA 3132284 A,2020-03-06,GB 201903074 A;;GB 2020050542 W,2019-03-07,GAS FLOW ALARM,"Aspects and embodiments relate to a gas flow alarm apparatus and gas flow alarm method. The apparatus comprises: a device configurable to introduce back pressure into a flow of gas, a supply sensor configured to determine whether gas flow to the device is enabled; a pressure sensor configured to determine whether a flow of gas through the device has developed back pressure; and logic circuitry in communication with the supply sensor and the pressure sensor configured to determine whether gas flow to the device is enabled and whether a flow of gas through the device has developed back pressure and, if not, to activate an alarm condition. Aspects and embodiments can provide a system which operates to warn a user against various adverse conditions in which a flow of therapeutic gas to a patient is required, yet not being provided.",BPR MEDICAL LTD,JOHNSON BENJAMIN;;COOPER MARTIN;;BRUDENELL MICHAEL;;RADFORD RICHARD,,https://lens.org/111-585-185-194-594,Patent Application,no,0,0,12,12,0,F17C2221/011;;F17C2223/0123;;F17C2223/0161;;F17C2223/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025;;F17C2250/036;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C7/00;;A61M16/0051;;A62B9/006;;A61M2016/0027;;A61M2016/003;;A61M16/0003;;A61M16/1005;;A61M16/0051;;A61M16/208;;A61M2016/0027;;A61M2016/0033;;A61M2205/581;;F17C13/02;;F17C2205/0329;;F17C2205/0335;;F17C2205/0338;;F17C2205/035;;F17C2221/011;;F17C2223/0123;;F17C2250/036;;F17C2250/043;;F17C2250/0443;;F17C2270/025,F17C7/00;;A61M16/00,,0,0,,,,PENDING
438,HU,B,HU 191069 B,118-020-487-425-737,1987-01-28,1987,HU 216582 A,1982-07-01,DE 3126021 A,1981-07-02,PROCESS FOR PREPARING OPTICALLY PURE D- OR L-LACTIC ACID,,BASF AG,COOPER BRYAN;;KUESTERS WERNER;;MARTIN CHRISTOPH;;SIEGEL HARDO,,https://lens.org/118-020-487-425-737,Granted Patent,no,0,0,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,,0,0,,,,EXPIRED
439,EP,A3,EP 0444829 A3,105-713-333-303-569,1992-06-03,1992,EP 91301431 A,1991-02-22,GB 9004396 A;;GB 9009485 A,1990-02-27,IMMUNOSUPPRESSIVE COMPOUNDS,"Compounds of formula I,
  
 wherein R¹ represents H, OH, protected OH or alkoxy; R² represents H; R³ represents O or (H,OH); R⁴ represents methyl, ethyl, propyl or allyl; R⁵ represents OH, protected OH or alkoxy; R⁶ represents OH; R⁷ represents OH, alkoxy or NR⁸R⁹ where R⁸ and R⁹ independently represent H, alkyl or aryl; in addition, R¹ and R² may together represent a second bond between the carbon atoms to which they are attached; and R⁶ and R⁷ may together represent O; and pharmaceutically acceptable salts thereof; are useful inter alia as immunosuppressive agents. The invention also provides the novel compounds of formula I.","FISONS PLC;;FUJISAWA PHARMACEUTICAL CO., LTD.","COOPER, MARTIN EDWARD;;DONALD, DAVID KEITH;;TANAKA, HIROKAZU",,https://lens.org/105-713-333-303-569,Search Report,yes,1,0,4,6,0,A61P37/06;;C07D309/30;;C07D309/30;;C07C69/734;;C07C69/734;;C07C69/738;;C07C69/738;;C07C235/30;;C07C235/30;;C07C403/20;;C07C403/20;;C07C2601/14;;C07C2601/14,A61K31/16;;A61K31/165;;A61K31/19;;A61K31/215;;A61K31/23;;A61P37/06;;C07C59/62;;C07C59/90;;C07C69/734;;C07C69/738;;C07C233/10;;C07C235/30;;C07C235/78;;C07D309/30;;C07D498/18,,1,1,156-051-682-183-884,10.3987/com-88-s70,"HETEROCYCLES vol. 28, no. 1, 1989, SENDAI, JP pages 157 - 161; R. S. COLEMAN ET AL: 'DEGRADATION AND MANIPULATIONS OF THE IMMUNOSUPPRESSANT FK506'",DISCONTINUED
440,CA,A1,CA 3034606 A1,133-260-761-322-607,2018-03-08,2018,CA 3034606 A,2017-08-30,US 201662382153 P;;US 2017/0049400 W,2016-08-31,SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE,"The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.",TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/133-260-761-322-607,Patent Application,no,0,1,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,A61K31/395;;A61K31/4164;;A61K31/4178;;A61K31/513;;A61K31/55;;A61K45/00,,0,0,,,,DISCONTINUED
441,US,B2,US 6770646 B2,182-180-974-713-473,2004-08-03,2004,US 624401 A,2001-12-10,US 624401 A;;SE 9704542 A;;SE 9801989 A;;SE 9802191 W;;US 21475599 A,1997-12-05,Substituted fused pyridazinone compounds; composition and use thereof,"
    The invention provides certain pyrrolo-, thieno-, furano-and pyrazolo-3,4-d-pyridazinones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use. 
",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/182-180-974-713-473,Granted Patent,yes,6,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,514/248;;544/235,8,3,017-674-977-915-385;;026-439-945-178-209;;001-381-613-772-520,7728930;;10.1248/cpb.43.236;;10.3987/com-94-s47;;10.1016/0040-4020(84)85076-0,"Chemical Abstracts, 28-Heterocycles, vol. 115, pp. 869 (1991).;;Chemical Abstracts, Accession No. 115:256193, Ohi et al, 1991.;;Yamaguchi et al, ""Novel Antiasthmatic Agents with Dual . . . ,"" Chem. Pharm. Bull., vol. 43, No. 2, pp. 236-240 (1995).;;Bulletin De La Societe Chimique De France, vol. 11, 1967; par Max Robba et al; ""No. 727. -Contribution à l' étude de la thiéno-[2,3-d] pyridazine et de la thiéno-[3,4-d] pyridazine ("")""; pp. 4220-4235, p. 4220, Nos. 14, 15; p. 4221, Nos. 19, 10; p. 4223, Nos. 10,46, 40,15.;;STN International, File CAPLUS, CAPLUS accession No. 1995:932946, Yutilov, Yu. M. et al; ""Reaction of 7-nitrothieno(3,2-c)pyridine-4-one with hydrazine"", Zh. Org. Khim. (1995), 31(2), 304.;;Heterocycles; vol. 40, No. 1, 1995, Francisco Farina et al.; ""1,3-Dipolar Cycloadditions of an Aziridine via Azomethine Ylide to 2-Methylpyridazin-3(2H)-Ones""; pp. 379-386.;;Tetrahedron, vol. 40, No. 20, 1984, Sermin Inel, ""Pyrrole Studies: 31.1 The Structures of Potentially Tautomeric 1,2-Dihydro-6H-Pyrrolo(3,4-d)Pyridazine-1-Ones and 1,2,3,4-Tetrahydro-6H-Pyrrolo(3,4-d)Pyridazine-1,4-Diones"", pp. 3979-3986, p. 3981, Nos. 10 a,b,c,d,e; p. 3980 Nos. 2a,b,c,d,e.;;Société Chimiquede France Paris Bulletin; vol. 7, 1967, par Max Robba et al, ""No. 447. -Syntése de thiéno-(2,3-d)pyridazines et de thiéno-(3,4-d) pyridazines à partir de dérivés thiophéniques""; pp. 2495-2507, p. 2499, Nos. 46-48, 61-65.",EXPIRED
442,US,A,US 4309287 A,024-226-399-479-677,1982-01-05,1982,US 14582980 A,1980-05-01,US 14582980 A,1980-05-01,Reverse-osmosis tubular membrane,"A membrane module which includes a unitary, curved, backing support which retains all the U bends, serially connecting the membrane tubes, in a sealing relationship, and which includes an annular permeate-collector ring system at the end of each membrane tube and channels with a permeate manifold passageway, to provide efficient removal and easy cleaning of the permeate flow path.",ABCOR INC,ROOS MARTIN;;EYKAMP WILLIAM;;COOPER IV WILLIAM W,KOCH MEMBRANE SYSTEMS INC (1986-05-20),https://lens.org/024-226-399-479-677,Granted Patent,yes,8,27,7,7,0,B01D61/10;;B01D63/063;;B01D65/02;;B01D2321/02;;B01D61/10;;B01D2321/02;;B01D63/063;;B01D65/02,B01D61/08;;B01D61/10;;B01D61/18;;B01D61/20;;B01D63/06;;B01D65/02;;B01D65/06;;B01D69/04,210/247,1,0,,,"Kremen, S. S., ""Technology and Eng. of Roga Spiral-Wound R.O. Memb. Modules"", in R.O. and Synthetic Membranes, S. Sourirajan Editor 1977.",EXPIRED
443,MX,A,MX PA00005506 A,052-250-499-613-576,2008-09-11,2008,MX PA00005506 A,1998-12-01,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,NOVEL COMPOUNDS.,"The invention provides certain pyrrolo-, thieno-, furano- and pyrazolo-[3,4-d]-pyridazinones of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.",ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/052-250-499-613-576,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,C07D487/04;;A61K31/00;;A61K31/5025;;A61P11/00;;A61P37/06;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
444,DE,T2,DE 69725994 T2,122-998-417-889-067,2004-09-02,2004,DE 69725994 T,1997-09-19,US 2644296 P;;US 9716690 W,1996-09-19,KONZENTRIERTE QUATERNÄRE AMMONIUMGEWEBEWEICHMACHERZUSAMMENSETZUNGEN MIT KATIONISCHEN POLYMEREN,,PROCTER & GAMBLE,COOPER A;;TRINH TOAN;;WAHL HOFFMAN;;WARD MARTIN,,https://lens.org/122-998-417-889-067,Granted Patent,no,0,1,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,D06M13/322;;C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,EXPIRED
445,DE,D1,DE 69912618 D1,163-678-546-545-978,2003-12-11,2003,DE 69912618 T,1999-08-18,SE 9802895 A;;SE 9901400 W,1998-08-28,"NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE","Compounds of formula (I):wherein R1, R2, and R3 are defined in the specification. The compounds are useful for treating or reducing the risk of reversible obstructive airways disease.",ASTRAZENECA AB,BANTICK JOHN;;COOPER MARTIN;;PERRY MATTHEW;;THORNE PHILIP,,https://lens.org/163-678-546-545-978,Granted Patent,no,0,0,15,15,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04,A61K31/522;;A61P1/00;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/02;;A61P11/06;;A61P13/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/06;;A61P27/16;;A61P29/00;;A61P31/08;;A61P31/18;;A61P37/02;;A61P37/06;;A61P43/00;;C07D495/04,,0,0,,,,EXPIRED
446,US,A1,US 2018/0057481 A1,054-611-414-631-809,2018-03-01,2018,US 201715691191 A,2017-08-30,US 201715691191 A;;US 201662382153 P,2016-08-31,SOLID FORMS OF CENICRIVIROC MESYLATE AND PROCESSES OF MAKING SOLID FORMS OF CENICRIVIROC MESYLATE,"The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.",TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/054-611-414-631-809,Patent Application,yes,1,1,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,C07D403/12;;C07C309/04,,0,0,,,,ACTIVE
447,SE,L,SE 7502003 L,076-852-437-649-206,1976-08-23,1976,SE 7502003 A,1975-02-21,SE 7502003 A,1975-02-21,SYSTEM FOR VAL OCH INDIKERING AV VISUELL INFORMATION,,INST PERSONAL DEV,MARTIN G;;COOPER K;;DARL A;;HARRIS S,,https://lens.org/076-852-437-649-206,Abstract,no,0,0,1,1,0,G09B5/00,G09B5/00,,0,0,,,,DISCONTINUED
448,PL,A1,PL 340836 A1,069-871-822-543-07X,2001-02-26,2001,PL 34083698 A,1998-12-01,SE 9704542 A;;SE 9801989 A,1997-12-05,NOVEL COMPOUNDS,,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/069-871-822-543-07X,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
449,SE,D0,SE 9801989 D0,080-682-854-379-572,1998-06-04,1998,SE 9801989 A,1998-06-04,SE 9801989 A,1998-06-04,Novel compounds,,ASTRA PHARMA PROD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/080-682-854-379-572,Patent Application,no,0,0,1,29,0,,C07D/,,0,0,,,,PENDING
450,EP,A3,EP 0039583 A3,083-781-145-182-884,1982-02-24,1982,EP 81301910 A,1981-04-30,US 14582980 A,1980-05-01,REVERSE-OSMOSIS TUBULAR MEMBRANE MODULE,A reverse-osmosis tubular membrane module has a plurality of tubular membrane tubes (50) arranged in a set of parallel supporting tubes (12) with an axial annular permeate flow channel (64) defined between each membrane tube and the supporting tubes (12) within which it is contained and containing an open neck resilient material (54). Supports (18) are provided at each end of the supporting tubes to receive the opposite ends of the membrane tubes and have permeate collection passageways (24) therein connected (at 46) to receive permeate from the annular channels (64). U-shaped connecting tubes (26) connect the adjacent ends of pairs of membrane tubes to provide a continuous flow path with the interior of the membrane tubes of the module. Means are provided for forcing the U-shaped connecting tubes (26) at each end of the module into a resilient grommet (56) to provide a sealing relationship with the interior of the membrane tubes (50).,"ABCOR, INC.","ROOS, MARTIN;;EYKAMP, WILLIAM;;COOPER IV, WILLIAM W.",,https://lens.org/083-781-145-182-884,Search Report,yes,13,0,7,7,0,B01D61/10;;B01D63/063;;B01D65/02;;B01D2321/02;;B01D61/10;;B01D2321/02;;B01D63/063;;B01D65/02,B01D61/08;;B01D61/10;;B01D61/18;;B01D61/20;;B01D63/06;;B01D65/02;;B01D65/06;;B01D69/04,,0,0,,,,DISCONTINUED
451,GB,A,GB 2331666 A,096-516-056-611-979,1999-05-26,1999,GB 9724612 A,1997-11-20,GB 9724612 A,1997-11-20,Subscriber Terminal for a Wireless Telecommunications System,"A subscriber terminal comprises a first signal processing unit (110) associated with an antenna to transmit and receive signals over the wireless link at first frequencies within an operating frequency band. The first signal processing unit comprises a frequency converter for converting signals between said first frequencies and a second frequency. A second signal processing unit (130) is provided remote from the first signal processing unit and associated with an item of telecommunications equipment. The second signal processing unit is formed from signal processing circuitry which is independent of the operating frequency band, the signals being passed between the first signal processing unit and the second signal processing unit at the second frequency via a connection medium (120) connecting the first and second signal processing units. Hence, the same second signal processing unit can be used irrespective of the operating frequency band used for the wireless communications between the subscriber terminal and a central terminal. Further, the above approach significantly reduces the amounts of circuitry required within the first signal processing unit associated with the antenna and typically located outside a building.",DSC TELECOM LP,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/096-516-056-611-979,Patent Application,no,4,6,17,17,0,H04B7/26;;H04B7/26,H04B7/26,H4L LECX          LECX;;H4L L30           LECX,0,0,,,,DISCONTINUED
452,KR,A,KR 20190057066 A,141-287-369-076-827,2019-05-27,2019,KR 20197008786 A,2017-08-30,US 201662382153 P;;US 2017/0049400 W,2016-08-31,세니크리비록 메실레이트의 고체 형태 및 세니크리비록 메실레이트의 고체 형태의 제조 방법,"본 발명은 세니크리비록 메실레이트의 고체 형태, 이의 제조 방법, 이의 약제학적 조성물 및 이들의 사용 방법에 관한 것이다.",TOBIRA THERAPEUTICS INC,PHIASIVONGSA PASIT;;COOPER MARTIN IAN;;SHARP EMMA KAY,,https://lens.org/141-287-369-076-827,Patent Application,no,0,0,17,17,0,C07D403/12;;C07B2200/13;;C07C309/04;;A61P1/16;;A61P13/12;;A61P1/16;;A61K31/395;;C07C309/04;;C07D403/12;;C07B2200/13;;C07D403/12;;C07B2200/13;;C07C309/04,C07D403/12;;A61K31/395;;A61P1/16;;C07C309/04,,0,0,,,,DISCONTINUED
453,CZ,A3,CZ 20002039 A3,151-196-303-219-150,2000-10-11,2000,CZ 20002039 A,1998-12-01,CZ 20002039 A,1998-12-01,"Novel pyridazinone compounds, process of their preparation and pharmaceutical preparation containing thereof",,ASTRAZENECA UK LTD,BANTICK JOHN;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/151-196-303-219-150,Patent Application,no,0,0,1,1,0,,A61K31/415;;A61K31/50;;A61P11/00;;C07D487/04;;C07D491/04;;C07D495/04,,0,0,,,,PENDING
454,HU,A2,HU P0002104 A2,165-551-894-553-397,2001-01-29,2001,HU P0002104 A,1998-04-07,SE 9701398 A,1997-04-15,"PYRAZOLO[3,4-D]PYRIMIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","Atalálmány tárgyát az (I) általános képletű, új pirazolo[3,4-d]pirimidindion-származékok - ahol az (I) általános képletben aszubsztituensek főbb jelentései: R1 és R2 alkil- vagy alkenilcsoport;R3 -CHR4(CH2)nAr általános képletű csoport, amelyben n értéke 0, R4hidrogénatom, és Ar kinolil-, naftil-, adott esetben szubsztituáltbenzodioxolil- vagy fenilcsoport; W hidrogénatom, hidroxi-metil-,karboxi-, alkoxi-karbonil- vagy piridilcsoport; X vegyértékvonal vagyalkiléncsoport; és Y kénatom vagy etiléncsoport - és előállításukraszolgáló eljárás, immunszuppresszánsként való gyógyászatialkalmazásuk, hatóanyagként ezeket tartalmazó gyógyszerkészítmények,valamint ezek előállítása képezik. Ó",ASTRA PHARMA PROD,CHESHIRE DAVID;;COOPER MARTIN;;DONALD DAVID;;THORNE PHILIP,,https://lens.org/165-551-894-553-397,Patent Application,no,0,0,26,26,0,A61K31/506;;C07D487/04;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04;;A61K31/519;;C07D487/04;;A61K31/506,A61K31/506;;A61K31/519;;A61P11/06;;A61P17/00;;A61P19/02;;A61P27/16;;A61P31/18;;A61P37/06;;A61P43/00;;C07D487/04,,0,0,,,,PENDING
455,TR,T2,TR 200001446 T2,189-846-241-485-04X,2000-09-21,2000,TR 200001446 T,1998-11-13,GB 9724612 A,1997-11-20,Telsiz iletişim sistemi için abone terminali.,"Bu bulus telsiz bir baglanti üzerinden telsiz bir telekomünikasyon sisteminin merkez terminali ile iletisim kurmak için bir abone terminali saglar, ve abone terminali, telsiz baglanti üzerinden bir çalisma frekansi bandindaki birinci frekanslarda sinyaller göndermek ve almak için bir antene (100) bagli bir sinyal isleme biriminden (110) olusur.",AIRSPAN NETWORKS INC,LYSEJKO MARTIN;;COOPER IAN LESLIE;;GOHLAR TARLOCHAN SINGH,,https://lens.org/189-846-241-485-04X,Patent Application,no,0,0,17,17,0,H04B7/26;;H04B7/26,H04B7/26,,0,0,,,,PENDING
456,SE,D0,SE 0300120 D0,199-801-730-223-773,2003-01-17,2003,SE 0300120 A,2003-01-17,SE 0300120 A,2003-01-17,Novel compounds,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN;;GUILE SIMON;;INGALL TONY;;RASUL RUKHSANA,,https://lens.org/199-801-730-223-773,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,PENDING
457,GB,A,GB 2219078 A,063-833-344-944-868,1989-11-29,1989,GB 8910415 A,1989-05-05,GB 8810723 A;;GB 8826225 A;;GB 8815941 A;;GB 8906853 A,1988-05-06,Identifying the position of objects or zones,"In order to identify diamonds in gangue, incident radiation from laser 3 is scanned along an extended line across particulate gangue, and the diamonds 2 are identified by detecting the Raman radiation which is emitted, using a narrow pass band filter 9 in order to block out other radiation. In order to identify the position along the scan line from which the Raman radiation was emitted, the incident laser radiation is pulsed at a pulse frequency which changes along the scan line, and the frequency of the Raman radiation detected is sensed. In this way, one can simplify the equipment needed. <IMAGE>",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/063-833-344-944-868,Patent Application,no,7,0,8,118,0,B07C5/366;;B07C5/3427;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01S17/06,G01B15/00;;B07C5/342;;G01N21/27;;G01N21/63;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01S17/06,G1A AA4           TA;;G1A AD1           TA;;G1A AD10          TA;;G1A AD3           TA;;G1A AG1           TA;;G1A AG2           TA;;G1A AG6           TA;;G1A AG9           TA;;G1A AP1           TA;;G1A AP15          TA;;G1A AP16          TA;;G1A AP17          TA;;G1A AP6           TA;;G1A AP9           TA;;G1A AR2           TA;;G1A AR7           TA;;G1A AS10          TA;;G1A AS12          TA;;G1A AS4           TA;;G1A AS5           TA;;G1A ATA           TA;;G1A AT14          TA;;G1A AT15          TA;;G1A AT23          TA;;G1A AT3           TA;;G1A AT7           TA;;G1A AT8           TA;;H3H HCD           CD;;H3H H1C           CD;;H3H H5D           CD;;U1S S1488,0,0,,,,EXPIRED
458,IN,B,IN 174165 B,128-360-385-059-995,1994-10-01,1994,IN 356MA1989 A,1989-05-08,GB 8810723 A,1988-05-06,Apparatus for identifying objects or zones of an article for use with means for projecting modulated incident radiation to strike the objects or zones along an extended line,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/128-360-385-059-995,Granted Patent,no,0,0,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
459,ZA,B,ZA 893365 B,144-161-763-037-418,1991-01-30,1991,ZA 893365 A,1989-05-08,GB 8810723 A,1988-05-06,IDENTIFYING GEMSTONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;MARTIN PHILLIP SMITH;;STEWART ANDREW DAVID GARRY;;ANDREW DAVID GARRY STEWART;;COOPER MARTIN;;MARTIN COOPER;;SPEAR PAUL MARTIN;;PAUL MARTIN SPEAR;;WELBOURN CHRISTOPHER MARK;;CHRISTOPHER MARK WELBOURN,,https://lens.org/144-161-763-037-418,Granted Patent,no,0,1,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
460,AU,A,AU 1989/034542 A,094-990-054-260-947,1989-11-09,1989,AU 1989/034542 A,1989-05-08,GB 8810723 A;;GB 8815941 A;;GB 8826223 A;;GB 8906853 A,1988-05-06,IDENTIFYING THE POSITION OF OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/094-990-054-260-947,Patent Application,no,0,1,2,118,0,,B07C5/344;;G01N21/64;;G01N21/65;;G01N21/87;;G01N23/223,,0,0,,,,EXPIRED
461,AU,B2,AU 622667 B2,100-253-803-204-295,1992-04-16,1992,AU 1989/034544 A,1989-05-08,GB 8810723 A;;GB 8816156 A;;GB 8826225 A,1988-05-06,A METHOD OF IDENTIFYING INDIVIDUAL OBJECTS OR ZONES,,GERSAN ETS,COOPER MARTIN;;SMITH ROBIN WYNCLIFFE;;WELBOURN CHRISTOPHER MARK;;SMITH MARTIN PHILLIP;;SPEAR PAUL MARTIN,,https://lens.org/100-253-803-204-295,Granted Patent,no,3,0,2,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,B07C5/342;;B07C5/344;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87;;G01N23/223,,0,0,,,,EXPIRED
462,GB,B,GB 2219078 B,176-008-681-498-739,1992-08-26,1992,GB 8910415 A,1989-05-05,GB 8810723 A;;GB 8826225 A;;GB 8815941 A;;GB 8906853 A,1988-05-06,IDENTIFYING THE POSITION OF OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/176-008-681-498-739,Granted Patent,no,7,0,8,118,0,B07C5/366;;B07C5/3427;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01S17/06,G01B15/00;;B07C5/342;;G01N21/27;;G01N21/63;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01S17/06,G1A AA4           TA;;G1A AD1           TA;;G1A AD10          TA;;G1A AD3           TA;;G1A AG1           TA;;G1A AG2           TA;;G1A AG6           TA;;G1A AG9           TA;;G1A AP1           TA;;G1A AP15          TA;;G1A AP16          TA;;G1A AP17          TA;;G1A AP6           TA;;G1A AP9           TA;;G1A AR2           TA;;G1A AR7           TA;;G1A AS10          TA;;G1A AS12          TA;;G1A AS4           TA;;G1A AS5           TA;;G1A ATA           TA;;G1A AT14          TA;;G1A AT15          TA;;G1A AT23          TA;;G1A AT3           TA;;G1A AT7           TA;;G1A AT8           TA;;H3H HCD           CD;;H3H H1C           CD;;H3H H5D           CD;;U1S S1488,0,0,,,,EXPIRED
463,ZA,B,ZA 893362 B,158-688-573-258-358,1991-01-30,1991,ZA 893362 A,1989-05-08,GB 8810723 A,1988-05-06,A METHOD OF IDENTIFYING INDIVIDUAL OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;MARTIN PHILLIP SMITH;;STEWARD ANDREW DAVID GARRY;;ANDREW DAVID GARRY STEWARD;;COOPER MARTIN;;MARTIN COOPER;;WELBOURN CHRISTOPHER MARK;;CHRISTOPHER MARK WELBOURN;;SPEAR MARTIN PAUL;;MARTIN PAUL SPEAR,,https://lens.org/158-688-573-258-358,Granted Patent,no,0,0,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
464,BR,A,BR 8902137 A,076-012-618-047-034,1990-01-02,1990,BR 8902137 A,1989-05-08,GB 8810723 A;;GB 8815941 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,PROCESSO PARA OBTER INFORMACAO DE UM ESTIMULO DE EXCITACAO MODULADO;APARELHO PARA OBTER INFORMACAO A PARTIR DE UMA RESPOSTA A UM ESTIMULO MODULADO EXCITANTE;E PROCESSO E APARELHO PARA IDENTIFICAR OBJETOS OU ZONAS DE UM ARTIGO,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/076-012-618-047-034,Patent Application,no,0,0,8,118,0,B07C5/366;;B07C5/3427;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01S17/06,G01B15/00;;B07C5/342;;G01N21/27;;G01N21/63;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01S17/06,,0,0,,,,EXPIRED
465,EP,A3,EP 0341095 A3,168-033-019-015-08X,1991-02-06,1991,EP 89304640 A,1989-05-08,GB 8810723 A;;GB 8815941 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,IDENTIFYING THE POSITION OF OBJECTS OR ZONES,"In order to identify diamonds in gangue, incident laser radiation is scanned along an extended line across particulate gangue, and the diamonds 2 are identified by detecting the Raman radiation which is emitted, using a narrow pass band filter 9 in order to block out other radiation. In order to identify the position along the scan line from which the Raman radiation was emitted, the incident laser radiation is pulsed at a pulse frequency which changes along the scan line, and the frequency of the Raman radiation detected is sensed. In this way, one can simplify the equipment needed.  ",GERSAN ESTABLISHMENT,"SMITH, MARTIN PHILLIP;;SMITH, ROBIN WYNCLIFFE;;COOPER, MARTIN;;WELBOURN, CHRISTOPHER MARK;;SPEAR, PAUL MARTIN",,https://lens.org/168-033-019-015-08X,Search Report,yes,6,0,8,118,0,B07C5/366;;B07C5/3427;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01S17/06,G01B15/00;;B07C5/342;;G01N21/27;;G01N21/63;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01S17/06,,0,0,,,,DISCONTINUED
466,EP,A2,EP 0341095 A2,140-973-523-302-487,1989-11-08,1989,EP 89304640 A,1989-05-08,GB 8810723 A;;GB 8815941 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,Identifying the position of objects or zones.,"In order to identify diamonds in gangue, incident laser radiation is scanned along an extended line across particulate gangue, and the diamonds 2 are identified by detecting the Raman radiation which is emitted, using a narrow pass band filter 9 in order to block out other radiation. In order to identify the position along the scan line from which the Raman radiation was emitted, the incident laser radiation is pulsed at a pulse frequency which changes along the scan line, and the frequency of the Raman radiation detected is sensed. In this way, one can simplify the equipment needed.  ",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/140-973-523-302-487,Patent Application,yes,0,5,8,118,0,B07C5/366;;B07C5/3427;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01S17/06,G01B15/00;;B07C5/342;;G01N21/27;;G01N21/63;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01S17/06,,0,0,,,,DISCONTINUED
467,AU,A,AU 1989/034544 A,122-321-579-876-854,1989-11-09,1989,AU 1989/034544 A,1989-05-08,GB 8810723 A;;GB 8816156 A;;GB 8826225 A,1988-05-06,A METHOD OF IDENTIFYING INDIVIDUAL OBJECTS OR ZONES,,GERSAN ETS,STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/122-321-579-876-854,Patent Application,no,0,0,2,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,B07C5/342;;B07C5/344;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87;;G01N23/223,,0,0,,,,EXPIRED
468,BR,A,BR 9306479 A,054-139-009-905-785,1998-09-15,1998,BR 9306479 A,1993-05-28,GB 9211734 A;;GB 9301127 W,1992-06-03,Processo e aparelho para detectar diamantes em uma amostra de rocha,,GERSAN ETS,SMITH MARTIN PHILLIP;;ROONEY MARIE-LINE;;COOPER MARTIN;;SMITH JAMES GORDON CHARTERS,,https://lens.org/054-139-009-905-785,Patent Application,no,0,0,11,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083,G01N23/14;;G01N33/38,,0,0,,,,EXPIRED
469,AU,B2,AU 666560 B2,060-691-966-104-927,1996-02-15,1996,AU 1993/043368 A,1993-05-28,GB 9211734 A;;GB 9301127 W,1992-06-03,Detecting diamonds in a rock sample,,GERSAN ETS,ROONEY MARIE-LINE;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,,https://lens.org/060-691-966-104-927,Granted Patent,no,3,0,11,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083,G01N23/14;;G01N33/38,,0,0,,,,EXPIRED
470,CA,C,CA 2137224 C,128-903-231-227-325,2007-08-14,2007,CA 2137224 A,1993-05-28,GB 9211734 A;;GB 9301127 W,1992-06-03,DETECTING DIAMONDS IN A ROCK SAMPLE,"In order to provide secure and simple detection of diamonds when prospecting , a rock sample is reduced to powder parti-cles which are automatically checked to see if they contain diamond particles (30) by processing an image of X-radiation trans-mitted by a layer of the particles. The image may be processed by comparing it with a further image of visible light transmitted by the layer of particles.",GERSAN ETS,ROONEY MARIE-LINE;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,,https://lens.org/128-903-231-227-325,Granted Patent,no,0,0,2,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083,G01N23/083;;G01N21/87;;G01N23/04,,0,0,,,,EXPIRED
471,AU,A,AU 1993/043368 A,161-103-386-327-540,1993-12-30,1993,AU 1993/043368 A,1993-05-28,GB 9211734 A;;GB 9301127 W,1992-06-03,Detecting diamonds in a rock sample,,DE BEERS CENTENARY AG,ROONEY MARIE-LINE;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,,https://lens.org/161-103-386-327-540,Patent Application,no,0,0,11,16,0,G01N33/381;;G01N23/083;;G01N33/381;;G01N23/083,G01N23/14;;G01N33/38,,0,0,,,,EXPIRED
472,GB,B,GB 2282882 B,088-600-660-392-540,1995-11-15,1995,GB 9423841 A,1993-05-28,GB 9423841 A;;GB 9301127 W;;GB 9211734 A,1992-06-03,Detecting diamonds in a rock sample,,GERSAN ETS,ROONEY MARIE-LINE;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,,https://lens.org/088-600-660-392-540,Granted Patent,no,5,0,3,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083;;G01N23/12;;G01N23/12,G01N23/14;;G01N33/38,G1A AA4           MHR;;G1A AG17          MHR;;G1A AG6           MHR;;G1A AMHR          MHR;;G1A AR2           MHR;;G1A AR6           MHR;;G1A AR7           MHR;;G1A AT20          MHR;;G1A AT27          MHR;;G1A AT3           MHR;;U1S S1252;;U1S S1488;;U1S S1911,0,0,,,,EXPIRED
473,US,A,US 5603414 A,104-130-709-478-236,1997-02-18,1997,US 34352595 A,1995-01-25,GB 9211734 A;;GB 9301127 W,1992-06-03,Detecting diamonds in a rock sample,"In order to provide secure and simple detection of diamonds when prospecting, a rock sample is reduced to powder particles which are automatically checked to see if they contain diamond particles (30) by processing an image of X-radiation transmitted through a layer of the particles. The image may be processed by comparing it with a further image of visible light transmitted by the layer of particles.",GERSAN ETS,ROONEY MARIE-LINE;;SMITH JAMES G C;;SMITH MARTIN P;;COOPER MARTIN,GERSAN ESTABLISHMENT (1994-11-30),https://lens.org/104-130-709-478-236,Granted Patent,yes,13,16,11,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083,G01N23/14;;G01N33/38,209/588;;209/589,1,0,,,"B. W. Anderson, GEM Testing, Jan. 1942, (3 pages), Butterworth & Co. (Tenth Edition).",EXPIRED
474,AU,B2,AU 698438 B2,133-388-961-244-415,1998-10-29,1998,AU 1995/033953 A,1995-09-05,GB 9418050 A;;GB 9502092 W,1994-09-07,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,,https://lens.org/133-388-961-244-415,Granted Patent,no,2,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
475,GB,A,GB 2282882 A,016-505-087-785-757,1995-04-19,1995,GB 9423841 A,1993-05-28,GB 9423841 A;;GB 9301127 W;;GB 9211734 A,1992-06-03,Detecting diamonds in a rock sample,"In order to provide secure and simple detection of diamonds when prospecting, a rock sample is reduced to powder particles which are automatically checked to see if they contain diamond particles (30) by processing an image of X-radiation transmitted by a layer of the particles. The image may be processed by comparing it with a further image of visible light transmitted by the layer of particles. <IMAGE>",GERSAN ETS,ROONEY MARIE-LINE;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,,https://lens.org/016-505-087-785-757,Patent Application,no,5,0,3,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083;;G01N23/12;;G01N23/12,G01N23/14;;G01N33/38,G1A AA4           MHR;;G1A AG17          MHR;;G1A AG6           MHR;;G1A AMHR          MHR;;G1A AR2           MHR;;G1A AR6           MHR;;G1A AR7           MHR;;G1A AT20          MHR;;G1A AT27          MHR;;G1A AT3           MHR;;U1S S1252;;U1S S1488;;U1S S1911,0,0,,,,EXPIRED
476,US,A,US 5883388 A,058-523-135-555-087,1999-03-16,1999,US 80915097 A,1997-06-19,GB 9418050 A;;GB 9502092 W,1994-09-07,Examining a diamond,"In order to test whether a diamond has had a layer of synthetic diamond material deposited thereon, infrared radiation including radiation of wavelength substantially 7 .mu.m to 25 .mu.m preferably 7 .mu.m to 10 .mu.m emitted or transmitted by the diamond is observed, to detect differences between the compositions of different zones of the diamond.",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,GERSAN ESTABLISHMENT (1997-06-27),https://lens.org/058-523-135-555-087,Granted Patent,yes,10,26,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,250/330;;356/30,0,0,,,,EXPIRED
477,EP,B1,EP 0779977 B1,103-572-713-772-464,1998-11-25,1998,EP 95930636 A,1995-09-05,GB 9502092 W;;GB 9418050 A,1994-09-07,EXAMINING A DIAMOND,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,,https://lens.org/103-572-713-772-464,Granted Patent,yes,2,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
478,GB,B,GB 2293250 B,079-128-939-970-624,1998-06-24,1998,GB 9518227 A,1995-09-06,GB 9418050 A,1994-09-07,"Examinging a diamond for synthetic diamond, using infra red radiation",,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICHARDO SIMON,,https://lens.org/079-128-939-970-624,Granted Patent,no,1,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,G1A AA1           MHL;;G1A AA4           MHL;;G1A AG6           MHL;;G1A AR6           MHL;;G1A AT28          MHL;;G1A AT3           MHL;;G2J JX3           JX3;;U1S S1488,0,0,,,,EXPIRED
479,CA,A1,CA 2199242 A1,156-134-559-240-808,1996-03-14,1996,CA 2199242 A,1995-09-05,GB 9418050 A,1994-09-07,EXAMINING A DIAMOND,"In order to test whether a diamond (3) has had a layer of synthetic diamond material deposited thereon, infrared radiation including radiation of wavelength substantially 7.mu.m to 25.mu.m, preferably 7.mu.m to 10.mu.m emitted or transmitted by the diamond is observed, to detect differences between the compositions of different zones of the diamond 3.",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,,https://lens.org/156-134-559-240-808,Patent Application,no,0,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,DISCONTINUED
480,ZA,B,ZA 933844 B,156-492-747-531-119,1993-12-28,1993,ZA 933844 A,1993-06-02,GB 9211734 A,1992-06-03,Detecting diamonds in a rock sample,,GERSAN ETS,ROONEY MARIE-LINE;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,,https://lens.org/156-492-747-531-119,Granted Patent,no,0,0,11,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083,G01N23/14;;G01N33/38,,0,0,,,,EXPIRED
481,EP,A1,EP 0779977 A1,183-429-743-510-035,1997-06-25,1997,EP 95930636 A,1995-09-05,GB 9502092 W;;GB 9418050 A,1994-09-07,EXAMINING A DIAMOND,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,,https://lens.org/183-429-743-510-035,Patent Application,yes,0,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
482,WO,A1,WO 1993/024833 A1,192-151-990-525-210,1993-12-09,1993,GB 9301127 W,1993-05-28,GB 9211734 A,1992-06-03,DETECTING DIAMONDS IN A ROCK SAMPLE,"In order to provide secure and simple detection of diamonds when prospecting, a rock sample is reduced to powder particles which are automatically checked to see if they contain diamond particles (30) by processing an image of X-radiation transmitted by a layer of the particles. The image may be processed by comparing it with a further image of visible light transmitted by the layer of particles.",GERSAN ETS;;ROONEY MARIE LINE;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,ROONEY MARIE-LINE;;SMITH JAMES GORDON CHARTERS;;SMITH MARTIN PHILLIP;;COOPER MARTIN,,https://lens.org/192-151-990-525-210,Patent Application,yes,5,2,11,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083,G01N23/14;;G01N33/38,G1A AA4           MHR;;G1A AG17          MHR;;G1A AG6           MHR;;G1A AMHR          MHR;;G1A AR2           MHR;;G1A AR7           MHR;;G1A AT20          MHR;;G1A AT27          MHR;;G1A AT3           MHR,0,0,,,,PENDING
483,GB,A,GB 2293250 A,131-710-478-608-266,1996-03-20,1996,GB 9518227 A,1995-09-06,GB 9418050 A,1994-09-07,Examining a diamond by infra red radiation for synthetic diamond,"In order to test whether a diamond 3 has had a layer of synthetic diamond material deposited thereon, infra red radiation from 6 including radiation of wavelength substantially 7 mu m to 25 mu m, preferably 7 mu m to 10 mu m emitted or transmitted by the diamond is observed at 2, 10, to detect differences between the compositions of different zones of the diamond 3. Background 5 may be cooled by 7. Visible radiation may be provided by lamp 8. A fibre optic probe (14, Fig. 3) may pass infra red radiation to a detector (15, Fig. 3). <IMAGE>",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICHARDO SIMON,,https://lens.org/131-710-478-608-266,Patent Application,no,1,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,G1A AA1           MHL;;G1A AA4           MHL;;G1A AG6           MHL;;G1A AR6           MHL;;G1A AT28          MHL;;G1A AT3           MHL;;G2J JX3           JX3;;U1S S1488,0,0,,,,EXPIRED
484,ZA,B,ZA 957477 B,009-890-583-094-912,1997-03-06,1997,ZA 957477 A,1995-09-06,GB 9418050 A,1994-09-07,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;COOPER MARTIN;;SMITH JAMES GORDON CHARTERS;;SUSSMANN RICARDO SIMON,,https://lens.org/009-890-583-094-912,Granted Patent,no,0,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
485,WO,A1,WO 1996/007895 A1,088-357-106-113-842,1996-03-14,1996,GB 9502092 W,1995-09-05,GB 9418050 A,1994-09-07,EXAMINING A DIAMOND,"In order to test whether a diamond (3) has had a layer of synthetic diamond material deposited thereon, infrared radiation including radiation of wavelength substantially 7νm to 25νm, preferably 7νm to 10νm emitted or transmitted by the diamond is observed, to detect differences between the compositions of different zones of the diamond 3.",GERSAN ETS;;SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,,https://lens.org/088-357-106-113-842,Patent Application,yes,2,3,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,PATENTED
486,AU,A,AU 1995/033953 A,079-005-452-896-303,1996-03-27,1996,AU 1995/033953 A,1995-09-05,GB 9418050 A;;GB 9502092 W,1994-09-07,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;SUSSMANN RICARDO SIMON,,https://lens.org/079-005-452-896-303,Patent Application,no,0,0,19,19,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
487,CA,A1,CA 2137224 A1,157-384-518-990-985,1993-12-09,1993,CA 2137224 A,1993-05-28,GB 9211734 A;;GB 9301127 W,1992-06-03,DETECTING DIAMONDS IN A ROCK SAMPLE,"2137224 9324833 PCTABS00028 In order to provide secure and simple detection of diamonds when prospecting, a rock sample is reduced to powder particles which are automatically checked to see if they contain diamond particles (30) by processing an image of X-radiation transmitted by a layer of the particles. The image may be processed by comparing it with a further image of visible light transmitted by the layer of particles.",GERSAN ETS,ROONEY MARIE-LINE;;SMITH JAMES G C;;SMITH MARTIN P;;COOPER MARTIN,,https://lens.org/157-384-518-990-985,Patent Application,no,0,0,2,16,0,G01N33/381;;G01N33/381;;G01N23/083;;G01N23/083,G01N23/083;;G01N23/04,,0,0,,,,EXPIRED
488,IN,B,IN 174985 B,129-224-027-579-878,1995-04-08,1995,IN 358MA1989 A,1989-05-08,GB 8810723 A;;GB 8816157 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,Apparatus for sorting diamonds,,GERSAN ESTABLISHMENT OF STAED,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;SPEAR PAUL MARTIN;;COOPER MARTIN;;WEIBOURN CHRISTOPHER MARK,,https://lens.org/129-224-027-579-878,Granted Patent,no,0,0,11,118,0,B07C5/3427;;B07C5/368;;G01N21/6456;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N23/223,,0,0,,,,EXPIRED
489,EP,A3,EP 0341094 A3,043-172-995-167-360,1991-03-06,1991,EP 89304639 A,1989-05-08,GB 8810723 A;;GB 8816157 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,IDENTIFYING SPECIFIC OBJECTS OR ZONES,"In order to identify specific objects such as diamonds 2 in gangue on a conveyor belt, a line across the conveyor belt is irradiated with X-rays so that wanted particles 2 luminesce, and the luminescence is detected using an optical system 5 and a photo-multiplier tube 6. The response of the photo-multiplier tube 6 is scanned so that the location from which the luminescence was omitted is determined from the position of the scan at the instant of detection. The arrangement is useful for sorting minerals, including diamond, which luminesce.  ",GERSAN ESTABLISHMENT,"SMITH, MARTIN PHILLIP;;STEWART, ANDREW DAVID GARRY;;COOPER, MARTIN;;SPEAR, PAUL MARTIN;;WELBOURN, CHRISTOPHER MARK",,https://lens.org/043-172-995-167-360,Search Report,yes,5,0,11,118,0,B07C5/3427;;B07C5/368;;G01N21/6456;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N23/223,,1,0,,,"OPTICAL ENGINEERING, vol. 24, no. 2, March/April 1985, pages 352-355, Bellingham, Washington, US; M.D. DUNCAN et al.: ""Imaging biological compounds using the coherent anti-Stokes Raman scattering microscope""",DISCONTINUED
490,EP,A3,EP 0341096 A3,096-677-187-373-349,1991-02-27,1991,EP 89304641 A,1989-05-08,GB 8810723 A;;GB 8816156 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,A METHOD OF IDENTIFYING INDIVIDUAL OBJECTS OR ZONES,"In order to separate diamonds from gangue, the particles 2 of the gangue are carried along a belt 1, and are irradiated with a beam from a laser 3. The luminescence emitted by the particles 2 is then detected by two spaced optical modules 5,5′. The difference in the luminescence detected is related to the nature of the material, and a simple microprocessor 11 and ejection jet 12 can be used to eject diamonds into a sort bin.  ",GERSAN ESTABLISHMENT,"SMITH, MARTIN PHILIP;;STEWARD, ANDREW DAVID GARRY;;COOPER, MARTIN;;WELBOURN, CHRISTOPHER MARK;;SPEAR, PAUL MARTIN",,https://lens.org/096-677-187-373-349,Search Report,yes,5,0,8,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,DISCONTINUED
491,EP,A2,EP 0341094 A2,143-450-124-380-062,1989-11-08,1989,EP 89304639 A,1989-05-08,GB 8810723 A;;GB 8816157 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,Identifying specific objects or zones.,"In order to identify specific objects such as diamonds 2 in gangue on a conveyor belt, a line across the conveyor belt is irradiated with X-rays so that wanted particles 2 luminesce, and the luminescence is detected using an optical system 5 and a photo-multiplier tube 6. The response of the photo-multiplier tube 6 is scanned so that the location from which the luminescence was omitted is determined from the position of the scan at the instant of detection. The arrangement is useful for sorting minerals, including diamond, which luminesce.  ",GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;SPEAR PAUL MARTIN;;WELBOURN CHRISTOPHER MARK,,https://lens.org/143-450-124-380-062,Patent Application,yes,0,11,11,118,0,B07C5/3427;;B07C5/368;;G01N21/6456;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N23/223,,0,0,,,,DISCONTINUED
492,AU,A,AU 1989/034541 A,189-410-978-345-378,1989-11-09,1989,AU 1989/034541 A,1989-05-08,GB 8810723 A;;GB 8816157 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,IDENTIFYING GEMSTONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;SPEAR PAUL MARTIN;;WELBOURN CHRISTOPHER MARK,,https://lens.org/189-410-978-345-378,Patent Application,no,0,1,11,118,0,B07C5/3427;;B07C5/368;;G01N21/6456;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N23/223,,0,0,,,,EXPIRED
493,GB,A,GB 2219081 A,049-180-972-217-044,1989-11-29,1989,GB 8910418 A,1989-05-05,GB 8810723 A;;GB 8826225 A;;GB 8816157 A;;GB 8906853 A,1988-05-06,Identifying specific objects or zones,"In order to identify specific objects such as diamonds 2 in gangue on a conveyor belt, a line across the conveyor belt is irradiated with X-rays so that wanted particles 2 luminesce, and the luminescence is detected using an optical systems and a photo-multiplier tube 6. The response of the photo-multiplier tube 6 is scanned so that the location from which the luminescence was omitted is determined from the position of the scan at the instant of detection. The arrangement is useful for sorting minerals, including diamond, which luminesce. <IMAGE>",GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;SPEAR PAUL MARTIN;;WELBOURN CHRISTOPHER MARK,,https://lens.org/049-180-972-217-044,Patent Application,no,5,0,11,118,0,B07C5/3427;;B07C5/368;;G01N21/6456;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N23/223,G1A AA4           CJ;;G1A AA4           EDP;;G1A ACJ           CJ;;G1A ACJ           EDP;;G1A ACJX          CJX;;G1A AC8           CJ;;G1A AC8           EDP;;G1A AD1           CJ;;G1A AD1           EDP;;G1A AD3           CJ;;G1A AD3           EDP;;G1A AD6           CJ;;G1A AD6           EDP;;G1A AEDP          EDP;;G1A AG1           CJ;;G1A AG1           EDP;;G1A AG2           CJ;;G1A AG2           EDP;;G1A AG6           CJ;;G1A AG6           EDP;;G1A AG9           CJ;;G1A AG9           EDP;;G1A AP17          CJ;;G1A AP17          EDP;;G1A AR2           CJ;;G1A AR2           EDP;;G1A AR7           CJ;;G1A AR7           EDP;;G1A AT14          CJ;;G1A AT14          EDP;;G1A AT15          CJ;;G1A AT15          EDP;;G1A AT23          CJ;;G1A AT23          EDP;;G1A AT3           CJ;;G1A AT3           EDP;;G1A AT8           CJ;;G1A AT8           EDP;;U1S S1488,0,0,,,,EXPIRED
494,GB,B,GB 2219079 B,194-075-741-112-547,1992-09-09,1992,GB 8910416 A,1989-05-05,GB 8810723 A;;GB 8816156 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,A METHOD OF IDENTIFYING INDIVIDUAL OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/194-075-741-112-547,Granted Patent,no,4,0,8,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,G1A AA4           CJ;;G1A AA6           CJ;;G1A ACJ           CJ;;G1A AD1           CJ;;G1A AD10          CJ;;G1A AD3           CJ;;G1A AD4           CJ;;G1A AD6           CJ;;G1A AG1           CJ;;G1A AG2           CJ;;G1A AG6           CJ;;G1A AG9           CJ;;G1A AP16          CJ;;G1A AP17          CJ;;G1A AP6           CJ;;G1A AP9           CJ;;G1A AR2           CJ;;G1A AR7           CJ;;G1A AS4           CJ;;G1A AT14          CJ;;G1A AT15          CJ;;G1A AT23          CJ;;G1A AT3           CJ;;G1A AT7           CJ;;G1A AT8           CJ;;U1S S1488,0,0,,,,EXPIRED
495,IN,B,IN 174124 B,196-982-152-870-27X,1994-09-17,1994,IN 357MA1989 A,1989-05-08,GB 8810723 A,1988-05-06,Apparatus for identifying among ore particles diamonds or other specific luminescing minerals,,GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/196-982-152-870-27X,Granted Patent,no,0,0,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
496,EP,A2,EP 0341096 A2,171-040-753-635-535,1989-11-08,1989,EP 89304641 A,1989-05-08,GB 8810723 A;;GB 8816156 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,A method of identifying individual objects or zones.,"In order to separate diamonds from gangue, the particles 2 of the gangue are carried along a belt 1, and are irradiated with a beam from a laser 3. The luminescence emitted by the particles 2 is then detected by two spaced optical modules 5,5′. The difference in the luminescence detected is related to the nature of the material, and a simple microprocessor 11 and ejection jet 12 can be used to eject diamonds into a sort bin.  ",GERSAN ETS,SMITH MARTIN PHILIP;;STEWARD ANDREW DAVID GARRY;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/171-040-753-635-535,Patent Application,yes,0,14,8,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,DISCONTINUED
497,GB,A,GB 2219079 A,126-161-287-268-318,1989-11-29,1989,GB 8910416 A,1989-05-05,GB 8810723 A;;GB 8816156 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,Identifying individual objects or zones,"In order to separate diamonds from gangue, the particles 2 of the gangue are carried along a belt 1, and are irradiated with a beam from a laser 3. The luminescence emitted by the particles 2 is then detected immediately and after an interval by two spaced optical modules 5,5'. The difference in the luminescence detected is related to the nature of the material, and a simple microprocessor 11 and ejection jet 12 can be used to eject diamonds into a sort bin. <IMAGE>",GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/126-161-287-268-318,Patent Application,no,3,2,8,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,G1A AA4           CJ;;G1A AA6           CJ;;G1A ACJ           CJ;;G1A ACJC          CJC;;G1A ACJT          CJT;;G1A AD1           CJ;;G1A AD10          CJ;;G1A AD3           CJ;;G1A AD4           CJ;;G1A AD6           CJ;;G1A AG1           CJ;;G1A AG2           CJ;;G1A AG6           CJ;;G1A AG9           CJ;;G1A AP16          CJ;;G1A AP17          CJ;;G1A AP6           CJ;;G1A AP9           CJ;;G1A AR2           CJ;;G1A AR7           CJ;;G1A AS4           CJ;;G1A AT14          CJ;;G1A AT15          CJ;;G1A AT23          CJ;;G1A AT3           CJ;;G1A AT7           CJ;;G1A AT8           CJ;;U1S S1488,0,0,,,,EXPIRED
498,BR,A,BR 8902135 A,012-682-538-623-020,1990-09-04,1990,BR 8902135 A,1989-05-08,GB 8810723 A;;GB 8816156 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,PROCESSO E APARELHO PARA IDENTIFICAR OBJETOS OU ZONAS ESPECIFICOS,,GERSAN ETS,SMITH MARTIN PHILLIP;;STEWARD ANDREW DAVID GARRY;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/012-682-538-623-020,Patent Application,no,0,0,8,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,EXPIRED
499,GB,B,GB 2219081 B,186-287-814-761-957,1992-12-02,1992,GB 8910418 A,1989-05-05,GB 8810723 A;;GB 8826225 A;;GB 8816157 A;;GB 8906853 A,1988-05-06,IDENTIFYING SPECIFIC OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;SPEAR PAUL MARTIN;;WELBOURN CHRISTOPHER MARK,,https://lens.org/186-287-814-761-957,Granted Patent,no,6,0,11,118,0,B07C5/3427;;B07C5/368;;G01N21/6456;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N23/223,G1A AA4           CJ;;G1A AA4           ED;;G1A ACJ           CJ;;G1A ACJ           ED;;G1A AC8           CJ;;G1A AC8           ED;;G1A AD1           CJ;;G1A AD1           ED;;G1A AD3           CJ;;G1A AD3           ED;;G1A AD6           CJ;;G1A AD6           ED;;G1A AED           ED;;G1A AG1           CJ;;G1A AG1           ED;;G1A AG2           CJ;;G1A AG2           ED;;G1A AG6           CJ;;G1A AG6           ED;;G1A AG9           CJ;;G1A AG9           ED;;G1A AP17          CJ;;G1A AP17          ED;;G1A AR2           CJ;;G1A AR2           ED;;G1A AR7           CJ;;G1A AR7           ED;;G1A AT14          CJ;;G1A AT14          ED;;G1A AT15          CJ;;G1A AT15          ED;;G1A AT23          CJ;;G1A AT23          ED;;G1A AT3           CJ;;G1A AT3           ED;;G1A AT8           CJ;;G1A AT8           ED;;U1S S1488,0,0,,,,EXPIRED
500,US,B2,US 8285138 B2,060-710-733-015-959,2012-10-09,2012,US 51876707 A,2007-12-17,GB 0625108 A;;GB 2007004850 W,2006-12-16,Optical correlation apparatus,"An optical correlation apparatus is described which forms first and second parallel optical signals in response to a serial input data stream. The first parallel optical signal is arranged to have bright pulses represent binary 1 and the second parallel optical signal is arranged to have bright pulses represent binary 0. A channel select means, such as an optical switch or amplitude modulator, deselects or blocks channels in the first parallel optical signal which correspond to binary 1 in a reference data string and also deselects or blocks channels in the second parallel optical signal which correspond to binary 0 in the reference data string. The remaining optical signals are combined at one or more detectors. Where the input data matches the reference data string each bright pulse in the first and second parallel optical signals is deselected and the detector registers zero intensity. However when there is any mismatch at least one channel will pass a bright pulse to the detector. An instance of zero intensity can therefore be used as an indication of pattern match.",LEWIN ANDREW CHARLES;;ORCHARD DAVID ARTHUR;;COOPER MARTIN JAMES;;QINETIQ LTD,LEWIN ANDREW CHARLES;;ORCHARD DAVID ARTHUR;;COOPER MARTIN JAMES,QINETIQ LIMITED (2009-03-02),https://lens.org/060-710-733-015-959,Granted Patent,yes,19,9,6,6,0,G06E3/00;;H04Q11/0005;;H04Q2011/003;;H04Q2011/0032;;H04Q2011/0035;;G06E3/005;;G06V10/88;;H04Q2011/003;;H04Q2011/0032;;H04Q2011/0035;;H04Q11/0005;;G06E3/00,H04B17/00;;G02F1/01;;G02F2/00,398/16;;398/17;;398/25;;398/174;;398/175;;398/176;;398/177;;708/191;;708/831,2,2,018-297-950-420-53X;;173-878-584-604-739,10.1109/jlt.2003.819144;;10.1049/el:19940500,"Hauer et al.; ""Optically Assisted Internet Routing Using Arrays of Novel Dynamically Reconfigurable FBG-Based Correlators;"" Journal of Lightwave Technology; 2003; pp. 2765-2778; vol. 21; No. 11.;;Tancevski et al.; ""Incoherent asynchronous optical CDMA using gold codes;"" Electronics Letters; 1994; pp. 721-723; vol. 30; No. 9.",INACTIVE
501,EP,B1,EP 2630126 B1,078-876-769-055-614,2015-01-07,2015,EP 11772961 A,2011-10-19,US 40525210 P;;EP 2011068220 W,2010-10-21,"PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, IMMUNE AND INFLAMMATORY CONDITIONS",,GLAXO GROUP LTD,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,,https://lens.org/078-876-769-055-614,Granted Patent,yes,3,0,8,8,0,A61K31/415;;A61K31/415;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P43/00;;C07D231/40;;C07D231/40;;C07F9/222;;C07F9/65031;;C07F9/65031,C07D231/38;;A61K31/415;;A61P11/00;;A61P29/00;;A61P37/00,,4,0,,,"YONETOKU Y ET AL: ""Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 15, 1 August 2006 (2006-08-01), pages 5370-5383, XP025133434, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2006.03.039 [retrieved on 2006-08-01];;YONETOKU Y ET AL: ""Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 1: Synthesis and inhibitory activity of 5-(1-methyl-3-trifluoromethyl-1H-pyrazol-5 -yl)-2-thiophenecarboxamides"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 14, 15 July 2006 (2006-07-15) , pages 4750-4760, XP025133377, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2006.03.024 [retrieved on 2006-07-15];;YONETOKU Y ET AL: ""Novel potent and selective Ca<2+> release-activated Ca<2+> (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4'-[(trifluoromethyl)pyrazol-1-yl]carboxan ilides"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 16, no. 21, 1 November 2008 (2008-11-01), pages 9457-9466, XP025545771, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2008.09.047 [retrieved on 2008-09-20];;HALL A ET AL: ""Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 11, 1 June 2008 (2008-06-01), pages 3392-3399, XP022711234, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.04.018 [retrieved on 2008-04-11]",ACTIVE
502,NO,L,NO 20002788 L,099-670-597-142-110,2000-08-01,2000,NO 20002788 A,2000-05-31,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,Nye forbindelser,"Det er beskrevet visse pyrrolo-, tieno-, furano- og pyrazolo-[3,4-d]-pyridazinoner ifølge generell formel (l), fremgangsmåter for fremstilling derav, farmasøytiske sammensetninger inneholdende disse, og en fremgangsmåte for fremstilling av farmasøytiske blandinger og fremgangsmåter for behandling innbefattende anvendelse derav.",ASTRAZENECA UK LTD,BANTICK JOHN RAYMOND;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/099-670-597-142-110,Abstract,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
503,ES,T3,ES 2071681 T3,145-419-025-952-210,1995-07-01,1995,ES 89900628 T,1988-12-02,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,COMPUESTOS MACROCICLICOS.,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/145-419-025-952-210,Granted Patent,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
504,WO,A1,WO 2016/137792 A1,155-027-114-800-104,2016-09-01,2016,US 2016/0018196 W,2016-02-17,US 201514629611 A,2015-02-24,VIBRATION STABILIZER FOR ENCLOSURE COOLING FINS,"An enclosure for an electrical apparatus includes a tank having a bank of corrugate affixed to one or more walls thereof, with the bank of corrugate including a plurality of cooling fins in fluid communication with a volume of the tank via a plurality of openings formed in the walls, such that cooling fluid can flow into the cooling fins. A cross member is affixed to the bank of corrugate along each of a top surface and a bottom surface thereof and extends along a length of the corrugate at a distal end of the cooling fins. Vibration stabilizers are provided to control vibrations in the corrugate bank, with the vibration stabilizer having a gusset plate joined to the cross member and extending between a pair of adjacent cooling fins and stabilizer with a first end attached to the tank and a second end attached to the gusset plate.",COOPER TECHNOLOGIES CO,COOPER JERAMIE ALLEN;;BUNYER SCOTT LISTON;;MARTIN NOLE THOMAS,,https://lens.org/155-027-114-800-104,Patent Application,yes,5,1,3,3,0,H01F27/025;;H01F27/08;;H01F27/02;;H01F27/025,F28F1/12;;H05K7/20,,0,0,,,,PENDING
505,CA,C,CA 2430327 C,177-388-418-442-854,2010-02-09,2010,CA 2430327 A,2003-05-29,US 16001902 A,2002-06-04,WIRE UNWINDING CONTROLLER,"A controller for controlling the dispensing of wire from a reel of wire positioned within a container. The wire is dispensed from one end of the reel with the other end of the reel sitting on the bottom of the container. The controller has a main body member in the shape of a flat ring sized to rest within the container on the one end of the reel, the ring having concentric, circular, inner and outer edges. Flexible, wire guide flaps are on the inner edge of the ring, the guide flaps extending radially inwardly. Each guide flap has the general shape of a shallow triangle with the apex of the triangle farthest from the ring and the base of the triangle adjacent and integral with the ring.",AIR LIQUIDE CANADA INC,BLAIN DENIS;;COOPER EDWARD L;;PAQUET MARTIN;;VAIDYA VIWEK,,https://lens.org/177-388-418-442-854,Granted Patent,no,0,0,3,3,0,B65H49/02;;B65H49/08;;B65H57/18;;B65H59/06;;B65H2404/56;;B65H59/06;;B65H2404/56;;B65H49/02;;B65H49/08;;B65H57/18,B65H49/02;;B65H49/08;;B65H57/18;;B65H59/06,,0,0,,,,EXPIRED
506,AU,A1,AU 2021/349415 A1,006-694-068-363-519,2023-06-01,2023,AU 2021/349415 A,2021-09-22,US 202063082162 P;;US 202063084900 P;;IB 2021058662 W,2020-09-23,TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY,"This disclosure relates to methods of treating cancers in a human patient (e.g., metastatic pancreatic ductal adenocarcinoma (PD AC)), comprising administering an anti-CD73 antibody or antigen binding fragment thereof and chemotherapy. The disclosure also relates to methods for the treatment of tumors comprising administering an anti-CD73 antibody or antigen-binding fragment thereof in combination with a PD-L1 antibody or an antigen-binding fragment thereof and chemotherapy.",MEDIMMUNE LLC,KUMAR RAKESH;;ENGLERT JUDSON;;COOPER ZACHARY;;MARTIN PHILIP LLOYD,,https://lens.org/006-694-068-363-519,Patent Application,no,0,0,10,10,0,A61P35/00;;C07K16/2896;;C07K2317/21;;C07K16/2827;;A61K2039/507;;A61K39/39558;;A61K2039/505;;A61K2039/55;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;C07K16/2896;;A61K2039/55;;A61K31/7068;;A61K31/519;;A61P35/00;;A61K31/513;;C07K16/2827;;A61K39/39558;;A61K31/337;;A61K2039/505;;C07K2317/21;;A61K31/555;;A61K2039/507;;A61K45/06;;A61K2300/00;;C07K16/2896;;C07K16/2827;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;A61P35/00;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K2317/21;;A61P35/00;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;C07K16/2827;;C07K16/2896,A61P35/00;;A61K39/00;;A61K39/395;;C07K16/30,,0,0,,,,PENDING
507,PT,A,PT 85380 A,051-259-459-232-415,1987-08-01,1987,PT 8538087 A,1987-07-22,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/051-259-459-232-415,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;C07D217/20;;A61K31/675;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
508,HK,A,HK 8491 A,057-256-272-276-893,1991-02-01,1991,HK 8491 A,1991-01-24,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/057-256-272-276-893,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;C07D217/20;;A61K31/675;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
509,US,A1,US 2007/0097884 A1,077-128-512-537-909,2007-05-03,2007,US 56409506 A,2006-11-28,US 56409506 A;;US 64947800 A;;US 15112099 P,1999-08-27,Methods and Systems of Network Management,"A network management system (NMS) automatically models a path for a customer's services from a terminating unit through elements typically on a link-by-link basis, across networks if appropriate, to a network service provider (NSP) or Internet service provider (ISP). The path may be a private virtual circuit or connection (PVC), and it may traverse an “overall network” including other networks such as an asymmetric digital subscriber line (ADSL) service or sub-networks. To model a path, the NMS creates a topology including the elements and links in the overall network and respective features, functions, characteristics, and capacities thereof. The topology allows the NMS to speedily, efficiently, and automatically provision a customer's service from the terminating unit to connection to the customer's selected NSP or ISP for Internet access.",BELLSOUTH INTELLECT PTY CORP,CHEWNING WARD M III;;BEHI FARIBORZ;;COOPER MARTIN A,AT&T INTELLECTUAL PROPERTY I L.P (2008-09-30),https://lens.org/077-128-512-537-909,Patent Application,yes,8,18,3,3,0,H04L12/2856;;H04L41/0806;;H04L41/0886;;H04L41/12;;H04L41/22;;H04L41/32;;H04L41/5054;;H04L41/507;;H04L43/091;;H04L41/507;;H04L41/12;;H04L41/0886;;H04L41/22;;H04L12/2856;;H04L41/0806;;H04L41/32;;H04L41/5054;;H04L43/091,H04L12/56;;H04L12/28,370/254;;370/401,0,0,,,,EXPIRED
510,WO,A1,WO 2012/052459 A1,112-552-682-980-671,2012-04-26,2012,EP 2011068221 W,2011-10-19,US 40525410 P,2010-10-21,"PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS",The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.,GLAXO GROUP LTD;;COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,,https://lens.org/112-552-682-980-671,Patent Application,yes,73,4,5,5,0,A61K31/415;;A61K31/415;;A61K31/4439;;A61K31/4439;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P37/08;;A61P43/00;;C07D231/40;;C07D231/40;;C07D401/12;;C07D401/12,C07D231/38;;A61K31/415;;A61K31/4155;;A61P11/00;;A61P29/00;;A61P37/00;;C07D401/12,,15,9,030-096-802-881-282;;080-441-536-567-095;;046-537-529-679-295;;037-960-491-197-945;;007-364-858-655-289;;066-371-099-307-130;;077-295-491-167-117;;008-620-115-468-390;;047-269-960-171-542,10.1016/j.bmc.2006.03.039;;16616503;;16580212;;10.1016/j.bmc.2006.03.024;;18835179;;10.1016/j.bmc.2008.09.047;;10.1517/17460441.3.7.787;;23496221;;10.1002/jps.2600660104;;833720;;18219308;;10.1038/nrd2468;;10.1002/0471220574;;10.1021/jm0341047;;12954048;;10.1016/j.bmcl.2009.02.112;;19332369,"DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 14 May 2003 (2003-05-14), ""Benzamide, N-[1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl]-2,6-difluoro"", XP002663702, Database accession no. 515178-09-3;;YONETOKU Y ET AL: ""Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 15, 1 August 2006 (2006-08-01), pages 5370 - 5383, XP025133434, ISSN: 0968-0896, [retrieved on 20060801], DOI: 10.1016/J.BMC.2006.03.039;;YONETOKU Y ET AL: ""Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 1: Synthesis and inhibitory activity of 5-(1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamides"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 14, 15 July 2006 (2006-07-15), pages 4750 - 4760, XP025133377, ISSN: 0968-0896, [retrieved on 20060715], DOI: 10.1016/J.BMC.2006.03.024;;YONETOKU Y ET AL: ""Novel potent and selective Ca<2+> release-activated Ca<2+> (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4'-[(trifluoromethyl)pyrazol-1-yl]carboxanilides"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 16, no. 21, 1 November 2008 (2008-11-01), pages 9457 - 9466, XP025545771, ISSN: 0968-0896, [retrieved on 20080920], DOI: 10.1016/J.BMC.2008.09.047;;DERLER ET AL., EXPERT OPIN. DRUG DISCOVERY, vol. 3, no. 7, 2008, pages 787 - 800;;BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Burger's Medicinal Chemistry and Drug Discovery,5th Edition"", vol. 1, article ""Principles and Practice,"";;RAUTIO ET AL., NATURE REVIEWS, vol. 7, 2008, pages 255 - 270;;T.W. GREENE, P.G.M. WUTS: ""Protective groups in organic synthesis"", 1999, JOHN WILEY & SONS;;P.J. KOCIENSKI: ""Protecting Groups"", 1994, GEORG THIEME VERLAG;;HOFGEN, N. ET AL., 15TH EFMC INT SYMP MED CHEM, 6 September 1998 (1998-09-06), pages 98;;LANDELLS, L.J. ET AL., EUR RESP J [ANNU CONG EUR RESP SOC, vol. 12, no. 28, 19 September 1998 (1998-09-19), pages 2393;;FUJI, K. ET AL., J PHARMACOL EXP THER, vol. 284, no. 1, 1998, pages 162;;JABLONOWSKI ET AL., J. MED. CHEM., vol. 46, 2003, pages 3957 - 3960;;BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, 2009, pages 2599 - 2603",PENDING
511,EP,B1,EP 0346427 B1,124-018-478-051-838,1995-03-29,1995,EP 89900628 A,1988-12-02,GB 8801093 W;;GB 8728820 A;;GB 8728821 A;;GB 8809174 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,MACROCYCLIC COMPOUNDS.,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,"ASTELLAS PHARMA INC. (2008-06-25);;YAMANOUCHI PHARMACEUTICAL CO., LTD. (2006-02-28);;FUJISAWA PHARMACEUTICAL CO., LTD. (2005-01-31)",https://lens.org/124-018-478-051-838,Granted Patent,yes,2,1,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
512,CN,B,CN 1015059 B,162-657-414-625-459,1991-12-11,1991,CN 87105778 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILLIPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/162-657-414-625-459,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/675;;A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
513,NO,L,NO 872963 L,182-801-099-604-541,1988-02-01,1988,NO 872963 A,1987-07-15,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOKINOLINDERIVATER.,,GLAXO GROUP LTD,PHILLIPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/182-801-099-604-541,Abstract,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
514,HU,A,HU T46011 A,198-828-416-682-940,1988-09-28,1988,HU 346087 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,PROCESS FOR PRODUCING ISOQUINOLINE DERIVATIVES AND PHARMACEUTICS COMPRISING THESE COMPOUNDS AS ACTIVE INGREDIENT,,GLAXO GROUP LTD,PHILLIPPS GORDON H;;JONES PAUL S;;COOPER MARTIN E,,https://lens.org/198-828-416-682-940,Unknown,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;A61K31/675;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
515,CN,A,CN 87105778 A,006-492-125-944-075,1988-02-24,1988,CN 87105778 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD.,GORDON HANLEY PHILLIPPS;;PAUL SPENCER JONES;;MARTIN EDWARD COOPER,,https://lens.org/006-492-125-944-075,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/675;;A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
516,CA,A1,CA 3194926 A1,007-822-427-452-039,2022-03-31,2022,CA 3194926 A,2021-09-22,US 202063082162 P;;US 202063084900 P;;IB 2021058662 W,2020-09-23,TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY,"This disclosure relates to methods of treating cancers in a human patient (e.g., metastatic pancreatic ductal adenocarcinoma (PD AC)), comprising administering an anti-CD73 antibody or antigen binding fragment thereof and chemotherapy. The disclosure also relates to methods for the treatment of tumors comprising administering an anti-CD73 antibody or antigen-binding fragment thereof in combination with a PD-L1 antibody or an antigen-binding fragment thereof and chemotherapy.",MEDIMMUNE LLC,KUMAR RAKESH;;ENGLERT JUDSON;;COOPER ZACHARY;;MARTIN PHILIP LLOYD,,https://lens.org/007-822-427-452-039,Patent Application,no,0,0,10,10,16,A61P35/00;;C07K16/2896;;C07K2317/21;;C07K16/2827;;A61K2039/507;;A61K39/39558;;A61K2039/505;;A61K2039/55;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;C07K16/2896;;A61K2039/55;;A61K31/7068;;A61K31/519;;A61P35/00;;A61K31/513;;C07K16/2827;;A61K39/39558;;A61K31/337;;A61K2039/505;;C07K2317/21;;A61K31/555;;A61K2039/507;;A61K45/06;;A61K2300/00;;C07K16/2896;;C07K16/2827;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;A61P35/00;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K2317/21;;A61P35/00;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;C07K16/2827;;C07K16/2896,A61K39/00;;A61K39/395;;A61P35/00;;C07K16/30,,0,0,,,,PENDING
517,ES,T3,ES 2532213 T3,001-768-460-688-024,2015-03-25,2015,ES 11772961 T,2011-10-19,US 40525210 P;;EP 2011068220 W,2010-10-21,"Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias",Un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo**Fórmula**,GLAXO GROUP LTD,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,,https://lens.org/001-768-460-688-024,Granted Patent,no,0,0,8,8,0,A61K31/415;;A61K31/415;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P43/00;;C07D231/40;;C07D231/40;;C07F9/222;;C07F9/65031;;C07F9/65031,C07D231/38;;A61K31/415;;A61P11/00;;A61P29/00;;A61P37/00,,0,0,,,,ACTIVE
518,US,B1,US 9463859 B1,098-652-248-822-673,2016-10-11,2016,US 201514621992 A,2015-02-13,US 201514621992 A,2015-02-13,"Adapter plate, heat shield, and method for thermally isolating a mount coupled to an adapter plate","An outboard motor adapter plate couples a marine engine to a driveshaft housing, and includes an upper rim configured to be coupled to a lower surface of a cylinder block of the engine. A lower rim of the adapter plate is configured to be coupled to an upper surface of a sump located in the driveshaft housing. A wall defines a passageway having an inner perimetral surface, and the inner perimetral surface extends from the upper rim to the lower rim. A mounting area is configured for coupling a mount to the adapter plate. A shield covers at least a portion of the inner perimetral surface adjacent the mounting area, so as to at least partially thermally isolate the mount from heated fluid that drains from the cylinder block, through the passageway, and into the sump. A method and a shield for thermal isolation are also described.",BRUNSWICK CORP,COOPER III ROBERT D;;MARTIN JUSTIN;;ANDERSON JR DONALD,BRUNSWICK CORPORATION (2013-02-12),https://lens.org/098-652-248-822-673,Granted Patent,yes,11,3,1,1,0,B63H20/32;;B63H20/32;;B63H20/002;;F01M2011/0016;;F01M2011/0016,B63H20/32;;B63H20/00,,1,0,,,"Eichinger et al., Midsection Housing for an Outboard Motor with Water-Cooled Mounts, Unpublished U.S. Appl. No. 14/591,493, filed Jan. 7, 2015.",ACTIVE
519,AU,A1,AU 2016/207996 A1,128-554-150-852-265,2017-08-10,2017,AU 2016/207996 A,2016-01-14,GB 201500596 A;;EP 2016050671 W,2015-01-14,Multiplexed fibre sensor,"The present invention provides a multiplexed fibre sensor for a fibre optic hydrophone array. A signal receiver is adapted to receive a signal from the fibre optic hydrophone sensor array and an interferometer is provided. The interferometer is adapted to produce a first signal component and a second signal component from the signal received from the hydrophone array. The interferometer is also provided with a first polarisation controller adapted to control the polarisation of the first signal component and a second polarisation controller adapted to control the polarisation of the second signal component. In addition a modulated carrier signal generator adapted to generate a modulated carrier signal component based on the first signal component is also provided. A detector adapted to output a demodulated output signal derived from the modulated signal component and the second signal component is included, wherein the modulated signal component and the second signal component are output separately from the interferometer.",QINETIQ LTD,LEWIN ANDREW CHARLES;;COOPER MARTIN JAMES;;ORCHARD DAVID ARTHUR,,https://lens.org/128-554-150-852-265,Patent Application,no,0,0,7,7,0,G01V1/38;;G01D5/35325;;G01D5/35383;;G01H9/004;;G01D5/353;;G01H9/004;;G01V1/38;;G01D5/35325;;G01V1/38;;G01D5/35383;;G01H9/004;;G02B6/4213;;G02B6/4214;;G02B6/4246;;H01S3/0675;;H01S3/094003;;H01S3/10053;;H01S3/1608,G01H9/00;;G01D5/353;;G01V1/38,,0,0,,,,DISCONTINUED
520,ES,A6,ES 2007666 A6,161-807-306-769-089,1989-07-01,1989,ES 8702210 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,Isoquinoline derivatives and their use as anti-cancer agents,"There are provided compounds of the general formula (1) < IMAGE > (1) (wherein R1 and R2, which may be the same or different, each represents a hydrogen atom, a hydroxyl group or a group -OP(O) (OH) (OR4) [where R4 represents a hydrogen atom or an alkyl (optionally substituted by a hydroxyl, alkoxy, cyclic ether or cycloalkyl group), alkenyl cycloalkyl, aryl, aralkyl or aroylalkyl group], with the proviso that at least one of R1 and R2 represents a group -OP(O) (OH) (OR4) and R3 represents a hydrogen or halogen atom or a methyl group), and salts thereof. The novel compounds exhibit interesting anti-cancer activity.",GLAXO GROUP LTD,PHILLIPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/161-807-306-769-089,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558;;A61K31/675,,0,0,,,,EXPIRED
521,FR,A1,FR 2602233 A1,161-992-033-820-420,1988-02-05,1988,FR 8710763 A,1987-07-29,GB 8618398 A;;GB 8710608 A,1986-07-29,DERIVES DE L'ISOQUINOLEINE,"<P>L'INVENTION CONCERNE DES ISOQUINOLEINES. CE SONT DES COMPOSES DE LA FORMULE 1 (DANS LAQUELLE R ET R, QUI PEUVENT ETRE IDENTIQUES OU DIFFERENTS, REPRESENTENT CHACUN UN ATOME D'HYDROGENE, UN RADICAL HYDROXYLE OU UN RADICAL -OP(O) (OH) (OR) OU R REPRESENTE UN ATOME D'HYDROGENE OU UN RADICAL ALKYLE (EVENTUELLEMENT SUBSTITUE PAR UN GROUPE HYDROXYLE, ALCOXY, ETHER CYCLIQUE OU CYCLOALKYLE), ALCENYLE, CYLOALKYLE, ARYLE, ARALKYLE, OU AROYLALKYLE, AVEC LA CONDITION QU'AU MOINS L'UN DES SYMBOLES R ET R REPRESENTE UN GROUPE -OP(O)(OH)(OR); ET R REPRESENTE UN ATOME D'HYDROGENE OU UN ATOME D'HALOGENE OU LE RADICAL METHYLE; AINSI QUE LES SELS DE CES COMPOSES.</P><P>LES NOUVEAUX COMPOSES MANIFESTENT UNE ACTIVITE ANTI-CANCEREUSE.<BR/>(CF DESSIN DANS BOPI)<BR/></P>",GLAXO GROUP LTD,HANLEY PHILLIPPS GORDON;;SPENCER JONES PAUL;;EDWARD COOPER MARTIN,,https://lens.org/161-992-033-820-420,Patent Application,no,1,1,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;C07D217/20;;A61K31/675;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
522,CN,A,CN 1033458 A,009-209-342-623-81X,1989-06-21,1989,CN 88108277 A,1988-12-09,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,PROCESS TO IMMUNOSUPPRESSIVE MACROLIDES,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/009-209-342-623-81X,Patent Application,no,0,1,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,DISCONTINUED
523,NO,D0,NO 872963 D0,024-191-028-996-491,1987-07-15,1987,NO 872963 A,1987-07-15,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOKINOLINDERIVATER.,,GLAXO GROUP LTD,PHILLIPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/024-191-028-996-491,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
524,US,A1,US 2016/0247619 A1,051-926-702-103-565,2016-08-25,2016,US 201514629611 A,2015-02-24,US 201514629611 A,2015-02-24,VIBRATION STABILIZER FOR ENCLOSURE COOLING FINS,"An enclosure for an electrical apparatus includes a tank having a bank of corrugate affixed to one or more walls thereof, with the bank of corrugate including a plurality of cooling fins in fluid communication with a volume of the tank via a plurality of openings formed in the walls, such that cooling fluid can flow into the cooling fins. A cross member is affixed to the bank of corrugate along each of a top surface and a bottom surface thereof and extends along a length of the corrugate at a distal end of the cooling fins. Vibration stabilizers are provided to control vibrations in the corrugate bank, with the vibration stabilizer having a gusset plate joined to the cross member and extending between a pair of adjacent cooling fins and stabilizer with a first end attached to the tank and a second end attached to the gusset plate.",COOPER TECHNOLOGIES CO,COOPER JERAMIE ALLEN;;BUNYER SCOTT LISTON;;MARTIN NOLE THOMAS,EATON INTELLIGENT POWER LIMITED (2017-12-31);;COOPER TECHNOLOGIES COMPANY (2015-02-11),https://lens.org/051-926-702-103-565,Patent Application,yes,0,2,3,3,0,H01F27/025;;H01F27/08;;H01F27/02;;H01F27/025,H01F27/08;;H01F27/02,,0,0,,,,ACTIVE
525,AU,B2,AU 630866 B2,056-284-103-037-447,1992-11-12,1992,AU 1989/028228 A,1989-12-02,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,MACROCYCLIC COMPOUNDS,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,MARTIN EDWARD COOPER;;DAVID KEITH DONALD;;DAVID NORMAN HARDERN,,https://lens.org/056-284-103-037-447,Granted Patent,no,3,1,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
526,PH,A,PH 25494 A,100-927-363-683-12X,1991-07-24,1991,PH 35592 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILIPPS GORDON HANLEY;;JONES PAUL S;;COOPER MARTIN EDWARD,,https://lens.org/100-927-363-683-12X,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
527,EP,A4,EP 1018068 A4,142-682-830-617-991,2004-09-22,2004,EP 98943539 A,1998-09-02,US 9818412 W;;US 92974297 A,1997-09-15,SCROLLING NAVIGATIONAL DISPLAY SYSTEM,,SONY TRANS COM INC,GREENWOOD WAYNE EUGENE;;COOPER ALAN MARTIN;;EVENSON KAREN LOUISE,,https://lens.org/142-682-830-617-991,Search Report,no,4,0,7,7,0,G06F3/0485;;G06F3/0489;;G06F2200/1632;;G06F3/0489;;G06F3/0485;;G06F2200/1632,A63F13/00;;B64D11/06;;G06F1/16;;G06F3/023;;G06F3/033;;G06F3/0485;;G06F3/0488;;H03M11/04,,1,0,,,See also references of WO 9914655A1,DISCONTINUED
528,AU,A,AU 1989/028228 A,157-747-749-360-93X,1989-07-05,1989,AU 1989/028228 A,1989-12-02,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,MACROCYCLIC COMPOUNDS,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/157-747-749-360-93X,Patent Application,no,0,5,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
529,US,A1,US 2013/0217658 A1,165-571-790-256-476,2013-08-22,2013,US 201113879652 A,2011-10-19,US 201113879652 A;;US 40525410 P;;EP 2011068221 W,2010-10-21,"PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS",The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID;;GLAXO GROUP LTD,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,GLAXO GROUP LIMITED (2011-10-24),https://lens.org/165-571-790-256-476,Patent Application,yes,1,1,5,5,0,A61K31/415;;A61K31/415;;A61K31/4439;;A61K31/4439;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P37/08;;A61P43/00;;C07D231/40;;C07D231/40;;C07D401/12;;C07D401/12,A61K31/415;;A61K31/4439;;A61K45/06;;C07D231/40;;C07D401/12,514/171;;548/372.5;;514/407;;546/275.4;;514/341,0,0,,,,INACTIVE
530,US,A,US 5823443 A,084-538-206-610-501,1998-10-20,1998,US 77239796 A,1996-12-23,US 77239796 A,1996-12-23,Poppet nozzle for fuel injection,"A fuel system including a fuel nozzle is disclosed. The fuel nozzle is adapted to receive pulsed pressurized fuel from a source and includes a valve seat assembly having a valve seat body with a longitudinally extending passage. The passage of the valve seat body has a valve seat extending thereabout and interfaces with a downstream opening valve element which is disposed within the longitudinally extending passage and operates to move into and out of sealing engagement with the valve seat to regulate the flow of pressurized fuel though the passage. The valve element has a spherically configured upstream surface for sealing engagement with the valve seat which includes an annular drag groove extending thereabout. The drag groove functions to increase viscous drag force, in the downstream opening direction, which is imparted on the valve element by fuel flow over the spherical upstream surface. The nozzle also has an annular, fuel directing orifice disc which is disposed downstream of the valve seat. The orifice disc includes fuel directing orifices which extend therethrough from a first, upstream side to a second downstream side. The annular fuel directing orifice disc limits downstream movement of the valve member and directs fuel through the orifices into a desired fuel pattern.",GEN MOTORS CORP,COOPER RICHARD LLOYD;;SALEMI MICHAEL RAYMOND;;KNEBEL ALBERT MARTIN,GENERAL MOTORS CORPORATION (1996-12-12),https://lens.org/084-538-206-610-501,Granted Patent,yes,7,8,1,1,0,F02M61/08;;F02M61/08;;F02M63/0007;;F02M63/0007;;F02M69/50;;F02M69/50,F02M61/08;;F02M63/00;;F02M69/50,239/533.9;;239/533.12,0,0,,,,EXPIRED
531,TW,B,TW 384359 B,084-786-884-992-986,2000-03-11,2000,TW 85113967 A,1996-11-14,US 56878895 A,1995-12-07,Rotary compressor with reduced lubrication sensitivity,"Lubrication deficiencies related to the use of synthetic lubricants such as POE oils in refrigeration compressors can be mitigated by providing a diamond-like carbon coating on a member subject to wear due to lubrication deficiencies. Specifically, the tip of the vane of a rotary compressor is coated with a diamond-like-carbon coating made up of alternating layers of tungsten carbide and a lubricious material 0.5 to 5.0 microns thick.",CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/084-786-884-992-986,Granted Patent,no,0,0,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C18/356;;F04C29/00;;F04C23/00,,0,0,,,,EXPIRED
532,GB,A,GB 2195636 A,119-483-832-474-140,1988-04-13,1988,GB 8717864 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/119-483-832-474-140,Patent Application,no,0,1,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;C07D217/20;;A61K31/675;;C07D471/04;;C07F9/62;;C07F9/6558,C2P PA            P2E;;C2P PA            P3B;;C2P PA1           P2E;;C2P PA1           P3B;;C2P P1L1          P3B;;C2P P2E13         P2E;;C2P P2E15A        P2E;;C2P P2E19E        P2E;;C2P P2E26D        P2E;;C2P P3B12B        P3B;;C2P P3B13         P3B;;C2P P3B15A        P3B;;C2P P3B16         P3B;;C2P P3B18C        P3B;;C2P P3B19C        P3B;;C2P P3B19E        P3B;;C2P P3B20         P3B;;C2P P5A           P3B;;C2P P5B           P3B;;C2P P7            P2E;;C2P P7            P3B;;C2P P9            P3B;;U1S S1313,0,0,,,,EXPIRED
533,GB,A,GB 2177296 A,133-629-240-229-148,1987-01-21,1987,GB 8513186 A,1985-05-24,GB 8513186 A,1985-05-24,Stacking device for coat hangers,"A stacking or trapping device for coat hangers, for use at point of sale in a garment store comprises a base 1 mounted on castors 2 with its upper surface inclined to the horizontal. Shaft 5 and parallel rods 6 extend from the base at more or less the mid point of the upper edge, and handle 4 at more or less the mid point of the lower edge. Coat hangers of various configurations can be held in a neat accumulation by placing the hook over shaft 5 and holding the neck between the two rods 6. When the stacking device is full it can be wheeled or carried away and a new such device put ready for use. <IMAGE>",MARKS SPENCER PLC,COOPER ALISON BARBARA;;FOLEY MARTIN WILLIAM;;SANGER ROBERT ANTHONY,,https://lens.org/133-629-240-229-148,Patent Application,no,3,1,2,2,0,A47G25/1464,A47G25/14,A4L LABA          LABA;;A4L L130          LABA,0,0,,,,DISCONTINUED
534,PT,B,PT 85380 B,123-689-045-633-999,1990-04-30,1990,PT 8538087 A,1987-07-22,GB 8618398 A;;GB 8710608 A,1986-07-29,PROCESSO PARA A PREPARACAO DE DERIVADOS DE ISOQUINOLINA E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM,,GLAXO GROUP LTD,COOPER MARTIN EDWARD;;PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER,,https://lens.org/123-689-045-633-999,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558;;A61K31/675,,0,0,,,,EXPIRED
535,US,A,US 4698200 A,144-099-979-743-632,1987-10-06,1987,US 81204585 A,1985-12-23,US 81204585 A,1985-12-23,Self-actuated nuclear reactor shutdown system using induction pump to facilitate sensing of core coolant temperature,"A self-actuated shutdown system incorporated into a reactivity control assembly in a nuclear reactor includes pumping means for creating an auxiliary downward flow of a portion of the heated coolant exiting from the fuel assemblies disposed adjacent to the control assembly. The shutdown system includes a hollow tubular member which extends through the outlet of the control assembly top nozzle so as to define an outer annular flow channel through the top nozzle outlet separate from an inner flow channel for primary coolant flow through the control assembly. Also, a latching mechanism is disposed in an inner duct of the control assembly and is operable for holding absorber bundles in a raised position in the control assembly and for releasing them to drop them into the core of the reactor for shutdown purposes. The latching mechanism has an inner flow passage extending between and in flow communication with the absorber bundles and the inner flow channel of the top nozzle for accommodating primary coolant flow upwardly through the control assembly. Also, an outer flow passage separate from the inner flow passage extends through the latching mechanism between and in flow communication with the inner duct and the outer flow channel of the top nozzle for accommodating inflow of a portion of the heated coolant from the adjacent fuel assemblies. The latching mechanism contains a magnetic material sensitive to temperature and operable to cause mating or latching together of the components of the latching mechanism when the temperature sensed is below a known temperature and unmating or unlatching thereof when the temperature sensed is above a given temperature. The temperature sensitive magnetic material is positioned in communication with the heated coolant flow through the outer flow passage for directly sensing the temperature thereof. Finally, the pumping means includes a jet induction pump nozzle and diffuser disposed adjacent the bottom nozzle of the control assembly and in flow communication with the inlet thereof. The pump nozzle is operable to create an upward driving flow of primary coolant through the pump diffuser and then to the absorber bundles. The upward driving flow of primary coolant, in turn, creates a suction head within the outer flow channel of the top nozzle and thereby an auxiliary downward flow of the heated coolant portion exiting from the upper end of the adjacent fuel assemblies through the outer flow channel to the pump nozzle via the outer flow passage of the latching mechanism and an annular space between the outer and inner spaced ducts of the control assembly housing. The temperature of the heated coolant exiting from the adjacent fuel assemblies can thereby be sensed directly by the temperature sensitive magnetic material in the latching mechanism.",US ENERGY,SIEVERS ROBERT K;;COOPER MARTIN H;;TUPPER ROBERT B,UNITED STATES OF AMERICA THE AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (1987-01-08);;WESTINGHOUSE ELECTRIC CORPORATION (1985-10-31),https://lens.org/144-099-979-743-632,Granted Patent,yes,7,2,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,376/233;;376/336;;376/352;;376/335,0,0,,,,EXPIRED
536,DK,A,DK 392187 A,160-457-672-761-200,1988-01-30,1988,DK 392187 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINDERIVATER OG FARMACEUTISKE PRAEPARATER INDEHOLDENDE DEM,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/160-457-672-761-200,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
537,CA,A1,CA 2303530 A1,003-110-408-594-014,1999-03-25,1999,CA 2303530 A,1998-09-02,US 92974297 A;;US 9818412 W,1997-09-15,SCROLLING NAVIGATIONAL DISPLAY SYSTEM,"A user-interface system (350) adapted to navigate through a plurality of menus is disclosed. The system comprises a display system (300) comprising a display (310) having a category area (332 a-e) on a first portion of the display, the category area displaying a plurality of categories, including a currently displayed category. Each of the plurality of categories has a plurality of items. The display also has a marquee area (352 a-c) on a second portion of the display, which displays items of the currently displayed category. The system further comprises a scrolling mechanism (360) for scrolling through items of each category of the plurality of categories. The marquee area is updated by the scrolling mechanism to display the corresponding items in each category. The scrolling mechanism also indicates a position of a currently displayed item of a currently displayed category by updating the category area. Various embodiments are disclosed.",SONY TRANS COM INC,EVENSON KAREN LOUISE;;GREENWOOD WAYNE EUGENE;;COOPER ALAN MARTIN,,https://lens.org/003-110-408-594-014,Patent Application,no,0,0,7,7,0,G06F3/0485;;G06F3/0489;;G06F2200/1632;;G06F3/0489;;G06F3/0485;;G06F2200/1632,A63F13/00;;B64D11/06;;G06F1/16;;G06F3/023;;G06F3/033;;G06F3/0485;;G06F3/0488;;H03M11/04,,0,0,,,,DISCONTINUED
538,US,B2,US 10223130 B2,004-605-584-592-086,2019-03-05,2019,US 201414888863 A,2014-04-30,GB 201308085 A;;GB 2014051348 W,2013-05-03,System for connecting a display over a general-purpose data transport,"A system to enable a computer to provide output to a display over a general-purpose data transmission medium, such as USB. The system includes provision of a plurality of display interface components, each display interface component adapted to receive display data and transmission of the display data to the display via the general-purpose data transmission medium. Each component is associated with a respective stage of operation of the system. The system is configured to use a respective one of the display interface components during each of a plurality of distinct operational stages.",DISPLAYLINK UK LTD,TURNOCK MARTIN ANDREW;;EDMONDS TIMOTHY MARK;;COOPER PATRICK DAVID,DISPLAYLINK (UK) LIMITED (2018-07-10),https://lens.org/004-605-584-592-086,Granted Patent,yes,24,1,7,7,0,G06F13/10;;G06F13/385;;G06F3/14;;G06F9/4401;;G06F13/10;;G06F13/10;;G06F9/4406;;G06F9/4411;;G06F13/385,G06F9/44;;G06F9/4401;;G06F13/10;;G06F13/38,,3,0,,,"“PCT Notification of the International Search Report and the Written Opinion of the International Searching Authority”, dated Jun. 30, 2014 (Jun. 30, 2014), for International Application No. PCT/GB2014/051348, 10pgs.;;“VESA Net2Display Remoting Standard”, Video Electronics Standards Association, Version 1, Oct. 22, 2009 (Oct. 22, 2009), (pp. 1-276), XP007917342.;;“Communication pursuant to Article 94(3) EPC”, dated Nov. 26, 2018 (Nov. 26, 2018), European Patent Office, for European Application No. 14721942.2-1224, 6 pgs.",ACTIVE
539,EP,A1,EP 0808423 A1,065-025-348-124-936,1997-11-26,1997,EP 96936362 A,1996-10-09,US 9616284 W;;US 56878895 A,1995-12-07,ROTARY COMPRESSOR WITH REDUCED LUBRICATION SENSITIVITY,,CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/065-025-348-124-936,Patent Application,yes,0,0,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C18/356;;F04C23/00;;F04C29/00,,0,0,,,,EXPIRED
540,EP,A1,EP 3047388 A1,065-168-787-770-102,2016-07-27,2016,EP 14845963 A,2014-09-20,US 201361880286 P;;US 2014/0056701 W,2013-09-20,A FRAMEWORK FOR DETERMINING THE RELATIVE EFFECT OF GENETIC VARIANTS,,UNIV WASHINGTON CT COMMERCIALI;;HUDSONALPHA INST FOR BIOTECHNOLOGY,SHENDURE JAY;;COOPER GREGORY M;;KIRCHER MARTIN;;WITTEN DANIELA,,https://lens.org/065-168-787-770-102,Patent Application,yes,0,0,6,6,0,G06N20/00;;G16B30/00;;G16B40/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20;;B05B7/0416;;G06N20/10;;G16B40/20;;G16B30/00;;G16B20/20;;G16B40/30;;G16B30/00;;G16B40/00;;G06N20/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20,G16B20/20;;C12Q1/68;;G06N3/00;;G06N3/08;;G06N20/10;;G16B30/00;;G16B40/20;;G16B40/30,,0,0,,,,DISCONTINUED
541,GB,A,GB 2165983 A,080-681-532-602-351,1986-04-23,1986,GB 8525237 A,1985-10-14,GB 8426497 A,1984-10-19,Optical pattern recognition apparatus,"Optical pattern recognition apparatus uses three beams (B1, B2, B3) of light shone onto a crystal of bismuth silicon oxide (15). Two of the beams (B1, B2) encode an effective grating structure within the crystal (15) from which the third beam (B3) is diffracted to generate an output beam (B4) which is representative of the correlation product of two images (17, 11) contained within two of the beams (B1, B2) incident on the crystal (15). Each of the beams (B1, B2) which encode the grating structure comprises a series of synchronised pulses which reduce the requirements of vibrational stability for the apparatus. <IMAGE>",GEN ELECTRIC CO PLC,COOPER IAN ROBERT;;MCCALL MARTIN WILLIAM;;PETTS COLIN ROY,,https://lens.org/080-681-532-602-351,Patent Application,no,0,2,3,3,0,G06E3/003;;G06V10/88;;G06E3/003;;G06V10/88,G06E3/00;;G06V10/88,G4R RRH           RRH;;G4R R1X           RRH;;G4R R11E          RRH;;G4R R12A          RRH;;G4R R12F          RRH;;G4R R3E           RRH;;G4R R5B           RRH;;G4R R9F           RRH,0,0,,,,EXPIRED
542,EP,A1,EP 0323042 A1,104-351-064-226-806,1989-07-05,1989,EP 88311422 A,1988-12-02,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,Process to macrocyclic compounds.,"Compounds of formula I
   in which [R¹ and R²], [R³ and R⁴] and [R⁵ and R⁶] represent a carbon-carbon bond or two hydrogen atoms; 
R² additionally represents alkyl; 
R⁷, R⁸ and R⁹ represent groups including H or OH, 
R¹⁰ has various significances including alkyl and alkenyl; 
X and Y represent groups including O and (H,OH); 
  R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³ represent H or alkyl; 
R²⁰ and R²¹ represent groups including O, (H,OH) and (H,O-alkyl), 
n is 1, 2, or 3, 
and in addition, Y, R¹⁰ and R²³, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, 
(with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.  ",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/104-351-064-226-806,Patent Application,yes,3,95,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,1,0,,,"D. ASKIN ET AL., TETRAHEDRON LETTS, vol. 29, 1988, pages 277",PENDING
543,WO,A1,WO 1999/014655 A1,117-117-811-196-900,1999-03-25,1999,US 9818412 W,1998-09-02,US 92974297 A,1997-09-15,SCROLLING NAVIGATIONAL DISPLAY SYSTEM,"A user-interface system (350) adapted to navigate through a plurality of menus is disclosed. The system comprises a display system (300) comprising a display (310) having a category area (332 a-e) on a first portion of the display, the category area displaying a plurality of categories, including a currently displayed category. Each of the plurality of categories has a plurality of items. The display also has a marquee area (352 a-c) on a second portion of the display, which displays items of the currently displayed category. The system further comprises a scrolling mechanism (360) for scrolling through items of each category of the plurality of categories. The marquee area is updated by the scrolling mechanism to display the corresponding items in each category. The scrolling mechanism also indicates a position of a currently displayed item of a currently displayed category by updating the category area. Various embodiments are disclosed.",SONY TRANS COM INC,GREENWOOD WAYNE EUGENE;;COOPER ALAN MARTIN;;EVENSON KAREN LOUISE,,https://lens.org/117-117-811-196-900,Patent Application,yes,5,24,7,7,0,G06F3/0485;;G06F3/0489;;G06F2200/1632;;G06F3/0489;;G06F3/0485;;G06F2200/1632,A63F13/00;;B64D11/06;;G06F1/16;;G06F3/023;;G06F3/033;;G06F3/0485;;G06F3/0488;;H03M11/04,,1,0,,,See also references of EP 1018068A4,PENDING
544,EP,A1,EP 2630126 A1,129-090-979-070-285,2013-08-28,2013,EP 11772961 A,2011-10-19,US 40525210 P;;EP 2011068220 W,2010-10-21,"PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, IMMUNE AND INFLAMMATORY CONDITIONS",,GLAXO GROUP LTD,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,,https://lens.org/129-090-979-070-285,Patent Application,yes,0,0,8,8,0,A61K31/415;;A61K31/415;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P43/00;;C07D231/40;;C07D231/40;;C07F9/222;;C07F9/65031;;C07F9/65031,C07D231/38;;A61K31/415;;A61P11/00;;A61P29/00;;A61P37/00,,1,0,,,See references of WO 2012052458A1,ACTIVE
545,FI,A0,FI 893750 A0,007-383-263-217-101,1989-08-09,1989,FI 893750 A,1989-08-09,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,Menetelmä valmistaa terapeuttisesti aktiivista makrosyklistä johdannaista,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/007-383-263-217-101,Patent Application,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
546,DK,D0,DK 392187 D0,036-652-421-898-892,1987-07-28,1987,DK 392187 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINDERIVATER OG FARMACEUTISKE PRAEPARATER INDEHOLDENDE DEM,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/036-652-421-898-892,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
547,CA,C,CA 1339128 C,024-249-740-337-560,1997-07-29,1997,CA 585220 A,1988-12-07,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,COMPOUNDS,"Compounds of formula I (see fig. I) in which ¢R1 and R2!, ¢R3 and R4! and ¢R5 and R6! represent a carbon-carbon bond or two hydrogen atoms; R2 additionally represents alkyl; R7, R8 and R9 represent groups including H or OH, R10 has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R14, R15, R16, R17, R18, R19, R22 and R23 represent H or alkyl; R20 and R21 represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R10 and R23, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/024-249-740-337-560,Granted Patent,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,D32600228    M;;1670202    S,0,0,,,,EXPIRED
548,WO,A1,WO 1997/021033 A1,075-170-379-507-28X,1997-06-12,1997,US 9616284 W,1996-10-09,US 56878895 A,1995-12-07,ROTARY COMPRESSOR WITH REDUCED LUBRICATION SENSITIVITY,"Lubrication deficiencies related to the use of synthetic lubricants such as POE oils in refrigeration compressors can be mitigated by providing a diamond-like-carbon coating on a member subject to wear due to lubrication deficiencies. Specifically, the tip of the vane of a rotary compressor is coated with a diamond-like-carbon coating made up of alternating layers of tungsten carbide and a lubricious material 0.5 to 5.0 microns thick.",CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/075-170-379-507-28X,Patent Application,yes,3,3,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C18/356;;F04C29/00;;F04C23/00,,1,0,,,"DATABASE WPI Section PQ Week 9638, Derwent World Patents Index; Class Q56, Page 7, AN 96-373902, XP002024345",PATENTED
549,FI,A,FI 873289 A,137-040-175-283-722,1988-01-30,1988,FI 873289 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOKINOLINDERIVAT.,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/137-040-175-283-722,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
550,EP,A4,EP 3047388 A4,138-434-314-296-733,2017-08-02,2017,EP 14845963 A,2014-09-20,US 201361880286 P;;US 2014/0056701 W,2013-09-20,A FRAMEWORK FOR DETERMINING THE RELATIVE EFFECT OF GENETIC VARIANTS,,UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION;;HUDSONALPHA INST FOR BIOTECHNOLOGY,SHENDURE JAY;;COOPER GREGORY M;;KIRCHER MARTIN;;WITTEN DANIELA,,https://lens.org/138-434-314-296-733,Search Report,no,0,0,6,6,0,G06N20/00;;G16B30/00;;G16B40/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20;;B05B7/0416;;G06N20/10;;G16B40/20;;G16B30/00;;G16B20/20;;G16B40/30;;G16B30/00;;G16B40/00;;G06N20/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20,G16B20/20;;G06N20/10;;G16B30/00;;G16B40/20;;G16B40/30,,3,2,026-036-673-320-286;;048-758-579-692-174,18005451;;pmc2216041;;10.1186/1471-2105-8-450;;pmc3992975;;24487276;;10.1038/ng.2892,"TIAN JIAN ET AL: ""Predicting the phenotypic effects of non-synonymous single nucleotide polymorphisms based on support vector machines"", BMC BIOINFORMATICS, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 16 November 2007 (2007-11-16), pages 450, XP021031593, ISSN: 1471-2105;;MARTIN KIRCHER ET AL: ""A general framework for estimating the relative pathogenicity of human genetic variants"", NATURE GENETICS., vol. 46, no. 3, 1 March 2014 (2014-03-01), NEW YORK, US, pages 310 - 315, XP055266510, ISSN: 1061-4036, DOI: 10.1038/ng.2892;;See also references of WO 2015042496A1",DISCONTINUED
551,WO,A1,WO 2008/075021 A1,179-297-576-897-810,2008-06-26,2008,GB 2007004850 W,2007-12-17,GB 0625108 A,2006-12-16,OPTICAL CORRELATION APPARATUS,"An optical correlation apparatus is described which forms first and second parallel optical signals in response to a serial input data stream (301). The first parallel optical signal is arranged to have bright pulses represent binary 1 and the second parallel optical signal is arranged to have bright pulses represent binary 0. A channel select means (310a, 310b), such as an optical switch or amplitude modulator, deselects or blocks channels in the first parallel optical signal which correspond to binary 1 in a reference data string and also deselects or blocks channels in the second parallel optical signal which correspond to binary 0 in the reference data string. The remaining optical signals are combined at one or more detectors (312). Where the input data matches the reference data string each bright pulse in the first and second parallel optical signals is deselected and the detector registers zero intensity. However when there is any mismatch at least one channel will pass a bright pulse to the detector. An instance of zero intensity can therefore be used as an indication of pattern match.",QINETIQ LTD;;LEWIN ANDREW CHARLES;;ORCHARD DAVID ARTHUR;;COOPER MARTIN JAMES,LEWIN ANDREW CHARLES;;ORCHARD DAVID ARTHUR;;COOPER MARTIN JAMES,,https://lens.org/179-297-576-897-810,Patent Application,yes,4,1,6,6,0,G06E3/00;;H04Q11/0005;;H04Q2011/003;;H04Q2011/0032;;H04Q2011/0035;;G06E3/005;;G06V10/88;;H04Q2011/003;;H04Q2011/0032;;H04Q2011/0035;;H04Q11/0005;;G06E3/00,G06K9/74;;H04Q11/00,,2,2,018-297-950-420-53X;;173-878-584-604-739,10.1109/jlt.2003.819144;;10.1049/el:19940500,"HAUER M C ET AL: ""Optically assisted internet routing using arrays of novel dynamically reconfigurable FBG-based correlators"", JOURNAL OF LIGHTWAVE TECHNOLOGY, vol. 21, no. 11, November 2003 (2003-11-01), pages 2765 - 2778, XP011103955, ISSN: 0733-8724;;TANCEVSKI L ET AL: ""Incoherent asynchronous optical CDMA using gold codes"", ELECTRONICS LETTERS, IEE STEVENAGE, GB, vol. 30, no. 9, 29 April 1994 (1994-04-29), pages 721 - 723, XP006000488, ISSN: 0013-5194",PENDING
552,US,A,US 5376663 A,187-743-679-570-105,1994-12-27,1994,US 39153889 A,1989-07-25,GB 8728820 A;;GB 8801093 W,1987-12-09,Macrocyclic compounds,"Compounds of formula (I), in which [R.sup.1 and R.sup.2 ], [R.sup.3 and R.sup.4 ] and [R.sup.5 and R.sup.6 ] represent a carbon-carbon bond or two hydrogen atoms; R.sup.2 additionally represents alkyl; R.sup.7, R.sup.8 and R.sup.9 represent groups including H or OH, R.sup.10 has various significances including alkyl and alkenyl; X and Y represent groups including O and (H, OH); R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.22 and R.sup.23 represent H or alkyl; R.sup.20 and R.sup.21 represent groups including O, (H, OH) and (H, O-alkyl), n is 1, 2 or 3, and in addition, Y, R.sup.10 and R.sup.23, together with the carbon atoms to which they are attached, may represent a heterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, e.g. for use as immunosuppressive agents, are also described. ##STR1##",FISONS PLC,COOPER MARTIN E;;DONALD DAVID K;;HARDERN DAVID N,FISONS PLC (1989-06-22);;FUJISAWA PHARMACEUTICAL CO. LTD (2004-11-23),https://lens.org/187-743-679-570-105,Granted Patent,yes,5,10,3,44,0,C07D498/18;;C07D498/22;;C07H19/01;;C07D498/18;;C07D498/22;;C07H19/01,C07D498/18;;C07D498/22;;C07H19/01,514/291;;514/418;;514/183;;540/456,5,2,006-182-274-942-90X;;045-638-892-844-861,10.1021/ja00414a088;;10.1021/ja01543a056,"Morrison and Boyd, Organic Chemistry (Boston, Allyn and Bacon, 1979) pp. 556 to 558.;;Williams et al JACS 1981 103 7398 7399.;;Casepio, et al JACS 1958 80 2584 2585.;;Chang, et al JACS 1960 82 1401 5.;;Morrison and Boyd, Organic Chemistry (Allyn and Bacon, 1979, Boston) pp. 639 to 640.",EXPIRED
553,US,B2,US 10060786 B2,021-641-473-673-013,2018-08-28,2018,US 201615543553 A,2016-01-14,GB 201500596 A;;EP 2016050671 W,2015-01-14,Multiplexed fiber sensor,"Some embodiments are directed to a multiplexed fiber sensor for a fiber optic hydrophone array, including a signal receiver configured to receive a signal from the fiber optic hydrophone sensor array and an interferometer. The interferometer is configured to produce a first signal component and a second signal component from the signal received from the hydrophone array, and also provided with a first polarization controller configured to control the polarization of the first signal component and a second polarization controller configured to control the polarization of the second signal component. A modulated carrier signal generator configured to generate a modulated carrier signal component based on the first signal component is also provided. A detector configured to output a demodulated output signal from the modulated signal component and the second signal component is included, wherein the modulated signal component and the second signal component output separately from the interferometer.",QINETIQ LTD,LEWIN ANDREW CHARLES;;COOPER MARTIN JAMES;;ORCHARD DAVID ARTHUR,QINETIQ LIMITED (2017-08-10),https://lens.org/021-641-473-673-013,Granted Patent,yes,7,0,7,7,0,G01V1/38;;G01D5/35325;;G01D5/35383;;G01H9/004;;G01D5/353;;G01H9/004;;G01V1/38;;G01D5/35325;;G01V1/38;;G01D5/35383;;G01H9/004;;G02B6/4213;;G02B6/4214;;G02B6/4246;;H01S3/0675;;H01S3/094003;;H01S3/10053;;H01S3/1608,G01D5/353;;G01H9/00;;G02B6/42;;H01S3/067;;H01S3/094;;H01S3/10;;H01S3/16,,5,0,,,"Foster, S., et al., “A Fibre Laser Hydrophone,” Proceedings of SPIE 2005;5855:627-630.;;Hill, D. J., et al., “A Fiber Laser Hydrophone Array,” Proceedings of SPIE 1999;3860:55-66.;;Search Report for Great Britain Patent App. No. GB1500596.0 (dated Jul. 29, 2015).;;International Search Report for PCT Patent App. No. PCT/EP2016/050671 (dated Apr. 6, 2016).;;Written Opinion for PCT Patent App. No. PCT/EP2016/050671 (dated Apr. 6, 2016).",ACTIVE
554,DE,A1,DE 3725185 A1,048-611-508-588-680,1988-02-04,1988,DE 3725185 A,1987-07-29,GB 8618398 A;;GB 8710608 A,1986-07-29,"DIOXOBENZ-(5,6)-ISOINDOLO-(2,1-B)- ISOCHINOLYLDERIVATE",,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/048-611-508-588-680,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/675;;A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
555,WO,A1,WO 2022/064399 A1,064-690-921-782-506,2022-03-31,2022,IB 2021058662 W,2021-09-22,US 202063082162 P;;US 202063084900 P,2020-09-23,TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY,"This disclosure relates to methods of treating cancers in a human patient (e.g., metastatic pancreatic ductal adenocarcinoma (PD AC)), comprising administering an anti-CD73 antibody or antigen binding fragment thereof and chemotherapy. The disclosure also relates to methods for the treatment of tumors comprising administering an anti-CD73 antibody or antigen-binding fragment thereof in combination with a PD-L1 antibody or an antigen-binding fragment thereof and chemotherapy.",MEDIMMUNE LLC,KUMAR RAKESH;;ENGLERT JUDSON;;COOPER ZACHARY;;MARTIN PHILIP LLOYD,,https://lens.org/064-690-921-782-506,Patent Application,yes,3,0,10,10,16,A61P35/00;;C07K16/2896;;C07K2317/21;;C07K16/2827;;A61K2039/507;;A61K39/39558;;A61K2039/505;;A61K2039/55;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;C07K16/2896;;A61K2039/55;;A61K31/7068;;A61K31/519;;A61P35/00;;A61K31/513;;C07K16/2827;;A61K39/39558;;A61K31/337;;A61K2039/505;;C07K2317/21;;A61K31/555;;A61K2039/507;;A61K45/06;;A61K2300/00;;C07K16/2896;;C07K16/2827;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;A61P35/00;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K2317/21;;A61P35/00;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;C07K16/2827;;C07K16/2896,A61P35/00;;A61K39/00;;A61K39/395;;C07K16/30,,0,0,,,,PENDING
556,US,A,US 5430398 A,079-106-648-614-374,1995-07-04,1995,US 17655894 A,1994-01-03,US 17655894 A,1994-01-03,BiCMOS buffer circuit,"A BiCMOS non-inverting buffer circuit (40) with small fan-in capacitance and excellent bipolar output drive. The circuit is ideal for buffering CMOS logic gates from excessive fan-out loads. The circuit also is less complex and more silicon efficient than present buffer circuit implementations, it provides improved transient saturation charge clamping and one buffer macro in an ASIC library can provide extended drive capability to all CMOS logic gates in the library.",TEXAS INSTRUMENTS INC,COOPER MICHAEL D;;MARTIN ROBERT C;;KEENEY STANLEY C,TEXAS INSTRUMENTS INCORPORATED (1994-01-03),https://lens.org/079-106-648-614-374,Granted Patent,yes,4,4,1,1,0,H03K19/09448;;H03K19/09448,H03K19/0944,326/110;;326/109,1,1,036-805-745-390-299,10.1109/4.98993,"Yano, et al., Quasi Complementary BiCMOS for Sub 3 V Digital Circuits , IEEE Journal of Solid State Circuits, vol. 26, No. 11, Nov. 1991, pp. 1708 1719.",EXPIRED
557,EP,A1,EP 2630127 A1,073-507-021-341-535,2013-08-28,2013,EP 11772962 A,2011-10-19,US 40525410 P;;EP 2011068221 W,2010-10-21,"PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS",,GLAXO GROUP LTD,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,,https://lens.org/073-507-021-341-535,Patent Application,yes,0,0,5,5,0,A61K31/415;;A61K31/415;;A61K31/4439;;A61K31/4439;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P37/08;;A61P43/00;;C07D231/40;;C07D231/40;;C07D401/12;;C07D401/12,C07D231/38;;A61K31/415;;A61K31/4155;;A61P11/00;;A61P29/00;;A61P37/00;;C07D401/12,,1,0,,,See references of WO 2012052459A1,DISCONTINUED
558,NO,D0,NO 20002788 D0,113-458-259-434-767,2000-05-31,2000,NO 20002788 A,2000-05-31,SE 9704542 A;;SE 9801989 A;;SE 9802191 W,1997-12-05,Nye forbindelser,,ASTRAZENECA UK LTD,BANTICK JOHN RAYMOND;;COOPER MARTIN;;THORNE PHILIP;;PERRY MATTHEW,,https://lens.org/113-458-259-434-767,Patent Application,no,0,0,27,29,0,C07D487/04;;C07D491/04;;C07D495/04;;A61P11/00;;A61P11/06;;A61P29/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D495/04;;C07D487/04;;C07D491/04;;C07D495/04,A61K31/5025;;A61P11/00;;A61P37/06;;C07D487/04;;C07D491/04;;C07D491/048;;C07D495/04;;C07D519/00,,0,0,,,,DISCONTINUED
559,US,A1,US 2018/0003552 A1,112-054-181-605-601,2018-01-04,2018,US 201615543553 A,2016-01-14,GB 201500596 A;;EP 2016050671 W,2015-01-14,MULTIPLEXED FIBER SENSOR,"Some embodiments are directed to a multiplexed fiber sensor for a fiber optic hydrophone array, including a signal receiver configured to receive a signal from the fiber optic hydrophone sensor array and an interferometer. The interferometer is configured to produce a first signal component and a second signal component from the signal received from the hydrophone array, and also provided with a first polarisation controller configured to control the polarisation of the first signal component and a second polarisation controller configured to control the polarisation of the second signal component. A modulated carrier signal generator configured to generate a modulated carrier signal component based on the first signal component is also provided. A detector configured to output a demodulated output signal from the modulated signal component and the second signal component is included, wherein the modulated signal component and the second signal component output separately from the interferometer.",QINETIQ LTD,LEWIN ANDREW CHARLES;;COOPER MARTIN JAMES;;ORCHARD DAVID ARTHUR,QINETIQ LIMITED (2017-08-10),https://lens.org/112-054-181-605-601,Patent Application,yes,2,3,7,7,0,G01V1/38;;G01D5/35325;;G01D5/35383;;G01H9/004;;G01D5/353;;G01H9/004;;G01V1/38;;G01D5/35325;;G01V1/38;;G01D5/35383;;G01H9/004;;G02B6/4213;;G02B6/4214;;G02B6/4246;;H01S3/0675;;H01S3/094003;;H01S3/10053;;H01S3/1608,G01H9/00;;G01D5/353;;G02B6/42;;H01S3/067;;H01S3/094;;H01S3/10;;H01S3/16,,0,0,,,,ACTIVE
560,IT,B,IT 1211683 B,135-219-564-449-770,1989-11-03,1989,IT 4823787 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,"DERIVATI DI ISOCHINOLINA, COMPOSIZIONI CHE LI CONTENGONO E PROCEDIMENTO PER PREPARARLI ED APPLICARLI",,GLAXO GROUP LTD,HANLEY PHILLIPPS GORDON;;SPENCER JONES PAUL;;EDWARD COOPER MARTIN,,https://lens.org/135-219-564-449-770,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
561,KR,A,KR 20170103948 A,143-568-692-578-02X,2017-09-13,2017,KR 20177022611 A,2016-01-14,GB 201500596 A;;EP 2016050671 W,2015-01-14,다중화된 섬유 센서,"본 발명은 섬유 광학 하이드로폰 어레이에 대한 다중화된 섬유 센서를 제공한다. 신호 수신기가 섬유 광학 하이드로폰 센서 어레이로부터 신호를 수신하도록 적응되고 간섭계가 제공된다. 상기 간섭계는 하이드로폰 어레이로부터 수신된 신호로부터 제 1 신호 성분 및 제 2 신호 성분을 생성하도록 적응된다. 상기 간섭계에는 또한 상기 제 1 신호 성분의 편광을 제어하도록 적응된 제 1 편광 제어기 및 상기 제 2 신호 성분의 편광을 제어하도록 적응된 제 2 편광 제어기가 제공된다. 추가적으로, 상기 제 1 신호 성분에 기초하여 변조된 반송파 신호 성분을 발생시키도록 적응된 변조된 반송파 신호 발생기가 또한 제공된다. 상기 변조된 신호 성분 및 상기 제 2 신호 성분으로부터 도출된 복조된 출력 신호를 출력하도록 적응된 검출기가 포함되며, 상기 변조된 신호 성분 및 상기 제 2 신호 성분은 상기 간섭계로부터 개별적으로 출력된다.",QINETIQ LTD,LEWIN ANDREW CHARLES;;COOPER MARTIN JAMES;;ORCHARD DAVID ARTHUR,,https://lens.org/143-568-692-578-02X,Patent Application,no,0,0,7,7,0,G01V1/38;;G01D5/35325;;G01D5/35383;;G01H9/004;;G01D5/353;;G01H9/004;;G01V1/38;;G01D5/35325;;G01V1/38;;G01D5/35383;;G01H9/004;;G02B6/4213;;G02B6/4214;;G02B6/4246;;H01S3/0675;;H01S3/094003;;H01S3/10053;;H01S3/1608,G01V1/38;;G01D5/353;;G01H9/00,,0,0,,,,PENDING
562,FI,A,FI 930597 A,161-034-040-713-27X,1993-02-11,1993,FI 930597 A,1993-02-11,FI 893750 A;;GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,MACROCYKLISKA FOERENINGAR,,FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/161-034-040-713-27X,Patent Application,no,0,0,2,44,0,,C07D498/18,,0,0,,,,DISCONTINUED
563,FI,B,FI 90550 B,165-857-105-418-961,1993-11-15,1993,FI 893750 A,1989-08-09,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,Menetelmä valmistaa terapeuttisesti aktiivista makrosyklistä johdannaista,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/165-857-105-418-961,Patent Application,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
564,DE,A1,DE 3628505 A1,186-710-298-485-815,1987-07-02,1987,DE 3628505 A,1986-08-22,US 81204585 A,1985-12-23,KERNREAKTOR MIT EINEM SELBSTAUSLOESENDEN ABSCHALTSYSTEM,,WESTINGHOUSE ELECTRIC CORP,SIEVERS ROBERT KEVIN;;COOPER MARTIN HOWARD;;TUPPER ROBERT BRUCE,,https://lens.org/186-710-298-485-815,Patent Application,no,0,2,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,,0,0,,,,DISCONTINUED
565,GB,B,GB 2195636 B,173-189-831-068-846,1990-05-30,1990,GB 8717864 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/173-189-831-068-846,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,C2P PA            P2E;;C2P PA            P3B;;C2P PA1           P2E;;C2P PA1           P3B;;C2P P1L1          P3B;;C2P P2E13         P2E;;C2P P2E15A        P2E;;C2P P2E19E        P2E;;C2P P2E26D        P2E;;C2P P3B12B        P3B;;C2P P3B13         P3B;;C2P P3B15A        P3B;;C2P P3B16         P3B;;C2P P3B18C        P3B;;C2P P3B19C        P3B;;C2P P3B19E        P3B;;C2P P3B20         P3B;;C2P P5A           P3B;;C2P P5B           P3B;;C2P P7            P2E;;C2P P7            P3B;;C2P P9            P3B;;U1S S1313,0,0,,,,EXPIRED
566,EP,A1,EP 0346427 A1,032-637-367-725-868,1989-12-20,1989,EP 89900628 A,1988-12-02,GB 8801093 W;;GB 8728820 A;;GB 8728821 A;;GB 8809174 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,MACROCYCLIC COMPOUNDS.,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,"ASTELLAS PHARMA INC. (2008-06-25);;YAMANOUCHI PHARMACEUTICAL CO., LTD. (2006-02-28);;FUJISAWA PHARMACEUTICAL CO., LTD. (2005-01-31)",https://lens.org/032-637-367-725-868,Patent Application,yes,0,2,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
567,US,A1,US 2016/0357903 A1,040-095-085-284-095,2016-12-08,2016,US 201415023355 A,2014-09-20,US 201415023355 A;;US 201361880286 P;;US 2014/0056701 W,2013-09-20,A FRAMEWORK FOR DETERMINING THE RELATIVE EFFECT OF GENETIC VARIANTS,"Current methods for annotating and interpreting human genetic variation typically exploit only a single information type (e.g., conservation) and/or are restricted in scope (e.g., to missense changes). Here, a method for objectively integrating many diverse annotations into a single measure (integrated deleteriousness score, or C-score) for each variant is described. The method may be implemented as a support vector machine (SVM) trained to differentiate high-frequency human-derived alleles from simulated variants. C-scores were precomputed for all 8.6 billion possible human single-nucleotide variants and allow scoring of short insertions-deletions. C-scores correlate with allelic diversity, annotations of functionality, pathogenicity, disease severity, experimentally measured regulatory effects and complex trait associations, and they highly rank known pathogenic variants within individual genomes. The ability of CADD to prioritize functional, deleterious and pathogenic variants across many functional categories, effect sizes and genetic architectures is unmatched by any current single-annotation method.",UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION;;HUDSONSALPHA INST FOR BIOTECHNOLOGY,SHENDURE JAY;;COOPER GREGORY M;;KIRCHER MARTIN;;WITTEN DANIELA,HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY (2014-03-13);;UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (2014-08-20),https://lens.org/040-095-085-284-095,Patent Application,yes,0,36,6,6,0,G06N20/00;;G16B30/00;;G16B40/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20;;B05B7/0416;;G06N20/10;;G16B40/20;;G16B30/00;;G16B20/20;;G16B40/30;;G16B30/00;;G16B40/00;;G06N20/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20,G16B20/20;;G06N20/10;;G16B30/00;;G16B40/20;;G16B40/30,,1,1,026-036-673-320-286,18005451;;pmc2216041;;10.1186/1471-2105-8-450,"Tian et al. (BMC Bioinformatics 2007, 8:450, pp.1-9) (Year: 2007)",DISCONTINUED
568,WO,A1,WO 2012/052458 A1,070-390-645-803-544,2012-04-26,2012,EP 2011068220 W,2011-10-19,US 40525210 P,2010-10-21,"PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, IMMUNE AND INFLAMMATORY CONDITIONS","The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy.",GLAXO GROUP LTD;;COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,,https://lens.org/070-390-645-803-544,Patent Application,yes,72,5,8,8,0,A61K31/415;;A61K31/415;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P43/00;;C07D231/40;;C07D231/40;;C07F9/222;;C07F9/65031;;C07F9/65031,C07D231/38;;A61K31/415;;A61P11/00;;A61P29/00;;A61P37/00,,14,9,030-096-802-881-282;;080-441-536-567-095;;046-537-529-679-295;;017-613-641-405-884;;037-960-491-197-945;;007-364-858-655-289;;066-371-099-307-130;;077-295-491-167-117;;008-620-115-468-390,10.1016/j.bmc.2006.03.039;;16616503;;16580212;;10.1016/j.bmc.2006.03.024;;18835179;;10.1016/j.bmc.2008.09.047;;18462938;;10.1016/j.bmcl.2008.04.018;;10.1517/17460441.3.7.787;;23496221;;10.1002/jps.2600660104;;833720;;18219308;;10.1038/nrd2468;;10.1002/0471220574;;10.1021/jm0341047;;12954048,"YONETOKU Y ET AL: ""Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 15, 1 August 2006 (2006-08-01), pages 5370 - 5383, XP025133434, ISSN: 0968-0896, [retrieved on 20060801], DOI: 10.1016/J.BMC.2006.03.039;;YONETOKU Y ET AL: ""Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 1: Synthesis and inhibitory activity of 5-(1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamides"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 14, 15 July 2006 (2006-07-15), pages 4750 - 4760, XP025133377, ISSN: 0968-0896, [retrieved on 20060715], DOI: 10.1016/J.BMC.2006.03.024;;YONETOKU Y ET AL: ""Novel potent and selective Ca<2+> release-activated Ca<2+> (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4'-[(trifluoromethyl)pyrazol-1-yl]carboxanilides"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 16, no. 21, 1 November 2008 (2008-11-01), pages 9457 - 9466, XP025545771, ISSN: 0968-0896, [retrieved on 20080920], DOI: 10.1016/J.BMC.2008.09.047;;HALL A ET AL: ""Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 11, 1 June 2008 (2008-06-01), pages 3392 - 3399, XP022711234, ISSN: 0960-894X, [retrieved on 20080411], DOI: 10.1016/J.BMCL.2008.04.018;;DERLER ET AL., EXPERT OPIN. DRUG DISCOVERY, vol. 3, no. 7, 2008, pages 787 - 800;;BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Burger's Medicinal Chemistry and Drug Discovery, 5th Edition"", vol. 1, article ""Principles and Practice"";;RAUTIO ET AL., NATURE REVIEWS, vol. 7, 2008, pages 255 - 270;;T.W. GREENE, P.G.M. WUTS: ""Protective groups in organic synthesis"", 1999, JOHN WILEY & SONS;;P.J. KOCIENSKI: ""Protecting Groups"", 1994, GEORG THIEME VERLAG;;HOFGEN, N. ET AL., 15TH EFMC INT SYMP MED CHEM, 6 September 1998 (1998-09-06), pages 98;;LANDELLS, L.J. ET AL., EUR RESP J [ANNU CONG EUR RESP SOC, vol. 12, no. 28, 19 September 1998 (1998-09-19);;TANABE SEIYAKU, FUJI, K. ET AL., J PHARMACOL EXP THER, vol. 284, no. 1, 1998, pages 162;;JABLONOWSKI ET AL., J. MED. CHEM., vol. 46, 2003, pages 3957 - 3960",PENDING
569,FR,B1,FR 2592204 B1,091-384-658-771-159,1989-05-05,1989,FR 8612003 A,1986-08-22,US 81204585 A,1985-12-23,SYSTEME AUTOMATIQUE D'ARRET DE REACTEURS NUCLEAIRES,,WESTINGHOUSE ELECTRIC CORP,SIEVERS ROBERT KEVIN;;COOPER MARTIN HOWARD;;TUPPER ROBERT BRUCE,,https://lens.org/091-384-658-771-159,Granted Patent,no,0,0,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,,0,0,,,,EXPIRED
570,BR,A2,BR 112023004594 A2,102-338-888-451-02X,2023-04-11,2023,BR 112023004594 A,2021-09-22,IB 2021058662 W;;US 202063082162 P;;US 202063084900 P,2020-09-23,MÉTODOS DE TRATAMENTO USANDO ANTICORPOS ANTI-CD73 E ANTI-PD-L1 E QUIMIOTERAPIA,"MÉTODOS DE TRATAMENTO USANDO ANTICORPOS ANTI-CD73 e ANTI-PD-L1 E QUIMIOTERAPIA. A presente divulgação refere-se a métodos de tratamento de cânceres em um paciente humano (por exemplo, adenocarcinoma ductal pancreático (ADP) metastático), que compreendem a administração de um anticorpo anti-CD73 ou fragmento de ligação ao antígeno do mesmo e quimioterapia. A divulgação também se refere a métodos para o tratamento de tumores, que compreendem a administração de um anticorpo anti-CD73 ou fragmento de ligação ao antígeno do mesmo em combinação com um anticorpo anti-PD-L1 ou um fragmento de ligação ao antígeno do mesmo e quimioterapia.",MEDIMMUNE LLC,RAKESH KUMAR;;JUDSON ENGLERT;;ZACHARY COOPER;;PHILIP LLOYD MARTIN,,https://lens.org/102-338-888-451-02X,Patent Application,no,0,0,10,10,0,A61P35/00;;C07K16/2896;;C07K2317/21;;C07K16/2827;;A61K2039/507;;A61K39/39558;;A61K2039/505;;A61K2039/55;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;C07K16/2896;;A61K2039/55;;A61K31/7068;;A61K31/519;;A61P35/00;;A61K31/513;;C07K16/2827;;A61K39/39558;;A61K31/337;;A61K2039/505;;C07K2317/21;;A61K31/555;;A61K2039/507;;A61K45/06;;A61K2300/00;;C07K16/2896;;C07K16/2827;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;A61P35/00;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K2317/21;;A61P35/00;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;C07K16/2827;;C07K16/2896,A61P35/00;;A61K39/00;;A61K39/395;;C07K16/30,,0,0,,,,PENDING
571,US,A1,US 2013/0203705 A1,108-380-783-426-810,2013-08-08,2013,US 201113879650 A,2011-10-19,US 201113879650 A;;US 40525210 P;;EP 2011068220 W,2010-10-21,"Pyrazole Compounds Acting Against Allergic, Immune and Inflammatory Conditions","The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy.",COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID;;GLAXO GROUP LTD,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,GLAXO GROUP LIMITED (2011-10-24),https://lens.org/108-380-783-426-810,Patent Application,yes,0,2,8,8,0,A61K31/415;;A61K31/415;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P43/00;;C07D231/40;;C07D231/40;;C07F9/222;;C07F9/65031;;C07F9/65031,C07D231/38;;A61K31/415;;A61K45/06;;C07F9/22,514/94;;548/372.5;;548/119;;514/407,0,0,,,,INACTIVE
572,EP,B1,EP 0808423 B1,142-242-621-362-268,2002-02-27,2002,EP 96936362 A,1996-10-09,US 9616284 W;;US 56878895 A,1995-12-07,ROTARY COMPRESSOR WITH REDUCED LUBRICATION SENSITIVITY,,CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/142-242-621-362-268,Granted Patent,yes,3,0,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C18/356;;F04C23/00;;F04C29/00,,1,0,,,"DATABASE WPI Section PQ, Week 9638 Derwent Publications Ltd., London, GB; Class Q56,Page 7, AN 96-373902 XP002024345 & JP 08 177 772 A (KYOCERA CORP.) , 12 July 1996",EXPIRED
573,WO,A1,WO 1989/005304 A1,153-272-304-660-217,1989-06-15,1989,GB 8801093 W,1988-12-02,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,MACROCYCLIC COMPOUNDS,"Compounds of formula (I), in which [R?1 and R2], [R3 and R4¿] and [R?5 and R6¿] represent a carbon-carbon bond or two hydrogen atoms; R2 additionally represents alkyl; R?7, R8 and R9¿ represent groups including H or OH, R10 has various significances including alkyl and alkenyl; X and Y represent groups including O and (H, OH); R?14, R15, R16, R17, R18, R19, R22 and R23¿ represent H or alkyl; R?20 and R21¿ represent groups including O, (H, OH) and (H, O-alkyl), n is 1, 2 or 3, and in addition, Y, R?10 and R23¿, together with the carbon atoms to which they are attached, may represent a heterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, e.g. for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/153-272-304-660-217,Patent Application,yes,2,61,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,PATENTED
574,GB,B,GB 2513660 B,177-256-705-249-745,2018-11-14,2018,GB 201308085 A,2013-05-03,GB 201308085 A,2013-05-03,System for connecting a display over a general-purpose data transport,,DISPLAYLINK UK LTD,MARTIN ANDREW TURNOCK;;TIMOTHY MARK EDMONDS;;PATRICK DAVID COOPER,,https://lens.org/177-256-705-249-745,Granted Patent,no,10,0,7,7,0,G06F13/10;;G06F13/385;;G06F3/14;;G06F9/4401;;G06F13/10;;G06F13/10;;G06F9/4406;;G06F9/4411;;G06F13/385,G06F9/4401;;G06F3/14,,0,0,,,,ACTIVE
575,US,A,US 5947710 A,050-155-980-490-332,1999-09-07,1999,US 87701897 A,1997-06-16,US 87701897 A;;US 56878895 A,1995-12-07,Rotary compressor with reduced lubrication sensitivity,"Lubrication deficiencies related to the use of lubricants in HFC refrigeration compressors can be mitigated by providing a diamond-like-carbon coating on a member subject to wear due to lubrication deficiencies. Specifically, the tip of the vane of a rotary compressor is coated with a diamond-like-carbon coating made up of alternating layers of tungsten carbide and a lubricious material 0.5 to 5.0 microns thick.",CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,CARRIER CORPORATION (1998-12-14),https://lens.org/050-155-980-490-332,Granted Patent,yes,25,79,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C29/00;;F04C18/356;;F04C23/00,418/63;;418/178;;428/408;;428/634,6,4,163-553-097-918-791;;064-742-003-825-150;;032-051-335-661-734;;055-765-786-347-276,10.1016/0257-8972(91)90297-a;;10.1016/0257-8972(91)90338-w;;10.1016/0925-9635(94)90297-6;;10.1016/0925-9635(94)05325-1,"Industrial Heating ; Title: Application and Utility of Industrial Diamond Like Films pp. 12 14, Jul. 1988.;;Surface and Coatings Technology , 47 (1991), pp. 315 326; Title: Physical Properties of Carbon Films Produced Using a Hybrid Physical Vapour Deposition Technique.;;Surface and Coatings Technology , 47 (1991), pp. 662 667, Title: Diamond Like Carbon Applied To Bioengineering Materials.;;Wear Protection for Gears , The Journal of Gear Manufacturing, Gear Technology, Heat Treating; Frederick J. Teeter & Manfred Berger, Mar./Apr. 1996, pp. 27 29.;;Diamond and Related Materials , International Journal on the Science and Technology of Diamond and Related Materials, Title: Engineering Applications for Diamond Like Carbon, A. Matthews and S.S Eskildsen, vol. 3, Nos. 4 6, Apr. 1994, ISSN 0925 9635, pp. 902 911.;;Diamond and Related Materials , International Journal on the Science and Technology of Diamond and ReElated Materials; Title: Tribology of Carbon Coatings: DLC, Diamond and Beyond; S.J. Bull, vol. 4, Nos. 5 6, May 1995, ISSN 0925 9635, pp. 827 836.",EXPIRED
576,KR,A,KR 20230074206 A,101-298-007-651-903,2023-05-26,2023,KR 20237013299 A,2021-09-22,US 202063082162 P;;US 202063084900 P;;IB 2021058662 W,2020-09-23,항-CD73 및 항-PD-L1 항체와 화학요법을 이용하는 치료 방법,"본 개시내용은 항-CD73 항체 또는 이의 항원 결합 단편 및 화학요법을 투여하는 단계를 포함하는, 인간 환자의 암(예를 들어, 전이성 췌장 도관 선암종(PD AC))을 치료하는 방법에 관한 것이다. 본 개시내용은 또한 PD-L1 항체 또는 이의 항원-결합 단편 및 화학요법과 병용하여 항-CD73 항체 또는 이의 항원-결합 단편을 투여하는 단계를 포함하는 종양의 치료 방법에 관한 것이다.",MEDIMMUNE LLC,KUMAR RAKESH;;ENGLERT JUDSON;;COOPER ZACHARY;;MARTIN PHILIP LLOYD,,https://lens.org/101-298-007-651-903,Patent Application,no,0,0,10,10,32,A61P35/00;;C07K16/2896;;C07K2317/21;;C07K16/2827;;A61K2039/507;;A61K39/39558;;A61K2039/505;;A61K2039/55;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;C07K16/2896;;A61K2039/55;;A61K31/7068;;A61K31/519;;A61P35/00;;A61K31/513;;C07K16/2827;;A61K39/39558;;A61K31/337;;A61K2039/505;;C07K2317/21;;A61K31/555;;A61K2039/507;;A61K45/06;;A61K2300/00;;C07K16/2896;;C07K16/2827;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;A61P35/00;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K2317/21;;A61P35/00;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;C07K16/2827;;C07K16/2896,C07K16/28;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;A61K39/00;;A61K45/06;;A61P35/00,,0,0,,,,PENDING
577,GB,B,GB 2165983 B,113-736-375-406-904,1988-05-25,1988,GB 8525237 A,1985-10-14,GB 8426497 A,1984-10-19,OPTICAL PATTERN RECOGNITION APPARATUS,,GEN ELECTRIC CO PLC,COOPER IAN ROBERT;;MCCALL MARTIN WILLIAM;;PETTS COLIN ROY,,https://lens.org/113-736-375-406-904,Granted Patent,no,0,0,3,3,0,G06E3/003;;G06V10/88;;G06E3/003;;G06V10/88,G06E3/00;;G06V10/88,G4R11E;;G4R12A;;G4R12F;;G4R1X;;G4R3E;;G4R5B;;G4R9F;;G4RRH,0,0,,,,EXPIRED
578,MY,A,MY 102457 A,138-773-210-154-69X,1992-06-30,1992,MY PI19871071 A,1987-07-21,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,"THERE ARE PROVIDED COMPOUNDS OF THE GENERAL FORMULA (1)(FORMULA 1)(WHEREIN R1 AND R2 WHICH MAY BE THE SAME OR DIFFERENT, EACH REPRESENTS A HYDROGEN ATOM, A HYDROXYL GROUP OR A GROUP- OP(O) (OH) (OR4) [ WHERE R4 REPRESENTS A HYDROGEN ATOM OR AN ALKYL (OPTIONALLY SUBSTITUTED BY A HYDROXYL, ALKOXY, CYCLIC ETHER OR CYCLOALKYL GROUP) ALKENYL, CYCLOALKYL, ARYL, ARALKYL OR AROYLALKYL GROUP ] WITH THE PROVISO THAT AT LEAST ONE OF R1 AND R2 REPRESENTS A GROUP- OP (0) (OH) (OR4); AND R3 REPRESENTS A HYDROGEN OR HALOGEN ATOM OR A METHYL GROUP AND SALTS THEREOF.THE NOVEL COMPOUNDS EXHIBIT INTERESTING ANTI- CANCER ACTIVITY.",GLAXO GROUP LTD,PAUL SPENCER JONES;;GORDON HANLEY PHILLIPPS;;MARTIN EDWARD COOPER,,https://lens.org/138-773-210-154-69X,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/675;;A61K31/395;;C07D221/18;;A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
579,WO,A8,WO 2015/042496 A8,150-652-383-886-50X,2015-07-23,2015,US 2014/0056701 W,2014-09-20,US 201361880286 P,2013-09-20,A FRAMEWORK FOR DETERMINING THE RELATIVE EFFECT OF GENETIC VARIANTS,"Current methods for annotating and interpreting human genetic variation typically exploit only a single information type (e.g., conservation) and/or are restricted in scope (e.g., to missense changes). Here, a method for objectively integrating many diverse annotations into a single measure (integrated deleteriousness score, or C-score) for each variant is described. The method may be implemented as a support vector machine (SVM) trained to differentiate high-frequency human-derived alleles from simulated variants. C-scores were precomputed for all 8.6 billion possible human single- nucleotide variants and allow scoring of short insertions-deletions. C-scores correlate with allelic diversity, annotations of functionality, pathogenicity, disease severity, experimentally measured regulatory effects and complex trait associations, and they highly rank known pathogenic variants within individual genomes. The ability of CADD to prioritize functional, deleterious and pathogenic variants across many functional categories, effect sizes and genetic architectures is unmatched by any current single-annotation method.",UNIV WASHINGTON CT COMMERCIALI;;HUDSONALPHA INST FOR BIOTECHNOLOGY,SHENDURE JAY;;COOPER GREGORY M;;KIRCHER MARTIN;;WITTEN DANIELA,,https://lens.org/150-652-383-886-50X,Amended Application,yes,0,0,6,6,0,G06N20/00;;G16B30/00;;G16B40/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20;;B05B7/0416;;G06N20/10;;G16B40/20;;G16B30/00;;G16B20/20;;G16B40/30;;G16B30/00;;G16B40/00;;G06N20/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20,G16B20/20;;C12Q1/68;;G06N3/00;;G06N3/08;;G06N20/10;;G16B30/00;;G16B40/20;;G16B40/30,,0,0,,,,PENDING
580,EP,B1,EP 0428609 B1,149-564-983-848-544,1993-04-28,1993,EP 89909587 A,1989-08-15,GB 8819351 A,1988-08-15,MAKING AN ELONGATE CUT USING HIGH ENERGY RADIATION,,ANSTALT GERSAN,"COOPER, MARTIN;;STEWART, ANDREW, DAVID, GARRY THE OLD RECTORY",ANSTALT GERSAN (1993-03-31),https://lens.org/149-564-983-848-544,Granted Patent,yes,1,0,13,30,0,B23K26/364;;B23K26/364,B23K26/06;;B23K26/00;;B23K26/073;;B23K26/36,,1,0,,,"IBM TECHNICAL DISCLOSURE BULLETIN. vol. 14, no. 9, February 1972, NEW YORK US, pages 2641-2642 ; M.A. GRIMM : ""Optical system for laser machining of narrow slots"".",EXPIRED
581,CN,C,CN 1078314 C,005-488-209-399-416,2002-01-23,2002,CN 96191699 A,1996-10-09,US 56878895 A,1995-12-07,Rotary compressor with reduced lubrication sensitivity,,CARRIER CORP,COOPER CLARK V;;BUSHENNL PAUL J;;MERTELL MARTIN M,,https://lens.org/005-488-209-399-416,Granted Patent,no,0,1,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F04C29/00;;F01C21/08;;F04C18/356;;F04C23/00,,0,0,,,,EXPIRED
582,CN,A,CN 1172521 A,039-245-485-828-835,1998-02-04,1998,CN 96191699 A,1996-10-09,US 56878895 A,1995-12-07,Rotary compressor with reduced lubrication sensitivity,,CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/039-245-485-828-835,Patent Application,no,0,0,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F04C29/00;;F01C21/08;;F04C18/356;;F04C23/00,,0,0,,,,EXPIRED
583,PT,A,PT 89203 A,100-341-050-382-74X,1989-12-29,1989,PT 8920388 A,1988-12-09,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803374 A,1987-12-09,New macrocyclic cpds. e.g. derived from FR-900506 - useful as immunosuppressants for treating transplant rejection or auto-immune diseases,"Macrocyclic cpds. of formula (I) and their salts are new. In (I), R1 = H or alkyl; R2-6 = H; or R1 + R2, R3 + R4, and/or R5 + R6 = bonds; R7 = H, oH or alkoxy; or R1 + R7 = O; R8, R9 = H or OH; R10 = H, alkyl; X = O, (H, OH), (H, H) or -CH2=-; Y = O, (H, OH), (H, H), N-NR11R12 or N-OR13; R11, R12 = H, alkyl, aryl or tosyl; R13-19, R22-23 = H or alkyl; R20 = O or (R200, H); R21 = O or (R210, H); R200, R210 = OH, alkoxy or OCH2OCH2CH2OMe; or R200 + R210 = O; n = 1-3; or Y, R10 and R23 together with the C atoms to which they are attached represent a 5- or 6- membered N-, S- or O- contg. heterocyclic ring which may be satd. or unsatd. and which may be substd. by 1 or more of alkyl, OH, alkoxy, benzyl and -CH2SePh; provided that when X = Y = O, R9 = OH, R14-19 = R22 = Me, R200 = OMe, R8 = R23 = H, R210 = OH, R3 + R4 and R5 + R6 = bonds, and (a) when n = 1, R7 = OH and R1 = R2 = H, then R10 is not allyl; (b) when n = 2, R7 = OH and R1 = R2 = H, then R10 is not Me, ET, Pr or allyl; and (c) when n = 2, R7 = H and R1 + R2 = a bond, then R10 is not allyl.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/100-341-050-382-74X,Patent Application,no,0,0,2,44,0,,A61K31/335;;A61K31/70;;C07D498/00;;C07H19/01,,0,0,,,,EXPIRED
584,ES,T3,ES 2171733 T3,111-185-348-922-267,2002-09-16,2002,ES 96936362 T,1996-10-09,US 56878895 A,1995-12-07,COMPRESOR ROTATORIO CON SENSIBILIDAD REDUCIDA A LA LUBRICACION.,"LAS DEFICIENCIAS EN LA LUBRICACION, DEBIDAS A LA UTILIZACION DE LUBRICANTES SINTETICOS COMO LOS LUBRICANTES A BASE DE POLIESTER, RECUBRIENDO LA PIEZA SOMETIDA A DESGASTE, DEBIDO A LAS DEFICIENCIAS DE LUBRICACION, CON UN REVESTIMIENTO DE CARBONO DE TIPO DIAMANTE. ESPECIFICAMENTE, LA PUNTA DE LA PALETA DE UN COMPRESOR ROTATORIO, SE REVISTE CON UN RECUBRIMIENTO DE CARBONO DE TIPO DIAMANTE, HECHO CON CAPAS ALTERNANTES DE CARBURO DE TUNGSTENO Y DE UN MATERIAL LUBRICANTE, Y CON UN GROSOR DE 0,5 A 5,0 MICRONES.",CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/111-185-348-922-267,Granted Patent,no,0,1,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C18/356;;F04C23/00;;F04C29/00,,0,0,,,,EXPIRED
585,BR,A,BR 9607029 A,150-493-485-071-859,1997-11-04,1997,BR 9607029 A,1996-10-09,US 56878895 A;;US 9616284 W,1995-12-07,Compressor de refrigeração lubrificado por óleo sintético e possuindo uma superficie sujeita a desgaste na ausência de lubrificante suficiente,,CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/150-493-485-071-859,Patent Application,no,0,0,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F04C29/00;;F01C21/08;;F04C18/356;;F04C23/00,,0,0,,,,EXPIRED
586,US,A1,US 2016/0077842 A1,003-238-117-425-168,2016-03-17,2016,US 201414888863 A,2014-04-30,GB 201308085 A;;GB 2014051348 W,2013-05-03,SYSTEM FOR CONNECTING A DISPLAY OVER A GENERAL-PURPOSE DATA TRANSPORT,"A system to enable a computer to provide output to a display over a general-purpose data transmission medium, such as USB. The system includes provision of a plurality of display interface components, each display interface component adapted to receive display data and transmission of the display data to the display via the general-purpose data transmission medium. Each component is associated with a respective stage of operation of the system. The system is configured to use a respective one of the display interface components during each of a plurality of distinct operational stages.",DISPLAYINK UK LTD,TURNOCK MARTIN ANDREW;;EDMONDS TIMOTHY MARK;;COOPER PATRICK DAVID,DISPLAYLINK (UK) LIMITED (2018-07-10),https://lens.org/003-238-117-425-168,Patent Application,yes,13,10,7,7,0,G06F13/10;;G06F13/385;;G06F3/14;;G06F9/4401;;G06F13/10;;G06F13/10;;G06F9/4406;;G06F9/4411;;G06F13/385,G06F13/38;;G06F9/44,,0,0,,,,ACTIVE
587,FR,B1,FR 2602233 B1,004-917-917-593-742,1990-08-17,1990,FR 8710763 A,1987-07-29,GB 8618398 A;;GB 8710608 A,1986-07-29,DERIVES DE L'ISOQUINOLEINE,,GLAXO GROUP LTD,HANLEY PHILLIPPS GORDON;;SPENCER JONES PAUL;;EDWARD COOPER MARTIN,,https://lens.org/004-917-917-593-742,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;A61K31/675;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
588,NZ,A,NZ 221238 A,045-248-021-558-321,1990-03-27,1990,NZ 22123887 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/045-248-021-558-321,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;A61K31/675;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
589,FI,A0,FI 873289 A0,064-276-029-332-703,1987-07-28,1987,FI 873289 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOKINOLINDERIVAT.,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/064-276-029-332-703,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
590,WO,A1,WO 2016/113352 A1,086-167-343-074-007,2016-07-21,2016,EP 2016050671 W,2016-01-14,GB 201500596 A,2015-01-14,MULTIPLEXED FIBRE SENSOR,"The present invention provides a multiplexed fibre sensor for a fibre optic hydrophone array. A signal receiver is adapted to receive a signal from the fibre optic hydrophone sensor array and an interferometer is provided. The interferometer is adapted to produce a first signal component and a second signal component from the signal received from the hydrophone array. The interferometer is also provided with a first polarisation controller adapted to control the polarisation of the first signal component and a second polarisation controller adapted to control the polarisation of the second signal component. In addition a modulated carrier signal generator adapted to generate a modulated carrier signal component based on the first signal component is also provided. A detector adapted to output a demodulated output signal derived from the modulated signal component and the second signal component is included, wherein the modulated signal component and the second signal component are output separately from the interferometer.",QINETIQ LTD,LEWIN ANDREW CHARLES;;COOPER MARTIN JAMES;;ORCHARD DAVID ARTHUR,,https://lens.org/086-167-343-074-007,Patent Application,yes,2,2,7,7,0,G01V1/38;;G01D5/35325;;G01D5/35383;;G01H9/004;;G01D5/353;;G01H9/004;;G01V1/38;;G01D5/35325;;G01V1/38;;G01D5/35383;;G01H9/004;;G02B6/4213;;G02B6/4214;;G02B6/4246;;H01S3/0675;;H01S3/094003;;H01S3/10053;;H01S3/1608,G01H9/00;;G01D5/353;;G01V1/38,,0,0,,,,PENDING
591,CN,A,CN 1049503 A,097-078-519-077-637,1991-02-27,1991,CN 90107149 A,1990-08-18,GB 8918927 A;;GB 8922653 A;;GB 9012426 A,1989-08-18,PROCESS FOR PREPARATION OF MACROCYCLIC COMPOUNDS,,FISONS PLC,DONALD DAVID KEITH;;HARDERN DAVID NORMAN;;COOPER MARTIN EDWARD,,https://lens.org/097-078-519-077-637,Patent Application,no,0,0,9,13,0,C07D498/18;;C07H19/01;;A61P37/06,A61K31/395;;A61K31/40;;A61P37/06;;A61K31/435;;C07D498/18;;C07H19/01,,0,0,,,,DISCONTINUED
592,MY,A,MY 112067 A,103-296-696-914-089,2001-03-31,2001,MY PI19964772 A,1996-11-18,US 56878895 A,1995-12-07,ROTARY COMPRESSOR WITH REDUCED LUBRICATION SENSITIVITY,"LUBRICATION DEFICIENCIES RELATED TO THE USE OF SYNTHETIC LUBRICANTS SUCH AS POE OILS IN REFRIGERATION COMPRESSORS CAN BE MITIGATED BY PROVIDING A DIAMOND-LIKE-CARBON COATING ON A MEMBER SUBJECT TO WEAR DUE TO LUBRICATION DEFICIENCIES. SPECIFICALLY, THE TIP OF THE VANE OF A ROTARY COMPRESSOR IS COATED WITH A DIAMOND-LIKE-CARBON COATING MADE UP OF ALTERNATING LAYERS OF TUNGSTEN CARBIDE AND A LUBRICIOUS MATERIAL 0.5 TO 5.0 MICRONS THICK.FIGURE 2 & 5",CARRIER CORP,PAUL J BUSHNELL;;CLARK V COOPER;;MARTIN M MERTELL,,https://lens.org/103-296-696-914-089,Granted Patent,no,0,0,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F04C18/356;;F01C21/08;;F04C29/00;;F04C23/00,,0,0,,,,EXPIRED
593,MX,A,MX 9706020 A,099-380-780-695-308,1997-11-29,1997,MX 9706020 A,1996-10-09,US 9616284 W;;US 56878895 A,1995-12-07,ROTARY COMPRESSOR WITH REDUCED LUBRICATION SENSITIVITY.,"Lubrication deficiencies related to the use of synthetic lubricants such as POE oils in refrigeration compressors can be mitigated by providing a diamond-like-carbon coating on a member subject to wear due to lubrication deficiencies. Specifically, the tip of the vane of a rotary compressor is coated with a diamond-like-carbon coating made up of alternating layers of tungsten carbide and a lubricious material 0.5 to 5.0 microns thick.",CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/099-380-780-695-308,Patent Application,no,0,0,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C18/356;;F04C29/00;;F04C23/00,,0,0,,,,EXPIRED
594,FR,A1,FR 2592204 A1,197-531-854-160-567,1987-06-26,1987,FR 8612003 A,1986-08-22,US 81204585 A,1985-12-23,SYSTEME AUTOMATIQUE D'ARRET DE REACTEURS NUCLEAIRES,"<P>Système automatique d'arrêt de réacteurs nucléaires. <BR/> Le système comprend un assemblage 16 de commande de la réactivité comportant un élément 42 d'absorption des neutrons mobile entre une position haute et une position basse, et un système 28 sensible à la température et formant un mécanisme de verrouillage, prévu pour maintenir le faisceau 42 en position haute mais pour libérer l'élément d'absorption quand la température détectée est supérieure à une température donnée. Un passage 68 d'écoulement se prolonge vers le bas jusqu'à un moyen 54 de pompage disposé à la partie inférieure de l'assemblage, de sorte que la température du fluide chauffé de refroidissement venant d'au-dessus de l'assemblage peut être détectée directement par un moyen 62 sensible à la température. <BR/> Applications : notamment aux réacteurs nucléaires refroidis par métal liquide. <BR/> (CF DESSIN DANS BOPI)<BR/> <BR/></P>",WESTINGHOUSE ELECTRIC CORP,SIEVERS ROBERT KEVIN;;COOPER MARTIN HOWARD;;TUPPER ROBERT BRUCE,,https://lens.org/197-531-854-160-567,Patent Application,no,2,0,8,8,0,G21C9/02;;G21C9/02;;Y02E30/30;;Y02E30/30,G21C9/02,,0,0,,,,EXPIRED
595,US,A1,US 2010/0040380 A1,012-277-359-191-702,2010-02-18,2010,US 51876707 A,2007-12-17,GB 0625108 A;;GB 2007004850 W,2006-12-16,OPTICAL CORRELATION APPARATUS,"An optical correlation apparatus is described which forms first and second parallel optical signals in response to a serial input data stream. The first parallel optical signal is arranged to have bright pulses represent binary 1 and the second parallel optical signal is arranged to have bright pulses represent binary 0. A channel select means, such as an optical switch or amplitude modulators deselects or blocks channels in the first parallel optical signal which correspond to binary 1 in a reference data string and also deselects or blocks channels in the second parallel optical signal which correspond to binary 0 in the reference data string. The remaining optical signals are combined at one or more detectors. Where the input data matches the reference data string each bright pulse in the first and second parallel optical signals is deselected and the detector registers zero intensity. However when there is any mismatch at least one channel will pass a bright pulse to the detector. An instance of zero intensity can therefore be used as an indication of pattern match.",QINETIQ LTD,LEWIN ANDREW CHARLES;;ORCHARD DAVID ARTHUR;;COOPER MARTIN JAMES,QINETIQ LIMITED (2009-03-02),https://lens.org/012-277-359-191-702,Patent Application,yes,16,17,6,6,0,G06E3/00;;H04Q11/0005;;H04Q2011/003;;H04Q2011/0032;;H04Q2011/0035;;G06E3/005;;G06V10/88;;H04Q2011/003;;H04Q2011/0032;;H04Q2011/0035;;H04Q11/0005;;G06E3/00,H04B10/00,398/158,0,0,,,,INACTIVE
596,IT,A0,IT 8748237 A0,029-325-200-013-913,1987-07-28,1987,IT 4823787 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,"DERIVATI DI ISOCHINOLINA, COMPOSIZIONI CHE LI CONTENGONO E PROCEDIMENTO PER PREPARARLI ED APPLICARLI",,GLAXO GROUP LTD,HANLEY PHILLIPPS GORDON;;SPENCER JONES PAUL;;EDWARD COOPER MARTIN,,https://lens.org/029-325-200-013-913,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61K31/675;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
597,HU,B,HU 201936 B,065-248-326-158-658,1991-01-28,1991,HU 346087 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,PROCESS FOR PRODUCING ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,COOPER MARTIN EDWARD;;PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER,,https://lens.org/065-248-326-158-658,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;C07D217/20;;A61K31/675;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
598,US,A,US 3188655 A,093-549-502-937-840,1965-06-15,1965,US 18541962 A,1962-04-05,US 18541962 A,1962-04-05,Harness for control of upper extremity prosthesis,,MARTIN COOPER CARL;;SULMONETTI WILLIAM B;;RENFRO CLARENCE A,MARTIN COOPER CARL;;SULMONETTI WILLIAM B;;RENFRO CLARENCE A,,https://lens.org/093-549-502-937-840,Granted Patent,no,6,3,1,1,0,A61F2/54;;A61F2/54,A61F2/54,,0,0,,,,EXPIRED
599,US,B1,US 6547176 B1,160-028-204-477-959,2003-04-15,2003,US 16001902 A,2002-06-04,US 16001902 A,2002-06-04,Wire unwinding controller,"
    A controller for controlling the dispensing of wire from a reel of wire positioned within a container. The wire is dispensed from one end of the reel with the other end of the reel sitting on the bottom of the container. The controller has a main body member in the shape of a flat ring sized to rest within the container on the one end of the reel, the ring having concentric, circular, inner and outer edges. Flexible, wire guide flaps are on the inner edge of the ring, the guide flaps extending radially inwardly. Each guide flap has the general shape of a shallow triangle with the apex of the triangle farthest from the ring and the base of the triangle adjacent and integral with the ring. 
",AIR LIQUIDE CANADA INC,BLAIN DENIS;;COOPER EDWARD L;;PAQUET MARTIN;;VAIDYA VIWEK,AIR LIQUIDE CANADA INC (2002-03-26),https://lens.org/160-028-204-477-959,Granted Patent,yes,8,62,3,3,0,B65H49/02;;B65H49/08;;B65H57/18;;B65H59/06;;B65H2404/56;;B65H59/06;;B65H2404/56;;B65H49/02;;B65H49/08;;B65H57/18,B65H49/02;;B65H49/08;;B65H57/18;;B65H59/06,242/423.1;;242/128;;242/156.1,0,0,,,,EXPIRED
600,US,B2,US 7720074 B2,167-112-863-104-239,2010-05-18,2010,US 56409506 A,2006-11-28,US 56409506 A;;US 64947800 A;;US 15112099 P,1999-08-27,Methods and systems of network management,"A network management system (NMS) automatically models a path for a customer's services from a terminating unit through elements typically on a link-by-link basis, across networks if appropriate, to a network service provider (NSP) or Internet service provider (ISP). The path may be a private virtual circuit or connection (PVC), and it may traverse an “overall network” including other networks such as an asymmetric digital subscriber line (ADSL) service or sub-networks. To model a path, the NMS creates a topology including the elements and links in the overall network and respective features, functions, characteristics, and capacities thereof. The topology allows the NMS to speedily, efficiently, and automatically provision a customer's service from the terminating unit to connection to the customer's selected NSP or ISP for Internet access.",AT & T IP I LP,CHEWNING WARD M III;;BEHI FARIBORZ;;COOPER MARTIN ALAN,AT&T INTELLECTUAL PROPERTY I L.P (2008-09-30),https://lens.org/167-112-863-104-239,Granted Patent,yes,8,4,3,3,0,H04L12/2856;;H04L41/0806;;H04L41/0886;;H04L41/12;;H04L41/22;;H04L41/32;;H04L41/5054;;H04L41/507;;H04L43/091;;H04L41/507;;H04L41/12;;H04L41/0886;;H04L41/22;;H04L12/2856;;H04L41/0806;;H04L41/32;;H04L41/5054;;H04L43/091,G06F15/173;;H04L12/28,370/395.21;;370/237;;370/254;;370/395.3;;709/223;;709/220;;709/238,9,0,,,"Chewning; U.S. Appl. No. 09/649,478, filed Aug. 28, 2000.;;Chewning; Non- Final Rejection mailed Dec. 5, 2003; U.S. Appl. No 09/649,478, filed Aug. 28, 2000.;;Chewning; Non- Final Rejection mailed Jun. 22, 2004; U.S. Appl. No. 09/649,478, filed Aug. 28, 2000.;;Chewning; Examiner Interview Summary Record mailed Sep. 8, 2004; U.S. Appl. No. 09/649,478, filed Aug. 28, 2000.;;Chewning; Non- Final Rejection mailed Apr. 19, 2005; U.S. Appl. No. 09/649,478, filed Aug. 28, 2000.;;Chewning; Examiner Interview Summary Record mailed May 17, 2005; U.S. Appl. No. 09/649,478, filed Aug. 28, 2000.;;Chewning; Final Rejection mailed Oct. 17, 2005; U.S. Appl. No. 09/649,478, filed Aug. 28, 2000.;;Chewning; Examiner Interview Summary Record mailed Nov. 10, 2005; U.S. Appl. No. 09/649,478, filed Aug. 28, 2000.;;Chewning; Notice of Allowance and Fees Due mailed Jan. 11, 2006; U.S. Appl. No. 09/649,478, filed Aug. 28, 2000.",EXPIRED
601,EP,A1,EP 1018068 A1,183-617-023-757-871,2000-07-12,2000,EP 98943539 A,1998-09-02,US 9818412 W;;US 92974297 A,1997-09-15,SCROLLING NAVIGATIONAL DISPLAY SYSTEM,,SONY TRANS COM INC,GREENWOOD WAYNE EUGENE;;COOPER ALAN MARTIN;;EVENSON KAREN LOUISE,,https://lens.org/183-617-023-757-871,Patent Application,yes,0,0,7,7,0,G06F3/0485;;G06F3/0489;;G06F2200/1632;;G06F3/0489;;G06F3/0485;;G06F2200/1632,A63F13/00;;B64D11/06;;G06F1/16;;G06F3/023;;G06F3/033;;G06F3/0485;;G06F3/0488;;H03M11/04,,0,0,,,,DISCONTINUED
602,US,B1,US 7142530 B1,186-248-304-293-784,2006-11-28,2006,US 64947800 A,2000-08-28,US 64947800 A;;US 15112099 P,1999-08-27,Methods and systems of network management,"A network management system (NMS) automatically models a path for a customer's services from a terminating unit through elements typically on a link-by-link basis, across networks if appropriate, to a network service provider (NSP) or Internet service provider (ISP). The path may be a private virtual circuit or connection (PVC), and it may traverse an “overall network” including other networks such as an asymmetric digital subscriber line (ADSL) service or sub-networks. To model a path, the NMS creates a topology including the elements and links in the overall network and respective features, functions, characteristics, and capacities thereof. The topology allows the NMS to speedily, efficiently, and automatically provision a customer's service from the terminating unit to connection to the customer's selected NSP or ISP for Internet access.",BELLSOUTH INTELLECT PTY CORP,CHEWNING WARD M III;;BEHI FARIBORZ;;COOPER MARTIN ALAN,BELLSOUTH INTELLECTUAL PROPERTY CORP (2004-04-02),https://lens.org/186-248-304-293-784,Granted Patent,yes,21,17,3,3,0,H04L12/2856;;H04L41/0806;;H04L41/0886;;H04L41/12;;H04L41/22;;H04L41/32;;H04L41/5054;;H04L41/507;;H04L43/091;;H04L41/507;;H04L41/12;;H04L41/0886;;H04L41/22;;H04L12/2856;;H04L41/0806;;H04L41/32;;H04L41/5054;;H04L43/091,H04L12/28,370/351;;370/254;;709/223;;709/224,2,0,,,"U.S. Appl. No. 60/108,924.;;Ward Chewning; Bellsouth Telecommunications, Science and Technology, entitled: ADSL NMS Release 1.0 Turnover Evaluation; date is one year prior to Aug. 27, 1998; pp. 1-7.",EXPIRED
603,FI,C,FI 90550 C,003-855-317-050-261,1994-02-25,1994,FI 893750 A,1989-08-09,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,Menetelmä valmistaa terapeuttisesti aktiivista makrosyklistä johdannaista,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/003-855-317-050-261,Granted Patent,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
604,GB,A,GB 2513660 A,034-579-676-477-749,2014-11-05,2014,GB 201308085 A,2013-05-03,GB 201308085 A,2013-05-03,System for connecting a display over a general-purpose data transport,"Providing output to a display over a general-purpose data transmission medium, such as USB, LAN or Wi-Fi so that the display means can interact with the computer outside the operating system (OS). Provides a plurality of display interface components which maybe software such as drivers or hardware interface modules. Each component is associated with a respective stage of operation of the computer which is configured to use a respective one of the display interface components during each of a plurality of distinct operational stages. This allows display output during multiple operational stages of the computer. The operational stages may include operating stages prior to booting, after booting and during booting of the OS so the display maybe output during boot or pre-os or any of the operational stages. Operating stages may include powering up, booting, running and shutting down of OS and computer. Stages may also include stages of OS installation.",DISPLAYLINK UK LTD,TURNOCK MARTIN ANDREW;;EDMONDS TIMOTHY MARK;;COOPER PATRICK DAVID,,https://lens.org/034-579-676-477-749,Patent Application,no,10,2,7,7,0,G06F13/10;;G06F13/385;;G06F3/14;;G06F9/4401;;G06F13/10;;G06F13/10;;G06F9/4406;;G06F9/4411;;G06F13/385,G06F13/10;;G06F3/14;;G06F9/44,,0,0,,,,ACTIVE
605,US,A,US 6034688 A,073-485-020-603-981,2000-03-07,2000,US 92974297 A,1997-09-15,US 92974297 A,1997-09-15,Scrolling navigational display system,"A user-interface system adapted to navigate through a plurality of menus is disclosed. The system comprises a display system comprising a display having a category area on a first portion of the display, the category area displaying a plurality of categories, including a currently displayed category. Each of the plurality of categories has a plurality of items. The display also has a marquee area on a second portion of the display, which displays items of the currently displayed category. The system further comprises a scrolling mechanism for scrolling through items of each category of the plurality of categories. The marquee area is updated by the scrolling mechanism to display the corresponding items in each category. The scrolling mechanism also indicates a position of a currently displayed item of a currently displayed category by updating the category area. Various embodiments are disclosed.",SONY CORP;;SONY TRANS COM INC,GREENWOOD WAYNE EUGENE;;COOPER ALAN MARTIN;;EVENSEN KAREN LOUISE,SONY TRANS COM INC (1998-01-16),https://lens.org/073-485-020-603-981,Granted Patent,yes,15,166,7,7,0,G06F3/0485;;G06F3/0489;;G06F2200/1632;;G06F3/0489;;G06F3/0485;;G06F2200/1632,A63F13/00;;B64D11/06;;G06F1/16;;G06F3/023;;G06F3/033;;G06F3/0485;;G06F3/0488;;H03M11/04,345/353;;345/346,0,0,,,,EXPIRED
606,AU,A,AU 1987/076203 A,075-697-354-932-264,1988-02-04,1988,AU 1987/076203 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/075-697-354-932-264,Patent Application,no,0,1,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/675;;A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
607,DK,A,DK 387889 A,103-418-633-345-31X,1989-08-08,1989,DK 387889 A,1989-08-08,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,"MAKROLIDER, OG FARMACEUTISKE PRAEPARATER MED INDHOLD AF SAADANNE FORBINDELSER","Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/103-418-633-345-31X,Patent Application,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,DISCONTINUED
608,WO,A1,WO 2015/042496 A1,113-782-690-630-137,2015-03-26,2015,US 2014/0056701 W,2014-09-20,US 201361880286 P,2013-09-20,A FRAMEWORK FOR DETERMINING THE RELATIVE EFFECT OF GENETIC VARIANTS,"Current methods for annotating and interpreting human genetic variation typically exploit only a single information type (e.g., conservation) and/or are restricted in scope (e.g., to missense changes). Here, a method for objectively integrating many diverse annotations into a single measure (integrated deleteriousness score, or C-score) for each variant is described. The method may be implemented as a support vector machine (SVM) trained to differentiate high-frequency human-derived alleles from simulated variants. C-scores were precomputed for all 8.6 billion possible human single- nucleotide variants and allow scoring of short insertions-deletions. C-scores correlate with allelic diversity, annotations of functionality, pathogenicity, disease severity, experimentally measured regulatory effects and complex trait associations, and they highly rank known pathogenic variants within individual genomes. The ability of CADD to prioritize functional, deleterious and pathogenic variants across many functional categories, effect sizes and genetic architectures is unmatched by any current single-annotation method.",UNIVERSTIY OF WASHINGTON THROUGH ITS CT FOR COMMERCIALIZATION;;HUDSONALPHA INST FOR BIOTECHNOLOGY,SHENDURE JAY;;COOPER GREGORY M;;KIRCHER MARTIN;;WITTEN DANIELA,,https://lens.org/113-782-690-630-137,Patent Application,yes,1,8,6,6,0,G06N20/00;;G16B30/00;;G16B40/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20;;B05B7/0416;;G06N20/10;;G16B40/20;;G16B30/00;;G16B20/20;;G16B40/30;;G16B30/00;;G16B40/00;;G06N20/00;;G06N20/10;;G16B40/30;;G16B40/20;;G16B20/20,G16B20/20;;C12Q1/68;;G06N3/00;;G06N3/08;;G06N20/10;;G16B30/00;;G16B40/20;;G16B40/30,,7,5,026-036-673-320-286;;003-507-517-380-096;;048-758-579-692-174;;150-829-498-403-281;;026-036-673-320-286,18005451;;pmc2216041;;10.1186/1471-2105-8-450;;10.1186/1471-2105-10-439;;20028521;;pmc2805646;;pmc3992975;;24487276;;10.1038/ng.2892;;10.1016/j.ygeno.2011.06.010;;21763417;;pmc3371640;;18005451;;pmc2216041;;10.1186/1471-2105-8-450,"TIAN ET AL.: ""Predicting the phenotypic effects of non-synonymous single nucleotide 1 polymorphisms based on support vector machines."", BMC BIOINFORMATICS, vol. 8, no. 1, 16 November 2007 (2007-11-16), pages 1 - 9, XP021031593;;RANGWALA ET AL.: ""svmPRAT: SVM-based protein residue annotation toolkit."", BMC BIOINFORMATICS, vol. 10, no. 1, 22 December 2009 (2009-12-22), pages 1 - 12, XP021065553;;KIRCHER ET AL.: ""A general framework for estimating the relative pathogenicity of human genetic 1 variants."", NATURE GENETICS, vol. 46, no. 3, 1 March 2014 (2014-03-01), pages 310 - 315, XP055266510, DOI: 10.1038/NG.2892;;CAPRIOTTI ET AL.: ""A new disease-specific machine learning approach for the prediction of cancer-causing missense variants."", GENOMICS, vol. 98, no. 4, 1 January 2011 (2011-01-01), pages 310 - 317, XP028304086, DOI: 10.1016/J.YGENO.2011.06.010;;CONSORTIUM ET AL., ENCODE PROJECT, 2012;;TIAN JIAN ET AL.: ""BMC BIOINFORMATICS"", vol. 8, 16 November 2007, BIOMED CENTRAL, article ""Predicting the phenotypic effects of non-synonymous single nucleotide polymorphisms based on support vector machines"", pages: 450;;See also references of EP 3047388A4",PENDING
609,EP,A1,EP 4217072 A1,136-084-552-675-894,2023-08-02,2023,EP 21871791 A,2021-09-22,US 202063082162 P;;US 202063084900 P;;IB 2021058662 W,2020-09-23,TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY,,MEDIMMUNE LLC,KUMAR RAKESH;;ENGLERT JUDSON;;COOPER ZACHARY;;MARTIN PHILIP LLOYD,,https://lens.org/136-084-552-675-894,Patent Application,yes,0,0,10,10,16,A61P35/00;;C07K16/2896;;C07K2317/21;;C07K16/2827;;A61K2039/507;;A61K39/39558;;A61K2039/505;;A61K2039/55;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;C07K16/2896;;A61K2039/55;;A61K31/7068;;A61K31/519;;A61P35/00;;A61K31/513;;C07K16/2827;;A61K39/39558;;A61K31/337;;A61K2039/505;;C07K2317/21;;A61K31/555;;A61K2039/507;;A61K45/06;;A61K2300/00;;C07K16/2896;;C07K16/2827;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;A61P35/00;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K2317/21;;A61P35/00;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;C07K16/2827;;C07K16/2896,A61P35/00;;A61K39/00;;A61K39/395;;C07K16/30,,0,0,,,,PENDING
610,US,A,US 5672054 A,177-752-949-899-608,1997-09-30,1997,US 56878895 A,1995-12-07,US 56878895 A,1995-12-07,Rotary compressor with reduced lubrication sensitivity,"Lubrication deficiencies related to the use of synthetic lubricants such as POE oils in refrigeration compressors can be mitigated by providing a diamond-like-carbon coating on a member subject to wear due to lubrication deficiencies. Specifically, the tip of the vane of a rotary compressor is coated with a diamond-like-carbon coating made up of alternating layers of tungsten carbide and a lubricious material 0.5 to 5.0 microns thick.",CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,CARRIER CORPORATIN (1995-12-05),https://lens.org/177-752-949-899-608,Granted Patent,yes,22,34,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C29/00;;F04C18/356;;F04C23/00,418/63;;418/178;;428/408;;428/634,6,4,163-553-097-918-791;;064-742-003-825-150;;032-051-335-661-734;;055-765-786-347-276,10.1016/0257-8972(91)90297-a;;10.1016/0257-8972(91)90338-w;;10.1016/0925-9635(94)90297-6;;10.1016/0925-9635(94)05325-1,"Industrial Heating ; Title: Application and Utility of Industrial Diamond Like Films pp. 12 14.;;Surface and Coatings Technology , 47 (1991) 315 326: Title Physical Properties of Carbon Films Produced Using a Hybrid Physical Vapour Desposition Technique.;;Surface and Coatings Technology, 47 (1991) 662 667 Diamond Like Carbon Applied To Bioengineering Materials.;;Wear Protection for Gears , The Journal of Gear Manufacturing, Gear Technology, Heat Treating, Frederick J. Teeter & Manfred Berger, Mar./Apr. 1996, pp. 27 29.;;Diamond and Related Materials, International Journal on the Science and Technology of Diamond and Related Materials, Engineering applications for diamond like carbon , A. Matthews and S.S. Eskildsen, vol. 3, No. 4 6, Apr. 1994, ISSN 0925 9635, pp. 902 911.;;Diamond and Related Materials, International Journal on the Science and Technology of Diamond and Related Materials, Tribology of carbon coatings: DLC, diamond and beyond , S.J. Bull, vol. 4, No. 5 6, May 1995, ISSN 0925 9635, pp. 827 836.",EXPIRED
611,US,B2,US 9156791 B2,008-425-509-577-094,2015-10-13,2015,US 201113879650 A,2011-10-19,US 201113879650 A;;US 40525210 P;;EP 2011068220 W,2010-10-21,"Pyrazole compounds acting against allergic, immune and inflammatory conditions","The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy.",COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID;;GLAXO GROUP LTD,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,GLAXO GROUP LIMITED (2011-10-24),https://lens.org/008-425-509-577-094,Granted Patent,yes,6,0,8,8,0,A61K31/415;;A61K31/415;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P43/00;;C07D231/40;;C07D231/40;;C07F9/222;;C07F9/65031;;C07F9/65031,C07D231/40;;A61K31/415;;A61K45/06;;C07F9/22;;C07F9/6503,,5,4,030-096-802-881-282;;080-441-536-567-095;;046-537-529-679-295;;017-613-641-405-884,10.1016/j.bmc.2006.03.039;;16616503;;16580212;;10.1016/j.bmc.2006.03.024;;18835179;;10.1016/j.bmc.2008.09.047;;18462938;;10.1016/j.bmcl.2008.04.018,"Yonetoku Y. et al., ""Novel Potent and selective calcium-release-activitated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles"", BioOrganic & Medicinal Chemistry, Pergamon, GB., vol. 14, No. 15, Aug. 1, 2006 pp. 5370-5383, XP025133434, ISSN: 0968-0896.;;Yonetoku Y. et al., ""Novel Potent and selective calcium-release-activitated calcium (CRAC) channel inhibitors. Part 1: Synthesis and inhibitory activity of 5-(1-methyl-3-trifluoromethy1-1H-pyrazol-5-yl)-2-thiophenecarboxamides"", BioOrganic & Medicinal Chemistry, Pergamon, GB., vol. 14, No. 14, Jul. 15, 2006 pp. 4750-4760, XP025133377, ISSN: 0968-0896.;;Yonetoku Y. et al., ""Novel Potent and selective Ca release-activated Ca (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4'-[trifluoromethyl)pyrazol-1-yl]carboxan ilides"", BioOrganic & Medicinal Chemistry, Pergamon, GB., vol. 16, No. 21, Nov. 1, 2008 pp. 9457-9466, XP025545771, ISSN: 0968-0896.;;Hall A., et al., ""Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy"", BioOrganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB, vol. 18, No. 11, Jun. 1, 2008, pp. 3392-3399, XP022711234, Issn: 0960-894X.;;Database Registry [online] chemical Abstracts Service, Columbus, Ohio, US; May 14, 2003, Benzamide, N-[1-[(2,4-dichlorophenyl)methyl]-1H-pyraz, XP 002663702, Database accession No. 515178-09-3, whole document.",INACTIVE
612,FI,A0,FI 930597 A0,006-787-446-691-388,1993-02-11,1993,FI 930597 A,1993-02-11,FI 893750 A;;GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,MACROCYKLISKA FOERENINGAR,,FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/006-787-446-691-388,Patent Application,no,0,0,2,44,0,,,,0,0,,,,DISCONTINUED
613,CH,A5,CH 672489 A5,007-970-394-827-344,1989-11-30,1989,CH 288587 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,CH 672489 A5,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/007-970-394-827-344,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/675;;A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
614,DK,D0,DK 387889 D0,009-385-304-710-480,1989-08-08,1989,DK 387889 A,1989-08-08,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,"MAKROLIDER, OG FARMACEUTISKE PRAEPARATER MED INDHOLD AF SAADANNE FORBINDELSER","Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/009-385-304-710-480,Patent Application,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,DISCONTINUED
615,US,B2,US 9149462 B2,078-702-877-475-915,2015-10-06,2015,US 201113879652 A,2011-10-19,US 201113879652 A;;US 40525410 P;;EP 2011068221 W,2010-10-21,"Pyrazole compounds acting against allergic, inflammatory and immune disorders",The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID;;GLAXO GROUP LTD,COOPER ANTHONY WILLIAM JAMES;;GORE PAUL MARTIN;;HOUSE DAVID,GLAXO GROUP LIMITED (2011-10-24),https://lens.org/078-702-877-475-915,Granted Patent,yes,5,0,5,5,0,A61K31/415;;A61K31/415;;A61K31/4439;;A61K31/4439;;A61K45/06;;A61P11/00;;A61P11/02;;A61P11/06;;A61P29/00;;A61P37/00;;A61P37/08;;A61P43/00;;C07D231/40;;C07D231/40;;C07D401/12;;C07D401/12,A61K31/415;;A61K31/4439;;A61K45/06;;C07D231/40;;C07D401/12,,5,4,030-096-802-881-282;;080-441-536-567-095;;046-537-529-679-295;;017-613-641-405-884,10.1016/j.bmc.2006.03.039;;16616503;;16580212;;10.1016/j.bmc.2006.03.024;;18835179;;10.1016/j.bmc.2008.09.047;;18462938;;10.1016/j.bmcl.2008.04.018,"Database Registry [online] chemical Abstracts Service, Columbus, Ohio, US; May 14, 2003, Benzamide, N-[1-[(2,4-dichlorophenyl)methyl]-1H-pyraz, XP 002663702, Database accession No. 515178-09-3, whole document.;;Yonetoku Y. et al., ""Novel Potent and selective calcium-release-activitated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles"", BioOrganic & Medicinal Chemistry, Pergamon, GB., vol. 14, No. 15, Aug. 1, 2006 pp. 5370-5383, XP025133434, ISSN: 0968-0896.;;Yonetoku Y. et al., ""Novel Potent and selective calcium-release-activitated calcium (CRAC) channel inhibitors. Part 1: Synthesis and inhibitory activity of 5-(1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamides"", BioOrganic & Medicinal Chemistry, Pergamon, GB., vol. 14, No. 14, Jul. 15, 2006 pp. 4750-4760, XP025133377, ISSN: 0968-0896.;;Yonetoku Y. et al., ""Novel Potent and selective Ca release-activated Ca (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4'-[trifluoromethyl)pyrazol-1-yl]carboxan ilides"", BioOrganic & Medicinal Chemistry, Pergamon, GB., vol. 16, No. 21, Nov. 1, 2008 pp. 9457-9466, XP025545771, ISSN: 0968-0896.;;Hall A., et al., ""Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy"", BioOrganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB, vol. 18, No. 11, Jun. 1, 2008, pp. 3392-3399, XP022711234, ISSN: 0960-894X.",INACTIVE
616,US,B2,US 9466414 B2,091-804-028-097-049,2016-10-11,2016,US 201514629611 A,2015-02-24,US 201514629611 A,2015-02-24,Vibration stabilizer for enclosure cooling fins,"An enclosure for an electrical apparatus includes a tank having a bank of corrugate affixed to one or more walls thereof, with the bank of corrugate including a plurality of cooling fins in fluid communication with a volume of the tank via a plurality of openings formed in the walls, such that cooling fluid can flow into the cooling fins. A cross member is affixed to the bank of corrugate along each of a top surface and a bottom surface thereof and extends along a length of the corrugate at a distal end of the cooling fins. Vibration stabilizers are provided to control vibrations in the corrugate bank, with the vibration stabilizer having a gusset plate joined to the cross member and extending between a pair of adjacent cooling fins and stabilizer with a first end attached to the tank and a second end attached to the gusset plate.",COOPER TECHNOLOGIES CO,COOPER JERAMIE ALLEN;;BUNYER SCOTT LISTON;;MARTIN NOLE THOMAS,EATON INTELLIGENT POWER LIMITED (2017-12-31);;COOPER TECHNOLOGIES COMPANY (2015-02-11),https://lens.org/091-804-028-097-049,Granted Patent,yes,11,0,3,3,0,H01F27/025;;H01F27/08;;H01F27/02;;H01F27/025,H01F27/10;;F24D3/16;;F28D15/00;;H01F27/02;;H01F27/08,,1,0,,,"PCT International Search Report and Written Opinion from corresponding PCT/US2016/018196, May 27, 2016.",ACTIVE
617,EP,A1,EP 3245490 A1,098-896-676-311-07X,2017-11-22,2017,EP 16700494 A,2016-01-14,GB 201500596 A;;EP 2016050671 W,2015-01-14,MULTIPLEXED FIBRE SENSOR,,QINETIQ LTD,LEWIN ANDREW CHARLES;;COOPER MARTIN JAMES;;ORCHARD DAVID ARTHUR,,https://lens.org/098-896-676-311-07X,Patent Application,yes,0,0,7,7,0,G01V1/38;;G01D5/35325;;G01D5/35383;;G01H9/004;;G01D5/353;;G01H9/004;;G01V1/38;;G01D5/35325;;G01V1/38;;G01D5/35383;;G01H9/004;;G02B6/4213;;G02B6/4214;;G02B6/4246;;H01S3/0675;;H01S3/094003;;H01S3/10053;;H01S3/1608,G01H9/00;;G01D5/353;;G01V1/38,,0,0,,,,DISCONTINUED
618,WO,A1,WO 2014/177869 A1,120-853-421-711-974,2014-11-06,2014,GB 2014051348 W,2014-04-30,GB 201308085 A,2013-05-03,SYSTEM FOR CONNECTING A DISPLAY OVER A GENERAL-PURPOSE DATA TRANSPORT,"Disclosed is a method of enabling a computer to provide output to a display over a general-purpose data transmission medium, such as USB. The method includes providing a plurality of display interface components, each display interface component adapted to receive display data and transmit the display data to the display via the general-purpose data transmission medium. Each component is associated with a respective stage of operation of the computer. The computer is configured to use a respective one of the display interface components during each of a plurality of distinct operational stages.",DISPLAYLINK UK LTD;;TURNOCK MARTIN ANDREW;;EDMONDS TIMOTHY MARK;;COOPER PATRICK DAVID,TURNOCK MARTIN ANDREW;;EDMONDS TIMOTHY MARK;;COOPER PATRICK DAVID,,https://lens.org/120-853-421-711-974,Patent Application,yes,4,5,7,7,0,G06F13/10;;G06F13/385;;G06F3/14;;G06F9/4401;;G06F13/10;;G06F13/10;;G06F9/4406;;G06F9/4411;;G06F13/385,G06F13/12;;G06F13/10;;H04L29/08,,2,0,,,"VESA: ""VESA Net2Display Remoting Standard"", VESA NET2DISPLAY STANDARD,, no. Version 1, 22 October 2009 (2009-10-22), pages 1 - 276, XP007917342;;See also references of EP 2992434A1",PENDING
619,US,A,US 4851399 A,136-758-755-676-81X,1989-07-25,1989,US 7871687 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,Isoquinoline derivatives and their use as anti-cancer agents,"There are provided compounds of the general formula (1) ##STR1## (wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom, a hydroxyl group or a group --OP(O) (OH) (OR.sup.4) [where R.sup.4 represents a hydrogen atom or an alkyl (optionally substituted by a hydroxyl, alkoxy, cyclic ether or cycloalkyl group), alkenyl cycloalkyl, aryl, aralkyl or aroylalkyl group], with the proviso that at least one of R.sup.1 and R.sup.2 represents a group --OP(O) (OH) (OR.sup.4); and R.sup.3 represents a hydrogen or halogen atom or a methyl group), and salts thereof. The novel compounds exhibit interesting anti-cancer activity.",GLAXO GROUP LTD,PHILLIPPS GORDON H;;JONES PAUL S;;COOPER MARTIN E,GLAXO GROUP LIMITED (1987-07-28),https://lens.org/136-758-755-676-81X,Granted Patent,yes,12,2,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;A61K31/675;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,514/80;;514/283;;546/23;;546/42,15,4,016-932-447-538-562;;061-443-039-842-586;;065-411-172-613-474;;129-036-035-523-278,10.1016/0305-7372(83)90008-7;;6347376;;10.1007/bf00255899;;6690066;;157808;;10.1021/jo00985a016,"deKernion, J. B., The Chemotheraphy of Advanced Bladder Carcinoma, Aug. 1971.;;Smith, I. E., Mitoxantrone (novantrone): A review . . . Cancer Treatment Reviews (1983) 10, 103 155.;;Stuart Harris, R. C., Mitoxantrone: An Active New Agent . . . Cancer Chemother Parmacol (1984) 12:1 4.;;Prestayko et al., CISPLATIN, Academic Press, 1980.;;Cummings et al., Phase I Study of 5 Fluorodeoxyruidine . . . , Cancer Treatment Reports, vol. 63, No. 8, Aug. 1979, p. 1371.;;CA, vol. 75, 143961y, (1971).;;CA, vol. 77, 88260h, (1972).;;CA, vol. 83, 152267u, (1975).;;CA, vol. 83, 168484y, (1975).;;CA, vol. 92, 75895d, (1980).;;J. Heterocyclic Chem., vol. 15, pp. 1303 1307, (1978).;;J. Organic Chemistry, vol. 37, No. 20, pp. 3111 3113, (1972).;;Reagents for Organic Synthesis by Fieser et al., John Wiley & Sons, New York (1967), pp. 682 684.;;Patent Abstracts of Japan, vol. 8, No. 130 (c 2290) 1567 , 6 16 84.;;Synthesis and Reactions in the 1,2,3,4 Tetrahydroisoquinoline Series, C. R. Spray (1980), pp. 161 162, 193 194, 208 221 and 243 (PhD thesis).",EXPIRED
620,EG,A,EG 21022 A,177-735-189-295-355,2000-09-30,2000,EG 108096 A,1996-12-05,US 56878895 A,1995-12-07,Rotary compressor with reduced lubrication sensitivity,,CARRIER CORP,COOPER CLARK V;;BUSHNELL PAUL J;;MERTELL MARTIN M,,https://lens.org/177-735-189-295-355,Patent of Addition,no,0,0,18,18,0,F01C21/0809;;F04C18/356;;F04C18/3564;;F04C23/008;;F04C2210/26;;F04C2230/91;;F05C2203/0808;;F05C2203/0813;;F05C2253/08;;Y10T428/30;;Y10T428/12625;;F04C29/02;;Y10T428/30;;Y10T428/12625;;F04C18/3564;;F04C18/356;;F04C2210/26;;F01C21/0809;;F05C2203/0813;;F05C2253/08;;F04C23/008;;F05C2203/0808;;F04C2230/91,F01C21/08;;F04C29/00;;F04C18/356;;F04C23/00,,0,0,,,,PENDING
621,US,A1,US 2024/0010746 A1,189-465-126-916-263,2024-01-11,2024,US 202118246206 A,2021-09-22,US 202118246206 A;;US 202063082162 P;;US 202063084900 P;;IB 2021058662 W,2020-09-23,TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY,"This disclosure relates to methods of treating cancers in a human patient (e.g., metastatic pancreatic ductal adenocarcinoma (PD AC)), comprising administering an anti-CD73 antibody or antigen binding fragment thereof and chemotherapy. The disclosure also relates to methods for the treatment of tumors comprising administering an anti-CD73 antibody or antigen-binding fragment thereof in combination with a PD-L1 antibody or an antigen-binding fragment thereof and chemotherapy.",MEDIMMUNE LLC,KUMAR RAKESH;;ENGLERT JUDSON;;COOPER ZACHARY;;MARTIN PHILIP LLOYD,MEDIMMUNE LLC (2021-02-12),https://lens.org/189-465-126-916-263,Patent Application,yes,0,0,10,10,16,A61P35/00;;C07K16/2896;;C07K2317/21;;C07K16/2827;;A61K2039/507;;A61K39/39558;;A61K2039/505;;A61K2039/55;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;C07K16/2896;;A61K2039/55;;A61K31/7068;;A61K31/519;;A61P35/00;;A61K31/513;;C07K16/2827;;A61K39/39558;;A61K31/337;;A61K2039/505;;C07K2317/21;;A61K31/555;;A61K2039/507;;A61K45/06;;A61K2300/00;;C07K16/2896;;C07K16/2827;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;A61P35/00;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K2317/21;;A61P35/00;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;C07K16/2827;;C07K16/2896,C07K16/28;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;A61P35/00,,0,0,,,,PENDING
622,EP,A1,EP 2992434 A1,195-356-432-945-841,2016-03-09,2016,EP 14721942 A,2014-04-30,GB 201308085 A;;GB 2014051348 W,2013-05-03,SYSTEM FOR CONNECTING A DISPLAY OVER A GENERAL-PURPOSE DATA TRANSPORT,,DISPLAYLINK UK LTD,TURNOCK MARTIN ANDREW;;EDMONDS TIMOTHY MARK;;COOPER PATRICK DAVID,DISPLAYLINK (UK) LIMITED (2016-08-10),https://lens.org/195-356-432-945-841,Patent Application,yes,8,0,7,7,0,G06F13/10;;G06F13/385;;G06F3/14;;G06F9/4401;;G06F13/10;;G06F13/10;;G06F9/4406;;G06F9/4411;;G06F13/385,G06F13/12;;G06F13/10;;H04L29/08,,1,0,,,See also references of WO 2014177869A1,DISCONTINUED
623,EP,A1,EP 2100261 A1,012-176-192-394-31X,2009-09-16,2009,EP 07848587 A,2007-12-17,GB 2007004850 W;;GB 0625108 A,2006-12-16,OPTICAL CORRELATION APPARATUS,,QINETIQ LTD,LEWIN ANDREW CHARLES;;ORCHARD DAVID ARTHUR;;COOPER MARTIN JAMES,QINETIQ LIMITED (2011-06-08),https://lens.org/012-176-192-394-31X,Patent Application,yes,0,1,6,6,0,G06E3/00;;H04Q11/0005;;H04Q2011/003;;H04Q2011/0032;;H04Q2011/0035;;G06E3/005;;G06V10/88;;H04Q2011/003;;H04Q2011/0032;;H04Q2011/0035;;H04Q11/0005;;G06E3/00,G06K9/74;;H04Q11/00,,0,0,,,,DISCONTINUED
624,CN,A,CN 116209468 A,029-500-268-181-847,2023-06-02,2023,CN 202180063881 A,2021-09-22,US 202063082162 P;;US 202063084900 P;;IB 2021058662 W,2020-09-23,Methods of treatment using anti-CD73 and anti-PD-L1 antibodies and chemotherapy,"The present disclosure relates to methods of treating cancer (e.g., metastatic pancreatic ductal adenocarcinoma (PDAC)) in a human patient comprising administering an anti-CD73 antibody or antigen-binding fragment thereof and chemotherapy. The disclosure also relates to methods for treating a tumor comprising administering an anti-CD73 antibody or antigen-binding fragment thereof in combination with a PD-L1 antibody or antigen-binding fragment thereof and chemotherapy.",MEDIMMUNE VACCINES INC,KUMAR RAVINDRA;;ENGLERT JOHN;;COOPER ZACHARY;;MARTIN PATRICK L,,https://lens.org/029-500-268-181-847,Patent Application,no,0,0,10,10,0,A61P35/00;;C07K16/2896;;C07K2317/21;;C07K16/2827;;A61K2039/507;;A61K39/39558;;A61K2039/505;;A61K2039/55;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;C07K16/2896;;A61K2039/55;;A61K31/7068;;A61K31/519;;A61P35/00;;A61K31/513;;C07K16/2827;;A61K39/39558;;A61K31/337;;A61K2039/505;;C07K2317/21;;A61K31/555;;A61K2039/507;;A61K45/06;;A61K2300/00;;C07K16/2896;;C07K16/2827;;A61K45/06;;A61K31/7068;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/555;;A61P35/00;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K2317/21;;A61P35/00;;A61K31/337;;A61K31/513;;A61K31/519;;A61K31/555;;A61K31/7068;;C07K16/2827;;C07K16/2896,A61K39/395,,0,0,,,,PENDING
625,IE,B1,IE 66163 B1,068-410-164-063-948,1995-12-13,1995,IE 366288 A,1988-12-08,GB 8728821 A;;GB 8803371 A;;GB 8803377 A;;GB 8803372 A;;GB 8803374 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8728820 A;;GB 8803370 A;;GB 8803373 A;;GB 8803375 A,1987-12-09,Macrocyclic compounds,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/068-410-164-063-948,Granted Patent,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,EXPIRED
626,AU,A,AU 1998/091306 A,110-528-760-018-582,1999-04-05,1999,AU 1998/091306 A,1998-09-02,US 92974297 A;;US 9818412 W,1997-09-15,Scrolling navigational display system,,SONY TRANS COM INC,GREENWOOD WAYNE EUGENE;;COOPER ALAN MARTIN;;EVENSON KAREN LOUISE,,https://lens.org/110-528-760-018-582,Patent Application,no,0,0,7,7,0,G06F3/0485;;G06F3/0489;;G06F2200/1632;;G06F3/0489;;G06F3/0485;;G06F2200/1632,A63F13/00;;B64D11/06;;G06F1/16;;G06F3/023;;G06F3/033;;G06F3/0485;;G06F3/0488;;H03M11/04,,0,0,,,,DISCONTINUED
627,AU,B2,AU 604731 B2,150-105-833-263-826,1991-01-03,1991,AU 1987/076203 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,"ISOINDOLO(2,1-B) ISOQUINOLIN PHOSPHORIC DERIVATIVES",,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/150-105-833-263-826,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/675;;A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
628,PT,B,PT 89203 B,179-871-592-741-115,1993-06-30,1993,PT 8920388 A,1988-12-09,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803374 A,1987-12-09,PROCESSO PARA A PREPARACAO DE MACROLIDOS IMUNOSSUPRESSORES E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM,,FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN,,https://lens.org/179-871-592-741-115,Granted Patent,no,0,0,2,44,0,,A61K31/335;;A61K31/70;;C07D498/00;;C07H19/01,,0,0,,,,EXPIRED
629,CA,A1,CA 2430327 A1,181-519-551-585-311,2003-12-04,2003,CA 2430327 A,2003-05-29,US 16001902 A,2002-06-04,WIRE UNWINDING CONTROLLER,"A controller for controlling the dispensing of wire from a reel of wire positioned within a container. The wire is dispensed from one end of the reel with the other end of the reel sitting on the bottom of the container. The controller has a main body member in the shape of a flat ring sized to rest within the container on the one end of the reel, the ring having concentric, circular, inner and outer edges. Flexible, wire guide flaps are on the inner edge of the ring, the guide flaps extending radially inwardly. Each guide flap has the general shape of a shallow triangle with the apex of the triangle farthest from the ring and the base of the triangle adjacent and integral with the ring.",AIR LIQUIDE CANADA INC,PAQUET MARTIN;;COOPER EDWARD L;;VAIDYA VIWEK;;BLAIN DENIS,,https://lens.org/181-519-551-585-311,Patent Application,no,0,0,3,3,0,B65H49/02;;B65H49/08;;B65H57/18;;B65H59/06;;B65H2404/56;;B65H59/06;;B65H2404/56;;B65H49/02;;B65H49/08;;B65H57/18,B65H49/02;;B65H49/08;;B65H57/18;;B65H59/06,,0,0,,,,EXPIRED
630,ZA,B,ZA 893366 B,128-287-152-799-249,1991-01-30,1991,ZA 893366 A,1989-05-08,GB 8810724 A,1988-05-06,SENSING A NARROW BAND OF FREQUENCIES,,GERSAN ETS,STEWART ANDREW DAVID GARRY;;ANDREW DAVID GARRY STEWART;;SMITH ROBIN WYNCLIFFE;;ROBIN WYNCLIFFE SMITH;;SMITH MARTIN PHILLIP;;MARTIN PHILLIP SMITH;;COOPER MARTIN;;MARTIN COOPER;;WELBOURN CHRISTOPHER MARK;;CHRISTOPHER MARK WELBOURN;;SPEAR PAUL MARTIN;;PAUL MARTIN SPEAR,,https://lens.org/128-287-152-799-249,Granted Patent,no,0,1,2,118,0,,B01D/;;B07B/;;B07C5/344;;G01D/;;G01T/;;G21H/,,0,0,,,,EXPIRED
631,GR,B,GR 871208 B,039-253-769-633-079,1987-11-30,1987,GR 870101208 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,PHILLIPS GORDON HANLEY DR;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/039-253-769-633-079,Granted Patent,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/675;;A61K31/4745;;A61P35/00;;C07D217/20;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,EXPIRED
632,US,A1,US 2015/0265852 A1,033-801-856-008-825,2015-09-24,2015,US 201314424376 A,2013-10-11,GB 201218307 A;;GB 2013052650 W,2012-10-12,PATIENT MONITOR,"Images obtained by a camera system ( 10 ) arranged to obtain stereoscopic images of a patient ( 20 ) undergoing radio-therapy are processed by a modeling unit ( 56,58 ) which generates a model of the surface of a patient ( 20 ) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient ( 20 ). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus ( 16 ). This can be facilitated by providing a number or retro-reflective markers ( 30 - 40 ) on a treatment apparatus ( 16 ) and a mechanical couch ( 18 ) used to position the patient ( 20 ) relative to the treatment apparatus ( 16 ) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera ( 10 ).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,VISION RT LIMITED (2015-05-04),https://lens.org/033-801-856-008-825,Patent Application,yes,5,33,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;A61B19/00;;G06T7/20;;H04N13/02,,0,0,,,,ACTIVE
633,CN,A,CN 104755136 A,035-413-110-879-569,2015-07-01,2015,CN 201380052008 A,2013-10-11,GB 2013052650 W;;GB 201218307 A,2012-10-12,Patient monitor,"Images obtained by a camera system (10) arranged to obtain stereoscopic images of a patient (20) undergoing radio-therapy are processed by a modeling unit (56,58) which generates a model of the surface of a patient (20) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient(20). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus (16). This can be facilitated by providing a number or retro-reflective markers (30-40) on a treatment apparatus (16) and a mechanical couch (18) used to position the patient (20) relative to the treatment apparatus (16) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera (10).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/035-413-110-879-569,Patent Application,no,0,6,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;G06T7/00,,0,0,,,,ACTIVE
634,AU,A1,AU 2019/213311 A1,139-232-003-399-410,2020-02-27,2020,AU 2019/213311 A,2019-08-06,US 201816059423 A,2018-08-09,"A train detection system for a railway track, a method for detecting a train on a railway track, and a controller for a train detection system for detecting a train on a railway track","A train detection system for a railway track, a method for detecting a train on a railway track, and a controller for a train detection system for detecting a train on a railway track The present disclosure relates to a train detection system for a railway track, the railway track defining a first lateral side and a second lateral side opposite the first lateral side, said train detection system comprising: - at least two cameras, said cameras being arranged along the railway track spaced apart from each other, each camera being placed on either the first lateral side or the second lateral side; - at least one passive target, each of said passive targets being placed within the field of view of at least one of the cameras and on the opposite lateral side of the railway track with respect to the at least one of the cameras in whose field of view the respective passive target is placed; and - at least one controller adapted to recognise the at least one passive target in the images provided by at least one of the cameras to the controller in order to determine whether a train is located on the railway track. The present invention also relates to a method for detecting a train on a railway track. The present invention equally relates to a controller for a train detection system for detecting a train on a railway track. Figure 1 Ir uj~ r-Lj",ALSTOM TRANSP TECH,FRIES JEFFREY;;COOPER JARED;;MARTIN PHILLIP;;SNYDER SENECA;;NAGRODSKY NICHOLAS,,https://lens.org/139-232-003-399-410,Patent Application,no,0,0,8,8,0,B61L29/228;;B61L29/30;;B61L23/041;;B61L23/007;;B61L23/041;;B61L23/34;;B61L29/22;;B61L29/30;;G06T7/0008;;G06T2207/30236;;G08G7/02;;G06V20/48,B61L23/24,,0,0,,,,ACTIVE
635,US,B2,US 10926109 B2,144-241-511-037-323,2021-02-23,2021,US 201816230739 A,2018-12-21,US 201816230739 A;;GB 201218307 A;;US 201514424376 A;;GB 2013052650 W,2012-10-12,Patient monitor,"Images obtained by a camera system ( 10 ) arranged to obtain images of a patient ( 20 ) undergoing radio-therapy are processed by a modeling unit ( 56,58 ) which generates a model of the surface of a patient ( 20 ) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient ( 20 ). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus ( 16 ). This can be facilitated by providing a number or retro-reflective markers ( 30 - 40 ) on a treatment apparatus ( 16 ) and a mechanical couch ( 18 ) used to position the patient ( 20 ) relative to the treatment apparatus ( 16 ) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera ( 10 ).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/144-241-511-037-323,Granted Patent,yes,24,0,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;A61B90/00;;G06T7/285;;G06T7/73;;H04N13/204,,4,0,,,"Aug. 1, 2016 Office Action issued in Chinese Patent Application No. 201380052008.6 (with English translation).;;Jan. 16, 2013 Combined Search and Examination Report issued in GB Patent Application No. 1218307.5.;;Jun. 6, 2016 Examination report issued in European Patent Application No. 13777329.7.;;Second Office Action dated Feb. 7, 2017 to Chinese patent application No. 201380052008.6.",ACTIVE
636,NZ,A,NZ 542281 A,194-535-586-426-742,2008-12-24,2008,NZ 54228102 A,2002-11-26,NZ 54228102 A,2002-11-26,Methods and compositions for normalizing muscle lipid levels using CGRP-1,"Disclosed is the use of an agonist of the high affinity CGRP receptor for treating a human subject for lipid accumulation in skeletal muscle or liver, wherein the agonist is present in an amount effective to preferentially stimulate activity of a high affinity CGRP receptor compared to the metabolic amylin receptor, and to stimulate tissue lipolysis, wherein the agonist is CGRP-1.",PROTEMIX CORP LTD,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;WATSON RACHEL NANCY,,https://lens.org/194-535-586-426-742,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
637,US,S,US D0633175 S,014-535-327-823-375,2011-02-22,2011,US 32417408 F,2008-09-08,US 32417408 F,2008-09-08,Dosing assembly,,DIVERSEY INC,SWAIN ANDREW;;COOPER MARTIN;;BERTUCCI MICHAEL H;;CROSSDALE GARRY W,DIVERSEY INC (2008-10-29),https://lens.org/014-535-327-823-375,Design Right,no,0,4,5,5,0,,,2301;;D23/225,0,0,,,,ACTIVE
638,US,A1,US 2019/0134426 A1,007-791-621-575-842,2019-05-09,2019,US 201816230739 A,2018-12-21,US 201816230739 A;;GB 201218307 A;;US 201514424376 A;;GB 2013052650 W,2012-10-12,PATIENT MONITOR,"Images obtained by a camera system ( 10 ) arranged to obtain images of a patient ( 20 ) undergoing radio-therapy are processed by a modeling unit ( 56,58 ) which generates a model of the surface of a patient ( 20 ) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient ( 20 ). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus ( 16 ). This can be facilitated by providing a number or retro-reflective markers ( 30 - 40 ) on a treatment apparatus ( 16 ) and a mechanical couch ( 18 ) used to position the patient ( 20 ) relative to the treatment apparatus ( 16 ) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera ( 10 ).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/007-791-621-575-842,Patent Application,yes,5,0,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;A61B90/00;;G06T7/285;;G06T7/73;;H04N13/204,,0,0,,,,ACTIVE
639,WO,A1,WO 2010/132110 A1,064-514-230-793-991,2010-11-18,2010,US 2010/0001415 W,2010-05-13,US 21622109 P,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE","Disclosed is a compound of formula ( I ); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula ( I ), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula ( I ), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC;;ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/064-514-230-793-991,Patent Application,yes,1,21,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61K31/52;;C07D487/04;;A61P35/00,,3,2,022-890-722-327-714;;022-890-722-327-714,10.1038/nature07884;;19360080;;10.1038/nature07884;;19360080,"SOUCY T A ET AL: ""An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer"", NATURE, vol. 458, 9 April 2009 (2009-04-09), pages 732 - 736, XP002596652;;SOUCY, T.A. ET AL., NATURE, vol. 458, 2009, pages 732 - 737;;See also references of EP 2430026A1",PENDING
640,US,A1,US 2024/0018245 A1,101-305-143-656-912,2024-01-18,2024,US 202318295539 A,2023-04-04,US 202318295539 A;;US 2021/0053636 W;;US 202063116597 P;;US 202163229019 P;;US 202063087623 P;;US 202163239859 P,2020-10-05,DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES,"The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.",GENENTECH INC,FINE BERNARD MARTIN;;SUMIYOSHI TEIKO;;LI MENGSONG;;COOPER JAMES NIALL,,https://lens.org/101-305-143-656-912,Patent Application,yes,0,0,12,12,0,C07K16/2809;;C07K16/283;;C07K2317/31;;A61K2039/545;;A61K2039/54;;A61K2039/507;;A61P35/00;;C07K2317/24;;C07K2317/71;;C07K2317/52;;C07K2317/73;;C07K16/2809;;C07K2317/71;;A61K2039/545;;C07K2317/31;;A61P35/00;;C07K2317/24;;A61K2039/54;;C07K2317/52;;A61K2039/507;;C07K16/283;;C07K16/283;;C07K16/2809;;A61P35/00;;C07K2317/31;;C07K2317/24;;C07K2317/71;;C07K2317/52;;A61K2039/507;;A61K2039/54;;A61K2039/545;;A61P35/00;;A61K31/137;;A61K31/167;;A61K31/573;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2809;;C07K16/283;;C07K16/2866;;C07K2317/24;;C07K2317/31;;C07K2317/41;;C07K2317/524;;C07K2317/526;;C07K2317/71,C07K16/28;;A61K31/137;;A61K31/167;;A61K31/573;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
641,AU,A1,AU 2003/303666 A1,143-736-458-362-140,2004-08-13,2004,AU 2003/303666 A,2003-01-29,IB 0306467 W;;NZ 51692002 A,2002-01-29,Suppression of cytotoxic protein conformers,,PROTEMIX DISCOVERY LTD,AITKEN JACQUELINE FIONA;;LOOMES KERRY MARTIN;;COOPER GARTH JAMES SMITH,,https://lens.org/143-736-458-362-140,Patent Application,no,0,0,9,9,0,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;G01N33/6896;;G01N2500/00;;A61P25/00;;A61P25/28;;A61P3/00;;A61P43/00;;A61P5/48;;A61P5/50;;A61P3/10;;A61K31/655;;A61K31/473;;G01N33/6896;;A61K31/00;;A61K31/015;;G01N2500/00;;A61K31/5415;;A61K31/65,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;A61P5/48;;A61P5/50;;A61P25/28;;A61P43/00;;G01N33/68,,0,0,,,,PENDING
642,AR,A1,AR 038000 A1,011-371-243-396-495,2004-12-22,2004,AR P020102842 A,2002-07-26,GB 0118479 A,2001-07-28,"COMPUESTO DERIVADO DE TIEN[2,3-D]PIRIMIDIN-2,4(1H,3H)-DIONA, COMPOSICION FARMACEUTICA, PROCESO PARA SU PREPARACION Y SU USO EN LA FABRICACION DE UN MEDICAMENTO","Compuesto derivado de tien[2,3-d]pirimidin-2,4(1H,3H)-diona de fórmula (1); donde: R1 y R2 representan cada uno independientemente un alquilo C1-6, alquenilo C3-6, cicloalquil C3-5-alquilo C1-3 o cicloalquilo C3-6; cada uno puede ser opcionalmente sustituido por entre 1 y 3 átomos de halógeno; R3 es isoxazolidin-2-ilcarbonilo o tetrahidroisoxazin-2-ilcarbonilo donde cada anillo es opcionalmente sustituido por un grupo hidroxi; Q es -CO- o -C(R4)(R5)- (donde R4 es un átomo de hidrógeno o alquilo C1-4 y R5 es un átomo de hidrógeno o un grupo hidroxi); Ar es un sistema de anillos aromático de 5 a 10 miembros donde hasta 4 átomos del anillo pueden ser heteroátomos seleccionados independientemente entre nitrógeno, oxígeno y azufre, estando el sistema de anillos opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente entre alquilo C1-4 ( opcionalmente sustituido por 1, 2 o 3 grupos hidroxi), alcoxi C1-4, halógeno, haloalquilo, dihaloquilo, trihaloquilo, alcoxi C1-4-alquilo C1-4, alquiltio C1-4, alcoxicarbonilo C1-4, alcanoilo C2-4, oxo, tioxo, nitro, ciano, -N(R6)R7 y -(CH2)pN(R8)R9, hidroxi, alquilsulfonilo C1-4, alquilsulfinilo C1-4, carbamoilo, alquilcarbamoilo C1-4, di-(alquil C1-4)carbamoilo, carboxi, o un anillo aromático de 5 o 6 miembros que contiene hasta 4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno y azufre; p es entre 1 y 4; R6 y R7 representan cada uno independiente un átomo de hidrógeno, alcanoilo C1-4 o alquilo C1-4, o junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico saturado de 5 a 7 miembros; R8 y R9 representan cada uno independientemente un átomo de hidrógeno, alcanoilo C1-4 o alquilo C1-4, o junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico saturado de 5 a 7 miembros; o una sal aceptable para uso farmacéutico o profármaco del mismo. También se relaciona con métodos de preparación, composiciones farmacéuticas que los contienen y usos del mismo en la fabricación de un medicamento particularmente útil en la modulación de una enfermedad autoinmune.",ASTRAZENECA AB,COOPER MARTIN;;GUILE SIMON;;INGALL ANTHONY;;RASUL RUKHSANA;;REYNOLDS RACHEL,,https://lens.org/011-371-243-396-495,Patent Application,no,0,0,41,41,0,C07D495/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/08;;A61P19/02;;A61P21/00;;A61P21/04;;A61P25/00;;A61P27/16;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/519;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/08;;A61P19/02;;A61P21/00;;A61P21/04;;A61P25/00;;A61P27/16;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D495/04;;C07D519/00,,0,0,,,,EXPIRED
643,EP,A4,EP 1461068 A4,086-135-563-713-791,2006-03-29,2006,EP 02803945 A,2002-11-26,NZ 0200262 W;;NZ 51573101 A;;US 33342201 P,2001-11-26,METHODS OF COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES,,PROTEMIX CORP LTD,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;WATSON RACHEL NANCY,PROTEMIX CORPORATION LIMITED (2010-11-10);;PHILERA NEW ZEALAND LIMITED (2011-11-16),https://lens.org/086-135-563-713-791,Search Report,no,3,0,9,10,0,A61K38/225;;G01N33/92;;G01N2500/00;;G01N2800/044;;A61P3/04;;A61P3/06;;A61P43/00;;A61P5/06;;A61P5/50;;A61P9/12;;A61P3/10,A61K38/22;;A61K38/23;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;G01N33/50;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/15;;G01N33/92,,5,3,009-402-473-124-783;;015-226-437-530-490;;040-211-592-454-920,10337861;;10.1016/s0026-0495(99)90058-6;;9374670;;10.1152/ajpendo.1997.273.5.e859;;10.1152/ajpendo.2001.280.4.e562;;11254462,"CHATZIPANTELI K ET AL: ""CALCITONIN GENE-RELATED PEPTIDE IS AN ADIPOSE-TISSUE NEUROPEPTIDE WITH LIPOLYTIC ACTIONS"", ENDOCRINOLOGY AND METABOLISM, LONDON, GB, vol. 3, no. 4, 1996, pages 235 - 242, XP008057490, ISSN: 1074-939X;;MOORE MARY COURTNEY ET AL: ""Insulin- and glucagon-independent effects of calcitonin gene-related peptide in the conscious dog"", METABOLISM CLINICAL AND EXPERIMENTAL, vol. 48, no. 5, May 1999 (1999-05-01), pages 603 - 610, XP002362125, ISSN: 0026-0495;;HETTIARACHCHI M ET AL: ""Rat amylin-(8-37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats"", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 273, no. 5 PART 1, November 1997 (1997-11-01), pages E859 - E867, XP002362126, ISSN: 0002-9513;;YE J-M ET AL: ""EVIDENCE THAT AMYLIN STIMULATES LIPOLYSIS IN VIVO: A POSSIBLE MEDIATOR OF INDUCED INSULIN RESISTANCE"", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 280, no. 4, PART 1, April 2001 (2001-04-01), pages E562 - E569, XP009009879, ISSN: 0002-9513;;See also references of WO 03045424A1",DISCONTINUED
644,CA,A1,CA 2426600 A1,082-138-649-754-699,2002-05-23,2002,CA 2426600 A,2001-10-25,US 24452800 P;;US 0151262 W,2000-10-31,PACKAGING AND DELIVERY SYSTEM FOR BONE GRAFT PARTICLES,"The present invention is directed to a packaging and delivery system for bon e graft particles (24) comprising an outer tray (32) which contains an inner tray (22) comprising a bowl (1) of the particles (24) and also, in some embodiments, a mixing and delivery tool (12) and/or a syringe containing a suspension material for the particles (24), such as a gel. The inner tray (2 2) is comprised of an anti-moisture coating and a lid (20) comprised of foil. T he mixing and delivery tool (12) preferably has a trowel (13) on one end and a tamping rod (14) on the other end, wherein both features facilitate delivery and compression of the bone graft particles (24) to a bone defect site.</SDO AB>",SMITH & NEPHEW INC,COOPER MICHAEL B;;MARTIN JEFF;;RILEY STEPHANIE;;HARBER JAMES C,,https://lens.org/082-138-649-754-699,Patent Application,no,0,0,7,7,0,A61F2/4644;;A61F2/4644;;A61B50/30;;A61B50/30;;A61B50/33;;A61B50/33;;A61B90/94;;A61B90/94;;A61B2050/0065;;A61B2050/0065;;A61F2/0095;;A61F2/0095;;A61F2/4601;;A61F2/4601;;A61F2002/2835;;A61F2002/2835;;A61F2002/3071;;A61F2002/3071;;A61F2250/0089;;A61F2250/0089,B65D25/14;;A61B19/00;;A61B19/02;;A61F2/00;;A61F2/28;;A61F2/46;;B65D77/04;;B65D77/08;;B65D77/20;;B65D81/20,,0,0,,,,DISCONTINUED
645,GB,A,GB 2433991 A,140-145-489-543-987,2007-07-11,2007,GB 0625888 A,2006-12-23,GB 0600114 A,2006-01-05,Growth hormone variations,"An isolated variant of the growth hormone (GH1) nucleic acid or protein molecule comprising one or more of the following substitutions: G>A+447 (Arg16His), T>G+1481 (Phe176Cys) and T>C+1519 (Cys189Arg) and the use of same in the diagnosis of growth hormone dysfunction, hypertension or stroke. Also claimed are kits comprising antibodies specific for the above substitutions.",UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN;;LEWIS MARK;;MILLAR DAVID STUART,,https://lens.org/140-145-489-543-987,Patent Application,no,3,0,8,8,0,C12N15/11;;C12Q1/6827;;C12Q1/6883;;C07K14/61;;C12Q2600/156,C12N15/18;;C12N15/11;;C12Q1/68,G1B BAC           BAC;;G1B B200          BAC;;G1B B224          BAC,1,1,030-253-099-402-484,10.1007/s00439-006-0166-5;;16572267,"Hum. Genet., Vol.119, 2006, Horan, M. et al., ""Genetic variation at the growth hormone..."", pp.527-540",DISCONTINUED
646,CA,A1,CA 2761256 A1,169-102-482-891-471,2010-11-18,2010,CA 2761256 A,2010-05-13,US 21622109 P;;US 2010/0001415 W,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE","Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENIUM PHARMACEUTICALS INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/169-102-482-891-471,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61K31/52;;C07D487/04;;A61P35/00,,0,0,,,,INACTIVE
647,EP,A2,EP 1565172 A2,176-257-965-453-812,2005-08-24,2005,EP 03809201 A,2003-01-29,IB 0306467 W;;NZ 51692002 A,2002-01-29,SUPPRESSION OF CYTOTOXIC PROTEIN CONFORMERS,,PROTEMIX CORP LTD,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,PROTEMIX DISCOVERY LIMITED (2006-02-01),https://lens.org/176-257-965-453-812,Patent Application,yes,0,0,9,9,0,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;G01N33/6896;;G01N2500/00;;A61P25/00;;A61P25/28;;A61P3/00;;A61P43/00;;A61P5/48;;A61P5/50;;A61P3/10;;A61K31/655;;A61K31/473;;G01N33/6896;;A61K31/00;;A61K31/015;;G01N2500/00;;A61K31/5415;;A61K31/65,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;A61P5/48;;A61P5/50;;A61P25/28;;A61P43/00;;G01N33/68,,0,0,,,,DISCONTINUED
648,AT,T1,AT E120466 T1,033-639-237-860-602,1995-04-15,1995,AT 89900628 T,1988-12-02,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A,1987-12-09,MAKROZYKLISCHE VERBINDUNGEN.,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;DONALD DAVID KEITH;;HARDERN DAVID NORMAN;;BONNINGTON,,https://lens.org/033-639-237-860-602,Granted Patent,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,DISCONTINUED
649,AT,T1,AT E374204 T1,122-628-576-426-619,2007-10-15,2007,AT 02749055 T,2002-07-24,GB 0118479 A,2001-07-28,THIENOPYRIMIDINEDIONE UND DEREN VERWENDUNG IN DER BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN,,ASTRAZENECA AB,REYNOLDS RACHEL;;INGALL ANTHONY;;RASUL RUKHSANA;;GUILE SIMON;;COOPER MARTIN,,https://lens.org/122-628-576-426-619,Granted Patent,no,0,0,41,41,0,C07D495/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/08;;A61P19/02;;A61P21/00;;A61P21/04;;A61P25/00;;A61P27/16;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/519;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/08;;A61P19/02;;A61P21/00;;A61P21/04;;A61P25/00;;A61P27/16;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D495/04;;C07D519/00,,0,0,,,,EXPIRED
650,NO,D0,NO 893166 D0,163-689-920-570-887,1989-08-04,1989,NO 893166 A,1989-08-04,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,MAKROCYKLISKE FORBINDELSER.,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;ORCHARDSIDE DAVID KEITH DONALD;;HARDERN DAVID NORMANN,,https://lens.org/163-689-920-570-887,Patent Application,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,DISCONTINUED
651,EP,A1,EP 2906289 A1,190-000-729-829-674,2015-08-19,2015,EP 13777329 A,2013-10-11,GB 201218307 A;;GB 2013052650 W,2012-10-12,PATIENT MONITOR,,VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/190-000-729-829-674,Patent Application,yes,0,0,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;A61B90/00;;G06T7/00;;G06T7/285;;G06T7/73;;H04N13/02,,0,0,,,,ACTIVE
652,SE,D0,SE 9701194 D0,187-083-831-269-958,1997-04-01,1997,SE 9701194 A,1997-04-01,SE 9701194 A,1997-04-01,Novel compounds,,ASTRA PHARMA PROD,CHESHIRE DAVID;;CLADINGBOEL DAVID;;COOPER MARTIN;;HARDERN DAVID;;STOCKS MICHAEL,,https://lens.org/187-083-831-269-958,Patent Application,no,0,0,2,30,0,,A61K/;;C07D/,,0,0,,,,PENDING
653,DE,A1,DE 102014114498 A1,193-042-397-549-995,2015-04-30,2015,DE 102014114498 A,2014-10-07,US 201314067661 A,2013-10-30,Tintenstrahl-Drucken auf Substraten,"Verfahren, Vorrichtungen und Bauelemente bezüglich eines Tintenstrahl-Druckens einer Deckschicht (106, 108) auf mindestens einer ersten Seite eines Substrats (100) in einem Randbereich davon werden diskutiert.",INFINEON TECHNOLOGIES AUSTRIA,COOPER JOHN;;GASSER KARL-HEINZ;;MISCHITZ MARTIN;;WANG KAE-HORNG,,https://lens.org/193-042-397-549-995,Patent Application,no,0,2,3,3,0,H01L21/56;;H01L21/6715;;H01L2924/0002;;H01L21/78;;H01L21/02118;;H01L21/02288;;H01L21/56;;H01L2924/0002;;H01L21/6715;;H01L21/78;;H01L21/02118;;H01L21/02288;;H01L23/293;;H01L21/67,H01L21/283;;B41J2/01;;B41M5/00;;H01L21/304;;H01L21/67,,0,0,,,,ACTIVE
654,AU,A1,AU 2002/356469 A1,077-214-510-364-750,2003-06-10,2003,AU 2002/356469 A,2002-11-26,NZ 51573101 A;;NZ 0200262 W;;US 33342201 P,2001-11-26,METHODS OF COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES,,PROTEMIX CORP LTD,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;WATSON RACHEL NANCY,,https://lens.org/077-214-510-364-750,Patent Application,no,0,0,9,10,0,A61K38/225;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/92;;G01N2500/00;;G01N2800/044,G01N33/50;;A61K38/22;;A61K38/23;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/15;;G01N33/92,,0,0,,,,DISCONTINUED
655,US,A1,US 2019/0185437 A1,087-135-317-510-098,2019-06-20,2019,US 201715842823 A,2017-12-14,US 201715842823 A,2017-12-14,Compounds For The Treatment Of Neuromuscular Disorders,"The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel.",NMD PHARMA APS,KNUTSEN LARS J S;;COOPER MARTIN E;;BROWN ANDREW W,NMD PHARMA A/S (2019-01-25),https://lens.org/087-135-317-510-098,Patent Application,yes,0,0,2,30,0,C07D261/08;;C07D213/30;;C07D271/06;;C07D277/66;;A61P21/00;;C07D233/56;;C07D231/12;;C07D333/16;;C07D271/10;;C07D277/24;;C07D261/08;;C07D213/30;;C07D271/06;;C07D277/66;;A61P21/00;;C07D233/56;;C07D231/12;;C07D333/16;;C07D271/10;;C07D277/24,C07D261/08;;A61P21/00;;C07D213/30;;C07D231/12;;C07D233/56;;C07D271/06;;C07D271/10;;C07D277/24;;C07D277/66;;C07D333/16,,0,0,,,,ACTIVE
656,US,A1,US 2009/0131422 A1,083-474-245-945-519,2009-05-21,2009,US 28859508 A,2008-10-22,US 28859508 A;;US 5107 P,2007-10-23,Salts of an IKK inhibitor,"The present invention is directed to the Tartrate, Mono-Hydrochloride, Malonate and p-Toluenesulfonate Salts of the compound of formula (I), or solvates thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the Salts, including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of the Salts, including crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.",MILLENNIUM PHARM INC,HICKS FREDERICK A;;COOPER MARTIN IAN;;ST CLAIR BROWN ADRIAN,MILLENNIUM PHARMACEUTICALS INC (2008-11-14),https://lens.org/083-474-245-945-519,Patent Application,yes,9,0,2,2,0,A61P29/00;;C07D471/04;;C07D471/04,A61K31/5377;;A61P29/00;;C07D413/14,514/232.5;;544/80,0,0,,,,DISCONTINUED
657,SE,D0,SE 9702001 D0,099-461-934-057-240,1997-05-28,1997,SE 9702001 A,1997-05-28,SE 9702001 A,1997-05-28,Novel compounds,,ASTRA PHARMA PROD,CHESHIRE DAVID;;COOKE ANDREW;;COOPER MARTIN;;DONALD DAVID;;FURBER MARK,,https://lens.org/099-461-934-057-240,Patent Application,no,0,0,45,49,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P31/00;;A61P31/18;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/10;;C07D495/04;;C07D495/04,A61K31/505;;C07D495/04;;A61K31/513;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P31/00;;A61P31/18;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D/;;C07D239/00;;C07D333/00,,0,0,,,,PENDING
658,CA,A1,CA 3051338 A1,153-313-825-777-179,2020-02-09,2020,CA 3051338 A,2019-08-06,US 201816059423 A,2018-08-09,"A TRAIN DETECTION SYSTEM FOR A RAILWAY TRACK, A METHOD FOR DETECTING A TRAIN ON A RAILWAY TRACK, AND A CONTROLLER FOR A TRAIN DETECTION SYSTEM FOR DETECTING A TRAIN ON A RAILWAY TRACK","The present disclosure relates to a train detection system for a railway track. The railway track defines a first lateral side and a second lateral side opposite the first lateral side. The train detection system includes: - at least two cameras, being arranged along the railway track spaced apart from each other, each camera being placed on either the first lateral side or the second lateral side; - at least one passive target, each of the passive targets being placed within the field of view of at least one of the cameras and on the opposite lateral side of the railway track with respect to the at least one of the cameras in whose field of view the respective passive target is placed; and - at least one controller adapted to recognise the at least one passive target in the images provided by at least one of the cameras to the controller in order to determine whether a train is located on the railway track. The present disclosure also relates to a method for detecting a train on a railway track. The present disclosure further relates to a controller for a train detection system for detecting a train on a railway track.",ALSTOM TRANSP TECH,FRIES JEFFREY;;COOPER JARED;;MARTIN PHILLIP;;SNYDER SENECA;;NAGRODSKY NICHOLAS,,https://lens.org/153-313-825-777-179,Patent Application,no,0,0,8,8,0,B61L29/228;;B61L29/30;;B61L23/041;;B61L23/007;;B61L23/041;;B61L23/34;;B61L29/22;;B61L29/30;;G06T7/0008;;G06T2207/30236;;G08G7/02;;G06V20/48,B61L25/02,,0,0,,,,PENDING
659,MX,A,MX 2023003756 A,030-704-823-021-27X,2023-04-24,2023,MX 2023003756 A,2021-10-05,US 202063087623 P;;US 202063116597 P;;US 202163229019 P;;US 202163239859 P;;US 2021/0053636 W,2020-10-05,DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES.,"The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CDS) bispecific antibodies.",GENENTECH INC,FINE BERNARD MARTIN;;SUMIYOSHI TEIKO;;LI MENGSONG;;COOPER JAMES NIALL,,https://lens.org/030-704-823-021-27X,Patent Application,no,0,0,12,12,0,C07K16/2809;;C07K16/283;;C07K2317/31;;A61K2039/545;;A61K2039/54;;A61K2039/507;;A61P35/00;;C07K2317/24;;C07K2317/71;;C07K2317/52;;C07K2317/73;;C07K16/2809;;C07K2317/71;;A61K2039/545;;C07K2317/31;;A61P35/00;;C07K2317/24;;A61K2039/54;;C07K2317/52;;A61K2039/507;;C07K16/283;;C07K16/283;;C07K16/2809;;A61P35/00;;C07K2317/31;;C07K2317/24;;C07K2317/71;;C07K2317/52;;A61K2039/507;;A61K2039/54;;A61K2039/545;;A61P35/00;;A61K31/137;;A61K31/167;;A61K31/573;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2809;;C07K16/283;;C07K16/2866;;C07K2317/24;;C07K2317/31;;C07K2317/41;;C07K2317/524;;C07K2317/526;;C07K2317/71,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
660,US,A1,US 2020/0047785 A1,024-194-095-906-154,2020-02-13,2020,US 201816059423 A,2018-08-09,US 201816059423 A,2018-08-09,"TRAIN DETECTION SYSTEM FOR A RAILWAY TRACK, A METHOD FOR DETECTING A TRAIN ON A RAILWAY TRACK, AND A CONTROLLER FOR A TRAIN DETECTION SYSTEM FOR DETECTING A TRAIN ON A RAILWAY TRACK",A train detection system for a railway track defines a first lateral side and a second lateral side opposite the first lateral side. Two cameras are arranged along the railway track spaced apart from each other. Each camera is placed on either the first lateral side or the second lateral side. The system includes at least one passive target. Each of the passive targets is placed within the field of view of at least one of the cameras and on the opposite lateral side of the railway track with respect to the at least one of the cameras in whose field of view the respective passive target is placed. The system also includes at least one controller adapted to recognise the passive target in the images provided by at least one of the cameras to the controller to determine whether a train is located on the railway track.,ALSTOM TRANSP TECH,FRIES JEFFREY;;COOPER JARED;;MARTIN PHILLIP;;SNYDER SENECA;;NAGRODSKY NICHOLAS,ALSTOM TRANSPORT TECHNOLOGIES (2018-08-20),https://lens.org/024-194-095-906-154,Patent Application,yes,6,2,8,8,0,B61L29/228;;B61L29/30;;B61L23/041;;B61L23/007;;B61L23/041;;B61L23/34;;B61L29/22;;B61L29/30;;G06T7/0008;;G06T2207/30236;;G08G7/02;;G06V20/48,B61L29/30;;B61L23/00,,0,0,,,,ACTIVE
661,AU,A,AU 2002/034184 A,082-819-165-317-867,2002-05-27,2002,AU 2002/034184 A,2001-10-25,US 24452800 P;;US 0151262 W,2000-10-31,Packaging and delivery system for bone graft particles,,SMITH & NEPHEW INC,COOPER MICHAEL B;;RILEY STEPHANIE;;HARBER JAMES C;;MARTIN JEFF,,https://lens.org/082-819-165-317-867,Patent Application,no,0,0,7,7,0,A61F2/4644;;A61F2/4644;;A61B50/30;;A61B50/30;;A61B50/33;;A61B50/33;;A61B90/94;;A61B90/94;;A61B2050/0065;;A61B2050/0065;;A61F2/0095;;A61F2/0095;;A61F2/4601;;A61F2/4601;;A61F2002/2835;;A61F2002/2835;;A61F2002/3071;;A61F2002/3071;;A61F2250/0089;;A61F2250/0089,B65D25/14;;A61B19/00;;A61B19/02;;A61F2/00;;A61F2/28;;A61F2/46;;B65D77/04;;B65D77/08;;B65D77/20;;B65D81/20,,0,0,,,,DISCONTINUED
662,BR,A2,BR PI1012142 A2,110-392-664-690-037,2016-03-29,2016,BR PI1012142 A,2010-05-13,US 2010/0001415 W;;US 21622109 P,2009-05-14,"sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato",,MILLENNIUM PHARM INC,ARMITAGE IAN G;;LANGSTON MARIANNE;;COOPER MARTIN IAN;;CHOPRA REENU,,https://lens.org/110-392-664-690-037,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61K31/52;;A61P35/00;;C07D487/04,,0,0,,,,DISCONTINUED
663,US,B2,US 10183177 B2,180-695-158-334-58X,2019-01-22,2019,US 201314424376 A,2013-10-11,GB 201218307 A;;GB 2013052650 W,2012-10-12,Patient monitor,"Images obtained by a camera system ( 10 ) arranged to obtain stereoscopic images of a patient ( 20 ) undergoing radio-therapy are processed by a modeling unit ( 56,58 ) which generates a model of the surface of a patient ( 20 ) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient ( 20 ). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus ( 16 ). This can be facilitated by providing a number or retro-reflective markers ( 30 - 40 ) on a treatment apparatus ( 16 ) and a mechanical couch ( 18 ) used to position the patient ( 20 ) relative to the treatment apparatus ( 16 ) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera ( 10 ).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,VISION RT LIMITED (2015-05-04),https://lens.org/180-695-158-334-58X,Granted Patent,yes,19,16,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;A61B90/00;;G06T7/285;;G06T7/73;;H04N13/204,,4,0,,,"Aug. 1, 2016 Office Action issued in Chinese Patent Application No. 201380052008.6 (with English translation).;;Jan. 16, 2013 Combined Search and Examination Report issued in GB Patent Application No. 1218307.5.;;Jun. 6, 2016 Examination report received issued in European Patent Application No. 13777329.7.;;Second Office Action dated Feb. 7, 2017 to Chinese patent application No. 201380052008.6.",ACTIVE
664,CN,A,CN 104016987 A,167-440-146-482-993,2014-09-03,2014,CN 201410200959 A,2010-05-13,US 21622109 P,2009-05-14,"Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate","Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/167-440-146-482-993,Patent Application,no,2,1,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02,,3,1,012-736-494-791-209,10.1016/j.ijpharm.2005.07.007;;16139971,"TERESA A. SOUCY等: ""An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer"", 《NATURE》;;JEAN-RENE AUTHELIN: ""Thermodynamics of non-stoichiometric pharmaceutical hydrates"", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》;;陆彬主编: ""《药剂学》"", 31 January 2003",DISCONTINUED
665,US,B2,US 10385028 B2,186-443-959-413-314,2019-08-20,2019,US 201715842823 A,2017-12-14,US 201715842823 A,2017-12-14,Compounds for the treatment of neuromuscular disorders,"The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.",NMD PHARMA APS;;NMD PHARMA AS,KNUTSEN LARS J S;;COOPER MARTIN E;;BROWN ANDREW W,NMD PHARMA A/S (2019-01-25),https://lens.org/186-443-959-413-314,Granted Patent,yes,48,1,2,30,0,C07D261/08;;C07D213/30;;C07D271/06;;C07D277/66;;A61P21/00;;C07D233/56;;C07D231/12;;C07D333/16;;C07D271/10;;C07D277/24;;C07D261/08;;C07D213/30;;C07D271/06;;C07D277/66;;A61P21/00;;C07D233/56;;C07D231/12;;C07D333/16;;C07D271/10;;C07D277/24,C07D261/08;;A61P21/00;;C07D213/30;;C07D231/12;;C07D233/56;;C07D271/06;;C07D271/10;;C07D277/24;;C07D277/66;;C07D333/16,,146,93,116-759-346-363-328;;005-754-249-675-947;;103-951-241-676-174;;080-150-466-743-072;;011-860-790-107-119;;021-575-265-341-222;;048-882-225-082-203;;035-999-528-675-644;;030-251-726-352-481;;024-159-339-126-629;;045-967-077-651-518;;044-169-383-848-981;;010-685-126-295-623;;022-902-289-186-978;;060-637-910-886-053;;020-091-757-316-747;;078-452-708-030-633;;065-891-650-501-174;;019-686-137-926-146;;016-888-861-919-269;;036-988-464-244-302;;052-286-659-870-462;;098-149-890-306-862;;040-550-497-152-250;;082-883-704-417-354;;080-371-513-967-474;;035-231-347-776-501;;069-073-888-551-527;;002-547-612-259-585;;102-335-278-370-800;;019-330-408-079-114;;068-405-687-101-628;;078-470-769-709-040;;067-818-976-674-376;;002-513-113-082-310;;142-547-745-489-786;;051-895-504-748-62X;;035-201-404-877-396;;002-713-896-462-972;;057-644-626-884-154;;081-158-376-645-455;;069-482-278-164-332;;073-451-192-212-463;;086-565-078-033-303;;057-425-053-797-95X;;021-982-127-437-822;;044-832-700-901-781;;165-897-565-394-792;;059-763-279-428-043;;079-616-286-970-506;;014-438-998-138-606;;004-399-150-548-454;;023-246-483-183-539;;023-246-483-183-539;;069-739-172-740-021;;028-000-635-912-588;;024-229-981-717-021;;027-579-465-856-868;;064-598-656-367-376;;137-174-807-023-720;;031-002-913-964-079;;082-768-984-314-080;;028-116-891-042-360;;002-963-741-836-329;;084-543-193-935-476;;109-927-107-191-836;;014-239-055-904-326;;026-426-988-818-082;;092-834-786-619-479;;016-014-551-030-002;;041-916-019-162-323;;023-438-937-800-404;;127-429-918-602-548;;026-398-674-596-645;;151-082-843-954-951;;076-405-871-871-868;;108-028-649-595-223;;019-067-984-396-075;;018-184-339-086-425;;069-482-278-164-332;;037-527-700-205-36X;;060-045-571-547-479;;085-913-768-835-356;;075-899-572-115-428;;071-074-121-888-737;;011-043-292-924-757;;011-043-292-924-757;;096-042-369-238-034;;027-882-126-098-830;;002-559-652-282-497;;049-601-800-750-435;;047-950-952-661-290;;009-771-135-402-107,10.1016/j.bbadis.2014.06.031;;24997454;;25979580;;10.1016/j.pop.2015.01.001;;8479300;;12849173;;10.1016/s1474-4422(03)00399-5;;10.1136/practneurol-2012-000404;;23468559;;12682465;;10.1097/01.ccm.0000053651.38421.d9;;22739110;;pmc3423102;;10.1152/ajpendo.00622.2011;;pmc1175469;;8410687;;2161128;;10.1055/s-2008-1041258;;10.1016/s0928-4680(03)00007-5;;14567934;;10.1002/mus.880170708;;8008001;;2455224;;10.1002/mus.880110609;;6100453;;10.1002/mus.880070608;;10.1016/s1474-4422(11)70178-8;;21939902;;23995274;;10.1097/wco.0b013e328364d6cd;;12130677;;10.1124/mol.62.2.265;;10.1002/14651858.cd006986.pub2;;25310725;;pmc7390275;;10.1002/14651858.cd006986.pub3;;21328290;;23911206;;10.1016/j.ymgme.2013.07.007;;11124133;;10.1152/ajpregu.2001.280.1.r48;;10.1085/jgp.200409173;;15684096;;pmc2217490;;25620417;;10.1016/j.expneurol.2015.01.007;;10.1113/jphysiol.2014.280529;;pmc4287736;;25128573;;10.1002/ana.410380118;;7611713;;10.1002/mus.24260;;24710922;;10.1093/bja/aep093;;19468024;;23444172;;10.1007/s13760-013-0189-3;;22094130;;10.1016/s1474-4422(11)70245-9;;1784551;;10.3928/0147-7447-19911201-11;;10.1212/wnl.0b013e3182749eca;;23115209;;10.1001/archinte.157.4.399;;9046891;;10.1001/archinte.1997.00440250045006;;10.1016/s0301-0082(00)00055-1;;11275359;;9077516;;10.1016/s0022-510x(96)00303-6;;pmc5373778;;10.1212/wnl.0000000000003772;;28251916;;10.1021/jm00391a002;;2441051;;10.1007/bf00581238;;2464159;;10.1021/jm00391a001;;2441050;;28029925;;10.1056/nejmra1602678;;10.4061/2011/847393;;22007295;;pmc3189457;;27576772;;10.1002/mus.25394;;10.1124/jpet.114.222224;;25678535;;10.1038/sj.bjp.0705364;;12890704;;pmc1573959;;14694153;;10.1097/01.asn.0000103226.28798.ea;;10.1016/j.yane.2011.08.002;;10.1085/jgp.201611582;;pmc4810071;;27022190;;10953042;;10.1124/mol.58.3.498;;17531480;;10.1016/j.bmcl.2007.05.019;;10.1002/chir.530040311;;10.1002/adsc.200600379;;10.1016/j.tetasy.2005.02.010;;10.1016/j.tetasy.2005.01.006;;10.1016/j.tetasy.2004.08.028;;8201606;;10.1021/jm00037a023;;18835719;;10.1016/j.bmc.2008.09.045;;18835719;;10.1016/j.bmc.2008.09.045;;pmc4339527;;25638499;;10.1016/j.bmc.2015.01.011;;10.1073/pnas.0711146105;;18391211;;pmc2291130;;10.2210/pdb3c6p/pdb;;pmc406039;;16655422;;10.1104/pp.35.6.773;;10.3891/acta.chem.scand.08-1493;;10.3891/acta.chem.scand.07-0698;;958208;;5964629;;10.1248/cpb.14.628;;10.1021/jf60145a032;;10.3168/jds.s0022-0302(64)88646-x;;10.3891/acta.chem.scand.14-0273;;10.2307/4040492;;10.2307/4040271;;10.1111/j.1744-7348.1957.tb00451.x;;10.1071/bi9560528;;10.1111/j.1744-7348.1955.tb02485.x;;10.1002/j.1537-2197.1954.tb14350.x;;10.1111/j.1744-7348.1953.tb01078.x;;10.3891/acta.chem.scand.07-0014;;10.3891/acta.chem.scand.05-0519;;10.1021/ja01148a073;;10.1021/ja01171a003;;20240584;;10.1021/jo01167a009;;10.1086/335374;;10.6023/cjoc201302021;;10.1016/j.jpba.2007.06.005;;17629437;;14694153;;10.1097/01.asn.0000103226.28798.ea;;12385519;;10.1016/s0014-827x(02)01264-8;;27929186;;10.1039/c6ob02237e;;10.3184/174751915x14285018213546;;10.1002/ijch.201300038;;22341573;;10.1016/j.bmc.2012.01.025;;10.1021/jm100181s;;20446681;;10.1021/jm100181s;;20446681;;10.1002/cmdc.200600307;;17357171;;10.1080/10426500600920007;;11718267;;10.1016/s0014-827x(01)01127-2;;10.1135/cccc19901278;;10.1039/jr9540001388;;8709096;;10.1021/jm950702c,"Combs, et al. Document No. 159:577331, retrieved from STN; entered in STN on Oct. 4, 2013.;;Diamanti, et al. Document No. 156:410758, retrieved from STN; entered in STN on Mar. 2, 2012.;;Chen, et al. Document No. 153:554937, retrieved from STN; entered in STN Oct. 29, 2010.;;Maslosz, et al. Document No. 117:26382, retrieved from STN; entered in STN Jul. 26, 1992.;;Del Bello, et al. Document No. 153:580197, retrieved from STN; entered in STN on Oct. 8, 2010.;;Hubbard, et al. Document No. 87:34423, retrieved from STN; entered in STN on May 12, 1984.;;Maslosz, et al. Document No. 116:194187, retreived from STN; entered in STN on May 16, 1992.;;Campiani, et al. Document No. 125:25616, retrieved from STN; entered in STN on Jun. 19, 1996.;;Richard Rips. Document No. 103:87769, retrieved from STN; entered in STN on Sep. 22, 1985.;;Myasthenia gravis[online]. Retrieved from the internet; URL https://medlineplus.gov/myastheniagravis.html.;;Myasthenia Gravis Diagnosis and Treatment [online]. Retrieved from internet; URL https://www.webmd.com/brain/understanding-myasthenia-gravis-treatment#2-4.;;Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. Apr. 2015; 1852(4):615-621.;;Ansar V, Valadi N. Guillain-Barré Syndrome. Prim Care. Jun. 2015;42(2):189-193.;;Birk TJ1. Poliomyelitis and the post-polio syndrome: exercise capacities and adaptation—current research, future directions, and widespread applicability. Med Sci Sports Exerc. Apr. 1993;25(4):466-72.;;Burton A. Take your pyridostigmine: that's an (ethical?) order! Lancet Neurol. May 2003;2(5):268.;;Finlayson S1, Beeson D, Palace J. Congenital myasthenic syndromes: an update. Pract Neurol. Apr. 2013; 13(2):80-91.;;Fletcher SN1, Kennedy DD, Ghosh IR, Misra VP, Kiff K, Coakley JH, Hinds CJ. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med. Apr. 2003; 31(4):1012-6.;;Garcia CC, Potian JG, Hognason K, Thyagarajan B, Sultatos LG, Souayah N, Routh VH, McArdle JJ. Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy. Am J Physiol Endocrinol Metab. Aug. 15, 2012;303(4):E551-61.;;Giniatullin RA, Khazipov RN, Oranska TI, Nikolsky EE, Voronin VA, Vyskocil F. The effect of non-quantal acetylcholine release on quantal miniature currents at mouse diaphragm. J Physiol. Jul. 1993;466:105-14.;;Howard JF Jr1. Adverse drug effects on neuromuscular transmission. Semin Neurol. Mar. 1990;10(1):89-102.;;Kawamura Y, Kihara M, Nishimoto K, Taki M. Efficacy of a half dose of oral pyridostigmine in the treatment of chronic fatigue syndrome: three case reports. Pathophysiology. May 2003;9(3):189-194.;;Killian JM1, Wilfong AA, Burnett L, Appel SH, Boland D. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve. Jul. 1994;17(7):747-54.;;Kwiecinski H1, Lehmann-Horn F, Rüdel R. Drug-induced myotonia in human intercostal muscle. Muscle Nerve. Jun. 1988;11(6):576-81.;;Kwiecinski H, Lehmann-Horn F, Rüdel R. Membrane currents in human intercostal muscle at varied extracellular potassium. Muscle Nerve. Jul.-Aug. 1984;7(6):465-9.;;Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011 10(10):931-41.;;Le Panse R1, Berrih-Aknin S. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation. Curr Opin Neurol. Oct. 2013;26(5):569-76.;;Liantonio A, Accardi A, Carbonara G, Fracchiolla G, Loiodice F, Tortorella P, Traverso S, Guida P, Pierno S, De Luca A, Camerino DC, Pusch M. Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid. Mol Pharmacol. Aug. 2002;62(2):265-71.;;Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. Oct. 13, 2014.;;Milone Ml, Wong LJ. Diagnosis of mitochondrial myopathies. Mol Genet Metab. Sep.-Oct. 2013;110(1-2):35-41.;;Overgaard K, Nielsen OB. Activity-induced recovery of excitability in K(+)-depressed rat soleus muscle. Am J Physiol Regul Integr Comp Physiol. Jan. 2001; 280(1):R48-55.;;Pedersen, T.H., F. de Paoli, and O.B. Nielsen. 2005. Increased excitability of acidified skeletal muscle: role of chloride conductance. J. Gen. Physiol. 125:237-246.;;Plomp JJ, Morsch M, Phillips WD, Verschuuren JJ. Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models. Exp Neurol. 2015. 270:41-54.;;Riisager A, Duehmke R, Nielsen OB, Huang CL, Pedersen TH. Determination of cable parameters in skeletal muscle fibres during repetitive firing of action potentials. J Physiol. Oct. 15, 2014; 592(Pt 20):4417-29.;;Roberts Ml, Willison HJ, Vincent A, Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol. Jul. 1995; 38(1):111-8.;;Skov M, De Paoli FV, Lausten J, Nielsen OB, Pedersen TH. Extracellular magnesium and calcium reduce myotonia in isolated ClC-1 chloride channel-inhibited human muscle. Muscle Nerve. Jan. 2015.;51(1):65-71.;;Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2009. 103(1):115-29.;;Stevic, Z.a, Peric, S.a , Pavlovic, S.b, Basta, I.a, Lavrnic, D.a. Myasthenic symptoms in a patient with Kennedy's disorder Acta Neurologica Belgica (Letter) vol. 114, Issue 1, Mar. 2014, pp. 71-73.;;Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. Dec. 2011;10(12):1098-107.;;Trojan DA1, Gendron D, Cashman NR. Electrophysiology and electrodiagnosis of the post-polio motor unit. Orthopedics. Dec. 1991;14(12):1353-61.;;Wadman RI1, Vrancken AF, van den Berg LH, van der Pol WL. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology. Nov. 13, 2012;79(20):2050-5.;;Wittbrodt, Drugs and myasthenia gravis. An update. Arch. Intern. Med., 157, 399-408, 1997.;;Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol. Jul. 2001.; 64(4):393-429.;;Yamada, M.ab, Inaba, A.a, Shiojiri, T.a. X-linked spinal and bulbar muscular atrophy with myasthenic symptoms (Article) Journal of the Neurological Sciences. vol. 146, Issue 2, Mar. 10, 1997, pp. 183-185.;;Aromataris, E.C., Pharmacology of the ClC-1 Chloride Channel, PhD Thesis, Dicipline of Physiology, school of Molecular and Biomedical Science, The University of Adelaide, 2009.;;Bansagi B, Griffin H, Whittaker RG, Antoniadi T, Evangelista T, Miller J, Greenslade M, Forester N, Duff J, Bradshaw A, Kleinle S, Boczonadi V, Steele H, Ramesh V, Franko E, Pyle A, Lochmüller H, Chinnery PF, Horvath R. Genetic heterogeneity of motor neuropathies. Neurology. 2017. 28;88(13):1226-1234).;;Bettoni, G. et al., J. Med. Chem. 1987, 30, 1267-1270.;;Conte-Camerino, D., Mambrini, M., DeLuca, A., Tricarico, D., Bryant, S.H., Tortorella, V., Bettoni, G. Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels, Pflugers Archiv., 1988, 413, 105-107.;;Feller, D.R., Kamanna, V.S., Newman, H.A.I., Romstedt, K.J., Witiak, D.T., Bettoni, G., Bryant, S.H., Conte-Camerino, D., Loiodice, F., Tortorella, V. Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers. J. Med. Chem., 1987, 30, 1265-1267.;;Gilhus, N.E. New England Journal of Medicine, 2016, 375, 2570-2581.;;Gilhus, N.E., Owe, J.F., Hoff, J.M., Romi, F., Skeie, G.O., Aarli, J.A. Myasthenia Gravis: A Review of Available Treatment Approaches, Autoimmune Diseases, 2011, Article ID 84739).;;Gilmore KJ, Morat T, Doherty TJ4, Rice CL. Motor unit number estimation and neuromuscular fidelity in 3 stages of sarcopenia. 2017 55(5):676-684).;;Hwee, D.T., Kennedy, A.R., Hartman, J.J., Ryans, J., Durham, N., Malik, F.I., Jasper, J.R. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 159-168).;;Liantonio, A. et al., Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1. Br. J. Phamacol., 2003, 129, 1255-1264.;;Liantonio, A. Pusch, M., Picollo, A., Guida, P., De Luca, A., Pierno, S., Fracchiolla, G., Loiodice, F., Tortorella, P., Conte-Camerino, D. Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride hannels blockers. J. Am. Soc. Nephrol., 2004, 15, 13-20.;;Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010 111(1):120-8.;;Pedersen, T.H., Riisager, A., Vincenzo de Paoli, F., Chen, T-Y, Nielsen, O.B. Role of physiological ClC-1 CI-ion channel regulation for the excitability and function of working skeletal muscle. J. Gen. Physiol. 2016, 147, 291-308.;;Pusch, M., Liantonio, A., Bertorello, L., Accardi, A., De Luca, A., Pierno, S., Tortorella, V., Conte-Camerino, D. Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives. Molecular Pharmacology, 2000, 58, 498-507.;;Sandham, D.A. et al., Bioorganic & Medicinal Letters, 17, 4347-4350.;;Bettoni, S. et al., Chiral beta-Aryloxy Acetic Acids: Synthesis, Absolute Configuration, Chemical Resolution, and Direct Separation by HPLC, CHIRALITY, 1992, 4:193-203.;;Maria Grazia Perrone et al., Stereoselective prostereogenic 3-oxo ester reduction mediated by a novel yeast alcohol dehydrogenase derived from Kluyveromyces marxianus CBS 6556, Advanced Synthesis & Catalysis (2007), 349(7), 1111-1118.;;Giuseppe Fracchiolla et al., Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARα and PPARγ agonist activity, ChemMedChem (2007), 2(6), 641-654.;;Maria Grazia Perrone et al., Screening yeasts for the stereoselective reduction of oxoester clofibrate analogues, Tetrahedron: Asymmetry (2005), 16(8), 1473-1477.;;Maria Grazia Perrone et al., Reaction of cesium 4-chlorophenate and chlorohydrins from threonines: synthesis of clofibrate analogs, Tetrahedron: Asymmetry (2005), 16(4), 783-792.;;Maria Grazia Perrone et al., Synthesis and biological evaluation of new clofibrate analogues as potential PPARα agonists, European Journal of Medicinal Chemistry (2005), 40(2), 143-154.;;Maria Grazia Perrone et al., Diastereo- and enantioselective bioreduction of ethyl 2-(4-chlorophenoxy)-3-oxobutanoate clofibrate analogues by Kluyveromyces marxianus and other whole cell biocatalysts, Tetrahedron: Asymmetry (2004), 15(22), 3511-3517.;;Maria Grazia Perrone et al., Baker's yeast-mediated reduction of ethyl 2-(4-chlorophenoxy)-3-oxoalkanoates intermediates for potential PPARα ligands, Tetrahedron: Asymmetry (2004), 15(22), 3501-3510.;;Fulvio Gualtieri et al., Presynaptic Cholinergic Modulators as Potent Cognition Enhancers and Analgesic Drugs. 2. 2-Phenoxy-, 2-(Phenylthio)-, and 2-(Phenylamino)alkanoic Acid Esters, Journal of Medicinal Chemistry (1994), 37(11), 1712-19.;;FCH Group, Chemical Catalog, 2167656-52-0 Registry.;;Ukrorgsyntez Ltd., Chemical Catalog, 1874151-65-1 Registry.;;Ukrorgsyntez Ltd., Chemical Catalog, 1855714-49-6 Registry.;;M. A. Mikhaleva et al., Use of the Amidomethylation Reaction for the Synthesis of 2-(Aryloxy)-3-Alanines, Novosibirsk Institute o f Organic Chemistry, Siberian Division, Academy o f Sciences, USSR Translated from Zhurnal Obshchei Khimii, 34(7):2153-2157, Jul. 1964.;;A. Chiriac et al., Quantitative Structure-Activity Relations With the MTD Procedure for Plant Growth-Regulation Optically Active Acetic Acid Derivatives, Revue Roumaine de Chimie, 27(4):561-568, 1982.;;G. Fracchiolla et al., Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARa and PPARc agonist activity, Bioorganic & Medicinal Chemistry 16:9498-9510, 2008.;;A. Chiriac et al., Quantitiavie Structure-Citostatic Activity Relations for Diketonato-Complexes of Tetravalent Transitional Metals, Universitatea din timisoara, Facultatea de Stiinte ale Naturii, Serie Chimie, 4:1-6, 1989.;;L. J. Edgerton et al., The Effect of Some Growth Substances on Leaf Petiole Abscission and Preharvest Drop of Several Apple Varieties, Proceedings of the American Society for Horticultural Science, 62:159-166, 1953.;;G. Fracchiolla et al., Supporting Information, Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARa and PPARc agonist activity, 2008.;;J. D. Williams et al., Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS), 23(5):1027-1043, 2015.;;K. Hayashi et al., Small-molecule agonists and antagonists of F-box protein-substrate interactions in auxin perception and signaling, PNAS, 105(14): 5632-5637, Apr. 8, 2008.;;R. C. Brian, Action of Plant Growth Regulators III, Adsorption of Aromatic Acids to Oat Monolayers, Plant Physiology, 35(6):773-782, Nov. 1960.;;E. Duintjer et al., Synthetic Plant Hormones, VI. Preparation of some alpha-Phenoxy and alpha-1-Naphtohoxy fatty Acids (Addition to Part IV), Short Communications, Part V. Aeta Chem. Scand., 8(119):1493-1494, 1954.;;M. Matell, On the Use of 2-Amino-1-phenyl-propane (Benzedrine) for Optical Resolution of Acids, Short Communications, Aeta Chem. Scand. 7(4):698-699, 1953.;;N. M. White (edited), Eurosensors XII, 1:511-514, Sep. 1998.;;E. J. Lien et al., Quantitative Structure-Activity Correlation of Optical Isomers: a Molecular Basis for Pfeiffer's Rule, Molecular Pharmacology, 12:598-604, Aug. 22, 1975.;;M. Ochiai et al., Studies on Herbicides and Plant Growth Regulators. II. Synthesis and Some Reactions of 1-Aryloxyacylpyrazoles, Chem. Pharm. Bull, 14(6):628-641, 1966.;;C. Stanley, Derivatization of Pesticide-Related Acids and Phenols for Gas Chromatographic Determination, 14(3):321-323, May-Jun. 1966.;;M. Alexander, Persistence and Biological Reactions of Pesticides in Soils, Soil Science Society of America Proceedings, 29(1):1-7, Jan.-Feb. 1965.;;C. A. Bache et al., Absence of Phenoxyacid Herbicide Residues in the Milk of Dairy Cows at High Feeding Levels, Journal of Dairy Science, 47(3):298-299, Mar. 1964.;;K. Burger et al., Decomposition of Phenoxyalkyl Carboxylic Acids, Soil Science Society of America Proceedings, 26(3):243-246, May-Jun. 1962.;;M. Alexander et al., Effect of Chemical Structure on Microbial Decomposition of Aromatic Herbicides, Agricultural and Food Chemistry, 9(1):44-47, Jan.-Feb. 1961.;;B. Sjoberg, Stereochemical studies. XI The relationship between optical rotatory dispersion and configuration for some ketones, Arkiv for Kemi Band 15(5):473-480, 1960.;;B. Sjoberg, Stereochemical studies. X The relationship between optical rotatory dispersion and configuration for some carboxylic acids, Arkiv for Kemi Band 15(5):473-480, 1960.;;D. Gowing et al., Uncommon Plant Growth Regulators for the control of Nutgrass and Oxalis, Weeds, pp. 279-283, 1960.;;W. C. Shaw et al., The Selective Herbicidal Properties of Several Variously Substituted Phenoxyalkylcarboxylic Acids, Journal of the Weed Society of America, V(2):75-92, Apr. 1957.;;C. H. Fawcett et al., Investigations on Fungicides, ii. Aryloxy- and Arylthio-Alkanecarboxylic Acids and Their Activity as Fungicides and Systemic Fungicides, Ann. appl. Biol., 45(r): 158-176, 1957.;;J. A. Zwar et al., Inhibition of Transport of Indole-3-Acetic Acid in the Etiolated Hypocotyl of Phaseolus Vulgaris L., Inhibition of IAA Transport, Jun. 11, 1956.;;C. H. Fawcett et al., Studies on Plant Growth-Regulationg Substances, VIII. The Growth-Promoting Activity of Certain Aryloxy- and Arylthio-Alkeanecarboxylic Acids, Ann. appl. Biol., 43(3): 342-354, 1955.;;A. W. Galston et al., The Adaptive Formation and Physiological Signaificance of Indoleacetic Acid Oxidase, American Journal of Botany, 41(5):373-380, May 1954.;;M. Matell, Stereochemical studies on plant growth regulators. VII, Optically active alpha-(2-methyl-4-chlorophenoxy)-propionic acid and alpha-(2,4-dichlorophenoxy)-n-butyric acid and their steric relations, Arkiv for Kemi, 6(4):365-373, 1953.;;M. Matell, Stereochemical Studies on Plant Growth Substances, Kungl. Lantbruks-Hogskolans Annaler, 20:206-240, 1953.;;C. H. Fawcett et al., Studies on Plant Growth-Regulating Substances, vi. Side-Chain Structure in Relation to Growth-Regulating Activity in the Aryloxyalkylcarboxylic Acids, 40(2):231-243, Jun. 1953.;;J. Munch-Petersen, alpha-Aryloxyesters. II. Further Studies on Certain Self-Condesations, Acta Chemica Scandinavica, 7:14-20, 1953.;;J. Munch-Petersen, Aryloxyesters. The Reacitivity of the alpha-Hydrogen and the Carbonyl Carbon towards GBasic Reagents, Acta Chemica Scandinavica, 5:519-528, 1951.;;C. M. Hill et al., The Synthesis, Propertis and Dehydrohalogenation of Some alpha-Phenoxy and 2,4-Dichlorophenoxy Substituted Acid Chlorides, Phenoxy Substituted Acid Chlorides, 73:1660-1662, Aug. 24, 1950.;;J. Munch-Petersen et al., Acylations of Certain alpha-Alkoxy and alpha-Aryloxy Ketones and Esters, University of Claifornia Los Angeles, 71:770-773, Mar. 1949.;;L. Haskelberg, The Halogenation of Aryloxyacetic Acids and Their Homologs, Daniel Sieff Research Institute, pp. 426-433, Dec. 16, 1946.;;H. E. Thompson et al., New Growth-Regulating Compounds. I. Summary of Growth-Inhibitory Activities of Some Organic Compounds as Determined by Three Tests, Botanical Gazette, pp. 476-507, 1946.;;C. Zhang et al., Synthesis and Bioactivity of Novel Inhibitors for Type III Secretion System of Pseudomonas aeruginosa PAO1, Chinese Journal of Organic Chemistry, 33:1309-1318, 2013.;;C. Temporini et al., Enantiomeric separation of 2-aryloxyalkyl- and 2-arylalkyl-2-aryloxyacetic acids on a Penicillin G Acylase-based chiral stationary phase: Influence of the chemical structure on retention and enantioselectivity; ESJPBA, ISSN: 0731-7085, 45(2):211-218, 2007.;;A. Liantonio et al., Investigations of Pharmacologic Properties of the Renal CLCK1 Chloride Channel Co-expressed with Barttin by the Use of 2-(p-Chlorophenoxy)Propionic Acid Derivatives and Other Structurally Unrelated Chloride Channels Blockers, J Am Soc Nephrol. 15:13-20, 2004.;;Kirkiacharian et al., Structure-activity relationships of some 3-substituted-4-hydroxycoumarins as HIV-1 protease inhibitors; EFARMA, ISSN: 0014-827X, 57(9):703-708, 2002.;;O. H. Rubio et al., A molecular receptor selective for zwitterionic alanine, Org. Biomol. Chem., 15:477-485, 2017.;;O. H. Rubio et al., A molecular receptor selective for zwitterionic alanine, Supplementary Material (ESI) for Organic & Biomolecular Chemistry, The Royal Society of Chemistry, 2016.;;N. Shams et al., Four-component reaction of alkyl isocyanide, acetylenic esters, phenols and pyrrole; synthesis of dialkyl 2-[(alkylimino)(1H-pyrrol-2-yl)methyl]-3-(aryloxy) succinate, Journal of Chemical Research, 39:270-273, May 2015.;;I. D. Jurberg et al., Synthesis of Functionalized Chromenes and Benzofurans from Aryloxy Proparagyl Malonates, Israel Journal of Chemistry, 53:915-922, 2013.;;I. D. Jurberg et al., A gold(I)-Catalyzed Cyclization / Photochemical Rearrangement Sequence for the Synthesis of Functionalized Benzofurans from Aryloxy Propargyl Malonates Supporting Information, 2013.;;G. Fracchiolla et al., Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors a/c dual agonists, Bioorganic & Medicinal Chemistry 20:2141-2151, 2012.;;M. Bolli et al., 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1 Receptor Agonists, J. Med. Chem., 53:4198-4211, 2010.;;M. Bolli et al., Supporting Information, 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1 Receptor Agonists, 2010.;;G. Fracchiolla et al., Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxyacetic Acid Analogues with PPARa and PPARg Agonist Activity, ChemMedChem, 2:641-654, 2007.;;A. Ramazani et al., Dipotassium Hydrogen Phosphate-Catalyzed Synthesis of Dialkyl 2-(4-Fluoro-Phenoxy)-2-Butendioates from Stabilized Phosphorus Ylides in Solven-Free Conditions, Phosphorus, Sulfur and Silicon, 182:413-417, 2007.;;G. Carbonara et al., Carboxylic acids and skeletal muscle chloride channel conductance: effects on the biological activity induced by the introduction of an aryloxyalkyl group alpha to the carboxylic function of 4-chloro-phenoxyacetic acid, II Farmaco, 56:749-754, 2001.;;M. Protiva et al., Potential Cerebral Stimulants: Esters of 2-Dimethyl-Aminoethanol With Some Lipophilic Carboxylic Acids, Collect Czech. Chem., 55:1278-1289, 1990.;;G. W. K. Cavill et al., The Chemistry of Plant Growth-regulators. Part II. Modification of the Side-chain of 2:4-Dichlorophenoxyacetic Acid, University of California-Los Angeles, pp. 1388-1391, 1954.;;K. Gasanov et al., Synthesis and Research of Tri-n-Butylstannyl Ester of 2,4-Dichlorophenoxy-∝-Butyric Acid, Academic Council of the Institute of Petrochemical Processes of the Academy of Sciences of Azerbaijan SSR, Deposited Doc. 309:10, 1980.;;V.P. Mamaev et al., Synthese of -aryloxy- -alanines, SSSR, News Bulletin of the Siberian Department of the USSR Academy of Science, 11:145-148, 1962.;;V. V. Dovlattan et al., 5-aryloxypyrimidines, Academy of the Agricultural Sciences of Armenia, 56(1-2):102-108, 2003.;;R. Nakashima et al., Effect of α-Substituted Carboxilyc Acids and Their Ethyl Esters on the Growth of Lettuces seedings, Japan Society of Agricultural Chemistry, 65(12):1777-1780, 1991.;;K. Gasanov et al., Proton NMR study of solavation of lead derivatives of aryloxy carboxylic acids, Azerbaidzhanskii Khimicheskii Zhurnal, 2:58-61, 1988.;;D. Khydyrov et al., Synthesis and herbicide activity of N-methylcarbamate derivatives of 2-hydroxyethyl 2,4-dichloroaryloxyalkanoates, Akademiya Nauk Azerbaidzhanskoi SSR, 43(1):38-41, 1987.;;V. D. Cihimil, Determination of Chlorophenoxylkankarbronic Acids and Chlorphenols in Water by the Method of Gas-Liquidchromatography in the Form of 2,2,2-Trichlorethyl and Ether and Pentaftorbenzyl Etherand Pentaf Etherether Journal of Analytical Chemistry, XXXI(4):711-714, 1984.;;K. Gasanov et al., Synthesis and carbon-13 NMR study of some organosilicon derivatives of aryloxycarboxylic acids, Azerbaidzhanskii Khimicheskii Zhumal, 5:47-50, 1982.;;G. Zeiger et al., Aryloxyalkanoic acids, their esters and cycling products as pesticide-active compounds, Scientific Journal of the “Karl Liebknecht” University of Pedagogic of Potsdam, 21(1):29-46, 1977.;;S. Mamedov et al., Synthesis of Complex Ethers of 3-Chlorethyl Ether α-(2,4-Dichlorophenoxy) Butyric Acid, Chemical Magazine of Azerbaijan, 4:79-82, 1977.;;A. I. Karaev et al., About the Injuries Healing Properties of Synthetic Growth Regulators, Reports of the Academy of Sciences of Azerbaijan SSR, IX(1):1-4, Sep. 18, 1952.;;S. N. Lutokhin, Parthenocarpy in Cucurbita Maxima L. Induced by Phytohormones With Glycerin, Reports of the Academy of Sciences of USSR, LVIII(7):1-3, 1947.;;V. V. Feofilaktov et al., Synthesis of α-(2,4-Dichloro-Phenoxy)-n.-Butyric Acid, Magazine General Chemistry, XVII(2):253-256, 1947.;;C. Rivalle et al., III.—Study of diversely-substituted α-aryloxy pinacolones, Newsletter of the French Chemistry Society, BSCFAS, 7:2555-3002, 1972.;;B. S. Kirkiacharian, No. 293.—Thermal free radicals: study of malonic and cyanoacetic esters, No. 5, 1971.;;M. Julia, No. 158.—Plant growth factors. VIII.—On some aliphatic α-dichloro-phenoxy-diacids, pp. 396-399, Jun. 1955.;;V. Koula et al., Analysis of the analogues of 2,4-dichlorophenoxyacetic acid and related substances, Annals of the Czechoslovak Academy of Agricultural Sciences, XXVII(A-4):289-294, 1954.;;International Search Report and Written Opinion dated Apr. 3, 2019 in counterpart lnternational Application No. PCT/JP2018/084989.;;DATABASE REGISTRY 13 March 2007 (2007-03-13), ""Propanoic acid, 2-¢2-(2-benzothiazolyl)phenoxy!- (CA INDEX NAME)"", XP002789551, retrieved from STN;;FABIO DEL BELLO, LAURA MATTIOLI, FRANCESCA GHELFI, MARIO GIANNELLA, ALESSANDRO PIERGENTILI, WILMA QUAGLIA, CLAUDIA CARDINALETTI, M: ""Fruitful Adrenergic α 2C -Agonism/α 2A -Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence(1) , †"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53, no. 21, 11 November 2010 (2010-11-11), US, pages 7825 - 7835, XP055484778, ISSN: 0022-2623, DOI: 10.1021/jm100977d;;FRANCESCO GENTILI, FRANCESCA GHELFI, MARIO GIANNELLA, ALESSANDRO PIERGENTILI, MARIA PIGINI, WILMA QUAGLIA, CRISTIAN VESPRINI, PIER: ""α 2 -Adrenoreceptors Profile Modulation. 2. 1 Biphenyline Analogues as Tools for Selective Activation of the α 2C -Subtype"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, no. 25, 1 December 2004 (2004-12-01), US, pages 6160 - 6173, XP055484835, ISSN: 0022-2623, DOI: 10.1021/jm0408215;;DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 June 2018 (2018-06-18), RAM, BHAGAT ET AL: ""Potential hypolipidemic agents part VI: synthesis and biological activity of some new 4-chloro/methyl-2-pyrazolylphenoxy alkanoates"", XP002782149, retrieved from STN;;CAMPIANI G, ET AL: ""Pyrrolobenzothiazepinones and Pyrrolobenzoxazepinones: Novel and Specific Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Antiviral Activity"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 14, 1 January 1996 (1996-01-01), US, pages 2672 - 2680, XP002564131, ISSN: 0022-2623, DOI: 10.1021/jm950702c",ACTIVE
666,US,B2,US 9177790 B2,006-164-992-919-799,2015-11-03,2015,US 201314067661 A,2013-10-30,US 201314067661 A,2013-10-30,Inkjet printing in a peripheral region of a substrate,"Methods, apparatuses and devices relate to inkjet printing a covering layer on at least a first side of a substrate in a peripheral region thereof are discussed.",INFINEON TECHNOLOGIES AUSTRIA,MISCHITZ MARTIN;;GASSER KARL HEINZ;;COOPER JOHN;;WANG KAE-HORNG,INFINEON TECHNOLOGIES AUSTRIA AG (2013-11-04),https://lens.org/006-164-992-919-799,Granted Patent,yes,14,0,3,3,0,H01L21/56;;H01L21/6715;;H01L2924/0002;;H01L21/78;;H01L21/02118;;H01L21/02288;;H01L21/56;;H01L2924/0002;;H01L21/6715;;H01L21/78;;H01L21/02118;;H01L21/02288;;H01L23/293;;H01L21/67,H01L23/58;;H01L21/02;;H01L21/56;;H01L21/67;;H01L23/29,,1,0,,,"Boulord, B., et al., ""Characterization and optimization of electroless nickel plating for front side silicon solar cells metallization,"" Institut des Nanotechnologies de Lyon and Institute National de L'Energie Solaire, 2nd Workshop on Metallization, Apr. 14, 2010, Konstanz, 16 pages.",ACTIVE
667,NO,L,NO 893166 L,020-198-075-250-517,1989-08-04,1989,NO 893166 A,1989-08-04,GB 8728820 A;;GB 8728821 A;;GB 8803370 A;;GB 8803371 A;;GB 8803372 A;;GB 8803373 A;;GB 8803374 A;;GB 8803375 A;;GB 8803377 A;;GB 8809174 A;;GB 8817624 A;;GB 8818426 A;;GB 8801093 W,1987-12-09,MAKROCYKLISKE FORBINDELSER.,"Compounds of formula I <CHEM> in which [R<1> and R<2>], [R<3> and R<4>] and [R<5> and R<6>] represent a carbon-carbon bond or two hydrogen atoms; R<2> additionally represents alkyl; R<7>, R<8> and R<9> represent groups including H or OH, R<1><0> has various significances including alkyl and alkenyl; X and Y represent groups including O and (H,OH); R<1><4>, R<1><5>, R<1><6>, R<1><7>, R<1><8>, R<1><9>, R<2><2> and R<2><3> represent H or alkyl; R<2><0> and R<2><1> represent groups including O, (H,OH) and (H,O-alkyl), n is 1, 2, or 3, and in addition, Y, R<1><0> and R<2><3>, together with the carbon atoms to which they are attached, may represent a neterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, eg for use as immunosuppressive agents, are also described.",FISONS PLC,COOPER MARTIN EDWARD;;ORCHARDSIDE DAVID KEITH DONALD;;HARDERN DAVID NORMANN,,https://lens.org/020-198-075-250-517,Abstract,no,0,0,26,44,0,C07D498/18;;C07D498/22;;C07H19/01;;A61P37/06;;C07H19/01,A61K31/40;;A61K31/445;;A61K31/55;;A61P37/06;;C07D498/00;;C07D498/04;;C07D498/18;;C07D498/20;;C07D498/22;;C07H19/01,,0,0,,,,DISCONTINUED
668,US,A1,US 2023/0293908 A1,042-631-726-012-161,2023-09-21,2023,US 202318122957 A,2023-03-17,US 202318122957 A;;GB 201218307 A;;US 202017087812 A;;US 201816230739 A;;US 201514424376 A;;GB 2013052650 W,2012-10-12,PATIENT MONITOR,"Images obtained by a camera system ( 10 ) arranged to obtain images of a patient ( 20 ) undergoing radio-therapy are processed by a modeling unit ( 56 , 58 ) which generates a model of the surface of a patient ( 20 ) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient( 20 ). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus ( 16 ). This can be facilitated by providing a number or retro-reflective markers ( 30 - 40 ) on a treatment apparatus ( 16 ) and a mechanical couch ( 18 ) used to position the patient ( 20 ) relative to the treatment apparatus ( 16 ) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera ( 10 ).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/042-631-726-012-161,Patent Application,yes,0,0,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61B90/00;;A61N5/10;;G06T7/285;;G06T7/73;;H04N13/204,,0,0,,,,PENDING
669,WO,A1,WO 2005/015789 A1,043-987-865-769-926,2005-02-17,2005,US 2004/0021330 W,2004-06-30,US 48546403 P;;US 48546603 P;;US 48546503 P;;US 85445304 A;;US 85406804 A;;US 85524304 A,2003-07-08,SYSTEM FOR COMMUNICATION IN PIPELINES,A system for sensing and communicating in a pipeline that contains a fluid. An acoustic signal containing information about a property of the fluid is produced in the pipeline. The signal is transmitted through the pipeline. The signal is received with the information and used by a control.,UNIV CALIFORNIA;;COOPER JOHN F;;BURNHAM ALAN K;;MARTIN LOUIS PETER II,COOPER JOHN F;;BURNHAM ALAN K;;MARTIN LOUIS PETER II,,https://lens.org/043-987-865-769-926,Patent Application,yes,2,2,3,7,0,H04B13/00;;H04B13/00;;Y10T436/11;;Y10T436/11;;Y10T436/117497;;Y10T436/117497;;Y10T436/193333;;Y10T436/193333,H04B13/00,,0,0,,,,PENDING
670,US,A1,US 2011/0021544 A1,116-349-156-197-937,2011-01-27,2011,US 77933110 A,2010-05-13,US 77933110 A;;US 21622109 P,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE","Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,MILLENNIUM PHARMACEUTICALS INC (2015-11-17);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-05-03),https://lens.org/116-349-156-197-937,Patent Application,yes,3,27,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61K31/519;;A61P35/02;;C07D487/04,514/265.1;;544/280,8,3,012-994-617-927-80X;;022-890-722-327-714;;007-364-858-655-289,10.1039/b504668h;;16027897;;10.1038/nature07884;;19360080;;10.1002/jps.2600660104;;833720,"Dean, J. A., Analytical Chemistry Handbook, 1995, pp. 10.24-10.26.;;West, Anthony R., ""Solid State Chemistry and its Applications"", Wiley, New York, 1988, pages 358 & 365;;Braga et al. (ChemComm., 2005, pp. 3635-3645);;Netterwald, ""Screened Gems"" Drug Discovery & Development, vol. 9(9), pages 22-26 (2007).;;Soucy et al. (Nature, 2009, 458, pp. 732-736).;;Soucy et al. (Nature, 2009, 458, supplemental, pp. 1-22).;;Berge (J. of Pharmaceutical Sciences, 1977, vol. 66(1), pp. 1-19).;;Bhattacharya et al. (Brittain, ed. Polymorphism in Pharmaceutical Solids, 2009, page 334.",INACTIVE
671,PE,A1,PE 20120907 A1,145-154-776-406-412,2012-08-18,2012,PE 2011001962 A,2010-05-13,US 21622109 P,2009-05-14,"SAL DE CLORHIDRATO DE ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHIDRO-1H-INDEN-1-ILAMINO]-7H-PIRROLO[2,3-D]PIRIMIDIN-7-IL}-2-HIDROXICICLOPENTIL)METILSULFAMATO","SE REFIERE A UNA SAL DE CLORHIDRATO DE ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHIDRO-1H-INDEN-1-ILAMINO]-7H-PIRROLO[2,3-D]PIRIMIDIN-7-IL}-2-HIDROXICICLOPENTIL)METILSULFAMATO QUE COMPRENDE: (A) UNA FORMA 1 QUE SE CARACTERIZA POR PRESENTAR UN PATRON DE DIFRACCION DE POLVO DE RAYOS X (XRPD) CON PICOS EN ANGULOS 2THETA DE: 9.6º, 13.6º Y 19.1º O 9.6º, 13.6º, 14.5º, 19.1º Y 23.7º; (B) UNA FORMA 2 QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 8.7º, 18.2º Y 23.8º O 8.7º, 18.2º, 19.4º, 23.8º, 24.3º Y 27.5º; (C) UNA FORMA 3A QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 10.9º, 14.6º, 19.5º Y 24.0º O 10.9º, 14.6º, 16.9º, 19.5º, 24.0º Y 25.9º; (D) UNA FORMA 3B QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 10.8º, 16.9º, 23.7º Y 24.0º O 10.8º, 14.5º, 16.9º, 19.3º, 21.2º, 23.7º, 24.0º Y 28.8º; (E) UNA FORMA 3C QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 11.0º, 12.2º Y 24.4º; 11.0º, 12.2º, 14.9º, 19.8º, 24.0º Y 24.4º; (F) UNA FORMA 5 QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 16.7º Y 22.9º O 16.7º, 17.2º, 18.1º Y 22.9º; (G) UNA FORMA 7 QUE SE CARACTERIZA POR PRESENTAR UN XRPD CON PICOS EN ANGULOS 2THETA DE: 15.4º, 17.3º, 19.6º Y 22.5º O 10.0º, 15.4º, 16.6º, 17.3º, 18.0º, 18.3º, 19.6º, 22.0º Y 22.5º. DICHO COMPUESTO ES UN INHIBIDOR DE ENZIMA ACTIVANTE DE E1 UTIL EN EL TRATAMIENTO DEL CANCER",MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGTON MARIANNE,,https://lens.org/145-154-776-406-412,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61K31/52;;A61P35/00;;C07D487/04,,0,0,,,,DISCONTINUED
672,BR,A2,BR 102019016475 A2,144-662-524-057-521,2020-03-03,2020,BR 102019016475 A,2019-08-08,US 201816059423 A,2018-08-09,"sistema de detecção de trem para via ferroviária, método para detecção de trem em via ferroviária e controlador para sistema de detecção de trem para detecção de trem em via ferroviária","sistema de detecção de trem para via ferroviária, método para detecção de trem em via ferroviária e controlador para sistema de detecção de trem para detecção de trem em via ferroviária a presente invenção se refere a um sistema de detecção de trem (10) para uma via ferroviária (11), em que a via ferroviária (11) define um primeiro lado lateral (16) e um segundo lado lateral (18) oposto ao primeiro lado lateral (16), o sistema de detecção de trem (10) compreende: - pelo menos, duas câmeras (26, 28), as câmeras (26, 28) sendo dispostas ao longo da via ferroviária (11) afastadas umas das outras, cada câmera (26, 28) sendo colocada no primeiro lado lateral (16) ou no segundo lado lateral; (18) - pelo menos, um alvo passivo (30, 32), cada um dos alvos passivos (30, 32) sendo colocado dentro do campo de visão de, pelo menos, uma das câmeras (26, 28) e no lado lateral oposto da via ferroviária (11) em relação a, pelo menos, uma das câmeras (26, 28), em cujo campo de visão, o respectivo alvo passivo (30, 32) está colocado; e - pelo menos, um controlador (38) adaptado para reconhecer, pelo menos, um alvo passivo (30, 32) nas imagens fornecidas por, pelo menos, uma das câmeras (26, 28) para o controlador (38), de maneira a determinar se um trem está localizado na via ferroviária (11).",ALSTOM TRANSP TECH,JARED COOPER;;JEFFREY FRIES;;NICHOLAS NAGRODSKY;;PHILLIP MARTIN;;SENECA SNYDER,,https://lens.org/144-662-524-057-521,Patent Application,no,0,0,8,8,0,B61L29/228;;B61L29/30;;B61L23/041;;B61L23/007;;B61L23/041;;B61L23/34;;B61L29/22;;B61L29/30;;G06T7/0008;;G06T2207/30236;;G08G7/02;;G06V20/48,B61L1/18,,0,0,,,,PENDING
673,US,B2,US 10137915 B2,002-270-291-490-073,2018-11-27,2018,US 201415108065 A,2014-12-24,US 201415108065 A;;US 201361920700 P;;US 2014/0072380 W,2013-12-24,System and method for detecting operational anomalies in train consists and railcars,A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,AMSTED RAIL COMPANY INC (2015-09-14),https://lens.org/002-270-291-490-073,Granted Patent,yes,40,13,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L27/00;;B61K9/00;;B61K9/04;;B61L15/00;;B61L25/02;;G01M17/10,,3,0,,,"Office Action dated Jul. 3, 2018 issued by Japanese Patent Office in related Japanese Patent application 2016-542732.;;“Mechanical Engineering Test Technologies”, Han Jianhai, et al., Beijing China: Tsinghua University Press, pp. 77-80, May 2010.;;Office Action dated Aug. 31, 2018 issued by the CPO in related Chinese patent application 201480076070.3. References D1 and D2 as cited in the Office Action, or US equivalents thereof, were previously made of record in the present application. D1 (CN101346268A) is a Chinese equivalent of U.S. Pat. No. 7,688,218.",ACTIVE
674,CN,A,CN 102421780 A,042-069-991-621-501,2012-04-18,2012,CN 201080021322 A,2010-05-13,US 2010/0001415 W;;US 21622109 P,2009-05-14,"Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate","Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,ARMITAGE IAN G;;REENU CHOPRA;;IAN COOPER MARTIN;;MARIANNE LANGSTON,,https://lens.org/042-069-991-621-501,Patent Application,no,2,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/52;;A61P35/00,,1,0,,,"TERESA A. SOUCY,等: ""An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer"", 《NATURE》",DISCONTINUED
675,WO,A1,WO 2000/035032 A1,169-237-776-582-162,2000-06-15,2000,US 9929350 W,1999-12-10,US 20874598 A,1998-12-10,MICRO-FUEL CELL POWER DEVICES,"Coupling miniature liquid fueled fuel cells (27) with portable electrical devices (12), with or without rechargeable batteries (34), lead to new appliance configurations: charging holster (11), piggyback charger (26), fuel cell (27) integral with rechargeable battery (34), fuel cell with voltage regulating electronics (73), supplying fuel through a tube (71) with a valve (72) or pump (41), and supplying power though an electric cable (74) between the fuel cell (27) and the electronic device (12) and the fuel cell power pack (84). There may be a window (24) showing the fuel level (105) of a disposable fuel ampoule (29) or refillable tank. Fuel is distributed through disposable fuel ampoules (29) in blister packages (23), or refueling bottles. These design features permit greater performance, workability, and convenience to the user of these portable electronics (12). Additionally, these micro fuel cell arrays (19), may be mass produced on a plastic film (7) in a reel to reel process.",HOCKADAY ROBERT G;;TURNER PATRICK S;;MASLOW MARVIN;;COOPER MARTIN,HOCKADAY ROBERT G;;TURNER PATRICK S;;MASLOW MARVIN;;COOPER MARTIN,,https://lens.org/169-237-776-582-162,Patent Application,yes,6,49,4,4,0,G06F1/1632;;G11B31/006;;H01M8/00;;H01M8/04186;;H01M8/1009;;H01M16/006;;H01M2300/0082;;H02J7/0044;;Y02E60/50;;Y02E60/10;;H01M50/247;;H01M50/227;;G06F1/1632;;H01M8/1009;;H01M8/00;;G11B31/006;;H01M8/04186;;H01M16/006;;H01M2300/0082;;H02J7/0044;;H01M50/227;;H01M50/247,G06F1/16;;G11B31/00;;H01M8/00;;H01M8/04;;H01M8/10;;H01M16/00;;H01M50/227;;H01M50/247;;H02J7/00,,0,0,,,,PENDING
676,EP,A1,EP 2430026 A1,166-948-697-051-541,2012-03-21,2012,EP 10732492 A,2010-05-13,US 2010/0001415 W;;US 21622109 P,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE",,MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/166-948-697-051-541,Patent Application,yes,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/52;;A61P35/00,,3,2,012-736-494-791-209;;102-953-259-304-865,10.1016/j.ijpharm.2005.07.007;;16139971;;10.1016/0040-6031(94)01952-d,"AUTHELIN ET AL: ""Thermodynamics of non-stoichiometric pharmaceutical hydrates"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 303, no. 1-2, 13 October 2005 (2005-10-13), pages 37 - 53, XP027624197, ISSN: 0378-5173, [retrieved on 20051013];;KHANKARI R K ET AL: ""PHARMACEUTICAL HYDRATES"", THERMOCHIMICA ACTA, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 248, 1 January 1995 (1995-01-01), pages 61 - 79, XP001162001, ISSN: 0040-6031, DOI: 10.1016/0040-6031(94)01952-D;;See also references of WO 2010132110A1",DISCONTINUED
677,EP,B1,EP 3608202 B1,176-030-993-046-855,2021-06-23,2021,EP 19190992 A,2019-08-09,US 201816059423 A,2018-08-09,A TRAIN DETECTION SYSTEM FOR A RAILWAY TRACK AND A METHOD FOR DETECTING A TRAIN ON A RAILWAY TRACK,,ALSTOM TRANSP TECH,FRIES JEFFREY;;COOPER JARED;;MARTIN PHILLIP;;SNYDER SENECA;;NAGRODSKY NICHOLAS,,https://lens.org/176-030-993-046-855,Granted Patent,yes,3,0,8,8,0,B61L29/228;;B61L29/30;;B61L23/041;;B61L23/007;;B61L23/041;;B61L23/34;;B61L29/22;;B61L29/30;;G06T7/0008;;G06T2207/30236;;G08G7/02;;G06V20/48,B61L29/22;;B61L23/04;;B61L29/30,,1,0,,,"S Oh: ""Development of a Vision based Railway Platform Safeguard"", 9TH WORLD CONGRESS ON RAILWAY RESEARCH, 22 May 2011 (2011-05-22), pages 1-10, XP055473839, Retrieved from the Internet: URL:http://www.railway-research.org/IMG/pd f/poster_oh_sehchan.pdf [retrieved on 2018-05-09]",ACTIVE
678,RU,C2,RU 2677840 C2,176-481-425-186-270,2019-01-21,2019,RU 2016127632 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS,"FIELD: machine building.SUBSTANCE: invention relates to railway equipment for detecting operational anomalies of wagons of a train consist. In the method, the system contains communication management units installed on railcars; sensors installed on the specified railcars, wherein the sensors are made with the possibility of measuring the operational parameters of the cars, with the ability to exchange data with the specified communication management units, the sensors contain one or more sensors made with the possibility of measuring the accelerations of a railcar; and filters with the ability to filter a part of the accelerations. Moreover, these communication management units perform the following functions: collecting data related to one or several operational parameters of a railcar; analyzing the data collected to identify trends or events indicating an abnormal operating condition; and communicating the message to the remote receiver when a specified trend or event is detected.EFFECT: improved monitoring reliability and traffic safety is achieved.36 cl, 14 dwg",AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/176-481-425-186-270,Granted Patent,no,6,1,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,ACTIVE
679,TW,B,TW I472515 B,194-936-144-216-77X,2015-02-11,2015,TW 98110003 A,2009-03-26,US 3975208 P,2008-03-26,Novel solid forms of bendamustine hydrochloride,,CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/194-936-144-216-77X,Granted Patent,no,1,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,,,0,0,,,,ACTIVE
680,AU,B2,AU 622666 B2,183-377-627-438-812,1992-04-16,1992,AU 1989/034542 A,1989-05-08,GB 8810723 A;;GB 8815941 A;;GB 8826223 A;;GB 8906853 A,1988-05-06,IDENTIFYING THE POSITION OF OBJECTS OR ZONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTYN,,https://lens.org/183-377-627-438-812,Granted Patent,no,3,1,2,118,0,,B07C5/344;;G01N21/64;;G01N21/65;;G01N21/87;;G01N23/223,,0,0,,,,EXPIRED
681,LU,A1,LU 86956 A1,003-909-163-792-772,1988-02-02,1988,LU 86956 A,1987-07-28,GB 8618398 A;;GB 8710608 A,1986-07-29,DERIVES DE L'ISOQUINOLEINE,,GLAXO GROUP LTD,PHILLIPPS GORDON HANLEY DR;;JONES PAUL SPENCER;;COOPER MARTIN EDWARD,,https://lens.org/003-909-163-792-772,Patent Application,no,0,0,42,51,0,C07D471/04;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/4745;;A61P35/00;;C07D217/20;;A61K31/675;;C07D471/04;;C07F9/62;;C07F9/6558,,0,0,,,,DISCONTINUED
682,US,A1,US 2004/0038292 A1,037-641-476-934-718,2004-02-26,2004,US 17518402 A,2002-06-18,US 17518402 A;;GB 0114869 A;;US 30534601 P,2001-06-18,Wound healing biomarkers,"
   This invention provides biomarkers such as genes and the corresponding mRNA transcripts or protein products that are identified as being involved in wound healing processes. Also provided are methods for identification of compounds useful for the treatment of wounds, wound healing disorders or inflammation and compounds identified by such methods. Methods are provided for monitoring the progress of wound healing and for identification of individuals with wound healing disorders. 
",BURSLEM MARTYN FRANK;;JOHNSON CLAIRE MICHELLE;;COOPER LISA;;MARTIN PAUL,BURSLEM MARTYN FRANK;;JOHNSON CLAIRE MICHELLE;;COOPER LISA;;MARTIN PAUL,,https://lens.org/037-641-476-934-718,Patent Application,yes,1,20,5,6,39,A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;A61P29/00;;C12Q1/6883;;C12Q1/6883;;C07K14/47;;C07K14/47;;C12Q2600/158;;C12Q2600/158;;G01N33/5091;;G01N33/5091;;G01N33/6893;;G01N33/6893;;G01N33/86;;G01N33/86;;G01N33/92;;G01N33/92,A61K45/00;;A61K48/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;C07K14/47;;C12N15/09;;C12Q1/02;;C12Q1/68;;G01N33/15;;G01N33/50;;G01N33/68;;G01N33/86;;G01N33/92,435/7.1;;435/69.1;;435/226;;435/320.1;;435/325;;536/23.2,0,0,,,,DISCONTINUED
683,WO,A1,WO 2003/045424 A1,031-786-993-971-065,2003-06-05,2003,NZ 0200262 W,2002-11-26,NZ 51573101 A;;US 33342201 P,2001-11-26,METHODS OF COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES,"The invention provides methods of stimulating lipolysis in a mammalian cells and tissues by contacting the cell or tissue with an agonist of a CGRP receptor such as the high affinity CGRP receptor. The agonist may preferentially stimulate the high affinity CGRP receptor compared to the metabolic amylin receptor. Methods for screening for identifying receptor agonists are provided, pharmaceutical compositions comprising such agonists, and therapeutic regimens using such agonists are provided.",PROTEMIX CORP LTD;;COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;WATSON RACHEL NANCY,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;WATSON RACHEL NANCY,,https://lens.org/031-786-993-971-065,Patent Application,yes,7,0,9,10,0,A61K38/225;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/92;;G01N2500/00;;G01N2800/044,G01N33/50;;A61K38/22;;A61K38/23;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/15;;G01N33/92,,17,11,021-394-570-232-791;;001-979-848-181-342;;016-613-557-095-75X;;053-073-886-901-406;;129-801-112-974-001;;009-402-473-124-783;;015-226-437-530-490;;040-211-592-454-920;;078-058-098-332-11X;;020-881-548-351-868;;025-671-507-507-121,8851500;;pmc1909412;;10.1111/j.1476-5381.1996.tb15270.x;;8386456;;10.1152/ajpendo.1993.264.4.e606;;10.2337/diabetes.50.7.1604;;11423482;;10.1096/fasebj.13.14.2051;;10544188;;10.1016/s0026-0495(00)91377-5;;10690948;;10337861;;10.1016/s0026-0495(99)90058-6;;9374670;;10.1152/ajpendo.1997.273.5.e859;;10.1152/ajpendo.2001.280.4.e562;;11254462;;12196117;;10.1042/bst0300468;;9546589;;10.1023/a:1006820907955;;10.1139/o59-099;;13671378,"PITTNER R. ET AL.: ""Different pharmacological characteristics in L6 and C2C12 muscle cells and intact skeletal muscle for amylin, CGRP and calcitonin"", BRIT. J. PHARM., vol. 117, no. 5, 1996, pages 847 - 852, XP008057600;;KREUTTER D. ET AL.: ""Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor"", AM. PHYSIOL. SOC., vol. 264, no. 4 PT 1, 1993, pages E606 - E613, XP002999215;;HAGSTROM-TOFT E. ET AL.: ""Evidence for a major role for skeletal lipolysis in the regulation of lipdi oxidation during caloric restriction in vivo"", DIABETES, vol. 50, no. 7, July 2001 (2001-07-01), pages 1604 - 1611, XP002999001;;MURRAY R. ET AL.: ""Harpers's Biochemistry"", 2000, MCGRAW-HILL USA, ISBN: 0-8385-3690-5, XP002999225;;See also references of EP 1461068A4;;SIMONEAU ET AL.: ""Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss"", FASEB J., vol. 13, no. 14, November 1999 (1999-11-01), pages 2051 - 60;;MANCO ET AL.: ""Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides"", METABOLISM, vol. 49, no. 2, February 2000 (2000-02-01), pages 220 - 4, XP004631491, DOI: doi:10.1016/S0026-0495(00)91377-5;;CHATZIPANTELI ET AL., ENDOCRINOLOGY AND METABOLISM, vol. 3, 1996, pages 235 - 242;;MOORE, METABOLISM, vol. 48, no. 5, 1999, pages 603 - 610;;HETTIARCHCHI ET AL., AM. J. PHYS. END. METAB., vol. 273, 1997, pages E859 - 867;;YE, AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 280, 2001, pages 562 - 569;;WU ET AL., BIOCHEM SOC. TRANS., vol. 30, 2002, pages 468 - 73;;MALLEE ET AL., JBIOL CHEM., vol. 277, 2002, pages 4294 - 98;;GORSKI ET AL., MOL & CELL BIOCHEM, vol. 178, 1988, pages 113 - 118;;BLIGH ET AL., CAN J BIOCHEM PHYSIOI, vol. 37, 1959, pages 911 - 917;;CORNISH ET AL., AM. J. PHYS., vol. 36, 1997, pages E1113 - E1120;;SAMBROOK J.: ""Molecular cloning: a laboratory manual"", 1989, COLD SPRING HARBOUR LABORATORY PRESS",PENDING
684,ZW,A1,ZW 888 A1,052-107-260-697-518,1988-06-01,1988,ZW 888 A,1988-01-22,ZW 888 A,1988-01-22,ISOQUINOLINE DERIVATIVES,,GLAXO GROUP LTD,DR GORDON HANLEY PHILLIPPS;;PAUL SPENCER JONES;;MARTIN EDWARD COOPER,,https://lens.org/052-107-260-697-518,Granted Patent,no,0,0,1,1,0,,A61K/,,0,0,,,,EXPIRED
685,WO,A2,WO 2002/039946 A2,089-038-452-295-720,2002-05-23,2002,US 0151262 W,2001-10-25,US 24452800 P,2000-10-31,PACKAGING AND DELIVERY SYSTEM FOR BONE GRAFT PARTICLES,"The present invention is directed to a packaging and delivery system for bone graft particles (24) comprising an outer tray (32) which contains an inner tray (22) comprising a bowl (1) of the particles (24) and also, in some embodiments, a mixing and delivery tool (12) and/or a syringe containing a suspension material for the particles (24), such as a gel. The inner tray (22) is comprised of an anti-moisture coating and a lid (20) comprised of foil. The mixing and delivery tool (12) preferably has a trowel (13) on one end and a tamping rod (14) on the other end, wherein both features facilitate delivery and compression of the bone graft particles (24) to a bone defect site.",SMITH & NEPHEW INC,COOPER MICHAEL B;;RILEY STEPHANIE;;HARBER JAMES C;;MARTIN JEFF,,https://lens.org/089-038-452-295-720,Patent Application,yes,0,13,7,7,0,A61F2/4644;;A61F2/4644;;A61B50/30;;A61B50/30;;A61B50/33;;A61B50/33;;A61B90/94;;A61B90/94;;A61B2050/0065;;A61B2050/0065;;A61F2/0095;;A61F2/0095;;A61F2/4601;;A61F2/4601;;A61F2002/2835;;A61F2002/2835;;A61F2002/3071;;A61F2002/3071;;A61F2250/0089;;A61F2250/0089,B65D25/14;;A61B19/00;;A61B19/02;;A61F2/00;;A61F2/28;;A61F2/46;;B65D77/04;;B65D77/08;;B65D77/20;;B65D81/20,,0,0,,,,PENDING
686,NZ,A,NZ 621128 A,143-216-738-865-632,2015-08-28,2015,NZ 62112810 A,2010-05-13,US 21622109 P;;NZ 59647010 A,2009-05-14,"Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate","Disclosed herein is a compound of formula (I), specifically the hydrochloride salt of ((1S,2S,4R)-4-{ 4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,CHOPRA REENU;;ARMITAGE IAN G;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/143-216-738-865-632,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/52;;A61P35/00,,0,0,,,,DISCONTINUED
687,US,A1,US 2002/0112981 A1,150-973-098-210-452,2002-08-22,2002,US 5452301 A,2001-10-25,US 5452301 A;;US 24452800 P,2000-10-31,Package and delivery system for bone graft particles,"
   The present invention is directed to a packaging and delivery system for bone graft particles comprising an outer tray which contains an inner tray comprising a bowl of the particles and also, in some embodiments, a mixing and delivery tool and/or a syringe containing a suspension material for the particles, such as a gel. The inner tray is comprised of an anti-moisture coating and a lid comprised of foil. The mixing and delivery tool preferably has a trowel on one end and a tamping rod on the other end, wherein both features facilitate delivery and compression of the bone graft particles to a bone defect site. 
",COOPER MICHAEL B.;;RILEY STEPHANIE;;HARBER JAMES C.;;MARTIN JEFF,COOPER MICHAEL B;;RILEY STEPHANIE;;HARBER JAMES C;;MARTIN JEFF,SMITH & NEPHEW INC (2002-03-14),https://lens.org/150-973-098-210-452,Patent Application,yes,4,62,7,7,0,A61F2/4644;;A61F2/4644;;A61B50/30;;A61B50/30;;A61B50/33;;A61B50/33;;A61B90/94;;A61B90/94;;A61B2050/0065;;A61B2050/0065;;A61F2/0095;;A61F2/0095;;A61F2/4601;;A61F2/4601;;A61F2002/2835;;A61F2002/2835;;A61F2002/3071;;A61F2002/3071;;A61F2250/0089;;A61F2250/0089,B65D25/14;;A61B19/00;;A61B19/02;;A61F2/00;;A61F2/28;;A61F2/46;;B65D77/04;;B65D77/08;;B65D77/20;;B65D81/20,206/438;;X20657,0,0,,,,DISCONTINUED
688,WO,A1,WO 2009/054965 A1,169-625-847-780-073,2009-04-30,2009,US 2008/0012006 W,2008-10-22,US 5107 P,2007-10-23,"SALTS OF N- (6-CHLORO-9H-PYRIDO [3,4-B] IND0L-8-YL) -4- [2- (2, 6-DIMETHYL-4-MORPHOLINYL) -2-0X0E THYL] -6, 6-DIMETHYL-MORPHOLINECARBOXAMIDE","The present invention is directed to the Tartrate, Mono-Hydrochloride, Malonate and p- Toluenesulfonate Salts of the compound of formula (I), or solvates thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the Salts, including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of the Salts, including crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.",MILLENNIUM PHARM INC;;HICKS FREDERICK A;;COOPER MARTIN IAN;;ST CLAIR BROWN ADRIAN,HICKS FREDERICK A;;COOPER MARTIN IAN;;ST CLAIR BROWN ADRIAN,,https://lens.org/169-625-847-780-073,Patent Application,yes,2,0,2,2,0,A61P29/00;;C07D471/04;;C07D471/04,C07D471/04,,0,0,,,,PENDING
689,MX,A,MX 2011012108 A,195-769-477-233-43X,2011-12-08,2011,MX 2011012108 A,2010-05-13,US 21622109 P;;US 2010/0001415 W,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN -1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTY L)METHYL SULFAMATE.","Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,LANGSTON MARIANNE;;ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN,,https://lens.org/195-769-477-233-43X,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61K31/52;;C07D487/04;;A61P35/00,,0,0,,,,DISCONTINUED
690,US,A1,US 2021/0128948 A1,051-944-690-760-160,2021-05-06,2021,US 202017087812 A,2020-11-03,US 202017087812 A;;GB 201218307 A;;US 201816230739 A;;US 201514424376 A;;GB 2013052650 W,2012-10-12,PATIENT MONITOR,"Images obtained by a camera system ( 10 ) arranged to obtain images of a patient ( 20 ) undergoing radio-therapy are processed by a modeling unit ( 56,58 ) which generates a model of the surface of a patient ( 20 ) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient ( 20 ). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus ( 16 ). This can be facilitated by providing a number or retro-reflective markers ( 30 - 40 ) on a treatment apparatus ( 16 ) and a mechanical couch ( 18 ) used to position the patient ( 20 ) relative to the treatment apparatus ( 16 ) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera ( 10 ).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/051-944-690-760-160,Patent Application,yes,1,0,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;A61B90/00;;G06T7/285;;G06T7/73;;H04N13/204,,0,0,,,,ACTIVE
691,KR,A,KR 20230082632 A,054-194-602-326-049,2023-06-08,2023,KR 20237012960 A,2021-10-05,US 202063087623 P;;US 202063116597 P;;US 202163229019 P;;US 202163239859 P;;US 2021/0053636 W,2020-10-05,항-FCRH5/항-CD3 이중특이성 항체를 사용한 치료를 위한 투약,"본 발명은 암, 예를 들어, 다발성 골수종을 치료하기 위해 항-단편 결정성 수용체-유사 5(FcRH5)/항-분화 클러스터 3(CD3) 이중특이성 항체를 투약하는 방법을 제공한다.",GENENTECH INC,FINE BERNARD MARTIN;;SUMIYOSHI TEIKO;;LI MENGSONG;;COOPER JAMES NIALL,,https://lens.org/054-194-602-326-049,Patent Application,no,0,0,12,12,74,C07K16/2809;;C07K16/283;;C07K2317/31;;A61K2039/545;;A61K2039/54;;A61K2039/507;;A61P35/00;;C07K2317/24;;C07K2317/71;;C07K2317/52;;C07K2317/73;;C07K16/2809;;C07K2317/71;;A61K2039/545;;C07K2317/31;;A61P35/00;;C07K2317/24;;A61K2039/54;;C07K2317/52;;A61K2039/507;;C07K16/283;;C07K16/283;;C07K16/2809;;A61P35/00;;C07K2317/31;;C07K2317/24;;C07K2317/71;;C07K2317/52;;A61K2039/507;;A61K2039/54;;A61K2039/545;;A61P35/00;;A61K31/137;;A61K31/167;;A61K31/573;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2809;;C07K16/283;;C07K16/2866;;C07K2317/24;;C07K2317/31;;C07K2317/41;;C07K2317/524;;C07K2317/526;;C07K2317/71,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
692,JP,A,JP 2017105816 A,063-329-949-540-521,2017-06-15,2017,JP 2017020911 A,2017-02-08,US 21622109 P,2009-05-14,"METHYL ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDENE-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDINE-7-YL}-2-HYDROXYCYCLOPENTYL)SULFAMATE HYDROCHLORIDE","PROBLEM TO BE SOLVED: To provide a compound as an E1 activation enzyme inhibitor, a crystal form thereof, a pharmaceutical composition containing the compound and use of the compound, or the crystal form thereof or a solvate thereof for treating patients suffered or having a risk to be suffered with pathological conditions including cancer which can be alleviated by inhibiting an E1 activation enzyme, especially NAE.SOLUTION: There is provided a method for manufacturing methyl((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-indene-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidine-7-yl}-2-hydroxycyclopentyl)sulfamate hydrochloride, a crystal form thereof or a solvate thereof. Further there is provided a use of a pharmaceutical composition containing the compound, a pharmaceutically acceptable carrier or diluent in patients who need a treatment for cancer. There is provided a use wherein the cancer is leukemia or lymphoma.SELECTED DRAWING: None",MILLENNIUM PHARM INC,IAN G ARMITAGE;;REENU CHOPRA;;MARTIN IAN COOPER;;MARIANNE LANGSTON,,https://lens.org/063-329-949-540-521,Patent Application,no,2,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02,,2,0,,,"TERESA A. SOUCY ET AL., NATURE, vol. 458, JPN6017050309, 9 April 2009 (2009-04-09), US, pages 732 - 737, ISSN: 0003887219;;平山令明, 有機化合物結晶作製ハンドブック, JPN6014022315, 2008, pages 10 - 11, ISSN: 0003887220",PENDING
693,WO,A3,WO 2004/065614 A3,171-678-667-309-904,2005-06-30,2005,IB 0306467 W,2003-01-29,NZ 51692002 A,2002-01-29,SUPPRESSION OF CYTOTOXIC PROTEIN CONFORMERS,Methods of preventing amyloid associated disease comprising preventing protofibril formation using polycyclic compounds related screens and methodologies disclosed.,PROTEMIX CORP LTD;;COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,,https://lens.org/171-678-667-309-904,Search Report,yes,2,0,9,9,0,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;G01N33/6896;;G01N2500/00;;A61P25/00;;A61P25/28;;A61P3/00;;A61P43/00;;A61P5/48;;A61P5/50;;A61P3/10;;A61K31/655;;A61K31/473;;G01N33/6896;;A61K31/00;;A61K31/015;;G01N2500/00;;A61K31/5415;;A61K31/65,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;A61P5/48;;A61P5/50;;A61P25/28;;A61P43/00;;G01N33/68,,2,2,025-677-285-000-997;;130-581-411-528-523,10.1016/s0014-5793(00)02380-2;;11163366;;9562501;;10.1016/s0197-4580(97)00164-4,"FORLONI ET AL: ""Anti-amyloidogenic activity of tetracyclines: studies in vitro"", FEBS LETTERS, vol. 487, no. 3, 2001, pages 404 - 407, XP004337906;;CARTER ET AL: ""A model for structure-dependent binding of Congo red to Alzheimer .beta.-amyloid"", NEUROBIOLOGY OF AGING, vol. 19, no. 1, 1998, pages 37 - 40, XP008053291, DOI: doi:10.1016/S0197-4580(97)00164-4",PENDING
694,ZA,B,ZA 201108347 B,172-671-677-412-643,2014-05-26,2014,ZA 201108347 A,2011-11-14,US 21622109 P;;US 2010/0001415 W,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO}-7H-PYROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE",,MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/172-671-677-412-643,Granted Patent,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61K/;;C07D/;;A61P/,,0,0,,,,ACTIVE
695,WO,A3,WO 2007/077423 A3,188-839-250-825-980,2007-10-25,2007,GB 2006004913 W,2006-12-27,GB 0600114 A,2006-01-05,GROWTH HORMONE VARIATIONS,"The invention relates to novel variants in the growth hormone gene and the corresponding variants in the protein structure and the use of same in the diagnosis of growth hormone dysfunction, hypertension or stroke.",UNIV CARDIFF;;COOPER DAVID NEIL;;HORAN MARTIN;;LEWIS MARK;;MILLAR DAVID STUART,COOPER DAVID NEIL;;HORAN MARTIN;;LEWIS MARK;;MILLAR DAVID STUART,,https://lens.org/188-839-250-825-980,Search Report,yes,3,0,8,8,0,C12N15/11;;C12Q1/6827;;C12Q1/6883;;C07K14/61;;C12Q2600/156,C07K14/61;;C12Q1/68,,3,2,019-295-994-151-244;;030-253-099-402-484,10.1002/humu.10168;;12655557;;10.1007/s00439-006-0166-5;;16572267,"DATABASE WPI Week 200623, Derwent World Patents Index; AN 2006-213612, XP002446446;;MILLAR DAVID S ET AL: ""Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature."", HUMAN MUTATION APR 2003, vol. 21, no. 4, April 2003 (2003-04-01), pages 424 - 440, XP002438469, ISSN: 1098-1004;;HORAN MARTIN ET AL: ""Genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke."", HUMAN GENETICS JUN 2006, vol. 119, no. 5, June 2006 (2006-06-01), pages 527 - 540, XP002438470, ISSN: 0340-6717",PENDING
696,EP,B1,EP 2906289 B1,193-597-351-460-281,2018-09-05,2018,EP 13777329 A,2013-10-11,GB 201218307 A;;GB 2013052650 W,2012-10-12,PATIENT MONITOR,,VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/193-597-351-460-281,Granted Patent,yes,2,0,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;A61B90/00;;G06T7/00;;G06T7/285;;G06T7/73,,0,0,,,,ACTIVE
697,PH,A1,PH 12015501925 A1,005-570-783-684-361,2018-01-22,2018,PH 12015501925 A,2015-09-01,US 21622109 P;;US 2010/0001415 W,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE","Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/005-570-783-684-361,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61K31/52;;A61P35/00;;C07D487/04,,0,0,,,,PENDING
698,EP,A1,EP 0335023 A1,104-860-319-779-273,1989-10-04,1989,EP 88302907 A,1988-03-31,EP 88302907 A,1988-03-31,Fungal enzymes.,"The invention provides an enzyme preparation comprising at least one protease derived from an entomopathogenic fungus of one of the following genera:  Metarhizium ,  Beauvaria ,  Verticillium , and  Aschersonia , and characterised by the following properties:
 (a) substantially no activity against hide protein azure, locust cuticle and elastin; (b) specificity for Bz-Phe-Val-Arg-NA; (C) not inhibited by soybean trypsin inhibitor.   ",AGRICULTURAL GENETICS CO,CHARNLEY ANTHONY KEITH;;COOPER RICHARD MARTIN;;ST LEGER RAYMOND JOHN,,https://lens.org/104-860-319-779-273,Patent Application,yes,2,9,1,3,0,C12N9/58,C12N9/58,,5,5,050-108-897-730-735;;130-075-836-234-641;;007-211-861-267-503;;026-960-830-557-695;;063-793-991-301-574,10.1016/0003-9861(87)90655-2;;3545084;;10.1016/0022-2011(86)90043-1;;10.1016/0022-2011(86)90146-1;;pmc203930;;16347395;;10.1128/aem.53.7.1679-1684.1987;;10.1016/0022-2011(80)90166-4,"ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 253, no. 1, 15th February 1987, pages 221-232, Academic Press, Inc.; R.J.ST. LEGER et al.: ""Characterization of cuticle-degrading proteases produced by the entomopathogen Metarhizium anisopliae"";;JOURNAL OF INVERTEBRATE PATHOLOGY, vol. 47, no. 2, 1986, pages 167-177, Academic Press, Inc.; R.J.ST. LEGER et al.: ""Cuticle-degrading enzymes of entomopathogenic fungi: cuticle degradation in vitro by enzymes from entomopathogens"";;JOURNAL OF INVERTEBRATE PATHOLOGY, vol. 48, 1986, pages 85-95, Academic Press, Inc.; R.J.ST. LEGER et al.: ""Cuticle-degrading enzymes of entomopathogenic fungi: synthesis in culture on cuticle"";;APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 53, no. 7, July 1987, pages 1679-1684, American Society for Microbiology; M.J. BIDOCHKA et al.: ""Purification and properties of an extracellular protease produced by the entomopathogenic fungus Beauveria bassiana"";;JOURNAL OF INVERTEBRATE PATHOLOGY, vol. 35, no. 3, 1980, pages 304-310, Academic Press, Inc.; M. KUCERA: ""Proteases from the fungus Metarhizium anisopliae toxic for Galleria mellonella larvae""",DISCONTINUED
699,AU,A,AU 2000/020500 A,098-299-817-548-746,2000-06-26,2000,AU 2000/020500 A,1999-12-10,US 20874598 A;;US 9929350 W,1998-12-10,Micro-fuel cell power devices,,HOCKADAY ROBERT G;;TURNER PATRICK S;;MASLOW MARVIN;;COOPER MARTIN,HOCKADAY ROBERT G;;TURNER PATRICK S;;MASLOW MARVIN;;COOPER MARTIN,,https://lens.org/098-299-817-548-746,Patent Application,no,0,0,4,4,0,G06F1/1632;;G11B31/006;;H01M8/00;;H01M8/04186;;H01M8/1009;;H01M16/006;;H01M2300/0082;;H02J7/0044;;Y02E60/50;;Y02E60/10;;H01M50/247;;H01M50/227;;G06F1/1632;;H01M8/1009;;H01M8/00;;G11B31/006;;H01M8/04186;;H01M16/006;;H01M2300/0082;;H02J7/0044;;H01M50/227;;H01M50/247,G06F1/16;;G11B31/00;;H01M8/00;;H01M8/04;;H01M8/10;;H01M16/00;;H01M50/227;;H01M50/247;;H02J7/00,,0,0,,,,DISCONTINUED
700,AR,A1,AR 072777 A1,125-445-780-503-228,2010-09-22,2010,AR P090101039 A,2009-03-23,US 3975208 P,2008-03-26,FORMAS SOLIDAS DE CLORHIDRATO DE BENDAMUSTINA,"Se describe una forma solida de clorhidrato de bendamustina que comprende clorhidrato de bendamustina, Forma 1 y/o clorhidrato de bendamustina, Forma 3 y/o clorhidrato de bendamustina, Forma 4 y/o clorhidrato de bendamustina amorfo, o una mezcla de ellas. La forma solida resultante de clorhidrato de bendamustina tiene un patron de difraccion de rayos X de polvo que contiene una o más de las siguientes reflexiones: 25,1; 24,9; 22,9; 22,0; y/o 14,1 +/- 0,2 grados 2theta; o 26,1; 27,9; y/o 28,1 +/- 0,2 grados 2theta; o 10,8; 15,5; 20,5; y/o 23,6 +/- 0,2 grados 2theta.",CEPHALON INC,COOPER MARTIN IAN;;EDDLESTON MARK;;COURVOISIER LAURENT;;MCKEAN ROBERT E,,https://lens.org/125-445-780-503-228,Patent Application,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,,,0,0,,,,DISCONTINUED
701,TW,B,TW 445661 B,133-981-611-350-944,2001-07-11,2001,TW 88117569 A,1999-10-12,US 20874598 A,1998-12-10,Micro fuel cell power devices,"Coupling miniature liquid fueled fuel cells with portable electrical devices, with or without rechargeable batteries, lead to new appliance configurations: charging holster, piggyback charger, fuel cell integral with rechargeable battery, fuel cell with voltage regulating electronics, supplying fuel through a tube with a valve or pump, and supplying power though an electric cable between the fuel cell and the electronic device and the fuel cell power pack having independent communication and functions from the portable electrical devices. In all of these configurations there may be a window showing the fuel level of a disposable fuel ampoule or refillable fuel tank. Fuel is distributed through disposable fuel ampoules in blister packages, or refueling bottles. Adjustable moisture and thermal internal insulation allows fuel cells to run at elevated temperatures. These design features permit greater performance, workability, and convenience to the user of these portable electronics. Additionally, these micro-fuel cell arrays, which pack more energy into a small space, may be mass produced on a plastic film in a reel-to-reel process.",HOCKADAY ROBERT G;;TURNER PATRICK S;;MASLOW MARVIN;;COOPER MARTIN,HOCKADAY ROBERT G;;TURNER PATRICK S;;MASLOW MARVIN;;COOPER MARTIN,,https://lens.org/133-981-611-350-944,Granted Patent,no,0,1,4,4,0,G06F1/1632;;G11B31/006;;H01M8/00;;H01M8/04186;;H01M8/1009;;H01M16/006;;H01M2300/0082;;H02J7/0044;;Y02E60/50;;Y02E60/10;;H01M50/247;;H01M50/227;;G06F1/1632;;H01M8/1009;;H01M8/00;;G11B31/006;;H01M8/04186;;H01M16/006;;H01M2300/0082;;H02J7/0044;;H01M50/227;;H01M50/247,G06F1/16;;G11B31/00;;H01M8/00;;H01M8/04;;H01M8/10;;H01M16/00;;H01M50/227;;H01M50/247;;H02J7/00,,0,0,,,,EXPIRED
702,TW,A,TW 200944508 A,135-997-545-395-886,2009-11-01,2009,TW 98110003 A,2009-03-26,US 3975208 P,2008-03-26,Novel solid forms of bendamustine hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/135-997-545-395-886,Patent of Addition,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/06;;A61K31/4184;;A61P35/00,,0,0,,,,ACTIVE
703,EP,A1,EP 4225443 A1,131-920-740-014-97X,2023-08-16,2023,EP 21801343 A,2021-10-05,US 202063087623 P;;US 202063116597 P;;US 202163229019 P;;US 202163239859 P;;US 2021/0053636 W,2020-10-05,DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES,,GENENTECH INC,FINE BERNARD MARTIN;;SUMIYOSHI TEIKO;;LI MENGSONG;;COOPER JAMES NIALL,,https://lens.org/131-920-740-014-97X,Patent Application,yes,0,0,12,12,0,C07K16/2809;;C07K16/283;;C07K2317/31;;A61K2039/545;;A61K2039/54;;A61K2039/507;;A61P35/00;;C07K2317/24;;C07K2317/71;;C07K2317/52;;C07K2317/73;;C07K16/2809;;C07K2317/71;;A61K2039/545;;C07K2317/31;;A61P35/00;;C07K2317/24;;A61K2039/54;;C07K2317/52;;A61K2039/507;;C07K16/283;;C07K16/283;;C07K16/2809;;A61P35/00;;C07K2317/31;;C07K2317/24;;C07K2317/71;;C07K2317/52;;A61K2039/507;;A61K2039/54;;A61K2039/545;;A61P35/00;;A61K31/137;;A61K31/167;;A61K31/573;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2809;;C07K16/283;;C07K16/2866;;C07K2317/24;;C07K2317/31;;C07K2317/41;;C07K2317/524;;C07K2317/526;;C07K2317/71,A61P35/00;;A61K39/00;;C07K16/28,,0,0,,,,PENDING
704,DE,D1,DE 50109716 D1,005-064-414-959-225,2006-06-08,2006,DE 50109716 T,2001-10-23,US 70935400 A;;EP 0112226 W,2000-11-13,VERFAHREN ZUR KONTINUIERLICHEN HERSTELLUNG VON POLYMERZUSAMMENSETZUNGEN SOWIE VERWENDUNG,"The present invention relates to a process for synthesis of polymer compositions, wherein ethylenically unsaturated monomers are polymerized by means of initiators containing a transferable atom or group of atoms and of one or more catalysts comprising at least one transition metal in the presence of ligands which can form a coordination compound with the metal catalyst or catalysts, the process being characterized in that the polymerization takes place by means of continuous process operation.",ROHMAX ADDITIVES GMBH,SCHERER MARKUS;;BOLLINGER MARTIN;;COOPER DAVID;;TILLERY STEPHEN;;WOODRUFF ROBERT,"EVONIK OIL ADDITIVES GMBH, DE (2012-11-13);;EVONIK ROHMAX ADDITVES GMBH, 64293 DARMSTADT, DE (2007-12-20)",https://lens.org/005-064-414-959-225,Granted Patent,no,0,0,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F2/01;;C08F4/00;;C08F4/40;;C08F4/44,,0,0,,,,EXPIRED
705,WO,A3,WO 2002/039946 A3,090-535-314-768-676,2003-04-17,2003,US 0151262 W,2001-10-25,US 24452800 P,2000-10-31,PACKAGING AND DELIVERY SYSTEM FOR BONE GRAFT PARTICLES,"The present invention is directed to a packaging and delivery system for bone graft particles (24) comprising an outer tray (32) which contains an inner tray (22) comprising a bowl (1) of the particles (24) and also, in some embodiments, a mixing and delivery tool (12) and/or a syringe containing a suspension material for the particles (24), such as a gel. The inner tray (22) is comprised of an anti-moisture coating and a lid (20) comprised of foil. The mixing and delivery tool (12) preferably has a trowel (13) on one end and a tamping rod (14) on the other end, wherein both features facilitate delivery and compression of the bone graft particles (24) to a bone defect site.",SMITH & NEPHEW INC,COOPER MICHAEL B;;RILEY STEPHANIE;;HARBER JAMES C;;MARTIN JEFF,,https://lens.org/090-535-314-768-676,Search Report,yes,5,0,7,7,0,A61F2/4644;;A61F2/4644;;A61B50/30;;A61B50/30;;A61B50/33;;A61B50/33;;A61B90/94;;A61B90/94;;A61B2050/0065;;A61B2050/0065;;A61F2/0095;;A61F2/0095;;A61F2/4601;;A61F2/4601;;A61F2002/2835;;A61F2002/2835;;A61F2002/3071;;A61F2002/3071;;A61F2250/0089;;A61F2250/0089,B65D25/14;;A61B19/00;;A61B19/02;;A61F2/00;;A61F2/28;;A61F2/46;;B65D77/04;;B65D77/08;;B65D77/20;;B65D81/20,,0,0,,,,PENDING
706,AU,A1,AU 2013/204831 A1,145-164-730-468-705,2013-05-09,2013,AU 2013/204831 A,2013-04-12,AU 2010/248151 A;;AU 2013/204831 A,2010-05-13,"Hydrochloride salt of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate","H:\SXD\Intenvoven\NRPorlbl\DCC\SXD\5072063_I.doc-12/04/2013 Disclosed is a compound of formula (1); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (1), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer. aN .. N .HCI",MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/145-164-730-468-705,Patent Application,no,0,0,1,1,0,,C07D487/04;;A61K31/52;;A61P35/00,,0,0,,,,DISCONTINUED
707,EP,A3,EP 1270044 A3,155-505-811-438-87X,2003-03-12,2003,EP 02254207 A,2002-06-17,GB 0114869 A;;US 30534601 P,2001-06-18,Wound healing biomarkers,"This invention provides biomarkers such as genes and the corresponding mRNA transcripts or protein products that are identified as being involved in wound healing processes. Also provided are methods for identification of compounds useful for the treatment of wounds, wound healing disorders or inflammation and compounds identified by such methods. Methods are provided for monitoring the progress of wound healing and for identification of individuals with wound healing disorders.",PFIZER LTD;;PFIZER,BURSLEM MARTYN FRANK;;COOPER LISA;;JOHNSON CLAIRE MICHELLE;;MARTIN PAUL,,https://lens.org/155-505-811-438-87X,Search Report,yes,3,0,5,6,0,C07K14/47;;C12Q1/6883;;G01N33/5091;;G01N33/6893;;G01N33/86;;G01N33/92;;C12Q2600/158;;A61P1/04;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;A61P29/00;;A61P9/00;;C12Q1/6883;;G01N33/6893;;C07K14/47;;G01N33/86;;G01N33/5091;;G01N33/92;;C12Q2600/158,A61K45/00;;A61K48/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;C07K14/47;;C12N15/09;;C12Q1/02;;C12Q1/68;;G01N33/15;;G01N33/50;;G01N33/68;;G01N33/86;;G01N33/92,,1,1,093-155-110-505-06X,8889548;;10.1101/gr.6.9.791,"BONALDO FATIMA DE M ET AL: ""NORMALIZATION AND SUBTRACTION: TWO APPROACHES TO FACILITATE GENE DISCOVERY"", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 6, no. 9, 1 September 1996 (1996-09-01), pages 791 - 806, XP002039972, ISSN: 1088-9051",DISCONTINUED
708,US,S,US D0654985 S,158-090-388-397-86X,2012-02-28,2012,US 201129394682 F,2011-06-20,US 201129394682 F;;US 201129383674 F;;US 32417408 F,2008-09-08,Dosing assembly,,SWAIN ANDREW;;COOPER MARTIN;;BERTUCCI MICHAEL H;;CROSSDALE GARRY W;;DIVERSEY INC,SWAIN ANDREW;;COOPER MARTIN;;BERTUCCI MICHAEL H;;CROSSDALE GARRY W,,https://lens.org/158-090-388-397-86X,Design Right,no,0,3,5,5,0,,,2301;;D23/225,0,0,,,,ACTIVE
709,EP,A2,EP 1339348 A2,027-579-660-244-277,2003-09-03,2003,EP 01985214 A,2001-10-25,US 0151262 W;;US 24452800 P,2000-10-31,PACKAGING AND DELIVERY SYSTEM FOR BONE GRAFT PARTICLES,,SMITH & NEPHEW INC,COOPER MICHAEL B;;RILEY STEPHANIE;;HARBER JAMES C;;MARTIN JEFF,,https://lens.org/027-579-660-244-277,Patent Application,yes,0,0,7,7,0,A61F2/4644;;A61F2/4644;;A61B50/30;;A61B50/30;;A61B50/33;;A61B50/33;;A61B90/94;;A61B90/94;;A61B2050/0065;;A61B2050/0065;;A61F2/0095;;A61F2/0095;;A61F2/4601;;A61F2/4601;;A61F2002/2835;;A61F2002/2835;;A61F2002/3071;;A61F2002/3071;;A61F2250/0089;;A61F2250/0089,B65D25/14;;A61B19/00;;A61B19/02;;A61F2/00;;A61F2/28;;A61F2/46;;B65D77/04;;B65D77/08;;B65D77/20;;B65D81/20,,1,0,,,See references of WO 0239946A3,DISCONTINUED
710,US,S,US D0668744 S,090-294-127-978-948,2012-10-09,2012,US 201229414278 F,2012-02-27,US 201229414278 F;;US 201129394682 F;;US 201129383674 F;;US 32417408 F,2008-09-08,Dosing assembly,,SWAIN ANDREW;;COOPER MARTIN;;BERTUCCI MICHAEL H;;CROSSDALE GARRY W;;DIVERSEY INC,SWAIN ANDREW;;COOPER MARTIN;;BERTUCCI MICHAEL H;;CROSSDALE GARRY W,DIVERSEY INC (2012-03-20),https://lens.org/090-294-127-978-948,Design Right,no,0,4,5,5,0,,,2301;;D23/225,0,0,,,,ACTIVE
711,AU,A1,AU 2009/201147 A1,094-541-843-823-796,2009-04-23,2009,AU 2009/201147 A,2009-03-26,AU 2002/356469 A;;AU 2009/201147 A;;NZ 0200262 W;;NZ 51573101 A;;US 33342201 P,2001-11-26,Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues,,PROTEMIX CORPORATION LTD,WATSON RACHEL NANCY;;LOOMES KERRY MARTIN;;COOPER GARTH JAMES SMITH,,https://lens.org/094-541-843-823-796,Patent Application,no,0,0,9,10,0,A61K38/225;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/92;;G01N2500/00;;G01N2800/044,G01N33/50;;A61K38/22;;A61K38/23;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/15;;G01N33/92,,0,0,,,,DISCONTINUED
712,AU,B2,AU 2019/213311 B2,156-504-095-979-502,2022-12-08,2022,AU 2019/213311 A,2019-08-06,US 201816059423 A,2018-08-09,"A train detection system for a railway track, a method for detecting a train on a railway track, and a controller for a train detection system for detecting a train on a railway track","A train detection system for a railway track, a method for detecting a train on a railway track, and a controller for a train detection system for detecting a train on a railway track The present disclosure relates to a train detection system for a railway track, the railway track defining a first lateral side and a second lateral side opposite the first lateral side, said train detection system comprising: - at least two cameras, said cameras being arranged along the railway track spaced apart from each other, each camera being placed on either the first lateral side or the second lateral side; - at least one passive target, each of said passive targets being placed within the field of view of at least one of the cameras and on the opposite lateral side of the railway track with respect to the at least one of the cameras in whose field of view the respective passive target is placed; and - at least one controller adapted to recognise the at least one passive target in the images provided by at least one of the cameras to the controller in order to determine whether a train is located on the railway track. The present invention also relates to a method for detecting a train on a railway track. The present invention equally relates to a controller for a train detection system for detecting a train on a railway track. Figure 1 Ir uj~ r-Lj",ALSTOM TRANSP TECH,FRIES JEFFREY;;COOPER JARED;;MARTIN PHILLIP;;SNYDER SENECA;;NAGRODSKY NICHOLAS,,https://lens.org/156-504-095-979-502,Granted Patent,no,6,0,8,8,0,B61L29/228;;B61L29/30;;B61L23/041;;B61L23/007;;B61L23/041;;B61L23/34;;B61L29/22;;B61L29/30;;G06T7/0008;;G06T2207/30236;;G08G7/02;;G06V20/48,B61L23/24,,0,0,,,,ACTIVE
713,JP,A,JP 2015096547 A,159-417-794-695-086,2015-05-21,2015,JP 2015006444 A,2015-01-16,US 21622109 P,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE","PROBLEM TO BE SOLVED: To provide a novel compound for treating a patient suffering from a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including cancer.SOLUTION: Disclosed is a hydrochloride salt of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl)methyl sulfamate represented by the formula (I) in the figure, crystalline forms thereof, and solvates thereof.",MILLENNIUM PHARM INC,IAN G ARMITAGE;;REENU CHOPRA;;MARTIN IAN COOPER;;MARIANNE LANGSTON,,https://lens.org/159-417-794-695-086,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02,,2,0,,,"JPN7014002162; Ｎａｔｕｒｅ Ｖｏｌ．４５８, 20090409, ７３２-７３６，ｓｕｐｐｌｅｍｅｎｔａｒｙ ｉｎｆｏｒｍａｔｉｏｎ １-２２;;JPN6016030354; 平山令明: 「有機化合物結晶作製ハンドブック-原理とノウハウ-」 , 20080725, 第５７-５８頁, 丸善株式会社",DISCONTINUED
714,CA,A1,CA 2471833 A1,183-612-952-672-589,2003-06-05,2003,CA 2471833 A,2002-11-26,NZ 51573101 A;;NZ 0200262 W;;US 33342201 P,2001-11-26,METHODS OF COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES,"The invention provides methods of stimulating lipolysis in a mammalian cells and tissues by contacting the cell or tissue with an agonist of a CGRP receptor such as the high affinity CGRP receptor. The agonist may preferentially stimulate the high affinity CGRP receptor compared to the metabolic amylin receptor. Methods for screening for identifying receptor agonists are provided, pharmaceutical compositions comprising such agonists, and therapeutic regimens using such agonists are provided.",PROTEMIX CORP LTD,WATSON RACHEL NANCY;;LOOMES KERRY MARTIN;;COOPER GARTH JAMES SMITH,,https://lens.org/183-612-952-672-589,Patent Application,no,0,0,9,10,15,A61K38/225;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/92;;G01N2500/00;;G01N2800/044,G01N33/50;;A61K38/22;;A61K38/23;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/15;;G01N33/92,,0,0,,,,DISCONTINUED
715,CL,A1,CL 2009000742 A1,179-955-006-201-270,2009-11-13,2009,CL 2009000742 A,2009-03-26,US 3975208 P,2008-03-26,"Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama.","Forma sólida de clorhidrato de bendamustina; composición farmacéutica; método de preparación y su uso en la leucemia linfocitica crónica, Enfermedad de Hodgkin, Linfoma no Hodgkiniano, mieloma múltiple, cáncer de mama.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/179-955-006-201-270,Patent Application,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K31/4184;;A61P35/00;;A61P35/02,,0,0,,,,PENDING
716,KR,A,KR 20120024715 A,195-290-381-031-345,2012-03-14,2012,KR 20117029162 A,2010-05-13,US 21622109 P,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE",,MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/195-290-381-031-345,Patent Application,no,0,1,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/52;;A61P35/00,,0,0,,,,DISCONTINUED
717,SG,A1,SG 175929 A1,032-465-071-923-795,2011-12-29,2011,SG 2011081957 A,2010-05-13,US 21622109 P;;US 2010/0001415 W,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE","Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/032-465-071-923-795,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,,,0,0,,,,PENDING
718,US,B2,US 11628313 B2,042-856-818-318-114,2023-04-18,2023,US 202017087812 A,2020-11-03,US 202017087812 A;;GB 201218307 A;;US 201816230739 A;;US 201514424376 A;;GB 2013052650 W,2012-10-12,Patient monitor,"Images obtained by a camera system ( 10 ) arranged to obtain images of a patient ( 20 ) undergoing radio-therapy are processed by a modeling unit ( 56,58 ) which generates a model of the surface of a patient ( 20 ) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient ( 20 ). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus ( 16 ). This can be facilitated by providing a number or retro-reflective markers ( 30 - 40 ) on a treatment apparatus ( 16 ) and a mechanical couch ( 18 ) used to position the patient ( 20 ) relative to the treatment apparatus ( 16 ) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera ( 10 ).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/042-856-818-318-114,Granted Patent,yes,25,0,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;A61B90/00;;G06T7/285;;G06T7/73;;H04N13/204,,4,0,,,"Aug. 1, 2016 Office Action issued in Chinese Patent Application No. 201380052008.6 (with English translation).;;Jan. 16, 2013 Combined Search and Examination Report issued in GB Patent Application No. 1218307.5.;;Jun. 6, 2016 Examination report received issued in European Patent Application No. 13777329.7.;;Second Office Action dated Feb. 7, 2017 to Chinese patent application No. 201380052008.6.",ACTIVE
719,US,A1,US 2016/0325767 A1,042-117-353-695-729,2016-11-10,2016,US 201415108065 A,2014-12-24,US 201415108065 A;;US 201361920700 P;;US 2014/0072380 W,2013-12-24,SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS,A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,AMSTED RAIL COMPANY INC (2015-09-14),https://lens.org/042-117-353-695-729,Patent Application,yes,0,51,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L27/00;;B61K9/00;;B61K9/04;;B61L25/02;;G01M17/10,,0,0,,,,ACTIVE
720,TW,A,TW 200734352 A,053-167-874-436-591,2007-09-16,2007,TW 95148927 A,2006-12-26,GB 0600114 A,2006-01-05,Growth hormone variations,"The invention relates to novel variants in the growth hormone gene and the corresponding variants in the protein structure and the use of same in the diagnosis of growth hormone dysfunction, hypertension or stroke.",UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN;;LEWIS MARK;;MILLAR DAVID STUART,,https://lens.org/053-167-874-436-591,Patent of Addition,no,0,0,8,8,0,C12N15/11;;C12Q1/6827;;C12Q1/6883;;C07K14/61;;C12Q2600/156,C07K14/61;;C12N15/18;;C12Q1/68;;G01N33/68,,0,0,,,,PENDING
721,AU,B2,AU 2010/248151 B2,092-362-654-953-261,2016-07-14,2016,AU 2010/248151 A,2010-05-13,US 21622109 P;;US 2010/0001415 W,2009-05-14,"Hydrochloride salt of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate",Disclosed is a compound of formula (,MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/092-362-654-953-261,Granted Patent,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/52;;A61P35/00,,0,0,,,,INACTIVE
722,WO,A1,WO 2014/057280 A1,108-152-430-609-06X,2014-04-17,2014,GB 2013052650 W,2013-10-11,GB 201218307 A,2012-10-12,PATIENT MONITOR,"Images obtained by a camera system (10) arranged to obtain stereoscopic images of a patient (20) undergoing radio-therapy are processed by a modeling unit (56,58) which generates a model of the surface of a patient (20) being monitored. Additionally the patient monitoring system processes image data not utilized to generate a model of the surface of a patient being monitored to determine further information concerning the treatment of the patient(20). Such additional data can comprise data identifying the relative location of the patient and a treatment apparatus (16). This can be facilitated by providing a number or retro-reflective markers (30-40) on a treatment apparatus (16) and a mechanical couch (18) used to position the patient (20) relative to the treatment apparatus (16) and monitoring the presence and location of the markers in the portions of the images obtained by the stereoscopic camera (10).",VISION RT LTD,MEIR IVAN;;COOPER KATHRYN;;SMITH NORMAN;;HALE GIDEON;;ALLEN MARTIN,,https://lens.org/108-152-430-609-06X,Patent Application,yes,3,10,16,16,0,A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;G06T7/73;;G06T7/285;;A61N5/1069;;H04N13/204;;A61N5/1081;;A61N5/1049;;G06T7/73;;A61N5/1049;;A61N2005/1059;;H04N13/204;;G06T7/73;;G06T7/285;;A61N2005/1059;;G06T2207/10021;;G06T2207/30196;;G06T2207/30204;;A61B2090/3904;;A61B90/39;;A61B2090/3937;;A61N5/1069;;A61N5/1049;;A61B2576/00;;A61N5/1081;;A61N2005/1074,A61N5/10;;G06T7/00,,0,0,,,,PENDING
723,AU,A1,AU 2010/248151 A1,109-853-438-595-57X,2011-12-01,2011,AU 2010/248151 A,2010-05-13,US 21622109 P;;US 2010/0001415 W,2009-05-14,"Hydrochloride salt of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate","Disclosed is a compound of formula (); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,ARMITAGE IAN G;;REENU CHOPRA;;IAN COOPER MARTIN;;MARIANNE LANGSTON,,https://lens.org/109-853-438-595-57X,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/52;;A61P35/00,,0,0,,,,INACTIVE
724,US,B2,US 10946883 B2,109-160-036-814-635,2021-03-16,2021,US 201816059423 A,2018-08-09,US 201816059423 A,2018-08-09,"Train detection system for a railway track, a method for detecting a train on a railway track, and a controller for a train detection system for detecting a train on a railway track",A train detection system for a railway track defines a first lateral side and a second lateral side opposite the first lateral side. Two cameras are arranged along the railway track spaced apart from each other. Each camera is placed on either the first lateral side or the second lateral side. The system includes at least one passive target. Each of the passive targets is placed within the field of view of at least one of the cameras and on the opposite lateral side of the railway track with respect to the at least one of the cameras in whose field of view the respective passive target is placed. The system also includes at least one controller adapted to recognise the passive target in the images provided by at least one of the cameras to the controller to determine whether a train is located on the railway track.,ALSTOM TRANSP TECH,FRIES JEFFREY;;COOPER JARED;;MARTIN PHILLIP;;SNYDER SENECA;;NAGRODSKY NICHOLAS,ALSTOM TRANSPORT TECHNOLOGIES (2018-08-20),https://lens.org/109-160-036-814-635,Granted Patent,yes,13,0,8,8,0,B61L29/228;;B61L29/30;;B61L23/041;;B61L23/007;;B61L23/041;;B61L23/34;;B61L29/22;;B61L29/30;;G06T7/0008;;G06T2207/30236;;G08G7/02;;G06V20/48,B61L29/30;;B61L23/00;;B61L23/04;;B61L23/34;;B61L29/22;;G06K9/00;;G06T7/00;;G08G7/02,,2,0,,,"European Search Report issued in corresponding EP 19 19 0992 dated Dec. 4, 2019.;;Oh, S. et al., “Development of a Vision based Railway Platform Safeguard” 9th World Congress on Railway Research, pp. 1-10 (May 2011).",ACTIVE
725,AU,A2,AU 2002/356469 A2,107-188-424-290-230,2003-06-10,2003,AU 2002/356469 A,2002-11-26,NZ 51573101 A;;NZ 0200262 W;;US 33342201 P,2001-11-26,Methods of compositions for normalizing lipid levels in mammalian tissues,,PROTEMIX CORPORATION LTD,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;WATSON RACHEL NANCY,,https://lens.org/107-188-424-290-230,Patent Application,no,0,0,9,10,0,A61K38/225;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/92;;G01N2500/00;;G01N2800/044,G01N33/50;;A61K38/22;;A61K38/23;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/15;;G01N33/92,,0,0,,,,DISCONTINUED
726,US,S,US D0640349 S,141-686-263-706-77X,2011-06-21,2011,US 201129383674 F,2011-01-20,US 201129383674 F;;US 32417408 F,2008-09-08,Dosing assembly,,DIVERSEY INC,SWAIN ANDREW;;COOPER MARTIN;;BERTUCCI MICHAEL H;;CROSSDALE GARRY W,,https://lens.org/141-686-263-706-77X,Design Right,no,0,4,5,5,0,,,2301;;D23/225;;D9/527,0,0,,,,ACTIVE
727,PE,A1,PE 20161222 A1,154-838-730-334-832,2016-12-01,2016,PE 2016001604 A,2010-05-13,US 21622109 P,2009-05-14,"SAL DE CLORHIDRATO DE ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHIDRO-1H-INDEN-1-ILAMINO]-7H-PIRROLO[2,3-D]PIRIMIDIN-7-IL}-2-HIDROXICICLOPENTIL)METILSULFAMATO","Se refiere a un cristal de clorhidrato ((1S,2S,4R)-4-{4-[(1S)-2,3-dihidro-1H-inden-1-ilamino]-7H-pirrolo[2,3-D]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato de formula I caracterizado por un patron XRPD que tiene picos de angulos 2(theta): 7.3º, 9.6º, 13.6º, 14.5º, 14.8º, 16.5º, 17.0º, 17.3º, 18.0º, 19.1º, 20.1º, 21.1º, 21.7º, 23.7º ± 0.2 grados. Tambien se refiere a un metodo de obtencion y a una formulacion farmaceutica. Dicho cristal es un inhibidor de enzima activante de E1, siendo util en el tratamiento del cancer",MILLENNIUM PHARM INC,ARMITAGE IAN G;;LANGSTON MARIANNE;;COOPER MARTIN IAN;;CHOPRA REENU,,https://lens.org/154-838-730-334-832,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,A61P35/00;;A61K31/52;;C07D487/04,,0,0,,,,DISCONTINUED
728,WO,A2,WO 2004/065614 A2,166-832-846-695-312,2004-08-05,2004,IB 0306467 W,2003-01-29,NZ 51692002 A,2002-01-29,SUPPRESSION OF CYTOTOXIC PROTEIN CONFORMERS,Methods of preventing amyloid associated disease comprising preventing protofibril formation using polycyclic compounds related screens and methodologies disclosed.,PROTEMIX CORP LTD;;COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,,https://lens.org/166-832-846-695-312,Patent Application,yes,0,10,9,9,0,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;G01N33/6896;;G01N2500/00;;A61P25/00;;A61P25/28;;A61P3/00;;A61P43/00;;A61P5/48;;A61P5/50;;A61P3/10;;A61K31/655;;A61K31/473;;G01N33/6896;;A61K31/00;;A61K31/015;;G01N2500/00;;A61K31/5415;;A61K31/65,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;A61P5/48;;A61P5/50;;A61P25/28;;A61P43/00;;G01N33/68,,0,0,,,,PENDING
729,EP,A2,EP 1270044 A2,163-118-227-931-446,2003-01-02,2003,EP 02254207 A,2002-06-17,GB 0114869 A;;US 30534601 P,2001-06-18,Wound healing biomarkers,"This invention provides biomarkers such as genes and the corresponding mRNA transcripts or protein products that are identified as being involved in wound healing processes. Also provided are methods for identification of compounds useful for the treatment of wounds, wound healing disorders or inflammation and compounds identified by such methods. Methods are provided for monitoring the progress of wound healing and for identification of individuals with wound healing disorders.",PFIZER LTD;;PFIZER,BURSLEM MARTYN FRANK;;COOPER LISA;;JOHNSON CLAIRE MICHELLE;;MARTIN PAUL,,https://lens.org/163-118-227-931-446,Patent Application,yes,0,9,5,6,39,A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;A61P29/00;;C12Q1/6883;;C12Q1/6883;;C07K14/47;;C07K14/47;;C12Q2600/158;;C12Q2600/158;;G01N33/5091;;G01N33/5091;;G01N33/6893;;G01N33/6893;;G01N33/86;;G01N33/86;;G01N33/92;;G01N33/92,A61K45/00;;A61K48/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;C07K14/47;;C12N15/09;;C12Q1/02;;C12Q1/68;;G01N33/15;;G01N33/50;;G01N33/68;;G01N33/86;;G01N33/92,,0,0,,,,DISCONTINUED
730,CN,A,CN 1688299 A,010-573-675-398-565,2005-10-26,2005,CN 03807531 A,2003-01-29,NZ 51692002 A,2002-01-29,Suppression of cytotoxic protein conformers,,PROTEMIX CORP LTD,SMITH COOPER GARTH JAMES;;MARTIN LOOMES KERRY;;FIONA AITKEN JACQUELINE,"PROT MEEKS FOUND CO., LTD. (2006-03-17)",https://lens.org/010-573-675-398-565,Patent Application,no,0,1,9,9,0,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;G01N33/6896;;G01N2500/00;;A61P25/00;;A61P25/28;;A61P3/00;;A61P43/00;;A61P5/48;;A61P5/50;;A61P3/10;;A61K31/655;;A61K31/473;;G01N33/6896;;A61K31/00;;A61K31/015;;G01N2500/00;;A61K31/5415;;A61K31/65,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;A61P5/48;;A61P5/50;;A61P25/28;;A61P43/00;;G01N33/68,,0,0,,,,DISCONTINUED
731,NZ,A,NZ 596470 A,033-943-585-479-564,2014-04-30,2014,NZ 59647010 A,2010-05-13,US 2010/0001415 W;;US 21622109 P,2009-05-14,"Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate","596470 Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an El activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/033-943-585-479-564,Patent Application,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/52;;A61P35/00,,0,0,,,,DISCONTINUED
732,EP,A1,EP 1461068 A1,035-542-514-023-047,2004-09-29,2004,EP 02803945 A,2002-11-26,NZ 0200262 W;;NZ 51573101 A;;US 33342201 P,2001-11-26,METHODS OF COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES,,PROTEMIX CORP LTD,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;WATSON RACHEL NANCY,PROTEMIX CORPORATION LIMITED (2010-11-10);;PHILERA NEW ZEALAND LIMITED (2011-11-16),https://lens.org/035-542-514-023-047,Patent Application,yes,0,0,9,10,0,A61K38/225;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/92;;G01N2500/00;;G01N2800/044,G01N33/50;;A61K38/22;;A61K38/23;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/50;;A61P9/12;;A61P43/00;;G01N33/15;;G01N33/92,,0,0,,,,DISCONTINUED
733,WO,A2,WO 2007/077423 A2,045-473-499-650-910,2007-07-12,2007,GB 2006004913 W,2006-12-27,GB 0600114 A,2006-01-05,GROWTH HORMONE VARIATIONS,"The invention relates to novel variants in the growth hormone gene and the corresponding variants in the protein structure and the use of same in the diagnosis of growth hormone dysfunction, hypertension or stroke.",UNIV CARDIFF;;COOPER DAVID NEIL;;HORAN MARTIN;;LEWIS MARK;;MILLAR DAVID STUART,COOPER DAVID NEIL;;HORAN MARTIN;;LEWIS MARK;;MILLAR DAVID STUART,,https://lens.org/045-473-499-650-910,Patent Application,yes,0,0,8,8,7,C12N15/11;;C12Q1/6827;;C12Q1/6883;;C07K14/61;;C12Q2600/156,C07K14/61;;C12N15/18;;C12Q1/68;;G01N33/74,,0,0,,,,PENDING
734,CA,A1,CA 2388761 A1,079-608-106-964-548,2002-12-18,2002,CA 2388761 A,2002-06-17,GB 0114869 A;;US 30534601 P,2001-06-18,WOUND HEALING BIOMARKERS,"This invention provides biomarkers such as genes and the corresponding mR NA transcripts or protein products that are identified as being involved in wou nd healing processes. Also provided are methods for identification of compounds useful for the treatment of wounds, wound healing disorders or inflammation and compounds identified by such methods. Methods are provided for monitoring the progress of wound healing and for identification of individuals with wound healing disorders.",PFIZER,COOPER LISA;;BURSLEM MARTYN FRANK;;JOHNSON CLAIRE MICHELLE;;MARTIN PAUL,,https://lens.org/079-608-106-964-548,Patent Application,no,0,1,5,6,39,A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;A61P29/00;;C12Q1/6883;;C12Q1/6883;;C07K14/47;;C07K14/47;;C12Q2600/158;;C12Q2600/158;;G01N33/5091;;G01N33/5091;;G01N33/6893;;G01N33/6893;;G01N33/86;;G01N33/86;;G01N33/92;;G01N33/92,A61K45/00;;A61K48/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P27/06;;C07K14/47;;C12N15/09;;C12Q1/02;;C12Q1/68;;G01N33/15;;G01N33/50;;G01N33/68;;G01N33/86;;G01N33/92,,0,0,,,,DISCONTINUED
735,CA,A1,CA 3193952 A1,078-701-838-668-808,2022-04-14,2022,CA 3193952 A,2021-10-05,US 202063087623 P;;US 202063116597 P;;US 202163229019 P;;US 202163239859 P;;US 2021/0053636 W,2020-10-05,DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES,"The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CDS) bispecific antibodies.",GENENTECH INC,FINE BERNARD MARTIN;;SUMIYOSHI TEIKO;;LI MENGSONG;;COOPER JAMES NIALL,,https://lens.org/078-701-838-668-808,Patent Application,no,0,1,12,12,0,C07K16/2809;;C07K16/283;;C07K2317/31;;A61K2039/545;;A61K2039/54;;A61K2039/507;;A61P35/00;;C07K2317/24;;C07K2317/71;;C07K2317/52;;C07K2317/73;;C07K16/2809;;C07K2317/71;;A61K2039/545;;C07K2317/31;;A61P35/00;;C07K2317/24;;A61K2039/54;;C07K2317/52;;A61K2039/507;;C07K16/283;;C07K16/283;;C07K16/2809;;A61P35/00;;C07K2317/31;;C07K2317/24;;C07K2317/71;;C07K2317/52;;A61K2039/507;;A61K2039/54;;A61K2039/545;;A61P35/00;;A61K31/137;;A61K31/167;;A61K31/573;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2809;;C07K16/283;;C07K16/2866;;C07K2317/24;;C07K2317/31;;C07K2317/41;;C07K2317/524;;C07K2317/526;;C07K2317/71,C07K16/28,,0,0,,,,PENDING
736,WO,A1,WO 2003/063880 A1,107-219-065-782-071,2003-08-07,2003,NZ 0300009 W,2003-01-29,NZ 51692002 A,2002-01-29,DISRUPTION OF ISLET AMYLOID BY POLYCYCLIC COMPOUNDS,Methods of preventing amyloid associated disease comprising preventing protofibril formation using polycyclic compounds related screens and methodologies disclosed.,PROTEMIX CORP LTD;;COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,,https://lens.org/107-219-065-782-071,Patent Application,yes,5,0,9,9,0,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;G01N33/6896;;G01N2500/00;;A61P25/00;;A61P25/28;;A61P3/00;;A61P43/00;;A61P5/48;;A61P5/50;;A61P3/10;;A61K31/655;;A61K31/473;;G01N33/6896;;A61K31/00;;A61K31/015;;G01N2500/00;;A61K31/5415;;A61K31/65,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;A61P5/48;;A61P5/50;;A61P25/28;;A61P43/00;;G01N33/68,,7,5,008-634-733-693-111;;025-677-285-000-997;;012-703-027-353-145;;117-394-093-906-028;;012-793-168-468-319,10899433;;10.1016/s0925-4439(00)00034-x;;10.1016/s0014-5793(00)02380-2;;11163366;;7991613;;10.1073/pnas.91.25.12243;;pmc45413;;10.1074/jbc.m102883200;;11445568;;10.1042/0264-6021:3430419;;pmc1220570;;10.1042/bj3430419;;10510309,"DATABASE WPI Derwent World Patents Index; Class B05, AN 1996-518298/51;;DATABASE WPI Derwent World Patents Index; Class B04, AN 1999-404944/34;;FINDEIS MARK A.: ""Approaches to discovery and characterisation of inhibitors of amyloid beta-peptide polymerisation"", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1502, 2000, pages 76 - 84;;FORLONI G. ET AL.: ""Anti-amyloidogenic activity of tetracyclines: studies in vitro"", FEBS LETTERS, vol. 487, 2001, pages 404 - 407, XP004337906, DOI: doi:10.1016/S0014-5793(00)02380-2;;LORENZO A. ET AL.: ""beta-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red"", PROC. NATL. ACAD. SCI. USA, vol. 91, December 1994 (1994-12-01), pages 12243 - 12247;;AZRIEL R. ET AL.: ""Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide"", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 36, 7 September 2001 (2001-09-07), pages 34156 - 34161, XP002555838, DOI: doi:10.1074/JBC.M102883200;;HOWLETT D.R. ET AL.: ""Common structural features determine the effectiveness of carvedilkol, daunomycin and rolitetracyckline as inhibitors of Alzheimer beta-amyloid fibril formation"", JOURNAL OF BIOCHEMISTRY, vol. 343, 1999, pages 419 - 423",PENDING
737,US,A1,US 2015/0115415 A1,178-936-009-672-051,2015-04-30,2015,US 201314067661 A,2013-10-30,US 201314067661 A,2013-10-30,Inkjet Printing on Substrates,"Methods, apparatuses and devices relate to inkjet printing a covering layer on at least a first side of a substrate in a peripheral region thereof are discussed.",INFINEON TECHNOLOGIES AUSTRIA,MISCHITZ MARTIN;;GASSER KARL HEINZ;;COOPER JOHN;;WANG KAE-HORNG,INFINEON TECHNOLOGIES AUSTRIA AG (2013-11-04),https://lens.org/178-936-009-672-051,Patent Application,yes,0,5,3,3,0,H01L21/56;;H01L21/6715;;H01L2924/0002;;H01L21/78;;H01L21/02118;;H01L21/02288;;H01L21/56;;H01L2924/0002;;H01L21/6715;;H01L21/78;;H01L21/02118;;H01L21/02288;;H01L23/293;;H01L21/67,H01L21/02;;H01L23/29,257/632;;438/780,0,0,,,,ACTIVE
738,TW,A,TW 202221037 A,011-000-508-720-498,2022-06-01,2022,TW 110137092 A,2021-10-05,US 202063087623 P;;US 202063116597 P;;US 202163229019 P;;US 202163239859 P,2020-10-05,Dosing for treatment with anti-FCRH5/anti-CD3 bispecific antibodies,"The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.",GENENTECH INC,FINE BERNARD MARTIN;;SUMIYOSHI TEIKO;;LI MENGSONG;;COOPER JAMES NIALL,,https://lens.org/011-000-508-720-498,Patent of Addition,no,0,0,12,12,0,C07K16/2809;;C07K16/283;;C07K2317/31;;A61K2039/545;;A61K2039/54;;A61K2039/507;;A61P35/00;;C07K2317/24;;C07K2317/71;;C07K2317/52;;C07K2317/73;;C07K16/2809;;C07K2317/71;;A61K2039/545;;C07K2317/31;;A61P35/00;;C07K2317/24;;A61K2039/54;;C07K2317/52;;A61K2039/507;;C07K16/283;;C07K16/283;;C07K16/2809;;A61P35/00;;C07K2317/31;;C07K2317/24;;C07K2317/71;;C07K2317/52;;A61K2039/507;;A61K2039/54;;A61K2039/545;;A61P35/00;;A61K31/137;;A61K31/167;;A61K31/573;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61K2039/545;;C07K16/2809;;C07K16/283;;C07K16/2866;;C07K2317/24;;C07K2317/31;;C07K2317/41;;C07K2317/524;;C07K2317/526;;C07K2317/71,C07K16/28;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
739,CA,C,CA 2761256 C,006-958-146-555-601,2021-01-05,2021,CA 2761256 A,2010-05-13,US 21622109 P;;US 2010/0001415 W,2009-05-14,"HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE","Disclosed is a compound of formula (I); crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a pa-tient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.",MILLENNIUM PHARM INC,ARMITAGE IAN G;;CHOPRA REENU;;COOPER MARTIN IAN;;LANGSTON MARIANNE,,https://lens.org/006-958-146-555-601,Granted Patent,no,0,0,36,36,0,C07D487/04;;C07D487/04;;A61K31/519;;A61P35/00;;A61P35/02;;A61P35/04;;A61P43/00;;A61K31/519;;A61K31/522;;C07D487/04;;C07D487/04;;A61K31/519,C07D487/04;;A61K31/52;;A61P35/00,,0,0,,,,INACTIVE
740,NL,A1,NL 1033169 A1,106-993-144-904-977,2007-07-09,2007,NL 1033169 A,2007-01-04,GB 0600114 A,2006-01-05,Groeihormoonvariaties.,,UNIV CARDIFF,COOPER DAVID NEIL;;HORAN MARTIN;;LEWIS MARK;;MILLAR DAVID STUART,,https://lens.org/106-993-144-904-977,Granted Patent,no,0,0,8,8,0,C12N15/11;;C12Q1/6827;;C12Q1/6883;;C07K14/61;;C12Q2600/156,C12Q1/68;;C07K14/61,,0,0,,,,ACTIVE
741,US,A1,US 2003/0186946 A1,151-637-752-486-909,2003-10-02,2003,US 35489303 A,2003-01-29,NZ 51692002 A,2002-01-29,Suppression of cytotoxic protein conformers,"
   Methods of preventing amyloid associated disease comprising preventing protofibril formation using polycyclic compounds related screens and methodologies disclosed. 
",COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,COOPER GARTH JAMES SMITH;;LOOMES KERRY MARTIN;;AITKEN JACQUELINE FIONA,PROTEMIX CORPORATION LIMITED (2003-05-21);;PROTEMIX DISCOVERY LIMITED (2005-06-08),https://lens.org/151-637-752-486-909,Patent Application,yes,10,24,9,9,0,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;G01N33/6896;;G01N2500/00;;A61P25/00;;A61P25/28;;A61P3/00;;A61P43/00;;A61P5/48;;A61P5/50;;A61P3/10;;A61K31/655;;A61K31/473;;G01N33/6896;;A61K31/00;;A61K31/015;;G01N2500/00;;A61K31/5415;;A61K31/65,A61K31/00;;A61K31/015;;A61K31/473;;A61K31/5415;;A61K31/65;;A61K31/655;;A61P5/48;;A61P5/50;;A61P25/28;;A61P43/00;;G01N33/68,51415;;514/228.2;;514/297;;X51428;;514/152;;514/765,0,0,,,,DISCONTINUED
742,SE,D0,SE 9702200 D0,169-387-779-564-633,1997-06-09,1997,SE 9702200 A,1997-06-09,SE 9702200 A,1997-06-09,Novel compounds,,ASTRA PHARMA PROD,CHESHIRE DAVID;;CLADINGBOEL DAVID;;COOPER MARTIN;;HARDERN DAVID;;STOCKS MICHAEL,,https://lens.org/169-387-779-564-633,Patent Application,no,0,0,1,30,0,,C07D/,,0,0,,,,PENDING
743,EP,A1,EP 3608202 A1,179-052-537-660-831,2020-02-12,2020,EP 19190992 A,2019-08-09,US 201816059423 A,2018-08-09,"A TRAIN DETECTION SYSTEM FOR A RAILWAY TRACK, A METHOD FOR DETECTING A TRAIN ON A RAILWAY TRACK, AND A CONTROLLER FOR A TRAIN DETECTION SYSTEM FOR DETECTING A TRAIN ON A RAILWAY TRACK","The present disclosure relates to a train detection system for a railway track, the railway track defining a first lateral side and a second lateral side opposite the first lateral side, said train detection system comprising: 
- at least two cameras, said cameras being arranged along the railway track spaced apart from each other, each camera being placed on either the first lateral side or the second lateral side; 
- at least one passive target, each of said passive targets being placed within the field of view of at least one of the cameras and on the opposite lateral side of the railway track with respect to the at least one of the cameras in whose field of view the respective passive target is placed; and 
- at least one controller adapted to recognise the at least one passive target in the images provided by at least one of the cameras to the controller in order to determine whether a train is located on the railway track. The present invention also relates to a method for detecting a train on a railway track. The present invention equally relates to a controller for a train detection system for detecting a train on a railway track.
",ALSTOM TRANSP TECH,FRIES JEFFREY;;COOPER JARED;;MARTIN PHILLIP;;SNYDER SENECA;;NAGRODSKY NICHOLAS,,https://lens.org/179-052-537-660-831,Patent Application,yes,3,0,8,8,0,B61L29/228;;B61L29/30;;B61L23/041;;B61L23/007;;B61L23/041;;B61L23/34;;B61L29/22;;B61L29/30;;G06T7/0008;;G06T2207/30236;;G08G7/02;;G06V20/48,B61L29/22;;B61L23/04;;B61L29/30,,1,0,,,"S OH: ""Development of a Vision based Railway Platform Safeguard"", 9TH WORLD CONGRESS ON RAILWAY RESEARCH, 22 May 2011 (2011-05-22), pages 1 - 10, XP055473839, Retrieved from the Internet <URL:http://www.railway-research.org/IMG/pdf/poster_oh_sehchan.pdf> [retrieved on 20180509]",ACTIVE
744,ZA,B,ZA 964156 B,182-983-387-809-090,1996-12-03,1996,ZA 964156 A,1996-05-23,GB 9511192 A,1995-06-02,Apparatus and method of establishment and maintaining communication paths in a wireless telecommunications system,,DSC COMMUNICATIONS,BHAGALIA SHASHIKANT;;COOPER IAN LESLIE;;THOMPSON JONATHAN ANDREW;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER;;YEUNG JOEMANNE CHI CHEUNG,,https://lens.org/182-983-387-809-090,Granted Patent,no,0,0,7,251,0,H04B1/70735;;H04B1/70775;;H04B7/2628;;H04L41/0226;;H04L41/0233;;H04L43/00;;H04W84/14;;H04L41/0233;;H04B1/70735;;H04B7/2628;;H04L43/00;;H04W84/14;;H04B1/70775;;H04L41/0226;;H04L69/32;;H04L69/08,H04B1/707;;H04B7/26;;H04L12/24;;H04L12/26;;H04L12/28;;H04L29/06;;H04L29/08;;H04W84/14,,0,0,,,,EXPIRED
745,ES,T3,ES 2150129 T3,178-081-960-710-222,2000-11-16,2000,ES 96917977 T,1996-06-03,GB 9510870 A;;GB 9511167 A;;GB 9511189 A;;GB 9511192 A;;GB 9513168 A;;GB 9513172 A;;GB 9513166 A;;GB 9513170 A;;GB 9511546 A,1995-06-02,APARATO Y PROCEDIMIENTO DE ESTABLECIMIENTO Y MANTENIMIENTO DE CAMINOS DE COMUNICACION EN UN SISTEMA DE TELECOMUNICACIONES INALAMBRICO.,"EL RECEPTOR (202) DE UN TERMINAL DEL SUSCRIPTOR (20) COMPARA UN CODIGO Y UNA FASE DE UNA SECUENCIA DE CODIGO MAESTRO EN UNA SEÑAL (212) A FAVOR DEL ENLACE CON UN CODIGO Y UNA FASE DE UNA SECUENCIA CODIGO SERVIDOR DEL RECEPTOR (202). EL RECEPTOR (202) AJUSTA LA FASE DE LA SECUENCIA CODIGO SERVIDOR HASTA QUE SE OBTIENE UNA CONCORDANCIA CON LA SECUENCIA CODIGO MAESTRO. LA SEÑAL (212) A FAVOR DEL ENLACE INCLUYE UN CANAL (224) DE CABECERA QUE TIENE UNA SEÑAL DE CONTROL (236) DE POTENCIA, UNA SEÑAL (234) DE SINCRONIZACION DE CODIGO Y UNA SEÑAL (232) DE ALINEACION DE TRAMA. UN RECEPTOR (206) EN EL TERMINAL CENTRAL (10) SUPERVISA UNA SEÑAL (214) DE ENLACE DE RETORNO TRANSMITIDA POR EL TRANSMISOR (204) EN EL TERMINAL DEL ABONADO Y SUMINISTRA CAMBIOS A LA SEÑAL (234) DE SINCRONIZACION DE CODIGO, DE FORMA QUE EL TRANSMISOR (204) ESTE SINCRONIZADO AL RECEPTOR (206). EL RECEPTOR (202) SUPERVISA LA SEÑAL (212) DEL ENLACE DE IDA PARA IDENTIFICAR LA SEÑAL (232) DE ALINEACION DE TRAMA Y ESTABLECE LA RUTA DECOMUNICACION DEL ENLACE DE IDA CUANDO DOS SEÑALES (232) DE ALINEACION DE TRAMA SUCESIVAS SE IDENTIFICAN. EN UN MODO DE ADQUISICION DURANTE EL ESTABLECIMIENTO DE LA RUTA DE COMUNICACION DEL ENLACE DE IDA, LA SEÑAL (212) DEL ENLACE DE IDA ES TRANSMITIDA A UN NIVEL DE ALTA POTENCIA Y A BAJA VELOCIDAD Y TRANSMISION. EN UN MODO DE ESPERA, TRAS EL ESTABLECIMIENTO DE LA RUTA DE COMUNICACION DEL ENLACE DE IDA, LA SEÑAL (212) DEL ENLACE DE IDA ES TRANSMITIDA A UN BAJO NIVEL DE POTENCIA Y A UNA BAJA VELOCIDAD DE TRANSMISION. EN UN MODO DE TRAFICO, TRAS UNA PETICION DE TRANSMISION DE COMUNICACIONES INALAMBRICA, LA SEÑAL (212) DEL ENLACE DE IDA ES TRANSMITIDA A UN ALTO NIVEL DE POTENCIA Y A UNA ALTA VELOCIDAD DE TRANSMISION.",AIRSPAN NETWORKS INC,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;BHAGALIA SHASHIKANT;;COOPER IAN LESLIE;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/178-081-960-710-222,Granted Patent,no,0,0,8,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/0631;;H04L41/069;;H04L41/0816;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14;;H04L69/32;;H04L69/325;;H04L69/324,G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J3/06;;H04J11/00;;H04J13/00;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04L29/08;;H04Q11/04;;H04W52/00;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
746,US,B1,US 6175560 B1,124-514-426-192-738,2001-01-16,2001,US 97358198 A,1998-03-16,US 97358198 A;;GB 9510870 A;;GB 9511167 A;;GB 9511189 A;;GB 9511192 A;;GB 9511546 A;;GB 9513166 A;;GB 9513168 A;;GB 9513170 A;;GB 9513172 A;;US 9608565 W,1995-06-02,Apparatus and method of establishing and maintaining communication paths in a wireless telecommunications system,A wireless telecommunications systems (1) includes a central terminal (10) for transmitting and receiving radio frequency signals to and from a subscriber terminal (20). A downlink communication path is established from a transmitter (200) of the central terminal (10) to a receiver (202) of the subscriber terminal (20). A downlink signal (212) is transmitted from the transmitter (200) to the receiver (202) during setup and operation of the wireless telecommunications system (1). The receiver (202) of the subscriber terminal (20) compares a code and phase of a master code sequence that includes an orthogonal code in the downlink signal (212) to a code and phase of a slave code sequence of the receiver (202). The receiver (202) adjusts the phase of the slave code sequence until a match is obtained with the master code sequence. The receiver (202) monitors the downlink signal (212) to identify the frame alignment signal (232) and establishes the downlink communication path when two successive frame alignment signals (232) are identified. A channel identifier signal within the downlink signal is identified and used to identify the orthogonal code included in the master code sequence. The channel identifier signal is matched to a reference identifier code to verify that the correct downlink signal is being read.,AIRSPAN NETWORKS INC,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN L;;LYSEJKO MARTIN;;COOPER GUY A;;THOMPSON JONATHAN A,DSC TELECOM L.P. A TEXAS LIMITED PARTNERSHIP (1995-08-13);;AIRSPAN MERGER CORPORATION (1999-08-06);;AIRSPAN NETWORKS INC (1999-12-15);;DSC TELECOM L.P (1998-01-01);;AIRSPAN COMMUNICATIONS CORPORATION (1999-08-06);;WI-LAN INC (2009-06-22);;MONUMENT BANK OF INTELLECTUAL PROPERTY LLC (2016-02-09),https://lens.org/124-514-426-192-738,Granted Patent,yes,7,53,1,251,0,H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B2201/70702;;H04J13/00;;H04L41/0226;;H04L41/0233;;H04L41/0654;;H04L41/0681;;H04L41/22;;H04W52/08;;H04W52/50;;H04W84/14;;H04J13/00;;H04B2201/70702;;H04W52/08;;H04W84/14;;H04B1/70775;;H04W52/50;;H04B1/707;;H04B1/7075;;H04L41/0233;;H04B1/70735;;H04L41/0654;;H04B1/7077;;H04L41/0226;;H04L41/22;;H04L41/0681,H04B1/707;;H04B7/005;;H04J11/00;;H04J13/00;;H04J13/02;;H04L12/24;;H04L12/28;;H04L12/56;;H04L29/06;;H04W52/00;;H04W52/08;;H04W52/50;;H04W84/14,370/342;;370/320,1,1,157-059-854-230-206,10.1002/ecja.4400660808,"Masayasu Hata, ""Frame Synchronization Characteristics in Degraded Bit-Error-Rate Conditions and Its Improvements"", Electronics and Communications in Japan, vol. 66-B, No. 8, 1983, pp. 53-62.",EXPIRED
747,EP,A1,EP 0872026 A1,036-493-078-066-769,1998-10-21,1998,EP 96917977 A,1996-06-03,GB 9510870 A;;GB 9511167 A;;GB 9511189 A;;GB 9511192 A;;GB 9511546 A;;GB 9513168 A;;GB 9513172 A;;GB 9513166 A;;GB 9513170 A;;US 9608565 W,1995-06-02,APPARATUS AND METHOD OF ESTABLISHING AND MAINTAINING COMMUNICATION PATHS IN A WIRELESS TELECOMMUNICATIONS SYSTEM,,DSC COMMUNICATIONS,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;BHAGALIA SHASHIKANT;;COOPER IAN LESLIE;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,AIRSPAN NETWORKS INC. (2000-10-18);;AIRSPAN COMMUNICATIONS CORPORATION (1999-03-17),https://lens.org/036-493-078-066-769,Patent Application,yes,0,0,8,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/0631;;H04L41/069;;H04L41/0816;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14;;H04L69/32;;H04L69/325;;H04L69/324,G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J3/06;;H04J11/00;;H04J13/00;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04L29/08;;H04Q11/04;;H04W52/00;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
748,EP,B1,EP 0872026 B1,068-588-090-553-220,2000-08-16,2000,EP 96917977 A,1996-06-03,GB 9510870 A;;GB 9511167 A;;GB 9511189 A;;GB 9511192 A;;GB 9511546 A;;GB 9513168 A;;GB 9513172 A;;GB 9513166 A;;GB 9513170 A;;US 9608565 W,1995-06-02,APPARATUS AND METHOD OF ESTABLISHING AND MAINTAINING COMMUNICATION PATHS IN A WIRELESS TELECOMMUNICATIONS SYSTEM,,AIRSPAN COMM CORP,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;BHAGALIA SHASHIKANT;;COOPER IAN LESLIE;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,AIRSPAN NETWORKS INC. (2000-10-18);;AIRSPAN COMMUNICATIONS CORPORATION (1999-03-17),https://lens.org/068-588-090-553-220,Granted Patent,yes,4,1,8,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/0631;;H04L41/069;;H04L41/0816;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14;;H04L69/32;;H04L69/325;;H04L69/324,G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J3/06;;H04J11/00;;H04J13/00;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04L29/08;;H04Q11/04;;H04W52/00;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,1,0,,,"ELECTRONICS AND COMMUNICATIONS IN JAPAN, vol. 66, no. 8, August 1983, NEW YORK US, pages 53-62, XP002013763 HATA: ""Frame synchronization characteristics in degraded bit-error-rate conditions and its improvement""",EXPIRED
749,WO,A1,WO 1996/038930 A1,083-947-728-661-673,1996-12-05,1996,US 9608565 W,1996-06-03,GB 9510870 A;;GB 9511167 A;;GB 9511192 A;;GB 9511189 A;;GB 9511546 A;;GB 9513170 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A,1995-06-02,APPARATUS AND METHOD OF ESTABLISHING AND MAINTAINING COMMUNICATION PATHS IN A WIRELESS TELECOMMUNICATIONS SYSTEM,"The receiver (202) of a subscriber terminal (20) compares a code and phase of a master code sequence in the downlink signal (212) to a code and phase of a slave code sequence of the receiver (202). The receiver (202) adjusts the phase of the slave code sequence until a match is obtained with the master code sequence. The downlink signal (212) includes an overhead channel (224) having a power control signal (236), a code synchronization signal (234), and a frame alignment signal (232). A receiver (206) in the central terminal (10) monitors an uplink signal (214) transmitted by the transmitter (204) in the subscriber terminal and provides changes to the code synchronization signal (234) such that the transmitter (204) is synchronized to the receiver (206). The receiver (202) monitors the downlink signal (212) to identify the frame alignment signal (232) and establishes the downlink communication path when two successive frame alignment signals (232) are identified. In an acquisition mode during establishment of the downlink communication path, the downlink signal (212) is transmitted at a high power level and a low transmit rate. In a standby mode after establishment of the downlink communication path, the downlink signal (212) is transmitted at a low power level and a low transmit rate. In a traffic mode upon a request for wireless communication transmission, the downlink signal (212) is transmitted at a high power level and a high transmit rate.",DSC COMMUNICATIONS;;YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;BHAGALIA SHASHIKANT;;COOPER IAN LESLIE;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;BHAGALIA SHASHIKANT;;COOPER IAN LESLIE;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/083-947-728-661-673,Patent Application,yes,6,13,8,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/0631;;H04L41/069;;H04L41/0816;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14;;H04L69/32;;H04L69/325;;H04L69/324,G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J3/06;;H04J11/00;;H04J13/00;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04L29/08;;H04Q11/04;;H04W52/00;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,1,1,157-059-854-230-206,10.1002/ecja.4400660808,"HATA: ""Frame synchronization characteristics in degraded bit-error-rate conditions and its improvement"", ELECTRONICS AND COMMUNICATIONS IN JAPAN, vol. 66, no. 8, August 1983 (1983-08-01), NEW YORK US, pages 53 - 62, XP002013763",PATENTED
750,BR,A,BR 9609300 A,122-856-576-851-230,1999-06-15,1999,BR 9609300 A,1996-06-03,GB 9510870 A;;GB 9511167 A;;GB 9511192 A;;GB 9511189 A;;US 9608565 W,1995-06-02,Aparelho e processo para estabelecer e manter trajetórias de comunicac o em sistema de telecomunicac o sem fio,,DSC COMMUNICATIONS,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;BHAGALIA SHASHIKANT;;COOPER IAN LESLIE;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/122-856-576-851-230,Patent Application,no,0,0,8,251,0,H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04L12/403;;H04L41/0226;;H04L41/0233;;H04L41/0654;;H04L41/0677;;H04L41/069;;H04L41/22;;H04L63/08;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/13199;;H04Q2213/13216;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/52;;H04W84/14;;H04L69/08;;H04L69/32;;H04B1/7073;;H04L69/08;;H04L69/32,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04L12/24;;H04L12/28;;H04L12/403;;H04L29/06;;H04L29/08;;H04W52/04;;H04W52/52;;H04W84/14,,0,0,,,,DISCONTINUED
751,AU,A,AU 1996/060348 A,080-711-608-181-78X,1996-12-18,1996,AU 1996/060348 A,1996-06-03,GB 9510870 A;;GB 9511167 A;;GB 9511189 A;;GB 9511192 A;;GB 9511546 A;;GB 9513168 A;;GB 9513172 A;;GB 9513166 A;;GB 9513170 A;;US 9608565 W,1995-06-02,Apparatus and method of establishing and maintaining communi cation paths in a wireless telecommunications system,,DSC COMMUNICATIONS,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;BHAGALIA SHASHIKANT;;COOPER IAN LESLIE;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/080-711-608-181-78X,Patent Application,no,0,0,8,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/0631;;H04L41/069;;H04L41/0816;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14;;H04L69/32;;H04L69/325;;H04L69/324,G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J3/06;;H04J11/00;;H04J13/00;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04L29/08;;H04Q11/04;;H04W52/00;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,PENDING
752,CA,A1,CA 2199359 A1,031-417-806-114-84X,1996-03-14,1996,CA 2199359 A,1995-09-05,GB 9418049 A,1994-09-07,EXAMINING A DIAMOND,"In order to test whether a diamond (4) has had a layer of synthetic diamond deposited thereon, the surface area of the natural part of the stone is measured by measuring the radiant-flux density of radiation substantially of wavelength 230 nm to 320 nm in an integrating sphere (2) containing the diamond. This is compared to the total surface area of the diamond.",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;MARTINEAU PHILIP MAURICE;;WELBOURN CHRISTOPHER MARK,,https://lens.org/031-417-806-114-84X,Patent Application,no,0,0,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,DISCONTINUED
753,ZA,B,ZA 957480 B,162-656-981-556-213,1997-03-06,1997,ZA 957480 A,1995-09-06,GB 9418049 A,1994-09-07,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SMITH JAMES GORDON CHARTERS;;MARTINEAU PHILIP MAURICE,,https://lens.org/162-656-981-556-213,Granted Patent,no,0,0,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
754,GB,A,GB 2293236 A,187-904-905-530-780,1996-03-20,1996,GB 9517882 A,1995-09-01,GB 9418049 A,1994-09-07,Examining a diamond,"To test a diamond 4 for synthetic diamond deposits, the surface area of the natural part of the stone is attained by measuring the radiant-flux density of U.V. radiation of wavelength 230nm to 320nm in an integrating sphere 2 containing the diamond on a fused silica shelf 5. The diamond's total measured area is similarly obtained by measuring the radiant-flux density at less than 230nm and the difference between the two areas is used to determine the amount of synthetic diamond present. Selection of the area being measured is obtained via rotatable filter 16 which has a band-pass filter 19 and a high pass filter 18 corresponding to the two frequency ranges. Photomultiplier tube 15 monitors the flux densities and feeds them, via amplifier 20, into a D/A convertor 21 which supplies processor 22 with digital values for the area difference calculation. <IMAGE>",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;MARTINEAU PHILIP MAURICE,,https://lens.org/187-904-905-530-780,Patent Application,no,2,13,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,G1A AA4           MHL;;G1A AA9           MHL;;G1A AG6           MHL;;G1A AMHL          MHL;;G1A AR6           MHL;;G1A AR7           MHL;;G1A AT20          MHL;;G1A AT3           MHL;;U1S S1488,0,0,,,,EXPIRED
755,AU,B2,AU 622665 B2,040-100-818-468-267,1992-04-16,1992,AU 1989/034541 A,1989-05-08,GB 8810723 A;;GB 8816157 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,IDENTIFYING GEMSTONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;SPEAR PAUL MARTYN;;WELBOURN CHRISTOPHER MARK,,https://lens.org/040-100-818-468-267,Granted Patent,no,3,1,11,118,0,B07C5/3427;;B07C5/368;;G01N21/6456;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N23/223,,0,0,,,,EXPIRED
756,US,A,US 5880504 A,137-725-350-535-811,1999-03-09,1999,US 80915297 A,1997-06-06,GB 9418049 A;;GB 9502093 W,1994-09-07,Examining a diamond,"In order to test whether a diamond has had a layer of synthetic diamond deposited thereon, the surface area of the natural part of the stone is measured by measuring the radiant-flux density of radiation substantially of wavelength 230 nm to 320 nm in an integrating sphere containing the diamond. This is compared to the total surface area of the diamond.",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;MARTINEAU PHILIP MAURICE,GERSAN ESTABLISHMENT (1997-04-04),https://lens.org/137-725-350-535-811,Granted Patent,yes,5,17,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,250/372;;356/30,0,0,,,,EXPIRED
757,WO,A1,WO 1996/007896 A1,129-041-596-303-220,1996-03-14,1996,GB 9502093 W,1995-09-05,GB 9418049 A,1994-09-07,EXAMINING A DIAMOND,"In order to test whether a diamond (4) has had a layer of synthetic diamond deposited thereon, the surface area of the natural part of the stone is measured by measuring the radiant-flux density of radiation substantially of wavelength 230 nm to 320 nm in an integrating sphere (2) containing the diamond. This is compared to the total surface area of the diamond.",GERSAN ETS;;SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;MARTINEAU PHILIP MAURICE;;WELBOURN CHRISTOPHER MARK,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;MARTINEAU PHILIP MAURICE;;WELBOURN CHRISTOPHER MARK,,https://lens.org/129-041-596-303-220,Patent Application,yes,4,1,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,PENDING
758,BR,A,BR 8902133 A,183-285-193-469-874,1990-01-02,1990,BR 8902133 A,1989-05-08,GB 8810723 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,"PROCESSO,E APARELHO,PARA IDENTIFICAR PEDRAS PRECIOSAS",,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;STEWART ANDREW DAVID GARRY;;BRINK DANIEL JOHANNES;;COOPER MARTIN,,https://lens.org/183-285-193-469-874,Patent Application,no,0,0,11,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,EXPIRED
759,GB,B,GB 2293236 B,146-459-125-819-567,1998-06-10,1998,GB 9517882 A,1995-09-01,GB 9418049 A,1994-09-07,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;MARTINEAU PHILIP MAURICE,,https://lens.org/146-459-125-819-567,Granted Patent,no,2,0,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,G1A AA4           MHL;;G1A AA9           MHL;;G1A AG6           MHL;;G1A AMHL          MHL;;G1A AR6           MHL;;G1A AR7           MHL;;G1A AT20          MHL;;G1A AT3           MHL;;U1S S1488,0,0,,,,EXPIRED
760,AU,A,AU 1995/033954 A,028-253-717-377-422,1996-03-27,1996,AU 1995/033954 A,1995-09-05,GB 9418049 A;;GB 9502093 W,1994-09-07,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;MARTINEAU PHILIP MAURICE;;WELBOURN CHRISTOPHER MARK,,https://lens.org/028-253-717-377-422,Patent Application,no,0,0,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
761,AU,B2,AU 698099 B2,119-872-999-571-208,1998-10-22,1998,AU 1995/033954 A,1995-09-05,GB 9418049 A;;GB 9502093 W,1994-09-07,Examining a diamond,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;MARTINEAU PHILIP MAURICE;;WELBOURN CHRISTOPHER MARK,,https://lens.org/119-872-999-571-208,Granted Patent,no,3,0,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,EXPIRED
762,TW,B,TW 324061 B,049-840-373-935-950,1998-01-01,1998,TW 84110048 A,1995-09-26,GB 9418049 A,1994-09-07,Examining a diamond,"A method for testing whether a diamond has had a layer of synthetic diamond deposited thereon comprises the following steps: a. radiating on the diamond by radiation substantially of wavelength 230 nm to 320 nm, b. measuring the surface area actively receiving the radiant-flux density and comparing it with the total surface area of the diamond, and c. obtaining the result that it does has a layer of synthetic diamond if the two surface areas are equal.",GERSAN ETS,MARTIN PHILLIP SMITH;;JAMES GORDON CHARTERS SMITH;;MARTIN COOPER;;PHILIP MAURICE MARTINEAU;;CHRISTOPHER MARK WELBOURN,,https://lens.org/049-840-373-935-950,Granted Patent,no,0,2,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,,,0,0,,,,EXPIRED
763,BR,A,BR 8902136 A,172-557-362-350-207,1990-09-04,1990,BR 8902136 A,1989-05-08,GB 8810723 A;;GB 8816157 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,PROCESSO E APARELHO PARA IDENTIFICAR OBJETOS OU ZONAS ESPECIFICOS,,GERSAN ETS,SMITH MARTIN PHILLIP;;STEWART ANDREW DAVID GARRY;;COOPER MARTIN;;SPEAR PAUL MARTINS;;WELBOURN CHRISTOPHER MARK,,https://lens.org/172-557-362-350-207,Patent Application,no,0,0,11,118,0,B07C5/3427;;B07C5/368;;G01N21/6456;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N23/223,,0,0,,,,EXPIRED
764,AU,A,AU 1998/079543 A,092-313-982-894-765,1998-12-30,1998,AU 1998/079543 A,1998-06-10,GB 9712172 A;;US 9811616 W,1997-06-11,Handling of telecommunications signals passed between elements of a telecommunications network,,DSC TELECOM LP;;DSC COMMUNICATIONS LIMITED,COOPER IAN L;;THOMPSON JONATHAN A;;LYSEJKO MARTIN;;YEUNG JOEMANNE CHI CHEUNG;;WALDING ANDREW M;;COOPER GUY A,,https://lens.org/092-313-982-894-765,Patent Application,no,0,0,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,,0,0,,,,DISCONTINUED
765,EP,A1,EP 0779978 A1,036-442-841-506-175,1997-06-25,1997,EP 95930637 A,1995-09-05,GB 9502093 W;;GB 9418049 A,1994-09-07,EXAMINING A DIAMOND,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH JAMES GORDON CHARTERS;;COOPER MARTIN;;MARTINEAU PHILIP MAURICE;;WELBOURN CHRISTOPHER MARK,,https://lens.org/036-442-841-506-175,Patent Application,yes,0,0,16,16,0,G01N21/87;;G01N21/87;;G01N21/87,G01N21/87,,0,0,,,,DISCONTINUED
766,WO,A2,WO 1998/057520 A2,104-171-648-751-235,1998-12-17,1998,US 9811616 W,1998-06-10,GB 9712172 A,1997-06-11,HANDLING OF TELECOMMUNICATIONS SIGNALS PASSED BETWEEN ELEMENTS OF A TELECOMMUNICATIONS NETWORK,"The present invention provides a system for handling telecommunications signals passed between a first and second element of a telecommunications network, the first element having an interface for transmitting and receiving signals in a first protocol, and the second element having an interface for transmitting and receiving signals in a second protocol. The system of the present invention comprises a first interface unit for receiving a first telecommunications signal transmitted in one of said first and second protocols between said first and second elements, the first interface unit being arranged to separate traffic bearing channels from non-traffic bearing channels within the first telecommunications signal. A traffic management element is then provided for performing a cross-connection function to map the traffic bearing channels to the appropriate format for the other of said protocols, whilst a protocol conversion element is provided for performing predetermined protocol conversion steps on the non-traffic bearing channels in order to regenerate those non-traffic bearing channels in the other of said protocols. Further, a second interface unit is provided for combining the channels as output by the traffic management element and the protocol conversion element in order to create a second telecommunications signal in the other of said protocols, the second interface unit being arranged to output the second telecommunications signal. Preferably, said first protocol has a concentrated format, and said second protocol has an unconcentrated format. By this approach, the present invention provides a technique for converting signals between interfaces employing different protocols so that an element of a telecommunications network using a first protocol may communicate with an element of the telecommunications network using a second protocol, the conversion between the two protocols being transparent to these elements of the telecommunications network.",DSC TELECOM LP;;DSC COMMUNICATIONS LIMITED,COOPER IAN L;;THOMPSON JONATHAN A;;LYSEJKO MARTIN;;YEUNG JOEMANNE CHI CHEUNG;;WALDING ANDREW M;;COOPER GUY A,,https://lens.org/104-171-648-751-235,Patent Application,no,0,0,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,,0,0,,,,PATENTED
767,US,B1,US 6181710 B1,103-202-227-421-601,2001-01-30,2001,US 102397 A,1997-12-30,GB 9712172 A,1997-06-11,Handling of telecommunications signals passed between elements of a telecommunications network,"The present invention provides a system for handling telecommunications signals passed between a first and second element of a telecommunications network, the first element having an interface for transmitting and receiving signals in a first protocol, and the second element having an interface for transmitting and receiving signals in a second protocol. The system of the present invention comprises a first interface unit for receiving a first telecommunications signal transmitted in one of said first and second protocols between said first and second elements, the first interface unit being arranged to separate traffic bearing channels from non-traffic bearing channels within the first telecommunications signal. A traffic management element is then provided for performing a cross-connection function to map the traffic bearing channels to the appropriate format for the other of said protocols, whilst a protocol conversion element is provided for performing predetermined protocol conversion steps on the non-traffic bearing channels in order to regenerate those non-traffic bearing channels in the other of said protocols. Further, a second interface unit is provided for combining the channels as output by the traffic management element and the protocol conversion element in order to create a second telecommunications signal in the other of said protocols, the second interface unit being arranged to output the second telecommunications signal. Preferably, said first protocol has a concentrated format, and said second protocol has an unconcentrated format.",ALCATEL USA SOURCING LP,COOPER IAN L;;THOMPSON JONATHAN A;;LYSEJKO MARTIN;;YEUNG JOEMANNE CHI CHEUNG;;WALDING ANDREW M;;COOPER GUY A,DSM TELECOM L.P (1997-06-09);;ALCATEL USA SOURCING L.P (1998-09-09);;AIRSPAN NETWORKS INC (2004-02-19),https://lens.org/103-202-227-421-601,Granted Patent,yes,13,21,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,370/467;;370/395;;370/401,3,2,003-777-278-394-182;;090-294-005-412-110,10.1080/02564602.1995.11416547;;10.1515/freq.1994.48.1-2.44,"Ashok Jhunjhunwala, et al., ""Wireless in Local Loop: Some Key Issues"", IETE Technical Review, vol. 12, No. 5-6, Sep.-Dec. 1995, pp. 309-314.;;Karim Khakzar, ""V5 Interfaces Between Digital Local Exchanges and Access Networks"", Frequenz, vol. 48, No. 1/2, Jan./Feb. 1994, pp. 44-50.;;PCT Search Report, dated Jan. 22, 1999.",EXPIRED
768,WO,A3,WO 1998/057520 A3,000-008-071-806-228,1999-04-01,1999,US 9811616 W,1998-06-10,GB 9712172 A,1997-06-11,HANDLING OF TELECOMMUNICATIONS SIGNALS PASSED BETWEEN ELEMENTS OF A TELECOMMUNICATIONS NETWORK,"The present invention provides a system for handling telecommunications signals passed between a first and second element of a telecommunications network, the first element having an interface for transmitting and receiving signals in a first protocol, and the second element having an interface for transmitting and receiving signals in a second protocol. The system of the present invention comprises a first interface unit for receiving a first telecommunications signal transmitted in one of said first and second protocols between said first and second elements, the first interface unit being arranged to separate traffic bearing channels from non-traffic bearing channels within the first telecommunications signal. A traffic management element is then provided for performing a cross-connection function to map the traffic bearing channels to the appropriate format for the other of said protocols, whilst a protocol conversion element is provided for performing predetermined protocol conversion steps on the non-traffic bearing channels in order to regenerate those non-traffic bearing channels in the other of said protocols. Further, a second interface unit is provided for combining the channels as output by the traffic management element and the protocol conversion element in order to create a second telecommunications signal in the other of said protocols, the second interface unit being arranged to output the second telecommunications signal. Preferably, said first protocol has a concentrated format, and said second protocol has an unconcentrated format.",ALCATEL USA SOURCING LP;;DSC COMMUNICATIONS LIMITED,COOPER IAN L;;THOMPSON JONATHAN A;;LYSEJKO MARTIN;;YEUNG JOEMANNE CHI CHEUNG;;WALDING ANDREW M;;COOPER GUY A,,https://lens.org/000-008-071-806-228,Search Report,yes,4,0,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,,2,2,003-777-278-394-182;;090-294-005-412-110,10.1080/02564602.1995.11416547;;10.1515/freq.1994.48.1-2.44,"JHUNJHUNWALA A ET AL: ""WIRELESS IN LOCAL LOOP: SOME KEY ISSUES"", IETE TECHNICAL REVIEW, vol. 12, no. 5-6, September 1995 (1995-09-01), pages 309 - 314, XP002089182;;KHAKZAR K: ""V5 INTERFACES BETWEEN DIGITAL LOCAL EXCHANGES AND ACCESS NETWORKS"", FREQUENZ, vol. 48, no. 1/02, 1 January 1994 (1994-01-01), pages 44 - 50, XP000439913",PATENTED
769,WO,A3,WO 1998/057520 A3,071-101-142-724-628,1998-12-17,1998,US US9811616,1998-06-10,GB 9712172.7,1997-06-11,HANDLING OF TELECOMMUNICATIONS SIGNALS PASSED BETWEEN ELEMENTS OF A TELECOMMUNICATIONS NETWORK,"The present invention provides a system for handling telecommunications signals passed between a first and second element of a telecommunications network, the first element having an interface for transmitting and receiving signals in a first protocol, and the second element having an interface for transmitting and receiving signals in a second protocol. The system of the present invention comprises a first interface unit for receiving a first telecommunications signal transmitted in one of said first and second protocols between said first and second elements, the first interface unit being arranged to separate traffic bearing channels from non-traffic bearing channels within the first telecommunications signal. A traffic management element is then provided for performing a cross-connection function to map the traffic bearing channels to the appropriate format for the other of said protocols, whilst a protocol conversion element is provided for performing predetermined protocol conversion steps on the non-traffic bearing channels in order to regenerate those non-traffic bearing channels in the other of said protocols. Further, a second interface unit is provided for combining the channels as output by the traffic management element and the protocol conversion element in order to create a second telecommunications signal in the other of said protocols, the second interface unit being arranged to output the second telecommunications signal. Preferably, said first protocol has a concentrated format, and said second protocol has an unconcentrated format.","ALCATEL USA SOURCING, L.P.;;DSC COMMUNICATIONS LIMITED","COOPER, Ian, L.;;THOMPSON, Jonathan, A.;;LYSEJKO, Martin;;YEUNG, Joemanne, Chi, Cheung;;WALDING, Andrew, M.;;COOPER, Guy, A.",,https://lens.org/071-101-142-724-628,Search Report,yes,0,0,1,1,0,,H04L29/06,,0,0,,,,UNKNOWN
770,EP,B1,EP 0988769 B1,022-527-799-108-599,2003-11-12,2003,EP 98930071 A,1998-06-10,GB 9712172 A;;US 9811616 W,1997-06-11,HANDLING OF TELECOMMUNICATIONS SIGNALS PASSED BETWEEN ELEMENTS OF A TELECOMMUNICATIONS NETWORK,,AIRSPAN NETWORKS INC,COOPER IAN L;;THOMPSON JONATHAN A;;LYSEJKO MARTIN;;YEUNG JOEMANNE CHI CHEUNG;;WALDING ANDREW M;;COOPER GUY A,AIRSPAN NETWORKS INC. (2000-10-18);;AIRSPAN COMMUNICATIONS CORPORATION (2000-05-24),https://lens.org/022-527-799-108-599,Granted Patent,yes,4,0,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,,2,0,,,"JHUNJHUNWALA A ET AL: ""WIRELESS IN LOCAL LOOP: SOME KEY ISSUES"" IETE TECHNICAL REVIEW, vol. 12, no. 5-6, September 1995, pages 309-314, XP002089182;;KHAKZAR K: ""V5 INTERFACES BETWEEN DIGITAL LOCAL EXCHANGES AND ACCESS NETWORKS"" FREQUENZ, vol. 48, no. 1/02, 1 January 1994, pages 44-50, XP000439913",EXPIRED
771,GB,A,GB 2326317 A,092-394-512-415-739,1998-12-16,1998,GB 9712172 A,1997-06-11,GB 9712172 A,1997-06-11,Protocol conversion,"It comprises a first interface unit for receiving a first telecommunications signal transmitted in one of said first and second protocols between said first and second elements, the first interface unit being arranged to separate traffic bearing channels from non-traffic bearing channels within the first telecommunications signal. A traffic management element is then provided for performing a cross-connection function to map the traffic bearing channels to the appropriate format for the other of said protocols, whilst a protocol conversion element is provided for performing predetermined protocol conversion steps on the non-traffic bearing channels in order to regenerate those non-traffic bearing channels in the other of said protocols. Further, a second interface unit is provided for combining the channels as output by the traffic management element and the protocol conversion element in order to create a second telecommunications signal in the other of said protocols, the second interface unit being arranged to output the second telecommunications signal. Preferably, said first protocol has a concentrated format, and said second protocol has an unconcentrated format and the network is wireless.",DSC TELECOM LP,COOPER IAN LESLIE;;THOMPSON JONATHAN ANDREW;;LYSEJKO MARTIN;;YEUNG JOEMANNE CHI CHEUNG;;WALDING ANDREW MERVYN;;COOPER GUY ALEXANDER,,https://lens.org/092-394-512-415-739,Patent Application,no,1,7,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,H4K KTA           KTA;;H4P PPEC          PPEC;;U1S S2204,0,0,,,,DISCONTINUED
772,EP,A2,EP 0988769 A2,184-475-582-796-872,2000-03-29,2000,EP 98930071 A,1998-06-10,GB 9712172 A;;US 9811616 W,1997-06-11,HANDLING OF TELECOMMUNICATIONS SIGNALS PASSED BETWEEN ELEMENTS OF A TELECOMMUNICATIONS NETWORK,,ALCATEL USA SOURCING LP;;DSC COMMUNICATIONS LIMITED,COOPER IAN L;;THOMPSON JONATHAN A;;LYSEJKO MARTIN;;YEUNG JOEMANNE CHI CHEUNG;;WALDING ANDREW M;;COOPER GUY A,AIRSPAN NETWORKS INC. (2000-10-18);;AIRSPAN COMMUNICATIONS CORPORATION (2000-05-24),https://lens.org/184-475-582-796-872,Patent Application,yes,0,0,10,10,0,H04Q2213/13031;;H04Q2213/13034;;H04Q2213/1309;;H04Q2213/13098;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/13292;;H04Q2213/13294;;H04Q2213/13298;;H04L69/08;;H04L9/40;;H04Q2213/13204;;H04Q2213/13176;;H04Q2213/13031;;H04Q2213/13292;;H04Q2213/13098;;H04Q2213/1309;;H04Q2213/13034;;H04Q2213/13298;;H04Q2213/13294;;H04L69/08;;H04L9/40,H04L29/06,,0,0,,,,EXPIRED
773,CZ,A3,CZ 94699 A3,014-464-034-317-932,2000-01-12,2000,CZ 94699 A,1997-09-19,CZ 94699 A,1997-09-19,Concentrated preparations for softening fabrics based on quaternary ammonium salts containing cation polymers,,PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/014-464-034-317-932,Patent Application,no,0,0,1,1,0,,C11D1/62;;C11D3/00;;C11D3/37;;C11D17/00,,0,0,,,,PENDING
774,CN,A,CN 107735042 A,004-823-218-988-633,2018-02-23,2018,CN 201680029784 A,2016-03-24,AU 2015/901083 A;;AU 2016/050220 W,2015-03-25,Alignment apparatus,"The present invention relates to an apparatus for aligning a sensor relative to at least two anatomical reference points of a patient's anatomy. In one embodiment, the apparatus includes: a body having a central axis; a sensor mount positioned relative to the body; at least two arms extending from the body, wherein two of said at least two arms are simultaneously and equidistantly moveable relative to the central axis; and at least two aligners connected to the at least two arms for aligning with said at least two anatomical reference points. The apparatus may also include an apparatus sensor.The present invention also relates to a surgical system for monitoring the orientation of a patient's anatomy, which includes the apparatus. Furthermore, the present invention also relates to a surgical system for guiding a surgical device to an optimal orientation relative to a patient's anatomy, wherein the surgical system includes the apparatus. The present invention also relates to: a methodof aligning a sensor relative to at least two anatomical reference points of a patient's anatomy, and to a method of guiding a surgical device to an optimal orientation relative to a patient's anatomy. In one embodiment, the patient's anatomy is the pelvis.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/004-823-218-988-633,Patent Application,no,3,0,7,7,0,A61B17/1746;;A61B17/1746;;A61B34/20;;A61B34/20;;A61B34/20;;A61B34/25;;A61B34/25;;A61B90/37;;A61B90/37;;A61B2017/00734;;A61B2017/00734;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61F2/4603;;A61F2/4607;;A61F2/4609;;A61F2/4657;;A61F5/11;;A61F5/11;;A61F2002/4687,A61B34/20;;A61F5/11,,0,0,,,,DISCONTINUED
775,BR,A8,BR 112016014887 A8,002-071-619-141-802,2020-06-09,2020,BR 112016014887 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,sistemas para detectar anomalias em uma composição de trem ou vagão ferroviário,um sistema para monitorar parâmetros operacionais de vagões ferroviários e composições de bondes e detectar anomalias na operação e condição dos mesmos usando sensores para alimentar dados a um motor distributivo de processamento de eventos complexos.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/002-071-619-141-802,Patent Application,no,0,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,ACTIVE
776,WO,A2,WO 2009/120386 A2,148-784-526-155-433,2009-10-01,2009,US 2009/0001956 W,2009-03-26,US 3975208 P,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC;;COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/148-784-526-155-433,Patent Application,yes,0,37,36,36,0,A61K9/19;;A61K31/4184;;A61K47/26;;C07D235/16;;A61K9/14;;A61K9/19;;A61K31/4184;;C07D235/16;;A61P35/00;;A61P35/02;;A61K9/14;;A61K9/19;;A61K31/4184;;C07D235/16;;A61K9/0019;;A61K47/26,A61K9/19,,0,0,,,,PENDING
777,WO,A1,WO 1996/038952 A1,159-779-040-803-050,1996-12-05,1996,US 9608547 W,1996-06-03,GB 9510870 A;;GB 9513169 A;;GB 9603700 A,1995-06-02,SUBSCRIBER TERMINAL FOR A WIRELESS TELECOMMUNICATIONS SYSTEM,A subscriber station of a wireless telecommunications system includes a transmitter/receiver (24) for wireless communication with a central station and for processing signals for transmission and/or received signals. The transmitter/receiver (24) is connected via a link (408) to a supply unit (30) for connection to one or more telephone lines for user telecommunications equipment. The link (408) carries telephone call data for one or more telephone lines and subscriber station control data in accordance with an internal protocol. The internal protocol control data comprises operational status parameters of the subscriber station. The provision of internal protocol control data including operation status parameters on a link between the transmitter/receiver and the supply unit thus provides a point of access for monitoring the operational status of the subscriber station.,DSC COMMUNICATIONS,LYSEJKO MARTIN;;LAMKIN RICHARD MORTIMER;;COOPER GUY ALEXANDER;;NETHERCOTT JONATHAN FRANCIS,,https://lens.org/159-779-040-803-050,Patent Application,yes,4,0,7,251,0,H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J11/00;;H04J13/00;;H04J13/004;;H04L12/2825;;H04L12/2836;;H04L12/403;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04L2012/2841;;H04L2012/2845;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02;;H04W88/021;;H04L9/12;;H04L9/3226;;H04L2209/34;;H04L2209/80;;H04L69/08;;H04L69/14;;H04W88/021;;H04L41/0233;;H04J13/00;;H04Q2213/13376;;H04Q2213/13093;;H04Q2213/13199;;H04J13/004;;H04Q2213/13216;;H04Q2213/13335;;H04B1/7085;;H04Q2213/13098;;H04Q2213/1319;;H04L41/22;;H04W52/52;;H04B1/707;;H04B1/7075;;H04B1/7077;;H04B2201/7071;;H04L12/2825;;H04L12/66;;H04Q2213/13299;;H04B1/70735;;H04L41/0226;;H04W52/08;;H04B2201/70702;;H04Q2213/13296;;H04Q2213/1305;;H04J3/0682;;H04L2012/2845;;H04J11/00;;H04L12/2836;;H04Q11/04;;H04Q2213/13202;;H04W24/08;;H04Q2213/13292;;H04B2201/709709;;H04Q2213/13204;;H04W88/02;;H04L2012/2841;;H04Q2213/13298;;H04B2201/70706;;H04B2201/70711;;H04L43/00;;H04B1/70775;;H04B2001/70706;;H04L12/403;;H04W24/00;;H04Q2213/13109;;H04Q2213/13196;;H04L9/3226;;H04L9/12;;H04L2209/80;;H04L2209/34;;H04L69/14;;H04L69/08,H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02,,1,1,085-487-649-791-216,10.1109/90.251918,"M.B.ABBOTT ET AL: ""INCREASING NETWORK THROUGHPUT BY INTEGRATING PROTOCOL LAYERS"", IEEE / ACM TRANSACTIONS ON NETWORKING, vol. 1, no. 5, October 1993 (1993-10-01), NEW YORK US, pages 600 - 610, XP000420858",PENDING
778,DE,D1,DE 69322986 D1,158-163-296-828-452,1999-02-25,1999,DE 69322986 T,1993-03-16,US 85610792 A,1992-03-20,Techniken für die automatische Erzeugung von Formularen durch Kombination von Teiloperationen,,XEROX CORP,COOPER MARTIN F N;;CARD STUART K;;JOHNSON WALTER A L,,https://lens.org/158-163-296-828-452,Granted Patent,no,0,0,8,8,0,G06F40/174;;G06F40/174,G06F3/14;;G06F3/048;;G06F17/24;;H04N1/00,,0,0,,,,EXPIRED
779,CA,A1,CA 2023485 A1,040-839-186-141-738,1991-02-19,1991,CA 2023485 A,1990-08-17,GB 8918886 A;;GB 8918929 A,1989-08-18,MACROCYCLIC COMPOUNDS,"MACROCYCLIC COMPOUNDS There are described compounds of formula I, I wherein R1 represents H or OH; R2 represents H; in addition, R1 and R2 may together represent a second carbon-carbon bond between the carbon atoms to which they are attached; R3 represents OH or OCH3; X represents O or (H,OH); and Y represents O or N-OR4, in which R4 represents H or alkyl C1-6; provided that when R1 is OH, R2 is H and X is O, then Y does not represent O. Processes for their production and compositions containing them, eg for use as immunosuppressive agents, are also described.",DONALD DAVID K;;HARDERN DAVID N;;COOPER MARTIN E;;FURBER MARK,DONALD DAVID K;;HARDERN DAVID N;;COOPER MARTIN E;;FURBER MARK,,https://lens.org/040-839-186-141-738,Patent Application,no,0,0,11,13,0,A61P37/06;;C07H15/26;;C07H19/01;;C07H19/01,C07D498/18;;A61K31/445;;A61P37/06;;C07H19/01,D32600228    M;;1670185    S,0,0,,,,DISCONTINUED
780,NO,D0,NO 20053827 D0,093-225-456-727-859,2005-08-15,2005,NO 20053827 A,2005-08-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,Nye forbindelser.,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,INGALL ANTHONY HOWARD;;COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;TASNEEM RUKHSANA,,https://lens.org/093-225-456-727-859,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,DISCONTINUED
781,US,A1,US 2016/0159748 A1,098-519-693-054-681,2016-06-09,2016,US 201615045523 A,2016-02-17,US 201615045523 A;;US 201414531023 A;;US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Novel Solid Forms Of Bendamustine Hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/098-519-693-054-681,Patent Application,yes,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/16;;A61K9/00;;A61K31/4184;;A61K47/26,,0,0,,,,ACTIVE
782,EP,A4,EP 3273895 A4,113-968-738-841-79X,2018-12-12,2018,EP 16767541 A,2016-03-24,AU 2015/901083 A;;AU 2016/050220 W,2015-03-25,ALIGNMENT APPARATUS,,INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/113-968-738-841-79X,Search Report,no,3,0,7,7,0,A61B17/1746;;A61B17/1746;;A61B34/20;;A61B34/20;;A61B34/20;;A61B34/25;;A61B34/25;;A61B90/37;;A61B90/37;;A61B2017/00734;;A61B2017/00734;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61F2/4603;;A61F2/4607;;A61F2/4609;;A61F2/4657;;A61F5/11;;A61F5/11;;A61F2002/4687,A61B34/20;;A61F5/11,,1,0,,,See also references of WO 2016149764A1,DISCONTINUED
783,US,A1,US 2013/0152067 A1,126-103-737-049-484,2013-06-13,2013,US 201213437494 A,2012-04-02,US 201213437494 A;;US 201161568056 P,2011-12-07,DEVELOPMENT OF PLATFORM INDEPENDENT APPLICATIONS,"Method, system, and programs for providing development of applications that are interoperable across different device platforms. Application parameters of an application are defined allowing the application to be executable on a plurality of device platforms. A framework is applied to the application facilitating transportable code between a client device and a server to execute the application. The application is deployed so that it may be served to a client device.",FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N;;YAHOO INC,FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,YAHOO! INC (2016-05-31);;EXCALIBUR IP LLC (2016-05-31);;R2 SOLUTIONS LLC (2020-04-28),https://lens.org/126-103-737-049-484,Patent Application,yes,16,10,5,13,0,G06F8/60;;G06F8/60;;G06F9/45529;;G06F9/45529,G06F9/44;;G06F15/16,717/172,1,1,042-748-563-752-489,10.1109/icse.2007.59,"Tucker et al., OPIUM: Optimal Package Install/Uninstall Manager, May 2007, 10 pages.",INACTIVE
784,EP,A4,EP 2911598 A4,127-934-003-369-570,2016-11-09,2016,EP 13849376 A,2013-09-18,AU 2012/904715 A;;AU 2013/001069 W,2012-10-26,SURGICAL SYSTEM,,INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/127-934-003-369-570,Search Report,no,5,0,10,10,0,A61B34/20;;A61B34/20;;A61F2/4657;;A61B5/1121;;A61B5/1121;;A61B5/1121;;A61B5/4504;;A61B5/4504;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/4528;;A61B5/4571;;A61B5/4571;;A61B5/4571;;A61B5/6832;;A61B5/6834;;A61B5/6834;;A61B5/6834;;A61B17/1666;;A61B17/1666;;A61B17/1666;;A61B34/25;;A61B34/25;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61B2090/3983;;A61B2090/3983;;A61B2505/05;;A61B2505/05;;A61B2505/05;;A61B2562/0219;;A61B2562/0219;;A61B2562/0219;;A61B2562/17;;A61B2562/17;;A61F2/4609;;A61F2/4609;;A61F2/4609;;A61F2/4657;;A61F2/4657;;A61F2002/4668;;A61F2002/4668;;A61F2002/4668;;G06F19/3481;;G16H20/40;;G16H20/40,A61B17/58;;A61B5/00;;A61B5/11;;A61B17/16;;A61B17/56;;A61B34/20;;A61B90/00;;A61F2/32;;A61F2/46;;G06F19/00,,1,0,,,See also references of WO 2014063181A1,DISCONTINUED
785,MX,A,MX 2010010398 A,176-366-481-265-535,2010-12-20,2010,MX 2010010398 A,2009-03-26,US 3975208 P;;US 2009/0001956 W,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE.,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/176-366-481-265-535,Patent Application,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/14;;A61K9/19;;A61K31/4184,,0,0,,,,ACTIVE
786,EP,A2,EP 0561605 A2,180-561-682-527-27X,1993-09-22,1993,EP 93301971 A,1993-03-16,US 85610792 A,1992-03-20,Techniques for automatic form creation by combining partial operations.,"An automatically created form (20) includes a field (28) for requesting a combined operation. A processor (66) creates the form in response to another form (10) that includes fields (12,16) that are marked to indicate a sequence of partial operations (A and C). The partial operations together constitute the combined operation (AC). The combined operation can, for example, be a facsimile transmission, in which case the partial operation fields (122,124,126) can specify the digits of a fax machine's telephone number. The automatically created form(140)can then include a single check box next to the name of the recipient. When the check box (150) is marked, the processor (66) responds to the form by performing the sequence of partial operations. The processor can execute input instructions (90) to receive data defining the image of each form and can execute response instructions (92) to respond to each form.",XEROX CORP,COOPER MARTIN F N;;CARD STUART K;;JOHNSON WALTER A L,,https://lens.org/180-561-682-527-27X,Patent Application,yes,0,1,8,8,0,G06F40/174;;G06F40/174,G06F3/14;;G06F3/048;;G06F17/24;;H04N1/00,,0,0,,,,EXPIRED
787,WO,A2,WO 1996/038938 A2,046-043-108-709-572,1996-12-05,1996,US 9608568 W,1996-06-03,GB 9510870 A;;GB 9511546 A;;GB 9513170 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A,1995-06-02,APPARATUS AND METHOD OF CONTROLLING TRANSMITTING POWER AND TRANSMIT RATE OF A WIRELESS TELECOMMUNICATIONS SYSTEM,"A wireless telecommunications system (1) includes a central terminal (10) for transmitting and receiving radio frequency signals to and from a subscriber terminal (20). The wireless telecommunications system (1) operates in one of three operating modes. In an acquisition mode during establishment of the downlink communication path, the downlink signal (212) is transmitted at a high power level and a low transmit rate with the receiver (202) operating at the low transmit rate. In a standby mode after establishment of the downlink communication path, the downlink signal (212) is transmitted at a low power level and a low transmit rate with the receiver (202) operating at the low transmit rate. In a traffic mode upon a request for wireless communication transmission, the downlink signal (212) is transmitted at a high power level and a high transmit rate with the receiver (202) adjusting to operate at the high transmit rate. Upon completion of the wireless communication transmission, the wireless telecommunications system (1) returns to the standby mode and the receiver (202) adjusts to operate at the low transmit rate.",DSC COMMUNICATIONS;;BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,,https://lens.org/046-043-108-709-572,Patent Application,no,0,21,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,PENDING
788,US,A1,US 2013/0245086 A1,086-639-380-518-335,2013-09-19,2013,US 201313874575 A,2013-05-01,US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Novel Solid Forms Of Bendamustine Hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/086-639-380-518-335,Patent Application,yes,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/16,514/394;;548/310.1,1,1,020-435-634-003-86X,10.1016/j.addr.2003.10.020;;14962582,"Morissette et al. in Drug Delivery Reviews, 56 (2004) 275 - 300",ACTIVE
789,US,B2,US 10039750 B2,094-460-888-300-644,2018-08-07,2018,US 201615359777 A,2016-11-23,US 201615359777 A;;US 201615045523 A;;US 201414531023 A;;US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Solid forms of bendamustine hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/094-460-888-300-644,Granted Patent,yes,56,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K31/4184;;A61K9/00;;A61K9/14;;A61K9/19;;A61K47/26;;C07D235/16,,54,39,020-435-634-003-86X;;057-331-944-087-540;;084-716-889-422-831;;007-364-858-655-289;;005-472-156-687-716;;009-214-187-079-899;;132-558-386-999-186;;123-775-514-819-528;;006-046-706-830-252;;069-673-960-292-160;;080-209-105-337-208;;027-084-824-706-497;;106-081-384-040-520;;074-470-545-310-545;;020-427-831-437-122;;044-553-566-435-465;;049-256-800-886-311;;067-512-968-604-94X;;023-549-427-997-819;;063-402-864-700-686;;113-421-979-742-187;;020-435-634-003-86X;;125-764-802-071-090;;111-707-255-990-821;;034-919-505-845-111;;023-237-704-770-485;;003-701-346-326-00X;;067-465-907-694-241;;127-003-929-505-550;;013-802-099-433-937;;055-433-061-655-828;;004-291-817-534-209;;108-687-604-265-588;;029-880-686-607-107;;093-799-759-321-023;;001-658-497-635-033;;091-079-688-402-134;;059-280-286-824-398;;057-884-013-276-829,10.1016/j.addr.2003.10.020;;14962582;;10.1053/sonc.2002.34875;;10.1016/s0093-7754(02)90010-2;;12170428;;10.2165/00003495-200161050-00009;;11368287;;10.1002/jps.2600660104;;833720;;12458340;;10.1007/s00432-002-0378-6;;10.1023/a:1016241927429;;7494814;;11801463;;12691159;;10.1080/1042819021000054670;;11410411;;12948851;;10.1016/s0006-2952(03)00410-6;;12170424;;10.1053/sonc.2002.34871;;10.3109/02652048609031561;;3508181;;18182663;;10.1200/jco.2007.12.5070;;12170425;;10.1053/sonc.2002.34872;;10.1007/bf00807895;;10.1097/00001813-200110000-00003;;11593053;;10.1007/s004320000180;;11206271;;15223642;;10.1080/1042819042000223822;;10.1097/00001813-200008000-00003;;11036955;;12029443;;10.1007/s00432-002-0331-8;;10.2165/00044011-200424100-00007;;17523723;;10.1016/j.addr.2003.10.020;;14962582;;10.1080/1042819042000198858;;15359644;;10.1053/sonc.2002.34876;;10.1016/s0093-7754(02)90011-4;;12170429;;4095129;;12170430;;10.1016/s0093-7754(02)90012-6;;10.1053/sonc.2002.34877;;12170426;;10.1016/s0093-7754(02)90008-4;;10.1053/sonc.2002.34873;;10.1007/bf02041437;;3380859;;15577312;;10.1097/00008390-200412000-00001;;10.1007/pl00008463;;10641748;;10.1016/s0093-7754(02)90009-6;;10.1053/sonc.2002.34874;;12170427;;10.1038/sj.leu.2402651;;12357363;;10.1097/00001813-199606000-00007;;8826610;;11999564;;10.1080/10428190290006107;;15621757;;10.1080/10428190400004521;;10.1093/annonc/mdf189;;12181253;;3615563;;11862482;;10.1007/s00432-001-0303-4,"EC Safety Data Sheet: Ribomustin® in www.asl.ri.it/staff/prevenzione/documentazione/Chemio/Ribomustin%20scheda%20di%20 sicurezza.pdf (published: Jul. 3, 1998; updated Mar. 1, 2007).;;Friedberg et al. in Blood 106 (11), 2005 (abstract 229).;;Morissette et al. in Drug Delivery Reviews, 56 (2004) 275-300 (Year: 2004).;;Aivado et al., “Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives”, Seminars in Oncology, Aug. 2002, 29(4), 19-22, Suppl. 13.;;Author Unknown, “Ribomustin: Bendamustine Product Monograph”, Ribosepharm GMBH, Munchen, Germany, Jan. 2002, 3-54.;;Author Unknown, “Ribomustin: Bendamustine Product Monograph”, Ribosepharm GMBH, Munchen, Germany, Mar. 2005, 3-73.;;Barman et al., “Bendamustine” Drugs, 2001, 61(5), 631-638, Auckland, New Zealand.;;Berge et al., “Pharmaceutical Salts”, Journal of pharmaceutical sciences, Jan. 1977, 66(1), 1-19.;;Bremer, “High Rates of Long-lasting remissions after 5-day bendamustine Chemotherapy Cycles in Pre-Treated low-grade non-hodgkin's-lymphomas”, Journal of Cancer Research and Clinical Oncology, Nov. 2002, 128(11), 603-609.;;BRITTAIN H.G: ""POLYMORPHISM IN PHARMACEUTICAL SOLIDS"", vol. 95, 1 January 1999, XX, XX, ISBN: 978-0-8247-0237-9, article BRITTAIN H.G.: ""Drugs and the Pharmaceutical Sciences"", pages: I - 228-239, XP003030775;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Consideration”, Pharmaceutical Research, Jul. 1995, 12(7), 945-954.;;Chow et al., “Anti-CD20 Antibody (DEC-C2B8, rituximab) enhances efficiency of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of Cytokines complement and caspases”, Hematologica, Jan. 2002, 87(1), 33-43.;;Chow et al., “In AML Cell Lines Ara-C combined with Purine Analogues is able to Exert Synergistic as well as Antagnostic Effects on Proliferation Apoptosis and Disruption of Mitochondrial Membrane Potential”, Leukemia & Lymphoma, 2003, 44(1), 165-173.;;Chow et al., “In Vitro Induction of Apoptosis of Neoplastic Cells in Low-Grade non-Hodgkin's Lymphomas by Combination of established cytotoxic drugs with bendamustine”, Hematologica, May 2001, 86(5), 485-493.;;Chow et al., “Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4(Par-4), death-associated protein (Dazz) and with enforced caspase activation”, Biochemical Pharmacology, Jan. 2003, 66(5), 711-724.;;Diehl et al., “Bendamustine in the Treatment of Hematologic Malignancies”, Semin. Oncol., Aug. 2002, 29(4), 1-3, Suppl. 13, Saundes, Philadelphia, PA.;;EC Safety Data Sheet: Ribomustin® in http://www.docstoc.com/docs/22323231/EC-Safety-Data-Sheet-Bendamustin (published: Jul. 3, 1998; updated Mar. 1, 2007).;;EC Safety Data Sheet: Ribomustin® in www.asl.ri.it/staff/prevenzione/documentazione/Chemio/Ribomustin%20scheda%20di%20sicurezza.pdf (Retrieved from the internet Jun. 11, 2013).;;Fichtner et al., “Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumor models”, Journal of Microencapsulation, Jan. 1986, 3(2), 77-87.;;Friedberg et al., “Bendamustine in patients with Rituximab-refractory indolent and transformed non-hodgkin's lymphoma”, Journal of Clinical Oncology, Jan. 10, 2008, vol. 26, No. 2, pp. 204-210.;;Friedberg et al., Bendamustine HCl (TRENDA™) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01), in Blood 106 (11), 2005 (Abstract 229).;;Gandhi, Varsha, “Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies”, Seminars in Oncology, Aug. 2002, 29(4), 4-11, Suppl. 13.;;Goodman et al., The Pharmacological Basis of Therapeutics, 1985, 7th edition, Macmillan publishing company, New York.;;Gust et al., “Investigation on the Stability of Bendamustin, a Cytostatic Agent of the Nitrogen Mustard Type I. Synthesis, Isolation and Characterization of Reference Substances”, Monatshefte fur Chemie, 1997, 128(3), 291-299.;;Heider et al., “Efficacy and Toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas”, Anti-Cancer Drugs, 2001, 12(9), 725-729.;;Kath et al., “Bendamustine Monotherapy in advanced and refractory chronic lymphocytic Leukemia”, Journal of Cancer Research and Clinical Oncology, 2001, 127(1), 48-54.;;Koenigsman et al., “Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)”, Leukemia & Lymphoma, 2004, 45(9), 1821-1827.;;Kollmannsberger et al., “Phase II study of Bendamustine in Patients with relapsed or cisplatin-refractory germ cell Cancer”, Anti-Cancer Drugs, 2000, 11(7), 535-539.;;Konstantinov et al., “Cytotoxic Efficacy of Bendamustine in Human Leukemia and Breast Cancer cell lines”, Journal of Cancer Research and Clinical Oncology, 2002, 128(5), 271-278.;;Köster et al., “Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small lung cancer (SCLC)”, Clinical Drug Investigation, 2004, 24(10), 611-618.;;Leoni et al., “Sdx-105 (Trenda), Active in Non-Hodgkin's Lymphoma Cells, Induces the Mitotic Catastrophe Death Pathway”, Blood, 2004, 104(11), (Abstract).;;Maas, “Stability of Bendamustine Hydrochloride in Infusion Solutions”, 1994, 49(10), 9 pages.;;Morissette et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids”, Advanced Drug Delivery Reviews, Feb. 2004, 56(3), 275-300.;;Niemeyer et al., “SDX-105 (bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action”, Proc Annu Meet Am Assoc Cancer Res, Mar. 2004, 45, 1st ed., 2 pages.;;Nowak et al., “Upon Drug-Induced Apoptosis in Lymphoma Cells X-linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus”, Leukemia & Lymphoma, Jul. 2004, 45(7), 1429-1436.;;Ozegowski et al., “IMET 3393, gamma-(1-methyl-5-bis-(ß-chloräthyl)-amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste”, Zbl Pharm., 1971;110, Heft 10, 1013-1019.;;Ponisch et al., “Bendamustine in the treatment of Multiple Myeloma: Results and future perspectives”, Seminars in Oncology, Aug. 2002, 29(4), 23-26, Suppl. 13.;;Preiss et al., “Pharmacokinetics of bendamustin (Cytostasan) in patients”, Pharmazie, Mar. 1985, 40(11), 782-784.;;Remington: Pharmaceutical Sciences, 1990, Mack Publishing company, Easton, Pennsylvania.;;Ribosepharm, “Product monograph ribosepharm passage”, Product Monograph, Ribosepharm, Jan. 1, 2005, pp. 3-73.;;Rummel et al., “Bendamustine in the Treatment of Non-Hodgkin's Lymphoma: Results and Future Perspectives”, Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 27-32.;;Rummel et al., “In Vitro Studies with Bendamustine: Enhanced Activity in Combination with Rituximab”, Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 12-14.;;Scasnar et al., “Radiochemical Assay of Stability of 14C-Cytostasan Solutions During Preparation and Storage”, Journal of Radioanalytical and Nuclear Chemistry, 1998, 121(2), 489-497.;;Scasnar et al., “Stability Studies of 14C-Cytostasan® solutions and its extraction using dicarbolide of cobalt”, Phamazie, Mar. 1988, 43, 176-179.;;Schmidt-Hieber et al., “A Phase II Study of bendamustine Chemotherapy as Second-line treatment in metastatic uveal Melanoma”, Melanoma Research, 2004, 14(6), 439-442.;;Schoffski, “Repeated Administration of Short Infusions of Bendamustine: A phase I study in Patients with Advanced Progressive Solid Tumors”, Journal of Cancer Research and Clinical Oncology, 2000, 126(1), 41-47.;;Schrijvers et al., “Phase I study with bendamustine: An update”, Seminars in Oncology, Suppl. 13, 2002, 29(4), 15-18.;;Schwanen et al., “In Vitro Evaluation of Bendamustine Induced Apoptosis in B-Chronic Lymphocytic Leukemia”, Leukemia, Oct. 2002, 16(10), 2096-2105.;;Strumberg et al., “Bendamustine Hydrochloride Activity against doxorubicin-resistant Human Breast Carcinoma Cell Lines”, Anti-Cancer Drugs, 1996, 7(4), 415-421.;;Weide et al., “Bendamustine Mitoxantrone and Rituximab (BMR): A New effective regimen for refractory or relapsed indolent lymphomas”, Leukemia & Lymphoma, 2002, 43(2), 327-331.;;Weide et al., “Bendamustine/ Mitoxantrone/Rituximab (BMR) : A very Effective, well tolerated Outpatient Chemoimmunotherapy for relapsed and refractory CD20-positive Indolent Malignancies Final Results of a Pilot Study”, Leukemia & Lymphoma, 2004, 45(12), 2445-2449.;;Weidmann et al., “Bendamustine is Effective in Relapsed or Refractory Aggressive non-Hodgkin's Lymphoma”, Annals of Oncology, 2002, 13(8), 1285-1289.;;Werner et al., “Hydrolyseprodukte des Cancerostaticums Cytostasan (Bendamustin)”, Pharmazie, 1987, 42, 272-273.;;Zulkowski et al., “Regression of Brain Metastases from Breast Carcinoma after Chemotherapy with bendamustine”, Journal of Cancer Research and Clinical Oncology, 2002, 128(2), 111-113.",ACTIVE
790,CN,A,CN 111332335 A,141-411-083-659-15X,2020-06-26,2020,CN 202010240339 A,2014-12-24,US 201361920700 P;;CN 201480076070 A,2013-12-24,System and method for detecting operational anomalies in train consists and railcars,The invention relates to a system and method for detecting operational anomalies in train consists and railcars. A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/141-411-083-659-15X,Patent Application,no,5,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00;;B61K9/00;;B61K9/04;;B61L25/02;;B61L27/00;;G01M17/10,,0,0,,,,DISCONTINUED
791,NO,D0,NO 903636 D0,155-964-028-716-594,1990-08-17,1990,NO 903636 A,1990-08-17,GB 8918886 A;;GB 8918929 A,1989-08-18,MAKROCYKLISKE FORBINDELSER OG FREMGANGSMAATE FOR DERES FREMSTILLING.,,FISONS PLC,DONALD DAVID KEITH;;HARDERN DAVID NORMAN;;COOPER MARTIN EDWARD;;FURBER MARK,,https://lens.org/155-964-028-716-594,Patent Application,no,0,0,11,13,0,A61P37/06;;C07H15/26;;C07H19/01;;C07H19/01,C07D498/18;;A61K31/445;;A61P37/06;;C07H19/01,,0,0,,,,PENDING
792,BR,A2,BR 112019018088 A2,149-524-014-734-728,2020-03-24,2020,BR 112019018088 A,2018-03-01,US 2018/0020440 W;;US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490465 P;;US 201762490567 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510660 P;;US 201762510672 P;;US 201762511218 P;;US 201715616874 A,2017-03-01,composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados,"são aqui reveladas novas composições que compreendem um canabinoide purificado e um terpeno purificado. em uma modalidade, as composições compreendem um ou mais canabinoides purificados. em uma modalidade, as composições compreendem um ou mais canabinoides purificados em combinação com um ou mais terpenos purificados. em uma modalidade, as composições compreendem razões de ocorrência não natural. em uma modalidade, as composições compreendem concentrações de ocorrência não natural. em uma modalidade, as composições compreendem efeitos inesperados e/ou sinérgicos.",CANOPY GROWTH CORP,BRIAN GEOFFREY REID;;JONATHAN MICHAEL COOPER;;JONATHAN REED MARTIN;;KURT LEVY,,https://lens.org/149-524-014-734-728,Patent Application,no,0,0,11,36,0,A61K31/05;;A61K31/352,A61K31/05;;A01N65/00;;A61K31/352,,0,0,,,,DISCONTINUED
793,CN,A,CN 106061821 A,016-655-895-011-331,2016-10-26,2016,CN 201480076070 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,System and method for detecting operational anomalies in train consists and railcars,A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/016-655-895-011-331,Patent Application,no,5,14,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,1,0,,,"韩建海等: ""《电子封装、微机电与微系统》"", 31 May 2010",DISCONTINUED
794,EP,A1,EP 3150197 A1,024-251-977-635-278,2017-04-05,2017,EP 16188467 A,2009-03-26,US 3975208 P;;EP 09723661 A,2008-03-26,SOLID FORMS OF BENDAMUSTINE HYDROCHLORID,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/024-251-977-635-278,Patent Application,yes,9,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/14;;A61K9/19;;A61K31/4184,,4,0,,,"W. OZEGOWSKI; D. KREBS: ""IMET 3393 y-[I-methyl-5-bis-(P-chloroethyl)-aminobenzimidazolo-(2)]-butyryl chloride, a new cytostatic agent of the group of benzimidazole nitrogen mustards"", ZBL. PHARM., vol. 110, no. 10, 1971, pages 1013 - 1019, XP002765583;;RIBOSEPHARM: ""Product monograph ribosepharm passage"", PRODUCT MONOGRAPH RIBOSEPHARM, XX, XX, 1 January 2005 (2005-01-01), pages 3 - 73, XP002368437;;W. OZEGOWSKI; D. KREBS: ""IMET 3393 y-[I-methyl-5-bis-(P-chloroethyl)-aminobenzimidazolo-(2)]-butyryl chloride, a new cytostatic agent of the group of benzimidazole nitrogen mustards"", ZBL. PHARM., vol. 110, no. 10, 1971, pages 1013 - 1019, XP002765583;;GENNARO, A. R.,: ""Remington: The Science and Practice of Pharmacy, 20th ed.;"", 2000, LIPPINCOTT WILLIAMS & WILKINS",DISCONTINUED
795,AU,A,AU 1996/059750 A,062-117-961-861-466,1996-12-18,1996,AU 1996/059750 A,1996-06-03,GB 9510870 A;;GB 9513169 A;;GB 9603700 A;;US 9608547 W,1995-06-02,Subscriber terminal for a wireless telecommunications system,,DSC COMMUNICATIONS,LYSEJKO MARTIN;;LAMKIN RICHARD MORTIMER;;COOPER GUY ALEXANDER;;NETHERCOTT JONATHAN FRANCIS,,https://lens.org/062-117-961-861-466,Patent Application,no,0,0,7,251,0,H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J11/00;;H04J13/00;;H04J13/004;;H04L12/2825;;H04L12/2836;;H04L12/403;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04L2012/2841;;H04L2012/2845;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02;;H04W88/021;;H04L9/12;;H04L9/3226;;H04L2209/34;;H04L2209/80;;H04L69/08;;H04L69/14;;H04W88/021;;H04L41/0233;;H04J13/00;;H04Q2213/13376;;H04Q2213/13093;;H04Q2213/13199;;H04J13/004;;H04Q2213/13216;;H04Q2213/13335;;H04B1/7085;;H04Q2213/13098;;H04Q2213/1319;;H04L41/22;;H04W52/52;;H04B1/707;;H04B1/7075;;H04B1/7077;;H04B2201/7071;;H04L12/2825;;H04L12/66;;H04Q2213/13299;;H04B1/70735;;H04L41/0226;;H04W52/08;;H04B2201/70702;;H04Q2213/13296;;H04Q2213/1305;;H04J3/0682;;H04L2012/2845;;H04J11/00;;H04L12/2836;;H04Q11/04;;H04Q2213/13202;;H04W24/08;;H04Q2213/13292;;H04B2201/709709;;H04Q2213/13204;;H04W88/02;;H04L2012/2841;;H04Q2213/13298;;H04B2201/70706;;H04B2201/70711;;H04L43/00;;H04B1/70775;;H04B2001/70706;;H04L12/403;;H04W24/00;;H04Q2213/13109;;H04Q2213/13196;;H04L9/3226;;H04L9/12;;H04L2209/80;;H04L2209/34;;H04L69/14;;H04L69/08,H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02,,0,0,,,,PENDING
796,CN,A,CN 104755036 A,083-298-749-043-324,2015-07-01,2015,CN 201380055181 A,2013-09-18,AU 2013/001069 W;;AU 2012/904715 A,2012-10-26,Surgical system,"The present invention relates to, inter alia, a surgical system for monitoring the orientation of a surgical device relative to a patient's anatomy, the system comprising: a. A patient sensor for sensing the orientation of the patient's anatomy; b. An orientation sensor for sensing the orientation of a surgical device; and c. A monitor for monitoring the orientation of the surgical device relative to the sensed patient's anatomy.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/083-298-749-043-324,Patent Application,no,7,1,10,10,0,A61B34/20;;A61B34/20;;A61F2/4657;;A61B5/1121;;A61B5/1121;;A61B5/1121;;A61B5/4504;;A61B5/4504;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/4528;;A61B5/4571;;A61B5/4571;;A61B5/4571;;A61B5/6832;;A61B5/6834;;A61B5/6834;;A61B5/6834;;A61B17/1666;;A61B17/1666;;A61B17/1666;;A61B34/25;;A61B34/25;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61B2090/3983;;A61B2090/3983;;A61B2505/05;;A61B2505/05;;A61B2505/05;;A61B2562/0219;;A61B2562/0219;;A61B2562/0219;;A61B2562/17;;A61B2562/17;;A61F2/4609;;A61F2/4609;;A61F2/4609;;A61F2/4657;;A61F2/4657;;A61F2002/4668;;A61F2002/4668;;A61F2002/4668;;G06F19/3481;;G16H20/40;;G16H20/40,A61B17/58;;A61B5/103;;A61B17/56;;A61B19/00;;A61F2/32;;A61F2/46;;G06F19/00,,0,0,,,,DISCONTINUED
797,WO,A1,WO 2014/063181 A1,109-930-071-050-771,2014-05-01,2014,AU 2013/001069 W,2013-09-18,AU 2012/904715 A,2012-10-26,SURGICAL SYSTEM,"The present invention relates to, inter alia, a surgical system for monitoring the orientation of a surgical device relative to a patient's anatomy, the system comprising: a. A patient sensor for sensing the orientation of the patient's anatomy; b. An orientation sensor for sensing the orientation of a surgical device; and c. A monitor for monitoring the orientation of the surgical device relative to the sensed patient's anatomy.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/109-930-071-050-771,Patent Application,yes,3,47,10,10,0,A61B34/20;;A61B34/20;;A61F2/4657;;A61B5/1121;;A61B5/1121;;A61B5/1121;;A61B5/4504;;A61B5/4504;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/4528;;A61B5/4571;;A61B5/4571;;A61B5/4571;;A61B5/6832;;A61B5/6834;;A61B5/6834;;A61B5/6834;;A61B17/1666;;A61B17/1666;;A61B17/1666;;A61B34/25;;A61B34/25;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61B2090/3983;;A61B2090/3983;;A61B2505/05;;A61B2505/05;;A61B2505/05;;A61B2562/0219;;A61B2562/0219;;A61B2562/0219;;A61B2562/17;;A61B2562/17;;A61F2/4609;;A61F2/4609;;A61F2/4609;;A61F2/4657;;A61F2/4657;;A61F2002/4668;;A61F2002/4668;;A61F2002/4668;;G06F19/3481;;G16H20/40;;G16H20/40,A61B17/58;;A61B5/103;;A61B17/56;;A61B19/00;;A61F2/32;;A61F2/46;;G06F19/00,,1,0,,,See also references of EP 2911598A4,PENDING
798,CA,A1,CA 3054690 A1,116-360-044-578-273,2018-09-07,2018,CA 3054690 A,2018-03-01,US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490465 P;;US 201762490567 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510660 P;;US 201762510672 P;;US 201762511218 P;;US 201715616874 A;;US 2018/0020440 W,2017-03-01,COMPOSITIONS PURPOSEFULLY SELECTED COMPRISING PURIFIED CANNABINOIDS AND/OR PURIFIED TERPENES,"Disclosed herein are new compositions comprising a purified cannabinoid and a purified terpene. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnaturally occurring ratios. In one embodiment, the compositions comprise unnaturally occurring concentrations. In one embodiment, the compositions comprise unexpected and/or synergistic effects.",CANOPY GROWTH CORP,LEVY KURT;;COOPER JONATHAN MICHAEL;;MARTIN JONATHAN REED;;REID BRIAN GEOFFREY,,https://lens.org/116-360-044-578-273,Patent Application,no,0,0,11,36,0,A61K31/05;;A61K31/352,A01N65/00;;A61K31/05;;A61K31/352,,0,0,,,,PENDING
799,AU,B2,AU 724130 B2,137-904-284-693-304,2000-09-14,2000,AU 1999/022458 A,1999-03-29,AU 1999/022458 A;;AU 1996/064758 A,1996-06-03,Apparatus and method of synchronising signals in a wireless telecommunications system,,AIRSPAN NETWORKS INC,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,"AIRSPAN NETWORKS, INC. (2000-06-29)",https://lens.org/137-904-284-693-304,Granted Patent,no,3,0,4,4,0,H04J13/0048;;H04J13/12;;G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04J13/00;;H04L9/0662;;H04L9/12;;H04L9/3271;;H04L12/66;;H04Q11/04;;H04W52/08;;H04W52/52;;H04W84/14;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04L2209/80;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04L9/40,G06F8/71;;G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04J13/12;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
800,GB,A,GB 2260320 A,181-536-024-149-539,1993-04-14,1993,GB 9121675 A,1991-10-11,GB 9121675 A,1991-10-11,Liquid crystalline fluorophenyl derivatives,"Optically active fluorophenyl derivatives of the formula I, <IMAGE> wherein R<1> is an unsubstituted alkyl, alkenyl, polyfluoroalkyl or polyfluoroalkenyl radical or an alkyl, alkenyl, @@@@ polyfluoroalkyl or polyfluoroalkenyl radical @@@@ monosubstituted by CN, halogen or CF3, @@@@ in which the radical contains up to 15 C atoms and @@@@ in which one or more CH2 or CF2 @@@@ groups may be replaced by a radical selected from @@@@ the group comprising -S-, O, Si(CH3)2- <IMAGE> or -CO-, -CO-O-, -O-CO- or -O-CO-O-, @@@@ two oxygen and/or sulfur atoms not being adjacent, R<2> is alkyl or alkenyl with up to 8 C atoms, in which one CH2 group may be replaced by O, R<3> and R<4> are each independently H or alkyl with up to 5 C atoms o is 1 to 8, Q<1> is CH2 or CO, Z is -CO-O-, -O-CO-, -O-CH2- or a single bond, one of the ligands L<1> and L<2> is F the other is H or F. X and Y are each independently N or CH, and m is 0 or 1 are suitable as components of ferroelectric liquid crystalline mixtures.",MERCK PATENT GMBH,STYRING PETER;;GOODBY JOHN WILLIAM;;COOPER MARTIN E;;RICHARDS ROBERT D,,https://lens.org/181-536-024-149-539,Patent Application,no,0,2,3,3,0,C09K19/588;;C07D239/34;;C09K19/126;;C09K19/321;;C09K19/3463,C07D239/34;;C09K19/12;;C09K19/32;;C09K19/34;;C09K19/58,C2C CAA;;C2C CWK;;C2C C1600;;C2C C200;;C2C C22Y;;C2C C220;;C2C C25Y;;C2C C250;;C2C C252;;C2C C31Y;;C2C C311;;C2C C36Y;;C2C C364;;C2C C443;;C2C C634;;C2C C662;;C2C C672;;C2C C695;;C2C C697;;C2C C80Y;;C2C C821;;C4X X12           X12;;U1S S1387;;U1S S2285,0,0,,,,EXPIRED
801,AU,B2,AU 705738 B2,191-222-598-725-997,1999-06-03,1999,AU 1996/064758 A,1996-06-03,GB 9510870 A;;GB 9511546 A;;GB 9513170 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A;;US 9608568 W,1995-06-02,Apparatus and method of controlling transmitting power and transmit rate of a wireless telecommunications system,,DSC COMMUNICATIONS,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,"AIRSPAN NETWORKS, INC. (2000-06-29)",https://lens.org/191-222-598-725-997,Granted Patent,no,3,0,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
802,GB,A,GB 2370447 A,013-514-552-049-348,2002-06-26,2002,GB 0102013 A,2001-01-26,GB 0024535 A,2000-10-06,"Establishing values for stations in a network and disconnecting old, low value stations","Over an existing internet work, such as the Internet, individual systems, identified as reception stations (<B>201</B>) establish connections with a plurality of supplying stations (<B>202, 203, 204</B>). A valuation process (<B>206</B>) establishes the value of each of the connected supplying stations. An ordering process (<B>207</B>) identifies one or more connected supplying stations that provide a relatively low value. A reconnection process (<B>208</B>) disconnects one or more of the old connections (<B>202</B>) of low value and connects one or more replacement supplying stations (<B>205</B>).",BRIGHT STATION PLC,COBBY MATTHEW PETER;;COOPER DAVID;;HARRIS IAN MURRAY;;SCHOUTEN HENDRICK MARTIN,,https://lens.org/013-514-552-049-348,Patent Application,no,3,0,6,6,0,H04L67/14;;H04L67/10;;H04L69/329;;H04L67/10015;;H04L67/1001,H04L29/06;;H04L29/08,H4K KFMA          KFMA,0,0,,,,DISCONTINUED
803,EP,B1,EP 2271315 B1,032-296-816-053-321,2016-09-14,2016,EP 09723661 A,2009-03-26,US 2009/0001956 W;;US 3975208 P,2008-03-26,SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,,CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,"CEPHALON LLC; US (2023-02-28);;CEPHALON LLC, WEST CHESTER, US (2022-10-21);;CEPHALON LLC (2023-01-30)",https://lens.org/032-296-816-053-321,Granted Patent,yes,3,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/14;;A61K9/19;;A61K31/4184,,1,0,,,"RIBOSEPHARM: ""Product monograph ribosepharm passage"" PRODUCT MONOGRAPH RIBOSEPHARM, XX, XX, 1 January 2005 (2005-01-01), pages 3-73, XP002368437",ACTIVE
804,GB,B,GB 2301743 B,044-581-450-027-943,2000-01-26,2000,GB 9603700 A,1996-02-21,GB 9603700 A;;GB 9510870 A;;GB 9513169 A,1995-06-02,Subscriber terminal for a wireless telecommunications system,,DSC COMMUNICATIONS;;DSC TELECOM LP;;AIRSPAN COMM CORP,LYSEJKO MARTIN;;LAMKIN RICHARD MORTIMER;;NETHERCOTT JONATHAN FRANCIS;;COOPER GUY ALEXANDER,,https://lens.org/044-581-450-027-943,Granted Patent,no,4,0,7,251,0,H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J11/00;;H04J13/00;;H04J13/004;;H04L12/2825;;H04L12/2836;;H04L12/403;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04L2012/2841;;H04L2012/2845;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02;;H04W88/021;;H04L9/12;;H04L9/3226;;H04L2209/34;;H04L2209/80;;H04L69/08;;H04L69/14;;H04W88/021;;H04L41/0233;;H04J13/00;;H04Q2213/13376;;H04Q2213/13093;;H04Q2213/13199;;H04J13/004;;H04Q2213/13216;;H04Q2213/13335;;H04B1/7085;;H04Q2213/13098;;H04Q2213/1319;;H04L41/22;;H04W52/52;;H04B1/707;;H04B1/7075;;H04B1/7077;;H04B2201/7071;;H04L12/2825;;H04L12/66;;H04Q2213/13299;;H04B1/70735;;H04L41/0226;;H04W52/08;;H04B2201/70702;;H04Q2213/13296;;H04Q2213/1305;;H04J3/0682;;H04L2012/2845;;H04J11/00;;H04L12/2836;;H04Q11/04;;H04Q2213/13202;;H04W24/08;;H04Q2213/13292;;H04B2201/709709;;H04Q2213/13204;;H04W88/02;;H04L2012/2841;;H04Q2213/13298;;H04B2201/70706;;H04B2201/70711;;H04L43/00;;H04B1/70775;;H04B2001/70706;;H04L12/403;;H04W24/00;;H04Q2213/13109;;H04Q2213/13196;;H04L9/3226;;H04L9/12;;H04L2209/80;;H04L2209/34;;H04L69/14;;H04L69/08,H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02,H4L LECC          NONE;;H4L LFM           LFM;;H4L LFMX          LFMX;;H4L L1H10         LFM;;H4L L30           LFM,0,0,,,,EXPIRED
805,US,B2,US 6939844 B2,095-939-304-561-041,2005-09-06,2005,US 87391304 A,2004-06-22,US 87391304 A;;US 30763402 A;;US 26908699 A;;US 2644296 P;;US 9716690 W,1996-09-19,"Concentrated, preferably biodegradable, quaternary ammonium fabric softener compositions containing cationic polymers and process for preparation","The present invention relates to aqueous stable, preferably concentrated, aqueous liquid textile softening compositions comprising fabric softener active and cationic polymer in the continuous aqueous phase to provide improved softening. The compositions of the present invention preferably contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 140. The cationic polymers can provide additional benefits such as dye transfer inhibition, chlorine scavenging to protect fabrics, cotton soil release benefits, etc.",PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMANN;;WARD RICHARD MARTIN,,https://lens.org/095-939-304-561-041,Granted Patent,yes,59,4,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D1/62;;D06M13/322;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,510/527;;510/470;;510/466;;510/522,2,0,,,"Marvin W. Formo, Eric Jungermann, Frank A. Norris, Norman O. V. Sonntag, Reactions in the Fatty Acid Chain, Bailey's Industrial Oil and Fat Products, 1979, pp. 114 & 115, 342-343, vol. 1, Fourth Edition, A Wiley-Interscience Publication, United States.;;Prof. Dr. J. Falbe, Cosmetics and Toiletries Guide Compositions, Surfactants in Consumer Products, 1987, Springer-Verlag Heidleberg, Germany.",EXPIRED
806,TR,T1,TR 199701493 T1,105-473-934-735-383,1998-04-21,1998,TR 9701493 T,1996-06-03,GB 9510870 A;;GB 9511546 A;;GB 9513170 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A,1995-06-02,Telsiz Telekomünikasyon sisteminin aktarim kontrolü için cihaz/yöntem.,"Bir abone terminaline (20) radyofrekans sinyalleri iletmeye ve buradan radyofrekans sinyalleri almaya yönelik merkezi bir terminali (l0) kapsayan, kablosuz bir telekomünikasyon sistemi.",DSC COMM CORP,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,,https://lens.org/105-473-934-735-383,Patent Application,no,0,0,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,PENDING
807,WO,A3,WO 2012/087616 A3,121-812-410-599-417,2012-08-23,2012,US 2011/0064207 W,2011-12-09,US 97421610 A,2010-12-21,POLYMER SUBSTRATES HAVING IMPROVED BIOLOGICAL RESPONSE FROM HKDCS,"A method of surface modification of a biocompatible, biodegradable polymer substrate using RF plasma treatment is disclosed. This method and the resulting surface provide for enhanced adhesion and proliferation of cells, such as hKDCs, and can be used with scaffolds for tissue regeneration and with other delivery vehicles such as medical devices.",ATRM LLC;;COOPER KEVIN L;;MARTIN ALISHA;;NATARAJAN SRIRAM;;VETRECIN ROBERT;;LIU CHANGDENG,COOPER KEVIN L;;MARTIN ALISHA;;NATARAJAN SRIRAM;;VETRECIN ROBERT;;LIU CHANGDENG,,https://lens.org/121-812-410-599-417,Search Report,yes,2,0,4,4,0,B29C59/14;;C08J3/28;;C08J7/12;;Y10T428/24355;;Y10T428/24355;;C08J3/28;;C08J7/12;;B29C59/14,B29C59/14;;C08J3/28;;C08J7/12,,0,0,,,,PENDING
808,MX,A,MX 2019010370 A,114-704-948-114-731,2019-10-22,2019,MX 2019010370 A,2018-03-01,US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490567 P;;US 201762490465 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510672 P;;US 201762510660 P;;US 201762511218 P;;US 201715616874 A;;US 2018/0020440 W,2017-03-01,COMPOSITIONS PURPOSEFULLY SELECTED COMPRISING PURIFIED CANNABINOIDS AND/OR PURIFIED TERPENES.,"Disclosed herein are new compositions comprising a purified cannabinoid and a purified terpene. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnaturally occurring ratios. In one embodiment, the compositions comprise unnaturally occurring concentrations. In one embodiment, the compositions comprise unexpected and/or synergistic effects.",CANOPY GROWTH CORP,JONATHAN MICHAEL COOPER;;KURT LEVY;;JONATHAN REED MARTIN;;BRIAN GEOFFREY REID,,https://lens.org/114-704-948-114-731,Patent Application,no,0,0,11,36,0,A61K31/05;;A61K31/352,A61K31/352;;A01N65/00;;A61K31/05,,0,0,,,,PENDING
809,NO,L,NO 991203 L,127-914-721-795-613,1999-05-19,1999,NO 991203 A,1999-03-11,US 2644296 P;;US 9716690 W,1996-09-19,Konsentrerte kvaternµre ammonium tekstilmykner-blandinger inneholdende katjoniske polymerer,"Vandige stabile, fortrinnsvis konsentrerte, vandige flytende tekstilmykgj ørende sammensetninger inneholder et tekstilmykningsaktivt middel og kationisk polymer i den kontinuerlige vandige fase for å tilveiebringe en forbedret mykgjøring. Sammensetningene ifølge forelig- gende oppfinnelse inneholder fortrinnsvis diester-kva- ternære ammonium-forbindelser hvor fettsyreacylgruppene har en IV-verdi fra 5-140. De kationiske polymerer kan tilveiebringe ytterligere fordeler såsom fargeoverfø- ringshemming, klorrensing for å beskytte tekstiler, bomullssmussløsende fordeler osv.",PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/127-914-721-795-613,Abstract,no,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D1/62;;D06M13/322;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,PENDING
810,WO,A1,WO 2016/149764 A1,165-964-317-246-624,2016-09-29,2016,AU 2016/050220 W,2016-03-24,AU 2015/901083 A,2015-03-25,ALIGNMENT APPARATUS,"The present invention relates to an apparatus for aligning a sensor relative to at least two anatomical reference points of a patient's anatomy. In one embodiment, the apparatus includes: a body having a central axis; a sensor mount positioned relative to the body; at least two arms extending from the body, wherein two of said at least two arms are simultaneously and equidistantly moveable relative to the central axis; and at least two aligners connected to the at least two arms for aligning with said at least two anatomical reference points. The apparatus may also include an apparatus sensor. The present invention also relates to a surgical system for monitoring the orientation of a patient's anatomy, which includes the apparatus. Furthermore, the present invention also relates to a surgical system for guiding a surgical device to an optimal orientation relative to a patient's anatomy, wherein the surgical system includes the apparatus. The present invention also relates to: a method of aligning a sensor relative to at least two anatomical reference points of a patient's anatomy, and to a method of guiding a surgical device to an optimal orientation relative to a patient's anatomy. In one embodiment, the patient's anatomy is the pelvis.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/165-964-317-246-624,Patent Application,yes,6,2,7,7,0,A61B17/1746;;A61B17/1746;;A61B34/20;;A61B34/20;;A61B34/20;;A61B34/25;;A61B34/25;;A61B90/37;;A61B90/37;;A61B2017/00734;;A61B2017/00734;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61F2/4603;;A61F2/4607;;A61F2/4609;;A61F2/4657;;A61F5/11;;A61F5/11;;A61F2002/4687,A61B34/20;;A61F5/11,,1,0,,,See also references of EP 3273895A4,PENDING
811,CA,C,CA 2935094 C,197-610-145-433-37X,2018-10-16,2018,CA 2935094 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS,A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/197-610-145-433-37X,Granted Patent,no,0,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,ACTIVE
812,ZA,B,ZA 964150 B,189-364-989-302-715,1996-12-03,1996,ZA 964150 A,1996-05-23,GB 9510870 A,1995-06-02,Apparatus and method of controlling transmitting power in a subscriber terminal of a wireless telecommunications system,,DSC COMMUNICATIONS,COOPER IAN LESLIE;;LYSEJKO MARTIN;;BHAGALIA SHASHIKANT;;YEUNG JOEMANN CHI CHEUNG,,https://lens.org/189-364-989-302-715,Granted Patent,no,0,0,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
813,US,B2,US 9158520 B2,196-539-255-306-253,2015-10-13,2015,US 201213550914 A,2012-07-17,US 201213550914 A;;US 201213437494 A;;US 201161568056 P,2011-12-07,Development of platform independent applications,"Method, system, and programs for providing packages to applications is disclosed. An application that is executable on a plurality of device platforms is generated. The application is deployed to a client device. A package list received from the client device is analyzed to determine package dependencies for packages on the package list. The packages on the package list and dependent packages are provided based on the package dependencies to the client device. The packages and dependent packages may be installed by the client device to ensure that the application is executable based on characteristics of the client device.",FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N;;YAHOO INC,FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,YAHOO! INC (2016-05-31);;EXCALIBUR IP LLC (2016-05-31);;R2 SOLUTIONS LLC (2020-04-28),https://lens.org/196-539-255-306-253,Granted Patent,yes,36,0,3,13,0,G06F8/60;;H04L67/01;;G06F8/60;;G06F8/65;;H04L67/10,G06F9/44;;G06F9/445,,22,1,042-748-563-752-489,10.1109/icse.2007.59,"International Search Report corresponding to PCT/US2012/64786 dated Mar. 28, 2013.;;Office Action issued on Jun. 12, 2014 in U.S. Appl. No. 13/437,494.;;Office Action issued on Jul. 25, 2014 in U.S. Appl. No. 13/437,462.;;Preliminary Report on Patentability issued on Jun. 19, 2014 in PCT/US2012/064786.;;Office Action issued on Apr. 9, 2014 in U.S. Appl. No. 13/729,162.;;Office Action issued on Sep. 9, 2014 in U.S. Appl. No. 13/719,437.;;Office Action issued on Sep. 11, 2014 in U.S. Appl. No. 13/729,162.;;Moshchuk et al., ""Resource Management for Web Applications in ServiceOS"", May 2010, Microsoft Research, Retrieved from http://research.microsoft.com/apps/pubs/default.aspx?id=131540, 15 pages.;;Office Action issued on Oct. 23, 2014 in U.S. Appl. No. 13/719,515.;;Notice of Allowance issued on Nov. 18, 2014 in U.S. Appl. No. 13/437,462.;;Office Action issued on Jan. 26, 2015 in U.S. Appl. No. 13/719,437.;;Office Action issued on Dec. 24, 2014 in U.S. Appl. No. 13/437,494.;;Office Action issued on Feb. 11, 2015 in U.S. Appl. No. 13/719,515.;;Office Action issued on Feb. 13, 2015 in U.S. Appl. No. 13/729,162.;;R. Haratsch, ""A client-server architecture for providing client-specific network services on the application layer"", 2001, In Proceedings of APC 2001, Munich, Germany, 10 pages.;;Office Action issued on May 6, 2015 in U.S. Appl. No. 13/437,494.;;Office Action issued on May 14, 2015 in U.S. Appl. No. 13/719,437.;;Office Action issued Jun. 4, 2015 in U.S. Appl. No. 13/719,515.;;Notice of Allowance issued Aug. 19, 2015 in U.S. Appl. No. 13/437,494.;;Chris Tucker, ""Opium: Optimal Package Install/Uninstall Manager,"" 29th International Conference on Software Engineering, 2007.;;Office Action issued Jul. 29, 2015 in U.S. Appl. No. 13/729,162.;;Kosta et al., ""Unleashing the Power of Mobile Cloud Computing using ThinkAir"", May 2011, retrieved from Cornell University Library, http://arvix.org/abs/1105.3232, 17 pages.",INACTIVE
814,WO,A1,WO 2013/085674 A1,024-047-446-279-173,2013-06-13,2013,US 2012/0064786 W,2012-11-13,US 201161568056 P;;US 201213437462 A,2011-12-07,DEVELOPMENT AND HOSTING FOR PLATFORM INDEPENDENT APPLICATIONS,"Method, system, and programs for providing development, deployment and hosting of applications that are interoperable across different device platforms, An application capable of being executed in a plurality of different device formats is generated. The application is deployed to a client device for execution at the client device. Execution of the same application is initiated at a server.",YAHOO INC;;FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,,https://lens.org/024-047-446-279-173,Patent Application,yes,4,0,5,13,0,G06F8/60;;G06F8/60;;G06F9/45529;;G06F9/45529,G06F9/44;;G06F9/30;;G06F15/16,,0,0,,,,PENDING
815,US,A1,US 2004/0235707 A1,102-722-514-534-409,2004-11-25,2004,US 87391304 A,2004-06-22,US 87391304 A;;US 30763402 A;;US 26908699 A;;US 2644296 P;;US 9716690 W,1996-09-19,"Concentrated, preferably biodegradable, quaternary ammonium fabric softener compositions containing cationic polymers and process for preparation","
   The present invention relates to aqueous stable, preferably concentrated, aqueous liquid textile softening compositions comprising fabric softener active and cationic polymer in the continuous aqueous phase to provide improved softening. 

   The compositions of the present invention preferably contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 140. The cationic polymers can provide additional benefits such as dye transfer inhibition, chlorine scavenging to protect fabrics, cotton soil release benefits, etc. 
",PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/102-722-514-534-409,Patent Application,yes,23,8,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D1/62;;D06M13/322;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,510/515,0,0,,,,EXPIRED
816,US,B1,US 6324208 B1,139-253-851-835-409,2001-11-27,2001,US 97329198 A,1998-04-20,US 97329198 A;;GB 9511546 A;;GB 9510870 A;;GB 9513166 A;;GB 9513168 A;;GB 9513170 A;;GB 9513172 A;;US 9608568 W,1995-06-02,Apparatus and method of controlling transmitting power in a subscriber of a wireless telecommunications system,"A wireless telecommunications systems (1) includes a central terminal (10) for transmitting and receiving radio frequency signals to and from a subscriber terminal (20). A downlink communication path is established from a transmitter (200) of the central terminal (10) to a receiver (202) of the subscriber terminal (20). A downlink signal (212) is transmitter from the transmitter (200) to the receiver (202) during setup and operation of the wireless telecommunications system (1). The receiver (202) of the subscriber terminal (20) compares a code and phase of a master code sequence in the downlink signal (212) to a code and phase of a slave code sequence of the receiver (202). The receiver (202) adjusts the phase of the slave code sequence until a match is obtained with the master code sequence. The downlink signal (212) includes an overhead channel (224) having a power control signal (236), a code synchronization signal (234), and a frame alignment signal (232). The power control signal (236) is capable of adjusting a transmitting power of a transmitter (204) in the subscriber terminal (20). The code synchronization signal (234) is capable of adjusting a phase of a transmitter (204) in the subscriber terminal (20). A receiver (206) in the central terminal (10) monitors an uplink signal (214) transmitted by the transmitter (204) in the subscriber terminal and provides changes to the code synchronization signal (234) such that the transmitter (204) is synchronized to the receiver (206). The receiver (202) monitors the downlink signal (212) to identify the frame alignment signal (232) and establishes the downlink communication path when two successive frame alignment signals (232) are identified. The wireless telecommunications system (1) operates in one of three operating modes. In an acquisition mode during establishment of the downlink communication path, the downlink signal (212) is transmitted at a high power level and a low transmit rate with the receiver (202) operating at the low transmit rate. In a standby mode after establishment of the downlink communication path, the downlink signal (212) is transmitted at a low power level and a low transmit rate with the receiver (202) operating at the low transmit rate. In a traffic mode upon a request for wireless communication transmission, the downlink signal (212) is transmitted at a high power level and a high transmit rate with the receiver (202) adjusting to operate at the high transmit rate. Upon completion of the wireless communication transmission, the wireless telecommunications system (1) returns to the standby mode and the receiver (202) adjusts to operate at the low transmit rate.",AIRSPAN NETWORKS INC,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN L;;LYSEJKO MARTIN,DSC COMMUNICATIONS CORPORATION (1996-06-28);;AIRSPAN MERGER CORPORATION (1999-08-06);;AIRSPAN NETWORKS INC (1999-12-15);;DSC TELECOM L.P (1998-01-01);;DSC COMMUNICATIONS CORPORATION A DE CORP (1996-08-19);;AIRSPAN COMMUNICATIONS CORPORATION (1999-08-06);;WI-LAN INC (2009-06-22);;MONUMENT BANK OF INTELLECTUAL PROPERTY LLC (2016-02-09),https://lens.org/139-253-851-835-409,Granted Patent,yes,9,1,1,251,0,H04B1/7075;;H04J13/00;;H04W52/08;;H04W84/14;;H04J13/00;;H04W52/08;;H04W84/14;;H04B1/7075,H04B1/7075;;H04B7/005;;H04J13/00;;H04L12/28;;H04W52/00;;H04W52/02;;H04W52/08;;H04W84/14,375/145;;375/367,0,0,,,,EXPIRED
817,US,B2,US 10517852 B2,175-791-401-464-616,2019-12-31,2019,US 201816037560 A,2018-07-17,US 201816037560 A;;US 201615045523 A;;US 201414531023 A;;US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Solid forms of bendamustine hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/175-791-401-464-616,Granted Patent,yes,110,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K47/26;;A61K9/00;;A61K9/14;;A61K9/19;;A61K31/4184;;C07D235/16,,184,106,020-435-634-003-86X;;034-919-505-845-111;;111-707-255-990-821;;111-707-255-990-821;;008-049-969-734-752;;047-514-341-188-034;;125-764-802-071-090;;125-764-802-071-090;;097-968-278-331-650;;001-057-881-376-802;;020-435-634-003-86X;;063-402-864-700-686;;063-402-864-700-686;;023-549-427-997-819;;023-549-427-997-819;;113-421-979-742-187;;113-421-979-742-187;;067-512-968-604-94X;;067-512-968-604-94X;;026-749-101-639-830;;049-256-800-886-311;;016-225-481-277-607;;000-824-480-216-064;;019-765-733-477-303;;044-553-566-435-465;;020-427-831-437-122;;020-427-831-437-122;;074-470-545-310-545;;074-470-545-310-545;;085-288-603-536-357;;106-081-384-040-520;;081-235-410-973-708;;027-084-824-706-497;;027-084-824-706-497;;080-209-105-337-208;;080-209-105-337-208;;069-673-960-292-160;;006-046-706-830-252;;123-775-514-819-528;;132-558-386-999-186;;069-673-960-292-160;;006-046-706-830-252;;123-775-514-819-528;;132-558-386-999-186;;009-214-187-079-899;;009-214-187-079-899;;005-472-156-687-716;;007-364-858-655-289;;084-716-889-422-831;;084-716-889-422-831;;038-837-301-231-480;;057-331-944-087-540;;057-331-944-087-540;;057-331-944-087-540;;129-761-775-931-754;;081-715-672-716-376;;032-762-736-441-020;;074-976-826-866-732;;018-401-488-842-341;;148-058-662-532-321;;073-979-246-973-627;;091-085-371-888-026;;035-170-074-738-780;;008-471-714-901-161;;145-863-150-069-92X;;089-369-742-180-813;;021-472-443-024-00X;;034-348-169-230-065;;084-716-889-422-831;;057-884-013-276-829;;057-884-013-276-829;;066-104-761-926-125;;111-136-664-680-684;;059-280-286-824-398;;059-280-286-824-398;;091-079-688-402-134;;091-079-688-402-134;;001-658-497-635-033;;001-658-497-635-033;;093-799-759-321-023;;015-536-704-932-237;;043-613-338-330-851;;022-818-443-442-270;;014-549-027-288-910;;029-880-686-607-107;;029-880-686-607-107;;125-900-851-516-31X;;108-687-604-265-588;;004-291-817-534-209;;004-291-817-534-209;;055-433-061-655-828;;055-433-061-655-828;;013-802-099-433-937;;127-003-929-505-550;;127-003-929-505-550;;067-465-907-694-241;;003-701-346-326-00X;;023-237-704-770-485;;003-701-346-326-00X;;023-237-704-770-485;;023-237-704-770-485;;034-919-505-845-111;;025-366-516-718-464;;016-893-762-306-578;;007-820-533-816-52X;;096-231-155-393-197,10.1016/j.addr.2003.10.020;;14962582;;4095129;;10.1053/sonc.2002.34876;;10.1016/s0093-7754(02)90011-4;;12170429;;10.1053/sonc.2002.34876;;10.1016/s0093-7754(02)90011-4;;12170429;;9653754;;10.3109/10837459809028493;;10927911;;10.1080/1042819042000198858;;15359644;;10.1080/1042819042000198858;;15359644;;11532568;;10.1016/s0378-5173(01)00757-8;;11107838;;10.1016/j.addr.2003.10.020;;14962582;;12029443;;10.1007/s00432-002-0331-8;;12029443;;10.1007/s00432-002-0331-8;;10.1097/00001813-200008000-00003;;11036955;;10.1097/00001813-200008000-00003;;11036955;;10.2165/00044011-200424100-00007;;17523723;;10.2165/00044011-200424100-00007;;17523723;;15223642;;10.1080/1042819042000223822;;15223642;;10.1080/1042819042000223822;;10.1021/js980001d;;9687336;;10.1007/s004320000180;;11206271;;10.1023/a:1016233408831;;7596981;;7596982;;10.1023/a:1016285425670;;10.3109/03639049609108353;;10.1097/00001813-200110000-00003;;11593053;;10.1007/bf00807895;;10.1007/bf00807895;;12170425;;10.1053/sonc.2002.34872;;12170425;;10.1053/sonc.2002.34872;;10.1158/1078-0432.ccr-08-3041;;pmc2795094;;19996200;;18182663;;10.1200/jco.2007.12.5070;;5471331;;10.3109/02652048609031561;;3508181;;10.3109/02652048609031561;;3508181;;12170424;;10.1053/sonc.2002.34871;;12170424;;10.1053/sonc.2002.34871;;12948851;;10.1016/s0006-2952(03)00410-6;;11410411;;12691159;;10.1080/1042819021000054670;;11801463;;12948851;;10.1016/s0006-2952(03)00410-6;;11410411;;12691159;;10.1080/1042819021000054670;;11801463;;10.1023/a:1016241927429;;7494814;;10.1023/a:1016241927429;;7494814;;12458340;;10.1007/s00432-002-0378-6;;10.1002/jps.2600660104;;833720;;10.2165/00003495-200161050-00009;;11368287;;10.2165/00003495-200161050-00009;;11368287;;10.1201/9780203743676;;10.1053/sonc.2002.34875;;10.1016/s0093-7754(02)90010-2;;12170428;;10.1053/sonc.2002.34875;;10.1016/s0093-7754(02)90010-2;;12170428;;10.1053/sonc.2002.34875;;10.1016/s0093-7754(02)90010-2;;12170428;;10.1021/jm00012a027;;7783158;;10.1002/app.1991.070420733;;10.3109/10715769409147509;;7516789;;9277127;;10.1023/b:rjac.0000024593.20803.6d;;1127599;;10.1002/jps.2600640243;;10.1201/9781420009552;;10.1201/9781420026054;;4087195;;10.1002/jps.2600741208;;14076497;;10.1002/jps.2600521003;;10.1021/jm00165a019;;2308133;;12379914;;10.1002/jps.10154;;10.1021/ac60175a029;;14907489;;10.1002/jps.3030410112;;10.2165/00003495-200161050-00009;;11368287;;11862482;;10.1007/s00432-001-0303-4;;11862482;;10.1007/s00432-001-0303-4;;11948553;;10.1002/jps.10113;;10.1021/js9702832;;9548903;;3615563;;3615563;;10.1093/annonc/mdf189;;12181253;;10.1093/annonc/mdf189;;12181253;;15621757;;10.1080/10428190400004521;;15621757;;10.1080/10428190400004521;;11999564;;10.1080/10428190290006107;;14762909;;10.1002/jps.10590;;15771242;;10.1007/s11095-004-9021-3;;11849908;;10.1016/s0928-0987(01)00221-4;;15032301;;10.1023/b:pham.0000016234.73023.75;;10.1097/00001813-199606000-00007;;8826610;;10.1097/00001813-199606000-00007;;8826610;;4032158;;10.1038/sj.leu.2402651;;12357363;;10.1016/s0093-7754(02)90009-6;;10.1053/sonc.2002.34874;;12170427;;10.1016/s0093-7754(02)90009-6;;10.1053/sonc.2002.34874;;12170427;;10.1007/pl00008463;;10641748;;10.1007/pl00008463;;10641748;;15577312;;10.1097/00008390-200412000-00001;;3380859;;3380859;;10.1007/bf02041437;;12170426;;10.1016/s0093-7754(02)90008-4;;10.1053/sonc.2002.34873;;12170430;;10.1016/s0093-7754(02)90012-6;;10.1053/sonc.2002.34877;;12170426;;10.1016/s0093-7754(02)90008-4;;10.1053/sonc.2002.34873;;12170430;;10.1016/s0093-7754(02)90012-6;;10.1053/sonc.2002.34877;;12170430;;10.1016/s0093-7754(02)90012-6;;10.1053/sonc.2002.34877;;4095129;;19860651;;10.2174/156652309789753392;;pmc2864134;;10.1038/nrd2155;;17159925;;21091654;;10.1111/j.1476-5381.2010.01127.x;;pmc3058157;;10.3816/clml.2010.n.002;;20223726,"EC Safety Data Sheet: Ribomustin® in www.asl.ri.it/staff/prevenzione/documentazione /Chemio/Ribomustin%20scheda%20di%20sicurezza.pdf (published: Jul. 3, 1998; updated Mar. 1, 2007) (Year: 2007).;;Morissette et al. In Drug Delivery Reviews, 56 (2004) 275-300 (Year: 2004).;;Preiss et al., “Pharmacokinetics of bendamustine (Cytostasan) in patients”, Pharmazie, 1985, 40(11), 782-784.;;Ponisch, Wolfram et al., Bendamustine in the treatment of Multiple Myeloma: Results and future perspectives, Seminars in Oncology, 2002, pp. 23-26, vol. 29 No. 4 Suppl. 13.;;Ponisch et al., “Bendamustine in the Treatment of Multiple Myeloma: Results and Future Perspectives”, Seminars in Oncology, Suppl. 13, 2002, 29(4), 23-26.;;Ozegowski et al., IMET 3393 y-[-methyl-5-bis-(P-chloroethyl)-aminoben zimidazolo-(2)]-butyryl chloride, a new cytostatic agent of the group of benzimidazole nitrogen mustards, ZBL Pharm, vol. 110, No. 10, 1971, pp. 1013-1019.;;Ozegowski et al., “IMET 3393, gamma-(1-methyl-5-bis-(.beta.-chlorathyl)-amino-benzimidazolyl(2)-butters-aure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste”, Zbl Pharm., 1971;110, Heft 10, 1013-1019.;;Oesterle, et al., “The influence of Tertiary Butyl Alcohol and Volatile Salts on the Sublimation of Ice from Frozen Sucrose Solutions: Implications for Freeze- Drying” Pharmaceutical Development and Technology, 1988, 3(2), 175-183.;;Nuijen, B., 37 Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Novel Antitumor Agent Aplidine PDA Journal of Pharmaceutical Science and Technology, May/Jun. 2000, 54(3), 193-208.;;Nowak, Daniel et al., Upon Drug-Induced Apoptosis in Lymphoma Cells X-linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus, Leukemia & Lymphoma, 2004, pp. 1429-1436, vol. 45(7).;;Nowak et al, “Upon Drug-Induced Apoptosis in Lymphoma Cells X-linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus”, Leukemia & Lymphoma, 2004, 45(7), 1429-1436.;;Niemeyer, Christina C. et al., SDX-105 (bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action, Proc Annu Meet Am Assoc Cancer Res, 2004, vol. 45:1st ed.;;Niemeyer et al., “SDX-105 (bendamustine) is a Clinically active Chemotherapeutic agent with a distinct mechanism of action”, Proc Annu Meet Am Assoc Cancer Res., 2004, 45(1), 2 pages.;;Ni et al, Use of pure t-butanol as a solvent for freeze-drying: a case study, 2001, International Journal of Pharmaceitcs, vol. 2001, pp. 39-46.;;Mundipharma GmbH, Ribomustin EC Safety Data Sheet in accordance with 91/155/EEC. Eight Pages, Jan. 3, 2007.;;Mottu et al., “Organic solvents for pharmaceutical parenterals and embolic liquids: A review of toxicity data,” PDA J. Pharma. Sci. & Tech. 54(6) Nov.-Dec. 2000, 456-469.;;Morissette et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids”, Advanced Drug Delivery Reviews, Feb. 2004, 56(3), 275-300.;;Morissette et al. In Drug Delivery Reviews, 56 (2004) 275-30.;;McKim et al., “Dimethyl Sulfoxide USP, PhEur in Approved Pharmaceutical Products and Medical Devices,” Pharmaceutical Technology, May 2, 2008, 1-7.;;Maas, Stabilitat von Benamustinhydrochlorid in Infusionslosungen Pharmazie, vol. 49, No. 10, 1994, pp. 775-777. (translation included).;;Maas, B., “Stability of bendamustine hydrochloride in infusions” Pharmazie, 1994, 775-777.;;Maas, “Stability of Bendamustine Hydrochloride in Infusion Solutions”, 1994, 49(10), 9 pages.;;Leoni, LM et al., Sdx-105 (Trenda), Active in Non-Hodgkins Lymphoma Cells, Induces the Mitotic Catastrophe Death Pathway, Blood, 2004, vol. 104(11): Abs 4593.;;Leoni et al., “Sdx-105 (Trenda), Active in Non-Hodgkin's Lymphoma Cells, Induces the Mitotic Catastrophe Death Pathway”, Blood, 2004, 104(11), (Abstract).;;Konstantinov, S. M. et al., Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines, Journal of Cancer Research and Clinical Oncology, 2002, pp. 271-278, vol. 128(5).;;Konstantinov et al., “Cytotoxic Efficacy of Bendamustine in Human Leukemia and Breast Cancer cell lines”, Journal of Cancer Research and Clinical Oncology, 2002, 128(5), 271-278.;;Kollmannsberger, Christian et al., Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer, Anti-Cancer Drugs, 2000, pp. 535-539, vol. 11(7).;;Kollmannsberger et al., “Phase II study of Bendamustine in Patients with relapsed or cisplatin-refractory germ cell Cancer”, Anti-Cancer Drugs, 2000, 11(7), 535-539.;;Koester, Wolf et al., Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small lung cancer (SCLC), Clinical Drug Investigation, 2004, pp. 611-618, vol. 24(10).;;Koester et al., “Carboplatin in Combination with bendamustine in previously untreated patients with extensive-stage small lung cancer (SCLC)”, Clinical Drug Investigation, 2004, 24(10), 611-618.;;Koenigsman, Michael et al., Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO), Leukemia & Lymphoma. 2004, pp. 1821-1827, vol. 45(9).;;Koenigsman et al., “Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase 1/11 Trial of the East German Society of Hematology and Oncology (OSHO)”, Leukemia & Lymphoma, 2004, 45(9), 1821-1827.;;Kim, et al., “The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute” Journal of Pharmaceutical Sciences, 87(8), Aug. 1998, 931-935.;;Kibbe, Arthur, H., Handbook Pharmaceutical Excipients, 3rd Edition, 2000, Mannitol, American Pharmaceutical Association and Pharmaceutical Press.;;Kath et al., “Bendamustine Monotherapy in advanced and refractory chronic lymphocytic Leukemia”, Journal of Cancer Research and Clinical Oncology, 2001, 127(1), 48-54.;;Kasraian et al., “Thermal analysis of the tertiary butyl alcohol-water system and its implications on freeze-drying”, 1995, Pharm. Res, 12(4), 484-90, hier: Zusammenfassung.;;Kasraian et al., “The effect of tertiary butyl alcohol on the resistance of the dry product layer during primary drying”, 1995, Pharm. Res, 12(4), 491-495, hier: Zusammenfassung.;;Kanekal et al., Kanekal et al. (SDX-105(TREANDA) Enhances the Tumor Growth Inhibitory Effect of Rituximab in Daudi Lymphoma Xenografts, 2004, Blood (ASH Annual Meeting Abstracts), vol. 104.;;Jonkmann-de Vries et al., “Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review Drug Development and Industrial Pharmacy”, 1996, 22(6), 475-494.;;Jennings,Thomas A, “Extracts from ”Lyophilization. Introduction and Basic Principles. 2002, by CRC Press LLC, Boca Raton, Florida, 33431.;;In the United States District Court in and for the District of Delaware; In Re Bendamustine Consolidated Civil Action No. 13-2046; Wilmington Delaware Wednesday, Dec. 3, 2015, Trial Day 3.;;In the United States District Court in and for the District of Delaware; In Re Bendamustine Consolidated Civil Action No. 13-2046; Wilmington Delaware Tuesday, Dec. 8, 2015, Trial Day 6.;;In the United States District Court in and for the District of Delaware; In Re Bendamustine Consolidated Civil Action No. 13-2046; Wilmington Delaware Tuesday, Dec. 2, 2015, Trial Day 2.;;In the United States District Court in and for the District of Delaware; In Re Bendamustine Consolidated Civil Action No. 13-2046; Wilmington Delaware Thursday, Dec. 4, 2015, Trial Day 4.;;In the United States District Court in and for the District of Delaware; In Re Bendamustine Consolidated Civil Action No. 13-2046; Wilmington Delaware Monday, Dec. 7, 2015, Trial Day 5.;;Heider et al., “Efficacy and Toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas”, Anti-Cancer Drugs, 2001, 12(9), 725-729.;;Gust, R. et al., Investigations on the Stability of Bendamustin, a Cytostatic Agent of the Nitrogen Mustard Type, I. Synthesis, Isolation, and Characterization of Reference Substances, Monatshefte fur Chemie, 1997, pp. 291-299, vol. 128(3).;;Gust et al., “Investigation on the Stability of Bendamustin, a Cytostatic Agent of the Nitrogen Mustard Type I. Synthesis, Isolation and Characterization if Reference Substances”, Monatshefte fur Chemie, 1997, 128(3), 291-299.;;Gust et al. In Monatshefte fur Chemie 128, 291-299 (1997).;;Goodman et al., The Pharmacological Basis of Therapeutics, 1985, 7th edition, Macmillan publishing company, New York.;;Goodman et al., The Pharmacological Basis of Therapeutics, 1985, 7.sup.th edition, Macmillan publishing company, New York.;;Ghandi, Varsha, Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies, Seminars in Oncology, 2002, pp. 4-11, vol. 29, No. 4, Suppl. 13.;;Ghandi, “Metabolism and Mechanisms of Action of Bendamustine: Rationales for Combination therapeutics”, Seminars in Oncology, Suppl. 13, 2002, 29(4), 4-11.;;Gandhi et al., “Bendamustine in B cell malignancies: the new, 46-year old kid on the block” Clinical Cancer Research, Dec. 2009, 15(24), 7456-7461.;;Furst et al., Pharmazeutische Zentralhalle Fur Deutschland 108(9), 1969, 608-614.;;Friedberg et al., Bendamustine HCI (TRENDA.TM.) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (NHL): Results from a Phase II Multicenter Single—Agent Study (SDX-105-01), in Blood 106 (11), 2005 (Abstract 229).;;Friedberg et al., “Bendamustine in patients with Rituximab-refractory indolent and transformed non-hodgkin's lymphoma”, Journal of Clinical Oncology, Jan. 10, 2008, vol. 26, No. 2, pp. 204-210.;;Friedberg et al. In Blood 106 (11), 2005 (abstract 229).;;Flamberg, et al., “Low Temperature Vacuum Drying of Sterile Parenterals from Ethanol” Bulletin of the Parenteral Druq Association, 24(5), Sep.-Oct. 1970, 209-217.;;Fichtner, I. et al., Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumor models, Journal of Microencapsulation, 1986, pp. 77-87, vol. 3(2).;;Fichtner et al., “Antineoplastic Activity and Toxicity of some Alkylating Cytostatics (Cyclophosphamide, CCNU, Cytostasan) Encapsulated in Liposomes in different murine tumor models”, Joumal of Microencapsulation, 1986, 3(2), 77-87.;;Excerpt from Rote Liste 2003, Arzneimittelverzeichnis fur Deutschland, 2 pages.;;EC Safety Data Sheet: Ribomustin® in http://www.docstoc.com/docs/22323231/EC-Safety-Data-Sheet-Bendamustin (published: Jul. 3, 1998; updated Mar. 1, 2007).;;EC Safety Data Sheet: Ribomustin.RTM. in http://www.docstoc.com/docs/22323231/EC-Safety-Data-Sheet-Bendamustin (published: Jul. 3, 1998; updated Mar. 1, 2007), 8 pages.;;EC Safety Data Sheet: Ribomustin (registered) in www.asl.ri.it/staff/prevenzione/documentazione/Chemio/Ribomustin%20scheda%20di%20sicurezza.pdf (Retrieved from the internet Jun. 11, 2013).;;EC Safety Data Sheet: Ribomustin (registered) in www.asl.ri.it/staff/prevenzione/documentazione/Chemio/Ribomustin%20scheda%20di%20 sicurezza.pdf (published: Jul. 3, 1998; updated Mar. 1, 2007).;;Diehl, Volker et al., Bendamustine in the Treatment of Hematologic Malignancies, Semin. Oncol., 2002, vol. 29(4) Suppl. 13, Saundes, Philadelphia, PA.;;Diehl et al., “Bendamustine in the Treatment of Hematologic Malignancies”, Semin. Oneal., Suppl. 13, 2002, Saundes, Philadelphia, 29(4), 3 pages.;;Department of Health and Human Services, Food and Drug Administration, “International Conference on Harmonisation; Guidance on Impurities: Residual Solvents,” Federal Register, Dec. 24, 1997, 62(247), 67377-67388.;;Corrected Trial Transcripts; In the United States District Court in and for the District of Delaware; In Re Bendamustine Consolidated Civil Action No. 13-2046; Wilmington Delaware Monday, Dec. 1, 2015, Trial Day 1.;;Chow, Kai Uwe et al., Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4(Par-4), death-associated protein (Danz) and with enforced caspase activation, Biochemical Pharmacology, 2003, pp. 711-724, vol. 66(5).;;Chow, Kai U. et al., In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodkin's lymphomas by combinations of established cytotoxic drugs with bendamustine, Haematologica, 2001, pp. 485-493, vol. 86(5).;;Chow, Kai U. et al., In AML Cell Lines Ara-C Combined with Purine Analogues is Able to Exert Synergistic as Well as Antagonistic Effects on Proliferation, Apoptosis and Disruption of Mitochondrial Membrane Potential, Leukemia & Lymphoma, 2003, pp. 165-173, vol. 44(1).;;Chow, Kai et al., Anti-CD20 antibody (IDEC-C2B8, rituximab) enchances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines complement, and caspases, Haematologica, Jan. 2002, pp. 33-43, vol. 87(1).;;Chow et al., “Synergistic Effects if Chemotherapeutic Drugs in Lymphoma Cells are associated with down-regulation if inhibitor of apoptosis proteins (IAPs), prostate-apoptosis- response-gene 4(Par-4), death-associated protein (Dazz) and with enforced caspase activation”, Biochemical Pharmacology, 2003, 66(5), 711-724.;;Chow et al., “In Vitro Induction of Apoptosis of Neoplastic Cells in Low-Grade non-Hodgkin's Lymphomas by Combination of established cytotoxic drugs with bendamustine”, Hematologica, 2001, 86(5), 485-493.;;Chow et al., “In AML Cell Lines Ara-C combined with Purine Analogues is able to Exert Synergistic as well as Antagnostic Effects on Proliferation Apoptosis and Disruption of Mitochondrial Membrane Potential”, Leukemia & Lymphoma, 2003, 44(1), 165-173.;;Chow et al., “Anti-CD20 Antibody (DEC-C2B8, rituximab) enhances efficiency of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of Cytokines complement and caspases”, Hematologica, Jan. 2002, 87(1), 33-43.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Consideration”, Pharmaceutical Research, Jul. 1995, 12(7), 945-954.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Consideration”, Pharmaceutical Research, 1995, 12(7), 945-954.;;BRITTAIN H.G: ""POLYMORPHISM IN PHARMACEUTICAL SOLIDS"", vol. 95, 1 January 1999, XX, XX, ISBN: 978-0-8247-0237-9, article BRITTAIN H.G.: ""Drugs and the Pharmaceutical Sciences"", pages: I - 228-239, XP003030775;;Bremer, “High Rates of Long-lasting remissions after 5-day bendamustine Chemotherapy Cycles in Pre-Treated low-grade non-hodgkin's-lymphomas”, Journal of Cancer Research and Clinical Oncology, 2002, 128(11), 603-609.;;Berge et al., “Pharmaceutical Salts”, Journal of pharmaceutical sciences, Jan. 1977, 66(1), 1-19.;;Barman et al., “Bendamustine” Drugs, 2001, 61(5), 631-638, Auckland, New Zealand.;;Barman Balfour, Julia A. et al., Bendamustine, Drugs, 2001, pp. 631-638, vol. 61(5), Auckland, New Zealand.;;Avis et al., “Pharmaceutical Dosage Forms: Parenteral Medications vol. 1” Marcel Dekker Inc, 1992, pp. 217-227.;;Author Unknown, “Ribomustin: Bendamustine Product Monograph”, Ribosepharm GMBH, Munchen, Germany, Mar. 2005, 3-73.;;Author Unknown, “Ribomustin: Bendamustine Product Monograph”, Ribosepharm GMBH, Munchen Germany, Jan. 2002, 59 pages.;;Author Unknown, “Ribomustin: Bendamustine Product Monograph”, Ribosepharm GMBH, Munchen, Germany, Jan. 2002, 3-54.;;Aivado, Manuel et al., Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives, Seminars in Oncology, 2002, pp. 19-22, vol. 29 No. 4, Suppl. 13.;;Aivado et al., “Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives”, Seminars in Oncology, Aug. 2002, 29(4), 19-22, Suppl. 13.;;Aivado et al., “Bendamustine in the Treatment of Chronic Lymphocytic Leukemia: Results and Future Perspectives”, Seminars in Oncology, 2002, 29(4) 19-22.;;Wilman et al., Application of 15N Nuclear Magnetic Resonance Spectroscopy to the Determination of the Stability of Aryl Nitrogen Mustards, J. Med. Chem. 1995, 2256 2258.;;U.S. Appl. No. 61/299,100.;;Treanda label (2008).;;Thermal Stability of Nonionic Polyoxyalkylene Surfactants; E. Santacesaria et al., Journal of Applied Polymer Science, vol. 42, 2053-2061 (1991).;;Testa et al., Hydrolysis in Drug and Prodrug Metabolism, Miscellaneous Reactions of Hydration and Dehydration, pp. 681-684, VHCA, Verlag Helvetica Chimica Acta AG, Z.;;Seedher et al., Solubilization of Nimesulide, Use of Co-solvents, Indian Journal of Pharmaceutical Sciences, 65(1), 2003, 58-61.;;Scott et al., 1994, entitled Lipoic and Dihydrolipoic Acids as Antioxidants. A Critical Evaluation, Free Radical Research, 202, 119-133, published 1994.;;SciFinder(r) Hydrolytic degradation of IMET.;;Safety datasheet lactic acid, 88%, published Feb. 20, 2013.;;Rowe et al. (ed) Handbook of Pharmaceutical Excipients, 5th ed., Pharmaceutical Press, p. 545-550 Polyethylene Glycol, 2006.;;Remington, entitled The Science and Practice of Pharmacy 20th Edition, Chapter 41, 780-786, published 2000.;;Remington's Pharmaceutical Sciences, 18th edition, (1990), pp. 1286-1288.;;Remington The Science and Practice of Pharmacy 21st ed Lippincott Williams & Wilkins Chapter 41 Parenteral Preparations 2005.;;Pramod K. Gupta Injectable Drug Development Techniques to Reduce pain and irritation.;;Pethrick et al Excerpt from Polymer Yearbook 13, CRC Press, Oct. 1, 1996, Technology & Engineering Vinogradova et al.;;Nema et al 1997, entitled Excipients and their use in injectable products, 51 4,166-171, published 1997.;;Mikhal'chuk et al: Antioxidative Stabilization of Polyethylene Glycol in Aqueous Solutions with Herb Phenols, Russian Journal of Applied Chemistry,vol. 77, No. 1,2004, pp. 131-135.;;McGinity et al. influence of Peroxide Impurities in Polyethylene Glycols on Drug Stability, Journal of Pharmaceutical Sciences, vol. 64, No. 2, Feb. 1975, p. 356-357.;;MAAS B: ""Stabilität von Bendamustinhydrochlorid in Infusionslösungen"", PHARMAZIE, GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, DE, vol. 49, no. 10, 1 January 1994 (1994-01-01), DE, pages 775 - 777, XP008060268, ISSN: 0031-7144;;Liu (ed.) Water-Insoluble Drug Formulation, 2nd ed., CRC Press, Chapters 7 and 9, 2008.;;Liu (ed.) Water-Insoluble Drug Formulation, 1st ed., CRC Press, Chapter 7, 2000.;;Kurt Bauer—Pharmazeutische Technologie—225-228.;;Kurt Bauer—Pharmazeutische Technologie 424-425.;;Kinetics of phosphoramide mustard hydrolysis in aqueous solution; Watson et al; Journal of Pharmaceutical Sciences; vol. 74, Issue 12, pp. 1283-1292, Dec. 1985.;;Journal of Pharmaceutical Sciences Oct. 1963, vol. 52, No. 10, Use of Nonaqueous Solvents in Parental products.;;Handbook of Pharmaceutical Excipients, sixth edition (2009); Rowe; p. 857 (extract from index).;;Handbook of Pharmaceutical Excipients, Seventh edition 2012, Pharmaceutical Press.;;Gamcsik et al., NMR Studies of the Conjugation of Mechlorefhamine with Glutathione, J. Med. Chem., 1990, 33, 1009-1014.;;Galacid Excel 88 fact sheet (lactic acid 88%).;;Furst et al., Ober den hydrolytischen Abbau von IMET 3393, Pharmazeutische Zentralhalle, Bd. 108, Heft 9,1969, Seiten 608-614.;;Experimental report.;;Excipient-Drug Interactions in Parenteral Formulations; Akers et.al., Journal of Pharmaceutical Sciences, vol. 91, issue 11, pp. 2283-2300, Nov. 2002.;;Excerpt from Manual DiscovIR-LC, Application Note 016, Mar. 2008 of Spectra Analysis, Inc.;;Colorimetric Estimation of Nitrogen Mustards in Aqueous Media. Hydrolytic Behavior of Bis-(0-chloroethyl)amine, norHN2; O.M. Friedman, Eliahu. Boger; Anal. Chem., 1961,33 (7), pp. 906-910.;;Carpenter el al A Study of the Poyethylene Glycols as vehicles for Intramuscular and Subcutaneous Injection 27-29 1952.;;Brown et al Organic Chemistry, Cengage Learning 1Q-Jan-2008 Science.;;Balfour & Goa., 2001, entitled Bendamustine, Drugs, 61(5), 631-638, published 2001.;;Zulkowski, K. et al., Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine, Journal of Cancer Research and Clinical Oncology, 2002, pp. 111-113, vol. 128(2).;;Zulkowski et al., “Regression of Brain Metastases from Breast Carcinoma after Chemotherapy with bendamustine”, Journal of Cancer Research and Clinical Oncology, 2002, 128(2), 111-113.;;Wittaya-Areekul, Sakchai et al., 37 Freeze-Drying of tert-Butanol/Water Cosolvent Systems: A Case Report on Formation of a Friable Freeze-Dried Powder of Tobramycin Sulfate Journal of Pharmaceutical Sciences, Apr. 2002, 91(4), 1147-1155.;;Wittaya-Areekul et al., “Freeze-drying of tert-butyl alcohol/water cosolvent systems: Effects of formulation and process variables on residual solvents,” Journal of Pharmaceutical Sciences, Apr. 1998, 87(4), 491-495.;;Werner W et al: “Hydrolyseprodukte des Cancerostaticums Cytostasan (Bendamustin)” Pharmazie, Die, Govi Verlag, Eschborn, DE, vol. 42, No. 4, 1987, pp. 272-273.;;Werner et al., “Hydrolyseprodukte des Cancerostaticums Cytostasan (Bendamustin)”, Pharmazie, 1987, 42, 272-273.;;Weidmann et al., “Bendamustine is Effective in Relapsed or Refractory Aggressive non-Hodgkin's Lymphoma”, Annals of Oncology, Aug. 2002, 13(8), 1285-1289.;;Weidmann et al., “Bendamustine is Effective in Relapsed or Refractory Aggressive non-Hodgkin's Lymphoma”, Annals of Oncology, 2002, 13(8), 1285-1289.;;Weide, Rudolf et al., Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study, Leukemia & Lymphoma, 2004, pp. 2445-2449, vol. 45(12).;;Weide et al., “Bendamustine/ Mitoxantrone/Rituximab (BMR) : A very Effective, well tolerated Outpatient Chemoimmunotherapy for relapsed and refractory CD20-positive Indolent Malignancies Final Results of a Pilot Study”, Leukemia & Lymphoma, 2004, 45(12), 2445-2449.;;Weide et al., “Bendamustine Mitoxantrone and Rituximab (BMR): A New effective regimen for refractory or relapsed indolent lymphomas”, Leukemia & Lymphoma, 2002, 43(2), 327- 331.;;Wade,A. and Weller, Handbook of Pharmaceutical Excipients, Second Edition, American Pharmaceutical Association, Washington and the Pharmaceutical Press, London, 1994, pp. 294-298.;;Van Drooge et al., “Incorporation of Lipophilic Drugs in Sugar Glasses by Lyophilixation using a Mixture of Water and Tertiary Butyl Alcohol as Solvent” Journal of Pharmaceitical Sciences, Mar. 2004, 93(3), 713-725.;;U.S. Appl. filed Dec. 19, 2012, Cephalon, Inc., U.S. Appl. No. 13/719,409.;;U.S. Appl. filed Dec. 19, 2012, Cephalon, Inc., U.S. Appl. No. 13/719,379.;;Treanda, DC Decision; In Re Bendamustine Consolidated Cases; Civil Action No. 13-2046-GMS; Document 472; Filed Jun. 10, 2016.;;Telang, Chitra et al., “Crystallization of Cephalothin Sodium During Lyophilization from tert-Butyl Alcohol-Water Cosolvent System” Pharmaceutical Research, Jan. 2005, 22(1), 153-160.;;Teagarden et al., “Practical aspects of lyophilization using non-aqueous co-solvent systems,” European Journal of Pharmaceutical Sciences, Mar. 2002, 15(2), 115-133.;;Tang, Xiaolin et al., “Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice” Pharmaceutical Research, Feb. 2004, 21(2) ,191-200.;;Strumberg, Dirk et al., Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines, Anti-Cancer Drugs, 1996, pp. 415-421, vol. 7(4).;;Strumberg et al., “Bendamustine Hydrochloride Activity against doxorubicin-resistant Human Breast Carcinoma Cell Lines”, Anti-Cancer Drugs, 1996, 7(4), 415-421.;;Seager et al., Structure of Products Prepared by Freeze-Drying Solutions Containing Organic Solvents, PDA J. Pharm. Sci and Technol. Jul.-Aug. 1985 vol. 39(4), 161-179, hier. Zusammenfassung.;;Schwanen et al., “In Vitro Evaluation of Bendamustine Induced Apoptosis in B-Chronic Lymphocytic Leukemia”, Leukemia, Oct. 2002, 16(10), 2096-2105.;;Schrijvers, Dirk et al., Phase I studies with bendamustine: an update, Seminars in Oncology, 2002, pp. 15-18, vol. 29 No. 4 Suppl. 13.;;Schrijvers et al., “Phase I study with bendamustine: An update”, Seminars in Oncology, Suppl. 13, 2002, 29(4), 15-18.;;Schoffski, P., Repeated administration of short infusions of Bendamustine: a phase I study in patients with advanced progressive solid tumors, Journal of Cancer Research and Clinical Oncology, 2000, pp. 41-47, vol. 126(1).;;Schoffski, “Repeated Administration of Short Infusions of Bendamustine: A phase I study in Patients with Advanced Progressive Solid Tumors”, Journal of Cancer Research and Clinical Oncology, 2000, 126(1), 41-47.;;Schmidt-Hieber et al., “A Phase II Study of bendamustine Chemotherapy as Second-line treatment in metastatic uveal Melanoma”, Melanoma Research, 2004, 14(6), 439-442.;;Scasnar, V., et al.., Stability Studies of .sup.14C-Cytostasan.RTM. solutions and its extraction using dicarbolide of cobalt, Pharmazie, 1988, pp. 176-179, vol. 43.;;Scasnar et al., Radiochemical Assay of Stability of .sup.14 C-Cytostasan Solutions During Preparation and Storage, vol. 121, No. 2m 1988 pp. 489-497.;;Scasnar et al., “Stability Studies of 14C-Cytostasan.RTM. solutions and its extraction using dicarbolide of cobalt”, Phamazie, Mar. 1988, 43, 176-179.;;Scasnar et al., “Radiochemical Assay of Stability of 14C-Cytostasan Solutions During Preparation and Storage”, 1988, 121(2m), 489-497.;;RxList, Treanda, 2013, pp. 1-2.;;Rxlist, The Internet Drug Index, Treanda(Registered), 2013, pp. 1-2, http://www.rxlist.com/scripUmain/rxlist.asp?articlekey=88624&pf=3&page=1.;;Rummel, Mathias J. et al., In Vitro Studies With Bendaustine: Enhanced Activity in Combination With Rituximab, Seminars in Oncology, Aug. 2002, pp. 12-14, vol. 29 No. 4 Suppl 13.;;Rummel, Mathias J. et al., Bendamustine in the treatment of non-Hodgkin's lymphoma: Results and future perspectives, Seminars in Oncology, 2002, pp. 27-32, vol. 29 No. 4 Suppl. 13.;;Rummel et al., “In Vitro Studies with Bendamustine: Enhanced Activity in Combination with Rituximab”, Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 12-14.;;Rummel et al., “Bendamustine in the Treatment of Non-Hodgkin's Lymphoma: Results and Future Perspectives”, Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 27-32.;;Rummel et al., “Bendamustine in the Treatment of Non-Hodgkin's Lymphoma: Results and Future Perspectives”, Seminars in Oncology, Suppl. 13, 2002, 29(4), 27-32.;;Rowe, et al, 37 Handbook of Pharmaceutical Excipients, Sixth Edition, Pharmaceutical Press and the American Pharmacists Association, Royal Pharmaceutical Society of Great Britain, 2009,16 pages.;;Rowe et al., “Handbook of Pharmaceutical Excipients” Fourth Edition, The Royal Pharmaceutical Society of Great Britain, 2003, pp. 373-377.;;Ribosepharm. Fachinformation (Zusammenfassung der Merkmale des Arzneimittels/SPC). Four Pages, Oct. 2005.;;Ribosepharm, “Product monograph ribosepharm passage”, Product Monograph, Ribosepharm, Jan. 1, 2005, pp. 3-73.;;Ribomustin: Bendamustine Product Monograph, Ribosepharm GMBH, Munchen, Germany, Mar. 2005, 3-73.;;Ribomustin: bendamustine Product Monograph, Mar. 2005, pp. 3-73, Ribosepharm MBH, Munchen, Germany.;;Ribomustin: bendamustine Product Monograph, Jan. 2002, pp. 3-54, Ribosepharm GMBH, Munchen, Germany.;;Rey et al., “Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products”, Second Edition, revised and expanded, New York, Taylor and Francis Group, 2004, Seiten 239-243.;;Remington: The Science and Practice of Pharmacy, 20th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000.;;Remington: Pharmaceutical Sciences, 1990, Mack Publishing company, Easton, Pennsylvania.;;Preiss, R. et al., Pharmacokinetics of bendamustin (Cytostasan) in patients, Pharmazie, 1985, pp. 782-784, vol. 40(11). Translation.;;Lowenstein et al. Curr Gene Ther. vol. 9(5), pp. 368-374. (Year: 2009).;;Kamb et al. Nature Rev Drug Discovery. vol. 6, pp. 115-120. (Year: 2007).;;Human Translation Olthoff et al. Process for Producing Stable Injection Solutions of Nitrogen Mustard Compounds. Translated by: FLS Inc. Provided on Aug. 2106. (Year: 1983).;;Hughes et al. BrJ Pharmacol. vol. 162, pp. 1239-1249. (Year: 2011).;;Cheson et al., Clinical Lymphoma, Myeloma & Leukemia, 2010, vol. 10. No., pp. 21-27.",ACTIVE
818,EP,A4,EP 3589129 A4,188-864-225-959-973,2020-11-25,2020,EP 18760302 A,2018-03-01,US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490465 P;;US 201762490567 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510660 P;;US 201762510672 P;;US 201762511218 P;;US 201715616874 A;;US 2018/0020440 W,2017-03-01,COMPOSITIONS PURPOSEFULLY SELECTED COMPRISING PURIFIED CANNABINOIDS AND/OR PURIFIED TERPENES,,CANOPY GROWTH CORP,LEVY KURT;;COOPER JONATHAN MICHAEL;;MARTIN JONATHAN REED;;REID BRIAN GEOFFREY,,https://lens.org/188-864-225-959-973,Search Report,no,0,0,11,36,0,A61K31/05;;A61K31/352,A01N65/00;;A61K31/05;;A61K31/352,,1,0,,,No further relevant documents disclosed,DISCONTINUED
819,WO,A3,WO 1996/038938 A3,198-730-154-458-774,1997-02-20,1997,US 9608568 W,1996-06-03,GB 9510870 A;;GB 9511546 A;;GB 9513170 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A,1995-06-02,APPARATUS AND METHOD OF CONTROLLING TRANSMITTING POWER AND TRANSMIT RATE OF A WIRELESS TELECOMMUNICATIONS SYSTEM,"A wireless telecommunications system (1) includes a central terminal (10) for transmitting and receiving radio frequency signals to and from a subscriber terminal (20). The wireless telecommunications system (1) operates in one of three operating modes. In an acquisition mode during establishment of the downlink communication path, the downlink signal (212) is transmitted at a high power level and a low transmit rate with the receiver (202) operating at the low transmit rate. In a standby mode after establishment of the downlink communication path, the downlink signal (212) is transmitted at a low power level and a low transmit rate with the receiver (202) operating at the low transmit rate. In a traffic mode upon a request for wireless communication transmission, the downlink signal (212) is transmitted at a high power level and a high transmit rate with the receiver (202) adjusting to operate at the high transmit rate. Upon completion of the wireless communication transmission, the wireless telecommunications system (1) returns to the standby mode and the receiver (202) adjusts to operate at the low transmit rate.",DSC COMMUNICATIONS;;BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,,https://lens.org/198-730-154-458-774,Search Report,yes,7,0,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,PENDING
820,EP,A2,EP 0872062 A2,192-543-948-920-674,1998-10-21,1998,EP 96924257 A,1996-06-03,GB 9510870 A;;GB 9511546 A;;GB 9513170 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A;;US 9608568 W,1995-06-02,APPARATUS AND METHOD OF CONTROLLING TRANSMITTING POWER AND TRANSMIT RATE OF A WIRELESS TELECOMMUNICATIONS SYSTEM,,DSC COMMUNICATIONS,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,AIRSPAN NETWORKS INC. (2000-10-18);;AIRSPAN COMMUNICATIONS CORPORATION (1999-02-03),https://lens.org/192-543-948-920-674,Patent Application,yes,0,0,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,DISCONTINUED
821,EP,A4,EP 3086992 A4,030-319-451-186-581,2018-12-12,2018,EP 14875798 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS,,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/030-319-451-186-581,Search Report,no,2,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00;;B61K9/00;;B61K9/04;;B61L25/02;;B61L27/00;;G01M17/10,,1,0,,,See also references of WO 2015100425A1,PENDING
822,AT,T1,AT E253626 T1,076-839-754-888-570,2003-11-15,2003,AT 97941709 T,1997-09-19,US 2644296 P;;US 9716690 W,1996-09-19,KONZENTRIERTE QUATERNÄRE AMMONIUMGEWEBEWEICHMACHERZUSAMMENSETZUNGEN MIT KATIONISCHEN POLYMEREN,,PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/076-839-754-888-570,Granted Patent,no,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,D06M13/322;;C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,DISCONTINUED
823,AU,A,AU 1997/043563 A,064-944-545-853-290,1998-04-14,1998,AU 1997/043563 A,1997-09-19,US 2644296 P;;US 9716690 W,1996-09-19,Concentrated quaternary ammonium fabric softener compositions containing cationic polymers,,PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/064-944-545-853-290,Patent Application,no,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,D06M13/322;;C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,PENDING
824,US,A,US 5179087 A,125-994-417-160-146,1993-01-12,1993,US 56885590 A,1990-08-17,GB 8918886 A;;GB 8918929 A,1989-08-18,MACROCYCLIC COMPOUNDS,"There are described compounds of formula I, ##STR1## wherein R.sup.1 represents H or OH; R.sup.2 represents H; in addition, R.sup.1 and R.sup.2 may together represent a second carbon-carbon bond between the carbon atoms to which they are attached; R.sup.3 represents OH or OCH.sub.3 ; X represents O or (H,OH); and Y represents O or N--OR.sup.4, in which R.sup.4 represents H or alkyl C.sub.1-6 ; provided that when R.sup.1 is OH, R.sup.2 is H and X is O, then Y does not represent O. Processes for their production and compositions containing them, eg. for use as immunosuppressive agents, are also described.",FISONS PLC,DONALD DAVID K;;HARDERN DAVID N;;COOPER MARTIN E;;FURBER MARK,FISONS PLC ENGLAND (1990-07-25),https://lens.org/125-994-417-160-146,Granted Patent,yes,10,6,11,13,0,A61P37/06;;C07H15/26;;C07H19/01;;C07H19/01,C07D498/18;;A61K31/445;;A61P37/06;;C07H19/01,514/183;;540/461,0,0,,,,EXPIRED
825,GB,A,GB 2260321 A,121-515-788-780-006,1993-04-14,1993,GB 9121676 A,1991-10-11,GB 9121676 A,1991-10-11,"Liquid crystalline fluorophenyl derivatives with optically active oxiran-2,3-diyl backbone","Optically active fluorophenyl derivatives of the formula I are claimed and of formula VI are exemplified <IMAGE> wherein one of the radicals R<1> and R<2> is (a) an unsubstituted alkyl, alkenyl, polyfluoroalkyl or polyfluoroalkenyl radical @@@@or the same monosubstituted by CN, halogen or @@@@CF3, in which the radical contains up to 15 C atoms and in which one @@@@or more CH2 or CF2 groups @@@@may be replaced by a radical selected from @@@@the group comprising -S-, -O-, @@@@-Si(CH3)2- <IMAGE> -CO-, CO-O- -O-CO- or -O-CO-O-, two oxygen and/or @@@@sulfur atoms not being adjacent, and the other of the radicals R<1> and R<2> is (b) a chiral radical of the formula II, -CH2)o-(CH*) @@@@2-R<3> II (wherein R<3> is alkyl or alkenyl with up @@@@to 8 C atom, in which one CH2 @@@@group may be replaced by O); <IMAGE> (wherein R<4> and R<5> are each @@@@indepedently H or C1-5-alkyl); o is 1 to 8) Q<1> is CH2 or CO; Z is -CO-O-, -O-CO-, -O-CH2- or a single bond; one of the ligands L<1> and L<2> is F the other is H or F; X and Y are each independently N or CH; and m is 0 or 1 are suitable as components of ferroelectric mixtures.",MERCK PATENT GMBH,STYRING PETER;;GOODBY JOHN WILLIAM;;COOPER MARTIN E;;RICHARDS ROBERT D,,https://lens.org/121-515-788-780-006,Patent Application,no,0,0,3,3,0,C07D405/12;;C09K19/3411;;C09K19/3466;;C09K19/588,C07D405/12;;C09K19/34;;C09K19/58,C2C CAA;;C2C CAA;;C2C CBA;;C2C CWA;;C2C C1300;;C2C C1300;;C2C C1600;;C2C C1600;;C2C C200;;C2C C215;;C2C C215;;C2C C22Y;;C2C C22Y;;C2C C220;;C2C C220;;C2C C246;;C2C C246;;C2C C25Y;;C2C C25Y;;C2C C250;;C2C C250;;C2C C252;;C2C C252;;C2C C253;;C2C C253;;C2C C28X;;C2C C28X;;C2C C31Y;;C2C C31Y;;C2C C311;;C2C C311;;C2C C36Y;;C2C C36Y;;C2C C364;;C2C C364;;C2C C366;;C2C C368;;C2C C50Y;;C2C C500;;C2C C624;;C2C C628;;C2C C634;;C2C C65X;;C2C C662;;C2C C662;;C2C C672;;C2C C678;;C2C C697;;C2C C697;;C2C C777;;C2C C80Y;;C2C C821;;C2C C821;;C4X X12           X12;;C4X X12           X12TC/TP;;C4X X12TC         X12TC/TP;;C4X X12TP         X12TC/TP;;U1S S1387,0,0,,,,EXPIRED
826,EP,A1,EP 0931132 A1,125-301-633-294-224,1999-07-28,1999,EP 97941709 A,1997-09-19,US 9716690 W;;US 2644296 P,1996-09-19,CONCENTRATED QUATERNARY AMMONIUM FABRIC SOFTENER COMPOSITIONS CONTAINING CATIONIC POLYMERS,,PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/125-301-633-294-224,Patent Application,yes,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,D06M13/322;;C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,EXPIRED
827,US,B2,US 9533955 B2,153-328-360-602-986,2017-01-03,2017,US 201615045523 A,2016-02-17,US 201615045523 A;;US 201414531023 A;;US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Solid forms of bendamustine hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/153-328-360-602-986,Granted Patent,yes,56,3,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/16;;A61K9/00;;A61K9/14;;A61K9/19;;A61K31/4184;;A61K47/26,,53,38,057-331-944-087-540;;084-716-889-422-831;;007-364-858-655-289;;005-472-156-687-716;;009-214-187-079-899;;132-558-386-999-186;;123-775-514-819-528;;006-046-706-830-252;;069-673-960-292-160;;080-209-105-337-208;;027-084-824-706-497;;106-081-384-040-520;;074-470-545-310-545;;020-427-831-437-122;;044-553-566-435-465;;049-256-800-886-311;;067-512-968-604-94X;;023-549-427-997-819;;063-402-864-700-686;;113-421-979-742-187;;020-435-634-003-86X;;125-764-802-071-090;;111-707-255-990-821;;034-919-505-845-111;;023-237-704-770-485;;003-701-346-326-00X;;067-465-907-694-241;;127-003-929-505-550;;013-802-099-433-937;;055-433-061-655-828;;004-291-817-534-209;;108-687-604-265-588;;029-880-686-607-107;;093-799-759-321-023;;001-658-497-635-033;;091-079-688-402-134;;059-280-286-824-398;;057-884-013-276-829,10.1053/sonc.2002.34875;;10.1016/s0093-7754(02)90010-2;;12170428;;10.2165/00003495-200161050-00009;;11368287;;10.1002/jps.2600660104;;833720;;12458340;;10.1007/s00432-002-0378-6;;10.1023/a:1016241927429;;7494814;;11801463;;12691159;;10.1080/1042819021000054670;;11410411;;12948851;;10.1016/s0006-2952(03)00410-6;;12170424;;10.1053/sonc.2002.34871;;10.3109/02652048609031561;;3508181;;18182663;;10.1200/jco.2007.12.5070;;12170425;;10.1053/sonc.2002.34872;;10.1007/bf00807895;;10.1097/00001813-200110000-00003;;11593053;;10.1007/s004320000180;;11206271;;15223642;;10.1080/1042819042000223822;;10.1097/00001813-200008000-00003;;11036955;;12029443;;10.1007/s00432-002-0331-8;;10.2165/00044011-200424100-00007;;17523723;;10.1016/j.addr.2003.10.020;;14962582;;10.1080/1042819042000198858;;15359644;;10.1053/sonc.2002.34876;;10.1016/s0093-7754(02)90011-4;;12170429;;4095129;;12170430;;10.1016/s0093-7754(02)90012-6;;10.1053/sonc.2002.34877;;12170426;;10.1016/s0093-7754(02)90008-4;;10.1053/sonc.2002.34873;;10.1007/bf02041437;;3380859;;15577312;;10.1097/00008390-200412000-00001;;10.1007/pl00008463;;10641748;;10.1016/s0093-7754(02)90009-6;;10.1053/sonc.2002.34874;;12170427;;10.1038/sj.leu.2402651;;12357363;;10.1097/00001813-199606000-00007;;8826610;;11999564;;10.1080/10428190290006107;;15621757;;10.1080/10428190400004521;;10.1093/annonc/mdf189;;12181253;;3615563;;11862482;;10.1007/s00432-001-0303-4,"EC Safety Data Sheet: Ribomustin® in www.asl.ri.it/staff/prevenzione/documentazione/Chemio/Ribomustiff%20scheda%20di%20 sicurezza.pdf (published: Jul. 3, 1998; updated Mar. 1, 2007).;;Friedberg et al. In Blood 106 (11), 2005 (abstract 229).;;Aivado et al., ""Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives"", Seminars in Oncology, Aug. 2002, 29(4), 19-22, Suppl. 13.;;Author Unknown, ""Ribomustin: Bendamustine Product Monograph"", Ribosepharm GMBH, Munchen, Germany, Jan. 2002, 3-54.;;Author Unknown, ""Ribomustin: Bendamustine Product Monograph"", Ribosepharm GMBH, Munchen, Germany, Mar. 2005, 3-73.;;Barman et al., ""Bendamustine"" Drugs, 2001, 61(5), 631-638, Auckland, New Zealand.;;Berge et al., ""Pharmaceutical Salts"", Journal of pharmaceutical sciences, Jan. 1977, 66(1), 1-19.;;Bremer, ""High Rates of Long-lasting remissions after 5-day bendamustine Chemotherapy Cycles in Pre-Treated low-grade non-hodgkin's-lymphomas"", Journal of Cancer Research and Clinical Oncology, Nov. 2002, 128(11), 603-609.;;Brittain, ""Drugs and the Pharmaceutical Sciences,"" vol. 95, 1999, Polymorphism in Pharmaceutical Solids, pp. I-V, 228-239, XP003030775.;;Byrn et al., ""Pharmaceutical Solids: A Strategic Approach to Regulatory Consideration"", Pharmaceutical Research, Jul. 1995, 12(7), 945-954.;;Chow et al., ""Anti-CD20 Antibody (DEC-C2B8, rituximab) enhances efficiency of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of Cytokines complement and caspases"", Hematologica, Jan. 2002, 87(1), 33-43.;;Chow et al., ""In AML Cell Lines Ara-C combined with Purine Analogues is able to Exert Synergistic as well as Antagnostic Effects on Proliferation Apoptosis and Disruption of Mitochondrial Membrane Potential"", Leukemia & Lymphoma, 2003, 44(1), 165-173.;;Chow et al., ""In Vitro Induction of Apoptosis of Neoplastic Cells in Low-Grade non-Hodgkin's Lymphomas by Combination of established cytotoxic drugs with bendamustine"", Hematologica, May 2001, 86(5), 485-493.;;Chow et al., ""Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4(Par-4), death-associated protein (Dazz) and with enforced caspase activation"", Biochemical Pharmacology, Jan. 2003, 66(5), 711-724.;;Diehl et al., ""Bendamustine in the Treatment of Hematologic Malignancies"", Semin. Oncol., Aug. 2002, 29(4), 1-3, Suppl. 13, Saundes, Philadelphia, PA.;;EC Safety Data Sheet: Ribomustin® in http://www.docstoc.com/docs/22323231/EC-Safety-Data-Sheet-Bendamustin (published: Jul. 3, 1998; updated Mar. 1, 2007).;;EC Safety Data Sheet: Ribomustin® in www.asi.ri.it/staff/prevenzione/documentazione/Chemio/Ribomustin%20scheda%20di%20si.curezza.pdf (Retrieved from the internet Jun. 11, 2013).;;Fichtner et al., ""Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumor models"", Journal of Microencapsulation, Jan. 1986, 3(2), 77-87.;;Friedberg et al., ""Bendamustine in patients with Rituximab-refractory indolent and transformed non-hodgkin's lymphoma"", Journal of Clinical Oncology, Jan. 10, 2008, vol. 26, No. 2, pp. 204-210.;;Friedberg et al., Bendamustine HCI (TRENDA(TM)) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01), in Blood 106 (11), 2005 (Abstract 229).;;Gandhi, Varsha, ""Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies"", Seminars in Oncology, Aug. 2002, 29(4), 4-11, Suppl. 13.;;Goodman et al., The Pharmacological Basis of Therapeutics, 1985, 7th edition, Macmillan publishing company, New York.;;Gust et al., ""Investigation on the Stability of Bendamustin, a Cytostatic Agent of the Nitrogen Mustard Type I. Synthesis, Isolation and Characterization of Reference Substances"", Monatshefte fur Chemie, 1997, 128(3), 291-299.;;Heider et al., ""Efficacy and Toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas"", Anti-Cancer Drugs, 2001, 12(9), 725-729.;;Kath et al., ""Bendamustine Monotherapy in advanced and refractory chronic lymphocytic Leukemia"", Journal of Cancer Research and Clinical Oncology, 2001, 127(1), 48-54.;;Koenigsman et al., ""Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma-a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)"", Leukemia & Lymphoma, 2004, 45(9), 1821-1827.;;Kollmannsberger et al., ""Phase II study of Bendamustine in Patients with relapsed or cisplatin-refractory germ cell Cancer"", Anti-Cancer Drugs, 2000, 11(7), 535-539.;;Konstantinov et al., ""Cytotoxic Efficacy of Bendamustine in Human Leukemia and Breast Cancer cell lines"", Journal of Cancer Research and Clinical Oncology, 2002, 128(5), 271-278.;;Köster et al., ""Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small lung cancer (SCLC)"", Clinical Drug Investigation, 2004, 24(10), 611-618.;;Leoni et al., ""Sdx-105 (Trenda), Active in Non-Hodgkin's Lymphoma Cells, Induces the Mitotic Catastrophe Death Pathway "", Blood, 2004, 104(11), (Abstract).;;Maas, ""Stability of Bendamustine Hydrochloride in Infusion Solutions"", 1994, 49(10), 9 pages.;;Morissette et al., ""High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids"", Advanced Drug Delivery Reviews, Feb. 2004, 56(3), 275-300.;;Niemeyer et al., ""SDX-105 (bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action"", Proc Annu Meet Am Assoc Cancer Res, Mar. 2004, 45, 1st ed., 2 pages.;;Nowak et al., ""Upon Drug-Induced Apoptosis in Lymphoma Cells X- linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus"", Leukemia & Lymphoma, Jul. 2004, 45(7), 1429-1436.;;Ozegowski et al., ""IMET 3393, gamma-(1-methyl-5-bis-(beta-chloräthyl)-amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste"", Zbl Pharm., 1971;110, Heft 10, 1013-1019.;;Ponisch et al., ""Bendamustine in the treatment of Multiple Myeloma: Results and future perspectives"", Seminars in Oncology, Aug. 2002, 29(4), 23-26, Suppl. 13.;;Preiss et al., ""Pharmacokinetics of bendamustin (Cytostasan) in patients"", Pharmazie, Mar. 1985, 40(11), 782-784.;;Remington: Pharmaceutical Sciences, 1990, Mack Publishing company, Easton, Pennsylvania.;;Ribosepharm, ""Product monograph ribosepharm passage"", Product Monograph, Ribosepharm, Jan. 1, 2005, pp. 3-73.;;Rummel et al., ""Bendamustine in the Treatment of Non-Hodgkin's Lymphoma: Results and Future Perspectives"", Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 27-32.;;Rummel et al., ""In Vitro Studies with Bendamustine: Enhanced Activity in Combination with Rituximab"", Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 12-14.;;Scasnar et al., ""Radiochemical Assay of Stability of 14C-Cytostasan Solutions During Preparation and Storage"", Journal of Radioanalytical and Nuclear Chemistry, 1998, 121(2), 489-497.;;Scasnar et al., ""Stability Studies of 14C-Cytostasan® solutions and its extraction using dicarbolide of cobalt"", Phamazie, Mar. 1988, 43, 176-179.;;Schmidt-Hieber et al., ""A Phase II Study of bendamustine Chemotherapy as Second-line treatment in metastatic uveal Melanoma"", Melanoma Research, 2004, 14(6), 439-442.;;Schoffski, ""Repeated Administration of Short Infusions of Bendamustine: A phase I study in Patients with Advanced Progressive Solid Tumors"", Journal of Cancer Research and Clinical Oncology, 2000, 126(1), 41-47.;;Schrijvers et al., ""Phase I study with bendamustine: An update"", Seminars in Oncology, Suppl. 13, 2002, 29(4), 15-18.;;Schwanen et al., ""In Vitro Evaluation of Bendamustine Induced Apoptosis in B-Chronic Lymphocytic Leukemia"", Leukemia, Oct. 2002, 16(10), 2096-2105.;;Strumberg et al., ""Bendamustine Hydrochloride Activity against doxorubicin-resistant Human Breast Carcinoma Cell Lines"", Anti-Cancer Drugs, 1996, 7(4), 415-421.;;Weide et al., ""Bendamustine Mitoxantrone and Rituximab (BMR): A New effective regimen for refractory or relapsed indolent lymphomas"", Leukemia & Lymphoma, 2002, 43(2), 327-331.;;Weide et al., ""Bendamustine/ Mitoxantrone/Rituximab (BMR) : A very Effective, well tolerated Outpatient Chemoimmunotherapy for relapsed and refractory CD20-positive Indolent Malignancies Final Results of a Pilot Study"", Leukemia & Lymphoma, 2004, 45(12), 2445-2449.;;Weidmann et al., ""Bendamustine is Effective in Relapsed or Refractory Aggressive non-Hodgkin's Lymphoma"", Annals of Oncology, 2002, 13(8), 1285-1289.;;Werner et al., ""Hydrolyseprodukte des Cancerostaticums Cytostasan (Bendamustin)"", Pharmazie, 1987, 42, 272-273.;;Zulkowski et al., ""Regression of Brain Metastases from Breast Carcinoma after Chemotherapy with bendamustine"", Journal of Cancer Research and Clinical Oncology, 2002, 128(2), 111-113.",ACTIVE
828,EP,A1,EP 0830763 A1,007-656-502-708-081,1998-03-25,1998,EP 96917060 A,1996-06-03,GB 9510870 A;;GB 9513169 A;;GB 9603700 A;;US 9608547 W,1995-06-02,SUBSCRIBER TERMINAL FOR A WIRELESS TELECOMMUNICATIONS SYSTEM,,DSC COMMUNICATIONS,LYSEJKO MARTIN;;LAMKIN RICHARD MORTIMER;;COOPER GUY ALEXANDER;;NETHERCOTT JONATHAN FRANCIS,AIRSPAN NETWORKS INC. (2000-10-18);;AIRSPAN COMMUNICATIONS CORPORATION (1998-12-30),https://lens.org/007-656-502-708-081,Patent Application,yes,0,0,7,251,0,H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J11/00;;H04J13/00;;H04J13/004;;H04L12/2825;;H04L12/2836;;H04L12/403;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04L2012/2841;;H04L2012/2845;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02;;H04W88/021;;H04L9/12;;H04L9/3226;;H04L2209/34;;H04L2209/80;;H04L69/08;;H04L69/14;;H04W88/021;;H04L41/0233;;H04J13/00;;H04Q2213/13376;;H04Q2213/13093;;H04Q2213/13199;;H04J13/004;;H04Q2213/13216;;H04Q2213/13335;;H04B1/7085;;H04Q2213/13098;;H04Q2213/1319;;H04L41/22;;H04W52/52;;H04B1/707;;H04B1/7075;;H04B1/7077;;H04B2201/7071;;H04L12/2825;;H04L12/66;;H04Q2213/13299;;H04B1/70735;;H04L41/0226;;H04W52/08;;H04B2201/70702;;H04Q2213/13296;;H04Q2213/1305;;H04J3/0682;;H04L2012/2845;;H04J11/00;;H04L12/2836;;H04Q11/04;;H04Q2213/13202;;H04W24/08;;H04Q2213/13292;;H04B2201/709709;;H04Q2213/13204;;H04W88/02;;H04L2012/2841;;H04Q2213/13298;;H04B2201/70706;;H04B2201/70711;;H04L43/00;;H04B1/70775;;H04B2001/70706;;H04L12/403;;H04W24/00;;H04Q2213/13109;;H04Q2213/13196;;H04L9/3226;;H04L9/12;;H04L2209/80;;H04L2209/34;;H04L69/14;;H04L69/08,H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02,,0,0,,,,DISCONTINUED
829,AU,B2,AU 2018/200075 B2,006-116-856-654-072,2019-02-28,2019,AU 2018/200075 A,2018-01-04,AU 2018/200075 A;;AU 2014/369839 A;;US 201361920700 P;;US 2014/0072380 W,2013-12-24,System and method for detecting operational anomalies in train consists and railcars,"SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS A system for detecting operational anomalies on a train consist (109) or railcar (103) comprising one or more communication management units (101) mounted on one or more railcars (103); one or more sensors located on said one or more railcars (103) for sensing an operational parameter of said one or more railcars (103), said sensors being in communication with said one or more communication management units (101); a powered wireless gateway (102) controlling a train based mesh network (107), wherein said train-based mesh network (107) includes said powered wireless gateway (102) and each of said communication management units (101), and said train based mesh network (107) configured to receive information from each communication management units (101) and draw inferences from this information regarding performance of said train consist (109); and one or more wireless sensor nodes (104) in communication with one of said communication management units (101), said one or more sensors forming part of said one or more wireless sensor nodes (104). The communication management unit (101) and said wireless sensor nodes (104) form a railcar-based mesh network (105), said railcar-based mesh network (105) being controlled by said communication management unit (101), and said communication management unit (101) configured to receive information from said wireless sensor nodes (104) and draw inferences from this information regarding performance of a respective railcar (103). The communication management units (101) perform the functions of: collecting data regarding said one or more railcar operational parameters; analyzing said collected data for trends or events indicative of an anomalous operational condition; and communicating a message to a remote receiver when said trend or event is detected.",AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/006-116-856-654-072,Granted Patent,no,2,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,ACTIVE
830,WO,A1,WO 2015/100425 A1,033-306-201-127-905,2015-07-02,2015,US 2014/0072380 W,2014-12-24,US 201361920700 P,2013-12-24,SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS,A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/033-306-201-127-905,Patent Application,yes,5,30,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,1,0,,,See also references of EP 3086992A4,PENDING
831,AU,A1,AU 2014/369839 A1,070-601-833-046-779,2016-08-04,2016,AU 2014/369839 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,System and method for detecting operational anomalies in train consists and railcars,A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/070-601-833-046-779,Patent Application,no,0,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,DISCONTINUED
832,US,A1,US 2015/0272696 A1,091-690-089-343-829,2015-10-01,2015,US 201314437805 A,2013-09-18,AU 2012/904715 A;;AU 2013/001069 W,2012-10-26,SURGICAL SYSTEM,"The present invention relates to, inter alia, a surgical system for monitoring the orientation of a surgical device relative to a patient's anatomy, the system comprising: a. A patient sensor for sensing the orientation of the patient's anatomy; b. An orientation sensor for sensing the orientation of a surgical device; and c. A monitor for monitoring the orientation of the surgical device relative to the sensed patient's anatomy.",INLINE ORTHOPAEDICS PT LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/091-690-089-343-829,Patent Application,yes,17,22,10,10,0,A61B34/20;;A61B34/20;;A61F2/4657;;A61B5/1121;;A61B5/1121;;A61B5/1121;;A61B5/4504;;A61B5/4504;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/4528;;A61B5/4571;;A61B5/4571;;A61B5/4571;;A61B5/6832;;A61B5/6834;;A61B5/6834;;A61B5/6834;;A61B17/1666;;A61B17/1666;;A61B17/1666;;A61B34/25;;A61B34/25;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61B2090/3983;;A61B2090/3983;;A61B2505/05;;A61B2505/05;;A61B2505/05;;A61B2562/0219;;A61B2562/0219;;A61B2562/0219;;A61B2562/17;;A61B2562/17;;A61F2/4609;;A61F2/4609;;A61F2/4609;;A61F2/4657;;A61F2/4657;;A61F2002/4668;;A61F2002/4668;;A61F2002/4668;;G06F19/3481;;G16H20/40;;G16H20/40,A61B19/00;;A61B5/11;;A61B17/16;;A61F2/46,,0,0,,,,DISCONTINUED
833,GB,A,GB 2301743 A,097-526-328-846-284,1996-12-11,1996,GB 9603700 A,1996-02-21,GB 9603700 A;;GB 9510870 A;;GB 9513169 A,1995-06-02,Wireless telecommunications based subscriber terminal with monitor facility,"A subscriber station of a wireless telecommunications system includes a transceiver 24 for wireless communication 26 with a central station and for processing signals for transmission and/or received signals. The transceiver is connected via a link 28 to a power supply unit 30 for connection, via network terminal unit 32, to one or more outlets for user telecommunications equipment 34,36,38. The link carries telephone call data for the telecommunication equipment and subscriber station control data in accordance with an internal protocol. The internal protocol control data comprises operational status parameters of the subscriber station. The provision of internal protocol control data on a link between the transmitter/receiver and the supply unit thus provides a point of access for monitoring the operational status of the subscriber station. This access point may also be used to invoke a system installation/configuration routine which may then be effected via the subscriber's telephone keypad.",DSC COMMUNICATIONS,LYSEJKO MARTIN;;LAMKIN RICHARD MORTIMER;;NETHERCOTT JONATHAN FRANCIS;;COOPER GUY ALEXANDER,,https://lens.org/097-526-328-846-284,Patent Application,no,2,5,7,251,0,H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J11/00;;H04J13/00;;H04J13/004;;H04L12/2825;;H04L12/2836;;H04L12/403;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04L2012/2841;;H04L2012/2845;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02;;H04W88/021;;H04L9/12;;H04L9/3226;;H04L2209/34;;H04L2209/80;;H04L69/08;;H04L69/14;;H04W88/021;;H04L41/0233;;H04J13/00;;H04Q2213/13376;;H04Q2213/13093;;H04Q2213/13199;;H04J13/004;;H04Q2213/13216;;H04Q2213/13335;;H04B1/7085;;H04Q2213/13098;;H04Q2213/1319;;H04L41/22;;H04W52/52;;H04B1/707;;H04B1/7075;;H04B1/7077;;H04B2201/7071;;H04L12/2825;;H04L12/66;;H04Q2213/13299;;H04B1/70735;;H04L41/0226;;H04W52/08;;H04B2201/70702;;H04Q2213/13296;;H04Q2213/1305;;H04J3/0682;;H04L2012/2845;;H04J11/00;;H04L12/2836;;H04Q11/04;;H04Q2213/13202;;H04W24/08;;H04Q2213/13292;;H04B2201/709709;;H04Q2213/13204;;H04W88/02;;H04L2012/2841;;H04Q2213/13298;;H04B2201/70706;;H04B2201/70711;;H04L43/00;;H04B1/70775;;H04B2001/70706;;H04L12/403;;H04W24/00;;H04Q2213/13109;;H04Q2213/13196;;H04L9/3226;;H04L9/12;;H04L2209/80;;H04L2209/34;;H04L69/14;;H04L69/08,H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02,H4L LDJ           NONE;;H4L LECC          NONE;;H4L LFM           NONE;;H4L LFMX          LFMX;;H4L L1H10         LFMX;;H4L L1H9          LFMX;;H4L L217          LFMX;;H4L L30           LFMX,0,0,,,,EXPIRED
834,AU,B2,AU 2013/334469 B2,106-803-557-600-007,2018-10-11,2018,AU 2013/334469 A,2013-09-18,AU 2012/904715 A;;AU 2013/001069 W;;AU 2013/334469 A,2012-10-26,Surgical system,"The present invention relates to, inter alia, a surgical system for monitoring the orientation of a surgical device relative to a patient's anatomy, the system comprising: a. A patient sensor for sensing the orientation of the patient's anatomy; b. An orientation sensor for sensing the orientation of a surgical device; and c. A monitor for monitoring the orientation of the surgical device relative to the sensed patient's anatomy.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/106-803-557-600-007,Granted Patent,no,6,0,10,10,0,A61B34/20;;A61B34/20;;A61F2/4657;;A61B5/1121;;A61B5/1121;;A61B5/1121;;A61B5/4504;;A61B5/4504;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/4528;;A61B5/4571;;A61B5/4571;;A61B5/4571;;A61B5/6832;;A61B5/6834;;A61B5/6834;;A61B5/6834;;A61B17/1666;;A61B17/1666;;A61B17/1666;;A61B34/25;;A61B34/25;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61B2090/3983;;A61B2090/3983;;A61B2505/05;;A61B2505/05;;A61B2505/05;;A61B2562/0219;;A61B2562/0219;;A61B2562/0219;;A61B2562/17;;A61B2562/17;;A61F2/4609;;A61F2/4609;;A61F2/4609;;A61F2/4657;;A61F2/4657;;A61F2002/4668;;A61F2002/4668;;A61F2002/4668;;G06F19/3481;;G16H20/40;;G16H20/40,A61B17/58;;A61B5/103;;A61B17/56;;A61F2/32;;A61F2/46;;G06F19/00,,0,0,,,,INACTIVE
835,US,B2,US 9946526 B2,098-767-819-817-131,2018-04-17,2018,US 201213437462 A,2012-04-02,US 201213437462 A;;US 201161568056 P,2011-12-07,Development and hosting for platform independent applications,"Method, system, and programs for providing development, deployment, and hosting of applications that are interoperable across different device platforms. An application capable of being executed in a plurality of different device formats is generated. The application is deployed to a client device for execution at the client device. Execution of the same application is initiated at a server.",FERNANDEZ RUIZ BRUNO;;LOW DARYL MUN KID;;COOPER MARTIN F N;;EXCALIBUR IP LLC,FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,YAHOO! INC (2016-05-31);;EXCALIBUR IP LLC (2016-05-31);;R2 SOLUTIONS LLC (2020-04-28),https://lens.org/098-767-819-817-131,Granted Patent,yes,38,8,5,13,0,G06F8/60;;G06F8/60;;G06F9/45529;;G06F9/45529,G06F9/44;;G06F9/445;;G06F9/455,,29,1,042-748-563-752-489,10.1109/icse.2007.59,"Office Action issued on Apr. 9, 2014 in U.S. Appl. No. 13/729,162.;;Office Action issued on May 9, 2014 in U.S. Appl. No. 13/550,914.;;International Search Report corresponding to PCT/US2012/64786 dated Mar. 28, 2013.;;Preliminary Report on Patentability issued on Jun. 19, 2014 in PCT/US2012/064786.;;Office Action issued on Jun. 12, 2014 in U.S. Appl. No. 13/437,494.;;Office Action issued on Sep. 9, 2014 in U.S. Appl. No. 13/719,437.;;Office Action issued on Sep. 11, 2014 in U.S. Appl. No. 13/729,162.;;Moshchuk et al., “Resource Management for Web Applications in ServiceOS”, May 2010, Microsoft Research, Retrieved from http://research.microsoft.com/apps/pubs/default.aspx?id=131540, 15 pages.;;Office Action dated Oct. 23, 2014 in U.S. Appl. No. 13/719,515.;;Office Action dated Dec. 24, 2014 in U.S. Appl. No. 13/437,494.;;Office Action dated Nov. 14, 2014 in U.S. Appl. No. 13/550,914.;;Office Action dated Jan. 26, 2015 in U.S. Appl. No. 13/719,437.;;Office Action dated May 6, 2015 in U.S. Appl. No. 13/437,494.;;Notice of Allowance dated May 8, 2015 in U.S. Appl. No. 13/550,914.;;Office Action dated May 14, 2015 in U.S. Appl. No. 13/719,437.;;Office Action dated Jul. 29, 2015 in U.S. Appl. No. 13/729,162.;;Kosta et al., “Unleashing the Power of Mobile Cloud Computing using ThinkAir”, May 2011, retreived from Cornell University Library, http://arvix.org/abs/1105.3232, 17 pages.;;Notice of Allowance dated Aug. 19, 2015 in U.S. Appl. No. 13/437,494.;;Chris Tucker, “Opium: Optimal Package Install/Uninstall Manager,”29th International Coference on Software Engineering, 2007.;;Notice of Allowance dated Sep. 17, 2015 in U.S. Appl. No. 13/719,437.;;Office Action dated Sep. 25, 2015 in U.S. Appl. No. 13/719,515.;;Office Action dated Apr. 8, 2016 in U.S. Appl. No. 13/719,515.;;Office Action dated Jan. 17, 2017 in U.S. Appl. No. 14/821,849.;;Office Action dated Jan. 31, 2017 in U.S. Appl. No. 13/719,515.;;Office Action dated Jun. 19, 2017 in U.S. Appl. No. 13/719,515.;;Office Action dated Jun. 20, 2017 in U.S. Appl. No. 14/821,849.;;Office Action dated Oct. 17, 2017 in U.S. Appl. No. 13/719,515.;;Office Action dated Nov. 28, 2017 in U.S. Appl. No. 14/821,849.;;Office Action dated Feb. 12, 2018 in U.S. Appl. No. 13/719,515.",INACTIVE
836,KR,A,KR 20170139553 A,129-422-215-346-227,2017-12-19,2017,KR 20177030661 A,2016-03-24,AU 2015/901083 A;;AU 2016/050220 W,2015-03-25,정렬 장치,"본 발명은 환자의 몸의 적어도 두 개의 해부학적 기준점에 대해 센서를 정렬하기 위한 장치에 관한 것이다. 일 실시예에서, 이 장치는: 중심축을 가진 바디; 바디에 대해 위치된 센서 마운트; 바디로부터 연장하는 적어도 두 개의 암으로서, 적어도 두 개의 암 중 두 개는 중심축에 대해 동시에 그리고 등거리로 이동 가능한, 적어도 두 개의 암; 및 적어도 두 개의 해부학적 기준점과 정렬하도록 적어도 두 개의 암에 접속된 적어도 두 개의 정렬기를 포함한다. 이 장치는 또한 장치 센서를 포함할 수 있다. 본 발명은 또한 장치를 포함하는, 환자의 몸의 배향을 모니터링하기 위한 수술 시스템에 관련된다. 또한, 본 발명은 환자의 몸에 대해 최적의 배향으로 수술 디바이스를 가이드하기 위한 수술 시스템에 관련되며, 이러한 수술 시스템은 장치를 포함한다. 본 발명은: 환자의 몸의 적어도 두 개의 해부학적 기준점에 대해 센서를 정렬하는 방법 및 환자의 몸에 대해 최적의 배향으로 수술 디바이스를 가이드하는 방법에 또한 관련된다. 일 실시예에서, 환자의 몸은 골반이다.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/129-422-215-346-227,Patent Application,no,0,0,7,7,0,A61B17/1746;;A61B17/1746;;A61B34/20;;A61B34/20;;A61B34/20;;A61B34/25;;A61B34/25;;A61B90/37;;A61B90/37;;A61B2017/00734;;A61B2017/00734;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61F2/4603;;A61F2/4607;;A61F2/4609;;A61F2/4657;;A61F5/11;;A61F5/11;;A61F2002/4687,A61B34/20;;A61B90/00;;A61F2/46,,0,0,,,,PENDING
837,WO,A1,WO 1998/012293 A1,140-904-461-810-902,1998-03-26,1998,US 9716690 W,1997-09-19,US 2644296 P,1996-09-19,CONCENTRATED QUATERNARY AMMONIUM FABRIC SOFTENER COMPOSITIONS CONTAINING CATIONIC POLYMERS,"The present invention relates to aqueous stable, preferably concentrated, aqueous liquid textile softening compositions comprising fabric softener active and cationic polymer in the continuous aqueous phase to provide improved softening. The compositions of the present invention preferably contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 140. The cationic polymers can provide additional benefits such as dye transfer inhibition, chlorine scavenging to protect fabrics, cotton soil release benefits, etc.",PROCTER & GAMBLE;;COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/140-904-461-810-902,Patent Application,yes,1,19,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;D06M13/322;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,PATENTED
838,US,A1,US 2009/0264488 A1,154-405-968-415-903,2009-10-22,2009,US 41192909 A,2009-03-26,US 41192909 A;;US 3975208 P,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON INC (2009-04-24),https://lens.org/154-405-968-415-903,Patent Application,yes,29,43,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K31/4184;;A61P35/00;;A61P35/02;;C07D235/12,514/394;;548/310.1,0,0,,,,DISCONTINUED
839,US,A1,US 2013/0152072 A1,167-958-425-383-038,2013-06-13,2013,US 201213550914 A,2012-07-17,US 201213550914 A;;US 201213437494 A;;US 201161568056 P,2011-12-07,Development of Platform Independent Applications,"Method, system, and programs for providing packages to applications is disclosed. An application that is executable on a plurality of device platforms is generated. The application is deployed to a client device. A package list received from the client device is analyzed to determine package dependencies for packages on the package list. The packages on the package list and dependent packages are provided based on the package dependencies to the client device. The packages and dependent packages may be installed by the client device to ensure that the application is executable based on characteristics of the client device.",FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N;;YAHOO INC,FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,YAHOO! INC (2016-05-31);;EXCALIBUR IP LLC (2016-05-31);;R2 SOLUTIONS LLC (2020-04-28),https://lens.org/167-958-425-383-038,Patent Application,yes,13,11,3,13,0,G06F8/60;;H04L67/01;;G06F8/60;;G06F8/65;;H04L67/10,G06F9/445;;G06F15/16,717/175,0,0,,,,INACTIVE
840,US,A1,US 2003/0104964 A1,189-216-619-903-172,2003-06-05,2003,US 30763402 A,2002-12-02,US 30763402 A;;US 26908699 A;;US 2644296 P,1996-09-19,"Concentrated, preferably biodegradable, quaternary ammonium fabric softener compositions containing cationic polymers and process for preparation","
   The present invention relates to aqueous stable, preferably concentrated, aqueous liquid textile softening compositions comprising fabric softener active and cationic polymer in the continuous aqueous phase to provide improved softening. 

   The compositions of the present invention preferably contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 140. The cationic polymers can provide additional benefits such as dye transfer inhibition, chlorine scavenging to protect fabrics, cotton soil release benefits, etc. 
",PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/189-216-619-903-172,Patent Application,yes,5,28,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D1/62;;D06M13/322;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,510/327;;510/329;;X51033;;510/515,0,0,,,,EXPIRED
841,EP,A2,EP 2655487 A2,186-032-654-191-021,2013-10-30,2013,EP 11805307 A,2011-12-09,US 97421610 A;;US 2011/0064207 W,2010-12-21,POLYMER SUBSTRATES HAVING IMPROVED BIOLOGICAL RESPONSE FROM HKDCS,,DEPUY SYNTHES PRODUCTS LLC,COOPER KEVIN L;;MARTIN ALISHA;;NATARAJAN SRIRAM;;VETRECIN ROBERT;;LIU CHANGDENG,,https://lens.org/186-032-654-191-021,Patent Application,yes,0,0,4,4,0,B29C59/14;;C08J3/28;;C08J7/12;;Y10T428/24355;;Y10T428/24355;;C08J3/28;;C08J7/12;;B29C59/14,C08J3/28,,0,0,,,,DISCONTINUED
842,NO,L,NO 20053827 L,001-634-087-234-054,2005-10-17,2005,NO 20053827 A,2005-08-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,Nye forbindelser.,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,INGALL ANTHONY HOWARD;;COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;TASNEEM RUKHSANA,,https://lens.org/001-634-087-234-054,Abstract,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,DISCONTINUED
843,US,A1,US 2018/0078266 A1,094-767-274-421-317,2018-03-22,2018,US 201615561366 A,2016-03-24,AU 2015/901083 A;;AU 2016/050220 W,2015-03-25,ALIGNMENT APPARATUS,"The present invention relates to an apparatus for aligning a sensor relative to at least two anatomical reference points of a patient's anatomy. In one embodiment, the apparatus includes: a body having a central axis; a sensor mount positioned relative to the body; at least two arms extending from the body, wherein two of said at least two arms are simultaneously and equidistantly moveable relative to the central axis; and at least two aligners connected to the at least two arms for aligning with said at least two anatomical reference points. The apparatus may also include an apparatus sensor. The present invention also relates to a surgical system for monitoring the orientation of a patient's anatomy, which includes the apparatus. Furthermore, the present invention also relates to a surgical system for guiding a surgical device to an optimal orientation relative to a patient's anatomy, wherein the surgical system includes the apparatus. The present invention also relates to: a method of aligning a sensor relative to at least two anatomical reference points of a patient's anatomy, and to a method of guiding a surgical device to an optimal orientation relative to a patient's anatomy. In one embodiment, the patient's anatomy is the pelvis.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/094-767-274-421-317,Patent Application,yes,1,10,7,7,0,A61B17/1746;;A61B17/1746;;A61B34/20;;A61B34/20;;A61B34/20;;A61B34/25;;A61B34/25;;A61B90/37;;A61B90/37;;A61B2017/00734;;A61B2017/00734;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61F2/4603;;A61F2/4607;;A61F2/4609;;A61F2/4657;;A61F5/11;;A61F5/11;;A61F2002/4687,A61B17/17;;A61B34/00;;A61B34/20;;A61B90/00;;A61F2/46,,0,0,,,,DISCONTINUED
844,EP,B1,EP 0561605 B1,133-697-013-548-899,1999-01-13,1999,EP 93301971 A,1993-03-16,US 85610792 A,1992-03-20,Techniques for automatic form creation by combining partial operations,,XEROX CORP,COOPER MARTIN F N;;CARD STUART K;;JOHNSON WALTER A L,,https://lens.org/133-697-013-548-899,Granted Patent,yes,10,0,8,8,0,G06F40/174;;G06F40/174,G06F3/14;;G06F3/048;;G06F17/24;;H04N1/00,,4,0,,,"PATENT ABSTRACTS OF JAPAN vol. 12, no. 162 (E-609) 17 May 1988 & JP-A-62 272 751 (MATSUSHITA) 26 November 1987;;PATENT ABSTRACTS OF JAPAN vol. 12, no. 334 (P-756) 8 September 1988 & JP-A-63 095 578 (CANON) 26 April 1988;;PATENT ABSTRACTS OF JAPAN vol. 13, no. 51 (E-712) 6 February 1989 & JP-A-63 242 060 (SANYO) 7 October 1988;;PATENT ABSTRACTS OF JAPAN vol. 8, no. 221 (E-271) 9 October 1984 & JP-A-59 103 460 (NIPPON DENSHIN) 14 June 1984",EXPIRED
845,US,A1,US 2013/0152066 A1,140-469-027-846-124,2013-06-13,2013,US 201213437462 A,2012-04-02,US 201213437462 A;;US 201161568056 P,2011-12-07,DEVELOPMENT AND HOSTING FOR PLATFORM INDEPENDENT APPLICATIONS,"Method, system, and programs for providing development, deployment, and hosting of applications that are interoperable across different device platforms. An application capable of being executed in a plurality of different device formats is generated. The application is deployed to a client device for execution at the client device. Execution of the same application is initiated at a server.",FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N;;YAHOO INC,FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,YAHOO! INC (2016-05-31);;EXCALIBUR IP LLC (2016-05-31);;R2 SOLUTIONS LLC (2020-04-28),https://lens.org/140-469-027-846-124,Patent Application,yes,4,12,5,13,0,G06F8/60;;G06F8/60;;G06F9/45529;;G06F9/45529,G06F9/44;;G06F15/16,717/172,0,0,,,,INACTIVE
846,IN,A,IN 3916DEN2015 A,172-328-617-060-422,2015-10-02,2015,IN 3916DEN2015 A,2015-05-07,AU 2012/904715 A;;AU 2013/001069 W,2012-10-26,SURGICAL SYSTEM,The present invention relates to inter alia a surgical system for monitoring the orientation of a surgical device relative to a patient s anatomy the system comprising: a. A patient sensor for sensing the orientation of the patient s anatomy; b. An orientation sensor for sensing the orientation of a surgical device; and c. A monitor for monitoring the orientation of the surgical device relative to the sensed patient s anatomy.,INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/172-328-617-060-422,Patent Application,no,0,0,10,10,0,A61B34/20;;A61B34/20;;A61F2/4657;;A61B5/1121;;A61B5/1121;;A61B5/1121;;A61B5/4504;;A61B5/4504;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/4528;;A61B5/4571;;A61B5/4571;;A61B5/4571;;A61B5/6832;;A61B5/6834;;A61B5/6834;;A61B5/6834;;A61B17/1666;;A61B17/1666;;A61B17/1666;;A61B34/25;;A61B34/25;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61B2090/3983;;A61B2090/3983;;A61B2505/05;;A61B2505/05;;A61B2505/05;;A61B2562/0219;;A61B2562/0219;;A61B2562/0219;;A61B2562/17;;A61B2562/17;;A61F2/4609;;A61F2/4609;;A61F2/4609;;A61F2/4657;;A61F2/4657;;A61F2002/4668;;A61F2002/4668;;A61F2002/4668;;G06F19/3481;;G16H20/40;;G16H20/40,A61B17/58;;A61B17/56;;A61F2/46,,0,0,,,,PENDING
847,MX,B,MX 339878 B,176-464-146-077-448,2016-06-15,2016,MX 2013011045 A,2009-03-26,US 3975208 P;;US 2009/0001956 W,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE.,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/176-464-146-077-448,Granted Patent,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K31/4184;;A61K9/14;;A61K9/19,,0,0,,,,ACTIVE
848,US,A1,US 2012/0156780 A1,197-103-776-508-407,2012-06-21,2012,US 97421610 A,2010-12-21,US 97421610 A,2010-12-21,Polymer Substrates Having Improved Biological Response From HKDCS,"A method of surface modification of a biocompatible, biodegradable polymer substrate using RF plasma treatment is disclosed. This method and the resulting surface provide for enhanced adhesion and proliferation of cells, such as hKDCs, and can be used with scaffolds for tissue regeneration and with other delivery vehicles such as medical devices.",COOPER KEVIN L;;MARTIN ALISHA;;NATARAJAN SRIRAM;;VETRECIN ROBERT;;LIU CHANGDENG,COOPER KEVIN L;;MARTIN ALISHA;;NATARAJAN SRIRAM;;VETRECIN ROBERT;;LIU CHANGDENG,DEPUY ORTHOPAEDICS INC (2012-12-30);;DEPUY SYNTHES PRODUCTS LLC (2012-12-30);;DEPUY SPINE LLC (2012-12-30);;ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE LLC (2011-01-21),https://lens.org/197-103-776-508-407,Patent Application,yes,0,0,4,4,0,B29C59/14;;C08J3/28;;C08J7/12;;Y10T428/24355;;Y10T428/24355;;C08J3/28;;C08J7/12;;B29C59/14,C12N5/071;;B32B3/00;;C08J3/28,435/396;;428/141;;522/166,1,1,059-923-391-585-911,8731156,"Park et al.; In vitro cell response to differences in poly-L-lactide crystallinity; Journal of Biomedical Materials Research, Vol. 31, 117-130 (1996)",DISCONTINUED
849,US,B2,US 9235398 B2,003-446-641-421-231,2016-01-12,2016,US 201213437494 A,2012-04-02,US 201213437494 A;;US 201161568056 P,2011-12-07,Development of platform independent applications,"Method, system, and programs for providing development of applications that are interoperable across different device platforms. Application parameters of an application are defined allowing the application to be executable on a plurality of device platforms. A framework is applied to the application facilitating transportable code between a client device and a server to execute the application. The application is deployed so that it may be served to a client device.",FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N;;YAHOO INC,FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,YAHOO! INC (2016-05-31);;EXCALIBUR IP LLC (2016-05-31);;R2 SOLUTIONS LLC (2020-04-28),https://lens.org/003-446-641-421-231,Granted Patent,yes,36,3,5,13,0,G06F8/60;;G06F8/60;;G06F9/45529;;G06F9/45529,G06F9/44;;G06F3/048;;G06F9/445;;G06F9/455,,24,2,042-748-563-752-489;;042-748-563-752-489,10.1109/icse.2007.59;;10.1109/icse.2007.59,"Tucker et al., Opium: Optimal Package Install/Uninstall Manager, May 2007, 10 pages.;;International Search Report corresponding to PCT/US2012/64786 dated Mar. 28, 2013.;;Office Action issued on May 9, 2014 in U.S. Appl. No. 13/550,914.;;Office Action issued on Apr. 9, 2014 in U.S. Appl. No. 13/729,162.;;Office Action issued on Oct. 23, 2014 in U.S. Appl. No. 13/719,515.;;Office Action issued on Sep. 9, 2014 in U.S. Appl. No. 13/719,437.;;Office Action issued on Sep. 11, 2014 in U.S. Appl. No. 13/729,162.;;Moshchuk et al., ""Resource Management for Web Applications in ServiceOS"", May 2010, Microsoft Research, Retrieved from http://research.microsoft.com/apps/pubs/default.aspx?id=131540, 15 pages.;;Office Action issued on Jul. 25, 2014 in U.S. Appl. No. 13/437,462.;;Preliminary Report on Patentability issued on Jun. 19, 2014 in PCT/US2012/064786.;;Office Action issued on Feb. 11, 2015 in U.S. Appl. No. 13/719,515.;;Office Action issued on Feb. 13, 2015 in U.S. Appl. No. 13/729,162.;;R. Haratsch, ""A client-server architecture for providing client-specific network services on the application layer"", 2001, In Proceedings of APC 2001, Munich, Germany, 10 pages.;;Office Action issued on Nov. 14, 2014 in U.S. Appl. No. 13/550,914.;;Notice of Allowance issued on Nov. 18, 2014 in U.S. Appl. No. 13/437,462.;;Office Action issued on Jan. 26, 2015 in U.S. Appl. No. 13/719,437.;;Office Action issued on May 14, 2015 in U.S. Appl. No. 13/719,437.;;Office Action issued Jun. 4, 2015 in U.S. Appl. No. 13/719,515.;;Notice of Allowance issued on May 8, 2015 in U.S. Appl. No. 13/550,914.;;Notice of Allowance issued Sep. 17, 2015 in U.S. Appl. No. 13/719,437.;;Office Action issued Jul. 29, 2015 in U.S. Appl. No. 13/729,162.;;Kosta et al., ""Unleashing the Power of Mobile Cloud Computing using ThinkAir"", May 2011, retrieved from Cornell University Library, http://arvix.org/abs/1105.3232, 17 pages.;;Notice of Allowance issued Aug. 19, 2015 in U.S. Appl. No. 13/437,494.;;Chris Tucker, ""Opium: Optimal Package Install/Uninstall Manager,"" 29th International Conference on Software Engineering, 2007.",INACTIVE
850,US,A,US 5918160 A,006-647-831-547-572,1999-06-29,1999,US 65660496 A,1996-05-31,GB 9510870 A;;GB 9513169 A;;GB 9603700 A,1995-06-02,Subscriber terminal for a wireless telecommunications system,A subscriber station of a wireless telecommunications system includes a transmitter/receiver (24) for wireless communication with a central station and for processing signals for transmission and/or received signals. The transmitter/receiver (24) is connected via a link (408) to a supply unit (30) for connection to one or more telephone lines for user telecommunications equipment. The link (408) carries telephone call data for one or more telephone lines and subscriber station control data in accordance with an internal protocol. The internal protocol control data comprises operational status parameters of the subscriber station. The provision of internal protocol control data including operation status parameters on a link between the transmitter/receiver and the supply unit thus provides a point of access for monitoring the operational status of the subscriber station.,AIRSPAN COMM CORP,LYSEJKO MARTIN;;LAMKIN RICHARD M;;NETHERCOTT JONATHAN F;;COOPER GUY A,DSC COMMUNICATIONS CORPORATION (1996-04-15);;AIRSPAN MERGER CORPORATION (1999-08-06);;AIRSPAN NETWORKS INC (1999-12-15);;DSC TELECOM L.P (1998-01-01);;AIRSPAN COMMUNICATIONS CORPORATION (1999-08-06),https://lens.org/006-647-831-547-572,Granted Patent,yes,13,24,7,251,0,H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J11/00;;H04J13/00;;H04J13/004;;H04L12/2825;;H04L12/2836;;H04L12/403;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04L2012/2841;;H04L2012/2845;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02;;H04W88/021;;H04L9/12;;H04L9/3226;;H04L2209/34;;H04L2209/80;;H04L69/08;;H04L69/14;;H04W88/021;;H04L41/0233;;H04J13/00;;H04Q2213/13376;;H04Q2213/13093;;H04Q2213/13199;;H04J13/004;;H04Q2213/13216;;H04Q2213/13335;;H04B1/7085;;H04Q2213/13098;;H04Q2213/1319;;H04L41/22;;H04W52/52;;H04B1/707;;H04B1/7075;;H04B1/7077;;H04B2201/7071;;H04L12/2825;;H04L12/66;;H04Q2213/13299;;H04B1/70735;;H04L41/0226;;H04W52/08;;H04B2201/70702;;H04Q2213/13296;;H04Q2213/1305;;H04J3/0682;;H04L2012/2845;;H04J11/00;;H04L12/2836;;H04Q11/04;;H04Q2213/13202;;H04W24/08;;H04Q2213/13292;;H04B2201/709709;;H04Q2213/13204;;H04W88/02;;H04L2012/2841;;H04Q2213/13298;;H04B2201/70706;;H04B2201/70711;;H04L43/00;;H04B1/70775;;H04B2001/70706;;H04L12/403;;H04W24/00;;H04Q2213/13109;;H04Q2213/13196;;H04L9/3226;;H04L9/12;;H04L2209/80;;H04L2209/34;;H04L69/14;;H04L69/08,H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W24/00;;H04W24/08;;H04W52/08;;H04W52/52;;H04W88/02,455/57;;455/425;;455/67.1,1,1,085-487-649-791-216,10.1109/90.251918,"Abbott, et al., Increasing Network Throughput by Integrating Protocol Layers , IEEE 1993, No. 5, pp. 600 610.",EXPIRED
851,EP,B1,EP 0931132 B1,019-252-276-999-582,2003-11-05,2003,EP 97941709 A,1997-09-19,US 9716690 W;;US 2644296 P,1996-09-19,CONCENTRATED QUATERNARY AMMONIUM FABRIC SOFTENER COMPOSITIONS CONTAINING CATIONIC POLYMERS,,PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/019-252-276-999-582,Granted Patent,yes,1,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,D06M13/322;;C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,EXPIRED
852,EP,A1,EP 2911598 A1,029-860-208-041-489,2015-09-02,2015,EP 13849376 A,2013-09-18,AU 2012/904715 A;;AU 2013/001069 W,2012-10-26,SURGICAL SYSTEM,,INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/029-860-208-041-489,Patent Application,yes,0,0,10,10,0,A61B34/20;;A61B34/20;;A61F2/4657;;A61B5/1121;;A61B5/1121;;A61B5/1121;;A61B5/4504;;A61B5/4504;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/4528;;A61B5/4571;;A61B5/4571;;A61B5/4571;;A61B5/6832;;A61B5/6834;;A61B5/6834;;A61B5/6834;;A61B17/1666;;A61B17/1666;;A61B17/1666;;A61B34/25;;A61B34/25;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61B2090/3983;;A61B2090/3983;;A61B2505/05;;A61B2505/05;;A61B2505/05;;A61B2562/0219;;A61B2562/0219;;A61B2562/0219;;A61B2562/17;;A61B2562/17;;A61F2/4609;;A61F2/4609;;A61F2/4609;;A61F2/4657;;A61F2/4657;;A61F2002/4668;;A61F2002/4668;;A61F2002/4668;;G06F19/3481;;G16H20/40;;G16H20/40,A61B17/58;;A61B5/00;;A61B5/11;;A61B17/16;;A61B17/56;;A61B34/20;;A61B90/00;;A61F2/32;;A61F2/46;;G06F19/00,,0,0,,,,DISCONTINUED
853,WO,A1,WO 2018/160827 A1,035-701-877-098-270,2018-09-07,2018,US 2018/0020440 W,2018-03-01,US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490465 P;;US 201762490567 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510660 P;;US 201762510672 P;;US 201762511218 P;;US 201715616874 A,2017-03-01,COMPOSITIONS PURPOSEFULLY SELECTED COMPRISING PURIFIED CANNABINOIDS AND/OR PURIFIED TERPENES,"Disclosed herein are new compositions comprising a purified cannabinoid and a purified terpene. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnaturally occurring ratios. In one embodiment, the compositions comprise unnaturally occurring concentrations. In one embodiment, the compositions comprise unexpected and/or synergistic effects.",EBBU LLC,LEVY KURT;;COOPER JONATHAN MICHAEL;;MARTIN JONATHAN REED;;REID BRIAN GEOFFREY,,https://lens.org/035-701-877-098-270,Patent Application,yes,5,9,11,36,0,A61K31/05;;A61K31/352,A61K31/05;;A01N65/00;;A61K31/352,,2,0,,,"MOSELEY: ""Ebbu Announces Groundbreaking Production Scale Purification Process"", BUSINESS WIRE, 13 June 2016 (2016-06-13), XP055546706, Retrieved from the Internet <URL:1-2>;;See also references of EP 3589129A4",PENDING
854,BR,A,BR 9608346 A,062-876-697-994-290,1999-01-05,1999,BR 9608346 A,1996-06-03,GB 9510870 A;;GB 9511546 A;;GB 9513170 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A;;US 9608568 W,1995-06-02,Aparelho e método para controle de força de transmissão e taxa de transmissão de um sistema de telecumunicações de radiotelefonia,,DSC COMMUNICATIONS,LYSEJKO MARTIN;;BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE,,https://lens.org/062-876-697-994-290,Patent Application,no,0,0,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,DISCONTINUED
855,EP,A2,EP 0413532 A2,074-866-345-793-045,1991-02-20,1991,EP 90308853 A,1990-08-10,GB 8918886 A;;GB 8918929 A,1989-08-18,Macrocyclic compounds.,"There are described compounds of formula I,
   wherein R¹ represents H or OH; R² represents H; in addition, R¹ and R² may together represent a second carbon-carbon bond between the carbon atoms to which they are attached; R³ represents OH or OCH₃; X represents O or (H,OH); and Y represents O or N-OR⁴, in which R⁴ represents H or alkyl C₁₋₆; provided that when R¹ is OH, R² is H and X is O, then Y does not represent O. Processes for their production and compositions containing them, eg for use as immunosuppressive agents, are also described.  ",FISONS PLC,DONALD DAVID KEITH;;HARDERN DAVID NORMAN;;COOPER MARTIN EDWARD;;FURBER MARK,,https://lens.org/074-866-345-793-045,Patent Application,yes,0,17,11,13,0,A61P37/06;;C07H15/26;;C07H19/01;;C07H19/01,C07D498/18;;A61K31/445;;A61P37/06;;C07H19/01,,0,0,,,,DISCONTINUED
856,AU,B2,AU 724307 B2,133-958-596-244-995,2000-09-14,2000,AU 1999/022457 A,1999-03-29,AU 1999/022457 A;;AU 1996/064758 A,1996-06-03,Apparatus and method of controlling transmitting power of a wireless telecommunications system,,AIRSPAN NETWORKS INC,BHAGALIA SASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,AIRSPAN NETWORKS INC. (2000-06-29),https://lens.org/133-958-596-244-995,Granted Patent,no,2,0,4,4,0,H04J13/0048;;H04J13/12;;G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04J13/00;;H04L9/0662;;H04L9/12;;H04L9/3271;;H04L12/66;;H04Q11/04;;H04W52/08;;H04W52/52;;H04W84/14;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04L2209/80;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04L9/40,G06F8/71;;G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04J13/12;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
857,EP,A3,EP 0561605 A3,136-223-663-251-936,1994-11-09,1994,EP 93301971 A,1993-03-16,US 85610792 A,1992-03-20,TECHNIQUES FOR AUTOMATIC FORM CREATION BY COMBINING PARTIAL OPERATIONS,"An automatically created form (20) includes a field (28) for requesting a combined operation. A processor (66) creates the form in response to another form (10) that includes fields (12,16) that are marked to indicate a sequence of partial operations (A and C). The partial operations together constitute the combined operation (AC). The combined operation can, for example, be a facsimile transmission, in which case the partial operation fields (122,124,126) can specify the digits of a fax machine's telephone number. The automatically created form(140)can then include a single check box next to the name of the recipient. When the check box (150) is marked, the processor (66) responds to the form by performing the sequence of partial operations. The processor can execute input instructions (90) to receive data defining the image of each form and can execute response instructions (92) to respond to each form.",XEROX CORP,COOPER MARTIN F N;;CARD STUART K;;JOHNSON WALTER A L,,https://lens.org/136-223-663-251-936,Search Report,yes,10,0,8,8,0,G06F40/174;;G06F40/174,G06F3/14;;G06F3/048;;G06F17/24;;H04N1/00,,4,0,,,"PATENT ABSTRACTS OF JAPAN vol. 12, no. 162 (E - 609) 17 May 1988 (1988-05-17);;PATENT ABSTRACTS OF JAPAN vol. 12, no. 334 (P - 756) 8 September 1988 (1988-09-08);;PATENT ABSTRACTS OF JAPAN vol. 13, no. 51 (E - 712) 6 February 1989 (1989-02-06);;PATENT ABSTRACTS OF JAPAN vol. 8, no. 221 (E - 271) 9 October 1984 (1984-10-09)",EXPIRED
858,US,A1,US 2012/0071532 A1,169-428-777-485-470,2012-03-22,2012,US 201113301979 A,2011-11-22,US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E;;CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2012-06-13),https://lens.org/169-428-777-485-470,Patent Application,yes,1,34,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K31/4184;;A61P35/00;;A61P35/02;;C07D235/16,514/394;;548/310.1,3,0,,,"EC Safety Data Sheet: Ribomustin® in http://www.docstoc.com/docs/22323231/EC-Safety-Data-Sheet-Bendamustin (published: July 3, 1998; updated March 1, 2007);;Gust et al. in Monatshefte fϋr Chemie 128, 291 - 299 (1997);;Morissette et al. in Drug Delivery Reviews, 56 (2004) 275 - 30",ACTIVE
859,CA,A1,CA 2265769 A1,191-314-567-146-093,1998-03-26,1998,CA 2265769 A,1997-09-19,US 2644296 P;;US 9716690 W,1996-09-19,CONCENTRATED QUATERNARY AMMONIUM FABRIC SOFTENER COMPOSITIONS CONTAINING CATIONIC POLYMERS,"The present invention relates to aqueous stable, preferably concentrated, aqueous liquid textile softening compositions comprising fabric softener active and cationic polymer in the continuous aqueous phase to provide improved softening. The compositions of the present invention preferably contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 140. The cationic polymers can provide additional benefits such as dye transfer inhibition, chlorine scavenging to protect fabrics, cotton soil release benefits, etc.",PROCTER & GAMBLE,WAHL ERROL HOFFMAN;;COOPER MEGAN A;;TRINH TOAN;;WARD RICHARD MARTIN,,https://lens.org/191-314-567-146-093,Patent Application,no,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,D06M13/322;;C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,EXPIRED
860,US,A1,US 2020/0323824 A1,188-698-128-530-875,2020-10-15,2020,US 201916686751 A,2019-11-18,US 201916686751 A;;US 201816037560 A;;US 201615045523 A;;US 201414531023 A;;US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/188-698-128-530-875,Patent Application,yes,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K31/4184;;A61K9/00;;A61K9/14;;A61K9/19;;A61K47/26;;C07D235/16,,0,0,,,,DISCONTINUED
861,CA,A1,CA 2718939 A1,034-287-587-759-731,2009-10-01,2009,CA 2718939 A,2009-03-26,US 3975208 P;;US 2009/0001956 W,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/034-287-587-759-731,Patent Application,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/19;;A61K31/4184,,0,0,,,,DISCONTINUED
862,US,B2,US 8883836 B2,044-072-757-600-34X,2014-11-11,2014,US 201414200738 A,2014-03-07,US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Solid forms of bendamustine hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/044-072-757-600-34X,Granted Patent,yes,56,11,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/16,514/394;;548/310.1,51,38,057-331-944-087-540;;084-716-889-422-831;;007-364-858-655-289;;005-472-156-687-716;;009-214-187-079-899;;132-558-386-999-186;;123-775-514-819-528;;006-046-706-830-252;;069-673-960-292-160;;080-209-105-337-208;;027-084-824-706-497;;106-081-384-040-520;;074-470-545-310-545;;020-427-831-437-122;;044-553-566-435-465;;049-256-800-886-311;;067-512-968-604-94X;;023-549-427-997-819;;063-402-864-700-686;;113-421-979-742-187;;020-435-634-003-86X;;125-764-802-071-090;;111-707-255-990-821;;034-919-505-845-111;;023-237-704-770-485;;003-701-346-326-00X;;067-465-907-694-241;;127-003-929-505-550;;013-802-099-433-937;;055-433-061-655-828;;004-291-817-534-209;;108-687-604-265-588;;029-880-686-607-107;;093-799-759-321-023;;001-658-497-635-033;;091-079-688-402-134;;059-280-286-824-398;;057-884-013-276-829,10.1053/sonc.2002.34875;;10.1016/s0093-7754(02)90010-2;;12170428;;10.2165/00003495-200161050-00009;;11368287;;10.1002/jps.2600660104;;833720;;12458340;;10.1007/s00432-002-0378-6;;10.1023/a:1016241927429;;7494814;;11801463;;12691159;;10.1080/1042819021000054670;;11410411;;12948851;;10.1016/s0006-2952(03)00410-6;;12170424;;10.1053/sonc.2002.34871;;10.3109/02652048609031561;;3508181;;18182663;;10.1200/jco.2007.12.5070;;12170425;;10.1053/sonc.2002.34872;;10.1007/bf00807895;;10.1097/00001813-200110000-00003;;11593053;;10.1007/s004320000180;;11206271;;15223642;;10.1080/1042819042000223822;;10.1097/00001813-200008000-00003;;11036955;;12029443;;10.1007/s00432-002-0331-8;;10.2165/00044011-200424100-00007;;17523723;;10.1016/j.addr.2003.10.020;;14962582;;10.1080/1042819042000198858;;15359644;;10.1053/sonc.2002.34876;;10.1016/s0093-7754(02)90011-4;;12170429;;4095129;;12170430;;10.1016/s0093-7754(02)90012-6;;10.1053/sonc.2002.34877;;12170426;;10.1016/s0093-7754(02)90008-4;;10.1053/sonc.2002.34873;;10.1007/bf02041437;;3380859;;15577312;;10.1097/00008390-200412000-00001;;10.1007/pl00008463;;10641748;;10.1016/s0093-7754(02)90009-6;;10.1053/sonc.2002.34874;;12170427;;10.1038/sj.leu.2402651;;12357363;;10.1097/00001813-199606000-00007;;8826610;;11999564;;10.1080/10428190290006107;;15621757;;10.1080/10428190400004521;;10.1093/annonc/mdf189;;12181253;;3615563;;11862482;;10.1007/s00432-001-0303-4,"Aivado et al., ""Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives"", Seminars in Oncology, Aug. 2002, 29(4), 19-22, Suppl. 13.;;Author Unknown, ""Ribomustin: Bendamustine Product Monograph"", Ribosepharm GMBH, Munchen, Germany, Jan. 2002, 3-54.;;Author Unknown, ""Ribomustin: Bendamustine Product Monograph"", Ribosepharm GMBH, Munchen, Germany, Mar. 2005, 3-73.;;Barman et al., ""Bendamustine"" Drugs, 2001, 61(5), 631-638, Auckland, New Zealand.;;Berge et al., ""Pharmaceutical Salts"", Journal of pharmaceutical sciences, Jan. 1977, 66(1), 1-19.;;Bremer, ""High Rates of Long-lasting remissions after 5-day bendamustine Chemotherapy Cycles in Pre-Treated low-grade non-hodgkin's-lymphomas"", Journal of Cancer Research and Clinical Oncology, Nov. 2002, 128(11), 603-609.;;Brittain, ""Drugs and the Pharmaceutical Sciences,"" vol. 95, 1999, Polymorphism in Pharmaceutical Solids, pp. I-V, 228-239, XP003030775.;;Byrn et al., ""Pharmaceutical Solids: A Strategic Approach to Regulatory Consideration"", Pharmaceutical Research, Jul. 1995, 12(7), 945-954.;;Chow et al., ""Anti-CD20 Antibody (DEC-C2B8, rituximab) enhances efficiency of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of Cytokines complement and caspases"", Hematologica, Jan. 2002, 87(1), 33-43.;;Chow et al., ""In AML Cell Lines Ara-C combined with Purine Analogues is able to Exert Synergistic as well as Antagnostic Effects on Proliferation Apoptosis and Disruption of Mitochondrial Membrane Potential"", Leukemia & Lymphoma, 2003, 44(1), 165-173.;;Chow et al., ""In Vitro Induction of Apoptosis of Neoplastic Cells in Low-Grade non-Hodgkin's Lymphomas by Combination of established cytotoxic drugs with bendamustine"", Hematologica, May 2001, 86(5), 485-493.;;Chow et al., ""Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4(Par-4), death-associated protein (Dazz) and with enforced caspase activation"", Biochemical Pharmacology, Jan. 2003, 66(5), 711-724.;;Diehl et al., ""Bendamustine in the Treatment of Hematologic Malignancies"", Semin. Oncol., Aug. 2002, 29(4), 1-3, Suppl. 13, Saundes, Philadelphia, PA.;;EC Safety Data Sheet: Ribomustin® in http://www.docstoc.com/docs/22323231/EC-Safety-Data-Sheet-Bendamustin (published: Jul. 3, 1998; updated Mar. 1, 2007).;;EC Safety Data Sheet: Ribomustin® in www.asl.ri.it/staff/prevenzione/documentazione/Chemio/Ribomustin%20scheda%20di%2Osicurrezza.pdf (Retrieved from the internet Jun. 11, 2013).;;Fichtner et al., ""Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumor models"", Journal of Microencapsulation, Jan. 1986, 3(2), 77-87.;;Friedberg et al., ""Bendamustine in patients with Rituximab-refractory indolent and transformed non-hodgkin's lymphoma"", Journal of Clinical Oncology, Jan. 10, 2008, vol. 26, No. 2, pp. 204-210.;;Friedberg et al., Bendamustine HCI (TRENDA(TM)) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01), in Blood 106 (11), 2005 (Abstract 229).;;Gandhi, Varsha, ""Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies"", Seminars in Oncology, Aug. 2002, 29(4), 4-11, Suppl. 13.;;Goodman et al., The Pharmacological Basis of Therapeutics, 1985, 7th edition, Macmillan publishing company, New York.;;Gust et al., ""Investigation on the Stability of Bendamustin, a Cytostatic Agent of the Nitrogen Mustard Type I. Synthesis, Isolation and Characterization of Reference Substances"", Monatshefte fur Chemie, 1997, 128(3), 291-299.;;Heider et al., ""Efficacy and Toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas"", Anti-Cancer Drugs, 2001, 12(9), 725-729.;;Kath et al., ""Bendamustine Monotherapy in advanced and refractory chronic lymphocytic Leukemia"", Journal of Cancer Research and Clinical Oncology, 2001, 127(1), 48-54.;;Koenigsman et al., ""Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma-a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)"", Leukemia & Lymphoma, 2004, 45(9), 1821-1827.;;Kollmannsberger et al., ""Phase II study of Bendamustine in Patients with relapsed or cisplatin-refractory germ cell Cancer"", Anti-Cancer Drugs, 2000, 11(7), 535-539.;;Konstantinov et al., ""Cytotoxic Efficacy of Bendamustine in Human Leukemia and Breast Cancer cell lines"", Journal of Cancer Research and Clinical Oncology, 2002, 128(5), 271-278.;;Köster et al., ""Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small lung cancer (SCLC)"", Clinical Drug Investigation, 2004, 24(10), 611-618.;;Leoni et al., ""Sdx-105 (Trenda), Active in Non-Hodgkin's Lymphoma Cells, Induces the Mitotic Catastrophe Death Pathway "", Blood, 2004, 104(11), (Abstract).;;Maas, ""Stability of Bendamustine Hydrochloride in Infusion Solutions"", 1994, 49(10), 9 pages.;;Morissette et al., ""High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids"", Advanced Drug Delivery Reviews, Feb. 2004, 56(3), 275-300.;;Niemeyer et al., ""SDX-105 (bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action"", Proc Annu Meet Am Assoc Cancer Res, Mar. 2004, 45, 1st ed., 2 pages.;;Nowak et al., ""Upon Drug-Induced Apoptosis in Lymphoma Cells X- linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus"", Leukemia & Lymphoma, Jul. 2004, 45(7), 1429-1436.;;Ozegowski et al., ""IMET 3393, gamma-(1-methyl-5-bis-(beta-chloräthyl)-amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste"", Zbl Pharm., 1971;110, Heft 10, 1013-1019.;;Ponisch et al., ""Bendamustine in the treatment of Multiple Myeloma: Results and future perspectives"", Seminars in Oncology, Aug. 2002, 29(4), 23-26, Suppl. 13.;;Preiss et al., ""Pharmacokinetics of bendamustin (Cytostasan) in patients"", Pharmazie, Mar. 1985, 40(11), 782-784.;;Remington: Pharmaceutical Sciences, 1990, Mack Publishing company, Easton, Pennsylvania.;;Ribosepharm, ""Product monograph ribosepharm passage"", Product Monograph, Ribosepharm, Jan. 1, 2005, pp. 3-73.;;Rummel et al., ""Bendamustine in the Treatment of Non-Hodgkin's Lymphoma: Results and Future Perspectives"", Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 27-32.;;Rummel et al., ""In Vitro Studies with Bendamustine: Enhanced Activity in Combination with Rituximab"", Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 12-14.;;Scasnar et al., ""Radiochemical Assay of Stability of 14C-Cytostasan Solutions During Preparation and Storage"", Journal of Radioanalytical and Nuclear Chemistry, 1998, 121(2), 489-497.;;Scasnar et al., ""Stability Studies of 14C-Cytostasan® solutions and its extraction using dicarbolide of cobalt"", Phamazie, Mar. 1988, 43, 176-179.;;Schmidt-Hieber et al., ""A Phase II Study of bendamustine Chemotherapy as Second-line treatment in metastatic uveal Melanoma"", Melanoma Research, 2004, 14(6), 439-442.;;Schoffski, ""Repeated Administration of Short Infusions of Bendamustine: A phase I study in Patients with Advanced Progressive Solid Tumors"", Journal of Cancer Research and Clinical Oncology, 2000, 126(1), 41-47.;;Schrijvers et al., ""Phase I study with bendamustine: An update"", Seminars in Oncology, Suppl. 13, 2002, 29(4), 15-18.;;Schwanen et al., ""In Vitro Evaluation of Bendamustine Induced Apoptosis in B-Chronic Lymphocytic Leukemia"", Leukemia, Oct. 2002, 16(10), 2096-2105.;;Strumberg et al., ""Bendamustine Hydrochloride Activity against doxorubicin-resistant Human Breast Carcinoma Cell Lines"", Anti-Cancer Drugs, 1996, 7(4), 415-421.;;Weide et al., ""Bendamustine Mitoxantrone and Rituximab (BMR): A New effective regimen for refractory or relapsed indolent lymphomas"", Leukemia & Lymphoma, 2002, 43(2), 327-331.;;Weide et al., ""Bendamustine/Mitoxantrone/Rituximab (BMR) : A very Effective, well tolerated Outpatient Chemoimmunotherapy for relapsed and refractory CD20-positive Indolent Malignancies Final Results of a Pilot Study"", Leukemia & Lymphoma, 2004, 45(12), 2445-2449.;;Weidmann et al., ""Bendamustine is Effective in Relapsed or Refractory Aggressive non-Hodgkin's Lymphoma"", Annals of Oncology, 2002, 13(8), 1285-1289.;;Werner et al., ""Hydrolyseprodukte des Cancerostaticums Cytostasan (Bendamustin)"", Pharmazie, 1987, 42, 272-273.;;Zulkowski et al., ""Regression of Brain Metastases from Breast Carcinoma after Chemotherapy with bendamustine"", Journal of Cancer Research and Clinical Oncology, 2002, 128(2), 111-113.",ACTIVE
863,CN,A,CN 101980698 A,048-841-089-961-252,2011-02-23,2011,CN 200980110767 A,2009-03-26,US 2009/0001956 W;;US 3975208 P,2008-03-26,Novel solid forms of bendamustine hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,IAN COOPER MARTIN;;COURVOISIER LAURENT D;;MARK EDDLESTON;;MCKEAN ROBERT E,,https://lens.org/048-841-089-961-252,Patent Application,no,0,5,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/14;;A61K9/19;;A61K31/4184,,0,0,,,,ACTIVE
864,US,B2,US 8669279 B2,053-634-970-516-292,2014-03-11,2014,US 201313874575 A,2013-05-01,US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Solid forms of bendamustine hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/053-634-970-516-292,Granted Patent,yes,53,17,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/16,514/394;;548/310.1,51,39,020-435-634-003-86X;;057-331-944-087-540;;084-716-889-422-831;;007-364-858-655-289;;005-472-156-687-716;;009-214-187-079-899;;132-558-386-999-186;;123-775-514-819-528;;006-046-706-830-252;;069-673-960-292-160;;080-209-105-337-208;;027-084-824-706-497;;074-470-545-310-545;;020-427-831-437-122;;044-553-566-435-465;;049-256-800-886-311;;067-512-968-604-94X;;023-549-427-997-819;;063-402-864-700-686;;113-421-979-742-187;;020-435-634-003-86X;;125-764-802-071-090;;111-707-255-990-821;;034-919-505-845-111;;023-237-704-770-485;;003-701-346-326-00X;;067-465-907-694-241;;127-003-929-505-550;;013-802-099-433-937;;055-433-061-655-828;;004-291-817-534-209;;108-687-604-265-588;;029-880-686-607-107;;093-799-759-321-023;;001-658-497-635-033;;091-079-688-402-134;;059-280-286-824-398;;057-884-013-276-829;;106-081-384-040-520,10.1016/j.addr.2003.10.020;;14962582;;10.1053/sonc.2002.34875;;10.1016/s0093-7754(02)90010-2;;12170428;;10.2165/00003495-200161050-00009;;11368287;;10.1002/jps.2600660104;;833720;;12458340;;10.1007/s00432-002-0378-6;;10.1023/a:1016241927429;;7494814;;11801463;;12691159;;10.1080/1042819021000054670;;11410411;;12948851;;10.1016/s0006-2952(03)00410-6;;12170424;;10.1053/sonc.2002.34871;;10.3109/02652048609031561;;3508181;;12170425;;10.1053/sonc.2002.34872;;10.1007/bf00807895;;10.1097/00001813-200110000-00003;;11593053;;10.1007/s004320000180;;11206271;;15223642;;10.1080/1042819042000223822;;10.1097/00001813-200008000-00003;;11036955;;12029443;;10.1007/s00432-002-0331-8;;10.2165/00044011-200424100-00007;;17523723;;10.1016/j.addr.2003.10.020;;14962582;;10.1080/1042819042000198858;;15359644;;10.1053/sonc.2002.34876;;10.1016/s0093-7754(02)90011-4;;12170429;;4095129;;12170430;;10.1016/s0093-7754(02)90012-6;;10.1053/sonc.2002.34877;;12170426;;10.1016/s0093-7754(02)90008-4;;10.1053/sonc.2002.34873;;10.1007/bf02041437;;3380859;;15577312;;10.1097/00008390-200412000-00001;;10.1007/pl00008463;;10641748;;10.1016/s0093-7754(02)90009-6;;10.1053/sonc.2002.34874;;12170427;;10.1038/sj.leu.2402651;;12357363;;10.1097/00001813-199606000-00007;;8826610;;11999564;;10.1080/10428190290006107;;15621757;;10.1080/10428190400004521;;10.1093/annonc/mdf189;;12181253;;3615563;;11862482;;10.1007/s00432-001-0303-4;;18182663;;10.1200/jco.2007.12.5070,"Friedberg et al. in Blood 106 (11), 2005 (abstract 229).;;EC Safety Data Sheet: Ribomustin® in www.asl.ri.it/staff/prevenzione/documentazione/Chemio/Ribomustin%20scheda%20di%20sicurezza.pdf (Retrieved from the internet Jun. 11, 2013).;;Morissette et al. In Drug Delivery Reviews, 56 (2004) 275-300.;;Aivado et al., ""Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives"", Seminars in Oncology, Aug. 2002, 29(4), 19-22, Suppl. 13.;;Author Unknown, ""Ribomustin: Bendamustine Product Monograph"", Ribosepharm GMBH, Munchen, Germany, Jan. 2002, 3-54.;;Author Unknown, ""Ribomustin: Bendamustine Product Monograph"", Ribosepharm GMBH, Munchen, Germany, Mar. 2005, 3-73.;;Barman et al., ""Bendamustine"" Drugs, 2001, 61(5), 631-638, Auckland, New Zealand.;;Berge et al., ""Pharmaceutical Salts"", Journal of pharmaceutical sciences, Jan. 1977, 66(1), 1-19.;;Bremer, ""High Rates of Long-lasting remissions after 5-day bendamustine Chemotherapy Cycles in Pre-Treated low-grade non-hodgkin's-lymphomas"", Journal of Cancer Research and Clinical Oncology, Nov. 2002, 128(11), 603-609.;;Byrn et al., ""Pharmaceutical Solids: A Strategic Approach to Regulatory Consideration"", Pharmaceutical Research, Jul. 1995, 12(7), 945-954.;;Chow et al., ""Anti-CD20 Antibody (DEC-C2B8, rituximab) enhances efficiency of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of Cytokines complement and caspases"", Hematologica, Jan. 2002, 87(1), 33-43.;;Chow et al., ""In AML Cell Lines Ara-C combined with Purine Analogues is able to Exert Synergistic as well as Antagnostic Effects on Proliferation Apoptosis and Disruption of Mitochondrial Membrane Potential"", Leukemia & Lymphoma, 2003, 44(1), 165-173.;;Chow et al., ""In Vitro Induction of Apoptosis of Neoplastic Cells in Low-Grade non-Hodgkin's Lymphomas by Combination of established cytotoxic drugs with bendamustine"", Hematologica, May 2001, 86(5), 485-493.;;Chow et al., ""Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4(Par-4), death-associated protein (Dazz) and with enforced caspase activation"", Biochemical Pharmacology, Jan. 2003, 66(5), 711-724.;;Diehl et al., ""Bendamustine in the Treatment of Hematologic Malignancies"", Semin. Oncol., Aug. 2002, 29(4), 1-3, Suppl. 13, Saundes, Philadelphia, PA.;;EC Safety Data Sheet: Ribomustin® in http://www.docstoc.com/docs/22323231/EC-Safety-Data-Sheet-Bendamustin (published: Jul. 3, 1998; updated Mar. 1, 2007).;;Fichtner et al., ""Antineoplastic activity and toxicity of some alkylating cytostatics (cyclophosphamide, CCNU, cytostasan) encapsulated in liposomes in different murine tumor models"", Journal of Microencapsulation, Jan. 1986, 3(2), 77-87.;;Gandhi, Varsha, ""Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies"", Seminars in Oncology, Aug. 2002, 29(4), 4-11, Suppl. 13.;;Goodman et al., The Pharmacological Basis of Therapeutics, 1985, 7th edition, Macmillan publishing company, New York.;;Gust et al., ""Investigation on the Stability of Bendamustin, a Cytostatic Agent of the Nitrogen Mustard Type I. Synthesis, Isolation and Characterization of Reference Substances"", Monatshefte fur Chemie, 1997, 128(3), 291-299.;;Heider et al., ""Efficacy and Toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas"", Anti-Cancer Drugs, 2001, 12(9), 725-729.;;Kath et al., ""Bendamustine Monotherapy in advanced and refractory chronic lymphocytic Leukemia"", Journal of Cancer Research and Clinical Oncology, 2001, 127(1), 48-54.;;Koenigsman et al., ""Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma-a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)"", Leukemia & Lymphoma, 2004, 45(9), 1821-1827.;;Kollmannsberger et al., ""Phase II study of Bendamustine in Patients with relapsed or cisplatin-refractory germ cell Cancer"", Anti-Cancer Drugs, 2000, 11(7), 535-539.;;Konstantinov et al., ""Cytotoxic Efficacy of Bendamustine in Human Leukemia and Breast Cancer cell lines"", Journal of Cancer Research and Clinical Oncology, 2002, 128(5), 271-278.;;Köster et al., ""Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small lung cancer (SCLC)"", Clinical Drug Investigation, 2004, 24(10), 611-618.;;Leoni et al., ""Sdx-105 (Trenda), Active in Non-Hodgkin's Lymphoma Cells, Induces the Mitotic Catastrophe Death Pathway "", Blood, 2004, 104(11), (Abstract).;;Maas, ""Stability of Bendamustine Hydrochloride in Infusion Solutions"", 1994, 49(10), 9 pages.;;Morissette et al., ""High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids"", Advanced Drug Delivery Reviews, Feb. 2004, 56(3), 275-300.;;Niemeyer et al., ""SDX-105 (bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action"", Proc Annu Meet Am Assoc Cancer Res, Mar. 2004, 45, 1st ed., 2 pages.;;Nowak et al., ""Upon Drug-Induced Apoptosis in Lymphoma Cells X-linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus"", Leukemia & Lymphoma, Jul. 2004, 45(7), 1429-1436.;;Ozegowski et al., ""IMET 3393, gamma-(1-methyl-5-bis-(beta-chloräthyl)-amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste"", Zbl Pharm., 1971;110, Heft 10, 1013-1019.;;Ponisch et al., ""Bendamustine in the treatment of Multiple Myeloma: Results and future perspectives"", Seminars in Oncology, Aug. 2002, 29(4), 23-26, Suppl. 13.;;Preiss et al., ""Pharmacokinetics of bendamustin (Cytostasan) in patients"", Pharmazie, Mar. 1985, 40(11), 782-784.;;Remington: Pharmaceutical Sciences, 1990, Mack Publishing company, Easton, Pennsylvania.;;Rummel et al., ""Bendamustine in the Treatment of Non-Hodgkin's Lymphoma: Results and Future Perspectives"", Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 27-32.;;Rummel et al., ""In Vitro Studies with Bendamustine: Enhanced Activity in Combination with Rituximab"", Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 12-14.;;Scasnar et al., ""Radiochemical Assay of Stability of 14C-Cytostasan Solutions During Preparation and Storage"", Journal of Radioanalytical and Nuclear Chemistry, 1998, 121(2), 489-497.;;Scasnar et al., ""Stability Studies of 14C-Cytostasan® solutions and its extraction using dicarbolide of cobalt"", Phamazie, Mar. 1988, 43, 176-179.;;Schmidt-Hieber et al., ""A Phase II Study of bendamustine Chemotherapy as Second-line treatment in metastatic uveal Melanoma"", Melanoma Research, 2004, 14(6), 439-442.;;Schoffski, ""Repeated Administration of Short Infusions of Bendamustine: A phase I study in Patients with Advanced Progressive Solid Tumors"", Journal of Cancer Research and Clinical Oncology, 2000, 126(1), 41-47.;;Schrijvers et al., ""Phase I study with bendamustine: An update"", Seminars in Oncology, Suppl. 13, 2002, 29(4), 15-18.;;Schwanen et al., ""In Vitro Evaluation of Bendamustine Induced Apoptosis in B-Chronic Lymphocytic Leukemia"", Leukemia, Oct. 2002, 16(10), 2096-2105.;;Strumberg et al., ""Bendamustine Hydrochloride Activity against doxorubicin-resistant Human Breast Carcinoma Cell Lines"", Anti-Cancer Drugs, 1996, 7(4), 415-421.;;Weide et al., ""Bendamustine Mitoxantrone and Rituximab (BMR): A New effective regimen for refractory or relapsed indolent lymphomas"", Leukemia & Lymphoma, 2002, 43(2), 327-331.;;Weide et al., ""Bendamustine/ Mitoxantrone/Rituximab (BMR) : A very Effective, well tolerated Outpatient Chemoimmunotherapy for relapsed and refractory CD20-positive Indolent Malignancies Final Results of a Pilot Study"", Leukemia & Lymphoma, 2004, 45(12), 2445-2449.;;Weidmann et al., ""Bendamustine is Effective in Relapsed or Refractory Aggressive non-Hodgkin's Lymphoma"", Annals of Oncology, 2002, 13(8), 1285-1289.;;Werner et al., ""Hydrolyseprodukte des Cancerostaticums Cytostasan (Bendamustin)"", Pharmazie, 1987, 42, 272-273.;;Zulkowski et al., ""Regression of Brain Metastases from Breast Carcinoma after Chemotherapy with bendamustine"", Journal of Cancer Research and Clinical Oncology, 2002, 128(2), 111-113.;;Ribosepharm, ""Product monograph ribosepharm passage"", Product Monograph, Ribosepharm, Jan. 1, 2005, pp. 3-73.;;Friedberg et al., ""Bendamustine in patients with Rituximab-refractory indolent and transformed non-hodgkin's lymphoma"", Journal of Clinical Oncology, Jan. 10, 2008, vol. 26, No. 2, pp. 204-210.",ACTIVE
865,BR,A,BR 9713213 A,090-054-701-339-751,2000-04-04,2000,BR 9713213 A,1997-09-19,US 2644296 P;;US 9716690 W,1996-09-19,Composições amaciantes para tecido concentradas de amÈnio quaternário contendo polìmeros catiÈnicos.,"Patente de Invenção: <B>""COMPOSIçõES AMACIANTES PARA TECIDO CONCENTRADAS DE AMÈNIO QUATERNáRIO CONTENDO POLìMEROS CATIÈNICOS""<D>. A presente invenção refere-se a composições aquosas amaciantes para têxteis líquidas estáveis, de preferência concentrada compreendendo ativo amaciante para tecido e polímero catiónico na fase aquosa contíbnua para fornecer amaciamento melhorado. As composições da presente invenção de preferência contêm compostos diéster de amónio quaternário em que os grupos acila graxo têm um Valor de Iodo de desde maior do que aproximadamente 5 até menor do que aproximadamente 140. Os polímeros catiónicos podem fornecer vantagens adicionais tais como inibição de transferência de corante, expulsão de cloro para proteger tecidos, vantagens de liberação de sujeira de algodão etc..",PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/090-054-701-339-751,Patent Application,no,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,D06M13/322;;C11D1/62;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,DISCONTINUED
866,MX,A,MX 2016008372 A,039-020-536-709-792,2017-01-09,2017,MX 2016008372 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS.,A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,WILLIAM LEFEBVRE;;ANDREW H MARTIN;;FRANCIS JAMES COOPER;;RACHEL W ADAMEC,,https://lens.org/039-020-536-709-792,Patent Application,no,0,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,PENDING
867,US,A,US 5282052 A,038-964-873-198-104,1994-01-25,1994,US 85610792 A,1992-03-20,US 85610792 A,1992-03-20,Techniques for automatic form creation by combining partial operations,"An automatically created form includes a field for requesting a combined operation. A processor creates the form in response to another form that includes fields that are marked to indicate a sequence of partial operations. The partial operations together constitute the combined operation. The combined operation can, for example, be a facsimile transmission, in which case the partial operation fields can specify the digits of a fax machine's telephone number. The automatically created form can then include a single check box next to the name of the recipient. When the check box is marked, the processor responds to the form by performing the sequence of partial operations. The processor can execute input instructions to receive data defining the image of each form and can execute response instructions to respond to each form.",XEROX CORP,JOHNSON WALTER A L;;CARD STUART K;;COOPER MARTIN F N,XEROX CORPORATION A CORP. OF NEW YORK (1992-05-19),https://lens.org/038-964-873-198-104,Granted Patent,yes,11,47,8,8,0,G06F40/174;;G06F40/174,G06F3/14;;G06F3/048;;G06F17/24;;H04N1/00,358/402;;358/407;;358/440;;358/468;;358/450;;382/61,1,0,,,"DoveFax Installation and User s Manual, Dove Computer Corporation, Sep. 1990.",EXPIRED
868,US,B2,US 6797688 B2,091-494-463-100-643,2004-09-28,2004,US 30763402 A,2002-12-02,US 30763402 A;;US 26908699 A;;US 2644296 P,1996-09-19,"Concentrated, preferably biodegradable, quaternary ammonium fabric softener compositions containing cationic polymers and process for preparation","
    The present invention relates to aqueous stable, preferably concentrated, aqueous liquid textile softening compositions comprising fabric softener active and cationic polymer in the continuous aqueous phase to provide improved softening. 

    The compositions of the present invention preferably contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 140. The cationic polymers can provide additional benefits such as dye transfer inhibition, chlorine scavenging to protect fabrics, cotton soil release benefits, etc. 
",PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/091-494-463-100-643,Granted Patent,yes,31,17,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D1/62;;D06M13/322;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,510/516;;510/522;;510/527,0,0,,,,EXPIRED
869,NO,D0,NO 991203 D0,090-597-987-912-20X,1999-03-11,1999,NO 991203 A,1999-03-11,US 2644296 P;;US 9716690 W,1996-09-19,Konsentrerte kvaternµre ammonium tekstilmykner-blandinger inneholdende katjoniske polymerer,,PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,,https://lens.org/090-597-987-912-20X,Patent Application,no,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D1/62;;D06M13/322;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,PENDING
870,CA,A1,CA 2222705 A1,130-707-281-531-652,1996-12-05,1996,CA 2222705 A,1996-06-03,GB 9510870 A;;GB 9511546 A;;GB 9513172 A;;GB 9513166 A;;GB 9513168 A;;GB 9513170 A,1995-06-02,APPARATUS AND METHOD OF CONTROLLING TRANSMITTING POWER AND TRANSMIT RATE OF A WIRELESS TELECOMMUNICATIONS SYSTEM,"A wireless telecommunications system (1) includes a central terminal (10) for transmitting and receiving radio frequency signals to and from a subscriber terminal (20). The wireless telecommunications system (1) operates in one of three operating modes. In an acquisition mode during establishment of the downlink communication path, the downlink signal (212) is transmitted at a high power level and a low transmit rate with the receiver (202) operating at the low transmit rate. In a standby mode after establishment of the downlink communication path, the downlink signal (212) is transmitted at a low power level and a low transmit rate with the receiver (202) operating at the low transmit rate. In a traffic mode upon a request for wireless communication transmission, the downlink signal (212) is transmitted at a high power level and a high transmit rate with the receiver (202) adjusting to operate at the high transmit rate. Upon completion of the wireless communication transmission, the wireless telecommunications system (1) returns to the standby mode and the receiver (202) adjusts to operate at the low transmit rate.",DSC COMMUNICATIONS,LYSEJKO MARTIN;;COOPER IAN LESLIE;;BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG,,https://lens.org/130-707-281-531-652,Patent Application,no,0,0,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,DISCONTINUED
871,CA,C,CA 2265769 C,140-604-487-634-308,2007-10-16,2007,CA 2265769 A,1997-09-19,US 2644296 P;;US 9716690 W,1996-09-19,CONCENTRATED QUATERNARY AMMONIUM FABRIC SOFTENER COMPOSITIONS CONTAINING CATIONIC POLYMERS,"The present invention relates to aqueous stable, preferably concentrated, aqueous liquid textile softening compositions comprising fabric softener active and cationic polymer in the continuous aqueous phase to provide improved softening. The compositions of the present invention preferably contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 140. The cationic polymers can provi de additional benefits such as dye transfer inhibition, chlorine scavenging to protect fabrics, cotton soil release benefits, etc.",PROCTER & GAMBLE,WARD RICHARD MARTIN;;COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN,,https://lens.org/140-604-487-634-308,Granted Patent,no,0,0,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D3/00;;D06M13/322;;C11D1/62;;C11D1/645;;C11D3/22;;C11D3/37;;C11D11/00;;C11D17/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,,0,0,,,,EXPIRED
872,BR,A2,BR 112016014887 A2,133-579-892-363-382,2017-08-08,2017,BR 112016014887 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,sistemas para detectar anomalias em uma composição de trem ou vagão ferroviário,,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/133-579-892-363-382,Patent Application,no,0,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,,,0,0,,,,ACTIVE
873,ZA,B,ZA 964147 B,151-106-223-164-100,1996-08-27,1996,ZA 964147 A,1996-05-23,GB 9510870 A,1995-06-02,Subscriber terminal for a wireless telecommunications system,,DSC COMMUNICATIONS,LYSEJKO MARTIN;;LAMKIN RICHARD MORTIMER;;COOPER GUY ALEXANDER;;NETHERCOTT JONATHAN FRANCIS,,https://lens.org/151-106-223-164-100,Granted Patent,no,0,0,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
874,AU,A1,AU 2016/236851 A1,199-986-121-626-925,2017-11-09,2017,AU 2016/236851 A,2016-03-24,AU 2015/901083 A;;AU 2016/050220 W,2015-03-25,Alignment apparatus,"The present invention relates to an apparatus for aligning a sensor relative to at least two anatomical reference points of a patient's anatomy. In one embodiment, the apparatus includes: a body having a central axis; a sensor mount positioned relative to the body; at least two arms extending from the body, wherein two of said at least two arms are simultaneously and equidistantly moveable relative to the central axis; and at least two aligners connected to the at least two arms for aligning with said at least two anatomical reference points. The apparatus may also include an apparatus sensor. The present invention also relates to a surgical system for monitoring the orientation of a patient's anatomy, which includes the apparatus. Furthermore, the present invention also relates to a surgical system for guiding a surgical device to an optimal orientation relative to a patient's anatomy, wherein the surgical system includes the apparatus. The present invention also relates to: a method of aligning a sensor relative to at least two anatomical reference points of a patient's anatomy, and to a method of guiding a surgical device to an optimal orientation relative to a patient's anatomy. In one embodiment, the patient's anatomy is the pelvis.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/199-986-121-626-925,Patent Application,no,0,0,7,7,0,A61B17/1746;;A61B17/1746;;A61B34/20;;A61B34/20;;A61B34/20;;A61B34/25;;A61B34/25;;A61B90/37;;A61B90/37;;A61B2017/00734;;A61B2017/00734;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61F2/4603;;A61F2/4607;;A61F2/4609;;A61F2/4657;;A61F5/11;;A61F5/11;;A61F2002/4687,A61B34/20;;A61F5/11,,0,0,,,,DISCONTINUED
875,GB,A9,GB 2370447 A9,092-299-971-594-435,2002-06-26,2002,GB 0102013 A,2001-01-26,GB 0024535 A,2000-10-06,"Establishing values for stations ina network and disconnecting old, low value stations",,BRIGHT STATION PLC,COBBY MATTHEW PETER;;COOPER DAVID;;HARRIS IAN MURRAY;;SCHOUTEN HENDRICK MARTIN,,https://lens.org/092-299-971-594-435,Patent Application,no,0,0,6,6,0,H04L67/14;;H04L67/10;;H04L69/329;;H04L67/10015;;H04L67/1001,H04L29/06;;H04L29/08,H4K KFMA          KFMA,0,0,,,,DISCONTINUED
876,US,B1,US 6492322 B1,109-402-343-455-520,2002-12-10,2002,US 26908699 A,1999-03-18,US 26908699 A;;US 2644296 P;;US 9716690 W,1996-09-19,Concentrated quaternary ammonium fabric softener compositions containing cationic polymers,"
    The present invention relates to aqueous stable, preferably concentrated, aqueous liquid textile softening compositions comprising fabric softener active and cationic polymer in the continuous aqueous phase to provide improved softening. The compositions of the present invention preferably contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 140. The cationic polymers can provide additional benefits such as dye transfer inhibition, chlorine scavenging to protect fabrics, cotton soil release benefits, etc. 
",PROCTER & GAMBLE,COOPER MEGAN A;;TRINH TOAN;;WAHL ERROL HOFFMAN;;WARD RICHARD MARTIN,PROCTER & GAMBLE COMPANY THE (1997-11-03),https://lens.org/109-402-343-455-520,Granted Patent,yes,5,129,39,40,0,C11D1/62;;C11D1/645;;C11D3/0015;;C11D3/227;;C11D3/3723;;C11D3/3773;;C11D3/3776;;C11D11/0094;;C11D3/00;;C11D3/227;;C11D3/3723;;C11D1/62;;C11D11/0094;;C11D3/3776;;C11D3/0015;;C11D3/3773;;C11D1/645,C11D1/62;;D06M13/322;;C11D1/645;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00;;D06M13/02;;D06M13/46;;D06M13/463;;D06M13/467,510/516;;510/522;;510/527,0,0,,,,EXPIRED
877,EP,A2,EP 2271315 A2,103-132-653-799-972,2011-01-12,2011,EP 09723661 A,2009-03-26,US 2009/0001956 W;;US 3975208 P,2008-03-26,SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,,CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,"CEPHALON LLC; US (2023-02-28);;CEPHALON LLC, WEST CHESTER, US (2022-10-21);;CEPHALON LLC (2023-01-30)",https://lens.org/103-132-653-799-972,Patent Application,yes,1,0,36,36,0,A61K9/19;;A61K31/4184;;A61K47/26;;C07D235/16;;A61K9/14;;A61K9/19;;A61K31/4184;;C07D235/16;;A61P35/00;;A61P35/02;;A61K9/14;;A61K9/19;;A61K31/4184;;C07D235/16;;A61K9/0019;;A61K47/26,A61K9/14;;A61K9/19;;A61K31/4184,,2,0,,,"OZEGOWSKI W. ET AL: ""IMET 3393, gamma-[1-Methyl-5-bis-(beta-chloräthyl)-amino-benzimidazolyl-(2)]-buttersäurehydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste"", ZBL. PHARM., vol. 110, no. 10, 1971, pages 1013 - 1019, XP003029699;;BRITTAIN H.G.: ""Drugs and the Pharmaceutical Sciences"", vol. 95, 1999, article ""Polymorphism in Pharmaceutical Solids"", pages: I - V, 228 - 239, XP003030775",ACTIVE
878,NO,L,NO 903636 L,142-334-798-874-814,1991-02-19,1991,NO 903636 A,1990-08-17,GB 8918886 A;;GB 8918929 A,1989-08-18,MAKROCYKLISKE FORBINDELSER OG FREMGANGSMAATE FOR DERES FREMSTILLING.,,FISONS PLC,DONALD DAVID KEITH;;HARDERN DAVID NORMAN;;COOPER MARTIN EDWARD;;FURBER MARK,,https://lens.org/142-334-798-874-814,Abstract,no,0,0,11,13,0,A61P37/06;;C07H15/26;;C07H19/01;;C07H19/01,C07D498/18;;A61K31/445;;A61P37/06;;C07H19/01,,0,0,,,,PENDING
879,AU,A1,AU 2018/200075 A1,169-765-008-285-543,2018-01-25,2018,AU 2018/200075 A,2018-01-04,AU 2018/200075 A;;AU 2014/369839 A;;US 201361920700 P;;US 2014/0072380 W,2013-12-24,System and method for detecting operational anomalies in train consists and railcars,"SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS A system for detecting operational anomalies on a train consist (109) or railcar (103) comprising one or more communication management units (101) mounted on one or more railcars (103); one or more sensors located on said one or more railcars (103) for sensing an operational parameter of said one or more railcars (103), said sensors being in communication with said one or more communication management units (101); a powered wireless gateway (102) controlling a train based mesh network (107), wherein said train-based mesh network (107) includes said powered wireless gateway (102) and each of said communication management units (101), and said train based mesh network (107) configured to receive information from each communication management units (101) and draw inferences from this information regarding performance of said train consist (109); and one or more wireless sensor nodes (104) in communication with one of said communication management units (101), said one or more sensors forming part of said one or more wireless sensor nodes (104). The communication management unit (101) and said wireless sensor nodes (104) form a railcar-based mesh network (105), said railcar-based mesh network (105) being controlled by said communication management unit (101), and said communication management unit (101) configured to receive information from said wireless sensor nodes (104) and draw inferences from this information regarding performance of a respective railcar (103). The communication management units (101) perform the functions of: collecting data regarding said one or more railcar operational parameters; analyzing said collected data for trends or events indicative of an anomalous operational condition; and communicating a message to a remote receiver when said trend or event is detected.",AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/169-765-008-285-543,Patent Application,no,0,1,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,ACTIVE
880,GB,B,GB 2260321 B,191-937-080-239-213,1995-12-06,1995,GB 9121676 A,1991-10-11,GB 9121676 A,1991-10-11,Optically active fluorophenyl derivatives,,MERCK PATENT GMBH,STYRING PETER;;GOODBY JOHN WILLIAM;;COOPER MARTIN E;;RICHARDS ROBERT D,,https://lens.org/191-937-080-239-213,Granted Patent,no,0,0,3,3,0,C07D405/12;;C09K19/3411;;C09K19/3466;;C09K19/588,C07D405/12;;C09K19/34;;C09K19/58,C2C CAA;;C2C CAA;;C2C CBA;;C2C CWA;;C2C C1300;;C2C C1300;;C2C C1600;;C2C C1600;;C2C C200;;C2C C215;;C2C C215;;C2C C22Y;;C2C C22Y;;C2C C220;;C2C C220;;C2C C246;;C2C C246;;C2C C25Y;;C2C C25Y;;C2C C250;;C2C C250;;C2C C252;;C2C C252;;C2C C253;;C2C C253;;C2C C28X;;C2C C28X;;C2C C31Y;;C2C C31Y;;C2C C311;;C2C C311;;C2C C36Y;;C2C C36Y;;C2C C364;;C2C C364;;C2C C366;;C2C C368;;C2C C50Y;;C2C C500;;C2C C624;;C2C C628;;C2C C634;;C2C C65X;;C2C C662;;C2C C662;;C2C C672;;C2C C678;;C2C C697;;C2C C697;;C2C C777;;C2C C80Y;;C2C C821;;C2C C821;;C4X X12           X12;;U1S S1387,0,0,,,,EXPIRED
881,US,A1,US 2015/0051258 A1,046-857-738-565-908,2015-02-19,2015,US 201414531023 A,2014-11-03,US 201414531023 A;;US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Novel Solid Forms Of Bendamustine Hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/046-857-738-565-908,Patent Application,yes,1,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/16;;A61K31/4184,514/394;;548/310.1,2,0,,,"Friedberg et al. in Blood 106 (11), 2005 (abstract 229);;EC Safety Data Sheet: Ribomustin® in www.asl.ri.it/staff/ prevenzione/documentazione/Chemio/Ribomustin%20scheda%20di%20sicurezza.pdf (Retrieved from the internet June 11, 2013)",DISCONTINUED
882,US,A1,US 2014/0187598 A1,053-686-197-996-317,2014-07-03,2014,US 201414200738 A,2014-03-07,US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,Novel Solid Forms Of Bendamustine Hydrochloride,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/053-686-197-996-317,Patent Application,yes,0,4,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/16,514/394;;548/310.1,0,0,,,,ACTIVE
883,EP,A1,EP 3589129 A1,068-985-860-707-484,2020-01-08,2020,EP 18760302 A,2018-03-01,US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490465 P;;US 201762490567 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510660 P;;US 201762510672 P;;US 201762511218 P;;US 201715616874 A;;US 2018/0020440 W,2017-03-01,COMPOSITIONS PURPOSEFULLY SELECTED COMPRISING PURIFIED CANNABINOIDS AND/OR PURIFIED TERPENES,,CANOPY GROWTH CORP,LEVY KURT;;COOPER JONATHAN MICHAEL;;MARTIN JONATHAN REED;;REID BRIAN GEOFFREY,,https://lens.org/068-985-860-707-484,Patent Application,yes,0,0,11,36,0,A61K31/05;;A61K31/352,A01N65/00;;A61K31/05;;A61K31/352,,0,0,,,,DISCONTINUED
884,EP,A1,EP 3086992 A1,079-271-120-508-847,2016-11-02,2016,EP 14875798 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS,,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/079-271-120-508-847,Patent Application,yes,0,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,PENDING
885,WO,A2,WO 2012/087616 A2,097-332-766-288-643,2012-06-28,2012,US 2011/0064207 W,2011-12-09,US 97421610 A,2010-12-21,POLYMER SUBSTRATES HAVING IMPROVED BIOLOGICAL RESPONSE FROM HKDCS,"A method of surface modification of a biocompatible, biodegradable polymer substrate using RF plasma treatment is disclosed. This method and the resulting surface provide for enhanced adhesion and proliferation of cells, such as hKDCs, and can be used with scaffolds for tissue regeneration and with other delivery vehicles such as medical devices.",ATRM LLC;;COOPER KEVIN L;;MARTIN ALISHA;;NATARAJAN SRIRAM;;VETRECIN ROBERT;;LIU CHANGDENG,COOPER KEVIN L;;MARTIN ALISHA;;NATARAJAN SRIRAM;;VETRECIN ROBERT;;LIU CHANGDENG,,https://lens.org/097-332-766-288-643,Patent Application,yes,16,0,4,4,0,B29C59/14;;C08J3/28;;C08J7/12;;Y10T428/24355;;Y10T428/24355;;C08J3/28;;C08J7/12;;B29C59/14,C08J3/28,,3,3,005-138-199-239-987;;134-213-148-568-259;;104-789-034-325-455,8268389;;10.1016/0142-9612(93)90139-s;;9019486;;10.1002/(sici)1097-4636(199602)30:2<209::aid-jbm11>3.0.co;2-h;;2148939;;10.1002/jbm.820241207,"LEE, J-S. ET AL., BIOMATER, vol. 14, 1993, pages 958 - 960;;KOTTKE-MARCHANT, K. ET AL., J BIOMED MATER RES, vol. 30, 1996, pages 209 - 220;;ERTEL, S. I. ET AL., J BIOMED MATER RES, vol. 24, 1990, pages 1637 - 1659",PENDING
886,US,A1,US 2017/0071913 A1,141-720-630-952-793,2017-03-16,2017,US 201615359777 A,2016-11-23,US 201615359777 A;;US 201615045523 A;;US 201414531023 A;;US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/141-720-630-952-793,Patent Application,yes,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K31/4184;;A61K9/00;;A61K47/26,,0,0,,,,ACTIVE
887,US,A1,US 2019/0015390 A1,159-542-463-781-089,2019-01-17,2019,US 201816037560 A,2018-07-17,US 201816037560 A;;US 201615045523 A;;US 201414531023 A;;US 201414200738 A;;US 201313874575 A;;US 201113301979 A;;US 41192909 A;;US 3975208 P,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,CEPHALON LLC (2022-06-30),https://lens.org/159-542-463-781-089,Patent Application,yes,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K31/4184;;A61K9/00;;A61K9/14;;A61K9/19;;A61K47/26;;C07D235/16,,0,0,,,,ACTIVE
888,CN,A,CN 105693620 A,157-374-766-517-012,2016-06-22,2016,CN 201610027378 A,2009-03-26,US 3975208 P;;CN 200980110767 A,2008-03-26,Solid Forms Of Bendamustine Hydrochlorid,"Solid forms of bendamustine hydrochloride are described. The invention relates to a composition containing bendamustine, a pharmaceutical composition containing the bendamustine, methods for their repeat preparation, and pharmaceutical uses thereof.",CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/157-374-766-517-012,Patent Application,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,C07D235/16;;A61K9/19;;A61K31/4184;;A61P35/00;;A61P35/02,,0,0,,,,DISCONTINUED
889,FI,A0,FI 904072 A0,183-298-539-167-527,1990-08-17,1990,FI 904072 A,1990-08-17,GB 8918886 A;;GB 8918929 A,1989-08-18,MACROCYKLISKA BLANDNINGAR.,,FISONS PLC,DONALD DAVID KEITH;;HARDERN DAVID NORMAN;;COOPER MARTIN EDWARD;;FURBER MARK,,https://lens.org/183-298-539-167-527,Patent Application,no,0,0,11,13,0,A61P37/06;;C07H15/26;;C07H19/01;;C07H19/01,C07D498/18;;A61K31/445;;A61P37/06;;C07H19/01,,0,0,,,,DISCONTINUED
890,CA,A1,CA 2935094 A1,173-706-992-701-035,2015-07-02,2015,CA 2935094 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,SYSTEM AND METHOD FOR DETECTING OPERATIONAL ANOMALIES IN TRAIN CONSISTS AND RAILCARS,A system for monitoring railcar and tram consist operational parameters and detecting anomalies in the operation and condition thereof using sensors to feed data to a distributive complex event processing engine.,AMSTED RAIL CO INC,LEFEBVRE WILLIAM;;MARTIN ANDREW H;;COOPER FRANCIS JAMES;;ADAMEC RACHEL W,,https://lens.org/173-706-992-701-035,Patent Application,no,0,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,ACTIVE
891,CN,A,CN 103550159 A,042-166-678-546-204,2014-02-05,2014,CN 201310415249 A,2009-03-26,US 3975208 P;;CN 200980110767 A,2008-03-26,Novel solid forms of bendamustine hydrochloride,"The present invention describes novel solid forms of bendamustine hydrochloride. This invention pertains to bendamustine-containing compositions, pharmaceutical compositions comprising bendamustine, processes to reproducibly make them, and methods of treating patients using them.",CEPHALON INC,MARTIN IAN COOPER;;LAURENT D COURVOISIER;;MARK EDDLESTON;;ROBERT E MCKEAN,,https://lens.org/042-166-678-546-204,Patent Application,no,1,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/14;;A61K9/19;;A61K31/4184;;A61P35/00;;A61P35/02,,0,0,,,,ACTIVE
892,WO,A3,WO 2009/120386 A3,057-256-616-996-465,2009-12-03,2009,US 2009/0001956 W,2009-03-26,US 3975208 P,2008-03-26,NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE,"Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.",CEPHALON INC;;COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/057-256-616-996-465,Search Report,yes,3,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/14;;A61K9/19;;A61K31/4184,,2,0,,,"RIBOSEPHARM: ""Product monograph ribosepharm passage"", PRODUCT MONOGRAPH RIBOSEPHARM, XX, XX, 1 January 2005 (2005-01-01), pages 3 - 73, XP002368437;;See also references of EP 2271315A2",PENDING
893,AU,A,AU 1996/064758 A,057-161-355-852-014,1996-12-18,1996,AU 1996/064758 A,1996-06-03,GB 9510870 A;;GB 9511546 A;;GB 9513170 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A;;US 9608568 W,1995-06-02,Apparatus and method of controlling transmitting power and t ransmit rate of a wireless telecommunications system,,AIRSPAN NETWORKS INC,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,"AIRSPAN NETWORKS, INC. (2000-06-29)",https://lens.org/057-161-355-852-014,Patent Application,no,0,0,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
894,US,A1,US 2016/0011864 A1,073-028-658-306-966,2016-01-14,2016,US 201514821849 A,2015-08-10,US 201514821849 A;;US 201213550914 A;;US 201213437494 A;;US 201161568056 P,2011-12-07,Development of Platform Independent Applications,"Method, system, and programs for providing packages to applications is disclosed. An application that is executable on a plurality of device platforms is generated. The application is deployed to a client device. A package list received from the client device is analyzed to determine package dependencies for packages on the package list. The packages on the package list and dependent packages are provided based on the package dependencies to the client device. The packages and dependent packages may be installed by the client device to ensure that the application is executable based on characteristics of the client device.",YAHOO INC,FERNANDEZ-RUIZ BRUNO;;LOW DARYL MUN-KID;;COOPER MARTIN F N,YAHOO! INC (2016-05-31);;EXCALIBUR IP LLC (2016-05-31),https://lens.org/073-028-658-306-966,Patent Application,yes,35,3,3,13,0,G06F8/60;;H04L67/01;;G06F8/60;;G06F8/65;;H04L67/10,G06F9/445;;H04L29/06;;H04L29/08,,0,0,,,,DISCONTINUED
895,ZA,B,ZA 964142 B,083-574-588-331-744,1996-12-03,1996,ZA 964142 A,1996-05-23,GB 9510870 A,1995-06-02,Apparatus and method of controlling transmitting power in a subscriber terminal of a wireless telecommunications system,,DSC COMMUNICATIONS,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,,https://lens.org/083-574-588-331-744,Granted Patent,no,0,0,35,251,0,G06F9/546;;H04B1/707;;H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04B1/7085;;H04B2001/70706;;H04B2201/70702;;H04B2201/70706;;H04B2201/7071;;H04B2201/70711;;H04B2201/709709;;H04J3/0682;;H04J13/00;;H04L9/32;;H04L12/2856;;H04L12/2874;;H04L12/2898;;H04L12/66;;H04L41/0226;;H04L41/0233;;H04L41/22;;H04L43/00;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W12/06;;H04W52/08;;H04W52/52;;H04L2209/08;;H04L2209/80;;H04L69/08;;H04L69/14;;H04L63/0876;;H04L41/0816;;H04L12/403;;H04W52/04;;H04W84/14;;Y04S40/00;;H04W12/71;;H04Q11/04;;G06F8/71;;G06F9/546;;H04B1/7075;;H04W52/08;;H04W84/14;;H04J13/00;;H04L12/66;;H04W52/52;;H04L69/08;;H04Q11/04;;H04B1/7077;;H04W52/52;;H04J3/0682;;H04B2201/70711;;H04L41/22;;H04L12/2898;;H04L41/0816;;H04L12/2874;;H04Q2213/13298;;H04Q2213/13292;;H04L2209/08;;H04Q2213/13376;;H04B1/70775;;H04L41/0226;;H04L69/14;;H04Q2213/13199;;H04J13/00;;H04L12/2856;;H04Q2213/13093;;H04B1/70735;;H04W52/08;;H04L41/0233;;H04Q2213/13109;;H04Q2213/1319;;H04W84/14;;H04Q2213/13299;;H04B2201/7071;;H04B1/7085;;H04B2201/709709;;H04L12/66;;H04B2201/70706;;H04Q2213/13204;;H04L69/08;;H04Q2213/13216;;H04L9/32;;H04W12/06;;H04B2001/70706;;H04Q2213/13202;;H04B1/7075;;H04B2201/70702;;H04L43/00;;H04L12/403;;H04L2209/80;;H04W52/04;;H04Q2213/13296;;H04L63/0876;;G06F9/546;;H04Q2213/13098;;H04Q2213/13335;;H04Q2213/1305;;H04Q2213/13196;;H04B1/707;;Y04S40/00;;Y04S40/20;;H04W12/71,H04B7/26;;G06F9/46;;H04B1/707;;H04B7/005;;H04J3/06;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/24;;H04L12/26;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/06;;H04Q11/04;;H04W12/06;;H04W52/04;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
896,BR,B1,BR 112016014887 B1,133-873-794-676-016,2022-09-06,2022,BR 112016014887 A,2014-12-24,US 201361920700 P;;US 2014/0072380 W,2013-12-24,"SISTEMA PARA DETECTAR ANOMALIAS OPERACIONAIS EM UM VAGÃO FERROVIÁRIO, E, SISTEMA PARA DETECTAR ANOMALIAS OPERACIONAIS EM UMA COMPOSIÇÃO DE TREM","SISTEMAS PARA DETECTAR ANOMALIAS EM UMA COMPOSIÇÃO DE TREM OU VAGÃO FERROVIÁRIO E PARA DETECTAR ANOMALIAS OPERACIONAIS EM UM VAGÃO FERROVIÁRIO, E, MÉTODO PARA DETECTAR ANOMALIAS OPERACIONAIS EM UMA COMPOSIÇÃO DE TREM OU VAGÃO FERROVIÁRIO. Um sistema para monitorar parâmetros operacionais de vagões ferroviários e composições de bondes e detectar anomalias na operação e condição dos mesmos usando sensores para alimentar dados a um motor distributivo de processamento de eventos complexos.",AMSTED RAIL CO INC,WILLIAM LEFEBVRE;;ANDREW H MARTIN;;FRANCIS JAMES COOPER;;RACHEL W ADAMEC,,https://lens.org/133-873-794-676-016,Granted Patent,no,0,0,20,20,0,B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L15/0027;;B61L15/0027;;B61L15/0081;;B61L15/0036;;B61L27/57;;B61L27/40;;B61K9/00;;B61K9/04;;B61L25/021;;B61L25/025;;G01M17/10,B61L15/00,,0,0,,,,ACTIVE
897,AU,A1,AU 2013/334469 A1,129-539-337-021-200,2015-04-30,2015,AU 2013/334469 A,2013-09-18,AU 2012/904715 A;;AU 2013/001069 W;;AU 2013/334469 A,2012-10-26,Surgical system,"The present invention relates to, inter alia, a surgical system for monitoring the orientation of a surgical device relative to a patient's anatomy, the system comprising: a. A patient sensor for sensing the orientation of the patient's anatomy; b. An orientation sensor for sensing the orientation of a surgical device; and c. A monitor for monitoring the orientation of the surgical device relative to the sensed patient's anatomy.",INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/129-539-337-021-200,Patent Application,no,0,0,10,10,0,A61B34/20;;A61B34/20;;A61F2/4657;;A61B5/1121;;A61B5/1121;;A61B5/1121;;A61B5/4504;;A61B5/4504;;A61B5/4504;;A61B5/4528;;A61B5/4528;;A61B5/4528;;A61B5/4571;;A61B5/4571;;A61B5/4571;;A61B5/6832;;A61B5/6834;;A61B5/6834;;A61B5/6834;;A61B17/1666;;A61B17/1666;;A61B17/1666;;A61B34/25;;A61B34/25;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61B2090/3983;;A61B2090/3983;;A61B2505/05;;A61B2505/05;;A61B2505/05;;A61B2562/0219;;A61B2562/0219;;A61B2562/0219;;A61B2562/17;;A61B2562/17;;A61F2/4609;;A61F2/4609;;A61F2/4609;;A61F2/4657;;A61F2/4657;;A61F2002/4668;;A61F2002/4668;;A61F2002/4668;;G06F19/3481;;G16H20/40;;G16H20/40,A61B17/58;;A61B5/103;;A61B17/56;;A61B19/00;;A61F2/32;;A61F2/46;;G06F19/00,,0,0,,,,INACTIVE
898,DE,T2,DE 69322986 T2,140-574-189-053-965,1999-07-08,1999,DE 69322986 T,1993-03-16,US 85610792 A,1992-03-20,Techniken für die automatische Erzeugung von Formularen durch Kombination von Teiloperationen,,XEROX CORP,COOPER MARTIN F N;;CARD STUART K;;JOHNSON WALTER A L,,https://lens.org/140-574-189-053-965,Granted Patent,no,0,0,8,8,0,G06F40/174;;G06F40/174,G06F3/14;;G06F3/048;;G06F17/24;;H04N1/00,,0,0,,,,EXPIRED
899,TR,T2,TR 199802088 T2,147-600-746-780-841,1999-05-21,1999,TR 9802088 T,1996-06-03,GB 9513170 A;;GB 9510870 A;;GB 9511546 A;;GB 9513166 A;;GB 9513172 A;;GB 9513168 A,1995-06-02,Kablosuz telekomünikasyon sisteminin verici gücünün kontrolü cihazi/yöntemi.,"Bir abone terminaline (20) radyofrekans sinyalleri iletmeye ve buradan rayofrekans sinyalleri almaya yönelik merkezi bir terminali (10) kapsayan, kablosuz bir telekomünikasyon sistemi.",DSC COMM CORP,BHAGALIA SHASHIKANT;;YEUNG JOEMANNE CHI CHEUNG;;COOPER IAN LESLIE;;LYSEJKO MARTIN,,https://lens.org/147-600-746-780-841,Patent Application,no,0,0,10,251,0,G06F8/71;;G06F9/546;;H04B1/707;;H04B1/7075;;H04B2201/70706;;H04B2201/7071;;H04B2201/709709;;H04J13/00;;H04L12/66;;H04Q11/04;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/1319;;H04Q2213/13196;;H04Q2213/13199;;H04Q2213/13202;;H04Q2213/13204;;H04Q2213/13216;;H04Q2213/13292;;H04Q2213/13296;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/08;;H04W52/52;;H04W84/14;;H04L9/12;;H04L2209/80;;H04L9/0662;;H04L9/3271,G06F9/44;;G06F9/46;;H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04J13/00;;H04L9/32;;H04L12/28;;H04L12/403;;H04L12/56;;H04L12/66;;H04L29/02;;H04L29/06;;H04Q11/04;;H04W52/00;;H04W52/08;;H04W52/52;;H04W84/14,,0,0,,,,PENDING
900,CO,A2,CO 2019009413 A2,176-186-511-218-185,2019-09-09,2019,CO 2019009413 A,2019-08-29,US 2018/0020440 W;;US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490465 P;;US 201762490567 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510660 P;;US 201762510672 P;;US 201762511218 P;;US 201715616874 A,2017-03-01,Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados,"En este documento se divulgan nuevas composiciones que comprenden un cannabinoide purificado y un terpeno purificado. En una realización, las composiciones comprenden uno o más cannabinoides purificados. En una realización, las composiciones comprenden uno o más cannabinoides purificados en combinación con uno o más terpenos purificados. En una realización, las composiciones comprenden proporciones no naturales. En una realización, las composiciones comprenden concentraciones no naturales. En una realización, las composiciones comprenden efectos inesperados y/o sinérgicos.",CANOPY GROWTH CORP,LEVY KURT;;COOPER JONATHAN MICHAEL;;MARTIN JONATHAN REED;;REID BRIAN GEOFFREY,,https://lens.org/176-186-511-218-185,Patent Application,no,0,0,11,36,0,A61K31/05;;A61K31/352,A01N65/00;;A61K31/05;;A61K31/352,,0,0,,,,PENDING
901,GB,B,GB 2260320 B,020-159-043-872-029,1995-05-24,1995,GB 9121675 A,1991-10-11,GB 9121675 A,1991-10-11,Optically active fluorophenyl derivatives,,MERCK PATENT GMBH,STYRING PETER;;GOODBY JOHN WILLIAM;;COOPER MARTIN E;;RICHARDS ROBERT D,,https://lens.org/020-159-043-872-029,Granted Patent,no,0,0,3,3,0,C09K19/588;;C07D239/34;;C09K19/126;;C09K19/321;;C09K19/3463,C07D239/34;;C09K19/12;;C09K19/32;;C09K19/34;;C09K19/58,C2C CAA;;C2C CWK;;C2C C1600;;C2C C200;;C2C C22Y;;C2C C220;;C2C C25Y;;C2C C250;;C2C C252;;C2C C31Y;;C2C C311;;C2C C36Y;;C2C C364;;C2C C443;;C2C C634;;C2C C662;;C2C C672;;C2C C695;;C2C C697;;C2C C80Y;;C2C C821;;C4X X12           X12;;U1S S1387;;U1S S2285,0,0,,,,EXPIRED
902,PE,A1,PE 20200383 A1,105-048-401-241-578,2020-02-24,2020,PE 2019001790 A,2018-03-01,US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490465 P;;US 201762490567 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510660 P;;US 201762510672 P;;US 201762511218 P;;US 201715616874 A;;US 2018/0020440 W,2017-03-01,COMPOSICIONES INTENCIONALMENTE SELECCIONADAS QUE COMPRENDEN CANNABINOIDES PURIFICADOS Y/O TERPENOS PURIFICADOS,"Referido a una composicion que comprende un primer cannabinoide purificado; y un compuesto elegido de un segundo cannabinoide purificado o un primer terpeno purificado. En donde el primer terpeno purificado se elige entre 7,8-dihidro-alfa-ionona, acetanisol, limoneno, entre otros; el primer cannabinoide purificado se elige entre acido cannabigerolico (CBGA), cannabigerol (CBG), tetrahidrocannabinol (THC), entre otros. En donde dicha composicion tiene una pureza superior al 80 % y su formulacion comprende combinaciones intencionalmente disenadas de proporciones y concentraciones no naturales.",CANOPY GROWTH CORP,LEVY KURT;;COOPER JONATHAN MICHAEL;;MARTIN JONATHAN REED;;REID BRIAN GEOFFREY,,https://lens.org/105-048-401-241-578,Patent Application,no,0,0,11,36,0,A61K31/05;;A61K31/352,A01N65/00;;A61K31/05;;A61K31/352,,0,0,,,,PENDING
903,CN,B,CN 101980698 B,096-481-928-669-063,2013-10-16,2013,CN 200980110767 A,2009-03-26,US 2009/0001956 W;;US 3975208 P,2008-03-26,Novel solid forms of bendamustine hydrochloride,,CEPHALON INC,COOPER MARTIN IAN;;COURVOISIER LAURENT D;;EDDLESTON MARK;;MCKEAN ROBERT E,,https://lens.org/096-481-928-669-063,Granted Patent,no,0,0,36,36,0,A61K31/4184;;A61K31/4184;;A61K9/0019;;A61K9/14;;A61K9/14;;A61K9/19;;A61K9/19;;A61K9/19;;A61K31/4184;;A61K47/26;;A61K47/26;;A61P35/00;;A61P35/02;;C07D235/16;;C07D235/16;;C07D235/16,A61K9/14;;A61K9/19;;A61K31/4184,,0,0,,,,ACTIVE
904,AU,A1,AU 2018/227544 A1,131-995-260-428-07X,2019-08-29,2019,AU 2018/227544 A,2018-03-01,US 201762465688 P;;US 201715616874 A;;US 201762511218 P;;US 201762510672 P;;US 201762510660 P;;US 201762510229 P;;US 201762509651 P;;US 201762469415 P;;US 201762475153 P;;US 201762491899 P;;US 201762491980 P;;US 201762491160 P;;US 201762491175 P;;US 201762490465 P;;US 201762490567 P;;US 201762477990 P;;US 201762489360 P;;US 2018/0020440 W,2017-03-01,Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes,"Disclosed herein are new compositions comprising a purified cannabinoid and a purified terpene. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnaturally occurring ratios. In one embodiment, the compositions comprise unnaturally occurring concentrations. In one embodiment, the compositions comprise unexpected and/or synergistic effects.",CANOPY GROWTH CORP,LEVY KURT;;COOPER JONATHAN MICHAEL;;MARTIN JONATHAN REED;;REID BRIAN GEOFFREY,,https://lens.org/131-995-260-428-07X,Patent Application,no,0,0,11,36,0,A61K31/05;;A61K31/352,A01N65/00;;A61K31/05;;A61K31/352,,0,0,,,,DISCONTINUED
905,EP,A3,EP 0413532 A3,155-281-755-305-334,1991-05-15,1991,EP 90308853 A,1990-08-10,GB 8918886 A;;GB 8918929 A,1989-08-18,MACROCYCLIC COMPOUNDS,"There are described compounds of formula I,
   wherein R¹ represents H or OH; R² represents H; in addition, R¹ and R² may together represent a second carbon-carbon bond between the carbon atoms to which they are attached; R³ represents OH or OCH₃; X represents O or (H,OH); and Y represents O or N-OR⁴, in which R⁴ represents H or alkyl C₁₋₆; provided that when R¹ is OH, R² is H and X is O, then Y does not represent O. Processes for their production and compositions containing them, eg for use as immunosuppressive agents, are also described.  ",FISONS PLC,"DONALD, DAVID KEITH;;HARDERN, DAVID NORMAN;;COOPER, MARTIN EDWARD;;FURBER, MARK",,https://lens.org/155-281-755-305-334,Search Report,yes,3,0,11,13,0,A61P37/06;;C07H15/26;;C07H19/01;;C07H19/01,C07D498/18;;A61K31/445;;A61P37/06;;C07H19/01,,1,1,085-780-398-733-144,2461926;;10.7164/antibiotics.41.1592,"THE JOURNAL OF ANTIBIOTICS, vol. 41, no. 11, November 1988, pages 1592-1601, Tokyo, JP; H. HATANAKA et al.: ""FR-900520 and FR-900523, novel immunosuppressants isolated from a streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics""",DISCONTINUED
906,EP,A1,EP 3273895 A1,150-580-116-657-200,2018-01-31,2018,EP 16767541 A,2016-03-24,AU 2015/901083 A;;AU 2016/050220 W,2015-03-25,ALIGNMENT APPARATUS,,INLINE ORTHOPAEDICS PTY LTD,FRY DON;;COOPER DAVID JOHN;;WADLEY DAVID JOHN;;FORD MARTIN JOHN,,https://lens.org/150-580-116-657-200,Patent Application,yes,0,0,7,7,0,A61B17/1746;;A61B17/1746;;A61B34/20;;A61B34/20;;A61B34/20;;A61B34/25;;A61B34/25;;A61B90/37;;A61B90/37;;A61B2017/00734;;A61B2017/00734;;A61B2034/2048;;A61B2034/2048;;A61B2090/372;;A61B2090/372;;A61F2/4603;;A61F2/4607;;A61F2/4609;;A61F2/4657;;A61F5/11;;A61F5/11;;A61F2002/4687,A61B34/20;;A61F5/11,,0,0,,,,DISCONTINUED
907,IN,B,IN 174123 B,059-289-858-429-678,1994-09-17,1994,IN 355MA1989 A,1989-05-08,GB 8810723 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,Apparatus for identifying diamonds or other specific luminescing minerals,,GERSAN ETS,PHILLIP MARTIN;;SMITH ROBIN WYNCLIFFEE;;GARRYSTEWART ANDREW DAVID;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/059-289-858-429-678,Granted Patent,no,0,0,11,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,EXPIRED
908,ZA,B,ZA 893368 B,022-492-748-302-95X,1991-01-30,1991,ZA 893368 A,1989-05-08,GB 8810723 A,1988-05-06,IDENTIFYING GEMSTONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;MARTIN PHILLIP SMITH;;SMITH ROBIN WYNCLIFFE;;ROBIN WYNCLIFFE SMITH;;STEWART ANDREW DAVID GARRY;;ANDREW DAVID GARRY STEWART;;BRINK DANIEL JOHANNES;;DANIEL JOHANNES BRINK;;COOPER MARTIN;;MARTIN COOPER;;WELBOURN CHRISTOPHER MARK;;CHRISTOPHER MARK WELBOURN;;SPEAR PAUL MARTIN;;PAUL MARTIN SPEAR,,https://lens.org/022-492-748-302-95X,Granted Patent,no,0,0,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
909,ZA,B,ZA 893364 B,188-229-158-873-48X,1991-01-30,1991,ZA 893364 A,1989-05-08,GB 8810723 A,1988-05-06,SENSING A NARROW FREQUENCY BAND OF RADIATION AND GEMSTONES,,GERSAN ETS,STEWART ANDREW DAVID GARRY;;ANDREW DAVID GARRY STEWART;;SMITH ROBIN WYNCLIFFE;;ROBIN WYNCLIFFE SMITH;;SMITH MARTIN PHILLIP;;MARTIN PHILLIP SMITH;;BRINK DANIEL JOHANNES;;DANIEL JOHANNES BRINK;;COOPER MARTIN;;MARTIN COOPER;;WELBOURN CHRISTOPHER MARK;;CHRISTOPHER MARK WELBOURN;;SPEAR PAUL MARTIN;;PAUL MARTIN SPEAR,,https://lens.org/188-229-158-873-48X,Granted Patent,no,0,1,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
910,US,A1,US 2009/0137579 A1,105-809-498-176-55X,2009-05-28,2009,US 28859608 A,2008-10-22,US 28859608 A;;US 1207 P,2007-10-23,Mesylate salt of an IKK inhibitor,"The present invention is directed to the compound of formula (II), or a solvate thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (II), including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of a compound of formula (II), or crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.",MILLENNIUM PHARM INC,HICKS FREDERICK A;;COOPER MARTIN IAN;;LANGSTON MARIANNE;;ST CLAIR BROWN ADRIAN,MILLENNIUM PHARMACEUTICALS INC (2008-11-14),https://lens.org/105-809-498-176-55X,Patent Application,yes,9,0,2,2,0,A61P29/00;;A61P35/00;;C07D471/04;;C07D471/04,A61K31/5377;;C07D413/14,514/232.5;;544/80,0,0,,,,DISCONTINUED
911,EP,A3,EP 0069291 A3,089-064-730-561-371,1983-07-20,1983,EP 82105598 A,1982-06-25,DE 3126021 A,1981-07-02,PROCESS FOR PREPARING OPTICALLY PURE D- OR L-LACTIC ACID,"Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung optisch reiner D- oder L-Milchsäure durch Fermentation eines wäßrigen Nährmediums, weiches Stickstoff, Vitamine, Aminosäuren, Zucker und Spurenelemente enthält, mit Hilfe eines Mikroorganismus bei pH 4 bis 6, welches dadurch gekennzeichnet ist, daß das Nährmedium als Quelle für Stickstoff Vitamine, Aminosäuren und Spurenelemente Bierhefe enthält.",BASF AKTIENGESELLSCHAFT,"COOPER, BRYAN, DR.;;KUESTERS, WERNER, DR.;;MARTIN, CHRISTOPH, DR.;;SIEGEL, HARDO, DR.",,https://lens.org/089-064-730-561-371,Search Report,yes,5,0,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,,5,0,,,"CHEMICAL ABSTRACTS, Band 65, Nr. 3, 01. August 1966, Spalte 4616, Auszug c, Columbus, Ohio, USA & CZ - A - 116 443 (V. KRUMPHANZL et al.), 15. Oktober 1965;;CHEMICAL ABSTRACTS, Band 29, Nr. 4, 20. Februar 1935, Spalte 1128, Auszug 5, Columbus, Ohio, USA;;CHEMICAL ABSTRACTS, Band 82, Nr. 9, 03. März 1975, Seite 445, Spalte 2, Nr. 56031w, Columbus, Ohio, USA;;CHEMICAL ABSTRACTS, Band 63, Nr. 3, 2. August 1965, Spalte 3348, Auszug e, Columbus, Ohio, USA;;CHEMICAL ABSTRACTS, Band 23, Nr. 16, 20. August 1929, Seite 3948, Absatz 5, Columbus, Ohio, USA",EXPIRED
912,AU,A,AU 1996/060377 A,021-306-091-725-14X,1996-12-18,1996,AU 1996/060377 A,1996-06-03,GB 9511167 A;;GB 9510870 A;;GB 9511192 A;;GB 9511189 A;;US 9608659 W,1995-06-02,Control message transmission in telecommunications systems,,DSC COMMUNICATIONS,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/021-306-091-725-14X,Patent Application,no,0,0,8,251,0,H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04L12/403;;H04L41/0226;;H04L41/0233;;H04L41/0654;;H04L41/0677;;H04L41/069;;H04L41/22;;H04L63/08;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/13199;;H04Q2213/13216;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/52;;H04W84/14;;H04L69/08;;H04L69/32;;H04B1/7073;;H04L69/08;;H04L69/32,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04L12/24;;H04L12/28;;H04L12/403;;H04L29/06;;H04L29/08;;H04W52/04;;H04W52/52;;H04W84/14,,0,0,,,,PENDING
913,CA,A1,CA 2428283 A1,049-264-633-306-390,2002-05-16,2002,CA 2428283 A,2001-10-23,EP 0112226 W;;US 70935400 A,2000-11-13,METHOD FOR THE CONTINUOUS PRODUCTION OF POLYMER COMPOSITIONSAND THE USE THEREOF,"The invention relates to a method for producing polymer compositions according to which ethylenically unsaturated monomers are polymerized in the presence of ligands that may form a coordination compound with the metal catalyst(s) by way of initiators that comprise a transferable group of atoms, and one or more catalysts that comprise at least one transition metal. The polymerization is characterized in that it is carried out continuously.",ROHMAX ADDITIVES GMBH,TILLERY LARRY STEPHEN;;SCHERER MARKUS;;BOLLINGER JOSEPH MARTIN;;WOODRUFF ROBERT;;COOPER DAVID,,https://lens.org/049-264-633-306-390,Patent Application,no,0,0,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F2/01;;C08F4/00;;C08F4/40;;C08F4/44,,0,0,,,,EXPIRED
914,AU,B2,AU 691023 B2,063-021-565-181-098,1998-05-07,1998,AU 1995/032065 A,1995-07-31,US 28347094 A;;US 9509651 W,1994-08-01,Spectrally efficient and high capacity acknowledgment radio paging system,,ARRAYCOMM INC,GOLDBURG MARC H;;ROY RICHAR H III;;COOPER MARTIN;;HARRIS ARLENE J,,https://lens.org/063-021-565-181-098,Granted Patent,no,3,0,7,7,0,G01S5/12;;H01Q1/246;;H01Q3/2605;;H01Q3/267;;H04B7/04;;H04B7/0408;;H04B7/0491;;H04B7/0615;;H04B7/0697;;H04B7/0842;;H04B7/0845;;H04W16/28;;H04W64/00;;H04W84/025;;H04B17/309;;H04W84/025;;H04B7/0408;;G01S5/12;;H04B7/0842;;H04B7/0491;;H04B7/04;;H04B7/0845;;H04B7/0697;;H04B7/0615;;H01Q3/267;;H04W16/28;;H01Q3/2605;;H01Q1/246;;H04W64/00;;H04B17/309,G01S5/12;;H01Q1/24;;H01Q3/26;;H04B7/04;;H04B7/06;;H04B7/08;;H04B17/00;;H04W16/28;;H04W64/00;;H04W84/02,,0,0,,,,EXPIRED
915,EP,B1,EP 0830775 B1,012-179-741-605-831,2002-08-14,2002,EP 96918014 A,1996-06-03,GB 9511167 A;;GB 9510870 A;;GB 9511192 A;;GB 9511189 A;;US 9608659 W,1995-06-02,CONTROL MESSAGE TRANSMISSION IN TELECOMMUNICATIONS SYSTEMS,,AIRSPAN NETWORKS INC,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,AIRSPAN NETWORKS INC. (2000-10-18);;AIRSPAN COMMUNICATIONS CORPORATION (1998-12-30),https://lens.org/012-179-741-605-831,Granted Patent,yes,4,12,8,251,0,H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04L12/403;;H04L41/0226;;H04L41/0233;;H04L41/0654;;H04L41/0677;;H04L41/069;;H04L41/22;;H04L63/08;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/13199;;H04Q2213/13216;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/52;;H04W84/14;;H04L69/08;;H04L69/32;;H04B1/7073;;H04L69/08;;H04L69/32,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04L12/24;;H04L12/28;;H04L12/403;;H04L29/06;;H04L29/08;;H04W52/04;;H04W52/52;;H04W84/14,,1,0,,,"IEEE JOURNAL ON SELECTED AREAS IN COMMUNICATION, vol. 8, no. 1, January 1990, NEW YORK US, pages 67-79, XP000133533 L.SVOBODOVA ET AL: ""HETEROGENEITY AND OSI""",EXPIRED
916,EP,A1,EP 1587809 A1,096-442-464-778-568,2005-10-26,2005,EP 04702471 A,2004-01-15,SE 2004000051 W;;SE 0300120 A,2003-01-17,THIENOPYRIDAZINONE DERIVATIVE AS MODULATORS OF AUTOIMMUNE DISEASES,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN E;;GUILE SIMON D;;INGALL ANTHONY H;;RASUL RUKHSANA T,,https://lens.org/096-442-464-778-568,Patent Application,yes,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,EXPIRED
917,US,A,US 2522665 A,175-128-986-306-718,1950-09-19,1950,US 4016448 A,1948-07-22,US 4016448 A,1948-07-22,Magnetic recording and reproduction,,ACME ALUMINUM ALLOYS INC,COOPER HUGH S;;MARTIN WAYNE E;;REICHES SOL L;;GRAY JOSEPH B,,https://lens.org/175-128-986-306-718,Granted Patent,no,6,1,1,1,0,G11B5/642;;G11B5/642;;Y10S29/028;;Y10S29/028,G11B5/64,C7A AB249         -           -;;C7A AB279         -           -;;C7A AB289         -           -;;C7A AB309         -           -;;C7A AB319         -           -;;C7A AB32X         -           -;;C7A AB32Y         -           -;;C7A AB320         -           -;;C7A AB34Y         -           -;;C7A AB347         -           -;;C7A AB349         -           -;;C7A AB369         -           -;;C7A AB37Y         -           -;;C7A AB370         -           -;;C7A AB375         -           -;;C7A AB377         -           -;;C7A AB379         -           -;;C7A AB38X         -           -;;C7A AB381         -           -;;C7A AB383         -           -;;C7A AB385         -           -;;C7A AB387         -           -;;C7A AB389         -           -;;C7A AB399         -           -;;C7A AB419         -           -;;C7A AB42Y         -           -;;C7A AB43X         -           -;;C7A AB431         -           -;;C7A AB433         -           -;;C7A AB435         -           -;;C7A AB437         -           -;;C7A AB439         -           -;;C7A AB459         -           -;;C7A AB489         -           -;;C7A AB50Y         -           -;;C7A AB500         -           -;;C7A AB509         -           -;;C7A AB51X         -           -;;C7A AB511         -           -;;C7A AB513         -           -;;C7A AB515         -           -;;C7A AB517         -           -;;C7A AB519         -           -;;C7A AB52X         -           -;;C7A AB52Y         -           -;;C7A AB54X         -           -;;C7A AB54Y         -           -;;C7A AB545         -           -;;C7A AB546         -           -;;C7A AB547         -           -;;C7A AB548         -           -;;C7A AB549         -           -;;C7A AB55Y         -           -;;C7A AB555         -           -;;C7A AB556         -           -;;C7A AB557         -           -;;C7A AB558         -           -;;C7A AB559         -           -;;C7A AB610         -           -;;C7A AB613         -           -;;C7A AB614         -           -;;C7A AB616         -           -;;C7A AB619         -           -;;C7A AB62X         -           -;;C7A AB62Y         -           -;;C7A AB621         -           -;;C7A AB624         -           -;;C7A AB627         -           -;;C7A AB630         -           -;;C7A AB635         -           -;;C7A AB636         -           -;;C7A AB66X         -           -;;C7A AB661         -           -;;C7A AB663         -           -;;C7A AB665         -           -;;C7A AB666         -           -;;C7A AB667         -           -;;C7A AB669         -           -;;C7A AB670         -           -;;C7A AB671         -           -;;C7A A716          -           -;;C7A A746          -           -;;C7A A747          -           -;;C7A A748          -           -;;C7A A749          -           -;;C7A A750          -           -;;C7A A751          -           -;;C7A A756          -           -;;C7A A757          -           -;;C7A A759          -           -,0,0,,,,EXPIRED
918,DE,D1,DE 3266373 D1,026-463-466-656-189,1985-10-24,1985,DE 3266373 T,1982-06-25,DE 3266373 T;;DE 3126021 A,1981-07-02,PROCESS FOR PREPARING OPTICALLY PURE D- OR L-LACTIC ACID,,BASF AG,COOPER BRYAN DR;;KUESTERS WERNER DR;;MARTIN CHRISTOPH DR;;SIEGEL HARDO DR,,https://lens.org/026-463-466-656-189,Granted Patent,no,0,0,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,,0,0,,,,EXPIRED
919,US,A,US 5465167 A,061-487-302-407-405,1995-11-07,1995,US 85538892 A,1992-03-20,US 85538892 A,1992-03-20,Using an image from a form in automatic creation of a form or sheet,"A page is automatically created and transmitted in response to data defining set of images. The data define an image showing a form that has been marked; the data also include information indicating an image destination. The page includes a segment that is a version of an image from the marked form. The page can be another form, a cover sheet, or an error sheet, for example. The segment can be a reduced version of the marked form, such as on an error sheet. Or the segment can be a version of the contents of a field in the marked form, such as on a form, a cover sheet, or a listing sheet. The field can be a cover note field, and if the processor determines that the cover note field has been marked, it can automatically create a cover sheet that includes a segment that is a version of an image of the cover note field. The field can be an identifier field. The processor can create a form with a request field that includes a segment that is a version of an image of the identifier field, identifying an item in relation to which an operation can be requested, such as the recipient of facsimile transmission or a document being facsimile transmitted; or the processor can create a cover sheet with a segment that is a version of an image of the identifier field; or the processor can create a listing sheet in which each item's entry includes a segment that is a version of an image of the item's identifier field. The image destination can be indicated by a check mark in a recipient field, by check marks indicating the telephone number of a fax machine, or by data from a transmitting fax machine indicating the fax machine's telephone number.",XEROX CORP,COOPER MARTIN F N;;JOHNSON WALTER A L;;SMITH III Z EROL,XEROX CORPORATION A CORPORATION OF NEW YORK (1992-05-19),https://lens.org/061-487-302-407-405,Granted Patent,yes,29,94,3,3,0,H04N1/00366;;H04N1/00376;;H04N1/32042;;H04N1/32101;;H04N1/32112;;H04N2201/3204;;H04N2201/3207;;H04N2201/3209;;H04N2201/3211;;H04N2201/3214;;H04N2201/3215;;H04N2201/3243;;H04N2201/3269;;H04N2201/3278;;H04N1/00366;;H04N2201/3207;;H04N2201/3209;;H04N2201/3278;;H04N2201/3215;;H04N1/32101;;H04N2201/3243;;H04N1/32042;;H04N1/00376;;H04N2201/3204;;H04N1/32112;;H04N2201/3214;;H04N2201/3269;;H04N2201/3211,G06F13/00;;H04N1/32;;H04N1/387,358/468;;358/402;;358/403;;358/462,5,0,,,"The Complete PC Inc. Title: The Complete Fax/9600 (Chpater 4) 1988.;;Suenaga, Y., and Nagura, M., A Facsimile Based Manuscript Layout and Editing System by Auxiliary Mark Recognition, 5th International Conference on Pattern Recognition Proceedings, Dec. 1 4, 1980, vol. 2, pp. 856 858.;;Suenaga, Y., A Facsimile Based Text Editor Using Handwritten Mark Recognition, IJCAI 79: Proceedings of the Sixth International Joint Conference on Artificial Intelligence, Tokyo, Aug. 20 23, 1979, vol. 2, pp. 856 858.;;Kramer, M., Windows Based FAx Tools Deliver More than Just the Fax Cardiff s Teleform Eases Remote Data Entry, PC Week, Mar. 30, 1992, p. 14.;;DoveFax Installation and User s Manual, Dove Computer Corporation. Sep. 1990.",EXPIRED
920,NZ,A,NZ 541216 A,064-628-009-869-294,2008-05-30,2008,NZ 54121604 A,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,Thienopyridazinone derivatives as modulators of autoimmune diseases,"Disclosed is a compound of formula (I), wherein R3 is a group CO-G or SO2-G and the remaining substituents are as defined in the specification. The compounds are inhibitors of T-cell proliferation and are useful in the modulation of autoimmune disease.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/064-628-009-869-294,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,DISCONTINUED
921,US,A,US 4304632 A,164-985-732-006-296,1981-12-08,1981,US 6798979 A,1979-08-20,US 6798979 A,1979-08-20,Nuclear reactor shutdown system,"An inherent shutdown system for a nuclear reactor having neutron absorbing rods affixed to an armature which is held in an upper position by a magnetic flux flowing through a Curie temperature material. The Curie temperature material is fixedly positioned about the exterior of an inner duct in an annular region through which reactor coolant flows. Elongated fuel rods extending from within the core upwardly toward the Curie temperature material are preferably disposed within the annular region. Upon abnormal conditions which result in high neutron flux and coolant temperature, the Curie material loses its magnetic permeability, breaking the magnetic flux path and allowing the armature and absorber rods to drop into the core, thus shutting down the fissioning reaction. The armature and absorber rods are retrieved by lowering the housing for the electromagnet forming coils which create a magnetic flux path which includes the inner duct wall. The coil housing then is raised, resetting the armature.",WESTINGHOUSE ELECTRIC CORP,BHATE SURESH K;;COOPER MARTIN H;;RIFFE DELMAR R;;KINNEY CALVIN L,ENERGY THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF (1981-08-04),https://lens.org/164-985-732-006-296,Granted Patent,yes,6,12,7,7,0,G21C7/12;;G21C9/027;;Y02E30/30;;G21C9/027;;G21C7/12;;Y02E30/30,G21C7/12;;G21C9/02;;G21C9/027,376/336,0,0,,,,EXPIRED
922,ZA,B,ZA 200505273 B,055-467-014-690-140,2006-04-26,2006,ZA 200505273 A,2005-06-29,SE 0300120 A,2003-01-17,Novel compound,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN E;;INGALL ANTHONY H;;GUILE SIMON D;;RASUL RUKHSANA T,,https://lens.org/055-467-014-690-140,Granted Patent,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K/;;A61K31/50;;C07D/;;C07D495/04,,0,0,,,,ACTIVE
923,WO,A1,WO 1996/038967 A1,085-048-511-967-94X,1996-12-05,1996,US 9608659 W,1996-06-03,GB 9511167 A;;GB 9510870 A;;GB 9511192 A;;GB 9511189 A,1995-06-02,CONTROL MESSAGE TRANSMISSION IN TELECOMMUNICATIONS SYSTEMS,A communications protocol interface is arranged at a central station of a telecommunications network and is responsive to a control message received from a network controller in accordance with a first message protocol to transmit the control message in accordance with a second message protocol to subscriber stations and is responsive to a control message received in accordance with the second message protocol to transmit the control message to the network controller in accordance with the first message protocol. The first message protocol is a balanced protocol with the communications protocol converter or the network controller able to initiate an exchange of information. The second message protocol is a master-slave protocol with the communications protocol interface acting as master. The second control message protocol operates over central station bus for communicating with at least one network element in the central station.,DSC COMMUNICATIONS;;YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/085-048-511-967-94X,Patent Application,yes,4,9,8,251,0,H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04L12/403;;H04L41/0226;;H04L41/0233;;H04L41/0654;;H04L41/0677;;H04L41/069;;H04L41/22;;H04L63/08;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/13199;;H04Q2213/13216;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/52;;H04W84/14;;H04L69/08;;H04L69/32;;H04B1/7073;;H04L69/08;;H04L69/32,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04L12/24;;H04L12/28;;H04L12/403;;H04L29/06;;H04L29/08;;H04W52/04;;H04W52/52;;H04W84/14,,1,0,,,"L.SVOBODOVA ET AL: ""HETEROGENEITY AND OSI"", IEEE JOURNAL ON SELECTED AREAS IN COMMUNICATION, vol. 8, no. 1, January 1990 (1990-01-01), NEW YORK US, pages 67 - 79, XP000133533",PATENTED
924,CA,C,CA 2428283 C,105-564-147-072-158,2011-02-01,2011,CA 2428283 A,2001-10-23,EP 0112226 W;;US 70935400 A,2000-11-13,PROCESSES FOR CONTINUOUS SYNTHESIS OF POLYMER COMPOSITIONS AS WELL AS USE OF SAME,"The invention relates to a method for producing polymer compositions according to which ethylenically unsaturated monomers are polymerized in the presence of ligands that may form a coordination compound with the metal catalyst(s) by way of initiators that comprise a transferable group of atoms, and one or more catalysts that comprise at least one transition metal. The polymerization is characterized in that it is carried out continuously.",ROHMAX ADDITIVES GMBH,SCHERER MARKUS;;BOLLINGER JOSEPH MARTIN;;COOPER DAVID;;TILLERY LARRY STEPHEN;;WOODRUFF ROBERT,,https://lens.org/105-564-147-072-158,Granted Patent,no,0,0,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F2/01;;C08F2/04;;C08F4/00;;C08F4/40;;C08F4/44;;C08F4/50;;C08F10/02;;C08F12/08;;C08F20/10,,0,0,,,,EXPIRED
925,US,A1,US 2006/0223809 A1,113-542-029-401-603,2006-10-05,2006,US 44734306 A,2006-06-06,US 44734306 A;;SE 0300120 A;;US 54219405 A;;SE 2004000051 W,2003-01-17,Novel compounds,"The invention relates to thienopyridazinones of formula (I): wherein: R 1 is C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl which is optionally substituted by C 1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R 2 is C 1-6 alkyl; R 3 is a group CO-G or SO 2 -G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C 1-4 alkyl; Q is CR 5 R 6 where R 5 and R 6 are as defined in the specification; and R 4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB A SWEDEN CORP,COOPER MARTIN E;;GUILE SIMON D;;INGALL ANTHONY H;;RASUL RUKHSANA T,,https://lens.org/113-542-029-401-603,Patent Application,yes,13,4,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/503;;A61K31/50;;C07D/;;C07D495/04;;C07D498/02,514/248;;544/235,0,0,,,,DISCONTINUED
926,CA,A1,CA 2512736 A1,162-751-050-712-295,2004-08-05,2004,CA 2512736 A,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,NOVEL COMPOUNDS,"The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1- 6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1- 6 alkyl, each of the above being optionally substituted by one or more halog en atoms; R2 is C1-6 alkyl; R3 is a group CO-G or SO2-G where G is a 5- or 6- membered ring containing a nitrogen atom and a second heteroatom selected fr om oxygen and sulphur adjacent to the nitrogen, and optionally substituted by u p to 3 groups selected from hydroxyl and C1-4 alkyl; Q is CR5R6 where R5 and R 6 are as defined in the specification; and R4 is a 5- to 10-membered mono- or bi- cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptab le salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,GUILE SIMON DAVID;;COOPER MARTIN EDWARD;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/162-751-050-712-295,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,DISCONTINUED
927,DE,D1,DE 602004009407 D1,174-448-090-412-944,2007-11-22,2007,DE 602004009407 T,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,THIENOPYRIDAZINON-DERIVATE ALS MODULATOREN VON AUTOIMMUNKRANKHEITEN,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN E TM;;GUILE LOUGHBOROUGH;;INGALL ANTHONY H;;RASUL RUKHSANA T,,https://lens.org/174-448-090-412-944,Granted Patent,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,EXPIRED
928,ES,T3,ES 2738048 T3,038-201-352-251-621,2020-01-20,2020,ES 08770514 T,2008-06-09,US 2315808 P;;US 93388507 P;;US 2008/0066336 W,2007-06-08,Aparato y método de dispensación de fluidos,"Un dispensador (10, 110, 210, 310, 410, 510, 610, 710) de fluido para contener y dispensar cantidades medidas de fluido e incluir una bomba (20, 120, 220, 320, 620, 720), el dispensador (10, 110, 210, 310, 410, 510, 610, 710) de fluido que comprende: un depósito para contener fluido; una cámara (24, 124, 424) colocada sustancialmente dentro del depósito para contener una cantidad del fluido; un pistón (35, 135, 235, 435, 535) movible dentro de la cámara (24, 124, 424) para atraer fluido hacia la cámara (24, 124, 424) cuando el pistón (35, 135, 235, 435, 535) se mueve en una primera dirección con respecto a la cámara (24, 124, 424), y para descargar fluido de la cámara (24, 124, 424) cuando el pistón (35, 135, 235, 435, 535) se mueve en una segunda dirección opuesta a la primera dirección; un control (40, 140, 240, 340, 440, 540, 640, 740) manipulable por el usuario acoplado al pistón (35, 135, 235, 435, 535) y movible para mover el pistón (35, 135, 235, 435, 535) con respecto a la cámara (24, 124, 424); y un gatillo de retención (277, 477, 577, 579, 877, 977) ubicado entre el pistón (35, 135, 235, 435, 535) y una pared de la bomba (20, 120, 220, 320, 620, 720), el gatillo de retención móvil con respecto al pistón (35, 135, 235, 435, 535) para permitir e inhibir selectivamente el movimiento del pistón (35, 135, 235, 435, 535) en al menos una de las direcciones primera y segunda; caracterizado porque el pistón (35, 135, 235, 435, 535) y la cámara (24, 124, 424) definen colectivamente al menos una porción de la bomba (20, 120, 220, 320, 620, 720); y en un primer estado de la bomba, el pistón (35, 135, 235, 435, 535) está limitado en movimiento a una primera distancia de carrera para descargar una primera cantidad de fluido de la cámara (24, 124, 424), y en donde en un segundo estado de la bomba, el pistón (35, 135, 235, 435, 535) está limitado en movimiento a una segunda distancia de carrera diferente de la primera distancia de carrera para descargar una segunda cantidad de fluido diferente de la primera cantidad de fluido.",DIVERSEY INC,CROSSDALE GARRY;;SWAIN ANDREW;;COOPER MARTIN;;BERTUCCI MICHAEL;;HAGUE BARRY;;THORNHILL GUY,,https://lens.org/038-201-352-251-621,Granted Patent,no,0,0,32,32,0,B67D7/64;;B05B11/0005;;B05B11/00;;B67D7/645;;B05B11/1005;;B05B11/10;;B05B11/0056;;B05B11/0089;;B05B11/0097;;B67B7/24;;B67D7/0227;;G01F11/028;;B05B11/1007;;B05B11/1005;;B05B11/1015;;B05B11/106;;B05B11/1059;;B05B11/1052;;B05B11/0056;;B05B11/0089;;B05B11/0097;;B67B7/24;;B67D7/0227;;G01F11/028;;B05B11/1007;;B05B11/106;;B05B11/1005;;B05B11/1015;;B05B11/1052;;B05B11/1059,B05B11/00;;B67B7/00;;B67D7/02;;B67D7/58;;G01F11/02,,0,0,,,,ACTIVE
929,ZA,B,ZA 964154 B,090-050-042-434-377,1996-12-03,1996,ZA 964154 A,1996-05-23,GB 9511189 A,1995-06-02,Control message transmission in telecommunications systems,,DSC COMMUNICATIONS,LYSEJKO MARTIN;;COOPER GUY ALEXANDER;;YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW,,https://lens.org/090-050-042-434-377,Granted Patent,no,0,0,7,251,0,H04L41/0233;;H04L41/0677;;H04L41/22;;H04L43/00;;H04L43/10;;H04W84/14;;H04L41/0677;;H04L41/22;;H04L43/10;;H04L43/00;;H04L41/12;;H04W84/14;;H04L41/0233,H04L12/24;;H04L12/26;;H04W84/14,,0,0,,,,EXPIRED
930,WO,A1,WO 2021/086671 A1,104-670-433-761-408,2021-05-06,2021,US 2020/0056340 W,2020-10-19,US 201962929100 P,2019-10-31,IMAGE-PROCESSING-BASED OBJECT CLASSIFICATION USING BOOTSTRAPPING OF REGION-LEVEL ANNOTATIONS,"Techniques relate to object classifications using bootstrapping of region-level annotations. For each of multiple images, regions within the image can be identified. For each region, a region-specific label can be identified, a set of objects within the region can be detected, and an object-specific label can be assigned to each object. The object-specific label can be the same as the region-specific label assigned to the region within which the object is located. A training data set can be defined to include, for each image of the multiple images, object-location data (indicating intra-image location data for the detected object) and label data (indicating the object-specific labels assigned to the objects). An image-processing model can be trained using the training data. Training can include learning values for a set of parameters that define calculations performed by the image-processing model.",VENTANA MED SYST INC,TAGELDIN MOHAMED AMGAD;;COOPER LEE ALEX DONALD;;KURKURE UDAY;;MARTIN JIM F,,https://lens.org/104-670-433-761-408,Patent Application,yes,3,3,5,5,0,G06V20/698;;G06V10/454;;G06V10/25;;G06V10/82;;G06F18/41;;G06F18/2155;;G06F18/24143;;G06V10/7747;;G06V20/698;;G06V10/82;;G06V2201/03;;G06V10/764;;G06T7/0014;;G06T2207/20081;;G06T2207/20084;;G06T2207/30096;;G06V10/25;;G06V10/454,G06K9/00;;G06K9/32;;G06K9/46;;G06K9/62,,2,2,014-457-629-987-577;;053-217-691-749-360,10.1109/cbms.2015.89;;10.1109/rbme.2016.2515127;;pmc5233461;;26742143,"ANOOP HARIDAS ET AL: ""Interactive Segmentation Relabeling for Classification of Whole-Slide Histopathology Imagery"", 2015 IEEE 28TH INTERNATIONAL SYMPOSIUM ON COMPUTER-BASED MEDICAL SYSTEMS, 1 June 2015 (2015-06-01), pages 84 - 87, XP055707133, ISBN: 978-1-4673-6775-2, DOI: 10.1109/CBMS.2015.89;;FUYONG XING ET AL: ""Robust Nucleus/Cell Detection and Segmentation in Digital Pathology and Microscopy Images: A Comprehensive Review"", IEEE REVIEWS IN BIOMEDICAL ENGINEERING, vol. 9, 1 January 2016 (2016-01-01), USA, pages 234 - 263, XP055555739, ISSN: 1937-3333, DOI: 10.1109/RBME.2016.2515127",PENDING
931,EP,B1,EP 0069291 B1,118-868-555-338-79X,1985-09-18,1985,EP 82105598 A,1982-06-25,DE 3126021 A,1981-07-02,PROCESS FOR PREPARING OPTICALLY PURE D- OR L-LACTIC ACID,,BASF AKTIENGESELLSCHAFT,"COOPER, BRYAN, DR.;;KUESTERS, WERNER, DR.;;MARTIN, CHRISTOPH, DR.;;SIEGEL, HARDO, DR.",,https://lens.org/118-868-555-338-79X,Granted Patent,yes,0,0,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,,0,0,,,,EXPIRED
932,IL,A,IL 268929 A,135-147-899-643-401,2019-10-31,2019,IL 26892919 A,2019-08-26,US 201762465688 P;;US 201762469415 P;;US 201762475153 P;;US 201762477990 P;;US 201762489360 P;;US 201762490465 P;;US 201762490567 P;;US 201762491160 P;;US 201762491175 P;;US 201762491899 P;;US 201762491980 P;;US 201762509651 P;;US 201762510229 P;;US 201762510660 P;;US 201762510672 P;;US 201762511218 P;;US 201715616874 A;;US 2018/0020440 W,2017-03-01,Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes,,CANOPY GROWTH CORP;;KURT ARON LEVY;;JONATHAN MICHAEL COOPER;;JONATHAN REED MARTIN;;BRIAN GEOFFREY REID,KURT ARON LEVY;;JONATHAN MICHAEL COOPER;;JONATHAN REED MARTIN;;BRIAN GEOFFREY REID,,https://lens.org/135-147-899-643-401,Patent Application,no,0,0,11,36,0,A61K31/05;;A61K31/352,,,0,0,,,,PENDING
933,AU,B2,AU 2004/205617 B2,130-913-856-444-97X,2007-03-08,2007,AU 2004/205617 A,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,Novel compounds,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,RASUL RUKHSANA TASNEEM;;COOPER MARTIN EDWARD;;INGALL ANTHONY HOWARD;;GUILE SIMON DAVID,,https://lens.org/130-913-856-444-97X,Granted Patent,no,1,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,EXPIRED
934,KR,A,KR 20050092759 A,176-145-505-281-953,2005-09-22,2005,KR 20057013124 A,2005-07-15,SE 0300120 A,2003-01-17,NOVEL COMPOUNDS,"The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO-G or SO2-G where G is a 5- or 6- membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C1-4 alkyl; Q is CR5R6 where R5 and R6 are as defined in the specification; and R4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/176-145-505-281-953,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,ACTIVE
935,US,B1,US 6422669 B1,178-871-275-744-033,2002-07-23,2002,US 18847198 A,1998-11-09,US 18847198 A,1998-11-09,Carrying case for defibrillator,"
    A carrying case for external defibrillator having at least one surface-mounted operational features. The carrying case includes a main interior compartment that securely holds a defibrillator such that at least one of surface-mounted operational features of the defibrillator is accessible to the operator without removing the defibrillator from the carrying case. This enables the defibrillator to be used while held in said main interior compartment. At least one storage compartment is provided having an interior dimension adapted to hold at least one item associated with the defibrillator. The storage compartment has an associated aperture formed on an exterior of the carrying case such that the storage compartment is accessible from an exterior of the carrying case. 
",KONINKL PHILIPS ELECTRONICS NV,SALVATORI PHILLIP H;;MAIERS MARTIN JOHN;;COOPER STEPHEN V;;ANDREWS JONATHAN NEAL,HEWLETT-PACKARD COMPANY (1998-11-05);;AGILENT TECHNOLOGIES INC (1999-11-01);;KONINKLIJKE PHILIPS ELECTRONICS N.V (2001-08-01);;AGILENT TECHNOLGIES INC (2000-05-12),https://lens.org/178-871-275-744-033,Granted Patent,yes,20,72,3,3,0,A61N1/3968;;A61N1/3968;;A61N1/3904;;A61N1/3904,A61N1/39,312/213;;206/320,0,0,,,,EXPIRED
936,US,A1,US 2022/0262145 A1,181-855-567-456-701,2022-08-18,2022,US 202217730406 A,2022-04-27,US 202217730406 A;;US 2020/0056340 W;;US 201962929100 P,2019-10-31,IMAGE-PROCESSING-BASED OBJECT CLASSIFICATION BOOTSTRAPPING OF REGION-LEVEL ANNOTATIONS,"Techniques relate to object classifications using bootstrapping of region-level annotations. For each of multiple images, regions within the image can be identified. For each region, a region-specific label can be identified, a set of objects within the region can be detected, and an object-specific label can be assigned to each object. The object-specific label can be the same as the region-specific label assigned to the region within which the object is located. A training data set can be defined to include, for each image of the multiple images, object-location data (indicating intra-image location data for the detected object) and label data (indicating the object-specific labels assigned to the objects). An image-processing model can be trained using the training data. Training can include learning values for a set of parameters that define calculations performed by the image-processing model.",VENTANA MED SYST INC,TAGELDIN MOHAMED AMGAD;;COOPER LEE ALEX DONALD;;KUKURE UDAY;;MARTIN JIM F,VENTANA MEDICAL SYSTEMS INC (2022-09-22),https://lens.org/181-855-567-456-701,Patent Application,yes,0,0,5,5,0,G06V20/698;;G06V10/454;;G06V10/25;;G06V10/82;;G06F18/41;;G06F18/2155;;G06F18/24143;;G06V10/7747;;G06V20/698;;G06V10/82;;G06V2201/03;;G06V10/764;;G06T7/0014;;G06T2207/20081;;G06T2207/20084;;G06T2207/30096;;G06V10/25;;G06V10/454,G06V20/69;;G06T7/00;;G06V10/22;;G06V10/764;;G06V10/774;;G06V10/82,,0,0,,,,PENDING
937,US,A1,US 2006/0052380 A1,045-895-619-093-435,2006-03-09,2006,US 54219405 A,2005-07-14,SE 0300120 A;;SE 2004000051 W,2003-01-17,Novel compounds,"The invention relates to thienopyridazinones of formula (I): wherein: R 1 is C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl which is optionally substituted by C 1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R 2 is C 1-6 alkyl; R 3 is a group CO-G or SO 2 -G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C 1-4 alkyl; Q is CR 5 R 6 where R 5 and R 6 are as defined in the specification; and R 4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",COOPER MARTIN E;;GUILE SIMON D;;INGALL ANTHONY H;;RASUL RUKHSANA T,COOPER MARTIN E;;GUILE SIMON D;;INGALL ANTHONY H;;RASUL RUKHSANA T,ASTRAZENECA AB (2005-06-16),https://lens.org/045-895-619-093-435,Patent Application,yes,1,7,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/503;;A61K31/50;;C07D/;;C07D495/04;;C07D498/02,514/248;;544/235,0,0,,,,EXPIRED
938,AU,A,AU 1998/076808 A,112-805-082-774-754,1998-12-30,1998,AU 1998/076808 A,1998-05-18,SE 9702001 A;;SE 9800935 W,1997-05-28,Novel compounds,,ASTRAZENECA AB,COOKE ANDREW;;COOPER MARTIN;;DONALD DAVID;;FURBER MARK;;PERRY MATTHEW;;THORNE PHILIP,ASTRAZENECA AB (2001-01-04),https://lens.org/112-805-082-774-754,Patent Application,no,0,0,45,49,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P31/00;;A61P31/18;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/505;;A61K31/513;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P31/00;;A61P31/18;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D/;;C07D239/00;;C07D333/00,,0,0,,,,EXPIRED
939,IS,B,IS 2503 B,169-947-775-476-33X,2009-04-15,2009,IS 7982 A,2005-08-15,SE 2004000051 W;;SE 0300120 A,2003-01-17,Ný efnasambönd,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,INGALL ANTHONY HOWARD;;COOPER MARTIN EDWARD;;RASUL RUKHSANA TASNEEM;;GUILE SIMON DAVID,,https://lens.org/169-947-775-476-33X,Granted Patent,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,EXPIRED
940,PL,A1,PL 378223 A1,043-091-835-350-129,2006-03-20,2006,PL 37822304 A,2004-01-15,SE 0300120 A,2003-01-17,NOVEL COMPOUNDS,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/043-091-835-350-129,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,PENDING
941,EP,A4,EP 0775391 A4,124-332-699-130-076,1999-04-14,1999,EP 95928217 A,1995-07-31,US 9509651 W;;US 28347094 A,1994-08-01,SPECTRALLY EFFICIENT AND HIGH CAPACITY ACKNOWLEDGMENT RADIO PAGING SYSTEM,,ARRAYCOMM INC,GOLDBURG MARC H;;ROY RICHARD H III;;COOPER MARTIN;;HARRIS ARLENE J,"ARRAYCOMM LLC (2007-09-26);;ARRAYCOMM, INC. (2000-09-06)",https://lens.org/124-332-699-130-076,Search Report,no,3,0,7,7,0,G01S5/12;;H01Q1/246;;H01Q3/2605;;H01Q3/267;;H04B7/04;;H04B7/0408;;H04B7/0491;;H04B7/0615;;H04B7/0697;;H04B7/0842;;H04B7/0845;;H04W16/28;;H04W64/00;;H04W84/025;;H04B17/309;;H04W84/025;;H04B7/0408;;G01S5/12;;H04B7/0842;;H04B7/0491;;H04B7/04;;H04B7/0845;;H04B7/0697;;H04B7/0615;;H01Q3/267;;H04W16/28;;H01Q3/2605;;H01Q1/246;;H04W64/00;;H04B17/309,G01S5/12;;H01Q1/24;;H01Q3/26;;H04B7/04;;H04B7/06;;H04B7/08;;H04B17/00;;H04W16/28;;H04W64/00;;H04W84/02,,2,0,,,"HARBIN S A ET AL: ""A LOW POWER WIRELESS MOBILE COMMUNICATIONS SYSTEM"", PROCEEDINGS OF THE VEHICULAR TECHNOLOGY CONFERENCE, STOCKHOLM, JUNE 8 - 10, 1994, vol. 1, no. CONF. 44, 8 June 1994 (1994-06-08), INSTITUTE OF ELECTRICAL AND ELECTRONICS ENGINEERS, pages 673 - 676, XP000496759;;See also references of WO 9604717A1",DISCONTINUED
942,AU,A1,AU 2004/205617 A1,004-804-993-006-705,2004-08-05,2004,AU 2004/205617 A,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,Novel compounds,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/004-804-993-006-705,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,EXPIRED
943,EP,A2,EP 1334133 A2,003-677-844-296-889,2003-08-13,2003,EP 01993626 A,2001-10-23,EP 0112226 W;;US 70935400 A,2000-11-13,METHOD FOR THE CONTINUOUS PRODUCTION OF POLYMER COMPOSITIONS AND THE USE THEREOF,"The present invention relates to a process for synthesis of polymer compositions, wherein ethylenically unsaturated monomers are polymerized by means of initiators containing a transferable atom or group of atoms and of one or more catalysts comprising at least one transition metal in the presence of ligands which can form a coordination compound with the metal catalyst or catalysts, the process being characterized in that the polymerization takes place by means of continuous process operation.",ROHMAX ADDITIVES GMBH,SCHERER MARKUS;;BOLLINGER JOSEPH MARTIN;;COOPER DAVID;;TILLERY LARRY STEPHEN;;WOODRUFF ROBERT,"EVONIK ROHMAX ADDITIVES GMBH (2009-12-01);;EVONIK OIL ADDITIVES GMBH, DE (2016-02-22);;EVONIK OIL ADDITIVES GMBH; DE (2016-04-22)",https://lens.org/003-677-844-296-889,Patent Application,yes,0,0,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F2/01;;C08F4/00;;C08F4/40;;C08F4/44,,0,0,,,,EXPIRED
944,WO,A2,WO 2002/038618 A2,014-316-783-617-460,2002-05-16,2002,EP 0112226 W,2001-10-23,US 70935400 A,2000-11-13,METHOD FOR THE CONTINUOUS PRODUCTION OF POLYMER COMPOSITIONS AND THE USE THEREOF,"The invention relates to a method for producing polymer compositions according to which ethylenically unsaturated monomers are polymerized in the presence of ligands that may form a coordination compound with the metal catalyst(s) by way of initiators that comprise a transferable group of atoms, and one or more catalysts that comprise at least one transition metal. The polymerization is characterized in that it is carried out continuously.",ROHMAX ADDITIVES GMBH,SCHERER MARKUS;;BOLLINGER JOSEPH MARTIN;;COOPER DAVID;;TILLERY LARRY STEPHEN;;WOODRUFF ROBERT,,https://lens.org/014-316-783-617-460,Patent Application,yes,0,5,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F4/00;;C08F4/40;;C08F2/01;;C08F4/44,,0,0,,,,PATENTED
945,EP,B1,EP 0024783 B1,036-511-125-080-085,1984-03-14,1984,EP 80301278 A,1980-04-21,US 6798979 A,1979-08-20,NUCLEAR REACTOR SHUTDOWN SYSTEM,,WESTINGHOUSE ELECTRIC CORPORATION,"BHATE, SURESH KRISHNAJI;;COOPER, MARTIN HOWARD;;RIFFE, DELMAR RAY;;KINNEY, CALVIN ENTZ",,https://lens.org/036-511-125-080-085,Granted Patent,yes,0,0,7,7,0,G21C7/12;;G21C9/027;;Y02E30/30;;G21C9/027;;G21C7/12;;Y02E30/30,G21C9/02;;G21C7/12;;G21C9/027,,0,0,,,,EXPIRED
946,US,B1,US 6185197 B1,047-015-834-546-630,2001-02-06,2001,US 97328398 A,1998-03-17,US 97328398 A;;GB 9510870 A;;GB 9511167 A;;GB 9511189 A;;GB 9511192 A;;US 9608659 W,1995-06-02,Control message transmission in telecommunications systems,A communications protocol interface is arranged at a central station of a telecommunications network and is responsive to a control message received from a network controller in accordance with a first message protocol to transmit the control message in accordance with a second message protocol to subscriber stations and is responsive to a control message received in accordance with the second message protocol to transmit the control message to the network controller in accordance with the first message protocol. The first message protocol is a balanced protocol with the communications protocol converter or the network controller able to initiate an exchange of information. The second message protocol is a master-slave protocol with the communications protocol interface acting as master. The second control message protocol operates over central station bus for communicating with at least one network element in the central station.,AIRSPAN NETWORKS INC,CHEUNG YEUNG JOEMANNE CHI;;THOMPSON JONATHAN A;;LYSEJKO MARTIN;;COOPER GUY A,AIRSPAN MERGER CORPORATION (1999-08-06);;AIRSPAN NETWORKS INC (1999-12-15);;DSC TELECOM L.P (1998-01-01);;AIRSPAN COMMUNICATIONS CORPORATION (1999-08-06),https://lens.org/047-015-834-546-630,Granted Patent,yes,7,70,1,251,0,H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B2201/70702;;H04L41/0226;;H04L41/0233;;H04L41/0681;;H04L41/22;;H04W52/52;;H04W84/14;;H04L41/22;;H04L41/0226;;H04L41/0233;;H04B2201/70702;;H04B1/70775;;H04L41/0681;;H04W52/52;;H04B1/707;;H04W84/14;;H04B1/70735;;H04B1/7077,H04B1/707;;H04B1/7073;;H04B1/7077;;H04B7/005;;H04J11/00;;H04L12/24;;H04L12/403;;H04L29/06;;H04W52/52;;H04W84/14,370/328;;370/401;;370/466,1,1,116-821-204-658-336,10.1109/49.46847,"Liba Svobodova, et al., ""Heterogeneity and OSI"", IEEE, Jan. 1990, vol. 8, No. 1, pp. 67-79.",EXPIRED
947,US,A1,US 2003/0036775 A1,033-960-799-788-180,2003-02-20,2003,US 15764502 A,2002-05-29,US 15764502 A;;US 18847198 A,1998-11-09,Carrying case for defibrillator,"
   A carrying case for external defibrillator having at least one surface-mounted operation features. The carrying case includes a main interior compartment that securely holds a defibrillator such that at least one of surface-mounted operational features of the defibrillator is accessible to the operator without removing the defibrillator from the carrying case. This enables the defibrillator to be used while held in said main interior compartment. At least one storage compartment is provided having an interior dimension adapted to hold at least one item associated with the defibrillator. The storage compartment has an associated aperture formed on an exterior of the carrying case such that the storage compartment is accessible from an exterior of the carrying case. 
",KONINKL PHILIPS ELECTRONICS NV,SALVATORI PHILLIP H;;MAIERS MARTIN JOHN;;COOPER STEPHEN V;;ANDREWS JONATHAN NEAL,,https://lens.org/033-960-799-788-180,Patent Application,yes,0,7,3,3,0,A61N1/3968;;A61N1/3968;;A61N1/3904;;A61N1/3904,A61N1/39,607/5,0,0,,,,EXPIRED
948,WO,A1,WO 2004/065393 A1,061-502-237-688-054,2004-08-05,2004,SE 2004000051 W,2004-01-15,SE 0300120 A,2003-01-17,NOVEL COMPOUNDS,"The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO-G or SO2-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C1-4 alkyl; Q is CR5R6 where R5 and R6 are as defined in the specification; and R4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB;;COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/061-502-237-688-054,Patent Application,yes,2,12,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,1,1,017-674-977-915-385,7728930;;10.1248/cpb.43.236,"YAMAGUCHI MASAHISA ET AL.: ""Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilatation.V.1' thienopyridazinone derivatives"", CHEM. PHARM. BULL., vol. 43, no. 2, 1995, pages 236 - 240, XP000941321",PATENTED
949,CA,A1,CA 2196068 A1,075-325-858-764-084,1996-02-15,1996,CA 2196068 A,1995-07-31,US 28347094 A,1994-08-01,SPECTRALLY EFFICIENT AND HIGH CAPACITY ACKNOWLEDGMENT RADIO PAGING SYSTEM,"An improved radio paging system providing automatic acknowledgment of message delivery, including a base station with a spatially directive reception means (19, 24 and 30) and a pager capable of transmitting acknowledgment signals. The spatially directive reception means (19, 24 and 30) at the base station enhances the reception quality of the acknowledgment signals transmitted by the pager over that obtainable with conventional omnidirectional reception means, thereby compensating for the disparity in the base station and pager transmission powers.",ARRAYCOMM INC,GOLDBURG MARC H;;ROY RICHARD H III;;COOPER MARTIN;;HARRIS ARLENE J,,https://lens.org/075-325-858-764-084,Patent Application,no,0,0,7,7,0,G01S5/12;;H01Q1/246;;H01Q3/2605;;H01Q3/267;;H04B7/04;;H04B7/0408;;H04B7/0491;;H04B7/0615;;H04B7/0697;;H04B7/0842;;H04B7/0845;;H04W16/28;;H04W64/00;;H04W84/025;;H04B17/309;;H04W84/025;;H04B7/0408;;G01S5/12;;H04B7/0842;;H04B7/0491;;H04B7/04;;H04B7/0845;;H04B7/0697;;H04B7/0615;;H01Q3/267;;H04W16/28;;H01Q3/2605;;H01Q1/246;;H04W64/00;;H04B17/309,G01S5/12;;H01Q1/24;;H01Q3/26;;H04B7/04;;H04B7/06;;H04B7/08;;H04B17/00;;H04W16/28;;H04W64/00;;H04W84/02,,0,0,,,,DISCONTINUED
950,GB,A,GB 2515871 A,076-397-139-732-966,2015-01-07,2015,GB 201407106 A,2014-04-22,GB 201307141 A,2013-04-19,Heating appliance,"The heater 10 comprises a heat source and a first heat exchanger arranged to heat a working fluid such as water passing through a housing (12, figure 3) of the heater. Ideally, a gas-fired condensing boiler 60 provides the heat source and first heat exchanger. A water-to-air heat exchanger 78 uses the heated water to heat a source of air. The heat source, first heat exchanger and water-to-air heat exchanger are mounted within the housing to provide a compact heater. The boiler is located above the water-to-air heat exchanger. Preferably the source of air is received via an air inlet 24 in a roof of the heater, and is drawn by a fan 76 along an air duct 56, through an air filter (40, figure 3), through an air guide 80 and into a box 82 of the water-to-air heat exchanger before exiting the heater via one or more air outlets, which can be connected to air ducts. The boiler may be mounted on an outer wall 72 of the duct by brackets 74 to reduce operational noise of the heater. Water may be passed through the housing via inflow 26 and outflow 28 pipes. Another heater is also claimed.",JOHNSON & STARLEY,DEE TOM;;WILLIAMS IAN;;JELLEY ADRIAN;;COOPER TIM;;WHITLOCK MARTIN;;PAGE GLEN,,https://lens.org/076-397-139-732-966,Patent Application,no,3,2,6,6,0,F24H6/00;;F24H6/00;;F24H6/00;;F24H9/0005,F24H6/00,,0,0,,,,DISCONTINUED
951,EP,B1,EP 1334133 B1,120-583-302-616-360,2006-05-03,2006,EP 01993626 A,2001-10-23,EP 0112226 W;;US 70935400 A,2000-11-13,METHOD FOR THE CONTINUOUS PRODUCTION OF POLYMER COMPOSITIONS AND THE USE THEREOF,"The present invention relates to a process for synthesis of polymer compositions, wherein ethylenically unsaturated monomers are polymerized by means of initiators containing a transferable atom or group of atoms and of one or more catalysts comprising at least one transition metal in the presence of ligands which can form a coordination compound with the metal catalyst or catalysts, the process being characterized in that the polymerization takes place by means of continuous process operation.",ROHMAX ADDITIVES GMBH,SCHERER MARKUS;;BOLLINGER JOSEPH MARTIN;;COOPER DAVID;;TILLERY LARRY STEPHEN;;WOODRUFF ROBERT,"EVONIK ROHMAX ADDITIVES GMBH (2009-12-01);;EVONIK OIL ADDITIVES GMBH, DE (2016-02-22);;EVONIK OIL ADDITIVES GMBH; DE (2016-04-22)",https://lens.org/120-583-302-616-360,Granted Patent,yes,1,0,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F2/01;;C08F4/00;;C08F4/40;;C08F4/44,,0,0,,,,EXPIRED
952,UA,C2,UA 80175 C2,176-556-932-231-922,2007-08-27,2007,UA 2005006375 A,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,"THIENOPYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE","The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6alkyl, C2-6alkenyl or C3-6cycloalkyl which is optionally substituted by C1-6alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6alkyl; R3 is a group CO-G or SO2-G where G is a 5- or 6-membcrcd ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C1-4alkyl; Q is CR5R6 where R5 and R6 are as defined in the specification; and R4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in thespecification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/176-556-932-231-922,Limited Patent,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,EXPIRED
953,DE,D1,DE 69812145 D1,015-214-345-521-978,2003-04-17,2003,DE 69812145 T,1998-11-12,EP 9807243 W;;US 97070697 A,1997-11-14,VERFAHREN UND ZUSAMMENSETZUNG ZUR HERSTELLUNG VON GEFÄRBTEN OPHTHALMISCHEN LINSEN,,NOVARTIS AG;;NOVARTIS PHARMA GMBH WIEN,LALLY MARTIN;;STOCKINGER FRIEDRICH;;COOPER LYNN;;MUELLER ACHIM;;MULCAHY JEAN;;SEIFERLING BERNHARD,,https://lens.org/015-214-345-521-978,Granted Patent,no,0,0,26,26,0,G02B1/043;;B29D11/00913;;B29D11/00038;;G02B1/043;;B29D11/00317;;C08L29/04,G02C7/04;;B29D11/00;;C08L29/04;;C08L29/14;;G02B1/04,,0,0,,,,EXPIRED
954,US,B2,US 7141232 B2,106-491-496-530-761,2006-11-28,2006,US 10749605 A,2005-04-14,US 10749605 A;;US 67131303 A,2003-09-24,Preparation of molecular sieves involving spray drying,"Molecular sieves are prepared by forming a reaction mixture slurry, spray drying the reaction mixture slurry to form particles, and heating the spray dried reaction mixture at a temperature and pressure sufficient to cause crystallization of the molecular sieve. The reaction mixture contains an organic templating agent capable of forming the molecular sieve. The template may be added to the reaction mixture either by adding all of the template prior to spray drying, or by adding a portion of the template prior to spray drying with the remainder being added after spray drying.",PQ CORP,MILLER STEPHEN J;;COOPER DAVID ALLEN;;WOLTERMANN GERALD MARTIN;;CORMIER WILLIAM EDWARD,ECOVYST CATALYST TECHNOLOGIES LLC (2021-07-29);;CHEVRON U.S.A. INC (2006-08-11);;PQ LLC (2021-07-30),https://lens.org/106-491-496-530-761,Granted Patent,yes,26,7,4,4,0,C01B39/40;;C01B39/40;;C01B37/02;;C01B37/02;;C01B39/48;;C01B39/48;;Y10S423/22;;Y10S423/22;;Y10S423/27;;Y10S423/27,C01B39/04;;B01J21/00;;B01J29/00;;B01J29/06;;B01J29/40;;C01B33/36;;C01B37/02;;C01B39/00;;C01B39/40;;C01B39/48;;C01F7/00,423/716;;423/709;;423/717;;X423DIG 22;;X423DIG 27;;502/60;;502/77,6,4,193-361-233-423-606;;062-911-070-827-342;;065-040-508-822-027;;137-910-630-181-290,10.1016/0144-2449(92)90028-n;;10.1016/0144-2449(90)90057-x;;10.1016/0144-2449(89)90040-7;;10.1038/317157a0,"Aiello et al., Materials Engineering, 1992, vol. 3, No. 3 pp. 407-416.;;Li et al., Zeolites, 1992, vol. 12, Apr./May. pp. 343-346.;;Wenyang et al., Zeolites, vol. 10, Nov./Dec. 1990, pp. 753-759.;;Webyang et al., Zeolites, vol. 9, Nov. 1989, vol. 9, pp. 468-473.;;Bibby et al., Nature, vol. 317(12), Sep. 1985, pp. 157-158.;;Qisheng et al., J. Chem., Soc., Chem. Commun., 1988, pp. 659.",EXPIRED
955,WO,A1,WO 2009/054970 A1,101-376-856-621-937,2009-04-30,2009,US 2008/0012015 W,2008-10-22,US 1207 P,2007-10-23,MESYLATE SALT OF AN IKK INHIBITOR,"The present invention is directed to the compound of formula (II), or a solvate thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (II), including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of a compound of formula (II), or crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.",MILLENNIUM PHARM INC;;HICKS FREDERICK A;;COOPER MARTIN IAN;;LANGSTON MARIANNE;;ST CLAIR BROWN ADRIAN,HICKS FREDERICK A;;COOPER MARTIN IAN;;LANGSTON MARIANNE;;ST CLAIR BROWN ADRIAN,,https://lens.org/101-376-856-621-937,Patent Application,yes,1,0,2,2,0,A61P29/00;;A61P35/00;;C07D471/04;;C07D471/04,C07D471/04;;A61K31/5377;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
956,US,A1,US 2005/0063901 A1,097-448-188-765-966,2005-03-24,2005,US 67131303 A,2003-09-24,US 67131303 A,2003-09-24,Preparation of molecular sieves involving spray drying,"Molecular sieves are prepared by forming a reaction mixture slurry, spray drying the reaction mixture slurry to form particles, and heating the spray dried reaction mixture at a temperature and pressure sufficient to cause crystallization of the molecular sieve. The reaction mixture contains an organic templating agent capable of forming the molecular sieve. The template may be added to the reaction mixture either by adding all of the template prior to spray drying, or by adding a portion of the template prior to spray drying with the remainder being added after spray drying.",MILLER STEPHEN J.;;COOPER DAVID ALLEN;;WOLTERMANN GERALD MARTIN;;CORMIER WILLIAM EDWARD,MILLER STEPHEN J;;COOPER DAVID ALLEN;;WOLTERMANN GERALD MARTIN;;CORMIER WILLIAM EDWARD,,https://lens.org/097-448-188-765-966,Patent Application,yes,20,10,4,4,0,C01B39/40;;C01B39/40;;C01B37/02;;C01B37/02;;C01B39/48;;C01B39/48;;Y10S423/22;;Y10S423/22;;Y10S423/27;;Y10S423/27,B01J21/00;;B01J29/00;;C01B33/36;;C01B37/02;;C01B39/00;;C01B39/40;;C01B39/48;;C01F7/00,423/709;;423/712;;423/716;;423/717;;X502 6;;502/77,0,0,,,,DISCONTINUED
957,DE,T2,DE 602004009407 T2,195-316-084-872-642,2008-07-24,2008,DE 602004009407 T,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,THIENOPYRIDAZINON-DERIVATE ALS MODULATOREN VON AUTOIMMUNKRANKHEITEN,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN E;;GUILE SIMON D;;INGALL ANTHONY H;;RASUL RUKHSANA T,,https://lens.org/195-316-084-872-642,Granted Patent,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,EXPIRED
958,CN,A,CN 114902297 A,002-018-197-362-329,2022-08-12,2022,CN 202080090113 A,2020-10-19,US 201962929100 P;;US 2020/0056340 W,2019-10-31,Image processing-based object classification using bootstrapping of region-level annotations,"The present technology relates to object classification using bootstrapping of region-level annotations. For each image of a plurality of images, a region within the image may be identified. For each region, a region-specific tag may be identified, a set of objects within the region may be detected, and an object-specific tag may be assigned to each object. The object-specific tag may be the same as the region-specific tag assigned to the region in which the object is located. For each image of the plurality of images, a training data set may be defined to include object position data (indicating intra-image position data for a detected object) and tag data (indicating the object-specific tag assigned to the object). An image processing model may be trained using the training data. The training may include learning values of a set of parameters defining calculations performed by the image processing model.",VENTANA MED SYST INC,TIEGELDING MARK A;;COOPER LEONARD A D;;KOCUR UDO;;MARTIN JAMES F,,https://lens.org/002-018-197-362-329,Patent Application,no,0,0,5,5,0,G06V20/698;;G06V10/454;;G06V10/25;;G06V10/82;;G06F18/41;;G06F18/2155;;G06F18/24143;;G06V10/7747;;G06V20/698;;G06V10/82;;G06V2201/03;;G06V10/764;;G06T7/0014;;G06T2207/20081;;G06T2207/20084;;G06T2207/30096;;G06V10/25;;G06V10/454,G06V20/69;;G06K9/62;;G06N3/08;;G06V10/25;;G06V10/44;;G06V10/764;;G06V10/774;;G06V10/778;;G06V10/82,,0,0,,,,PENDING
959,AT,T1,AT E325137 T1,046-085-034-828-75X,2006-06-15,2006,AT 01993626 T,2001-10-23,US 70935400 A,2000-11-13,VERFAHREN ZUR KONTINUIERLICHEN HERSTELLUNG VON POLYMERZUSAMMENSETZUNGEN SOWIE VERWENDUNG,"The present invention relates to a process for synthesis of polymer compositions, wherein ethylenically unsaturated monomers are polymerized by means of initiators containing a transferable atom or group of atoms and of one or more catalysts comprising at least one transition metal in the presence of ligands which can form a coordination compound with the metal catalyst or catalysts, the process being characterized in that the polymerization takes place by means of continuous process operation.",ROHMAX ADDITIVES GMBH,SCHERER MARKUS;;BOLLINGER JOSEPH MARTIN;;COOPER DAVID;;TILLERY LARRY STEPHEN;;WOODRUFF ROBERT,,https://lens.org/046-085-034-828-75X,Granted Patent,no,0,0,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F2/01;;C08F4/00;;C08F4/40;;C08F4/44,,0,0,,,,EXPIRED
960,US,S,US D0426955 S,048-433-280-660-623,2000-06-27,2000,US 10119699 F,1999-02-26,US 10119699 F,1999-02-26,Carrying case,,HEWLETT PACKARD CO,SALVATORI PHILLIP H;;MAIERS MARTIN JOHN;;COOPER STEPHEN V;;ANDREWS JONATHAN NEAL,HEWLETT-PACKARD COMPANY (1998-05-20);;NEWLETT-PACKARD COMPANY (1999-04-28);;AGILENT TECHNOLOGIES INC (1999-11-01);;KONINKLIJKE PHILIPS ELECTRONICS N.V (2001-08-01),https://lens.org/048-433-280-660-623,Design Right,yes,12,4,1,1,0,,,D 3301;;0301,0,0,,,,EXPIRED
961,EP,A2,EP 0069291 A2,092-505-724-038-110,1983-01-12,1983,EP 82105598 A,1982-06-25,DE 3126021 A,1981-07-02,Process for preparing optically pure D- or L-lactic acid.,"Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung optisch reiner D- oder L-Milchsäure durch Fermentation eines wäßrigen Nährmediums, weiches Stickstoff, Vitamine, Aminosäuren, Zucker und Spurenelemente enthält, mit Hilfe eines Mikroorganismus bei pH 4 bis 6, welches dadurch gekennzeichnet ist, daß das Nährmedium als Quelle für Stickstoff Vitamine, Aminosäuren und Spurenelemente Bierhefe enthält.",BASF AG,COOPER BRYAN DR;;KUESTERS WERNER DR;;MARTIN CHRISTOPH DR;;SIEGEL HARDO DR,,https://lens.org/092-505-724-038-110,Patent Application,yes,0,4,15,15,0,C12N1/38;;C12P7/56;;Y10S435/853;;Y10S435/856;;Y10S435/94;;Y10S435/835;;C12P7/56;;C12N1/38;;Y10S435/853;;Y10S435/856;;Y10S435/835;;Y10S435/94,C12N1/20;;C12N1/38;;C12P7/56;;C12R1/865,,0,0,,,,EXPIRED
962,IS,A,IS 7982 A,099-432-458-767-811,2005-08-15,2005,IS 7982 A,2005-08-15,SE 2004000051 W;;SE 0300120 A,2003-01-17,Ný efnasambönd,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/099-432-458-767-811,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,EXPIRED
963,US,B2,US 7064126 B2,149-599-465-899-886,2006-06-20,2006,US 54219405 A,2005-07-14,SE 0300120 A;;SE 2004000051 W,2003-01-17,Compounds,"The invention relates to thienopyridazinones of formula (I): wherein: R 1 is C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl which is optionally substituted by C 1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R 2 is C 1-6 alkyl; R 3 is a group CO—G or SO 2 —G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C 1-4 alkyl; Q is CR 5 R 6 where R 5 and R 6 are as defined in the specification; and R 4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,ASTRAZENECA AB (2005-06-16),https://lens.org/149-599-465-899-886,Granted Patent,yes,8,17,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;A61K31/5025;;C07D/,514/248;;544/235,1,1,017-674-977-915-385,7728930;;10.1248/cpb.43.236,"Yamaguchi et al., ""Novel Antiasthmatic Agents with Dual Activities of Thromboxane A<SUB>2 </SUB>Synthetase Inhibition and Bronchodilation. V.<SUP>1)</SUP>Thienopyridazinone Derivatives"", Chem. Pharm. Bull. 43(2):236-240 (1995).",EXPIRED
964,US,A,US 5625880 A,002-237-904-957-824,1997-04-29,1997,US 28347094 A,1994-08-01,US 28347094 A;;US 80669591 A,1991-12-12,Spectrally efficient and high capacity acknowledgement radio paging system,"An improved radio paging system providing automatic acknowledgment of message delivery, including a base station with spatially directive reception means and a pager capable of transmitting acknowledgment signals. The spatially directive reception means at the base station enhances the reception quality of the acknowledgment signals transmitted by the pager over that obtainable with conventional omnidirectional reception means, thereby compensating for the disparity in the base station and pager transmission powers.",ARRAYCOMM INC,GOLDBURG MARC H;;ROY III RICHARD H;;COOPER MARTIN;;HARRIS ARLENE J,ARRAYCOMM LLC (2005-11-16);;INTEL CORPORATION (2008-10-02),https://lens.org/002-237-904-957-824,Granted Patent,yes,14,84,7,7,0,G01S5/12;;H01Q1/246;;H01Q3/2605;;H01Q3/267;;H04B7/04;;H04B7/0408;;H04B7/0491;;H04B7/0615;;H04B7/0697;;H04B7/0842;;H04B7/0845;;H04W16/28;;H04W64/00;;H04W84/025;;H04B17/309;;H04W84/025;;H04B7/0408;;G01S5/12;;H04B7/0842;;H04B7/0491;;H04B7/04;;H04B7/0845;;H04B7/0697;;H04B7/0615;;H01Q3/267;;H04W16/28;;H01Q3/2605;;H01Q1/246;;H04W64/00;;H04B17/309,G01S5/12;;H01Q1/24;;H01Q3/26;;H04B7/04;;H04B7/06;;H04B7/08;;H04B17/00;;H04W16/28;;H04W64/00;;H04W84/02,455/38.1;;455/53.1;;455/51.1,1,1,166-149-774-256-09X,10.1109/acssc.1991.186515,"Friedlander et al., Direction Finding for Wideband Signals Using an Interpolated Array, 1991, IEEE 1058 6393/91, pp. 583 587.",EXPIRED
965,CN,C,CN 100358900 C,000-143-509-485-388,2008-01-02,2008,CN 200480007101 A,2004-01-15,SE 0300120 A,2003-01-17,Novel compounds,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,EDWARD COOPER MARTIN;;DAVID GUILE SIMON;;HOWARD INGALL ANTHONY;;TASNEEM RASUL RUKHSANA,,https://lens.org/000-143-509-485-388,Granted Patent,no,2,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,EXPIRED
966,IL,A,IL 169363 A,046-154-433-332-942,2011-02-28,2011,IL 16936305 A,2005-06-23,SE 0300120 A;;SE 2004000051 W,2003-01-17,"THIENOPYRIDAZINONES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS","The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM;;GUILE SIMON DAVID;;COOPER MARTIN EDWARD,INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM;;GUILE SIMON DAVID;;COOPER MARTIN EDWARD,,https://lens.org/046-154-433-332-942,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,EXPIRED
967,EP,A2,EP 0024783 A2,074-648-106-489-796,1981-03-11,1981,EP 80301278 A,1980-04-21,US 6798979 A,1979-08-20,Nuclear reactor shutdown system.,"A nuclear reactor shutdown system having neutron absorbing rods (68) affixed to an armature (54) which is held in an upper position by a magnetic flux flowing through a Curie temperature material (84). The Curie temperature material (84) is fixedly positioned about the exterior of duct (36) in an annular region through which reactor coolant flows. Upon abnormal conditions which result in high neutron flux and coolant temperature, the Curie material loses its magnetic permeability, breaking the magnetic flux path and allowing the armature and absorber rods to drop into the core, thus shutting down the fissioning reaction. The armature and absorber rods are retrieved by lowering the housing for the electromagnet forming coils which create a magnetic flux path which includes the inner duct wall. The coil housing then is raised, resetting the armature.",WESTINGHOUSE ELECTRIC CORP,BHATE SURESH KRISHNAJI;;COOPER MARTIN HOWARD;;RIFFE DELMAR RAY;;KINNEY CALVIN ENTZ,,https://lens.org/074-648-106-489-796,Patent Application,yes,0,3,7,7,0,G21C7/12;;G21C9/027;;Y02E30/30;;G21C9/027;;G21C7/12;;Y02E30/30,G21C9/02;;G21C7/12;;G21C9/027,,0,0,,,,EXPIRED
968,ZA,B,ZA 964148 B,083-582-038-333-999,1996-12-03,1996,ZA 964148 A,1996-05-23,GB 9511167 A,1995-06-02,Control message transmission in telecommunications systems,,DSC COMMUNICATIONS,YEUNG JOEMANN CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,,https://lens.org/083-582-038-333-999,Granted Patent,no,0,0,7,251,0,H04B1/70735;;H04B1/7075;;H04B1/7077;;H04B1/70775;;H04L41/0226;;H04L41/0233;;H04L41/069;;H04W84/14;;H04L69/324;;H04B1/7075;;H04B1/70775;;H04L41/0226;;H04L41/069;;H04W84/14;;H04B1/70735;;H04L41/0233;;H04B1/7077;;H04L69/324,H04B1/707;;H04L12/24;;H04L29/06;;H04L29/08;;H04W84/14,,0,0,,,,EXPIRED
969,US,B2,US 6609026 B2,110-103-044-994-343,2003-08-19,2003,US 15764502 A,2002-05-29,US 15764502 A;;US 18847198 A,1998-11-09,Carrying case for defibrillator,"
    A carrying case for external defibrillator having at least one surface-mounted operation features. The carrying case includes a main interior compartment that securely holds a defibrillator such that at least one of surface-mounted operational features of the defibrillator is accessible to the operator without removing the defibrillator from the carrying case. This enables the defibrillator to be used while held in said main interior compartment. At least one storage compartment is provided having an interior dimension adapted to hold at least one item associated with the defibrillator. The storage compartment has an associated aperture formed on an exterior of the carrying case such that the storage compartment is accessible from an exterior of the carrying case. 
",KONINKL PHILIPS ELECTRONICS NV,SALVATORI PHILLIP H;;MAIERS MARTIN JOHN;;COOPER STEPHEN V;;ANDREWS JONATHAN NEAL,,https://lens.org/110-103-044-994-343,Granted Patent,yes,4,5,3,3,0,A61N1/3968;;A61N1/3968;;A61N1/3904;;A61N1/3904,A61N1/39,607/5;;312/213;;206/320,0,0,,,,EXPIRED
970,AT,T1,AT E375352 T1,134-585-033-802-25X,2007-10-15,2007,AT 04702471 T,2004-01-15,SE 0300120 A,2003-01-17,THIENOPYRIDAZINON-DERIVATE ALS MODULATOREN VON AUTOIMMUNKRANKHEITEN,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN E;;GUILE SIMON D;;INGALL ANTHONY H;;RASUL RUKHSANA T,,https://lens.org/134-585-033-802-25X,Granted Patent,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,EXPIRED
971,AU,A,AU 2002/021727 A,177-877-877-422-016,2002-05-21,2002,AU 2002/021727 A,2001-10-23,EP 0112226 W;;US 70935400 A,2000-11-13,Method for the continuous production of polymer compositions and the use thereof,"The present invention relates to a process for synthesis of polymer compositions, wherein ethylenically unsaturated monomers are polymerized by means of initiators containing a transferable atom or group of atoms and of one or more catalysts comprising at least one transition metal in the presence of ligands which can form a coordination compound with the metal catalyst or catalysts, the process being characterized in that the polymerization takes place by means of continuous process operation.",ROHMAX ADDITIVES GMBH,SCHERER MARKUS;;BOLLINGER JOSEPH MARTIN;;COOPER DAVID;;TILLERY LARRY STEPHEN;;WOODRUFF ROBERT,,https://lens.org/177-877-877-422-016,Patent Application,no,0,0,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F2/01;;C08F4/00;;C08F4/40;;C08F4/44,,0,0,,,,PENDING
972,EP,A1,EP 0830775 A1,194-085-077-412-742,1998-03-25,1998,EP 96918014 A,1996-06-03,GB 9511167 A;;GB 9510870 A;;GB 9511192 A;;GB 9511189 A;;US 9608659 W,1995-06-02,CONTROL MESSAGE TRANSMISSION IN TELECOMMUNICATIONS SYSTEMS,,DSC COMMUNICATIONS,YEUNG JOEMANNE CHI CHEUNG;;THOMPSON JONATHAN ANDREW;;LYSEJKO MARTIN;;COOPER GUY ALEXANDER,AIRSPAN NETWORKS INC. (2000-10-18);;AIRSPAN COMMUNICATIONS CORPORATION (1998-12-30),https://lens.org/194-085-077-412-742,Patent Application,yes,0,41,8,251,0,H04B1/707;;H04B1/70735;;H04B1/7077;;H04B1/70775;;H04B7/2628;;H04B2201/70702;;H04L12/403;;H04L41/0226;;H04L41/0233;;H04L41/0654;;H04L41/0677;;H04L41/069;;H04L41/22;;H04L63/08;;H04Q2213/1305;;H04Q2213/13093;;H04Q2213/13098;;H04Q2213/13109;;H04Q2213/13199;;H04Q2213/13216;;H04Q2213/13298;;H04Q2213/13299;;H04Q2213/13335;;H04Q2213/13376;;H04W52/04;;H04W52/52;;H04W84/14;;H04L69/08;;H04L69/32;;H04B1/7073;;H04L69/08;;H04L69/32,H04B1/707;;H04B7/005;;H04B7/26;;H04J11/00;;H04L12/24;;H04L12/28;;H04L12/403;;H04L29/06;;H04L29/08;;H04W52/04;;H04W52/52;;H04W84/14,,0,0,,,,EXPIRED
973,BR,A,BR PI0406780 A,009-657-991-285-979,2006-01-17,2006,BR PI0406780 A,2004-01-15,SE 0300120 A;;SE 2004000051 W,2003-01-17,Novos compostos,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/009-657-991-285-979,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,A61K31/50;;C07D/;;C07D495/04,,0,0,,,,DISCONTINUED
974,HK,A1,HK 1081958 A1,035-602-772-093-066,2006-05-26,2006,HK 06102160 A,2006-02-17,SE 0300120 A;;SE 2004000051 W,2003-01-17,Thienopyridazinone derivative as modulators of autoimmune diseases,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN EDWARD;;GUILE SIMON DAVID;;INGALL ANTHONY HOWARD;;RASUL RUKHSANA TASNEEM,,https://lens.org/035-602-772-093-066,Patent Application,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D/;;A61K/;;A61K31/50;;C07D495/04,,0,0,,,,DISCONTINUED
975,AU,A,AU 1998/068611 A,097-875-223-744-308,1998-10-22,1998,AU 1998/068611 A,1998-03-27,SE 9701194 A;;SE 9702200 A;;SE 9704402 A;;SE 9800575 W,1997-04-01,Novel pyridine derivatives and pharmaceutical compositions containing them,,ASTRA PHARMA PROD,CLADINGBOEL DAVID;;COOPER MARTIN;;HARDERN DAVID;;HIRST SIMON;;MANNERS CAROL;;STOCKS MICHAEL,,https://lens.org/097-875-223-744-308,Patent Application,no,0,0,26,30,0,C07D213/30;;C07D213/64;;C07D213/85;;C07D401/12;;C07D405/06;;C07D405/12;;C07D409/12;;C07D413/12;;A61P11/06;;A61P29/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D213/30;;C07D213/63;;C07D213/85;;C07D401/12;;C07D405/06;;C07D405/12;;C07D409/12;;C07D413/12;;C07D213/30;;C07D401/12;;C07D413/12;;C07D405/06;;C07D213/85;;C07D405/12;;C07D213/64;;C07D409/12,A61K31/4402;;A61P11/06;;A61P29/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D213/30;;C07D213/64;;C07D213/85;;C07D401/12;;C07D405/06;;C07D405/12;;C07D409/12;;C07D413/12,,0,0,,,,DISCONTINUED
976,EP,A1,EP 4052172 A1,173-108-814-328-186,2022-09-07,2022,EP 20807184 A,2020-10-19,US 201962929100 P;;US 2020/0056340 W,2019-10-31,IMAGE-PROCESSING-BASED OBJECT CLASSIFICATION USING BOOTSTRAPPING OF REGION-LEVEL ANNOTATIONS,,VENTANA MED SYST INC,TAGELDIN MOHAMED AMGAD;;COOPER LEE ALEX DONALD;;KURKURE UDAY;;MARTIN JIM F,,https://lens.org/173-108-814-328-186,Patent Application,yes,0,0,5,5,0,G06V20/698;;G06V10/454;;G06V10/25;;G06V10/82;;G06F18/41;;G06F18/2155;;G06F18/24143;;G06V10/7747;;G06V20/698;;G06V10/82;;G06V2201/03;;G06V10/764;;G06T7/0014;;G06T2207/20081;;G06T2207/20084;;G06T2207/30096;;G06V10/25;;G06V10/454,G06K9/00;;G06K9/62,,0,0,,,,PENDING
977,ES,T3,ES 2184270 T3,184-694-973-503-600,2003-04-01,2003,ES 98924705 T,1998-05-18,SE 9702001 A,1997-05-28,NUEVOS COMPUESTOS.,"La invención se refiere a nuevos compuestos de fórmula (I), en la que R, R1, R2 y R3 tienen el significado dado en la descripción. El compuesto (I) es útil en el tratamiento (profiláctico) de enfermedades autoinmunes, inflamatorias, proliferantes e hiperproliferantes y enfermedades inmunológicamente inducidas incluyendo el rechazo de órganos o tejidos transplantados y el síndrome de inmunodeficiencia adquirido (SIDA).",ASTRAZENECA AB,CHESHIRE DAVID;;COOKE ANDREW;;COOPER MARTIN;;DONALD DAVID;;FURBER MARK;;PERRY MATTHEW,,https://lens.org/184-694-973-503-600,Granted Patent,no,0,0,45,49,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P31/00;;A61P31/18;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/10;;C07D495/04;;C07D495/04,A61K31/505;;A61K31/513;;C07D495/04;;A61K31/519;;A61P1/00;;A61P1/04;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P31/00;;A61P31/18;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07D/;;C07D239/00;;C07D333/00,,0,0,,,,EXPIRED
978,ES,T3,ES 2159943 T3,006-279-496-671-915,2001-10-16,2001,ES 98914202 T,1998-03-27,SE 9701194 A;;SE 9702200 A;;SE 9704402 A,1997-04-01,NEUVOS DERIVADOS DE PIRIDINA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.,"Un compuesto de fórmula I: en la cual: X esO,SoCH2; R 1 y R 2 son independientemente hidrógeno, alquilo C1-6 o cicloalquilo C3-6, oR 1 y R 2 junto con el átomo de carbono al que están unidos forman un grupo cicloalquilo C3-6; Ar 1 es un sistema bicíclico de anillos condensados que contiene uno o más heteroátomos, un sistema tricíclico de anillos condensados que contiene opcionalmente un átomo de oxígeno, o Ar 1 es un grupo R 3 -R 4 en el cual uno de R 3 /R 4 es un anillo de fenilo y el otro es un anillo heterocíclico de 5 ó 6 miembros que contiene uno o más heteroátomos, estando cada grupo Ar 1 sustituido opcionalmente con halo, nitro, alquilo C1-6 (sustituido opcionalmente con uno o más átomos de úor) CN, -Y-NR 6 C(O)NR 7 R 8 , -O-Y-C(O) NR 7 R 8 , -O-Y-C(S)NR 7 R 8 , -Y-C(O)NR 7 R 8 , -Y-C(S)NR 7 R 8 , -Y-SO2NR 7 R 8 , -Y-NR 7 R 8 , SO2NR 7 R 8 , C(O)NR 7 ,R 8 , C(S)NR 7 R 8 , C(O)R 9 , -OC(O)R 9 , -Y-OR 9 , -Y-CO2R 9 , -Y-NR 10 C(O)NR 11 -ZR 12 , SO2NR 10 C(O)NR 7 R 8 , -Y-SOsNHR 7 R 8 ,-Y-C(O)NR 11 -Z-R 12 , -Y-C(S)NR 11 -Z-R 12 , N(R 10 )SO2R 11 , N(R 10 )C(O)R 11 o N(R 10 )CO2R 11 donde: Y es un enlace, alquileno C1-6 o alquenileno C2-6; R 7 y R 8 son independientemente hidrógeno o alquilo C1-6 o, junto con el átomo de nitrógeno al cual están unidos, forman un anillo heterocíclico de 5 a 7 miembros opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional seleccionado de nitrógeno, oxígeno o azufre; R 5 , R 6 , R 9 , R 10 y R 11 son independientemente hidrógeno o alquilo C1-10 (sustituido opcionalmente con uno o más átomos de fluor); Z es alquileno C1-6; y R 12 es un grupo NR 10 C(O)R 11 , NR 10 CO2R 11 , OR 5 , NR 7 R 8 o CO2R 13 donde R 5 , R 7 , R 8 , R 10 y R 11 son como se define anteriormente y R 13 es hidrógeno, alquilo C1-6, alquilC1-6-arilo o arilo sustituido opcionalmente con hidroxi, o una sal o solvato de aquél.",ASTRAZENECA AB,CHESHIRE DAVID;;CLADINGBOEL DAVID;;COOPER MARTIN;;HARDERN DAVID;;HIRST SIMON;;MANNERS CAROL,,https://lens.org/006-279-496-671-915,Granted Patent,no,0,0,26,30,0,C07D213/30;;C07D213/64;;C07D213/85;;C07D401/12;;C07D405/06;;C07D405/12;;C07D409/12;;C07D413/12;;A61P11/06;;A61P29/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D213/30;;C07D213/63;;C07D213/85;;C07D401/12;;C07D405/06;;C07D405/12;;C07D409/12;;C07D413/12;;C07D213/30;;C07D401/12;;C07D413/12;;C07D405/06;;C07D213/85;;C07D405/12;;C07D213/64;;C07D409/12,A61K31/4402;;A61P11/06;;A61P29/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D213/30;;C07D213/64;;C07D213/85;;C07D401/12;;C07D405/06;;C07D405/12;;C07D409/12;;C07D413/12,,0,0,,,,EXPIRED
979,ES,T3,ES 2293208 T3,038-243-505-888-515,2008-03-16,2008,ES 04702471 T,2004-01-15,SE 0300120 A,2003-01-17,DERIVADOS DE TIENOPIRIDAZINONA COMO MODULADORES DE ENFERMEDADES AUTOINMUNES.,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN E;;GUILE SIMON D;;INGALL ANTHONY H;;RASUL RUKHSANA T,,https://lens.org/038-243-505-888-515,Granted Patent,no,0,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,0,0,,,,EXPIRED
980,EP,A3,EP 0024783 A3,069-606-643-751-992,1981-03-18,1981,EP 80301278 A,1980-04-21,US 6798979 A,1979-08-20,NUCLEAR REACTOR SHUTDOWN SYSTEM,"A nuclear reactor shutdown system having neutron absorbing rods (68) affixed to an armature (54) which is held in an upper position by a magnetic flux flowing through a Curie temperature material (84). The Curie temperature material (84) is fixedly positioned about the exterior of duct (36) in an annular region through which reactor coolant flows. Upon abnormal conditions which result in high neutron flux and coolant temperature, the Curie material loses its magnetic permeability, breaking the magnetic flux path and allowing the armature and absorber rods to drop into the core, thus shutting down the fissioning reaction. The armature and absorber rods are retrieved by lowering the housing for the electromagnet forming coils which create a magnetic flux path which includes the inner duct wall. The coil housing then is raised, resetting the armature.",WESTINGHOUSE ELECTRIC CORPORATION,"BHATE, SURESH KRISHNAJI;;COOPER, MARTIN HOWARD;;RIFFE, DELMAR RAY;;KINNEY, CALVIN ENTZ",,https://lens.org/069-606-643-751-992,Search Report,yes,3,0,7,7,0,G21C7/12;;G21C9/027;;Y02E30/30;;G21C9/027;;G21C7/12;;Y02E30/30,G21C9/02;;G21C7/12;;G21C9/027,,1,1,028-449-253-985-263,10.1109/tns.1977.4328809,"IEEE TRANSACTIONS ON NUCLEAR SCIENCE, vol. NS-24, no. 2, April 1977, pages 919-930, New York, U.S.A., J. JOSEPHSON et al.: ""The design and testing of a self-actuated shut down system for the protection of liquid metal fast breeder reactors (LMFBRs)"".",EXPIRED
981,WO,A1,WO 2005/030644 A1,083-340-328-006-740,2005-04-07,2005,US 2004/0031156 W,2004-09-22,US 67131303 A,2003-09-24,PREPARTION OF MOLECULAR SIEVES INVOLVING SPRAY DRYING,"Molecular sieves are prepared by forming a reaction mixture slurry, spray drying the reaction mixture slurry to form particles, and heating the spray dried reaction mixture at a temperature and pressure sufficient to cause crystallization of the molecular sieve. The reaction mixture contains an organic templating agent capable of forming the molecular sieve. The template may be added to the reaction mixture either by adding all of the template prior to spray drying, or by adding a portion of the template prior to spray drying with the remainder being added after spray drying.",CHEVRON USA INC;;PQ CORP;;MILLER STEPHEN J;;COOPER DAVID ALLEN;;WOLTERMANN GERALD MARTIN;;CORMIER WILLIAM EDWARD,MILLER STEPHEN J;;COOPER DAVID ALLEN;;WOLTERMANN GERALD MARTIN;;CORMIER WILLIAM EDWARD,,https://lens.org/083-340-328-006-740,Patent Application,yes,1,0,4,4,0,C01B39/40;;C01B39/40;;C01B37/02;;C01B37/02;;C01B39/48;;C01B39/48;;Y10S423/22;;Y10S423/22;;Y10S423/27;;Y10S423/27,B01J21/00;;B01J29/00;;C01B33/36;;C01B37/02;;C01B39/00;;C01B39/40;;C01B39/48;;C01F7/00,,0,0,,,,PENDING
982,WO,A3,WO 2002/038618 A3,083-949-513-147-449,2002-09-19,2002,EP 0112226 W,2001-10-23,US 70935400 A,2000-11-13,METHOD FOR THE CONTINUOUS PRODUCTION OF POLYMER COMPOSITIONS AND THE USE THEREOF,"The invention relates to a method for producing polymer compositions according to which ethylenically unsaturated monomers are polymerized in the presence of ligands that may form a coordination compound with the metal catalyst(s) by way of initiators that comprise a transferable group of atoms, and one or more catalysts that comprise at least one transition metal. The polymerization is characterized in that it is carried out continuously.",ROHMAX ADDITIVES GMBH,SCHERER MARKUS;;BOLLINGER JOSEPH MARTIN;;COOPER DAVID;;TILLERY LARRY STEPHEN;;WOODRUFF ROBERT,,https://lens.org/083-949-513-147-449,Search Report,yes,1,0,18,18,0,C08F4/00;;C08F2/04;;C08F4/00,C08F4/00;;C08F2/01;;C08F4/40;;C08F4/44,,0,0,,,,PATENTED
983,EP,B1,EP 1587809 B1,103-016-938-652-212,2007-10-10,2007,EP 04702471 A,2004-01-15,SE 2004000051 W;;SE 0300120 A,2003-01-17,THIENOPYRIDAZINONE DERIVATIVE AS MODULATORS OF AUTOIMMUNE DISEASES,"The invention relates to thienopyridazinones of formula (I): wherein: R<SUP>1 </SUP>is C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl or C<SUB>3-6 </SUB>cycloalkyl which is optionally substituted by C<SUB>1-6 </SUB>alkyl, each of the above being optionally substituted by one or more halogen atoms; R<SUP>2 </SUP>is C<SUB>1-6 </SUB>alkyl; R<SUP>3 </SUP>is a group CO-G or SO<SUB>2</SUB>-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C<SUB>1-4 </SUB>alkyl; Q is CR<SUP>5</SUP>R<SUP>6 </SUP>where R<SUP>5 </SUP>and R<SUP>6 </SUP>are as defined in the specification; and R<SUP>4 </SUP>is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.",ASTRAZENECA AB,COOPER MARTIN E;;GUILE SIMON D;;INGALL ANTHONY H;;RASUL RUKHSANA T,,https://lens.org/103-016-938-652-212,Granted Patent,yes,2,0,34,34,0,C07D495/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/08;;A61P21/04;;A61P25/00;;A61P25/04;;A61P27/14;;A61P29/00;;A61P3/04;;A61P31/08;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/50;;C07D/,,1,0,,,"YAMAGUCHI MASAHISA ET AL.: 'Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilatation.V.1' thienopyridazinone derivatives' CHEM. PHARM. BULL. vol. 43, no. 2, 1995, pages 236 - 240, XP000941321",EXPIRED
984,DE,T2,DE 69812145 T2,159-905-226-833-535,2003-12-11,2003,DE 69812145 T,1998-11-12,EP 9807243 W;;US 97070697 A,1997-11-14,VERFAHREN UND ZUSAMMENSETZUNG ZUR HERSTELLUNG VON GEFÄRBTEN OPHTHALMISCHEN LINSEN,,NOVARTIS AG;;NOVARTIS PHARMA GMBH WIEN,LALLY MARTIN;;STOCKINGER FRIEDRICH;;COOPER LYNN;;MUELLER ACHIM;;MULCAHY JEAN;;SEIFERLING BERNHARD,,https://lens.org/159-905-226-833-535,Granted Patent,no,0,0,26,26,0,G02B1/043;;B29D11/00913;;B29D11/00038;;G02B1/043;;B29D11/00317;;C08L29/04,G02C7/04;;B29D11/00;;C08L29/04;;C08L29/14;;G02B1/04,,0,0,,,,EXPIRED
985,DE,D1,DE 3066920 D1,151-514-737-403-431,1984-04-19,1984,DE 3066920 T,1980-04-21,US 6798979 A,1979-08-20,NUCLEAR REACTOR SHUTDOWN SYSTEM,,WESTINGHOUSE ELECTRIC CORP,BHATE SURESH KRISHNAJI;;COOPER MARTIN HOWARD;;RIFFE DELMAR RAY;;KINNEY CALVIN ENTZ,,https://lens.org/151-514-737-403-431,Granted Patent,no,0,0,7,7,0,G21C7/12;;G21C9/027;;Y02E30/30;;G21C9/027;;G21C7/12;;Y02E30/30,G21C9/02;;G21C7/12;;G21C9/027,,0,0,,,,EXPIRED
986,WO,A1,WO 2020/254558 A1,094-133-643-557-726,2020-12-24,2020,EP 2020067070 W,2020-06-19,US 201962863487 P;;EP 19183622 A,2019-06-19,5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS,"The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC-1 ion channel.",NMD PHARMA AS,KNUTSEN LARS;;BROCH-LIPS MARTIN;;COOPER MARTIN;;PEDERSEN THOMAS;;DUDEKULA DASTAGIRI;;SARASWAT NEERJA;;TAJ RAFIQ;;LABELLE MARC,,https://lens.org/094-133-643-557-726,Patent Application,yes,0,0,5,5,0,A61P21/00;;A61P21/02;;A61P21/04;;C07C261/04;;C07C311/51;;C07D207/12;;C07D257/04;;C07D261/08;;C07D285/08;;C07D271/06;;C07D249/08;;A61P21/04;;A61P21/02;;C07C261/04;;C07C311/51;;C07D207/12;;C07D249/08;;C07D257/04;;C07D261/08;;C07D271/06;;C07D285/08,C07D257/04;;A61K31/165;;A61K31/277;;A61K31/40;;A61K31/41;;A61K31/433;;A61P21/00;;A61P21/02;;A61P21/04;;C07C259/00;;C07C259/14;;C07C261/04;;C07C311/51;;C07D207/12;;C07D261/08;;C07D285/08,,43,40,087-863-925-269-803;;019-330-408-079-114;;035-231-347-776-501;;045-967-077-651-518;;002-547-612-259-585;;060-637-910-886-053;;022-902-289-186-978;;010-685-126-295-623;;044-169-383-848-981;;016-888-861-919-269;;078-452-708-030-633;;030-251-726-352-481;;051-895-504-748-62X;;086-565-078-033-303;;078-470-769-709-040;;068-405-687-101-628;;080-371-513-967-474;;098-149-890-306-862;;005-754-249-675-947;;069-073-888-551-527;;103-951-241-676-174;;048-882-225-082-203;;002-713-896-462-972;;080-150-466-743-072;;024-159-339-126-629;;110-043-009-234-056;;029-225-504-177-345;;021-575-265-341-222;;091-061-865-503-783;;100-129-698-124-331;;065-891-650-501-174;;082-883-704-417-354;;107-063-069-071-076;;083-350-419-426-803;;011-860-790-107-119;;035-201-404-877-396;;073-451-192-212-463;;057-644-626-884-154;;021-959-860-391-032;;052-286-659-870-462,10.1016/j.tetlet.2011.02.020;;10.1016/s0301-0082(00)00055-1;;11275359;;22094130;;10.1016/s1474-4422(11)70245-9;;10.1002/mus.880170708;;8008001;;10.1212/wnl.0b013e3182749eca;;23115209;;23995274;;10.1097/wco.0b013e328364d6cd;;10.1016/s1474-4422(11)70178-8;;21939902;;6100453;;10.1002/mus.880070608;;2455224;;10.1002/mus.880110609;;10.1085/jgp.200409173;;15684096;;pmc2217490;;10.1002/14651858.cd006986.pub2;;25310725;;pmc7390275;;10.1002/14651858.cd006986.pub3;;21328290;;2161128;;10.1055/s-2008-1041258;;28029925;;10.1056/nejmra1602678;;10.1085/jgp.201611582;;pmc4810071;;27022190;;pmc5373778;;10.1212/wnl.0000000000003772;;28251916;;9077516;;10.1016/s0022-510x(96)00303-6;;23444172;;10.1007/s13760-013-0189-3;;10.1002/ana.410380118;;7611713;;25979580;;10.1016/j.pop.2015.01.001;;1784551;;10.3928/0147-7447-19911201-11;;8479300;;22739110;;pmc3423102;;10.1152/ajpendo.00622.2011;;27576772;;10.1002/mus.25394;;12849173;;10.1016/s1474-4422(03)00399-5;;10.1016/s0928-4680(03)00007-5;;14567934;;10.21236/ada094643;;6115105;;10.1002/14651858.cd012604;;12682465;;10.1097/01.ccm.0000053651.38421.d9;;pmc3484867;;22645112;;10.1242/dmm.009746;;10.1111/ejn.13249;;27037492;;23911206;;10.1016/j.ymgme.2013.07.007;;10.1093/bja/aep093;;19468024;;pmc3662304;;23427324;;10.1212/wnl.0b013e3182886a0e;;10.1097/wco.0000000000000127;;25188014;;10.1136/practneurol-2012-000404;;23468559;;10.4061/2011/847393;;22007295;;pmc3189457;;10.1016/j.yane.2011.08.002;;10.1124/jpet.114.222224;;25678535;;10.1152/physrev.1987.67.2.618;;2436244;;10.1113/jphysiol.2014.280529;;pmc4287736;;25128573,"SANTOSH KURHADE ET AL: ""Synthesis of a novel tetracyclic azaindolo[2,1-][1,4]benzoxazine ring system"", TETRAHEDRON LETTERS, ELSEVIER LTD, AMSTERDAM, NL, vol. 52, no. 16, 7 February 2011 (2011-02-07), pages 1874 - 1877, XP028165600, ISSN: 0040-4039, [retrieved on 20110209], DOI: 10.1016/J.TETLET.2011.02.020;;AROMATARIS E C: ""Pharmacology of the CIC-1 Chloride channel"", INTERNET CITATION, 23 August 2010 (2010-08-23), pages 1 - 179, XP002781720, Retrieved from the Internet <URL:https://digital.library.adelaide.edu.au/dspace/bitstream/2440/58973/8/02whole.pdf> [retrieved on 20180606];;WOOD SJSLATER CR.: ""Safety factor at the neuromuscular junction"", PROG. NEUROBIOL., vol. 64, 2001, pages 393 - 429;;TITULAER MJLANG BVERSCHUUREN JJ.: ""Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies"", LANCET NEUROL., vol. 10, 2011, pages 1098 - 107;;KILLIAN JMWILFONG AABURNETT LAPPEL SHBOLAND D.: ""Decremental motor responses to repetitive nerve stimulation in ALS"", MUSCLE NERVE, vol. 17, 1994, pages 747 - 754;;WADMAN RIVRANCKEN AFVAN DEN BERG LHVAN DER POL WL.: ""Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3"", NEUROLOGY, vol. 79, 2012, pages 2050 - 2055;;LE PANSE RBERRIH-AKNIN S.: ""Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation"", CURR OPIN NEUROL., vol. 26, 2013, pages 569 - 576;;LATRONICO, N.BOLTON, C.F.: ""Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis"", LANCET NEUROL., vol. 10, 2011, pages 931 - 941;;KWIECINSKI HLEHMANN-HORN FRUDEL R.: ""Membrane currents in human intercostal muscle at varied extracellular potassium"", MUSCLE NERVE, vol. 7, 1984, pages 465 - 469;;KWIECINSKI H: ""Lehmann-Horn F, Rudel R. Drug-induced myotonia in human intercostal muscle"", MUSCLE NERVE, vol. 11, 1988, pages 576 - 581;;PEDERSEN, T.H.F. DE PAOLI: ""O.B. Nielsen. Increased excitability of acidified skeletal muscle: role of chloride conductance"", J. GEN. PHYSIOL., vol. 125, 2005, pages 237 - 246;;MEHNDIRATTA MMPANDEY SKUNTZER T.: ""Acetylcholinesterase inhibitor treatment for myasthenia gravis"", COCHRANE DATABASE SYST REV., 13 October 2014 (2014-10-13), pages 10;;HOWARD, J.F.: ""Jr. Adverse drug effects on neuromuscular transmission"", SEMIN NEUROL., vol. 10, 1990, pages 89 - 102;;GILHUS, N.E., NEW ENGLAND JOURNAL OF MEDICINE, vol. 375, 2016, pages 2570 - 2581;;PEDERSEN, T.H.RIISAGER, A.VINCENZO DE PAOLI, F.CHEN, T-YNIELSEN, O.B.: ""Role of physiological CIC-1 CI- ion channel regulation for the excitability and function of working skeletal muscle"", J. GEN. PHYSIOL., vol. 147, 2016, pages 291 - 308;;BANSAGI BGRIFFIN HWHITTAKER RGANTONIADI TEVANGELISTA TMILLER JGREENSLADE MFORESTER NDUFF JBRADSHAW A: ""Genetic heterogeneity of motor neuropathies"", NEUROLOGY, vol. 88, no. 13, 2017, pages 1226 - 1234;;YAMADA, M.INABA, A.SHIOJIRI, T.: ""X-linked spinal and bulbar muscular atrophy with myasthenic symptoms"", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 146, 1997, pages 183 - 185, XP027509692, DOI: 10.1016/S0022-510X(96)00303-6;;STEVIC, Z.PERIC, S.PAVLOVIC, S.BASTA, I.LAVRNIC, D.: ""Myasthenic symptoms in a patient with Kennedy's disorder"", ACTA NEUROLOGICA BELGICA, vol. 114, 2014, pages 71 - 73;;ROBERTS, M.WILLISON, H.J.VINCENT, A.NEWSOM-DAVIS, J.: ""Multifocal motor neuropathy human sera block distal motor nerve conduction in mice"", ANN NEUROL., vol. 38, 1995, pages 111 - 118;;ANSAR, V.VALADI, N.: ""Guillain-Barre Syndrome Prim."", CARE, vol. 42, 2015, pages 189 - 193;;TROJAN, D.A.GENDRON, D.CASHMAN, N.R.: ""Electrophysiology and electrodiagnosis of the post-polio motor unit"", ORTHOPEDICS, vol. 14, 1991, pages 1353 - 1361;;BIRKT.J.: ""Poliomyelitis and the post-polio syndrome: exercise capacities and adaptation - current research, future directions, and widespread applicability"", MED. SCI. SPORTS EXERC., vol. 25, 1993, pages 466 - 472;;GARCIA, C.C.POTIAN, J.G.HOGNASON, K.THYAGARAJAN, B.SULTATOS, L.G.SOUAYAH, N.ROUTH, V.H.MCARDLE, J.J.: ""Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy"", AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 15, 2012, pages E551 - 561;;GILMORE K.J.MORAT T.DOHERTY T.J.RICE C.L., MOTOR UNIT NUMBER ESTIMATION AND NEUROMUSCULAR FIDELITY IN 3 STAGES OF SARCOPENIA, vol. 55, no. 5, 2017, pages 676 - 684;;BURTON, A.: ""Take your pyridostigmine: that's an (ethical?) order!"", LANCET NEUROL., vol. 2, 2003, pages 268, XP004810090, DOI: 10.1016/S1474-4422(03)00399-5;;KAWAMURA, Y.KIHARA, M.NISHIMOTO, K.TAKI, M.: ""Efficacy of a half dose of oral pyridostigmine in the treatment of chronic fatigue syndrome: three case reports"", PATHOPHYSIOLOGY, vol. 9, 2003, pages 189 - 194;;SELLIN, L.C.: ""The action of botulinum toxin at the neuromuscular junction"", MED BIOL., vol. 59, 1981, pages 11 - 20;;SILVA A.MADUWAGE K.BUCKLEY N.A.LALLOO D.G.DE SILVA H.J.ISBISTER G.K.: ""Antivenom for snake venom-induced neuromuscular paralysis"", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, pages 3;;FLETCHER, S.N.KENNEDY, D.D.GHOSH, I.R.MISRA, V.P.KIFF, K.COAKLEY, J.H.HINDS, C.J.: ""Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness"", CRIT. CARE MED., vol. 31, 2003, pages 1012 - 1016;;DOWLING J.J.: ""Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models,"", DISEASE MODELS & MECHANISMS, vol. 5, 2012, pages 852 - 859;;VAN DER PIJL, M.M. ET AL.: ""Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models"", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 43, 2016, pages 1623 - 1635;;ANGELINI C.: ""Spectrum of metabolic myopathies"", BIOCHIM. BIOPHYS. ACTA, vol. 1852, 2015, pages 615 - 621, XP029196743, DOI: 10.1016/j.bbadis.2014.06.031;;MILONE, M.WONG, L.J.: ""Diagnosis of mitochondrial myopathies"", MOL. GENET. METAB., vol. 110, 2013, pages 35 - 41, XP028695384, DOI: 10.1016/j.ymgme.2013.07.007;;SRIVASTAVA, A.HUNTER, J.M.: ""Reversal of neuromuscular block"", BR. J. ANAESTH., vol. 103, 2009, pages 115 - 129;;WU, F.MI, W.CANNON, S.C., NEUROLOGY, vol. 80, 2013, pages 1110 - 1116;;SUETTERLIN, K., CURRENT OPINION NEUROLOGY, vol. 27, 2014, pages 583 - 590;;AMMAT, T., JOURNAL OF GENERAL PHYSIOLOGY, vol. 146, 2015, pages 509 - 525;;FINLAYSON, S.BEESON, D.PALACE, J.: ""Congenital myasthenic syndromes: an update"", PRACT. NEUROL., vol. 13, 2013, pages 80 - 91;;GILHUS, N.E.OWE, J.F.HOFF, J.M.ROMI, F.SKEIE, G.O.AARLI, J.A.: ""Myasthenia Gravis: A Review of Available Treatment Approaches"", AUTOIMMUNE DISEASES, 2011;;MURPHY GSBRULL SJ.: ""Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block"", ANESTH ANALG., vol. 111, no. 1, 2010, pages 120 - 8;;HWEE, D.T.KENNEDY, A.R.HARTMAN, J.J.RYANS, J.DURHAM, N.MALIK, F.I.JASPER, J.R.: ""The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure"", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 353, 2015, pages 159 - 168;;BRETAG, A H.: ""Muscle chloride channels"", PHYSIOLOGICAL REVIEWS, vol. 67, 1987, pages 618 - 724;;RIISAGER: ""Determination of cable parameters in skeletal muscle fibres during repetitive firing of action potentials"", JOURNAL OF PHYSIOLOGY, vol. 592, 2014, pages 4417 - 4429",PENDING
987,EP,A3,EP 1158293 A3,102-369-862-430-046,2003-04-02,2003,EP 01117365 A,1996-07-22,EP 96925014 A;;GB 9515143 A,1995-07-24,Examining a diamond,"In order to test whether a diamond has had a layer of synthetic diamond deposited thereon, it is irradiated with high energy ultraviolet radiation to cause emission of luminescence, the luminescence intensity produced by different zones of the diamond being measured and compared. In one embodiment an integrating enclosure (15) is used and the diamond (13) is mounted on a rotatable mount (14).",GERSAN ETS,WELBOURN CHRISTOPHER MARK;;SMITH MARTIN PHILLIP;;SMITH JAMES GORDON;;SPEAR PAUL MARTYN;;MARTINEAU PHILIP MAURICE;;COOPER MARTIN,,https://lens.org/102-369-862-430-046,Search Report,yes,5,0,18,22,0,G01N21/87;;G01N21/87,G01N21/64;;G01N21/87;;G01N21/62,,0,0,,,,DISCONTINUED
988,GB,A,GB 2219394 A,160-443-600-983-376,1989-12-06,1989,GB 8910414 A,1989-05-05,GB 8810723 A;;GB 8810724 A;;GB 8815941 A;;GB 8816156 A;;GB 8816157 A;;GB 8816164 A;;GB 8816165 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,Sorting diamond bearing ore,"In order to sort diamond-bearing ore particles 2 conveyed on a wide belt 1, exciting radiation strikes the belt along an extended line. Diamonds are detected by passing the emitted radiation through a narrow band pass filter 9 and sensing the Raman radiation with a photo-multiplier tube 14. Only nearby axial-parallel rays passing through the filter reach the photo-multiplier tube. An array of side-by-side rectangular converging lenses 15 can be used, the ore particles being in the plane of the foci of the lenses. To stop rays having an angle of incidence greater than the maximum permitted, to avoid identifying non-diamond material as diamond, a further converging lens 10 is used to focus the rays at the plane of a telecentric stop 11. The position of the diamond can be detected for instance by a CCD array or by a time domain technique. The calibration of the apparatus can be monitored by detecting when the radiation from reference stones and holes on either side of the belt differs from predetermined values. <IMAGE>",GERSAN ETS,STEWART ANDREW DAVID GARRY;;SMITH ROBIN WYNCLIFFE;;SMITH MARTIN PHILLIP;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/160-443-600-983-376,Patent Application,no,8,6,21,118,0,B07C5/366;;B07C5/3425;;B07C5/3427;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/653;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87;;G01N21/89;;G01N23/223,G1A AA4           BG;;G1A AA4           MHL;;G1A AA6           BG;;G1A AA6           MHL;;G1A ABG           BG;;G1A ABGG          BGG;;G1A AD1           BG;;G1A AD1           MHL;;G1A AD10          BG;;G1A AD10          MHL;;G1A AD3           BG;;G1A AD3           MHL;;G1A AD6           BG;;G1A AD6           MHL;;G1A AG1           BG;;G1A AG1           MHL;;G1A AG13          BG;;G1A AG13          MHL;;G1A AG16          BG;;G1A AG16          MHL;;G1A AG17          BG;;G1A AG17          MHL;;G1A AG2           BG;;G1A AG2           MHL;;G1A AG6           BG;;G1A AG6           MHL;;G1A AG9           BG;;G1A AG9           MHL;;G1A AMH           MHL;;G1A AMHL          MHL;;G1A AP1           BG;;G1A AP1           MHL;;G1A AP11          BG;;G1A AP11          MHL;;G1A AP15          BG;;G1A AP15          MHL;;G1A AP16          BG;;G1A AP16          MHL;;G1A AP17          BG;;G1A AP17          MHL;;G1A AP6           BG;;G1A AP6           MHL;;G1A AP7           BG;;G1A AP7           MHL;;G1A AP9           BG;;G1A AP9           MHL;;G1A AR2           BG;;G1A AR2           MHL;;G1A AR6           BG;;G1A AR6           MHL;;G1A AR7           BG;;G1A AR7           MHL;;G1A AS10          BG;;G1A AS10          MHL;;G1A AS12          BG;;G1A AS12          MHL;;G1A AS4           BG;;G1A AS4           MHL;;G1A AS5           BG;;G1A AS5           MHL;;G1A AT14          BG;;G1A AT14          MHL;;G1A AT15          BG;;G1A AT15          MHL;;G1A AT23          BG;;G1A AT23          MHL;;G1A AT3           BG;;G1A AT3           MHL;;G1A AT7           BG;;G1A AT7           MHL;;G1A AT8           BG;;G1A AT8           MHL;;U1S S1291;;U1S S1292;;U1S S1386;;U1S S1466;;U1S S1488;;U1S S1594;;U1S S1658;;U1S S1943;;U1S S2036,0,0,,,,EXPIRED
989,EP,A3,EP 0341093 A3,138-849-839-070-467,1991-02-27,1991,EP 89304636 A,1989-05-08,GB 8810723 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,IDENTIFYING GEMSTONES,"In order to determine whether a particle is a diamond, 514.5 nm laser radiation, modulated at a frequency of 10 MHz to 1 GHz, is projected onto the particle 2, and the radiation emitted by the particle 2 is collected by a wide aperture viewing system 23 with narrow band pass filtering of the diamond Stokes or anti-Stokes Raman frequency appropriate to the laser wavelength. The emitted radiation is detected by a detector 6, and an associated electronic circuit 13,14,15 detects signals modulated at the same frequency as the laser modulation frequency. In this way, only Raman radiation is detected as this has a very short rise/decay time; other luminescence forms a background which is not modulated and can be removed by for instance thresholding, or heterodyne techniques. The method can be used to sort diamond from gangue on a wide belt, without very complicated optics.  ",GERSAN ESTABLISHMENT,"SMITH, MARTIN PHILLIP;;SMITH, ROBIN WYNCLIFFE;;STEWART, ANDREW DAVID GARRY;;BRINK, DANIEL JOHANNES;;COOPER, MARTIN;;WELBOURN, CHRISTOPHER MARK;;SPEAR, PAUL MARTIN",,https://lens.org/138-849-839-070-467,Search Report,yes,8,0,11,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,1,0,,,"OPTICAL ENGINEERING, vol. 24, no. 2, March/April 1985, pages 352-355, Bellingham, Washington, US; M.D. DUNCAN et al.: ""Imaging biological compounds using the coherent anti-Stokes Raman scattering microscope""",DISCONTINUED
990,AU,A,AU 1989/034539 A,147-583-797-965-721,1989-11-09,1989,AU 1989/034539 A,1989-05-08,GB 8810723 A;;GB 8810724 A;;GB 8815941 A;;GB 8816156 A;;GB 8816157 A;;GB 8816164 A;;GB 8816165 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,SENSING A NARROW FREQUENCY BAND OF RADIATION AND GEMSTONES,,GERSAN ETS,STEWART ANDREW DAVID GARRY;;SMITH ROBIN WYNCLIFFE;;SMITH MARTIN PHILLIP;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/147-583-797-965-721,Patent Application,no,0,1,21,118,0,B07C5/3425;;B07C5/3427;;B07C5/366;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/653;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87;;G01N21/89;;G01N23/223,,0,0,,,,EXPIRED
991,GB,B,GB 2219080 B,176-195-307-498-241,1992-11-04,1992,GB 8910417 A,1989-05-05,GB 8816167 A;;GB 8906853 A;;GB 8810723 A;;GB 8826225 A,1988-05-06,IDENTIFYING GEMSTONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;STEWART ANDREW DAVID GARRY;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/176-195-307-498-241,Granted Patent,no,0,0,11,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,G1A AA4           MHL;;G1A AD3           MHL;;G1A AG1           MHL;;G1A AG7           MHL;;G1A AG9           MHL;;G1A AMH           MHL;;G1A AR7           MHL;;G1A AS12          MHL;;G1A AS4           MHL;;G1A AT14          MHL;;G1A AT23          MHL;;G1A AT27          MHL;;G1A AT3           MHL;;U1S S1431;;U1S S1605,0,0,,,,EXPIRED
992,EP,A2,EP 0341093 A2,100-388-580-932-276,1989-11-08,1989,EP 89304636 A,1989-05-08,GB 8810723 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,Identifying gemstones.,"In order to determine whether a particle is a diamond, 514.5 nm laser radiation, modulated at a frequency of 10 MHz to 1 GHz, is projected onto the particle 2, and the radiation emitted by the particle 2 is collected by a wide aperture viewing system 23 with narrow band pass filtering of the diamond Stokes or anti-Stokes Raman frequency appropriate to the laser wavelength. The emitted radiation is detected by a detector 6, and an associated electronic circuit 13,14,15 detects signals modulated at the same frequency as the laser modulation frequency. In this way, only Raman radiation is detected as this has a very short rise/decay time; other luminescence forms a background which is not modulated and can be removed by for instance thresholding, or heterodyne techniques. The method can be used to sort diamond from gangue on a wide belt, without very complicated optics.  ",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;STEWART ANDREW DAVID GARRY;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/100-388-580-932-276,Patent Application,yes,0,13,11,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,DISCONTINUED
993,EP,A2,EP 0345949 A2,153-603-129-230-247,1989-12-13,1989,EP 89304642 A,1989-05-08,GB 8810723 A;;GB 8810724 A;;GB 8815941 A;;GB 8816156 A;;GB 8816157 A;;GB 8816164 A;;GB 8816165 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,Sensing a narrow frequency band of radiation and examining objects or zones.,"In order to sort diamond-bearing ore particles (2) conveyed on a wide belt (1), exciting radiation strikes the belt along an extended line. Diamonds are detected by passing the emitted radiation through a narrow band pass filter (9) sensing the Raman radiation with a photo-multiplier tube (14).  Only axial-parallel rays passing through the filter reach the photo-multiplier tube. An array of side-by-side converging lenses (6) can be used, the lenses being of rectangular shape as seen looking along the optical axis with their long axes at right angles to the line of radiation. The ore particles are in the plane of the foci of the lenses, so that radiation emitted by each particle is passed in parallel rays through the filter. In order to stop rays having an angle of incidence greater than the maximum permitted, to avoid identifying non-diamond material as diamond, a further converging lens (10) is used to focus the rays at the plane of a telecentric stop (11). The stop stops rays having too great an angle of incidence. The position of the   diamond can be detected for instance by a CCD array or by a time domain technique. The apparatus can be monitored by giving a signal when the radiation from tracer stones and holes on either side of the belt, differs from predetermined values.  ",GERSAN ETS,STEWART ANDREW DAVID GARRY;;SMITH ROBIN WYNCLIFFE;;SMITH MARTIN PHILLIP;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/153-603-129-230-247,Patent Application,yes,0,40,21,118,0,B07C5/366;;B07C5/3425;;B07C5/3427;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/653;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87;;G01N21/89;;G01N23/223,,0,0,,,,DISCONTINUED
994,AU,A,AU 1989/034540 A,173-567-227-346-788,1989-11-09,1989,AU 1989/034540 A,1989-05-08,GB 8810723 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,IDENTIFYING GEMSTONES,,GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;STEWART ANDREW DAVID GARRY;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/173-567-227-346-788,Patent Application,no,0,0,11,118,0,B07C5/3427;;B07C5/366;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,,0,0,,,,EXPIRED
995,EP,A3,EP 0345949 A3,173-418-496-403-251,1991-03-06,1991,EP 89304642 A,1989-05-08,GB 8810723 A;;GB 8810724 A;;GB 8815941 A;;GB 8816156 A;;GB 8816157 A;;GB 8816164 A;;GB 8816165 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,SENSING A NARROW FREQUENCY BAND OF RADIATION AND EXAMINING OBJECTS OR ZONES,"In order to sort diamond-bearing ore particles (2) conveyed on a wide belt (1), exciting radiation strikes the belt along an extended line. Diamonds are detected by passing the emitted radiation through a narrow band pass filter (9) sensing the Raman radiation with a photo-multiplier tube (14).  Only axial-parallel rays passing through the filter reach the photo-multiplier tube. An array of side-by-side converging lenses (6) can be used, the lenses being of rectangular shape as seen looking along the optical axis with their long axes at right angles to the line of radiation. The ore particles are in the plane of the foci of the lenses, so that radiation emitted by each particle is passed in parallel rays through the filter. In order to stop rays having an angle of incidence greater than the maximum permitted, to avoid identifying non-diamond material as diamond, a further converging lens (10) is used to focus the rays at the plane of a telecentric stop (11). The stop stops rays having too great an angle of incidence. The position of the   diamond can be detected for instance by a CCD array or by a time domain technique. The apparatus can be monitored by giving a signal when the radiation from tracer stones and holes on either side of the belt, differs from predetermined values.  ",GERSAN ESTABLISHMENT,"STEWART, ANDREW DAVID GARRY;;SMITH, ROBIN WYNCLIFFE;;SMITH, MARTIN PHILLIP;;BRINK, DANIEL JOHANNES;;COOPER, MARTIN;;WELBOURN, CHRISTOPHER MARK;;SPEAR, PAUL MARTIN",,https://lens.org/173-418-496-403-251,Search Report,yes,10,0,21,118,0,B07C5/366;;B07C5/3425;;B07C5/3427;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/653;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87;;G01N21/89;;G01N23/223,,1,0,,,"OPTICAL ENGINEERING, vol. 24, no. 2, 1985, pages 352-355, Bellingham, Washington, US; M.D. DUNCAN et al.: ""Imaging biological compounds using the anti-stokes raman scattering microscope""",DISCONTINUED
996,GB,B,GB 2219394 B,150-065-175-788-124,1992-09-16,1992,GB 8910414 A,1989-05-05,GB 8810723 A;;GB 8810724 A;;GB 8815941 A;;GB 8816156 A;;GB 8816157 A;;GB 8816164 A;;GB 8816165 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,SENSING A NARROW FREQUENCY BAND OF RADIATION AND EXAMINING OBJECTS OR ZONES,,GERSAN ETS,STEWART ANDREW DAVID GARRY;;SMITH ROBIN WYNCLIFFE;;SMITH MARTIN PHILLIP;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/150-065-175-788-124,Granted Patent,no,8,0,21,118,0,B07C5/366;;B07C5/3425;;B07C5/3427;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/653;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87;;G01N21/89;;G01N23/223,G1A AA4           BG;;G1A AA4           MHL;;G1A AA6           BG;;G1A AA6           MHL;;G1A ABG           BG;;G1A AD1           BG;;G1A AD1           MHL;;G1A AD10          BG;;G1A AD10          MHL;;G1A AD3           BG;;G1A AD3           MHL;;G1A AD6           BG;;G1A AD6           MHL;;G1A AG1           BG;;G1A AG1           MHL;;G1A AG13          BG;;G1A AG13          MHL;;G1A AG16          BG;;G1A AG16          MHL;;G1A AG17          BG;;G1A AG17          MHL;;G1A AG2           BG;;G1A AG2           MHL;;G1A AG6           BG;;G1A AG6           MHL;;G1A AG9           BG;;G1A AG9           MHL;;G1A AMH           MHL;;G1A AP1           BG;;G1A AP1           MHL;;G1A AP11          BG;;G1A AP11          MHL;;G1A AP15          BG;;G1A AP15          MHL;;G1A AP16          BG;;G1A AP16          MHL;;G1A AP17          BG;;G1A AP17          MHL;;G1A AP6           BG;;G1A AP6           MHL,0,0,,,,EXPIRED
997,IN,B,IN 174122 B,173-565-460-429-070,1994-09-17,1994,IN 354MA1989 A,1989-05-08,GB 8810723 A,1988-05-06,Examining apparatus for sensing a narrow frequency band of radiation and gemstones,,GERSAN ETS,STEWART ANDREW DAVID GARRY;;SMITH ROBIN WYNCHLIFFE;;SMITH MARTIN PHILIP;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN;;BRINK DANIEL JOHANNES,,https://lens.org/173-565-460-429-070,Granted Patent,no,0,0,11,118,0,,B01D/;;B03C/;;B07B/;;B07C/;;B07C5/344;;C09K/;;F21K/;;G01J/;;G01N21/62;;G01N21/65;;G01T/;;G21H/;;G21K/;;H01J/;;H01S/;;H05G/,,0,0,,,,EXPIRED
998,GB,A,GB 2219080 A,039-853-587-149-197,1989-11-29,1989,GB 8910417 A,1989-05-05,GB 8816167 A;;GB 8906853 A;;GB 8810723 A;;GB 8826225 A,1988-05-06,Identifying gemstones,"In order to determine whether a particle is a diamond, 514.5 nm laser radiation, moulded at a frequency of 10 MHz to 1 GHz, is projected onto the particle 2, and the radiation emitted by the particle 2 is collected by a wide aperture viewing system 23 with narrow band pass filtering of the diamond Stokes or anit-Stokes Raman frequency appropriate to the laser wavelength. The emitted radiation is detected by a detector 6, and an associated electronic circuit 13, 14, 15 detects signals modulated at the same frequency as the laser modulation frequency. In this way, only Raman radiation is detected as this has a very short rise/decay time; other luminescence forms a background which is not modulated and can be removed by for instance thresholding, or heterodyne techniques. The method can be used to sort diamond from gangue on a wide belt, without very complicated optics. <IMAGE>",GERSAN ETS,SMITH MARTIN PHILLIP;;SMITH ROBIN WYNCLIFFE;;STEWART ANDREW DAVID GARRY;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/039-853-587-149-197,Patent Application,no,0,8,11,118,0,B07C5/366;;B07C5/3427;;G01N21/64;;G01N21/65;;G01N21/85;;G01N21/87;;G01N2021/1734;;G01N2021/1789;;G01N2021/845;;G01N2021/8636;;G01N2201/0697,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87,G1A AA4           MHL;;G1A AD3           MHL;;G1A AG1           MHL;;G1A AG7           MHL;;G1A AG9           MHL;;G1A AMH           MHL;;G1A AMHL          MHL;;G1A AR7           MHL;;G1A AS12          MHL;;G1A AS4           MHL;;G1A AT14          MHL;;G1A AT23          MHL;;G1A AT27          MHL;;G1A AT3           MHL;;U1S S1431;;U1S S1605,0,0,,,,EXPIRED
999,BR,A,BR 8902134 A,160-058-473-109-756,1990-01-02,1990,BR 8902134 A,1989-05-08,GB 8810723 A;;GB 8810724 A;;GB 8815941 A;;GB 8816156 A;;GB 8816157 A;;GB 8816164 A;;GB 8816165 A;;GB 8816167 A;;GB 8826225 A;;GB 8906853 A,1988-05-06,"APARELHO PARA E PROCESSO DE EXAMINAR,OBJETOS OU EXAMINAR UM ARTIGO",,GERSAN ETS,STEWART ANDREW DAVID GARRY;;SMITH ROBIN WYNCLIFFE;;SMITH MARTIN PHILLIP;;BRINK DANIEL JOHANNES;;COOPER MARTIN;;WELBOURN CHRISTOPHER MARK;;SPEAR PAUL MARTIN,,https://lens.org/160-058-473-109-756,Patent Application,no,0,0,21,118,0,B07C5/366;;B07C5/3425;;B07C5/3427;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/85;;G01N23/223;;G01N2021/1734;;G01N2021/1789;;G01N2021/653;;G01N2021/845;;G01N2021/8636;;G01N2201/0697;;G01N2223/076,G01N23/22;;B07C5/342;;G01N21/62;;G01N21/64;;G01N21/65;;G01N21/84;;G01N21/85;;G01N21/86;;G01N21/87;;G01N21/89;;G01N23/223,,0,0,,,,EXPIRED
1000,US,A1,US 2010/0253850 A1,082-880-652-987-684,2010-10-07,2010,US 41777509 A,2009-04-03,US 41777509 A,2009-04-03,VIDEO PRESENTATION SYSTEM,"A video presentation system including a single physical computing device, a video capture device in communication with the physical computing device; and a computer readable medium readable by the physical computing device and including a video capture code segment for reading a video signal comprising a first plurality of pixels from the video capture device and storing the first set of pixels a buffer, an desktop capture code segment for capturing a content of a desktop of physical computing device and storing the content of the desktop in a buffer, and a chroma key code segment for setting a color value for a pixel in a buffer equal based on the color information of another pixel in another buffer.",EJ4 LLC,COOPER DANIEL STEPHEN;;COOPER KENNETH CARLTON;;RUSSELL PAUL MARTIN;;IMHOFF MICHAEL WAYNE;;LAWLESS JOHN JOSEPH;;ITU ALEXANDRU MIHAIL;;NINH THEM DAC,EJ4 LLC (2009-04-14),https://lens.org/082-880-652-987-684,Patent Application,yes,16,26,1,1,0,G06Q10/00;;H04N7/147;;H04N7/155;;H04N9/75;;H04N21/4223;;H04N21/4334;;H04N21/4788;;H04N9/75;;G06Q10/00;;H04N21/4788;;H04N7/147;;H04N21/4223;;H04N21/4334;;H04N7/155,H04N9/74,348/587;;X348E09055,0,0,,,,DISCONTINUED
